SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES This application claims priority to U.S. Patent Application Serial No. 12/631,404, filed December 4, 2009, which is incorporated by reference in its entirety. FIELD OF THE INVENTION This invention pertains to compounds which selectively inhibit the activity of anti-apoptotic Bcl-2 family proteins, compositions containing the compounds, and methods of treating diseases during which anti-apoptotic Bcl-2 proteins are expressed. BACKGROUND OF THE INVENTION Anti-apoptotic Bcl-2 family proteins are associated with a number of diseases and are under investigation as potential therapeutic drug targets. These targets for interventional therapy include, for example, the Bcl-2 family proteins Bcl-2, BC1-XL and Bcl-w. Recently, inhibitors of Bcl-2 family proteins have been reported in commonly-owned PCT/US/2004/36770, pubUshed as WO 2005/049593 and PCT/US/2004/367911, published as WO 2005/049594. While this art teaches inhibitors having high binding to the target protein, compound binding affinity is only one of many parameters to be considered. One goal is to produce compounds that preferentially bind to, that is, are selective for, one protein over another protein. To exhibit this selectivity, it is well known that a compoimd not only displays a high binding affinity to a particular protein but a lower binding affinity for another member as well. A typical measure of binding affinity of an anti-apoptotic protein inhibitor is the balance between the binding and dissociation processes between the protein and the inhibitor (Ki). The inhibition constant (K,) is the dissociation constant of an enzyme-inhibitor complex or a protein/small molecule complex, wherein the small molecule is inhibiting binding of one protein to another protein. So a large Ki value indicates a low binding affinity, and a small Ki value indicates a high binding affinity. A typical measure of cellular activity of an anti-apoptotic protein inhibitor is the concentration eliciting 50% cellular effect (EC50). Accordingly, the inventors have discovered that while compounds taught in the art have utility for the treatment of various cancers and immune diseases, tfiey are not selective -1- for anti-apoptotic Bcl-2 proteins over anti-apoptotic BC1-XL proteins and thereby result in a higher probability of side effects characterized by inhibition of anti-apoptotic BC1-XL proteins such as, thrombocytopenia. This invention therefore comprises a series of compounds that demonstrate unexpected properties with respect to their selectivity for binding to, and inhibiting the activity of anti-apoptotic Bcl-2 protein over anti-apoptotic BC1-XL protein as significantly higher than those of the compounds taught in PCT/US/2004/36770 and PCT/US/2004/3679U. SUMMARY OF THE INVENTION One embodiment of this invention, therefore, pertains to compounds or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, which are useful as selective inhibitors one or more than one anti-apoptotic protein family member, the compounds having Formula (I) O 0 O ^^ (I), wherein A' is N or C(A^); one or two or three or each of A^, B*, D' and E* are independently selected R', 0R\ SR\ S(0)R', SOaR', C(0)R\ C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R^)2, NHC(0)R\ NHC(0)0R\ NR'C(0)NHR', NR^C(0)N(R^)2, SOaNHR', S02N(R^)2, NHSO2R', NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independently selected H, F, CI, Br, I, CN, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; and Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R", OR", C(0)R", C(0)0R", SR", NH2, NHR", N(R")2, NHC(0)R", C(0)NH2, C(0)NHR", C(0)N(R'^)2, NHS(0)R" or NHS02R'^; or B and Y', together with the atoms to which they are attached, are imidazole or triazole; and one or two or each of A^, D' and E' are independently selected R\ 0R\ SR', S(0)R\ SO2R', C(0)R', C(0)0R\ 0C(0)R\ NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', -2- NHC(0)0R', NHC(0)NHR\ N(CH3)C(0)N(CH3)R\ SO2NHR', S02N(R')2, NHSO2R', NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independently selected H, F, CI, Br, I, CF3, C(0)OH, C(0)NH2 or C(0)0R'^; R'isR^R^R''orR^ R"^ is C,-C6-alkyl, Cs-Cs-alkenyl or Cj-Ce-alkynyl; R^ is phenyl which is unfused or fused with arene, heteroarene or R^"^; R^^ is cycloalkane or heterocycloalkane; R^ is heteroaryl which is unfused or fused with benzene, heteroarene or R^'^; R^'^ is cycloalkane or heterocycloalkane; R'* is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with arene, heteroarene or R"*^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^ NC(R^)(R^"), R^ OR^ SR^ S(0)R^ S02R^ NHR^ N(R')2, C(0)R\ C(0)NH2, C(0)NHR^ NHC(0)R^ NHSOJR', NHC(0)0R^ SO2NH2, SOZNHR^ S02N(R')2, NHC(0)NH2, NHC(0)NHR^ NHC(0)CH(CH3)^fHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR', OH, (O), C(0)OH, (O), N3, CN, NHz, CF3, CF2CF3, F, CI, Br or I substituents; R* is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R*'^ and R*® are independently selected alkyl or, together with the N to which they are attached, R^; R^ is aziridin-l-yl, azetidin-1-yl, pyrrolidin-l-yl or piperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R^isR«,R',R'°orR"; R* is phenyl which is unfused or fused with arene, heteroarene or R*'^; R*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl which is unfused or fused with arene, heteroarene or R^^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'° is Cs-Cio-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fiised with arene, heteroarene or R'°^; R'""^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -3- R" is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independenUy selected R^^ OR'^, NHR", N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R'^)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R'^isR'^R'^R'^orR'^ R" is phenyl which is unfused or fused with arene, heteroarene or R"'^; R""^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''* is heteroaryl, each of which is unfused or fused with arene, heteroarene or R'"*^; R'"*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with arene, heteroarene or R'^'^; R'^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is alkyl, alkenyl or alkynyl; R"isR'^R>^R^orR^^ R'* is phenyl which is unfused or fused with arene, heteroarene or R'*^; R**'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is heteroaryl which is unfused or fused with arene, heteroarene or R*'^; R"*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^° is C3-Cio-cycloalkyl or C4-C]o-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is 00 A Ort A unfiised or fused with arene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or thiee independently selected R^, OR^^, NHR^^ N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^^isR^,R'^orR'^ R^^ is phenyl which is unfused or fused with arene, heteroarene or R^*; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'* is heteroarene which is unfused or fused with arene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is -4- unfused or fused with arene, heteroarene or R^'"^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; Z* is R^^ or R", each of which is substituted with R^, R^' or R^°, each of which is substituted with F, CI, Br, I, CHIR", CH(R^')(R^^), C(R^')(R^''^)(R"), C(0)R", OR", SR", S(0)R", S02R^^, NHR" or N(R^^)R^^; R^ is phenyl which is unfused or fused with arene or heteroarene; R^' is heteroarene which is unfused or fused with arene or heteroarene; R^ is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaiyl or R^''^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^*^ is cycloalkyl or cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^"^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' and R^'^ are independently F, CI, Br or alkyl or are taken together and are Ci-Cs-spiroalkyl; R^^ is R^^ C(0)R^^ or C(0)0R"; R^^isR^orR^^ R^'' is phenyl which is unfused or ftised with aryl, heteroaryl or R^'*'^; R^'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl which is unsubstituted or substituted with R^; R^^ is phenyl which is unfused or fiised with arene, heteroarene or R^^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is R^*, R^' or R*", each of which is substituted with F, CI, Br, I, R'^\ 0R'*\ NHR''\ N(R'»)2, NHC(0)OR^', SR^\ S(0)R'" or SOzR'"; R^* is phenyl which is unfused or fused with arene, heteroarene or R^*'^; R^*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaiyl which is unfused or fused with arene, heteroarene or R^'^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'"' is Cs-Cg-cycloalkyl or C4-Cg-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced witii independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is -5- unfused or fused with arene, heteroarene or R'"''^; R'"''^ cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'isR^^R^R^orR^^; R"*^ is phenyl which is unfused or fused with arene, heteroarene or R''^'^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''^ is heteroaryl which is unfiased or fused with arene, heteroarene or R"*^^; R*''' is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''^ is Cs-Cg-cycloalkyl or C4-C7-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fiised with arene, heteroarene or R'"'^; R**"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"*^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two independently selected R'^, OR'^, NHR''^ N(R^)2, C(0)NH2, QONHR"^, C(0)N(R'^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^isR^R^orR^'; R'*^ is phenyl which is unfused or fused with arene, heteroarene or R"*^"^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"** is heteroaryl or R'**^; R''*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'*''^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein the moieties represented by R^^ and R^' are fiirther substituted by one or two or three of mdependenUy selected R*"^, OR^""^, SR*^, S(0)R^°'^, SOjR^"'^ or NHR^""^; R^''^ is phenyl which is unfused or fused with benzene, heteroarene or R^'*^, wherein R^'^^ is cycloalkane, cycloalkene or heterocycloalkane heterocycloalkene, R^^"^ is heteroaryl; R*^'^ is Cs-Ce-cycloalkyl or C4-C6-cycloalkenyl; each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 -6- or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^^*^; wherein R ^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^"*"^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^^^, OR^^'^, SR^^'^, S(0)R^^'^, SOjR^^'^, j^jjj^ssAA N(R55AA)2, C(0)R'^'^, C(0)NH2, C(0)NHR^^'^, NHC(0)R^^'^, NHSOiR^^'^, NHC(0)OR^^'^, SO2NH2, SOaNHR^^'^, S02N(R^^'^)2, NHC(0)NH2, NHCCONHR^^'^, OH, (0), C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R*^'^ is alkyl, alkenyl, alkynyl, phenyl or heteroaryl, or R^*^; R^^"^ is Cs-Ce-cycloalkyl or C4-C6-cycloalkyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N; wherein moieties represented byRRR,R,R ,R,R R,R ,R ,R ,R , 18 19 20 23 24 25 ^26 27 28 29 30 ^34 „36 38 39 40 42 „43 K ,lx ,lx ,lV ,IV ,l\ ,J^ ,Ix jlN. ,'\. ,K. ,lx ,J\. ,IV ,1V ,X\ ,I\. , M\ , 44 47 48 49 R , R , R , and R are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five independendy selected R^""^, R^, OR^", SR^", S(0)R^°, S02R'°, C(0)R'°, C0(0)R^'', 0C(0)R^'', 0C(0)0R^, NH2, NHR^°, N(R^°)2, C(0)NH2, C(0)NHR^°, C(0)N(R^)2, C(0)NHOH, C(0)NHOR^°, C(0)NHS02R^'', C(0)NR^°S02R^°, SO2NH2, S02NHR^°, S02N(R''')2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^°, C(N)N(R^°)2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R*"'^ is spirocyclyl; R^°isR^',R",R^^orR^^ 51 51R 51B R is phenyl which is unfused or fused with arene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is heteroaryl; R^^ is Cs-Ce-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independendy selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^^®; wherein R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -7- R''' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^^ 0R^^ SR'^ S(0)R", S02R^^ NHR'', N(R")2, C(0)R", C(0)NH2, C(0)NHR^^ NHC(0)R*^ NHS02R^^ NHC(0)0R", SO2NH2, S02NHR'^ S02N(R^^)2, NHC(0)NH2, NHC(0)NHR^^ OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl or R^^; wherein the alkyl, alkenyl, alkynyl are unsubstituted or substituted with OCH3; and R^^ is C3-Cg-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N. Another embodiment of this invention pertains to compounds or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, which are useful as selective inhibitors of anti-apoptotic Bcl-2 proteins, the compounds having Formula (11) tfCQ r Pi" (H), wherein R'°" is as described for substituents on R^^; nisO, 1,2, or 3; A'isNorC(A^); one or two or three or each of A^, B\ D' and E' are independently selected R\ 0R\ SR\ S(0)R\ SO2R', C(0)R\ C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R^)2, NHC(0)R\ NHC(0)0R', NR'C(0)NHR', NR'C(0)N(R')2, SO2NHR', S02N(R')2, NHS02R\ NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independently selected H, F, CI, Br, I, CN, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; and -8- Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R", OR'', C(0)R", C(0)0R'^ SR", NH2, NHR'^ N(R'^)2, NHC(0)R", C(0)NH2, C(0)NHR", C(0)N(R'^)2, NHS(0)R'^ or NHS02R'^; or B' and Y\ together with the atoms to which they are attached, are imidazole or triazole; and one or two or each of A^, D' and E' are independently selected R\ OR', SR', S(0)R', SO2R', C(0)R', C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR\ C(0)N(R>)2, NHC(0)R\ NHC(0)0R\ NHC(0)NHR\ N(CH3)C(0)N(CH3)R', SO2NHR', S02N(R')2. NHSO2R', NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independently selected H, F, CI, Br, I, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; R' is R^ R^ R" or R^ R'"^ is Ci-Ce-alkyl, C3-C6-alkenyl or Cs-Ce-alkynyl; R^ is phenyl which is unfused or fused with arene, heteroarene or R^'^; R'^'^ is cycloalkane or heterocycloalkane; R^ is heteroaryl which is unfused or fused with benzene, heteroarene or R^^; R^'^ is cycloalkane or heterocycloalkane; R'* is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with arene, heteroarene or R"*^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^ NC(R^)(R^®), R'', OR^ SR\ S(0)R\ S02R\ NHR^ N(R^)2, C(0)R^ C(0)NH2, C(0)NHR^ NHC(0)R\ NHS02R^ NHC(0)0R^ SO2NH2, SO2NHR'. S02N(R')2, NHC(0)NH2, NHC(0)NHR', NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR', OH, (0), C(0)OH, (O), N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^ is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R*^ and R^^ are independently selected alkyl or, together with the N to which they are attached, R^; R^ is aziridin-l-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R'isR«,R',R"'orR"; R* is phenyl which is unfused or fused with arene, heteroarene or R*'^; -9- R*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl which is unfused or fused with arene, heteroarene or R'^; R'* is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'° is Ca-Cio-cycloalkyl or C4-C]o-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'"^; R'"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or aUcynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^\ 0R'\ NHR'^ N(R'^)2, C(0)NH2, C(0)NHR'^ C(0)N(R'^)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R»MsR",R'^Rl^orR'^ R'^ is phenyl which is unfused or fused with arene, heteroarene or R"'^; R'^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'* is heteroaryl, each of which is unfused or fused with arene, heteroarene or R'*''; R"* is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'* is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fiised with arene, heteroarene or R^^^; R^*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is alkyl, alkenyl or alkynyl; R"isR'»,R'',R^orR^^ R'* is phenyl which is unfused or fused with arene, heteroarene or R^*^; R^*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is heteroaryl which is unfused or fused with arene, heteroarene or R^^^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^° is Cs-Cio-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^'''^; R^""^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^^ OR^^ NHR", N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^^isR^,R^orR"; -10- R^^ is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'' is heteroarene which is unfused or fused with arene, heteroarene or R^^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^* is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^''^; R^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^" is cycloalkyl or cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^"^; R^""^ is cycloalkane, cycloalkene, heterocycloalkane or hetenx;ycloalkene; each of which is substituted with F, CI, Br, I, CH2R", CH(R^')(R^^), C(R^')(R^''^)(R^'), C(0)R^^ OR^^ SR", S(0)R", SO2R", NHR" or N(R^^)R"; R^' and R^'"^ are independently F, CI, Br or alkyl or are taken together and are C2-C5-spiroalkyl; R^^ is B?\ C(0)R^' or C(0)OR^^ R^MsR^orR^^ R^"* is phenyl which is unfused or fused with aryl, heteroaryl or R^*"^; R^*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl which is unsubstituted or substituted with R^; R^* is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is R^*, R^' or R^^, each of which is substituted with F, CI, Br, I, R'*\ OR''', NHR"', N(R'")2, NHC(0)0R'", SR'", S(0)R'" or SO2R'"; R^* is phenyl which is unfused or fused with arene, heteroarene or R^*'^; R^*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl which is unfused or fused with arene, heteroarene or R^''*; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"" is Cs-Cg-cycloalkyl or C4-C8-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is -11- unfused or fused with arene, heteroarene or R''"'^; R''"'^ cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'isR^^R^^R«orR^^ R'*^ is phenyl which is unfused or fused with arene, heteroarene or R*^'^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*^ is heteroaryl which is unfused or fused with arene, heteroarene or R"*^^; R''^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is Cs-Cg-cycloalkyl or C4-C7-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R''^'^; R'"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two independently selected R**, OR'^, NHR*^, N(R'^)2, C(0)NH2, C(0)NHR'^, C(0)N(R%, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^isR-'^R^orR'"; R'*^ is phenyl which is unfiised or fused with arene, heteroarene or R''^'^; R''^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'** is heteroaryl or R'**'^; R''*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R*' is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected 0, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'*''^; R"^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein moieties represented by R^ R^^, R\ R^^, R\ R*"^, R^ R"^, R^ R*'^, R', R'°, DIOA T>13 D13A T>14 I,14A jylS ^ISA n'S D18A ^19 r)I9A n^O t)20A D23 n^SA D24 D24A T>25 K ,K,K ,K,K ,K,I\ ,IV,K. ,J\,R ,R.,IV ,K,Jt\. ,I\,I\ ,K, „25A „26 n27 ^28 p28A n29 n29A p30 n30A n34 „34A n36 n36A ^38 |^38A ^39 n39A ^40 n40A ^42 j^42A j^43 ^43A j^44 j^44A j^47 j^47A j^48 R4«A J^49 ^„^ R49A ^^ independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five independendy selected R'"'^, R'°, OR^", SR^", S(0)R''', SOiR^", C(0)R^'', COCOR^", 0C(0)R^'', 0C(0)0R^"', NH2, NHR^", N(R^*')2, C(0)NH2, C(0)NHR^", C(0)N(R^°)2, C(0)NHOH, C(0)NHOR^", C(0)NHS02R^°, C(0)NR^°S02R^°, SO2NH2, S02NHR^'', S02N(R^)2, CF3, CF2CF3. C(0)H, C(0)OH, C(N)NH2, C(N)NHR^'', -12- C(N)N(R"')2, OH, (O), CN, N3. NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R^"^ is spirocyclyl; R^^sR^\R",R^'orR^*; R^' is phenyl which is unfused or fused with aiene, heteroarene or R^'*; R^'^ is cycloalkane, cycloalkene, heteiocycloalkane or heterocycloalkene; R^^ is heteroaryl; R*^ is Cs-Ce-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected 0, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^^^; wherein R'^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^"* is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^^ 0R^^ SR^^ S(0)R^^ S02R^^ NHR^^ N(R^^)2, C(0)R^^ C(0)NH2, C(0)NHR^^ NHC(0)R^^ NHSO2R", NHC(0)0R", SO2NH2, SO2NHR", S02N(R^')2, NHC(0)NH2, NHC(0)NHR'^ OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R^* is alkyl, alkenyl, alkynyl, phenyl, heteroaryl or R^*; wherein the alkyl, alkenyl, alkynyl are unsubstituted or substituted with OCH3; and R^* is Cs-Cg-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N. Another embodiment of this invention pertains to compounds or dierapeutically acceptable salts, prodrugs or salts of prodrugs thereof, which are useful as selective inhibitors of anti-apoptotic Bcl-2 proteins, the compounds having Formula (HI) -13- Y' r (HI), wherein R'*"' is as described for substituents on R^^; n is 0,1,2, or 3; A' is N or C(A^); one or two or three or each of A^, B\ D' and E' are independently selected R\ 0R\ SR\ S(0)R', SO2R', C(P)R\ C(0)0R', 0C(0)R\ NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NHC(0)0R', NR'C(0)NHR', NR'C(0)N(R')2, SOaNHR', S02N(R')2, NHS02R\ NHS02NHR^ or N(CH3)S02N(CH3)R\ and the remainder are independently selected H, F, CI, Br, I, CN, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; and Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R", 0R'\ C(0)R", C(0)0R", SR",NH2, NHR", N(R")2, NHC(0)R", C(0)NH2, C(0)NHR", C(0)N(R'^)2, NHS(0)R" or NHSO2R"; or B' and Y', together with the atoms to which they are attached, are imidazole or triazole; and one or two or each of A^, D' and E' are independently selected R', OR', SR', S(0)R', S02R\ C(0)R\ C(0)0R\ 0C(0)R\ NHR', N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R', NHC(0)0R', NHC(0)NHR', N(CH3)C(0)N(CH3)R', SO2NHR', S02N(R')2, NHSO2R', NHSO2NHR* or N(CH3)S02N(CH3)R', and the remainder are independently selected H, F, CI, Br, I, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; R' is R^ R^ R"* or R^ -14- R"^ is Ci-C6-alkyl, Cs-Ce-alkenyl or Cj-Ce-alkynyl; R^ is phenyl which is unfused or fused with arene, heteroarene or R^; R^'^ is cycloalkane or heterocycloalkane; R^ is heteroaryl which is unfused or fused with benzene, heteroarene or R^'^; R^^ is cycloalkane or heterocycloalkane; R'' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with arene, heteroarene or R'*^; R'*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^ NC(R^)(R^"), R\ OR^ SR^ S(0)R\ SOaR^ NHR^ N(R^)2, C(0)R^ C(0)NH2, C(0)NHR^ NHC(0)R^ NHS02R^ NHC(0)0R^ SO2NH2, S02NHR^ S02N(R')2, NHC(0)NH2, NHC(0)NHR^ NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR', OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^ is C2-C5-spiroaIkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R^"^ and R^ are independently selected alkyl or, together with the N to which they are attached, R^; R**^ is aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R'isR^R^R'%rR"; R* is phenyl which is unfused or fused with arene, heteroarene or R*^; R*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl which is unfused or fused with arene, heteroarene or R'^; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is C3-C]o-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is imfiised or fused with arene, heteroarene or R'*"^; R'"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R'^ OR'^ NHR'^ N(R'^)2, C(0)NH2, C(0)NHR'^ C(0)N(R'^)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R'^isR'^R'^R'^orR'^ -15- R" is phenyl which is unfused or fused with arene, heteroarene or R"'^; R"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"' is heteroaryl, each of which is unfused or fused with arene, heteroarene or R''*'^; R"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with arene, heteroarene or R'^^; R'^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is alkyl, alkenyl or alkynyl; R"isR'^R",R^orR^^ R'* is phenyl which is unfused or fused with arene, heteroarene or R'*"^; R'*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'' is heteroaryl which is unfiised or fused with arene, heteroarene or R"^; R'''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; is Cs-Cio-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unieplaced or replaced with independenUy selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^"'^; R^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^^ OR^^ NHR^^ N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^^isR^.R^orR^^ R^^ is phenyl which is unfused or fiised with arene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroarene which is unfused or fused with arene, heteroarene or R^'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is Cs-Cfe-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^^^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^** is cycloalkyl or cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused -16- with arene, heteroarene or R^"'^; R^"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is substituted with F, CI, Br, I, CH2R", CH(R^')(R"), C(R^')(R^'^)(R"), C(0)R^', OR", SR'\ S(0)R", SO2R", NHR" or N(R")R"; R^' and R^'"^ are independently F, CI, Br or alkyl or are taken together and are Ci-Cs-spiroalkyl; R^^ is R^^ C(0)R^^ or C(0)OR^^; R^^isR^orR'^ R^'* is phenyl which is unfused or fused with aryl, heleroaryl or R^'*'^; R^'*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl which is unsubstituted or substituted with R^; R^* is phenyl which is unfused or fused with arene, heteroarene or R^"^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is R^^ R^' or R"*", each of which is substituted with F, CI, Br, I, R^', OR*', NHR"', N(R'")2, NHC(0)0R*', SR"', S(0)R'" or SOZR'"; R^* is phenyl which is unfused or fused with arene, heteroarene or R^*'^; R^*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl which is unfused or fused with arene, heteroarene or R^'^; R^'^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''" is C3-C8-cycloalkyl or C4-C8-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'*°'^; R''*''^ cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R*'isR*^R*^R^orR*^ R'*^ is phenyl which is unfused or fused with arene, heteroarene or R''^^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''^ is heteroaryl which is unfused or fused with arene, heteroarene or R"^^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''* is C3-C9-cycloalkyl or C4-C7-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R**^; R''*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -17- R''^ is alkyl, alkenyl or alkynyl, each of which is unsubsdtuted or substituted with one or two independently selected R^^, OR'^, NHR''^ N(R'^)2, C(0)NH2, C(0)NHR'^, C(0)N(R'^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^isR^U'^orR^'; R"*^ is phenyl which is unfused or fused with arene, heteroarene or R'*^'^; R"*^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''* is heteroaiyl or R"**^; R"*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"*' is Cj-Cfi-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected 0, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'"'^; R'"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein moieties represented by R^ R^"^, R^ R^'^, R^ R"^, R^ R^, R^ R*^, R', R'", DIOA 1)13 D13A DM D14A I>15 E>15A n\S nlSA r>19 D19A n20 r>20A T)23 r)23A o24 r>24A D25 K ,rv,K ,K,K ,iv,K ,1\,K ,K,X\ ,l\.,lv ,K,K ,lv,l\ >K> n25A „26 ^27 j^28 j^28A p29 T>29A n30 n30A n34 n34A n36 n36A r,3S n38A T^39 n39A T^40 TI40A R'\ R'^\ R*\ R*'^ R^, R**^, R^\ R^'\ R^, R'^^, R''', and R^'^ are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five independently selected R*°^, R^^ 0R^°, SR^°, S(0)R^° S02R*°, C(0)R^'', CO(0)R^^ OC(0)R^° OC(0)OR^°, NH2, NHR*°, N(R^2, C(0)NH2, C(0)NHR^°, C(0)N(R^**)2, C(0)NHOH, C(0)NHOR^, C(0)NHS02R^, C(0)NR*°S02R^°, SO2NH2, S02NHR^°, S02N(R*°)2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^°, C(N)N(R'°)2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R^"'^ is spirocyclyl; R^^sR^^R^^R^^o^R'^ R^' is phenyl which is unfused or fused with arene, heteroarene or R^'®; R^'® is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroaiyl; R^^ is Ca-Ce-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^'"; wherein R ^® is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -18- R is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R'^ 0R^^ SR^^ S(0)R^^ S02R^^ NHR^^ N(R*^)2, C(0)R^^ C(0)NH2, C(0)NHR^^ NHC(0)R^^ NHS02R'^ NHC(0)0R^^ SO2NH2, S02NHR*^ S02N(R^^)2, NHC(0)NH2, NHC(0)NHR*^ OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I subsUtuents; R ^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl or R^^; wherein the alkyl, alkenyl, alkynyl are unsubstituted or substituted with CK3H3; and is Cs-Cg-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N. Another embodiment of this invention pertains to compounds or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, which are useful as selective inhibitors of anti-apoptotic Bcl-2 proteins, the compounds having Formula (IV) q^^ NH □' r R" (IV), wherein R'"" is as described for substituents on R^^; n is 0,1, 2, or 3; A' is N or C(A^); one or two or three or each of A^, B', D' and E' are independently selected R', 0R\ SR', S(0)R', S02R\ C(0)R', C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NHC(0)0R\ NR'C(0)NHR', NR'C(0)N(R')2, SO2NHR', S02N(R')2, NHSO2R', NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independenUy selected H, F, CI, Br, I, CN, CF3, C(0)OH, C(0)NH2 or C(0)0R'^; and -19- Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OGF2CF3, R", 0R'\ C(0)R", C(0)0R", SR", NH2, NHR'^ N(R")2, NHC(0)R'^ C(0)NH2, C(0)NHR", C(0)N(R'^)2, NHS(0)R'' or NHS02R'^; or B' and Y', together with the atoms to which they are attached, are imidazole or triazole; and one or two or each of A^, D' and E' are independently selected R\ 0R\ SR\ S(0)R\ S02R\ C(0)R\ C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NHC(0)0R', NHC(0)NHR\ N(CH3)C(0)N(CH3)R\ SO2NHR', S02N(R')2, NHSO2R', NHSO2NHR' or N(CH3)S02N(CH3)R', and the remamder are independenUy selected H, F, CI, Br, I, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; R' is R^ R\ R" or R^ R'"^ is C]-C6-alkyl, Cs-Ce-alkenyl or C3-C6-alkynyl; R^ is phenyl which is unfused or fused with arene, heteroarene or R^^; R^'' is cycloalkane or heterocycloalkane; R^ is heteroaryl which is unfused or fused with benzene, heteroarene or R^^; R^^ is cycloalkane or heterocycloalkane; R'' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with arene, heteroarene or R"*^; R"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^ NC(R^)(R^®), R^ OR^ SR\ S(0)R^ S02R\ NHR', N(R^)2, C(0)R\ C(0)NH2, C(0)NHR^ NHC(0)R\ NHSOZR^ NHC(0)0R\ SO2NH2, S02NHR^ S02N(R^)2, NHC(0)NH2, NHC(0)NHRNHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR', OH, (0), C(0)OH, (O), N3, CN, NH2, CF3, CF2CF3, F, CI, Bror I substituents; R* is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R*"^ and R*^ are independently selected alkyl or, together with the N to which they are attached, R*^; R**^ is aziridin-1-yl, azetidin-l-yl, pyrrolidin-1-yl or piperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R'isR«,R',R'%rR"; R* is phenyl which is unfused or fused with arene, heteroarene or R*'^; -20- R*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl which is unfused or fused with arene, heteroarene or R''^; R''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'° is C3-C]o-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'""^; R'"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or aUcynyl, each of which is unsubstituted or substituted with one or two or three independently selected R'^ OR'^ NHR'^ N(R'^)2, C(0)NH2, C(0)NHR'^ C(0)N(R'^)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R'^isR",R".R''orR'^ R" is phenyl which is unfused or fused with arene, heteroarene or R'^^; R'^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''* is heteroaryl, each of which is unfused or fused with arene, heteroarene or R''*'^; R^'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with arene, heteroarene or R^^^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is alkyl, alkenyl or alkynyl; R"isR^R".R^orR"; R'* is phenyl which is unfused or fused with arene, heteroarene or R'*^; R'**^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is heteroaryl which is unfused or fused with arene, heteroarene or R*'^; R*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^° is C3-C]o-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^"'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^^ OR^^ NHR^^ N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^^isR^,R^orR^^ -21- R^^ is phenyl which is unfused or fused with arena, heteroarene or R^^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'* is heteroarene which is unfused or fused with arene, heteroarene or R^"^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^* is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'"' is cycloalkyl or cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^°^; R^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is substituted with F, CI, Br, I, CH2R", CH(R^')(R^'), C(R^')(R^"^)(R^^), C(0)R^\ OR", SR", S(0)R", SO2R", NHR" or N(R^^)R"; R^'andR^'^ are independently F, CI, Br or alkyl or are taken together and are C2-C5-spiroalkyl; R^^ is R^^ C(0)R^^ or C(0)0R"; R^^isR^orR^^ R^* is phenyl which is unfused or fused with aryl, heteroaryl or R^**^; R^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl which is unsubstituted or substituted with R^; R^* is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is R^*, R^' or R'^, each of which is substituted with F, Cl, Br, I, R'", OR'*', NHR"', NCR"')!, NHC(0)OR'", SR'", S(0)R^' or SOzR'*'; R^* is phenyl which is unfused or fused with arene, heteroarene or R^*'^; R^*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl which is unfused or fused with arene, heteroarene or R^'^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*" is Cs-Cg-cycloalkyl or C4-C8-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is -22- unfiised or fiised with arene, heteroarene or R''"'^; R''*''^ cycloalkane, cycloalkene, heterocycloalkane or heteiocycloalkene; R*'isR^^R«R^orR^^ R''^ is phenyl which is unfused or fused with arene, heteroarene or R''^'^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R*^ is heteroaiyl which is unfused or fused with arene, heteroarene or R*^^; R''^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"^ is Cs-Cg-cycloalkyl or C4-C7-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independenUy selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'"'^; R**'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"*^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two independenUy selected R^, OR'^, NHR'^, N(R**)2, C(0)NH2, CCONHR'^, C(0)N(R%, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^isR^U^orR""; R'*' is phenyl which is unfused or fused with arene, heteroarene or R"*^"^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'** is heteroaiyl or R'**'^; R''*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R*' is Cs-Cfi-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'*''^; R'"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein moieties represented by R^ R^'^, R\ R^-^, R^ R"^, R^ R^, R*, R*'^, R', R'°, DIOA nl3 D13A ^14 nl4A niS r,\SA ^18 r>18A D19 ril9A r,20 n20A r,23 D23A n24 D24A ^25 K. ^ K. , K. ,l\,Iv ,lv,tv ,Xv,Xv ,lv,r\. ,K,I^ ,Iv,K ,K,K ,K, D25A D26 D27 U28 D28A T>29 D29A r)30 „30A r>34 D34A r>36 T>36A D38 T>38A D39 D39A D40 D^OA K. , iv , Ix , Iv , Ix , Iv , 1\ , Ix , 1\ , l\. , Ix , Jx , Iv , 1\ , is. , IX , xx , Ix , IX , R'\ R'^\ R«, R^^^, R-", R^^, R^^ R^^^, R-^, R^^, R'', and R^'^ are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five independenUy selected R^"^, R^", 0R^°, SR^", S(0)R^°, S02R^", C(0)R''', CO(0)R^°, OC(0)R^°, OC(0)OR^'', NH2, NHR^°, N(R*'')2, C(0)NH2, C(0)NHR^°, C(0)N(R^'')2, C(0)NH0H, C(0)NHOR^°, C(0)NHS02R^'', C(0)NR^"S02R^°, SO2NH2, S02NHR^'', S02N(R'°)2, CF3, CF2CF3,C(0)H, C(0)OH, C(N)NH2, C(N)NHR^'', -23- C(N)N(R'*')2, OH, (O), eN, Nj, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R^°^ is spirocyclyl; R^°isR^\R^^R53orR^^ R*' is phenyl which is unfused or fused with arena, heteroarene or R^'^; R*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroaiyl; R^^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfiised or fused with arene, heteroarene or R^'^; wherein R'^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'* is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^^ 0R^^ SR'^ S(0)R", S02R^^ NHR'^ N(R^^)2, C(0)R", C(0)NH2, C(0)NHR^^ NHC(0)R*^ NHSO2R", NHC(0)0R", SO2NH2, S02NHR'^ S02N(R^')2, NHC(0)NH2, NHC(0)NHR^^ OH, (O). C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R^* is alkyl, alkenyl, alkynyl, phenyl, heteroaryl or R^^; wherein the alkyl, alkenyl, alkynyl are unsubstituted or substituted with OCH3; and R^* is Cj-Cg-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N. Another embodiment of this invention pertains to compounds or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, which are useful as selective inhibitors of anti-apoptotic Bcl-2 proteins, the compounds having Formula (V) -24- Y' Q^ NH D' (R'-^jn I o / r' (V), wherein R"* is as described for substituents on R^*; n is 0,1,2, or 3; A' is N or C(A^); one or two or three or each of A^, B', D' and E' are independently selected R', OR', SR\ S(0)R\ SO2R', C(0)R\ C(0)0R\ 0C(0)R\ NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NHC(0)0R', NR'C(0)NHR', NR^C(0)N(R')2, SO2NHR', S02N(R')2, NHSO2R', NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independently selected H, F, CI, Br, I, CN, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; and Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R", OR'^ C(0)R'\ C(0)0R", SR". NH2, NHR", N(R")2, NHC(0)R", C(0)NH2, C(0)NHR^\ C(0)N(R")2, NHS(0)R'^ or NHS02R'^; or B' and Y\ together with the atoms to which they are attached, are imidazole or triazole; and one or two or each of A^, D' and E' are independently selected R\ OR', SR', S(0)R\ S02R\ C(0)R\ C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NHC(0)0R\ NHC(0)NHR', N(CH3)C(0)N(CH3)R\ S02NHR\ S02N(R')2, NHSO2R', NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independenUy selected H, F, CI, Br, I, CF3, C(0)OH, C(0)NH2 or C(0)0R'^; R' is R^ R^ R" or R^ -25- R''^ is Ci-Ce-alkyl, Cs-Ce-alkenyl or Cs-Cs-alkynyl; R^ is phenyl which is unfused or fused with arene, heteroarene or R^; R''^ is cycloalkane or heterocycloalkane; R^ is heteroaryl which is unfused or fused with benzene, heteroarene or R^^; R^'^ is cycloalkane or heterocycloalkane; R'* is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with arene, heteroarene or R"*^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloaUcene; R^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^ NC(R^^)(R*'*), R^ OR^ SR^ S(0)R^ SOaR^ NHR^ N(R^)2, CCOR'', C(0)NH2, C(0)NHR^ NHC(0)R\ NHSOaR^ NHC(0)0R\ SO2NH2, S02NHR^ S02N(R^)2, NHC(0)NH2, NHC(0)NHR^ NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR', OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R* is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R^'^ and R^® are independently selected alkyl or, together with the N to which they are attached, R*^; R*' is aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0). SO2 or NH; R'isR^R^R'%rR"; R* is phenyl which is unfused or fused with arene, heteroarene or R*^; R*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloaUcene; R' is heteroaryl which is unfused or fused with arene, heteroarene or R'^; R''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is Cj-Cio-cycloalkyl or CvCio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fiised with arene, heteroarene or R'"'^; R'"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R", OR'^, NHR'^ N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R'^)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R'^isR",R'^R^5orR'^ -26- R" is phenyl which is unfiased or fused with arene, heteroarene or R"'^; R"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"* is heteroaryl, each of which is unfiised or fused with arene, heteroarene or R""^; R''*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with arene, heteroarene or R'^'^; R'^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'* is alkyl, alkenyl or alkynyl; R"isR^R'',R^orR^'; R'* is phenyl which is unfused or fused with arene, heteroarene or R'*'^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is heteroaryl which is unfused or fused with arene, heteroarene or R'''^; R'''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^" is C3-Cio-cycloalkyI or C4-Cio-cycloalkenyl, each having one or two CH2 moieties umeplaced or replaced with independenUy selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^°'^; R^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^, OR^^ NHR^^ N(R")2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^^isR^,R^orR^^ R^^ is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroarene which is unfused or fused with arene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^^^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^° is cycloalkyl or cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused -27- with arene, heteroarene or R^"'*^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is substituted with F, CI, Br, I, CH2R", CH(R'')(R"), C(R^')(R^"^)(R^^), C(0)R^'', OR", SR", S(0)R", SO2R". NHR" or N(R^^)R"; R^' and R^''^ are independently F, CI, Br or alkyl or are taken together and are Ca-Cs-spiroalkyl; R^^ is R^\ C(0)R^^ or C(0)OR^^; R^'isR^orR^^ R^" is phenyl which is unfiised or fused with aryl, heteroaryl or R^'*'^; R^'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl which is unsubstituted or substituted with R^; R^* is phenyl which is unfused or fiised with arene, heteroarene or R^'^; R^*'* is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is R^, R^' or R"^, each of which is substituted with F, CI, Br, I, R"', OR"', NHR"', N(R'")2, NHC(0)OR^', SR*\ SCOR"' or SOzR""; R''* is phenyl which is unfused or fused with arene, heteroarene or R^*'^; R^*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl which is unfused or fused with arene, heteroarene or R^''^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'"' is Cs-Cs-cycloalkyl or C4-C8-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R''"'^; R"""^ cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^•isR^^R^^R^orR^^ R*^ is phenyl which is unfused or fused with arene, heteroarene or R'*^'^; R"*^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''^ is heteroaryl which is unfused or fused with arene, heteroarene or R"*^^; R"*^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is C3-C9-cycloalkyl or C4-C7-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected 0, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R*''*; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -28- R*^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two independently selected R'^, OR'^, NHR''^ N(R'^2, C(0)NH2, C(0)NHR'**, C(0)N(R'^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^isR^^R^orR^'; R*' is phenyl which is unfused or fused with arene, heteroarene or R''^^'^; R'*''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'** is heteroaryl or R"**^; R"*** is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"' is Ca-Ce-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'"'^; R"*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein moieties represented by R^ R^"^, R^ R^'^, R^ R''^, R*, R^, R*, R^'^, R', R^", nlOA DI3 r)I3A T>I4 r>14A ijIS n ISA r>18 rjlSA ^19 nl9A T>20 r>20A D23 n23A r>24 i>24A r>25 K ,iv,xv ,lx,l\ ,l^,lv ,x\.,l\ ,l\,r^ ,t\,i\. ,l\,i\. ,lv,l\. ,Jv, D25A D26 r,n n2& o^SA D29 D29A r)30 r)30A D34 I>34A r>36 T>36A ^38 T)38A T)39 I}39A r)40 o^OA Jx , Iv , Ix , ix ,K ,1^ , XV , r\. , Ix , IV , Iv , IV , XV , iv ,iv , Iv ,iv ,lv ,iv , R'^ R*^^, R'\ R^'\ R*", R*'^ R'\ R''\ R^, R'^^, R'\ and R^'^ are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five independenUy selected R^*"^, R^", OR^", SR^", S(0)R^, S02R^*', C(0)R^", CO(0)R^°, OC(0)R*°, OC(0)OR^°, NH2, NHR^", N(R^%, C(0)NH2, C(0)NHR^'', C(0)N(R'°)2, C(0)NH0H, C(0)NH0R'", C(0)NHS02R'°, C(0)NR'"S02R^^ SO2NH2, SOZNHR'", S02N(R^'')2, CF3, CF2CF3.C(0)H, C(0)OH, C(N)NH2, C(N)NHR^'', C(N)N(R^°)2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R^"'^ is spirocyclyl; R^^sR^^R^^R"orR'^ R*' is phenyl which is unfused or fused with arene, heteroarene or R^'®; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is heteroaryl; R^^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^^^; wherein R"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -29- R^'' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independenUy selected R^^ OR^', SR", S(0)R", S02R'^ NHR", N(R")2, C(0)R^^ C(0)NH2, C(0)NHR^^ NHC(0)R^^ NHS02R^^ NHC(0)0R^^ SO2NH2, S02NHR^^ S02N(R^^)2, NHC(0)NH2, NHC(0)NHR^^ OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl or R^ ; wherein the alkyl, alkenyl, alkynyl are unsubstituted or substituted with OCH3; and R** is Cs-Cg-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independenUy selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N. Another embodiment pertains to compounds of Formula (I), Formula (II), Formula (in). Formula (IV), or Formula (V) wherein A' is C(A^); and A^ is H. Another embodiment pertains to compounds of Formula (I), Formula (II), Formula (HI), Formula (IV), or Formula (V) wherein A' is C(A^) or N; A^ is H; and B' is NHR'. Another embodiment pertains to compounds of Formula (I), Formula (11), Formula (m). Formula (IV), or Formula (V) wherein A' is C(A^) or N; A^ is H; B' is NHR'; and D' is H. Another embodiment pertains to compounds of Formula (I), Formula (II), Formula (ffl). Formula (W), or Formula (V) wherein A' is C(A^) or N; A^ is H; B' is NHR';D' is H; and E' is H. Another embodiment pertains to compounds of Formula (I), Formula (II), Formula (ffl). Formula (IV), or Formula (V) wherein A' is C(A^) or N; A^ is H; B' is NHR';D' is H; E' is H; and Y' is NO2. Still another embodiment pertains to compounds having Formula I which are 4-(4-((4'-chIoro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(benzyloxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3 -nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(2-phenylethoxy)benzamide; -30- 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(phenylthio)benzanu(le; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(phenylthio)-N-((4-((tetrahydio- 2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(phenylthio)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(phenylsulfonyl)benzaniide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(phenylsulfinyl)benzamide; 2-benzyl-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3 -nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-benzyl-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-benzyl-4-(4-((4'-chloro-l,r-biphenyl-2-yI)methyI)piperazin-l-yI)-N-((4-((3-moipholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(2-phenylethyl)benzamide; 2-(benzylamino)-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazm-l-yl)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)aiiiino)phenyl)sulfonyl)benzamide; 2-anilino-4-(4-((4'-chloio-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)aniino)phenyl)sulfonyl)benzamide; 2-anilino-4-(4-((4'-chloro-l,r-biphenyI-2-yl)methyl)piperazin-l-yl)-N-((4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-methoxy-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)anuno)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- morpholin-4-ylpiopyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indazol-5-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indazol-5-yloxy)-N-((4-((l-methylpiperidin-4-yl)ammo)-3-nitiophenyl)sulfonyl)benzamide; -31- 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-( 1,2,3,4-tetrahydroquinolin-6- yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(( 1- methylpiperidin-4-yl)amino)-3-nitiophenyl)sulfonyl)-2-(l,2,3,4-tetrahydroquinolin-6- yloxy)benzamide; 4-(4-((4'-chloro-4-(pynolidin-1 -ylmethyl)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((3-mtro-4-((tetrahydro-2H-pyTan-4- ylmethyl)aniino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-pyiTolidin-1 -ylethyl)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((l- cyclopentylpiperidin-4-yl)amino)-3-mtrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide 4-(4-((4'-chIoro-l,r-biphenyI-2-yl)methyI)-3-isobutyIpiperazin-l-yI)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)aniino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-(2,4-dioxo-3- azabicyclo(3.2.0)hept-3-yl)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-(4-methyl-6-oxo-1,4,5,6- tetrahydropyridazin-3-yl)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-(3,3-dimethyl-2- oxoazetidin-1 -yl)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-(4-nitro-2H-l,2,3-triazol-2- yl)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-phenoxy-N-((2-(2-piperidin-1 - ylethoxy)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-((((l-ethylpynolidin-2- yl)methyl)ammo)carbonyl)-4-methoxyphenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-2-( 1-naphthyloxy)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyI)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-naphthyloxy)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-niorpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(2-naphthyloxy)benzamide; -32- 4-(4-((4'-chloro-l,r-biphenyl-2-yl)niethyl)piperazin-l-yl)-2-(2-naphthyloxy)-N-((4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methy l)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(quinolin-7-yloxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(quinolm-6-yloxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(l H-indol-5-yloxy)-N-((3-nitio- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(isoquinolin-5-yloxy)-N-((3- nitro-4-((tetTahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylammo)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(isoquinolin-5-yloxy)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(quinolin-6-yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy )-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitTOphenyl)sulfonyI)-2-(lH-indol-4-yloxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((4-((3- (dimethylamino)propyl)ammo)-3-nitrophenyl)sulfonyl)-2-(lH-indol-6-yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(isoquinolin-7-yloxy)-N-((4-((3- morpholin-4-ylpiopyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)ammo)-3-nitrophenyl)sulfonyl)-2-(isoquinolin-7-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex- 1-en-l -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yIoxy)-N-((4-((3-morpholin-4-ylpropyl)aniino)-3-nitrophenyl)sulfonyl)benzamide; -33- 4-(4-((2-(4-chlorophenyl)-4,4'dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(lH-indol-5-yIoxy)benzamide; 4-(4-((2-(4-ch]orophenyl)-5,5-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-( IH- indol-4-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)ben2amide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazm-1 -yl)-2-( 1H- indol-4-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(lH-indol-4-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)ammo)-3-nitrophenyl)sulfonyl)-2-(lH-indol-4-yloxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyI)piperazin-1 -yl)-2-( 1 H-indoI-4-yloxy)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(lH-indol-5-yloxy)-N-((4-((3- morpholin-4-ylpropy])amino)-3-nilrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-niethoxyphenyl)sulfonyl)-2- phenoxybenzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((4-methylphenyl)sulfonyl)-2- phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-5-y loxy)-N-((4- ((tetrahydro-2H-pyran-4-ylmethyl)aniino)-3- ((trifluoromethyl)suIfonyl)phenyl)sulfonyI)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)-N-((4- ((tetrahydro-2H-pyran-4-y]methyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-((tTifluoromethyl)sulfonyl)phenyl)sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-((4-((3- morpholin-4-ylpiopyl)amino)-3-((tTifluoroniethyl)sulfonyl)phenyl)sulfonyl)benzaniide; N-((3-((chloro(difluoro)methyl)sulfonyl)-4-((3- (dimethylamino)pfopyl)amino)phenyi)sulfonyl)-4-(4-((2-(4-chlorophenyI)-4,4- dimethylcyclohex-1 -en- l-yl)methyl)piperazin- l-yl)-2-( lH-indol-5-yloxy)benzamide; -34- 2-( 1 H-indol-4-yloxy)-4-(4-((2-(4-methoxyphenyl)-4,4-dimethy Icyclohex-1 -en-1 - y])methyI)piperazin-l-yI)-N-((3-nitro-4-((3-pyrrolidin-l- ylpropyl)aiiuao)phenyl)sulfonyl)beiizamide; 4-(4-((4,4-dimediyl-2-(4-(trifluoromelhyl)phenyl)cyclohex-1 -en-1 -yl)methyl)piperazin-1 -y])- 2-(lH-indol-4-yloxy)-N-((3-nitro-4-((3-pyiTOlidin-l- ylpropyl)aniino)phenyl)sulfonyl)benzamide; 4-(4-((4,4-dimethyl-2-(4-(trifluoromethoxy)phenyl)cyclohex-l-en-l-yl)methyl)piperazin-l- y])-2-(lH-indo]-4-y]oxy)-N-((3-nitro-4-((3-pynio]idin-l- ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4,4-dimethyl-2-(3-(trifluoromethyl)pheny])cyclohex-1 -en-1 -y])methyl)piperazin-l -y])- 2-( lH-indol-4-yIoxy)-N-((3-nitro-4-((3-pyrrolidin-1 - ylpropyl)aniino)phenyl)sulfonyl)benzamide; 4-(4-((2-(3-fluorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((3-nitro-4-((3 -pyirolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-fluorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-((3-nitro-4-((3-pyirolidin-l-ylpropyl)amino)phenyl)sulfonyl)benzamide; N-((3-((chloro(difluoro)methyl)sulfonyl)-4-((l-methylpiperidin-4-yl)amino)phenyl)sulfonyl)- 4-(4-((2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- mdol-5-yloxy)benzamide; 4-(4-((2-(4-chlorophenyI)cyclohex-1 -en- l-yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-5 -yloxy)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitio-4-((tetrahydro-2H- pyran-4-ylmethyI)aniino)phenyl)sulfonyl)-2-(phenoxymethyl)benzanude; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-((3-morpholm-4- ylpropyl)aniino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(pyridin-3-yloxy)benzamide; 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-2-(pyridin-3-yloxy)-N-((4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-l,l'-biphenyI-2-yI)methyl)piperazin-l-yl)-N-((4-(((lR)-3-(dimethylamino)- l-((phenylthio)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; -35- 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(pyridin-4-yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitiophenyl)sulfonyl)-2-(pyridin-3-yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(pyridin-4-yloxy)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((2-(4-methylpiperazin-1 - yl)ethyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-(4-methylpiperazin-l- yl)propyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4.(4.((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)(methyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-(((l -methylpiperidin-4- yl)niethyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-ch]oro-1,1'-bipheny l-2-yl)methyl)piperazin-1 -yl)-N-((4-(( 1 -methy lpiperidin-4- yI)amino)-3-nitrophenyI)sulfonyI)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-cyano-4-((3- (dimethylammo)propyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((3 -pyrrolidin-1 - ylpiopyl)aniino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-(trifluoromethyl)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (isopiopyl(methyl)amino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-(3- (dimethylammo)propoxy)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH- mdol-5-yloxy)-N-((4-((2-(4-methylpiperazin-l-yl)ethyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH- indo]-5-y]oxy)-N-((4-((3-(4-inethylpiperazin-l-yl)propyl)amino)-3- mtrophenyl)sulfonyl)benzanude; 4-(4-((2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamide -36- 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((4-((3-(4-methylpiperazin-l-yl)propyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(3- (diniethylamino)propoxy)-3-nitrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-((4-((2-(4-methylpiperazin-l-yl)ethyl)amino)-3- nitrophenyl)sulfonyl)benzaniide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((3-nitro-4-((3-pyirolidin-l-ylpropyl)ammo)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((4-((l-methylpiperidin-4-yl)ammo)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((4-(((l-methylpiperidin-4-yl)methyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yIoxy)-N-((4-(((l-methylpiperidin-4-yl)methyl)amino)-3- nitrophenyl)sulfonyl)benzaniide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(3- (dimethylamino)propoxy)-3-nitrophenyl)sulfonyl)-2-(lH-indol-4-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((4-(4-methylpiperazin-l-yl)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((3-nitro-4-((l-(2,2,2-trifluoroethyl)piperidin-4- yl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-(((4-(dimethylamino)-l-methylpiperidm-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-2-(1 H-indol-5-yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2,3-dihydro-l,4-benzodioxin-5-yloxy)-N-((3-nitTO-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 5-(4-((4'-chloro-1, l'-biphenyl-2-yl)niethyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-1, r-biphenyl-2-carboxamide; -37- 5-(4-((4'-ch]oro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitiophenyl)sulfonyl)-l,r-biphenyl-2-carboxamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)ammo)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-4-(3-piperidin-l-ylpropoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-4-(2-morpholin-4-ylethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3- nitio-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-4-(3-(dimethylaniino)propoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2- phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylraethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(3-piperidin-l-ylpropoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylraethy])aniino)-3- ((trifluoromethyl)sidfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(3-(dimethylamino)propoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2- phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((tiifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-4-(2-(dimethylamino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin-l-yl)-N- ((3-nitK)-4-((3-pyrrolidin-l-ylpropyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N- ((3-nitro-4-((tetrahydio-2H-pyran-4-ylmethyl)aniino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-3-(2-(dimethylanuno)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N- ((3-mtro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-3-(2-(dimethylaniino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2- phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (lH-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)aniino)phenyl)sulfonyl)benzamide; -38- 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-1,1 '-biphenyI-2-yI)methyl)piperazin-1 -yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylniethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-morpholin-4-ylethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylrnethyl)amino)phenyl)sulfonyl)benzamide; 4.(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (lH-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylniethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- yliiiethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2- (lH-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylniethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-3-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2- (lH-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- yln)ethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-3-(2-morpholin-4-ylethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylinethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin-l-yl)-N- ((4-(( 1 -methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-ch]oro-3-(2-(dimethylaniino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((3-pyrrolidin-l- ylpropyl)ainino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylanuno)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((3-pyrrolidin-l- ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-cliloro-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((3-pyrrolidin-l- ylpropyl)amino)phenyl)sulfonyl)benzamide; -39- 4-(4-((4'-chIoro-4-(2-(dimethylamino)ethoxy)-1,1 '-biphenyl-2-yl)niethyl)piperazin-1 -yl)-N- ((3-nitro-4-((l-(2,2,2-trifluoroethyl)piperidin-4-yl)amino)phenyl)sulfonyl)-2- phenoxybenzamide; 4-(4-((4'-chloro-4-(2-pyn-o!idin-1 -ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-4-(2-(diisopropylamino)ethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-l -yl)- N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2- phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-2-(2,3-dihydro-1 H-indol-5-yloxy)- N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclohept-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)- N-((3-nitro-4-((3-pyrrolidin-l-ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclooct-1 -en-1 -yl)methyl)piperazin- l-yl)-2-( 1 H-indol-4-yloxy)-N- ((3-nitiD-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclopent-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH-indol-4-yloxy)- N-((3-nitro-4-((3-pyrrolidin-l-ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -en-1 -yl)metiiyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((4-((l-methylpiperidm-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yl)-2- (1 H-indol-4-yloxy)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclooct-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( lH-indol-4-yloxy)-N- ((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclohept-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclopent-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclohex-1 -en- l-yl)methyl)piperazin-1 -yl)-2-(lH-indol-4-yloxy)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yl)-2- (1 H-indoI-5-yloxy)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitiophenyl)sulfonyl)benzamide; 4-(4-((2-(4-ch]orophenyl)cyclohept-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH-indol-5-yloxy)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; -40- 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(( 1 - methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((2- (dimethylamino)ethyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)melhyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((4- (dimethylamino)butyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((l - (phenylsulfonyl)piperidin-4-yl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((l-(quinolin-8- ylsulfonyl)piperidin-4-yl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-phenoxy-N-((4-(( 1 - (phenylsulfonyl)piperidin-4-yl)amino)-3- ((trifluoromediyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin- l-yl)-2-phenoxy-N-((4-(( 1 -(quinolin-8- ylsulfonyl)piperidin-4-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-(((lS)-3-(dimethylamino)-l- thien-2-ylpropyl)amino)-3-iiitrDphenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((3-nitro-4-((thien-2- ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-2-phenoxy-N-((4-((tetrahydro-2H- pyran-4-ylmethyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-mtio-4-((2-(lH-l,2,3- triazol-1 -yl)ethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((2-(2H-l,2,3- triazol-2-yl)ethyl)ainino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-mtrophenyl)sulfonyl)-2-(2-naphthyloxy)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((2-(2-oxopyridin- l(2H)-yl)ethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; -41- 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((2-(pyridin-2' yloxy)ethyl)amino)phenyl)sulfonyl)-2-phenoxybeiizamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((2-pyridin-4- ylethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-(trifluoromethyl)phenyl)sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((3- cyano-4-((3-(dimethylamino)propyl)amino)phenyl)sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1 //- indol-5-yloxy)-iV-((3-nitro-4-((l-tetrahydro-2//-pyran-4-ylpiperidin-4- yl)aniino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1 //- indol-5-yloxy)-N-((4-((4-methylpiperazin-l-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-( 1 -(4'-chloro-1, l'-biphenyl-2-yl)ethyl)piperazin- l-yl)-2-( l//-indol-4-yloxy)-A^-((3-nitro- 4-((tetrahydro-2H-pyran-4-yImethyl)amino)phenyl)sulfonyl)benzamide; ^-((4-(((4-aminotetrahydro-2//-pyran-4-yl)methyl)aniino)-3-nitrophenyl)sulfonyl)-4-(4-((2- (4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH-indol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)anuno]pheny 1) sulfonyl)benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2- (lH-indol-5-yloxy)-N-({4-[(4-moipholin-4-ylcyclohexyl)amino]-3- nitrophenyl) sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl)sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-[(3-nitro-4-{[(3S)-tetTahydro-2H-pyran-3- ylmethyl]amino}phenyl)sulfonyl]benzamide; -42- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-pyran-3- ylmethyl]amino)phenyl)sulfonyl]benzamide; 4-(4-{[4-(4-chloropheny])-6,6-dimethyl-5,6-dihydK)-2H-pyran-3-yl]methyl)piperazin-l-yl)- 2-(lH-indol-5-yloxy)-N-({3-nitio-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyI}piperazin-l-yl)-N-[(4- {[(4-hydroxy-l-methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-3-fluoro- 2-(lH-indol-5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-3-fluoro- 2-(lH-indol-5-yloxy)-N-({3-nitro-4-((l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)beiizamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- [(4- {[(4-hydroxy-l-methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzaniide; N-[(4-{ [(3S,4R)-1 -benzyl-3-hydroxypiperidin-4-yl]amino} -3-nitrophenyl)sulfonyl]-4-(4- {[2- (4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5- yloxy)benzaniide; N-[(4-{[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino)-3-nitrophenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5- yloxy)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(4-{[l-(2-methoxyethyl)piperidin-4-yl]amino)-3- nitrophenyl)sulfonyl]benzaniide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-({4-[(4-methyIpiperazin-l-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl) piperazin- l-yl)-N-[(4- {[l-(2-hydroxyethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzainide; -43- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-[(4- {[ l-(2-methoxyethyl)piperidin-4-yl]amino) -3- nitrophenyl)sulfonyl]benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl jpiperazin- l-yl)-N-[(4- {[l-(3-hydroxypropyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide; 4-[4-({4'-chloro-3-[3-(dimethylamino)propyl]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-2- (lH-itidol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyraii-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N- [(4- {[ 1 -(3-hydroxypropyl)piperidin-4-yl]amino} -3-nitrophenyl)sulfonyl]-2-( lH-indol-5- yloxy)benzamide; 4- {4-[(4'-chloro-4-morpholin-4-yl-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-( lH-indol-4- yloxy)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)aniino]phenyl} sulfonyl)benzamide; 4-[4-({4'-chloro-3-[2-(diniethylamino)ethoxy]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-2- (lH-indol-4-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-N- [(4- {[4-(diethylamino)cyclohexyl]amino)-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin- l-yl)-N- [(4- {[4-(dimethylainino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzainide; 4-(4-{[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[4-(diethylamino)cyclohexyl]aniino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( IH- indol-4-yloxy)-N-({4-[(4-morpholin-4-ylcyclohexyl)anuno]-3- nitxophenyl) sulfonyl)benzamide; 4-[4-({4'-chloro-3-[2-(dimethylamino)ethoxy]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-2- (lH-indol-4-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl}sulfonyl)benzamide; 4- {4- [ 1 -(4'-chloro-1,1 '-biphenyl-2-yl)ethyl]piperazin-1 -yl} -2-( 1 H-indol-4-yloxy)-N-( {4-[( 1 - methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide; -44- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl ]methyl} piperazin-1 -yl)-N- {[4- ({[4-(dimethylamino)tetiahydro-2H-pyran-4-yl]methyl} amino)-3-nitrophenyl]sulfonyl} -2- (lH-indol-5-yloxy)benzamide; N-( {4-[(2-aminocyclohexyl)amino]-3-iutrophenyl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex- 1-en- l-yl]methyl} piperazin-1 -yl)-2-( lH-indol-5-yloxy)benzamide; 4- [4-( {4'-chloro-4- [3-(dimethylamino)prop-1 -ynyl]-1,1 '-biphenyl-2-yl} methyl)piperazin-1 - yl]-2-(lH-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny I} sulfony l)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-[(3-mtro-4-{[l-(4,4,4-trifluorobutyl)piperidin-4- yl]amino} phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[2-(4-hydroxy-1 -methylpiperidin-4-yl)ethyl]amino} -3-nitrophenyl)sulfonyl]-2-(l H-indol-5- yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin-l-yl)-2-( IH- indol-5 -yloxy)-N-[(3-nitro-4- {[!-(! ,3-thiazol-2-yl)piperidin-4- yl]amino) phenyl)sulfonyl]benzamide; 4-(4- {[4'-chloro-4-(2-hydroxyethoxy)-1,1 '-biphenyl-2-yl]methyl} piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-({3-nitTO-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfony l)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[l-(cyclopropylmethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sidfonyl)benzamide; 4-(4-{(2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(3-nitro-4- {[ l-(4,4,4-trifluorobutyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzainide; 4-{4-[l-(4'-chloro-l,l'-biphenyl-2-yl)ethyl]piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-({4-[(4- methylpiperazin-1 -yl)amino]-3 -nitrophenyl} sulfony l)benzamide; 4-[4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) -3- (hydroxymethyl)piperazin-1 -yl]-2-( lH-indol-5-yloxy)-N-( {4-[( 1 -methylpiperidin-4- yl)amino]-3-nitrophenyl} sulfonyl)benzamide; -45- 4-[4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]niethyl) -3- (hydroxymethyl)piperazin-1 -yl]-2-( 1 H-indol-5-yloxy)-N-( {3-nitro-4- [(1 -tetrahydio-2H- pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; 4-(4- {[4'-chloro-4-(2-hydroxyethoxy)-1,1 '-biphenyl-2-yl]methyl) piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-[(3-nitro-4- {[3-(3-oxopiperazin-1 - yl)propyl]amino)phenyl)sulfonyl]benzaniide; 4-(4-{[2-(4-chloTophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-[(3-nitro-4-{[3-(3-oxopiperazin-l- yl)propyl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitiDphenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl jpiperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-( {3-nitro-4-[( l-tetxahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-5-hydrDxycyclohex-1 -en-1 -yl]methyl Jpiperazin-1 -yl)-2-( 1 H-indol- 5-yIoxy)-N-({4-[(4-methylpiperazin-l-yl)anuno]-3-mtrophenyl)sulfonyl)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-N- [(4- {[l-(2,3-dihydro-lH-inden-2-yl)piperidin-4-yl]aniino}-3-nitrophenyl)sulfonyI]-2-(lH-indol- 4-yloxy)benzaniide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-N- [(4- {[l-(2,3-dihydro-lH-inden-2-yl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol- 5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethyIcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(4- {[(l-morpholin-4-ylcyclohexyl)methyl]amino} -3- nitiophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl) piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(3-nitro-4-{[l-(l,3-thiazol-2-ylmethyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamide; -46- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(3-nitro-4-{[l-(l,3-thiazol-4-ylmethyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[4- ({[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2- (lH-indol-5-yloxy)benzamide; 4-(4-{[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[4-(2-hydroxyethyl)piperazin- l-yl]amino) -3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)beiizamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(4-{[(3S)-l-methylpyrrolidin-3-yl]amino)-3- nitiophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N- [(4- {[l-(3-fluoropropyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzaniide; 4- [4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} -3- (hydroxymethyl)piperazin-l-yl]-2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran- 4-ylmethyl)amino]phenyl} sulfonyl)benzatnide; N-[(4- {[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino} -3-nitiDphenyl)sulfonyl]-4-[4- {[2- (4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) -3-(hydroxymethyl)piperazin-1 - yl]-2-(lH-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N- [(4- {[(l-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( IH- indol-4-yloxy)-N-( {4- [(2-methoxyethyl)amino] -3-nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N- [(4- {[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol- 5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]amino} -3-nitrophenyl)sulfonyl]-2-( IH-indol- 4-yloxy)benzamide; -47- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-N-({ 4- [(2-hydroxy-l-tetrahydro-2H-pyran-4-yIethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-{[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-{[3-mtro-4-({l-[2-(lH-pyrazol-l-yl)ethyl]piperidin-4- yl} amino)phenyl]sulfonyl }benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-2-( IH- indol-4-yloxy)-N-( {3-nitro-4-[(tetnJiydro-2H-pyran-4- ylmethyl)aniino]phenyl} sulfonyl)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N- {[4-(methylamino)-3-nitrophenyl]sulfonyl} benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin- l-yl)-2-( IH- indol-4-yloxy)-N-{[4-(methylamino)-3-nitroplienyl]sulfonyl}benzamide; 4.{4.[l-(4'.chloro-l,l'-biphenyl-2-yl)ethyl]piperazin-l-yl}-2-(lH-indol-4-yloxy)-N-({4-[(3- moipholin-4-ylpropyl)aniino]-3-nitrophenyl}sulfonyI)benzamide; 4-(4- {[2-(4-chlorophenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-({3-mtro-4-[(tetrahydro-2H-pyran-4- ylmethyI)amino]pheayl)sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-5-morpholin-4-ylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2- (lH-indol-5-yloxy)-N-(l3-nitio-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl) sulfonyl)benzamide; N-[(4- {[(l-aininocyclohexyl)methyl]amino} -3-nitrophenyl)sulfonyl]-4-(4- {[2-(4- chlorophenyl)-4,4-dimethyIcyclohex-1 -en-1 -yljmethyl jpiperazin-1 -yl)-2-( 1 H-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indoI-5-yloxy)-N-[(3-nitro-4-{[2-(2-oxopyiTolidin-l- yl)ethyI]amino}phenyl)sulfonyl]benzamide; 4-{4-[l-(4'-chloro-l,l'-biphenyl-2-yl)ethyl]piperazin-l-yl}-2-(lH-indol-5-yloxy)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4-{l-[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]ethyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethy l)amino]pheny 1} sulfonyl)benzamide; 4-(4- {1 -[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl }piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; -48- 4- {4-[( 1R)-1 -(4'-chloro-1,1 '-biphenyl-2-yl)ethyl]piperazin- 1-yl} -2-( 1 H-indol-4-yloxy)-N- ({3-nitio-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide; 4.{4.[(lS)-l-(4'-chloro-l,l'-biphenyl-2-yl)ethyl]piperazin-l-yl]-2-(lH-indol-4-yloxy)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {1 -[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl }piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(3-inorpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {1 -[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl }piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)anaino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N-( {4- [(cyclohexylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-{[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl}benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({3-nitK)-4-[(tetrahydro-2H-pyran-3- ylmethyl)aniino]phenyl}suIfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-{[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl}benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl)piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-{[3-mtro-4-(tetrahydro-2H-pyran-4-ylamino)phenyl]sulfonyl}benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(4- {[(3-methyloxetan-3-yl)methyl]aniino) -3- nitrophenyI)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({4-[(4-methoxycyclohexyI)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl Ipiperazin- l-yl)-N-[(4- {[3-(l,l-dioxidothiomorpholin-4-yI)propyl]amino)-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(3-nitro-4- {[2-(2-oxopiperidin-1- yl)ethyl]ammo}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-[(3-nitro-4- {[2-(2-oxoimidazolidin-1- yl)ethyl]amino}phenyl)sulfonyl]benzamide; -49- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl) piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-({3-nitio-4-[(2-pyridin-4-ylethyl)amino]phenyl)sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(4-morpholin-4-yl-3-nitiophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-diinethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-{[4-(4-methoxypiperidin-l-yl)-3-nitrophenyl]sulfonyl}benzamide; 4-(4- {[2-(4-chlorophenyl)-5-pyrrolidin-1 -ylcyclohex- 1-en-l -yl]n)ethyl )piperazin-1 -yl)-2- (lH-indo]-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1) sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-l -yl]methyl} piperazin-1 -yl)-2-( IH- indoI-5-yIoxy)-N-[(3-nitro-4- {[2-(3-oxopiperazin-1 - yl)ethyl]amino}phenyl)sulfonyl]benzamide; 4-[4-({4'-chloro-4-[2-(dimethylamino)ethoxy]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-2- (lH-indol-4-yloxy)-N-({4-[(4-methylpiperazin-l-yl)anuno]-3- niliophenyl}sulfonyl)benzanude; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[(l,l-dioxidotetrahydrothien-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzanude; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl Jpiperazin-1 -yl)-N-( {4- [(l,l-dioxidotetrahydrothien-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-l -yl]methyl) piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-{[4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3- (trifluoromethyl)phenyl]sulfonyl} benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin- l-yl)-N-( {4- [2- (1,3-dioxolan-2-yl)ethyl]-3-nitiophenyl} sulfonyl)-2-( 1 H-indol-5-yloxy)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl) piperazin-1 -yl)-2-( 1H- indol-5 -yloxy)-N- {[3-nitro-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl}benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-[(3-nitro-4- {[2-(3-oxopiperazin-1 - yl)ethyl]amino}phenyl)sulfonyI]benzamide; -50- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(l-methyl-5-oxopyrrolidin-3-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({4-[(l-methyl-6-oxopiperidin-3-yl)amino]-3- nitrophenyl} sulfonyl)benzainide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( IH- indol-4-yloxy)-N-{[3-mtn)-4-(piperidin-l-y]amino)phenyl]sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indoI-5-yIoxy)-N- {[3-nitio-4-(piperidin-1 -ylamino)phenyI]suIfonyl jbenzamide; 4-(4- {[4-(4-chlorophenyl)-1-methyl-1 H-pyrazol-5-yl]methyl }piperazin-1 -yl)-2-( lH-indol-5- yloxy)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(3-methyloxetan-3-yl)methoxy]-3-nitiDphenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5 -yloxy)-N-[(3-nitro-4- {[(1 -oxidotetrahydiD-2H-thiopyran-4- y])methy]]anuno}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]metiiyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({3-nitio-4-[(l,3-thiazol-5-ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-2-( IH- indol-4-yloxy)-N- {[3-nitro-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl)benzanude; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({3-nitio-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethyIcyclohex- 1-en- l-yl]methyl}piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-( {3-nitro-4-[(2-tettahydro-2H-pyran-4- ylethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-[(3-nitro-4- {[2-(trifluoromethoxy)ethyl]amino }phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-[(4-{[2-(2-methoxyethoxy)ethyl]amino}-3- nitrophenyl)sulfonyl]benzamide; -51- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl) piperazin- l-yl)-2-( 1H-indol-4-yloxy)-N-[(4- {[3-(methylsulfonyl)propyl]amino) -3-nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl Ipiperazin- l-yl)-N-[(4-{ [3 -(1,1 -dioxidothiomoipholin-4-yl)propyl]amino} -3 -nitrophenyl)sulfony 1] -2-( 1 H-indol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-{[3-nitio-4-(2-tetrahydro-2H-pyran-4-ylethyl)phenyl]su]fonyl)ben2amide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl )piperazin- l-yl)-N- {[4-(l,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl )piperazin- l-yl)-2-( IH-indol-5-yloxy)-N-[(4- {[2-(2-methoxyethoxy)ethyl]amino) -3-nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({4-[(1,1 -dioxidotetrahydrothien-3 -yl)amino]-3-nitrophenyl} sulfonyl)-2-( 1 H-indol-4-yloxy)benzaniide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5-yloxy)-N-[(3-nitro-4- {[2-(trifluoromethoxy)ethyl]amino }phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin- l-y])-N-[(4-{[(1,1 -dioxidotetrahydro-2H-thiopyran-4-yl)methyl]amino} -3-nitrophenyl)sulfonyl]-2-( 1H-indol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N-( {4-[(2,2-difluoroethyl)aniino]-3-nitrophenyl) sulfonyl)-2-( lH-indol-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]metliyl)piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-( {4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5-yloxy)-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3-[(trifluoromethy])sulfonyl]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl Jpiperazin-1 -yl)-N-( {4-[(4,4-difluorocyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indoI-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N-( {4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-indol-4-yloxy)benzamide; -52- 4-(4- {[4-(4-chlorophenyl)- l-isopropy]-6-oxo-l ,6-dihydropyridin-3-yl]methyl )piperazin-1 - yl)-2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4-{ [2-(4-ch]oropheny])-4,4-dimethylcyclohex-1 -en- l-yl]methyl jpiperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-[(4- {[(tetrahydro-2H-pyran-4- ylmethyl)amino]carbonyl}phenyl)sulfonyl]benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcycIohex- 1-en- l-yl]methyl Jpiperazin- l-yl)-2-(lH- indol-4-yloxy)-N-({4-[(2-methoxyethyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-N-[(4- {[(4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl) piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3- nitrophenyl)suIfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[(4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chloroplienyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N- {[3-nitio-4-(2-tetrahydro-2H-pyran-4- ylethoxy)phenyl]sulfonyl}benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-({4-[(2-methoxyethyl)aniino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-( {4- [3-(methylsulfonyl)propoxy] -3-nitrophenyl} sulfonyl)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-({4-[(3-methoxypropyl)amino]-3-nitrophenyl}suIfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indoI-4-yloxy)-N-({4-[(3-methoxypropyl)amino]-3-nitrophenyl}sulfonyl)benzamide; -53- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(2-cyanoethyl)amiiio]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N-( {4- f (2-cyanoethyl)aniino]-3-nitK)phenyl) sulfonyl)-2-( 1 H-indol-4-yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl )piperazin-l-yl)-N- {[4- ({[(3R)-4-hydroxy-l-adamantyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N- {[4- ({[Cis-4-hydroxy-1 -adamantyl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-( 1 H-indol-5- yloxy)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indoI-4-yloxy)-N-({3-nitio-4-[(3,3.3-trifluoropropyl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-({3-nitro-4-[(3,3,3-trifluoropropyl)amino]phenyl)sulfonyl)benzamide; N-( {5 -bromo-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl) sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( 1 H-indol-4- yloxy)benzaniide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[(1,1 -dioxidotetrahydrothien-3-yl)methyl]amino} -3 -nitrophenyl)sulfonyl] -2-( 1 H-indol-4- yloxy)benzamide; 4-(4- {[2-(4-cWorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzanude; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({4-(methylamino)-3- [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; N-{[5-bromo-6-(tetrahydio-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-{[4-(4-chlorophenyl)-6-isopiopoxypyridin-3-yl]methyl)piperazin-l-yl)-2-(lH-indol-5- yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)anaino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl Ipiperazin- l-yl)-2-( IH- indo]-5-yloxy)-N- {[6-(tetrahydro-2H-pyran-4-ylmethoxy)-5-( 1,3-thiazol-2-yI)pyridin-3- yl]sulfonyl}benzamide; -54- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(4-{[(2-methoxyethyl)amino]cait)onyl}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-{[5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-indol-5- yloxy)benzamide; N-( {4-[( 1 -acetylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)- 4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(4- {[ l-(methylsulfonyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(l,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5-yloxy)benzamide; N-({4-[(l-acetylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( IH- indol-4-yloxy)-N-[(4- {[ l-(methylsulfonyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[4'-chloro-5-(trifluoromethyl)-1,1 '-biphenyl-2-yl]methyl} piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)aniino]phenyl} sulfonyl)benzamide; 4-(4- {[4'-cMoro-5-(trifluoromethyl)-1,1 '-biphenyl-2-yl]methyl} piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-{[3-nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}benzamide; 4- {4- [(5-tert-butyl-4'-chloio-1, r-biphenyl-2-yl)metliyl]piperazin-1 -yl} -2-( 1 H-indol-5-yloxy)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide; 4- {4-[(5-tert-butyl-4'-chloro-1, r-biphenyl-2-yl)methyl]piperazin-l -yl) -2-( lH-indol-5-yloxy)- N-{[3-nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-({3-nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({3-nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(3- {[(tetrahydro-2H-pyran-4- ylmethyl)amino]caibonyl}phenyl)sulfonyl]benzamide; -55- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-N-( {4- [(2R)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [(2S)-1,4-dioxan-2-ylmethoxy ]-3-nitrophenyl} sulfonyl)-2-( lH-indol-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({4-[(3-nioipholin-4-ylpropyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethy]cyclohex-1 -en-1 -yljmethyl jpiperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; N-({5-bromo-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl)sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-2-( 1 H-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({4-[(2-moipholin-4-ylethyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin- l-yl)-N-( {5- cyano-6- [(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl} sulfonyl)-2-( 1 H-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({4-[(l-methylpiperidin-4-ylX>xy]-3-nitrophenyl)sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)methoxy]-3-nitiophenyl}sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-l-(3-hydioxypropyl)-l,2,5,6-tetrahydropyridin-3- yl]methyl} piperazin-1 -yl)-2-( lH-indol-4-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; benzyl 4-({ [4-( {[4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 - yl]methyl}piperazin-l-yl)-2-(lH-indol-5-yloxy)benzoyl]amino}sulfonyl)-2- nitrophenyl]amino) methyl)piperidine-1 -carboxylate; N- {[3-(aminocarbonyl)-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl} -4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( 1 H-indol-5- yloxy)benzamide; -56- 4-(4- {[4'-chloro-5-(trifluoromethyl)-1,1 '-biphenyl-2-yl]methyl) piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-( {3-nitro-4-[( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)anuno]phenyl) sulfonyl)benzamide; 4-{4-[(5-tert-butyl-4'-chloro-l,r-biphenyl-2-yl)methyl]piperazm-l-yl}-2-(lH-indol-5-yloxy)- N-( {3 -nitro-4-[( 1 -tetrahydio-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(4-{[(l-methyl-lH-imidazol-5-yl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-l -yl]methyl )piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-{[4-(morpholin-4-ylsulfonyl)phenyl]sulfonyl}benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N-( {4- [(l,l-dioxidothiomorpholin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-l -yl]methyl) piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; N- {[5-bromo-6-(tetrahydro-2H-pyran-4-y]methoxy)pyridin-3-yl]sulfonyl} -4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-4- yloxy)benzanude; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -yl)-2-( IH- indol-4-yloxy)-N-{[6-[(tetrahydio-2H-pyran-4-ylmethyl)amino]-5-(l,3-thiazol-2-yl)pyridin- 3-yl]sulfonyl }benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({3- cyano-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl) sulfonyl)-2-( 1 H-indol-4- yloxy)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin- l-yl)-N-({ 3- cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin- l-yl)-N-( {4- [(3,3-dimethylbutyl)amino]-3-nittophenyl}sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4- {[2-(4-clilorophenyl)-4,4-dimethylcyclohex- 1-en-l -yl]methyl )piperazin-1 -yl)-N- [(4- {[(lS)-l-(hydroxymethyl)-3-methylbutyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; -57- 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(3-nitro-4-{[(2R)-tetrahydrofuran-2- ylmethyl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl Jmethyl} piperazin- l-yl)-N- [(4- {[(IR)-1 -(hydroxymethyl)-2-methylpropyl]ammo} -3-nitrophenyl)sulfonyl]-2-( lH-indol-5- yloxy)benzamide; 4-(4-{[2-(4-cMorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({4-[(4-methoxyphenyl)amino]-3-nitrophenyl}sulfonyl)benzamide; N-[(4-{[2-(l,3-benzodioxol-5-yl)ethyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin-1 -yl)-2-( lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-[(3-nitro-4-{[3-(2-oxopyrrolidin-l- yl)propyl]amino}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4- [(4-hydroxyphenyl)amino]-3-nitrophenyl} sulfonyl)-2-( lH-indol-5-yloxy)benzamide; N-{[4-({2-[4-(aminosulfonyl)phenyl]ethyl}amino)-3-nitrophenyl]sulfonyl}-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-[(4- {[3-(lH-imidazol-l-yl)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzaniide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(3-nitro-4-{[(lS)-l-phenylethyl]amino}phenyl)sulfonyl]benzamide; N-({2-chloiD-5-fluoro-4-[(tetrahydio-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl jpiperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(4-{[2-(2-methoxyethoxy)ethyl]thio}-3-nitiophenyl)sulfonyl]benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl} piperazin- l-yl)-2-( IH- indol-4-yloxy)-N-[(4-{[2-(2-methoxyethoxy)ethyl]thio}-3-nitiophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N- {[4-(methylsulfonyl)phenyl]sulfonyl} benzamide; -58- 4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex- 1-en- l-yljmethyl )piperazin- l-yl)-2-( IH- indol-4-yloxy)-N- {[4-(methylsulfonyl)phenyl]sulfonyl }benzamide; 4.(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [(2,2-dimethyltetrahydro-2H-pyran-4-yl)methoxy ]-3-nitrophenyl} sulfonyl)-2-( lH-indol-5- yloxy)benzaniide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({5- cyano-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl} piperazin-l-yl)-N- {[5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl} -2-( lH-indol-4- yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl )piperazin- l-yl)-N- {[5- chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl} -2-( 1 H-indol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-N- {[5- cyano-6-(2-moipholin-4-ylethoxy)pyridin-3-yl]sulfonyl} -2-( lH-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chloropheny])-4,4-dimethylcyclohex-1 -en-1 -yljmethyl jpiperazin-1 -y])-2-( IH- indol-5-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)oxy]phenyl)sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({4-[(4-morpholin-4-ylbut-2-ynyl)oxy]-3-nitiophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlcffophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl}piperazin- l-yl)-N- {[5- ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-indol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N- {[5- cyano-6-(2-moipholin-4-ylethoxy)pyridin-3-y]]sulfonyl}-2-(lH-indol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimetiiylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {5- cyano-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-indol-4- yloxy)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl) piperazin- l-yl)-N-( {4- [(3-hydroxy-4-methoxyphenyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzaniide; -59- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin-1 -yl)-2-(2,3- dihydro-lH-indol-4-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-({ 4- [(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(pyridm-3-ylamino)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yI]methyl}piperazin-l-yl)-N-({3- nitro-4-[( l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)-2-(pyridin-3- ylamino)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({3- nitro-4-[( l-tetxahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)-2-(pyridin-3- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-( 1,2,3,4- tetrahydroisoquinolin-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indazol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indazol-4-yloxy)-N-( {3-nitro-4-[(l -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)anuno]phenyl) sulfonyl)benzamide; Trans-4-(4- {[2-(4-cMorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2- (lH-indazol-4-yloxy)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-( lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)anuno]phenyl)sulfonyl)benzamide; N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl ]methyl }piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide; N-( {5-chloro-6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin- l-yl)-2-( lH-indol-4- yloxy)benzamide; -60- 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({5- cyano-6-[(4-fluoiotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-indazol- 4-yloxy)benzamide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chloiopheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(3R)-l-(2,2-difluoroethyl)pyrrolidiii-3-yl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-(l H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N- [(4- {[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indazol- 4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N- {[6- [(4-fluoiotetrahydro-2H-pyran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2- (lH-mdazol-4-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimetiiylcyclohex-l-en-l-yl]methyl)piperazm-l-yl)-N-[(4- {[(4-cycloprc)pylmoipholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indazol-4- yloxy)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]niethyl} piperazin-1 -yl)-N-[(4- {[(4,4-difluorocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indazol-4- yloxy)benzamide; N-[(5-chloro-6-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino)pyTidin-3-yl)sulfonyl]-4- (4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide; Trans-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide; 2-( lH-benziinidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl Jpiperazin- l-yl)-N- {[4-( {[4-(2,2-difluoroethyl)morpholin-2-yl]methyl} ainino)-3- nitrophenyl]sulfonyl jbenzaniide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({5- fluon)-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-indazol- 4-yloxy)benzaniide; -61- 2-(l H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyI}piperazin-l-yl)-N-({3-nitro-4-[(l-tetxahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl Jpiperazin- l-yl)-N-({4-[( l-methylpiperidin-4-yl)amino]-3- nitrophenyl)sulfonyl)benzamide; N-[(5-chloro-6-{[l-(cyanomethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- ([2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(l H- indazol-4-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[5- chloro-6-(tetrahydrofuran-3-ylmethoxy)pyridin-3-yl]sulfonyl)-2-(lH-indazol-4- yloxy)benzamide; Trans-N-({5-chloro-6-[(4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzamide; N-[(5-chloro-6-{[(3R)-l-(2,2-difluoioethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol- 4-yloxy)benzamide; 2-( lH-benzimidazol-4-yloxy)-N-[(5-chloro-6- {[(2S)-4-(N,N-dimethylglycyl)morpholin-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)benzaniide; 2-( lH-benzimidazol-4-yloxy)-N-[(5-ch]oro-6- {[(2R)-4-(N,N-dimethylglycyl)morpholin-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl Ipiperazin- l-yl)benzamide; N- [(5-chloro-6- {[(2S)-4-(N,N-dimethylglycyl)moipholm-2-yl]methoxy} pyridin-3 - yl)sulfonyl]-4-(4- {[2-(4-chloiophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yljmethyl jpiperazin-1 - yl)-2-(lH-indazol-4-yloxy)benzanude; N-[(5-chloro-6-{[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl]methyl} piperazin-1 - yl)-2-(lH-indazol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl jpiperazin- l-yl)-N- {[5- chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl)-2-(lH-indazol-4- yloxy)benzaniide; -62- 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(3R)-l-(cyanomethyl)pyiTolidin-3-yl]amino}-3- mtrophenyl)sulfonyl]benzamide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl }piperazin- l-yl)-N- {[4-( {(3R)- l-[2-(2-methoxyethoxy)ethyl]pyrrolidin-3- yl}amino)-3-nitrophenyl]sulfonyl}benzamide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- [(4- {[(3R)-1 -(N,N-dimethy lglycyl)pyrrolidin-3-yl]amino} -3- nitrophenyl)sulfonyl]benzamide; 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N- {[4-( {[4-(cyanoniethyl)morpholin-2-yl]methyl) aniino)-3 - nitrophenyl]sulfonyl}benzamide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]naethyl}piperazin-l-yl)-N-[(4-{[(4-cyclopropylmorpholin-2-yl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-(l H-benzinudazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- [(3-nitro-4- {[(4-oxetan-3-ylmorpholin-2- yl)methyl]amino)phenyl)sulfonyl]benzamide; N-{[5-chloro-6-({(3R)-l-[2-fluoro-l-(fluoromethyl)ethyl]pyrrolidin-3-yl}oxy)pyridin-3- yljsulfonyl} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 - yl)-2-(lH-indazol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N- {[4- ({(3R)-l-[2-fluoro-l-(fluoiomethyl)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2- (1 H-indazol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperaztn- l-yl)-N-( {4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)-2-( lH-indazol-4- yloxy)benzamide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- {[4-( {[(2R)-4-(N,N-dimethylglycyl)morpholin-2- yl]methyl}amino)-3-nitrophenyl]sulfonyl}benzamide; 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-{[4-({[(2S)-4-(N,N-dimethylglycyl)morpholin-2- yl]methyl} amino)-3-nitrophenyl]sulfonyl} benzamide; -63- 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorGphenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4- [(tetrahydrofuran-3- ylmethyl)amino]pheny 1) sulfonyl)benzamide; Trans-2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}-3- nitiophenyl)sulfonyl]benzamide; 2-( 1 H-benzinudazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({5-fluoro-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl}sulfonyl)benzamide; 2-( 1 H-benzimidazol-4-yloxy)-N-( {5-chloro-6- [(4-fluorotetrahydro-2H-pyran-4- yl)methoxy ]pyridin-3 -yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)benzannide; N-{[5-chloro-6-({(3R)-l-[2-fluoro-l-(fluoromethyl)ethyl]pyiTolidin-3-yl}methoxy)pyridin-3- yl]sulfonyl} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl]methyl jpiperazin-1 - yl)-2-(lH-indazoI-4-yloxy)benzamide; N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( IH- indazol-4-yloxy)benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2- (lH-indazol-4-yloxy)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[4- (l,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}-2-(lH-indazol-4-yloxy)benzamide; N-( {5 -chloro-6- [(1 -cyclopropylpiperidin-4-yl)amino]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzainide; 2-(lH-benziinidazol-4-yloxy)-N-({5-chloro-6-[(l-cyclopropylpiperidin-4-yl)amino]pyridin- 3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)benzamide; -64- 2-( 1 H-benzimidazol-4-yloxy)-4'(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l,4-dioxan-2-ylmethyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-(lH-benzimidazol-4-yloxy)-4'(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl Ipiperazin- l-yl)-N-( {4-[( l-cyclopropylpiperidin-4-yl)amino]-3- nitrophenyl}sulfonyl)benzamid6; Trans-2-( 1 H-benzimidazol-4-ylOxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 - yllmethyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-ylcyclohexyl)aminol-3- nitropheny 1} sulfonyl)benzamid6; 2-(lH-benzimidazol-4-yloxy)-4'(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex- 1-en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamid6; 2-( 1 H-benzitnidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- [(4- {[(1 -methylpiperidin-4-yl)methyl]amino} -3- nitrophenyl)sulfonyl]benzamide; 2-(l H-benzimidazol-4-yloxy)-4'(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[({(2R)-4-[2-(2-methoxyethoxy)ethyl]morpholin-2- yl) methyl)amino]-3-nitrophenyl} sulfonyl)benzamide; 2-(l H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyI)-4,4-dimethy Icyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(4,4-difluorocyclohexyl)methyl]amino}-3- mtrophenyl)sulfonyl]benzamide; N-[(4- {[(4-acetylmorpholin-2-yl)methyl]amino} -3-mtrophenyl)sulfonyl]-2-( IH- benzin)idazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 - yljmethyl }piperazin- l-yl)benzamide; 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl) piperazin- l-yl)-N- {[4-( {[4-(methylsulfonyl)moipholin-2-yl]methyl} amino)-3- nitiophenyl]sulfonyl }benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[6- ({4-fluoro-1 -[2-fluoro-1 -(fluoromethyl)ethyl]piperidin-4-yl} methoxy)-5- (trifluoiomethyl)pyridin-3-yl]sulfonyl}-2-(lH-indazol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin- l-yl)-N-( {3- nitio-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxybenzaniide; -65- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl ]methyl} piperazin-1 -yI)-N- {[5 - ch]oro-6-(2-tetrahydrofuran-2-ylethoxy)pyridin-3-yl]sulfonyI)-2-(lH-indazol-4- yIoxy)benzamide; Trans-2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(4-cyanocyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-(lH-benzimidazol-4-yloxy)-N-({5-ch]oro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl Jpiperazin-1- yl)benzamide; N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 -yl]methyl )piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzaniide; N-({5-chloio-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2- (lH-indazol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-AA- {[5 - cyano-6-(2-tetxahydro-2H-pyran-4-ylethoxy)pyridin-3-yl]sulfonyI}-2-(lH-indazol-4- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(4-{[(lR,5S)-8-methyl-8-azabicyclo[3.2. l]oct-3-yl]amino}-3- nitiophenyl)sulfonyl]benzamide; N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-2-phenoxy-4-(4- {(3-phenylpiDpanoyl)[(lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3- yl] amino} piperidin-1 -yl)benzamide; N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-phenoxy-4-(4-{(3- phenylpTOpanoyl)[(lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}piperidin-l- yl)benzamide; N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmetiiyl)amino]phenyl}sulfonyl)-2-phenoxy-4-(4- {(3-phenylpiopyl)[( 1 S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1 ]hept-3-yl]amino Jpiperidin-1 - yl)benzaniide; N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl)sulfonyl)-2-phenoxy-4-(4-{(3- phenylpropyl)[(lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}piperidin-l- yl)benzamide; -66- 4-[4-(2- {[(1 R,5S)-8-methyl-8-azabicyclo[3.2.1 ]oct-3-yl]amino} benzyl)piperazin-1 -yl]-N- ({4-[(3-morpholin-4-yIpropyl)amino]-3-nitrophenyl}sulfonyl)-2-phenoxybenzamide; 4-[4-(2-{[(lR,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}benzyl)piperazin-l-yl]-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxybenzamide; 4-{4-I2-(3-azabicyclo[3.2.2]non-3-yl)benzyl]piperazm-l-yl}-N-({3-nitro-4-[(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl} suIfonyl)-2-phenoxybenzamide; 4-{4-[2-(3-azabicyclo[3.2.2]non-3-yl)benzyl]piperazin-l-yl}-2-phenoxy-N-({4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide; 4-{4-[2-(3-azabicyclo[3.2.2]non-3-yl)benzyl]piperazin-l-yl}-2-phenoxy-N-({4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzaraide; 4- {4- [2-(3-azabicyclo[3.2.2]non-3 -yl)benzyl]piperazin-1 -yl} -N-( {4-[(3 -morpholin-4- ylpropyl)amino]-3-nitrophenyl} sulfonyl)-2-phenoxybenzaniide; 4-(4-{2-[(4R,7S)-2,3,3a,4,7,7a-hexahydro-lH-4,7-methanoinden-5-yl]benzyl Ipiperazin-1- yl)-N-({3-nitro-4-[(tetrahydio-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2- phenoxybenzamide; 4-[4-(2-{5-[(lR,5S)-8-azabicyclo[3.2.1]oct-8-ylmethyl]thien-2-yl}benzyl)piperazin-l-yl]-N- ({3-nitio-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxybenzamide; 4- [4-(2- {5-[( lR,5S)-8-azabicyclo[3.2.1 ]oct-8-ylmethyl]thien-2-yl }benzylidene)piperidin-1- yl]-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2- phenoxybenzamide; 4-[4-(3-{5-[(lR,5S)-8-azabicyclo[3.2.1]oct-8-ylmethyl]thien-2-yl)benzyl)piperazin-l-yl]-N- ({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-phenoxybenzamide; N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl }sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzamide; N-( {6-[(trans-4-caibamoylcyclohexyl)methoxy]-5-chloropyridin-3-yl) sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- [(4- {[(trans-4-cyanocyclohexyl)methyl]amino}-3-nitiophenyl)sulfonyl]-2-(lH-indazol-4- yloxy)benzamide; N-({5-chloio-6-[2-(lH-imidazol-l-yl)ethoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzaniide; -67- N-( {5 -chloro-6- [(1 -methyl-1 H-imidazol-5-yl)methoxy ]pyridin-3 -yl} sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]melhyl}piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[5- fluoro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl)-2-(lH-indazol-4- yloxy)benzamide; N- {[5-chloro-6-( 1,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl} -4-(4- {[2-(4-chlorophenyl)- 4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-mdazol-4-yloxy)benzamide; N-( {5-chloro-6- [(4,4-difluoio-1 -hydroxycyclohexy l)methoxy ]pyridin-3-yl} sulfony l)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide; N-({5-chloro-6-[(2,2-difluorocyclopropyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzamide; N-( {5-chloro-6- [(trans-4-cyanocyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzaniide; N-( {5-chloro-6-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl) sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide; N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide; N-({3-cMoro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[4-(4- chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2-(lH- indazol-4-yloxy)benzaraide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin- l-yl)-N-({ 4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(lH- indazol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N- {[3- chloro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-indazol-4- yloxy)benzamide; -68- 2-(lH-benzimidazol-4-yloxy)-N-({3-chloro-4-[(4-fluorotelTahydro-2H-pyran-4- yl)methoxy]phenyl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl }piperazin- l-yl)benzamide; 2-( 1 H-benziinidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl }piperazin- l-yl)-N- {[5-chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3- yl]sulfonyl} benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin- l-yl)-N-( {3- cyano-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-indazol-4- yloxy)benzaniide; N-{[3-chloro-4-(l,4-dioxan-2-ylmethoxy)phenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-2-( lH-indazol-4-yloxy)benzamide; 2-( 1 H-benzimidazol-4-yloxy)-N-[(5-chloro-6- {[(2S)-4-cyclopropylmorpholin-2- yl]methoxy)pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yljmethyl} piperazin-1 -yl)benzamide; N-[(5-chloro-6-{[(2S)-4-cyclopropylmorpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-l-yl]methyl }piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide; methyl 2- {[(4- {[4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-2-(lH-indazol-4-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl} morpholine-4-carboxylate; 2- {[(4- {[4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- 1-yl)- 2-( 1 H-indazol-4-yloxy)benzoyl]sulfamoyl} -2-nitrophenyl)amino]methyl) -N-ethyl-N- methylmorpholine-4-carboxamide; 2- {[(4- {[2-(l H-benzimidazoM-yloxy )-4-(4- {[2-(4-chlorophenyl)-4,4-dimethyIcyclohex-1 - en-1 -yl]methyl} piperazin- l-yl)benzoyllsulfamoyl} -2-nitiophenyl)amino]methyl} -N-ethyl-N- methylmorpholine-4-caiboxamide; N-({5-chloro-6-[(trans-4-ethyl-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-l-yl]methyl }piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide; N-({5-chloto-6-[(cis-4-ethyl-4-hydTOxycyclohexyl)methoxy]pyridin-3-yl)sulfonyl)-4-(4-([2- (4-chloiophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide; -69- 5-chloro-N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl jpiperazin-1- yl)-2-( lH-indazol-4-yloxy)benzamid e; 5-chloro-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)- N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)niethyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- indazol-4-yloxy)benzamide; N-((5-chloro-6-[(cis-l-fluoio-4-hydroxy-4-methylcyclohexyl)methoxylpyridin-3- yl) sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcy clohex-1 -en-1 -yl]methyl }piperazin-1 - yl)-2-(lH-indazol-4-yloxy)benzamide; N-({5-chloro-6-[(trans-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- {[2-(4-chIorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 - yl)-2-( 1 H-indazol-4-yloxy)benzamide; 2-( 1 H-benzotriazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]niethyl} piperazin- l-yl)-N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]aniino }-3- mtrophenyl)sulfonyl]benzamide; 2-( 1 H-benzotriazol-4-yloxy)-N-( {5 -chloro-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)benzamide; 2-( 1 H-benziniidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- {[3-chloro-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl}benzamide; N-[(3-chloro-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( lH-indazol-4- yloxy)benzainide; N-( {5-chloro-6- [(cis-1 -fluoro-4-hydroxycyclohexyl)methoxy]pyridin-3-yl) sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indazol- 4-yloxy)benzamide; 2-( 1 H-benzotriazol-4-yloxy)-4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl)sulfonyl)benzamide; N-[(5-chloro-6- {[(lR,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2. l]hept-2- yljmethoxy }pyridin-3-yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-2-(lH-indazol-4-yloxy)benzamide; -70- N-({5-chloio-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-5,5-difluorocyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol- 4-yloxy)benzaniide; N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy)pyridin-3-yl)sulfonyl]-4- (4-{[2-(4-chlorophenyl)-5,5-difluorocyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indazol-4-yloxy)benzaniide; 2-( 1 H-benzotriazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl) piperazin-1 -yl)-N-({ 3-nitro-4- [(tetTahydro-2H-pyran-4- ylmethyl)amino]phenyl) sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-5,5-difluorocyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indazol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[(traDS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- indazol-4-yloxy)benzaniide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazm-l-yl)-N-[(4- {[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nittophenyl)sulfonyl]-2-(lH-mdazol- 4-yloxy)benzamide; 2-( 1 H-benzotriazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin- l-yl)-N- {[4-( {[(2S)-4-cyclopropylmorpholin-2-yl]methyl) amino)-3- nitiophenyl]sulfonyl }benzamide; N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy)pyridin-3-yl)sulfonyl]-4- (4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl )piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N- {[4- ({[(2S)-4-cyclopropylmorpholin-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(lH-indazol- 4-yloxy)benzamide; 2-( lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-{[4-({[(2S)-4-cyclopropylmorpholin-2-yl]methyl}aniino)-3- nitrophenyl]sulfonyl}benzamide; N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-5,5-difluorocyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol- 4-yloxy)benzaniide; -71- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N-( {4- [(cis-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-indazol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N-( {4- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-indazol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimetiiylcyclohex-1 -en-1 -yl]metiiyl} piperazin- l-yl)-N- [(3 - cyano-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-2-(lH-indazol- 4-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]metiiyl}piperazin-l-yl)-2-(lH- indazol-4-yloxy)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7- ylmethoxy)phenyl]sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- {[5- chloro-6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyridin-6-ylmethoxy)pyridin-3-yl]sulfonyl}-2- (lH-indazol-4-yloxy)benzamide; 2-( 1 H-benzimidazol-4-yloxy)-N-( {5-chloro-6- [(trans-4-hydroxy-4- methylcyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -y l)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-[(5 - cyano-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(lH- indazol-4-yloxy)benzamide; N-( {5-chloro-6- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3 -yl) sulfonyl)-4-(4- {[2-(4-chlorophenyl)-5-(methoxymetliyl)-5-methylcycIohex-l-en-l-yl]methyl}piperazin-l- yl)-2-( lH-indazol-4-yloxy)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( 1H- indazol-4-yloxy)-N-{ [3-nitro-4-({ [(2S)-4-(oxetan-3-yl)morpholin-2- yl]methyl} amino)phenyl]sulfonyl }benzamide; 2-(lH-benziinidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-{[3-nitro-4-({[(2S)-4-(oxetan-3-yl)morpholin-2- yl]methyl}amino)phenyl]sulfonyl}benzamide; N-[(5-chloro-6-{[trans-4-(2-hydroxypropan-2-yl)cyclohexyl]methoxy}pyridin-3-yl)sulfonyl]- 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin- l-yl)-2-( 1H- indazol-4-yloxy)benzamide; -72- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N-( {3- cyano-4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-2-(lH-indazo]-4- yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl Ipiperazin- l-yl)-N-({ 5- cyano-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- indazol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-2-( 1H- indazol-4-yloxy)-N-({5-nitro-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3- yl) sulfonyl)benzamide; 2-(lH-benzotriazol-4-yloxy)-N-( {5 -chloro-6-[(trans-4-hydroxy-4- methylcyclohexyl)methoxy ]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -y l)benzamide; N-( {3-chloro-4- [(cis-4-cy ano- l-fluorocyclohexyl)methoxy]phenyl) sulfonyl)-4-(4- {[2-(4- ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl jpiperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide; N-({3-chloro-4-[(trans-4-cyano-l-fluorocyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide; N-({5-chloro-6-[(cis-4-cyano-l-fluorocyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzamide; N-( {5-chloro-6- [(trans-4-cyano-1 -fluorocyclohexyl)methoxy ]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol- 4-yloxy)benzamide; N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]inethyl}piperazin-l-yl)-2- (lH-indazol-4-yloxy)benzamide; 2-( lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 - yljmethyl} piperazin-1 -yl)-N- [(4- {[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino} -3 - mtiophenyl)sulfonyl]benzamide; N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide; -73- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N-[(5- chloro-6- {[ l-( 1,3 -thiazol-2-yl)pipericIin-4-yl]methoxy} pyiidin-3 -yl)sulfony l]-2-( 1 H-indazol- 4-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-diniethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(6- {[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino} -5-nitropyridin-3-yl)sulfonyl]-2-(lH- inda2ol-4-yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N-({ 6- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)- 2- (1 H-indazol-4-yloxy )benzamide; 2-(l H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; N-(4- {[4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- (lH-indazol-4-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)-4-cyanopiperidine-l-carboxamide; and therapeutically acceptable salts, prodrugs, salts of prcxirugs and metabolites thereof. Another embodiment pertains to a composition for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer, said composition comprising an excipient and a therapeutically effective amount of the compound of Formula (I). Another embodiment pertains to a method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient a therapeutically effective amount of Formula (I). Another embodiment pertains to a method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular -74- lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient therapeutically effective amount of the compound of Formula (I) and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent. DETAILED DESCRIPTION OF THE INVENTION Variable moieties herein are represented by identifiers (capital letters with numerical and/or alphabetical superscripts) and may be specifically embodied. It is meant to be understood that proper valences are maintained for all moieties and combinations thereof, that monovalent moieties having more than one atom are drawn from left to right and are attached through their left ends, and that divalent moieties are also drawn from left to right. It is also meant to be understood that a specific embodiment of a variable moiety herein may be the same or different as another specific embodiment having the same identifier. The term "alkenyl" as used herein, means a straight or branched hydrocarbon chain containing from 2 to 10 carbons and containing at least one caibon-carbon double bond. The term "Cx-Cy alkyl" means a straight or branched hydrocarbon chain containing at least one carbon-caibon double bond containing x to y carbon atoms. The term "Cs-Ce alkenyl" means an alkenyl group containing 3-6 carbon atoms. Representative examples of alkenyl include, but are not limited to, buta-2,3-dienyl, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-l-heptenyl, and 3-decenyl. The term "alkenylene" means a divalent group derived from a straight or branched chain hydrocarbon of 2 to 4 carbon atoms and contains at least one carbon-caibon double bond. The term "Cx-Cy alkylene" means a divalent group derived from a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond and containing x to y carbon atoms. Representative examples of alkenylene include, but are not limited to, -CH=CH- and -CH2CH=CH-. The term "alkyl" as used herein, means a straight or branched, saturated hydrocarbon chain containing from 1 to 10 carbon atoms. The term "Cx-Cy alkyl" means a straight or branched chain, saturated hydrocarbon containing x to y carbon atoms. For example "Cj-Ce alkyl" means a straight or branched chain, saturated hydrocarbon containing 2 to 6 carbon -75- atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl. The term "alkylene" means a divalent group derived from a straight or branched, saturated hydrocarbon chain of 1 to 10 carbon atoms, for example, of 1 to 4 carbon atoms. The term "Cx-Cy alkylene" means a divalent group derived from a straight or branched chain, saturated hydrocarbon containing x to y carbon atoms. For example "C2-C6 alkylene" means a straight or branched chain, saturated hydrocarbon containing 2 to 6 carbon atoms. Representative examples of alkylene include, but are not limited to, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2-, and -CH2CH(CH3)CH2-. The term "alkynyl" as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. The term "Cx-Cy alkynyl" means a straight or branched chain hydrocarbon group containing from x to y carbon atoms. For example "C3-C6 alkynyl" means a straight or branched chain hydrocarbon group containing from 3 to 6 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited to, acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl. The term "alkynylene," as used herein, means a divalent radical derived from a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one caibon-carbon triple bond. The term "aryl" as used herein, means phenyl. The term "cyclic moiety," as used herein, means benzene, phenyl, phenylene, cycloalkane, cycloalkyl, cycloalkylene, cycloalkene, cycloalkenyl, cycloalkenylene, cycloalkyne, cycloalkynyl, cycloalkynylene, heteroarene, heteroaryl, heterocycloalkane, heterocycloalkyl, heterocycloalkene, heterocycloalkenyl and spiroalkyl. The term "cycloalkylene" or cycloalkyl" or "cycloalkane" as used herein, means a monocyclic or bridged hydrocarbon ring system. The monocyclic cycloalkyl is a carbocyclic ring system containing three to ten carbon atoms, zero heteroatoms and zero double bonds. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The monocyclic ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system. Representative examples of such bridged cycloalkyl ring systems include, but are not limited to, bicyclo[3.1.1]heptane, -76- bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.1]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, bicyclo[4.2.1]nonane, tricyclo[3.3.1.0^'^]nonane (octahydio-2,5-methanopentalene or noradamantane), and tricyclo[3.3.1.1^'^]decane (adamantane). The monocyclic and bridged cycloalkyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring system. The term "cycloalkenylene," or "cycloalkenyl" or "cycloalkene" as used herein, means a monocyclic or a bridged hydrocarbon ring system. The monocyclic cycloalkenyl has four to ten carbon atoms and zero heteroatoms. The four-membered ring systems have one double bond, the five-or six-membeied ring systems have one or two double bonds, the seven- or eight-membered ring systems have one, two, or three double bonds, and the nine- or ten-membered rings have one, two, three, or four double bonds. Representative examples of monocyclic cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. The monocyclic cycloalkenyl ring may contain one or two all^lene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system. Representative examples of the bridged cycloalkenyl groups include, but are not limited to, bicyclo[2.2.1]hept-2-ene, 4,5,6,7-tetrahydro-3aH-indene, octahydronaphthalenyl, and 1,6-dihydro-pentalene. The monocyclic and bridged cycloalkenyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring systems. The term "cycloalkyne," or "cycloalkynyl," or "cycloalkynylene," as used herein, means a monocyclic or a bridged hydrocarbon ring system. The monocyclic cycloalkynyl has eight or more carbon atoms, zero heteroatoms, and one or more triple bonds. The monocyclic cycloalkynyl ring may contain one or two alkylene bridges, each consisting of one, two, or three carbon atoms, each linking two non-adjacent carbon atoms of the ring system. The monocyclic and bridged cycloalkynyl can be attached to the parent molecular moiety through any substitutable atom contained within the ring systems. The term "heteroarene," or "heteroaryl," or "heteroarylene," as used herein, means a five-membered or six-membered aromatic ring having at least one carbon atom and one or more than one independently selected nitrogen, oxygen or sulfur atom. The heteroarenes of this invention are connected through any adjacent atoms in the ring, provided that proper valences are maintained. Representative examples of heteroaryl include, but are not limited to, furanyl (including, but not limited thereto, furan-2-yl), imidazolyl (including, but not limited thereto, lH-imidazol-1-yl), isoxazolyl, isothiazolyl, oxadiazolyl, 1,3-oxazolyl, pyridinyl (e.g. pyridin-4-yl, pyridin-2-yl, pyridin-3-yl), pyridazinyl, pyrimidinyl, pyrazinyl, -77- pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, 1,3-thiazolyl, thienyl (including, but not limited thereto, thien-2-yl, thien-3-yl), triazolyl, and triazinyl. The term "heterocycloalkane," or "heterocycloalkyl," or "heterocycloalkylene," as used herein, means monocyclic or bridged three-, four-, five-, six-, seven-, or eight-membered ring containing at least one heteroatom independently selected from the group consisting of O, N, and S and zero double bonds. The monocyclic and bridged heterocycloalkane are coimected to the parent molecular moiety through any substitutable carbon atom or any substitutable nitrogen atom contained within the rings. The nitrogen and sulfur heteroatoms in the heterocycle rings may optionally be oxidized and the nitrogen atoms may optionally be quartemized. Representative examples of heterocycloalkane groups include, but are not limited to, 8-azabicyclo[3.2.1]octane, 3-azabicyclo[3.2.2]nonane, morpholinyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, dioxolanyl, tetrahydrofuranyl, thiomorpholinyl, 1,4-dioxanyl, tetrahydrothienyl, tetrahydrothiopyranyl, oxetanyl, piperazinyl, imidazolidinyl, azetidine, azepanyl, aziridinyl, diazepanyl, dithiolanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, oxadiazolidinyl, oxazolidinyl, pyrazolidinyl, tetrahydrothienyl, thiadiazolidinyl, thiazolidinyl, thiomorpholinyl, trithianyl, and trithianyl. The term "heterocycloalkene," or "heterocycloalkenyl," or "heterocycloalkenylene," as used herein, means monocyclic or bridged three-, four-, five-, six-, seven-, or eight-membered ring containing at least one heteroatom independently selected Irom the group consisting of O, N, and S and one or more double bonds. The monocyclic and bridged heterocycloalkene are coimected to the parent molecular moiety through any substitutable carbon atom or any substitutable nitrogen atom contained within the rings. The nitrogen and sulfur heteroatoms in the heterocycle rings may optionally be oxidized and the nitrogen atoms may optionally be quartemized. Representative examples of heterocycloalkene groups include, but are not limited to, 1,4,5,6-tetrahydropyridazinyl, 1,2,3,6-tetrahydropyridinyl, dihydropyranyl, imidazolinyl, isothiazolinyl, oxadiazolinyl, isoxazolinyl, oxazolinyl, pyranyl, pyrazolinyl, pyrrolinyl, thiadiazolinyl, thiazolinyl, and thiopyranyl. The term "phenylene," as used herein, means a divalent radical formed by removal of a hydrogen atom from phenyl. The term "spiroalkyl," as used herein, means alkylene, both ends of which are attached to the same carbon atom and is exemplified by Cz-spiroalkyl, Cs-sptroalkyl, C4-spiToalkyl, Cs-spiroalkyl, Cfi-spiroalkyl, C7-spiroalkyl, Cg-spiroalkyl, C9-spiroalkyl and the like. -78- The temi "spiroheteroalkyl," as used herein, means spiroalkyl having one or two CH2 moieties replaced with independently selected 0, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N. The term "spiroheteroalkenyl," as used herein, means spiroalkenyl having one or two CH2 moieties replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N and also means spiroalkenyl having one or two CH2 moieties unreplaced or replaced with independently selected 0, C(0). CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties replaced with N. The term, "spirocyclo," as used herein, means two substituents on the same carbon atom, that, together with the carbon atom to which they are attached, form a cycloalkane, heterocycloalkane, cycloalkene, or heterocycloalkene ring. The term "C2-C5-spiroalkyl," as used herein, means Ca-spiroalkyl, Cs-spiroalkyl, C4-spixioalkyl, and Cs-spiroalkyl. The term "C2-spiioa]kyl," as used herein, means eth-l,2-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "Cs-spiroalkyl," as used herein, means prop-l,3-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "C4-spiroalkyl," as used herein, means but-l,4-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "Cs-spiroalkyl," as used herein, means pent-I,5-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "Ce-spiioalkyl," as used herein, means hex-l,6-ylene, both ends of which replace hydrogen atoms of the same CH2 moiety. The term "NH protecting group," as used herein, means trichloroethoxycarbonyl, tribromoethoxycarbonyl, benzyloxycaibonyl, para-nitrobenzylcarbonyl, ortho-bromobenzyloxycatbonyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, phenylacetyl, formyl, acetyl, benzoyl, tert-amyloxycarbonyl, tert-butoxycarbonyl, para-methoxybenzyloxycarbony 1,3,4-dimethoxybenzyl-oxycarbonyl, 4-(phenylazo)benzyloxycarbonyl, 2-furfuryl-oxycarbonyl, diphenylmethoxycarbonyl, 1,1-dimethylpropoxy-carbonyl, isopropoxycarbonyl, phthaloyl, succinyl, alanyl, leucyl, 1-adamantyloxycarbonyl, 8-quinolyloxycarbonyl, benzyl, diphenylmethyl, triphenylmethyl, 2-nitiophenylthio, methanesulfonyl, para-toluenesulfonyl, N,N-dimethylaminomethylene, benzylidene, 2-hydroxybenzylidene, 2-hydroxy-5-chlorobenzylidene, 2-hydroxy-l-naphtiiyl- -79- methylene, 3-hydroxy-4-pyridylmethylene, cyclohexylidene, 2-ethoxycarbonylcyclohexylidene, 2-ethoxycaibonylcyclopentylidene, 2-acetylcyclohexylidene, 3,3-dimethyl-5-oxycyclo-hexylidene, diphenylphosphoryl, dibenzylphosphoryl, 5-methyl-2-oxo-2H-l,3-dioxol-4-yl-methyl, trimethylsilyl, triethylsilyl, and triphenylsilyl. The term "C(0)OH protecting group," as used herein, means methyl, ethyl, n-propyl, isopropyl, 1,1-dimethylpropyl, n-butyl, tert-butyl, phenyl, naphthyl, benzyl, diphenylmethyl, triphenylmethyl, para-nitrobenzyl, para-methoxybenzyl, bis(para-methoxyphenyl)methyl, acetylmethyl, benzoylmethyl, para-nitrobenzoylmethyl, para-bromobenzoylmethyl, para-methanesulfonylbenzoylmethyl, 2-tetrahydropyranyl 2-tetrahydrofuranyl, 2,2,2-trichloro-ethyl, 2-(trimethylsilyl)ethyl, acetoxymethyl, propionyloxymethyl, pivaloyloxymethyl, phthalimidomethyl, succinimidomethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxymethyl, methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, benzyloxymethyl, methylthiomethyl, 2-methylthioethyl, phenylthiomethyl, l,l-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, trimelhylsilyl, triethylsilyl, triisopropylsilyl, diethylisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethylsilyl, and tert-butylmethoxyphenylsilyl. The term "OH or SH protecting group," as used herein, means benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, methoxycaibonyl, ethoxycarbonyl, tert-butoxycaibonyl, 1,1-dimethylpropoxycarbonyl, isopropoxycarbonyl, isobutyloxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-tribromoethoxycarbonyl, 2-(trimethylsilyl)ethoxycaibonyl, 2-(phenylsulfonyl)ethoxycart)onyl, 2-(triphenylphosphonio)ethoxycarbonyl, 2-furfuryloxycarbonyl, 1-adamantyIoxycarbonyl, vinyloxycarbonyl, allyloxycaibonyl, S-benzylthiocarbonyl, 4-ethoxy-l-naphthyloxycarbonyl, 8-quinolyloxycarbonyl, acetyl, formyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, pivaloyl, benzoyl, methyl, tert-butyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, l,l-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl (phenylmethyl), para-methoxybenzyl, 3,4-dimethoxybenzyl, diphenylmethyl, triphenylmethyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiopyranyl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloro-ethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, 1-ethoxyethyl, methanesulfonyl, para-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, diethylisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethylsilyl, and tert-butylmethoxyphenylsilyl. -80- Compounds Geometric isomers may exist in the present compounds. Compounds of this invention may contain carbon-carbon double bonds or carbon-nitrogen double bonds in the E or Z configuration, wherein the term "E" represents higher order substituents on opposite sides of the carbon-caibon or carbon-nitrogen double bond and the term "Z" represents higher order substituents on the same side of the carbon-carbon or carbon-nitrogen double bond as determined by the Cahn-Ingold-Prelog Priority Rules. The compounds of this invention may also exist as a mixture of "E" and "Z" isomers. Substituents around a cycloalkyl or heterocycloalkyl are designated as being of cis or trans configuration. Furthermore, the invention contemplates the various isomers and mixtures thereof resulting from the disposal of substituents around an adamantane ring system. Two substituents aroimd a single ring within an adamantane ring system are designated as being of Z or E relative configuration. For examples, see C. D. Jones, M. Kaselj, R. N. Salvatore, W. J. le Noble J. Org. Chem. 1998, 63, 2758-2760 and E. L. Eliel, and S.H. Wilen. (1994) Stereochemistry of Organic Compounds. New York, NY: John Wiley & Sons, Inc. Compounds of this invention contain asymmetrically substituted carbon atoms in the R or S configuration, in which the terms "R" and "S" are as defined by the lUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-10. Compounds having asymmetrically substituted carbon atoms with equal amounts of R and S configurations are racemic at those carbon atoms. Atoms with an excess of one configuration over the other are assigned the configuration present in the higher amount, preferably an excess of about 85%-90%, more preferably an excess of about 95%-99%, and still more preferably an excess greater than about 99%. Accordingly, this invention includes racemic mixtures, relative and absolute stereoisomers, and mixtures of relative and absolute stereoisomers. Compounds of this invention containing NH, C(0)OH, OH or SH moieties may have attached thereto prodrug-forming moieties. The prodrug-forming moieties are removed by metabolic processes and release the compounds having the freed hydroxyl, amino or carboxylic acid in vivo. Prodrugs are useful for adjusting such pharmacokinetic properties of the compounds as solubility and/or hydrophobicity, absorption in the gastrointestinal tract, bioavailability, tissue penetration, and rate of clearance. Isotope Enriched or Labeled Compounds -81- Compounds of the invention can exist in isotope-labeled or -enriched form containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most abundantly found in nature. Isotopes can be radioactive or non¬radioactive isotopes. Isotopes of atoms such as hydrogen, carbon, phosphorous, sulfur, fluorine, chlorine, and iodine include, but are not limited to, ^H, ^H, "C, "C, '^N, '^0, ^¥, ^^S, '*F, ^Cl, and '^I. Compounds that contain other isotopes of these and/or other atoms are within the scope of this invention. In another embodiment, the isotope-labeled compounds contain deuterium (^H), tritium (^H) or ^*C isotopes. Isotope-labeled compounds of this invention can be prepared by the general methods well known to persons having ordinary skill in the art. Such isotope-labeled compounds can be conveniently prepared by carrying out the procedures disclosed in the Examples disclosed herein and Schemes by substituting a readily available isotope-labeled reagent for a non-labeled reagent. In some instances, compounds may be treated with isotope-labeled reagents to exchange a normal atom with its isotope, for example, hydrogen for deuterium can be exchanged by the action of a deuteric acid such as D2SO4/D2O. In addition to the above, relevant procedures and intermediates are disclosed, for instance, in Lizondo, J et al.. Drugs Fut, 21(11), 1116 (1996); Brickner, SJet al., J Med Chem, 39(3), 673 (1996); Mallesham, B et al.. Org Lett, 5(7), 963 (2003); PCT publications WO1997010223, WO2005099353, WO1995007271, WO2006008754; US Patent Nos. 7538189; 7534814; 7531685; 7528131; 7521421; 7514068; 7511013;and US Patent AppUcation Publication Nos. 20090137457; 20090131485; 20090131363; 20090118238; 20090111840;20090105338; 20090105307; 20090105147; 20090093422; 20090088416; and 20090082471, the methods are hereby incorporated by reference. The isotope-labeled compounds of the invention may be used as standards to determine the effectiveness of Bcl-2 inhibitors in binding assays. Isotope containing compounds have been used in pharmaceutical research to investigate the in vivo metabolic fate of the compounds by evaluation of the mechanism of action and metabolic pathway of the nonisotope-labeled parent compound (Blake et al. J. Pharm. Sci. 64, 3,367-391 (1975)). Such metabolic studies are important in the design of safe, effective therapeutic drugs, either because the in vivo active compound administered to the patient or because the metabolites produced from the parent compound prove to be toxic or carcinogenic (Foster et al.. Advances in Drug Research Vol. 14, pp. 2-36, Academic press, London, 1985; Kato et al., J. Labelled Comp. Radiopharmaceut, 36(10):927-932 (1995); Kushner et al., Can. J. Physiol. Pharmacol., 77,79-88 (1999). -82- In addition, non-radio active isotope containing drugs, such as deuterated drugs called "heavy drugs," can be used for the treatment of diseases and conditions related to Bcl-2 activity. Increasing the amount of an isotope present in a compound above its natural abundance is called enrichment. Examples of the amount of enrichment include from about 0.5,1,2, 3.4, 5, 6,7, 8, 9, 10, 12,16,21,25, 29, 33, 37, 42, 46,50, 54, 58, 63, 67,71, 75, 79, 84, 88, 92, 96, to about 100 mol %. Replacement of up to about 15% of normal atom with a heavy isotope has been effected and maintained for a period of days to weeks in mammals, including rodents and dogs, with minimal observed adverse effects (Czajka D M and Finkel A J, Ann. N.Y. Acad. Sci. 1960 84: 770; Thomson J F, Ann. New York Acad. Sci 1960 84: 736; Czakja D M et al.. Am. J. Physiol. 1961 201: 357). Acute replacement of as high as 15%-23% in human fluids with deuterium was found not to cause toxicity (Blagojevic N et al. in "Dosimetry & Treatment Planning for Neutron Capture Therapy", Zamenhof R, Solares G and Harling O Eds. 1994. Advanced Medical Publishing, Madison Wis. pp.125-134; Diabetes Metab. 23: 251 (1997)). Stable isotope labeling of a drug can alter its physico-chemical properties such as pKa and lipid solubility. These effects and alterations can affect the pharmacodynamic response of the drug molecule if the isotopic substitution affects a region involved in a ligand-receptor interaction. While some of the physical properties of a stable isotope-labeled molecule are different from those of the unlabeled one, the chemical and biological properties are the same, with one important exception: because of the increased mass of the heavy isotope, any bond involving the heavy isotope and another atom will be stronger than tiie same bond between the light isotope and that atom. Accordingly, the incorporation of an isotope at a site of metabolism or enzymatic transformation will slow said reactions potentially altering die pharmacokinetic profile or efficacy relative to the non-isotopic compound. -83- Amides, Esters and Prodrugs Prodrugs are derivatives of an active drug designed to ameliorate some identified, undesirable physical or biological property. The physical properties are usually solubility (too much or not enough lipid or aqueous solubility) or stability related, while problematic biological properties include too rapid metabolism or poor bioavailability which itself may be related to a physicochemical property. Prodrugs are usually prepared by: a) formation of ester, hemi esters, carbonate esters, nitrate esters, amides, hydroxamic acids, carbamates, imines, Mannich bases, phosphates, phosphate esters, and enamines of the active drug, b) functionalizing the drug with azo, glycoside, peptide, and ether functional groups, c) use of aminals, hemi-aminals, polymers, salts, complexes, phosphoramides, acetals, hemiacetals, and ketal forms of the drug. For example, see Andrejus Korolkovas's, "Essentials of Medicinal Chemistry", John Wiley-Interscience Publications, John Wiley and Sons, New York (1988), pp. 97-118, which is incorporated in its entirety by reference herein. Esters can be prepared from substrates of formula (I) containing either a hydroxyl group or a carboxy group by general methods known to persons skilled in the art. The typical reactions of these compounds are substitutions replacing one of the heteroatoms by another atom, for example: Scheme 1 11 + © ^ Jl^ + a® TT p**^^/"-! OCH2CH3 H3C OCH2CH3 Acyl Chloride Alkoxide Ester Amides can be prepared from substrates of formula (I) containing either an amino group or a carboxy group in similar fashion. Esters can also react with amines or ammonia to form amides. Scheme 2 CO o® f^ o X ► R_Lo-R' " R+O-R- ► A ■" H-O-R' ( ®NH3 NH2 ^ :NH3 Another way to make amides from compounds of formula (I) is to heat carboxylic acids and amines together. -84- Scheme 3 O heat O R-"-OH ■" HN(R')2 R-"-N(R')2 In Schemes 2 and 3 above, R and R' are independently substrates of formula (I), alkyl or hydrogen. Suitable groups for A\ B\ D\ E', Y\ and Z' in compounds of Formula (I) are independently selected. The described embodiments of the present invention may be combined. Such combination is contemplated and within the scope of the present invention. For example, it is contemplated that embodiments for any of A', B', D\ E', Y', and Z' can be combined with embodiments defined for any other of A\ B\ D', E\ Y\ and ZOne embodiment of this invention, therefore, pertains to compounds or therapeutically acceptable salts, prodrugs or salts of prodrugs thereof, which are useful as selective inhibitors one or more than one anti-apoptotic protein family member, the compounds having formula (I) O Q 0 E" (I). wherein A'is N or C(A^); one or two or three or each of A^, B\ D' and E* are independently selected R', 0R\ SR', S(0)R', SO2R', C(0)R\ C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R\ NHC(0)0R\ NR'C(0)NHR', NR'C(0)N(R')2, SO2NHR', S02N(R')2, NHS02R\ NHSO2NHR' or N(CH3)S02N(CH3)R\ and the remamder are independently selected H, F, CI, Br, I, CN, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; and Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R", OR", C(0)R", C(0)0R", SR'^ NH2, NHR", N(R'')2, NHC(0)R'', C(0)NH2, C(0)NHR'^ C(0)N(R")2, NHS(0)R" or NHS02R'^; or B' and Y', together with the atoms to which they are attached, are imidazole or triazole; and one or two or each of A^, D' and E' are independently selected R', 0R\ SR', S(0)R\ S02R\ C(0)R\ C(0)0R\ 0C(0)R', NHR', N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R', -85- NHC(0)0R', NHC(0)NHR\ N(CH3)C(0)N(CH3)R', S02NHR\ S02N(R')2, NHSOIR', NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independently selected H, F, CI, Br, I, CF3, C(0)OH, C(0)NH2 or C(0)0R"^; R' is R^ R^ R" or R^; R'"^ is Ci-C6-alkyl, C3-C6-alkenyl or Cs-Ce-alkynyl; R^ is phenyl which is unfused or fused with arena, heteroarene or R^'^; R^^ is cycloalkane or heterocycloalkane; R^ is heteroaryl which is unfused or fused with benzene, heteroarene or R^^; R^"^ is cycloalkane or heterocycloalkane; R'* is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with arene, heteroarene or R''^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^ NC(R^)(R^"), R', OR^ SR^ S(0)R^ SOiR^ NHR^ N(R^)2, C(0)R^ C(0)NH2, C(0)NHR^ NHC(0)R^ NHS02R^ NHC(0)0R\ SO2NH2, S02NHR^ S02N(R')2, NHC(0)NH2, NHC(0)NHR^ NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR', OH, (O), C(0)OH, (0), N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R* is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R^* and R^® are independently selected alkyl or, together with the N to which they are attached, R*^; R*^ is aziridin-1-yl, azetidin-1-yl, pyrrolidin-l-yl orpiperidin-l-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R^isR«,R',R'%rR"; R* is phenyl which is unfused or fused with arene, heteroarene or R*'*'; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl which is unfused or fused with arene, heteroarene or R''^; R''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is C3-C]o-cycloalkyl or C4-C]o-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^"'^; R"''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -86- R" i& alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R'^ OR'^, NHR'^ N(R'^)2, C(0)NH2, C(0)NHR'^ C(0)N(R'^)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R'^isR",R'\R'^orR'^ R'^ is phenyl which is unfused or fused with arene, heteroarene or R""^; R'^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''' is heteroaiyl, each of which is unfused or fused with arene, heteroarene or R"^; R'"*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with arene, heteroarene or R'^'^; R'*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is alkyl, alkenyl or alkynyl; R'^isR'«,R",R^orR^'; R'* is phenyl which is unfused or fused with arene, heteroarene or R'*^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is heteroaryl which is unfused or fused with arene, heteroarene or R"'^; R'''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is Cs-Cio-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independendy selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^^ 0R^^ NHR^^ N(R^^)2, C(0)NH2. C(0)NHR^^ C(0)N(R^^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^^isR^.R^orR^^ R is phenyl which is unfused or fused with arene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroarene which is unfused or fused with arene, heteroarene or R^'^; R^'*' is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independenUy selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is -87- unfused or fused with arene, heteroarene or R^*'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; 7} is R^^ or R", each of which is substituted with R^, R^' or R^", each of which is substituted with F, CI, Br, I, CHzR^^ CH(R^')(R"), C(R'')(R^'^)(R"), C(0)R", OR", SR^\ S(0)R", SOZR^^ NHR^^ or N(R^^)R^'; R^ is phenyl which is unfused or fused with arene or heteroarene; R^^ is heteroarene which is unfused or fused with arene or heteroarene; R^ is phenyl which is unfused or fused with arene, heteroarene or R^^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene R^' is heteroaryl or R^^'^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^° is cycloalkyl or cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independenUy selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfiased or fused with arene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' and R^'"^ are independently F, CI, Br or alkyl or are taken together and are Cz-Cs-spiroalkyl; R^^ is R^^ C(0)R^^ or C(0)0R"; R^^isR^orR^^ R^'* is phenyl which is unfused or fused with aryl, heteroaryl or R^^; R^"*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl which is unsubstituted or substituted with R^; R^^ is phenyl which is unfiised or fused with arene, heteroarene or R^^^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is R^, R^' or R"^, each of which is substituted with F, CI, Br, I, R"', OR"', NHR"", N(R^')2, NHCCOOR'", SR*\ S(0)R^^ or SOzR''^ R^* is phenyl which is unfused or fused with arene, heteroarene or R^*'^; R^*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl which is unfiised or fused with arene, heteroarene or R^''^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*" is Cs-Cg-cycloalkyl or C4-C8-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced widi independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is -88- unfused or fused with arene, heteroarene or R'*"'^; R''*''^ cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'•isR^^R^^R^orR^^ R"^ is phenyl which is unfused or fused with arene, heteroarene or R"*^"^; R*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroaryl which is unfused or fused with arene, heteroarene or R'*^*^; R''^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"*^ is Cs-Cg-cycloalkyl or C4-C7-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independenfly selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'*^^; R**^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"*^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two independently selected R"**, OR"^, NHR'^, N(R'^)2, C(0)NH2, aONHR^**, C(0)N(R'*^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^isR-^VR^orR^'; R''^ is phenyl which is unfused or fused with arene, heteroarene or R'*^'^; R"*^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'** is heteroaryl or R'**'^; R'**'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independenUy selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R*^^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein the moieties represented by R^^ and R^^ are further substituted by one or two or three of independently selected R^^, 0R'°^, SR^^, S(0)R^°^, S02R^'^^ or NHR^°*, R^°^isR''^R^'^R^'^orR''^ R^'^ is phenyl which is unfused or fused with benzene, heteroarene or R^'^^, wherein R'''^ is cycloalkane, cycloalkene or heterocycloalkane heterocycloalkene, R^^"^ is heteroaryl; R^^^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl; each having one or two CH2 moieties unreplaced or replaced widi independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 -89- or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with aiene, heteroarene or R^^'^; wherein R^^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'*'^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independenUy selected R^^^, OR^^^, SR"'^, S(0)R*^'^, S02R^^'^, j^j^55AA N(R55AA^2, C(P)R^^^, C(0)NH2, C(0)NHR"'^, NHC(0)R^^^, NHSOaR""^, NHC(0)OR^''^, SO2NH2, SOzNHR^^'^, S02N(R^^^)2, NHC(0)NH2, NHC(0)NHR^^'^, OH, (O), C(0)OH, (0), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R^*"^ is alkyl, alkenyl, alkynyl, phenyl or heteroaryl, or R*^"^; R^^'^ is Cj-Ce-cycloalkyl or C4-C6-cycloalkyl, each having one or two CH2 moieties unreplaced or replaced with independently selected 0, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N; wherein moieties represented by R^ R^'^, R^ R^'^, R\ R"^, R^ R*^, R*, R*^, R', R'°, DIOA r>13 1>13A nU D^A nlS r»15A r)18 plSA T)19 D19A r>20 T>20A D23 n23A r)24 i,24A ^25 is. ,l\,lv ,l\,lx ,l\,iv ,lv,i\. ,rv,ix ,lv,x\ ,i\.,l\. ,rv,K ,iv, p25A n26 n27 j>28 n28A j^29 n29A ^30 jj30A ^34 n34A p36 T>36A D38 n38A n39 p39A j,40 ji40A R'\ R*^, R*\ R''\ R^, R^^, R'^ R''\ R^, R^^, R"', and R^'^ are independenUy unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five independently selected R^", OR^", SR^", S(0)R^°, S02R^'', CCOR^", CO(0)R^'', OC(0)R^°, OC(0)OR^, NH2, NHR^", N(R^°)2, C(0)NH2, C(0)NHR^°, C(0)N(R^'')2, C(0)NHOH, C(0)NH0R'°, C(0)NHS02R^°, C(0)NR^''S02R'°, SO2NH2, S02NHR^'', S02N(R^°)2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, C(N)NHR''', C(N)N(R'°)2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R^''isR^\R",R^^orR^'*; R^' is phenyl which is unfused or fused with arene, heteroarene or R^'®; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is heteroaryl; R^^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfiised or fused with arene, heteroarene or R ; wherein R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^* is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^^ OR", SR^^ S(0)R", SOiR^^ NHR^^ N(R^^)2, -90- C(0)R^^ C(0)NH2, C(0)NHR^^ NHC(0)R^^ NHS02R^^ NHC(0)0R^^ SO2NH2, S02NHR^^ S02N(R^^)2, NHC(0)NH2, NHC(0)NHR^^ OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R^* is alkyl, alkenyl, alkynyl, phenyl, heteroaryl or R^^; and wherein the alkyl, alkenyl, alkynyl are unsubstituted or substituted with CXIlHs; and R^* is Cs-Cg-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N. Another embodiment of this invention pertains to compounds of Formula (I), wherein A' is N or C(A^); one or two or three or each of A^, B', D' and E' are independently selected R', 0R\ SR\ S(0)R', SO2R', C(0)R\ C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NHC(0)0R', NR'C(0)NHR', NR'C(0)N(R')2, SO2NHR', S02N(R')2, NHS02R\ NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independently selected H, F, CI, Br, I, CN, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; and Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R", OR", C(0)R", C(0)0R", SR'^ NH2, NHR'^ N(R'^)2, NHC(0)R", C(0)NH2, C(0)NHR'\ C(0)N(R'^)2, NHS(0)R" or NHSO2R"; or B' and Y\ together with the atoms to which they are attached, are imidazole or triazole; and one or two or each of A^, D' and E' are independently selected R', OR', SR', S(0)R\ SO2R', C(0)R', C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NHC(0)0R', NHC(0)NHR', N(CH3)C(0)N(CH3)R\ S02NHR\ S02N(R')2, NHSO2R', NHSO2NHR' or N(CH3)S02N(CH3)R\ and the remainder are independenUy selected H, F, CI, Br, I, CF3, C(0)OH, C(0)NH2 or C(0)0R'^; RMsR^R^R''orR^ R''^ is Ci-Ce-alkyl, C3-C6-alkenyl or Cs-Ce-alkynyl; R^ is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^'^ is cycloaUcane or heterocycloalkane; R^ is heteroaryl which is unfused or fused with benzene, heteroarene or R^^; R^^ is cycloalkane or heterocycloalkane; -91- R" is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with arene, heteroarene or R"*^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^ NC(R^)(R*^), R^ OR^ SR^ S(0)R^ SOzR^ NHR', N(R')2, C(0)R^ C(0)NH2, C(0)NHR\ NHC(0)R^ NHSOZR^ NHC(0)0R\ SO2NH2, SOaNHR^ S02N(R^)2, NHC(0)NH2, NHC(0)NHR^ NHC(0)CH(CH3)NHC(0)CH(CH3)NH2,NHC(0)CH(CH3)NHC(0)CH(CH3)NHR\OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^ is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R^^ and R^^ are independendy selected alkyl or, together widi the N to which they are attached, R^; R^ is aziridin-1-yl, azetidin-1-yl, pyrrolidin-l-yl or piperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R'isR^R^R'%rR"; R* is phenyl which is unfused or fused with arene, heteroarene or R*^; R*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroaryl which is unfused or fused with arene, heteroarene or R'^; R'*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is C3-Cio-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independendy selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^""^; R'""^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R'^ OR'^ NHR'^ N(R'^)2, C(0)NH2, C(0)NHR'^ C(0)N(R'^)2, OH, (O), C(0)0H, N3, CN, NH2, CF3. CF2CF3, F, CI, Br or I substituents; R'^isR",R^R'^orR^ R" is phenyl which is unfused or fused with arene, heteroarene or R'^^; R"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''' is heteroaryl, each of which is unfused or fused with arene, heteroarene or R''*'^; R''*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -92- R'* is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with arena, heteroarene or R'^'^; R'^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'* is alkyl, alkenyl or alkynyl; R'^sR^R",R^orR^'; R'* is phenyl which is unfused or fused with arene, heteroarene or R'*'^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'' is heteroaiyl which is unfused or fused with arene, heteroarene or R*'^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is C3-C]o-cycloalkyl or C4-C]o-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^°^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^^ 0R^^ NHR^^ N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^^isR^,R^orR^^ R^^ is phenyl which is unfused or fused with arene, heteroarene or R^"^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^" is heteroarene which is unfused or fused with arene, heteroarene or R^*^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is Cs-Ce-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fiised with arene, heteroarene or R^''^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; Z' is R^* or R^\ each of which is substituted with R^, R^' or R^", each of which is substituted with F, CI, Br, I, CH2R^^ CH(R^')(R"), C(R'')(R^'^)(R"), C(0)R", OR^^ SR", S(0)R", SO2R", NHR" or N(R^^)R^^; R^* is phenyl which is unfused or fused with arene or heteroarene; R^^ is heteroarene which is unfused or fused with arene or heteroarene; R is phenyl which is unfused or fused with arene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene -93- R^' is hetepoaiyl or R^''^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heteiocycloalkene; R^° is cycloalkyl or cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^"'*; R^"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' and R^'"^ are independently F, CI, Br or alkyl or are taken together and are Ca-Cs-spiroalkyl; R^^ is R^\ C(0)R^^ or C(0)0R"; R^isR^orR'^ R^'' is phenyl which is unfused or fused with aryl, heteroaryl or R^^; R^'*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl which is unsubstituted or substituted with R^; R^* is phenyl which is unfused or fused with arene, heteroarene or R^*'^; R^*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is R^, R^' or R'^, each of which is substituted with F, CI, Br, I, R"', OR*', NHR"", N(R'")2, NHC(0)OR'*\ SR*', S(0)R*' or SOaR^"; R^ is phenyl which is unfused or fused with arene, heteroarene or R^*"^; R^**^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^* is heteroaryl which is unfused or fused with arene, heteroarene or R^'^'; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R*" is Cs-Cg-cycloalkyl or C4-C8-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'*"'^; R''^'^ cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R*'isR*^R*^R^orR*^ R"^ is phenyl which is unfused or fused with arene, heteroarene or R"*^"^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*^ is heteroaryl which is unfused or fused with arene, heteroarene or R"*^^; R''^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R** is C3-C9-cycloalkyl or C4-C7-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 -94- or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'*^^; R**'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R*^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two independenUy selected R"^, OR'^, NHR'•^ N(R'^)2, C(0)NH2, C(0)NHR'^, C(0)N(R'^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R'^^isR^^R^orR^'; R*^ is phenyl which is unfused or fused with arene, heteroarene or R"^'^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'** is heteroaryl or R'**^; R''*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R*' is Ca-Ce-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'*''^; R'*''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein the moieties represented by R^^ and R^^ are further substituted with OR^""^; R^^^isR^^^ R^''^ is phenyl which is fiised with heteroarene; wherein moieties represented by R^ R^, R^ R^'^, R^ R'"^, R^ R^, R^ R*"^, R', R'", DIOA 1,13 D13A nU DMA n^i D15A D18 r,lhA D19 D19A ^20 T>20A „23 T>23A ^24 T>24A T>25 IV ,XV,lV ,I\.,IV ,I\.,lV ,XV,1\. ,£\.,lx ,IV,1\. ,IV,xV ,1\.,I\. ,1\, r>25A r,26 D27 n28 D^SA T>29 nNA ^30 D30A nM n34A i,36 r>36A r(38 r>38A p39 r.39A r>40 T)40A K , Iv , IV , Iv , Iv , Iv ,1V , Iv , Iv , Iv , Iv ,1V , IV , Iv , Iv , IV ,1V , Iv , IV , j^42 J^42A ^43 j^43A ^44 ^44A j^47 j^47A ^48 jj48A ^49 ^^^ j^49A ^^ independently unsubstituted, further unsubstituted, substituted or further substituted witii one or two or three or four or five independently selected R*", OR^", SR^", SCOR^", SOzR^", C(0)R^°, CO(0)R^'', OC(0)R^'', OC(0)OR^, NH2, NHR'°, N(R''')2, C(0)NH2, C(0)NHR^'', C(0)N(R^'')2, C(0)NHOH, C(0)NH0R'°, C(0)NHS02R^°, C(0)NR'''S02R^°, SO2NH2, S02NHR^'', S02N(R^°)2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^°, C(N)N(R^'')2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substitiients; R'"isR'',R",R5'orR5^ R^' is phenyl which is unfused or fiised with arene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroaiyl; -95- R^^ is Ca-Ce-cycloalkyI or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is vmfused or fused with arene, heleroarene or R^^^; wherein R'^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'* is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^^ 0R'^ SR", S(0)R", S02R^^ NHR", N(R^^)2, C(0)R^^ C(0)NH2, C(0)NHR^^ NHC(0)R^^ NHS02R^^ NHC(0)0R^^ SO2NH2, S02NHR^^ S02N(R^^)2, NHC(0)NH2, NHC(0)NHR", OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R'^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl or R^^; and wherein the alkyl, alkenyl, alkynyl are unsubstituted or substituted with OCH3; and R^* is Cs-Cs-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N. A' is N or C(A^); one or two or three or each of A^, B', D' and E' are independently selected R', OR', SR\ S(0)R', SOZR', C(0)R', C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NHC(0)0R\ NR'C(0)NHR', NR'C(0)N(R')2, SO2NHR', S02N(R')2, NHS02R\ NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independently selected H, F, CI, Br, I, CN, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; and Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R'^ OR", C(0)R", C(0)0R", SR", NH2, NHR", N(R")2, NHC(0)R'^ C(0)NH2, C(0)NHR'\ C(0)N(R")2, NHS(0)R" or NHSO2R"; or B' and Y', together with the atoms to which they are attached, are imidazole or triazole; and one or two or each of A^ D' and E' are independently selected R\ 0R\ SR', S(0)R\ SO2R', C(0)R', C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R', NHC(0)0R\ NHC(0)NHR', N(CH3)C(0)N(CH3)R\ SO2NHR', S02N(R^)2, NHSO2R', NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independently selected H, F, CI, Br, I, CF3, C(0)OH, C(0)NH2 or C(0)0R'^; R' is R^ R^ R" or R^ R"^ is Ci-C6-alkyl, Ca-Ce-alkenyl or Ca-Ce-alkynyl; -96- R^ is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^"^ is cycloalkane or heterocycloalkane; R^ is heteroaryl which is unfused or fused with benzene, heteroarene or R^^; R^'^ is cycloalkane or heterocycloalkane; R'* is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with arene, heteroarene or R'*'^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R* is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^ NC(R^)(R^^), R\ OR^ SR\ S(0)R^ S02R^ NHR\ N(R')2, C(0)R\ C(0)NH2, C(0)NHR^ NHC(0)R^ NHSOZR^ NHC(0)0R^ SO2NH2, S02NHR^ S02N(R^)2, NHC(0)NH2, NHC(0)NHRNHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR', OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R* is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R*"^ and R^® are independently selected alkyl or, together with the N to which they are attached, R^; R^ is aziridin-l-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R'isR*.R',R'%rR"; R* is phenyl which is unfused or fused with arene, heteroarene or R*'^; R*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl which is unfused or fused with arene, heteroarene or R''^; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is C3-C]o-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'"'^; R'""^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R'\ 0R'^ NHR'^ N(R^^)2, C(0)NH2, C(0)NHR*\ C(0)N(R'^)2, OH, (O), C(0)0H, N3, CN, NH2, CF3. CF2CF3, F, CI, Br or I substituents; R'^sR",R^R'^orR'^ -97- R' is phenyl which is unfused or fiised with arene, heteroarene or R"'^; R""^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is heteroaryl, each of which is unfused or fused with arene, heteroarene or R"'^; R''*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with arene, heteroarene or R"'^; R'^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'* is alkyl, alkenyl or alkynyl; R"isR'«,R^R^orR^'; R'* is phenyl which is unfused or fused with arene, heteroarene or R'*"^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'' is heteroaryl which is unfused or fiised with arene, heteroarene or R"^; R"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^° is Ca-Cio-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independenUy selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is Ort A O/^ A unfused or fused with arene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^^ 0R^^ NHR^^ N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^^isR^,R^orR"; R^ is phenyl which is unfused or fiised with arene, heteroarene or R^^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroarene which is unfused or fused with arene, heteroarene or R^^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^^'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; T} is R^^ or R^', each of which is substituted with R^, R^ or R^°, each of which is substituted with F, CI, Br, I, CH2R", CH(R^')(R"), C(R^')(R^''^)(R"), C(0)R", OR^^ SR", S(0)R", %0^, NHR" or N(R^^)R"; -98- R^^ is phenyl which is unfiised or fiised with arene or heteroarene; R^^ is heteroarene which is unfused or fused with arene or heteroarene; R^ is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaiyl or R^''^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^" is cycloalkyl or cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independenUy selected 0, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^°^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' and R'''^ are independently F, CI, Br or alkyl or are taken together and are C2-C5-spin)alkyl; R^^ is R^, C(0)R^^ or C(0)0R"; R^^isR^orR"; R^'* is phenyl which is unfused or fused with aryl, heteroaryl or R^'*'^; R^"*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl which is unsubstituted or substituted with R^; R^* is phenyl which is unfused or fused with arene, heteroarene or R^^'^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is R^, R^' or R'", each of which is substituted with F, CI, Br, I, R''\ 0R*\ NHR''\ N(R'")2, NHCCOpR'", SR''', S(0)R'" or SO2R'''; R^* is phenyl which is unfused or fused with arene, heteroarene or R^*'^; R^*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl which is unfused or fused widi arene, heteroarene or R^''^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'"' is Cs-Cs-cycloalkyl or C4-C8-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced vwth independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R""*^; R'"*'^ cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'isR*^R^^R«orR^^ R"*^ is phenyl which is unfused or fused with arene, heteroarene or R''^^; R''^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -99- R'*^ is heteroaiyl which is unfused or fused with arene, heteroarene or R"*^^; R''^'^ is cycloalkane, cycloalkene, heterocycloalkane or heteiocycloalkene; R**^ is C3-C9-cycloalkyl or C4-C7-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R**^; R'"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*^ is alky], alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two independently selected R^, OR^, NHR''^ N(R^)2, C(0)NH2, C(0)NHR'^, C(0)N(R%, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^isR^R^orR'"; R"*^ is phenyl which is unfused or fused with arene, heteroarene or R'*^'^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"* is heteroatyl or R''*'^; R"*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R*' is Cs-Ce-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'"''^; R'*'"* is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein the moieties represented by R^ and R^^ are further substituted by one or two or three of independenUy selected R^^, 0R^°'^, SR*'^, S(0)R''''^, S02R'°^ or NHR^°'^; R^«^isR^•^R^^.R^^^orR'^^ R^'"^ is phenyl which is unfused or fused with benzene, heteroarene or R^''^, wherein R^''^ is cycloalkane, cycloalkene or heterocycloalkane heterocycloalkene, R^^'^ is heteroaiyl; R^''^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl; each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^^'^; wherein R^^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R*'*'^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^^'^, OR^^'^, SR*''^, S(0)R^^^, SOaR^^'^, ^jjj^55AA N(R55AA^^ C(0)R^^^, C(0)NH2, C(0)NHR"'^, NHC(0)R^^^, NHS02R"^, -100- NHC(0)0R"*'^, SO2NH2, SOaNHR^^^, S02N(R^^^)2, NHC(0)NH2, NHG(0)NHR"'^, OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R^^'^ is alkyl, alkenyl, alkynyl, phenyl or heteroaiyl, or R^^^; R^*'^ is Cs-Ce-cycloalkyl or C4-C6-cycloalkyl, each having one or two CH2 moieties unieplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N; wherein moieties represented byRRR,R,R ,R,R R,R ,R ,R ,R , 18 „19 20 23 p24 25 p26 27 28 29 30 34 36 38 p39 40 42 43 R , R , R , and R are independendy unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five independently selected R^"'^, R^, 0R*°, SR*", S(0)R*'', SO2R*'', C(0)R^'', CO(0)R*'', OC(0)R^", 0C(0)0R^, NH2, NHR*", N(R^'')2, C(0)NH2, C(0)NHR^'', C(0)N(R^)2, C(0)NHOH, C(0)NHOR^'', C(0)NHS02R'^ C(0)NR^°S02R^°, SO2NH2, S02NHR^°, S02N(R'°)2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, C(N)NHR''', C(N)N(R'°)2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; j^soAA j^ spirocyclyl; R^^sR^^R^^R'^orR'^ R'' is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^'® is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroaiyl; R^^ is Cs-Ce-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with aiene, heteroarene or R^^^; wherein R^^* is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^** is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^^ OR", SR", S(0)R", SO2R", NHR", N(R")2, C(0)R", C(0)NH2, C(0)NHR", NHC(0)R", NHSO2R", NHC(0)0R", SO2NH2, SO2NHR", S02N(R")2, NHC(0)NH2, NHC(0)NHR", OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R'^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl or R^^; wherein the alkyl, alkenyl, alkynyl are unsubstituted or substituted with OCH3; and -101- R^^ is Cs-Cg-cycloalkyl or C4-C6-cycloalkenyI, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N. In one embodiment of Formula (I), A' is N or C(A^); one or two or three or each of A^, B\ D' and E' are independently selected R', 0R\ SR\ SO2R', NHC(0)R', NHR', N(R')2, or C(0)NHR', and the remainder are independently selected H, F, CI, Br, or I; Y' is H, CN, NO2, F, CI, Br, I, CF3, R", NHC(0)R", or C(0)NH2; R'isR^R^R''orR^ R^ is phenyl; R^ is heteroaryl; R" is cycloalkyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfiised or fused with R""^; R'*'^ is cycloalkane; R^ is alkyl, or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^ R\ OR', SR^ S02R\ N(R')2, OH, CN, CF3, F, CI, Br or I substituents; R^ is C2-C5-spiroalkyl; R'isR»,R',R>''orR"; R* is phenyl which is unfused or fused with R*^; R*'^ is heterocycloalkane; R' is heteroaryl; R'" is C3-Cio-cycloalkyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N; and each of which is unfused or fused with heteroarene; R" is alkyl, each of which is unsubstituted or substituted with one or two or three independently selected OR'^, F, CI, Br or I substituents; R'^isR'^ R'* is alkyl; R"isR"orR2'; R'' is heteroaryl which is unfused or fused with arene, heteroarene or R^'^; R'''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkynyl; -102- Z' is R^^, each of which is substituted with R^", each of which is substituted with F, CI, Br, I, CHZR'^ or CH(R")(R"); R^^ is phenyl; R^° is cycloalkyl, each having two CH2 moieties unreplaced or replaced with NH; R^' and R^''^ are independently alkyl; R" is R^, R^' or R"*", each of which is substituted with F, CI, Br, I, NHR'*', or R'*^ R^* is phenyl; R^' is heteroaryl; R'"' is Cs-Cs-cycloalkyl or C4-Cg-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 orNH; R'"isR'*^R*^orR'"; R''^ is phenyl; R"^ is heteroaryl; R''^ is Cs-Cg-cycloalkyl or C4-C7-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with R''^^; R'"'^ is cycloalkane; wherein the moiety represented by R^^is further substituted by one or two or three of independently selected R^"*^, OR^"", SR^°^, S(0)R*°'', SOzR^"^ or NHR^°''; R^''^ is phenyl which is unfused or fused with benzene, heteroarene or R^'^^; wherein R^'^^ is heterocycloalkane; R""^ is heteroaryl; R^'*'^ is alkyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^^AA^ ^^ OR^^^; R"^ is phenyl; wherein moieties represented by R^ R^ R\ R"^, R^ R\ R*'^, R', R'°, R'', R^^ R^", R^*, R^', R"", R"*^, R*^, R"^, and R**"^ are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five independently selected R^", 0R^°, SR^", S(0)R^'', S02R^'', CCOR^", CO(0)R^°, NH2, NHR^", C(0)NH2, C(0)N(R^")2, SO2NH2, OH, (O), CN, CF3, OCF3, F, CI, Br or I substituents; R^^sR^^R^^orR^^ -103- CI SIR 51R R is phenyl which is unfused or fused with arene, heteroarene or R ; R is heterocycloalkane; R^^ is heteroaryl; R^^ is Cs-Ce-cycloalkyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, and one or two CH moieties unreplaced or replaced with N; R^* is alkyl, each of which is unsubstituted or substituted with one or two or three independently selected R^^ 0R^^ N(R")2, OH, CN, F, CI, Br or I substituents; and R^^ is alkyl or phenyl; wherein the alkyl is unsubstituted or substituted with OCH3; and R^* is Cs-Cg-cycloalkyl, each having one or two CH2 moieties unreplaced or replaced with independently selected NH and one or two CH moieties unreplaced or replaced with N. In one embodiment of Formula (I), A' is N. In another embodiment of Formula (I), A' is C(A^). In another embodiment of Formula (I), A' is C(A^), and A^ is H. In one embodiment of Formula (I), B^ is R\ OR', SR\ SOaR*, NHC(0)R', NHR\ N(R')2, or C(0)NHR'. In another embodiment of Formula (I), B' is NHR\ In another embodiment of Formula (I), B' is NHR', and A' is C(A^), and A^ is H. In another embodiment of Formula (I), B' is NHR', and A' is C(A^) or N, and A^ is H. In another embodiment of Formula (I), B' is OR'. In another embodiment of Formula (I), B' is OR', and A' is C(A^), and A^ is H. In another embodiment of Formula (I), B' is 0R\ and A' is C(A^) or N, and A^ is H. In one embodiment of Formula (I), D' and E' are H. In another embodiment of Formula (I), B' is NHR', and A' is C(A^), A^ is H, and D' and E' are H. In another embodiment of Formula (I), B' is NHR', and A' is C(A^) or N, A^ is H, and D' and E' are H. In another embodiment of Formula (I), B' is OR', and A' is C(A^), A^ is H, and D' and E' are H. In another embodiment of Formula (I), B' is OR', and A' is C(A^) or N, A^ is H, and D' and E' are H. In one embodiment of Formula (I), Y' is H, CN, NO2, F, CI, Br, I, CF3, R'^ NHC(0)R'^ or C(0)NH2. In another embodiment of Formula (I), Y' is NO2. In another embodiment of Formula (I), Y' is CI. In another embodiment of Formula (I), B' is NHR', and A' is C(A^), A^ is H, D' and E' are H, and Y' is NO2. In another embodiment of Formula (I), B' is NHR', and A' is C(A^) or N, A^ is H, D' and E' are H, and Y' is NO2. In another embodiment of Formula (I), B' is OR', and A' is C(A^), A^ is H, D' and E' are H, and Y' is CI. In another embodiment of Formula (I), B' is OR', and A' is C(A^) or N, A^ is H, D' and E' are H, and Y' is CI. -104- In one embodiment of Formula (I), R' is R^, R^, R'* or R^. In another embodiment of Formula (I), R' is R^, and R^ is phenyl. In one embodiment of Formula (I), R' is R^, and R^ is heteroaryl. In another embodiment of Formula (I), R^ is triazolyl. In one embodiment of Formula (I), R' is R^. In another embodiment of Formula (I), R' is R'', and R^ is cycloalkyl. In another embodiment of Formula (I), R' is R'', and R'* is cyclohexyl. In another embodiment of Formula (I), R' is R"*, and R'* is heterocycloalkyl. In another embodiment of Formula (I), R' is R", and R" is 8-azabicyclo[3.2.1]octane, azetidinyl, piperidinyl, piperazinyl, pyrrolidinyl, morpholinyl, tetrahydropyranyl, or tetrahydrothiophenyl. In another embodiment of Formula (I), R' is R'*, and R"* is heterocycloalkenyl. In another embodiment of Formula (I), R' is R'', and R"* is tetrahydropyridazinyl. In one embodiment of Formula (I), R' is R^. In another embodiment of Formula (T), R' is R^ and R^ is aUcyl or alkynyl. In another embodiment of Formula (I), R' is R^ and R* is alkyl which is unsubstituted. In another embodiment of Formula (I), R' is R^ and R^ is alkyl which is substituted with one or two or three independently selected R*, R^, OR^, SR^, SOiR^, N(R^)2, OH, CN, CF3, F, CI, Br or I substituents. In another embodiment of Formula (I), R' is R' and R? is alkyl which is substituted with R^. In one embodiment of Formula (I), R^ is R*, R^, R'° or R". In another embodiment of Formula (I), R' is R*, and R* is phenyl which is unfused or fiased with R*'^, and R*^ is heterocycloalkane. In another embodiment of Formula (I), R^ is R*, and R^ is phenyl which is unfused. In another embodiment of Formula (I), R^ is R', and R' is heteroaryl. In another embodiment of Formula (I), R' is R', and R' is fiiranyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyI, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thiophenyl, triazinyl or 1,2,3-triazolyl. In another embodiment of Formula (I), R^ is R', and R' is pyridinyl, thiazolyl, imidazoyl, and 1,2,3-triazolyl. In another embodiment of Formula (I), R^ is R'**, and R'° is Cs-Cio-cycloalkyl. In another embodiment of Formula (I), R' is R'°, and R'° is C3, Ce, C7 or Cio-cycloalkyl. In another embodiment of Formula (I), R^ is R'", and R'" is cyclopropyl, cyclohexyl, bicyclo[2.2. l]heptanyl, or adamantanyl. In another embodiment of Formula (I), R^ is R''', and R'" is morpholinyl, piperazinyl, piperidinyl, tetrahydro-2H-pyranyl, 1,2-dihydropyridinyl, pyranyl, pyridin-I(H)-yl, pyrrolidinyl, oxetanyl, thiomoipholinyl, imidazolidinyl, tetrahydrothiophenyl, dioxolanyl, tetrahydrothiopyranyl, dioxanyl, 5,6,7,8-tetrahydroimidazp[l,2-a]pyridinyl, or tetrahydrofuranyl. In another embodiment of Formula -105- (I), R^ is R'", and R''* is morpholinyl, piperazinyl, piperidinyl, tetrahydro-2H-pyranyl, 1,2-dihydropyridinyl, pynolidinyl, oxetanyl, thiomorpholinyl, imidazolidinyl, tetrahydrothiophenyl, dioxolanyl, tetrahydrothiopyranyl, dioxanyl, 5,6,7,8-tetrahydroimidazo[l,2-a]pyridinyl, or tetrahydrofuranyl. In another embodiment of Formula (I), R^ is R", and R" is alkyl which is unsubstituted or substituted. In another embodiment of Formula (I), R^ is R", and R" is alkyl which is unsubstituted. In another embodiment of Formula (I), R' is R", and R" is alkyl which is substituted. In another embodiment of Formula (I), R' is R", and R" is alkyl which is substituted with one or two or three independently selected OR'^, F, CI, Br or I substituents. In another embodiment of Formula (I), R^ is R", R" is alkyl which is substituted with 0R'^ R'^ is R'^ and R^^ is alkyl. In one embodiment of Formula (I), R" is R^' or R^'. In another embodiment of Formula (I), R" is R", and R*' is heteroaryl. In another embodiment of Formula (I), R" is R'', and R" is thiazolyl. In another embodiment of Formula (I), R'^ is R^', and R^' is alkynyl. In another embodiment of Formula (I), R'^ is R^', and R^' is ethynyl. Still another embodiment pertains to compounds having Formula I which are 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyI)-2-phenoxybenzamide; benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-phenoxy-N-((4-((tetrahydro-2II-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(benzyloxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin- I-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2II-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(2-phenylethoxy)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(phenyltliio)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(phenylthio)-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(phenylthio)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(phenylsulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(phenylsulfmyl)benzamide; -106- 2-benzyl-4-(4-((4'-chIoro-1, l'-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylraethyl)amino)phenyl)sulfonyl)benzamide; 2-benzyl-4-(4-((4'-chloro-l, r-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-benzyl-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-moipholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(2-phenylethyl)benzamide; 2-(benzylamino)-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-anilino-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-anilino-4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-methoxy-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((2-(4-chlorophenyl)-5,5 -dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- moipholin-4-ylpropyl)aimno)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indazol-5-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indazol-5-yloxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitiophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethyIcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-nitTophenyl)sulfonyl)-2-(l,2,3,4-tetTahydroquinolin-6- yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((l- methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)-2-(l,2,3,4-tetrahydroquinolm-6- yloxy)benzamide; 4-(4-((4'-chloro-4-(pyrrolidin-1 -ylmethyl)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-( IH- indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; -107- 4-(4-((4'-chloro-4-(2-pyrrolidin-1 -ylethyl)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(( 1 - cyclopentylpiperidin-4-yl)amino)-3-nittophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)-3-isobutylpiperazin-l-yl)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-(2,4-dioxo-3- azabicyclo(3.2.0)hept-3-yl)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-(4-methyl-6-oxo-1,4,5,6- tetrahydropyridazin-3-yl)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-(3,3-dimethyl-2- oxoazetidin-l-yl)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-(4-nitro-2H-1,2,3-triazol-2- yl)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-phenoxy-N-((2-(2-piperidin-1 - ylethoxy)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-(((( 1 -ethylpynolidin-2- yl)methyl)ammo)carbonyl)-4-methoxyphenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(l-naphthyloxy)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)siilfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(2-naphthyloxy)-N-((3 -mtro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzainide; 4-(4-((4'-ch]oro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(2-naphthyloxy)beiizamide; 4-(4-((4'-chloro-l,r-biphenyl-2-y])methyl)piperazin-l-yl)-2-(2-naphthyloxy)-N-((4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmediyl)amino)phenyl)sulfonyl)-2-(quinolm-7-yloxy)benzainide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)suIfonyl)-2-(quinolm-6-yloxy)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-5-yloxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)su]fonyl)benzamide; -108- 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(isoquinolin-5-yloxy)-N-((3- mtro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylammo)propyI)amino)-3-nitiophenyl)sulfonyl)-2-(isoquinolin-5-yloxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(quinolin-6-yloxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyI)-2-(lH-indol-5-yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2Tyl)melhyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)ammo)-3-nitiophenyl)sulfonyl)-2-(lH-indol-4-yloxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylammo)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(lH-indol-6-yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(isoquinolin-7-yloxy)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-iiitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((4-((3- (dimethylammo)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(isoquinolin-7-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((4-((3-morpholm-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-mtrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcydohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitTOphenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-(l H- indol-4-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)ainino)-3-nitrophenyl)sulfonyl)-2-(lH-indol-4-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(lH-indol-4-yloxy)benzamide; -109- 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)-N-((4-((3- morpholin-4-ylpiopyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyI-2-yl)methyl)piperazin-l-yl)-2-(lH-indol-5-yloxy)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-methoxyphenyl)sulfonyl)-2- phenoxybenzamide; 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-methylphenyl)sulfonyl)-2- phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(lH-indol-5-yloxy)-N-((4- ((tetrahydro-2H-pyran-4-ylmethyl)aniino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-((4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4.(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylammo)propyl)amino)-3-((tTifluoromethyl)sulfonyl)phenyl)sulfonyl)-2-(lH-indol-5- y]oxy)ben2amide; 4.(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; N-((3-((chloro(difluoro)methyl)sulfonyl)-4-((3- (dimethylamino)propyl)amino)phenyl)sulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH-mdol-5-yloxy)benzamide; 2-( lH-indol-4-yloxy)-4-(4-((2-(4-methoxyphenyl)-4,4-dimethy Icyclohex-1 -en-1 - yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((3-pyrrolidin-1 - ylpiopyl)aimno)phenyl)sulfonyl)benzamide; 4-(4-((4,4-dimethy]-2-(4-(trifluororaethyl)phenyl)cyclohex-1 -en-1 -yl)niethyl)piperazin-1 -yl)- 2-(lH-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-l- ylpropyl)aniino)phenyl)sulfonyl)benzamide; 4-(4-((4,4-dimethyl-2-(4-(trifluoromethoxy)phenyl)cyclohex-1 -en-1 -yl)methyl)piperazin-1 - yl)-2-(lH-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-l- ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4,4-dimethyl-2-(3-(trifluoromethyl)phenyl)cyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)- 2-( lH-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 - ylpropyl)amino)phenyl)sulfonyl)benzamide; -110- 4-(4-((2-(3-fluorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((3-nitro-4-((3 -pyirolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-fluorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-l-ylpropyl)amino)phenyl)sulfonyl)benzamide; N-((3-((chloro(difluoro)methyl)sulfonyl)-4-((l-methylpiperidin-4-yl)amino)phenyl)sulfonyl)- 4-(4-((2-(4-chlorophenyl)-4,4-din[iethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- mdol-5-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)cyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH-indol-5-yloxy)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-ch]orophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(phenoxymethyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-morpholm-4- ylpropyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)suIfonyl)-2-(pyridin-3-yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(pyridin-3-yloxy)-N-((4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)siilfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-(((lR)-3-(dimethylamino)- l-((phenylthio)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)aniino)phenyl)sulfonyl)-2-(pyridin-4-yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-morpholin-4- ylpiopyl)anuno)-3-nitrophenyl)sulfonyl)-2-(pyridin-3-yloxy)benzamide; 4-(4-((4'-cMoro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(pyridin-4-yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((2-(4-methylpiperazin-l- yl)ethyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-(4-methylpiperazin-1 - yl)propyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4.(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)(methyl)aniino)-3-nitrophenyl)sulfonyI)-2-phenoxybenzamide; -111- 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-(((l -niethylpiperidin-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-(( 1-methylpiperidin-4-yl)amino)-3-nitIDphenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-N-((3 -cyano-4-((3 -(dimethylamino)propyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((3-pyrrolidin-l-ylpropyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((4-((3-(dimethylamino)propyl)amino)-3-(trifluoromethyl)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-(isopropyl(methyl)amino)propyl)ammo)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-N-((4-(3-(dimethylamino)propoxy)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-((4-((2-(4-methylpiperazin-l-yl)ethyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-((4-((3-(4-methylpiperazin-l-yl)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)raethyl)piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-((3-nitro-4-((3-pynx)lidin-l-ylpropyl)amino)phenyl)sulfonyl)benzamide 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H-indol-4-yloxy)-N-((4-((3-(4-methylpiperazin-l-yl)propyl)amino)-3-nilxophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(3-(dimethylamino)propoxy)-3-nitrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H-indol-4-yloxy)-N-((4-((2-(4-methylpiperazin-l-yl)ethyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-l-ylpropyl)amino)phenyl)sulfonyl)benzamide; -112- 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((4-((l-methylpiperidin-4-yl)aiiimo)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((4-(((l-methylpiperidin-4-yl)methyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((4-((( 1 -methylpiperidin-4-y l)methyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-(3- (dimethylamino)propoxy)-3-nitrophenyl)sulfonyl)-2-(lH-indol-4-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)niethyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((4-(4-methylpiperazin-l-yl)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-ch]orophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- mdol-4-yloxy)-N-((3-nitro-4-(( 1 -(2,2,2-trifluoroethyl)piperidin-4- yl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(((4-(dimethylamino)-l-methylpiperidin-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-2-(1 H-indol-5-yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2,3-dihydro-l,4-benzodioxm-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylniethyl)amino)phenyl)sulfonyl)benzamide; 5-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-1,1 '-biphenyl-2-carboxamide; 5-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazih-l-yl)-N-((4-((3-(dimethylammo)propyl)amino)-3-nitrophenyl)sulfonyl)-l,r-biphenyl-2-carboxamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-1,1 '-biphenyl-2-yl)methy l)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-4-(3-piperidin-1 -ylpropoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitio-4-((tetxahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-ch]oro-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-4-(3-(dimethylamino)propoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; -113- 4-(4-((4'-chloro-4-(2-morpholin-4-ylethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(3 -piperidin-1 -ylpropoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2- phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(3-(dimethylaniino)propoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N- ((3-nitro-4-((3-pyrrolidiii-l-ylpropyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N- ((3-nitio-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)pipera2in-l-yl)-N- ((3-nitro-4-((3-pyrrolidin-l-ylpropyl)anuno)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2- (lH-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)ainino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylanuno)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmediyl)amino)phenyl)sulfonyl)benzanude; 4-(4-((4'-chloro-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (lH-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyI)sulfonyl)benzamide; -114- 4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2- (lH-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-3-(2-morpholin-4-ylethoxy)-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2- (lH-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-3-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2- (1 H-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-N- ((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-3-(2-(dimethylaimno)ethoxy)-l,r-bipheny]-2-y])methyl)piperazin-l-yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((3-pyirolidin-l- ylpiopyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((3-pyrTolidin-l- ylpropyl)amino)phenyl)sulfonyl)benzainide; 4-(4-((4'-chloro-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((3-pyrrolidin-l- ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-N- ((3-nitro-4-((l-(2,2,2-lrifluoroethyl)piperidin-4-yl)amino)phenyl)sulfonyl)-2- phenoxybenzamide; 4-(4-((4'-chloro-4-(2-pyiTolidin-1 -ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-4-(2-(diisopropylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)- N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2- phenoxybenzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2,3-dihydro-lH-indol-5-yloxy)- N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylniethyl)amino)phenyl)sulfonyl)benzamide; -115- 4-(4-((2-(4-chlorophenyl)cyclohept-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)- N-((3-nitro-4-((3-pyrrolidin-l-ylpropyl)amino)phenyl)suIfonyl)ben2amide; 4-(4-((2-(4-chlorophenyl)cyclooct-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH-indol-4-yloxy)-N- ((3-nitio-4-((3-pyiTolidin-l-ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclopent-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)- N-((3-nitro-4-((3-pyniolidin-l-ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -en-1 -y l)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((4-((l-methylpiperidin-4-yl)ammo)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4-(4-ch]orophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yl)-2- (1 H-indol-4-yloxy)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclooct-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH-indol-4-yloxy)-N- ((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclohept-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)- N-((4-((l-methylpiperidm-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-ch]orophenyl)cyclopent-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)- N-((4-((l-methylpiperidin-4-yI)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH-indoI-4-yloxy)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4-(4-ch]orophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yl)-2- (lH-indol-5-yloxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzanude; 4-(4-((2-(4-chlorophenyl)cyclohept-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-5-yloxy)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(( 1 - methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4.(4-((4'-ch]oro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((2- (dimethylamino)ethyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-morpholin-4- ylpropyl)aniino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)niethyl)piperazin-1 -yl)-N-((4-((4- (dimethylaniino)butyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; -116- 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-(( 1 - (phenylsulfonyl)piperidin-4-yl)amino)phenyl)sulfonyl)-2-phenoxybeiizamide; 4-(4-((4'-ch]oro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-N-((3 -nitro-4-(( 1 -(quinolin-8- ylsulfonyl)piperidin-4-yl)aniino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-2-phenoxy-N-((4-(( 1 - (phenylsulfonyl)piperidin-4-yl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1'-bipheny l-2-yl)methyl)piperazin- l-yl)-2-phenoxy-N-((4-(( l-(quinolin-8- ylsulfonyl)piperidin-4-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-(((lS)-3-(dimethylamino)-l- thien-2-ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((thien-2- ylmethyl)aniino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-phenoxy-N-((4-((tetrahydro-2H- pyran-4-ylmethyl)aniino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((2-(lH-l,2,3- triazol-l-yl)ethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4.(4.((4'.chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((2-(2H-l,2,3- triazol-2-yl)ethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(2-naphthyloxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3 -nitro-4-((2-(2-oxopyridin- l(2H)-yl)ethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1'-bipheny l-2-yl)methyl)piperazin- l-yl)-N-((3-nitro-4-((2-(pyridin-2- yloxy)ethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-N-((3 -nitro-4-((2-pyridin-4- ylethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-(trifluoromethyl)phenyl)sulfonyl)-2-(lH-indol-5- yloxy)benzamide; -117- 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((3- cyano-4-((3-(dimethylamino)propyl)aimno)phenyl)sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1/f- indol-5-yloxy)-A'-((3-nitro-4-((l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1//- indol-5-yloxy)-^-((4-((4-methylpiperazin-l-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-( 1 -(4'-chloro-1,1 '-biphenyl-2-yl)ethyl)piperazin- l-yl)-2-( lH-indol-4-yloxy)-7V-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; ^-((4-(((4-aminotetrahydro-2f/-pyran-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-((2- (4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( l//-indol-4- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]mediyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- (lH-indol-5-yloxy)-N-({4-[(4-moipholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin- l-yl)-2-( IH- indol-5-yIoxy)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4-{[2-(4-cMorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(3-nitro-4- {[(3S)-tetrahydro-2H-pyran-3- ylmethyl]amino}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazm-l-yl)-2-(lH- indol-5-yloxy)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-pyran-3- ylmethyl]amino}phenyl)sulfonyl]benzamide; 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-( 1 H-indol-5-yloxy)-N-( {3-nitio-4-[(tetrahydro-2H-pyTan-4- ylmethyl)amino]phenyl) sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-[(4- {[(4-hydroxy-l-methylpiperidin-4-yl)methyl]amino)-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; -118- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-3-fluoro- 2-(lH-indol-5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitiophenyl} sulfonyl)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl jpiperazin- l-yl)-3-fluoro- 2-(lH-indol-5-yloxy)-N-({3-nitio-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl) sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-N- [(4- {[(4-hydroxy-l-methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide; N-[(4-{[(3S,4R)-l-benzyl-3-hydroxypiperidin-4-yl]amino)-3-nitrophenyl)sulfonyl]-4-(4-{[2- (4-chloiophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5- yloxy)benzamide; N-[(4-{[(4-aminotetrahydro-2H-pyran-4-yl)methyl]aniino}-3-nitrophenyl)sulfonyl]-4-(4-{[2- (4-chloK)phenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yI]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(4- {[ 1 -(2-methoxyethyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-[(4- {[l-(2-hydroxyethyl)piperidin-4-yl]aniino)-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin- l-yl)-2-( 1H- indol-4-yloxy)-N-[(4- {[ l-(2-methoxyethyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-[(4- {[l-(3-hydroxypropyl)piperidin-4-yl]amino}-3-nitrDphenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide; 4-[4-({4'-cliloro-3-[3-(dimethylamino)propyl]-l,r-biphenyl-2-yl}methyl)piperazin-I-yl]-2- (1 H-indol-4-yloxy)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)aniino]pheny 1} sulfonyl)benzamide; -119- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl ]methyl} piperazin-1 -yl)-N- [(4- {[l-(3-hydroxypropyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4- {4- [(4'-chloro-4-morpholin-4-yl-1,1 '-bipheny l-2-yl)methyl]pipera2in-1 -yl} -2-( 1 H-indol-4- yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)aimno]phenyl}sulfonyl)benzamide; 4- [4-( {4'-chloro-3- [2-(dimethylamino)ethoxy ]-1,1 '-biphenyl-2-yl} methyl)piperazin-1 -yl] -2- (lH-indol-4-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N- [(4- {[4-(diethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N- [(4- {[4-(dimethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N- [(4- {[4-(diethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-({4-[(4-moipholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-[4-( {4'-cliloro-3- [2-(dimethylamino)ethoxy]-1,1 '-biphenyl-2-yl} methyl)piperazin-1 -yl]-2- (1 H-indol-4-yloxy)-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3 - nitiophenyl} sulfonyl)benzamide; 4-{4.[l.(4'.chloro-l,l'-biphenyl-2-yl)ethyl]piperazin-l-yl}-2-(lH-indol-4-yloxy)-N-({4-[(l- methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-N- {[4- ({[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl }amino)-3-nittophenyl]sulfonyl} -2- (lH-indol-5-yloxy)benzamide; N-({4-[(2-aminocyclohexyl)amino]-3-nitrophenyl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indol-5-yloxy)benzamide; 4-[4-({ 4'-chloro-4-[3-(dimethylamino)prop-1 -ynyl]-1,1 '-biphenyl-2-yl} methyl)piperazin-1- yl]-2-( 1 H-indol-4-yloxy)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; -120- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-2-( 1H- indol-4-yloxy)-N-[(3-nitro-4- {[ l-(4,4,4-trifluorobutyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl ]methyl} piperazin-1 -yl)-N- [(4- {[2-(4-hydioxy-1 -methylpiperidin-4-yl)ethyl]amino} -3-nitiophenyl)sulfonyl]-2-( 1 H-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(3-nitro-4-{[l-(l,3-thiazol-2-yl)piperidin-4- yl]amino}phenyl)sulfonyl]benzanude; 4-(4-{[4'-chloro-4-(2-hydroxyethoxy)-l,r-biphenyl-2-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N- [(4- {[ 1 -(cyclopropylmethyl)piperidin-4-yl]amino} -3-nitrophenyl)sulfonyl]-2-( lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(3-nitro-4-{[l-(4,4,4-tiifluorobutyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamide; 4. {4.[ i-(4'-ch]oro-1,1 '-biphenyl-2-yl)ethyl]piperazin- 1-yl} -2-(lH-indol-4-yloxy)-N-( {4-[(4- methylpiperazin- l-yl)amino]-3-nitrophenyl }sulfonyl)benzamide; 4- [4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} -3- (hydioxymethyl)piperazin-l-yl]-2-(lH-indol-5-yloxy)-N-({4-[(l-methylpiperidin-4- yl)amino]-3-nitrophenyl) sulfonyl)benzamide; 4- [4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} -3- (hydroxymethyl)piperazin-l-yl]-2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H- pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-({4-[(4-methylpiperazin-l-yl)anuno]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4- {[4'-chloro-4-(2-hydroxyethoxy)-1,1 '-biphenyl-2-yl]methyl) piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; -121- 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl)piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(3-mtro-4- {[3-(3-oxopiperazin-1 - yl)propyl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-[(3-nitro-4- {[3-(3-oxopiperazin-1 - yl)propyl]ainino}phenyl)sulfonyl]benzainide; 4-(4- {[2-(4-chlorophenyl)-5-hydioxycyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-( {3-nitro-4- [(1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl) sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[l-(2,3-dihydro-lH-inden-2-yl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol- 4-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-[(4- {[ 1 -(2,3-dihydro-1 H-inden-2-yl)piperidin-4-yl]amino} -3-nitiophenyl)sulfonyl] -2-( 1 H-indol- 5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-diraethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-[(4-{[(l-morpholin-4-ylcyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(3-nitro-4- {[ 1 -(1,3-thiazol-2-ylmethyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-[(3-nitro-4- {[ l-( 1,3-thiazol-4-ylmethyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl}piperazin-l-yl)-N- {[4- ({[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]methyl) amino)-3-nitiophenyl]sulfonyl} -2- (lH-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcycloliex-1 -en- l-yl]methyl} piperazin-1 -yl)-N- [(4- {[4-(2-hydroxyethyl)piperazin-l-yl]amino)-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; -122- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl) piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-[(4- {[(3S)-1 -methylpyrrolidin-3-yl]amino} -3- nitiophenyI)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl ]methyl} piperazin- l-yl)-N- [(4- {[l-(3-fluoropropyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-[4-{[2-(4-chloiophenyl)-4,4-dimetiiylcyclohex-l-en-l-yl]methyl}-3- (hydroxymethyl)piperazin-l-yl]-2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran- 4-ylmethyl)amino]phenyl} sulfonyl)benzamide; N-[(4- {[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino} -3-nitrophenyl)sulfonyl]-4-[4- {[2- (4-chloTophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}-3-(hydroxymethyl)piperazin-l- yl]-2-(lH-indol-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yI]methyl)piperazin-l-yl)-N-[(4- {[(l-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( 1H- indol-4-yloxy)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin- l-yl)-N- [(4- {[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]amino} -3-nitrophenyl)sulfonyl]-2-( IH-indol- 5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N- [(4- {[4-(hydroxyniethyl)tetrahydro-2H-pyran-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol- 4-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-diniethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4- [(2-hydroxy-l-tetrahydro-2H-pyran-4-y]ethyl)amino]-3-nitrophenyl}su]fonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-{ [3-nitro-4-({ l-[2-(lH-pyrazol-l-yl)ethyl]piperidin-4- yl}amino)phenyl]sulfonyl}benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( IH- indol-4-yloxy)-N-( {3-nitio-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en- l-yl]methyl) piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-{[4-(methylamino)-3-nitrophenyl]sulfonyl)benzamide; -123- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( IH- indol-4-yloxy)-N-{[4-(methylamino)-3-nitrophenyl]sulfonyl}benzamide; 4-{4-[l-(4'-chloro-l,l'-biphenyl-2-yl)ethyl]piperazin-l-yl}-2-(lH-indol-4-yloxy)-N-({4-[(3- morpholin-4-ylpropyl)amino]-3-mtrophenyl} sulfonyl)benzaniide; 4-(4- {[2-(4-chlorophenyl)-5-hydrDxycyclohex-1 -en-1 -yl]methyl }piperazin-1 -y l)-2-( 1 H-indol- 5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-5-morpholin-4-ylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- (1 H-indol-5-yloxy)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)anuno]phenyl}sulfonyl)benzamide; N-[(4- {[(1 -aminocyclohexyl)methyl]amino} -3-nitropheny])sulfonyl]-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-[(3-nitro-4-{[2-(2-oxopyrTolidin-l- yl)ethyl]amino}phenyl)sulfonyl]benzamide; 4.{4.[l.(4'.chloro-l,l'-biphenyl-2-yl)etliyl]piperazin-l-yl}-2-(lH-indol-5-yloxy)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4-{l-[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]ethyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4- {l-[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]ethyl }piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-({4-[(4-metliylpiperazin-l-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4- {4-[( IR)- l-(4'-cMoio-l, 1 '-biphenyl-2-yl)ethyl]piperazin- 1-yl} -2-(lH-indol-4-yloxy)-N- ({3-nitro-4- [(tetxahydro-2H-pyran-4-ylmethyl)aniino]phenyl} sulfonyl)benzamide; 4-{4-[(lS)-l-(4'-chloro-l,l'-biphenyl-2-yl)ethyl]piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4- {1 -[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl }piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzaniide; 4-(4- {1 - [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl }piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-N-( {4- [(cyclohexylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5-yloxy)benzamide; -124- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-{[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl}benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({3-nitiD-4-[(tetrahydro-2H-pyran-3- ylmethyl)amino]pheny 1} sulfonyl)benzaraide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin- l-yl)-2-( IH- indol-4-yloxy)-N-{[4-(morpholm-4-ylamino)-3-nitrophenyl]sulfonyl}benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]niethyl }piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-{[3-mtro-4-(tetrahydro-2H-pyran-4-ylamino)phenyl]sulfonyl}benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-diniethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(4- {[(3-methyloxetan-3-yl)methyl]amino) -3- nitrophenyl)sulfonyl]benzanude; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(4-methoxycyclohexyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[3-(l,l-dioxidothiomoipholin-4-yl)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(3-nitro-4-{[2-(2-oxopiperidin-l- yl)ethyl]amino} phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(3-nitro-4- {[2-(2-oxoimidazolidin-1- yl)ethyl]amino}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({3-nitro-4-[(2-pyridin-4-ylethyl)amino]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcycloliex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(4-morpholin-4-yl-3-nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-{[4-(4-methoxypiperidin-l-yl)-3-nitrophenyl]sulfonyl}benzaniide; 4-(4- {[2-(4-chlorophenyl)-5-pyrrolidin-1 -ylcyclohex-1 -en-1 -yl]methy 1 jpiperazin-1 -yl)-2- (1 H-indol-5-yloxy )-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; -125- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-[(3-nitro-4- {[2-(3-oxopiperazin-1 - yl)ethyl]amino}phenyl)sulfonyl]benzamide; 4-[4-({4'-chloro-4-[2-(dimethylamino)ethoxy]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-2- (1 H-indol-4-yloxy)-N-( {4- [(4-methylpiperazin-1 -yl)anuno]-3 - nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N- [(4- {[(l,l-dioxidotetrahydrothien-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4- [(1,1 -dioxidotetrahydrothien-3-yl)amino]-3-nitrophenyl) sulfonyl)-2-( 1 H-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]metiiyl}piperazin-l-yl)-2-(lH- indoI-5-yloxy)-N-{[4-[(tetrahydio-2H-pyran-4-ylmethyl)amino]-3- (trifluoromethyl)phenyl]sulfonyl} benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin- l-yl)-N-( {4- [2- (l,3-dioxolan-2-yl)ethyl]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcycIohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N- {[3-nitro-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl }benzamide; 4-(4- {[2-(4-cMorophenyl)-4,4-dimetiiylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-[(3-nitro-4- {[2-(3-oxopiperazin-1 - yl)ethyl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(l-methyl-5-oxopyiTolidin-3-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(l-methyl-6-oxopiperidin-3-yl)anaino]-3- nitrophenyl} sulfonyl)benzanude; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin- l-yl)-2-( IH- indol-4-yloxy)-N- {[3-nitro-4-(piperidin-1 -ylamino)phenyl]sulfonyl} benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-{[3-nitro-4-(piperidin-l-ylamino)phenyl]sulfonyl}benzamide; -126- 4-(4- {[4-(4-chlorophenyl)-1 -methyl-1 H-pyrazol-5-yl]niethyl} piperazin-1 -yl)-2-( lH-indol-5- yloxy)-N-({3-nitro-4-[(tetrahydio-2H-pyran-4-ylmethyI)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(3-methyloxetan-3-yl)methoxy]-3-nitrophenyl)sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-[(3-nitro-4-{[(l-oxidotetrahydro-2H-thiopyran-4- yl)methyl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl jpiperazin- l-yl)-2-( IH- indol-5-yloxy)-N-({3-mtio-4-[(l,3-thiazol-5-ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-2-( 1H- indol-4-yloxy)-N- {[3-nitro-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl}benzaniide; 4-(4- {[2-(4-chlorophenyl)-5,5-dimethylcyclohex- 1-en- l-yl]methyl) piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-( {3-nitro-4-[(2-tetrahydro-2H-pyran-4- ylethyl)amino]phenyl) sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl )piperazin- l-yl)-2-( IH- indol-4-yloxy)-N-[(3-nitro-4- {[2-(trifluoromethoxy)ethyl]amino }phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin- l-yl)-2-( 1H- indol-4-yloxy)-N-[(4-{[2-(2-methoxyethoxy)ethyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-[(4- {[3-(methylsulfonyl)propyl]ainino} -3-nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[3-(l,l-dioxidothiomorpholin-4-yl)propyl]amino)-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-{[3-nitro-4-(2-tetrahydro-2H-pyran-4-ylethyl)phenyl]sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[4- (l,4-dioxan-2-ylmethoxy)-3-tutrophenyl]sulfonyl}-2-(lH-indol-5-yloxy)benzamide; -127- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-[(4-{[2-(2-methoxyethoxy)ethyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [(l,l-dioxidotetrahydrothien-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-4- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(3-nitro-4- {[2-(trifluoromethoxy)ethyl]amino }phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin-1 -yl)-N- [(4- {[(l,l-dioxidotetrahydro-2H-thiopyran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- indol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N-( {4- [(2,2-difluoroethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-2-( IH- indol-4-yloxy)-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3- [(trifluoroniethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl )piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin- l-yl)-N-( {4- [(4,4-difluorocyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5-yIoxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-indol-4- yloxy)benzamide; 4-(4- {[4-(4-chlorophenyl)- l-isopropyl-6-oxo-1,6-dihydropyridin-3-yl]methyl }piperazin-1 - yl)-2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)aniino]pheny 1} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(4-{[(tetrahydro-2H-pyran-4- ylmethyl)amino]caibonyl} phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-({4-[(2-methoxyethyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl)sulfonyl)benzamide; -128- 4-(4-{[2-(4-chIorophenyl)-4,4-dimethyIcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-[(4- {[(4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-N- [(4- {[(4-hydroxycyclohexyl)methyl]amino} -3-nitiophenyl)sulfonyl]-2-( 1 H-indol-5 - yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(4- {[(4-methoxycyclohexyl)methyl]amino} -3- nitrophenyl)siilfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( IH- indol-4-yloxy)-N- {[3-nitrD-4-(2-tetrahydro-2H-pyran-4- ylethoxy)phenyl]sulfonyl jbenzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-( {4- [(2-methoxyethyl)amino] -3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chloTophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indoI-4-yloxy)-N-({4-[3-(methylsulfonyl)propoxy]-3-nitrophenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({4-[(3-methoxypropyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-({4-[(3-methoxypropyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N-( {4- [(2-cyanoethyl)amino]-3-nitrophenyl) sulfonyl)-2-( 1 H-indol-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4- [(2-cyanoethyl)amino]-3-nitrophenyI}sulfonyl)-2-(lH-indol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl) piperazin- l-yl)-N- {[4- ({[(3R)-4-hydroxy- l-adamantyl]methyl} amino)-3-nitiophenyl]sulfonyl} -2-( lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N- {[4- ({[Cis-4-hydroxy-1 -adamantyljmethyl} amino)-3-nitrophenyl]sulfony]) -2-(l H-indol-5- yloxy)benzamide; -129- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-2-( 1H- indol-4-yloxy)-N-({3-nitro-4-[(3,3,3-trifluoropropyl)amino]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({3-nitio-4-[(3,3,3-trifluoiopropyl)amino]phenyl)sulfonyl)benzamide; N-({5-bromo-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-4- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-[(4- {[(l,l-dioxidotetrahydrothien-3-yl)methyl]aniino)-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-N-( {4- [(4-fluorotetrahydio-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({4-(methylainino)-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; N- {[5-bromo-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl} -4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indol-5- yloxy)benzamide; 4-(4-{[4-(4-chlorophenyl)-6-isopropoxypyridin-3-yl]methyl}piperazin-l-yl)-2-(lH-indol-5- yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en- l-yl]methyl} piperazin- l-yl)-2-(lH- indol-5-yloxy)-N-{[6-(tetrahydro-2H-pyran-4-ylmethoxy)-5-(l,3-thiazol-2-yl)pyridin-3- yljsulfonyl) benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(4- {[(2-methoxyethyl)amino]caibonyl }phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-indol-5- yloxy)benzaniide; N-( {4- [(1 -acetylpiperidin-4-yl)amino]-3-nitrophenyl) sulfonyl)-4-(4- {[2-(4-chlorophenyl)- 4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl) piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(4- {[ 1 -(methylsulfonyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzainide; -130- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl ]methyl} piperazin- l-yl)-N-({4- [(l,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5-yloxy)benzamide; N-( {4-[( 1 -acetylpiperidin-4-yl)araino] -3-nitrophenyl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)- 4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-4-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-[(4- {[ 1 -(methylsulfonyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[4'-chloro-5-(trifluoromethyl)-1,1 '-biphenyl-2-yl]methyl} piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[4'-chloro-5-(trifluoromethyl)-1, r-biphenyl-2-yl]methyl }piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-{[3-nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl)benzamide; 4- {4- [(5-tert-butyl-4'-chloro-1, i'-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-( 1 H-indol-5-yloxy)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)benzamide; 4-{4-[(5-teit-butyl-4'-chloro-l,r-biphenyl-2-yl)methyl]piperazin-l-yl}-2-(lH-indol-5-yloxy)- N-{ [3-nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl }benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-({3-mtro-4-[(2,2,2-tiifluoroethyl)amino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]niethyl} piperazin- l-y.l)-2-( IH- indol-5-yloxy)-N-({3-nitro-4-[(2,2,2-trifluoroethyl)amino]phenyl)sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(3- {[(tetrahydro-2H-pyran-4- ylmethyl)amino]carbonyl}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4- [(2R)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl jpiperazin-1 -yl)-N-( {4- [(2S)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-({4-[(3-morpholiii-4-ylpiopyl)amino]-3- [(difluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyI} sulfonyl)benzamide; -131- N-({5-bromo-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl)sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-({4-[(2-morpholin-4-ylethyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-N-( {5- cyano-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)oxy]-3-nitrophenyl)suIfonyl)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[4-(4-chlorophenyl)- l-(3-hydroxypropyl)-1,2,5,6-tetrahydropyridin-3- yl]methyl)piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)aimno]pheny 1} sulfonyl)benzamide; benzyl 4-( {[4-( {[4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 - yl]methyl}piperazin-l-yl)-2-(lH-indol-5-yloxy)benzoyl]amino}sulfonyl)-2- nitrophenyl]amino}methyl)piperidine-l-carboxylate; N- {[3-(aminocarbonyl)-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl} -4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[4'-chloro-5-(trifluoromethyl)-1,1 '-biphenyl-2-yl]methyl} piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 4- {4-[(5-teit-buty]-4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-l -yl} -2-( lH-indol-5-yloxy)- N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)aniino]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(4- {[(1-methyl- lH-imidazol-5-yl)methyl]amino} -3- nitrophenyl)sulfonyl]benzanaide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N- {[4-(morpholin-4-ylsulfonyl)phenyl]sulfonyl }benzamide; -132- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [(1,1 -dioxidothiomorpholin-4-yl)amino]-3 -nitrophenyl} sulfonyl)-2-( 1 H-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; N- {[5-bromo-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl} -4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperaziii-l-yl)-2-(lH-indol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N- {[6-[(tetrahydro-2H-pyran-4-ylniethyl)aniino]-5-( 1,3-thiazol-2-yl)pyridin- 3-yl]sulfonyl }benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl)piperazin- l-yl)-N-({3- cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-indol-4- yloxy)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin- l-yl)-N-( {3- cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4- [(3,3-dimethylbutyl)aniino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[(1S)-1 -(hydroxymethyl)-3-methylbutyl]amino} -3-nitrophenyl)sulfonyl]-2-( 1 H-indol-5 - yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(3-nitro-4- {[(2R)-tetrahydrofuran-2- ylmethyl]amino}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-diniethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[(lR)-l-(hydroxymethyl)-2-methylpropyllamino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indol-5 -yloxy)-N-( {4- [(4-methoxyphenyl)amino]-3 -nitrophenyl} sulfonyl)benzamide; N-[(4-{[2-(l,3-benzodioxol-5-yl)ethyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( lH-indol-5- yloxy)benzainide; -133- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-[(3-nitro-4-{[3-(2-oxopyrTolidin-l- yl)propyl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin- l-yl)-N-( {4- [(4-hydioxyphenyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5-yloxy)benzamide; N- {[4-({ 2-[4-(aminosulfonyl)phenyl]ethyl} aniino)-3-nitrophenyl]sulfonyl} -4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl )piperazin-1 -yl)-2-( 1 H-indol-5- yloxy)benzanude; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-N- [(4- {[3-(lH-iimdazol-l-yl)propyl]ainino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(3-nitro-4-{[(lS)-l-phenylethyl]amino}phenyl)sulfonyl]benzamide; N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5- yloxy)benzainide; 4-(4- {[2-(4-chlorophenyl)-4,4-" (greater than) a certain numerical value, it is intended to mean that the binding affinity value (e.g., for BC1-XL) is greater than the limits of detection of the assay used. Where the binding selectivity ratio for a compound is represented as ">" (greater than) a certain numerical value, it is intended to mean that the selectivity of a particular compound for Bcl-2 over BC1-XL is at least as great as the number indicated. Where the Kj for a compoimd is represented as "<" (less than) a certain numerical value, it is intended to mean that the binding affinity value -214- (e.g., for Bcl-2) is lower than the limit of detection of the assay used. Inhibition constants were determined using Wang's equation (Wang Z-X., An Exact Mathematical Expression For Describing Competitive Binding Of Two Different Ligands To A Protein Molecule. FEBSLett. 1995, 360:111-4). TABLE 2. TR-FRET Binding Affinity Binding selectivity ratio (BCI-XLKI/Bcl-2 Bcl-2 Ki, BC1-XL Ki K;) Example (HM) (HM) ABT-737 0.000088 0.00008 09 i 0.006773 0.57833 SSii 18 0.000238 0.008131 3I2 19 0.000847 0.020027 216 20 0.002365 0.077593 318 21 0.005428 0.19038 35l 22 0.006218 0.1253 202 23 0.006639 0.16782 753 24 0.000194 >0.66 >3402.I 25 0.00005 020519 4103.8 26 0.00014 >0.66 >4714.3 28 0.033705 >0.66 >19.6 29 0.011911 >0.66 >55.4 30 0.10292 >0.66 '^A 31 0.036614 >0.66 >18.0 32 0.061123 >0.66 >10.8 33 0.006684 033339 49^9 34 0.001986 0088007 443 36 0.000796 0.008995 Til 37 0.000464 0.044422 95?7 40 0.000534 >0.66 >1236.0 42 0.000048 0003841 80 -215- 45 I 0.000828 I >0.66 I >797.1 46 0.000159 0.018958 mJ. 47 0.00663 0.10428 TSJ 50 0.000471 0.090073 1913 51 0.000252 0.015646 62l 52 0.000239 0.079805 333.9 53 0.000081 0.004845 59^8 54 0.000757 0.082015 lOSl 55 0.000196 0.02488 i26!9 56 0.000268 0.012924 48^2 57 0.000068 0.004674 68?7 58 0.001085 0.28807 265.5 59 0.000672 llss 1867.6 60 0.01893 >0.66 >34.9 61 0.05221 >0.66 >12.6 62 0.003516 0.5711 1614 64 0.000523 0.040334 fjl 65 0.004558 0.021805 48 67 0.28867 >0.66 >23 68 0.001227 0.013969 UA 69 0.001245 0.092074 74 70 0.001192 0.074407 6l4 71 0.006233 >0.66 >105.9 72 0.003022 0.052359 TO 73 0.001697 0.016885 9^9 74 0.00002 0.025249 1262.5 75 0.000125 0.10653 852.2 76 0.000051 0.003288 645 78 0.11251 >0.66 >5'!9 79 0.00205 0.0972 4M 85 0.000236 0.011521 40 86 0.000212 0.010522 49^6 -216- 87 I 0.000762 I 0.40679 I 533.8 88 0.000069 0.004642 67J 89 0.000129 0.007453 57^ 90 0.002134 0.28384 133 91 0.000193 0.010191 5Z8 92 0.004375 0.34857 79J 93 0.000231 0.013861 60 94 0.00007 0.002317 33l 95 0.00006 0.015699 261.7 96 0.000047 0.008781 1861 97 0.000027 0.002611 96?7 98 0.000013 >0.66 >50769.2 99 0.00004 0.00553 1381 100 0.000116 0.008288 7L4 iol 0.000092 0.011152 1213 m 0.000035 0.002242 64J 103 0.000056 0.11738 2096.1 104 0.000077 0.049106 637.7 105 0.00008 0.005016 62?7 107 0.002087 0.13041 6l5 108 0.002342 0.059639 253 109 0.000161 >0.66 >4099.4 114 0.000096 0.014325 l49!2 lis 0.000176 0.027527 T56A 116 0.000036 0.008305 2307 UT 0.002299 >0.66 >287.1 US 0.000769 >0.66 >858.3 119 0.000622 0.23029 370.2 120 0.000443 0.099593 224.8 m 0.000001 0.000388 388 122 0.000058 0.012144 209.4 123 0.000015 0.001372 9L5 -217- 124 I 0.000335 I 0.073725 I 220.1 125 0.000003 0.011637 3879 126 0.000012 0.1629 13575 127 0.000459 >0.66 >1437.9 128 0.000051 0.363 7117.6 129 0.000056 >0.66 >11785.7 130 0.00014 >0.66 >4714.3 m 0.000106 0.24297 2292.2 132 0.000553 0.31529 5701 133 0.000009 0.000281 3L2 134 0.000052 0.01805 3471 135 0.000008 0.006239 779.9 136 0.000259 0.061863 238.9 137 0.000305 0.015977 52A 138 0.000009 0.005174 574.9 139 0.000101 0.010416 TdH. 140 0.004726 >0.66 >139.7 141 0.000673 0.028642 4l6 142 0.003664 0.10184 2X8 143 0.002232 0.075383 SIs 144 0.053902 >0.66 >12.2 145 0.00003 0.012029 401 146 0.044184 >0.66 >14.9 147 0.000514 >0.66 > 1284.0 148 0.00289 >0.66 >228.4 149 0.000265 >0.66 >2490.6 150 0.000014 0.009338 667 m 0.000162 >0.66 >4074.1 152 0.000026 0.000412 TIs 153 0.000265 0.093006 351 154 0.000133 0.005375 404 155 0.000484 0.037667 TTS -218- 156 I 0.000116 I 0.006155 I 511 157 0.004454 >0.66 > 148.2 158 0.06478 >0.66 >10.2 161 0.00171 >0.66 >386.0 162 0.001348 0.16692 1231 163 0.005616 >0.66 >117.5 AM 0.000963 0.13795 1431 V^ 0.000823 0.036585 445 166 0.000459 0.00327 ~l 169 0.00097 0.088637 914 170 0.000126 0.003802 302 m 0.002942 0.052053 TTTT 172 0.002048 0.06569 321 173 0.000108 0.022102 204.6 174 0.000105 0.062087 591.3 175 0.0001 >0.660 >6600 176 0.00018 0.032 ITTI 177 0.000165 0.132 799.7 178 0.000226 >0.660 >2915.8 179 0.000181 >0.660 >3642.4 180 0.000192 >0.660 >3438.6 181 0.000291 >0.660 >2271.9 182 0.000087 >0.660 >7595.8 183 0.000039 0.009428 240.5 184 0.000281 >0.660 >2345.3 185 0.000228 0.082582 3611 186 0.00001 0.011199 1069.2 187 0.000329 >0.660 >2003.9 188 0.000102 0.11529 1135.4 189 0.000144 0.051724 3581 190 0.000512 0.097064 189.6 m 0.000073 0.009162 1251 -219- 194 I 0.000151 I 0.032029 I 212.4 195 0.000039 0.00671 1702 1% 0.000032 >0.660 >20552.4 197 0.000025 0.004837 193 198 0.003966 >0.660 >166.4 199 0.000014 0.005231 mS 200 0.0001 >0.660 >6588.8 201 0.000125 0.024585 196.6 202 0.000052 0.005073 9X1 203 0.000031 0.004305 1391 204 0.000145 0.042341 291.3 205 0.000005 0.003573 658.6 206 0.000083 >0.660 >7916.4 207 0.000218 >0.660 >3021.3 208 0.000589 >0.660 >1120.6 209 0.000267 >0.660 >2476.0 210 0.000624 >0.660 >1057.6 211 0.000009 0.005612 6511 212 0.000737 >0.660 >895.1 213 < 0.00001 >0.660 >66000 214 0.000082 0.064044 776.6 215 0.000503 0.060768 1208 216 0.000615 >0.660 >1073.2 217 0.000262 0.044761 ITU 218 0.000131 0.096873 738.2 219 0.000236 0.029861 ml 220 0.000192 0.031387 16377 221 0.000057 0.1701 3005.2 222 0.000107 0.13661 1275.3 223 0.000169 0.097266 5741 224 <0.00001 0.000999 >99.9 225 0.00001 0.003482 >348.2 -220- 226 I 0.000017 I 0.009928 I 577.7 227 0.006831 >0.660 >96.6 228 0.004669 >0.660 >141.4 229 0.049413 >0.660 >13.4 230 0.008819 >0.660 >74.8 231 0.000918 >0.660 >718.8 232 0.00046 0.19749 429.1 233 0.000243 >0.660 >2714.3 234 0.000369 0.024503 663 235 0.000252 0.058196 231.4 236 0.000369 >0.660 >1787.6 237 0.000401 0.268 668.3 238 0.00043 >0.660 >1534.3 239 0.000252 0.10842 4309 240 0.00083 >0.660 >795.4 241 0.006091 >0.660 >108.3 242 0.001796 >0.660 >367.6 243 0.00028 >0.660 >2357.6 244 0.00016 >0.660 >4136.9 245 0.001617 >0.660 >408.2 246 0.000783 0.38418 490.9 247 0.000188 0.027265 145.3 248 0.000013 0.15503 12079.6 249 0.00009 >0.660 >7302.0 250 0.000266 0.21547 STI 251 0.000328 0.47166 1438.5 252 0.000077 >0.660 >8570.3 253 0.000142 >0.660 >4663.3 254 0.000126 0.053315 421.7 255 0.007834 >0.660 >84.2 256 0.00012 >0.660 >5519.8 257 0.000171 0.017126 100.2 -221- 258 I 0.000048 I 0.004085 I 86 259 0.001995 >0.660 >330.9 260 0.001087 >0.660 >607.2 261 0.000088 >0.660 >7530.1 262 0.003001 >0.660 219.9 263 0.000316 >0.660 >2090.0 264 0.000235 >0.660 >2808.4 265 0.001698 >0.660 >388.8 266 0.000183 >0.660 >3607.7 267 0.000454 >0.660 >1453.3 268 0.000092 0.14465 1563.9 269 iid iid iid 270 0.003314 >0.660 >199.1 271 0.006156 >0.660 > 107.2 272 0.000011 >0.660 >58011.8 273 0.000076 0.18104 2396.1 274 0.000135 0.032908 244.6 275 0.000097 >0.660 >6832.4 276 0.000144 0.38147 2650.8 277 0.029684 >0.660 >22.2 278 0.00071 >0.660 >929.4 279 0.000095 >0.660 >6923.2 280 0.000178 0.19477 1097.2 281 0.000076 0.11925 1558.9 282 0.000164 0.56153 3434.4 283 0.047464 >0.660 >13.9 284 0.001552 >0.660 >425.2 285 0.006994 >0.660 >94.4 286 0.000567 >0.660 >1165.0 287 nd iid iid 288 0.000177 >0.660 >3730.9 289 0.000112 >0.660 >5917.7 -222- 290 I 0.000365 I >0.660 I >1808.5 291 0.00056 >0.660 >1179.1 292 0.000598 >0.660 >1104.2 293 0.000516 0.2604 5051 294 0.000258 0.065126 252 295 0.000183 0.10971 599.4 296 0.000651 >0.660 > 1014.4 297 0.000128 0.28281 2209.5 298 0.000315 0.44593 1415.7 299 0.000425 0.24551 577.7 300 lid >0.660 iid 301 0.000291 >0.660 >2268.0 302 0.000504 >0.660 >1309.5 303 0.00148 >0.660 >445.9 304 0.000678 >0.660 >973.5 305 0.003684 >0.660 >179.2 306 0.000077 0.047895 622 307 0.003727 >0.660 >177.1 308 0.057376 >0.660 >11.5 309 0.004417 >0.660 >149.4 310 0.000049 >0.660 >13469.4 311 0.00026 >0.660 >2538.5 312 0.00034 >0.660 >1941.2 313 0.000044 0066 Tm 314 0.003066 >0.660 >215.3 315 0.003461 >0.660 >190.7 316 0.000149 0.079528 533.7 317 0.002798 >0.660 >235.9 318 0.001468 0.15067 Iol6 ' 319 0.000413 0.20791 503.4 320 0.001243 0.12873 103.6 321 0.000689 >0.660 >957.9 -223- 322 I 0.000184 I >0.660 | >3591.4 323 0.000949 >0.660 >695!2 324 0.001481 >0.660 >445.7 325 0.002331 >0.660 >283.1 326 0.000116 >0.660 >5708.8 327 0.000031 0.095575 3035.4 328 0.001859 >0.660 >355.0 329 0.000285 >0.660 >2319.5 330 0.074915 >0.660 >8!8 331 0.008266 >0.660 >79.8 332 0.012582 >0.660 >52.5 333 0.000089 >0.660 >7415.7 334 0.000179 >0.660 >3697.5 335 0.000438 >0.660 >1508.2 336 0.000105 0.24152 2301.3 337 0.000535 >0.660 >1233.3 338 0.000403 >0.660 >1637.7 339 0.014136 >0.660 >46.7 340 0.007593 >0.660 >86.9 341 0.012998 >0.660 >50.8 342 0.025752 >0.660 >25.6 343 0.000576 >0.660 >1145.9 344 0.000284 0.44708 1576.9 345 0.001146 >0.660 >575.9 346 0.000018 0.20364 11405.2 347 0.000243 0.30556 1256.7 348 0.000302 0.029266 97l 349 0.000467 0.024235 5L9 350 0.00597 >0.660 > 110.6 351 0.001576 >0.660 >418.7 352 0.006825 >0.660 >96.7 353 0.000292 >0.660 >2260.0 -224- 354 I 0.000036 I 0.00541 I MO 355 0.00012 >0.660 >5489.5 356 0.005015 >0.660 >131.6 357 0.001336 >0.660 >493.9 358 0.005417 >0.660 >121.8 359 0.013481 >0.660 >49.0 360 0.000228 0.14423 633.9 361 0.007128 >0.660 >92.6 362 0.000082 0.28999 3548.2 363 0.00018 >0.660 >3670.5 364 0.000006 0.07596 12197.3 365 0.001077 >0.660 >612.9 366 0.005457 >0.660 >121.0 367 0.004608 >0.660 >143.2 368 >1.195 >0.660 iid 369 0.8382 >0.660 >a8 370 0.000904 >0.660 >729.9 371 0.008376 >0.660 >78.8 372 >1.195 >0.660 iid 374 0.002266 >0.660 >291.2 375 0.011254 >0.660 >58.6 376 0.022405 >0.660 >29.5 377 0.00014 0.32457 2317.4 378 0.063003 >0.660 >10.5 379 0.25595 >0.660 >I6 380 0.000083 0.17491 2107.3 381 0.000054 0.024207 448.3 382 0.00115 >0.660 >573.9 383 0.00217 >0.660 >304.1 384 0.000076 >0.660 >8684.2 385 0.000062 0.12998 2096.5 386 0.000239 0.11818 494.5 -225- 387 I 0.000162 I 0.27983 I 1723.4 388 0.000188 0.034845 1851 389 0.000098 0.067181 685.5 390 0.000341 0.11581 339.6 391 0.00354 >0.660 >186.4 392 0.00038 0.121691 320.2 393 0.000083 0.0921 1109.6 394 0.002507 >660 > 263262.9 395 0.000798 0.018843 23!6 396 0.11567 >660 >5705.9 397 0.022972 > 660 >28730.6 398 0.001233 0.083449 67?7 399 0.002923 > 660 > 225764.5 400 < 0.00001 0.036438 > 3643.8 401 < 0.00001 0.001621 > 162.1 402 0.00003 0.004152 TdTA 403 0.000003 0.024340 8250.6 404 0.000012 0.030268 2423.5 405 0.000040 0.055325 1394.8 406 0.000035 0.044553 1263.8 407 0.000015 0.074556 4930.6 408 0.000002 0.028131 13701.7 409 < 0.000010 0.017485 1748.5 410 0.000055 0.101630 1838.6 411 0.000003 0.007453 2352.3 412 0.000021 0.135210 6545.5 413 0.000120 0.096802 803.8 414 0.000007 0.095640 13930.5 415 0.000002 0.026900 17326.9 416 0.000023 0.059112 2569.0 417 0.000046 0.003986 8X1 418 0.000004 0.001566 404.7 -226- 419 I 0.000197 I 0.211240 I 1070.8 420 0.000063 0.072108 TTsIs 421 0.000026 0.054039 20891 422 0.000071 0.289500 4073.4 423 < 0.000010 0.007566 756^6 424 < 0.000010 0.007825 782.5 425 0.000003 0.003995 1282.2 426 0.000007 0.004311 604.2 427 0.000002 0.085636 34408.6 4^ 0.000003 0.015643 5832.2 429 < 0.000010 0.001407 i40?7 430 < 0.000010 0.000998 99^8 431 < 0.000010 0.006774 677.4 432 0.000023 0.009298 408.8 433 < 0.000010 0.002286 228.55 434 0.000052 0.075474 1459.4 435 0.000017 0.032896 1935.1 436 0.000011 0.006500 590.9 437 < 0.000010 0.000514 5L4 438 < 0.000010 0.000345 345 439 < 0.000010 0.014968 i496!8 440 < 0.000010 0.045491 4549.1 441 < 0.000010 0.024219 2421.9 442 < 0.000010 0.033589 3358.9 443 < 0.000010 0.019357 i935?7 444 0.000112 0.081494 727.6 445 0,000028 0.013557 484.2 446 0.000038 0.019318 508.4 447 0.000028 0.065838 2373.1 448 0.000005 0.014610 3119.3 449 0.000240 0.017841 74!4 450 0.000299 0.032065 WJ3 -227- 451 I < 0.000010 I 0.003599 I 359.9 452 < 0.000010 0.006004 600.4 453 < 0.000010 0.003630 363.0 454 0.000026 0.018906 735.2 455 0.000004 0.000619 139^4 456 < 0.000010 0.000540 540 457 0.000045 0.330930 7413.6 458 < 0.000010 0.002372 237.2 459 < 0.000010 0.005416 541.6 460 0.000049 0.028982 586.5 461 0.000093 0.003650 39^4 462 0.000026 0.018425 710.8 463 0.000007 0.043884 6042.9 464 0.000081 0.521110 6431.8 465 0.000025 0.037216 1472.4 467 0.000080 0.13291 1653.0 473 0.079276 0.19124 14 474 0.0081 iid iid 475 nd nd nd 476 nd nd nd 477 0.0085 nd iid 478 iid iid iid 479 iid iid iid 480 iid iid iid 481 iid iid iid 482 0.000064 0.349890 5442.9 483 < 0.000010 0.005630 >563.0 484 < 0.000010 0.034339 >3433.9 485 0.000167 0.054207 324.0 486 0.000328 0.025460 77!6 487 0.000033 0.075419 2287.2 488 < 0.000010 0.023459 >2345.9 -228- 490 I 0.001144 I 0.106070 I 92?7 491 0.000017 0.077183 4600.5 492 < 0.000010 0.045096 >4509.6 493 < 0.000010 0.041883 >4188.3 494 < 0.000010 0.015566 >1556.6 496 0.000078 0.043348 558^9 497 0.000082 0.124230 1517.4 498 < 0.000010 0.124910 >12491.0 499 < 0.000010 0.104150 >10415.0 500 < 0.000010 0.147340 >14734.0 501 0.000027 0.162530 6025.7 502 0.000025 0.144860 5754.1 503 0.000062 0.146640 2356.5 504 < 0.000010 0.005499 >549.9 505 < 0.000010 0.004861 >486.1 506 < 0.000010 0.004457 >445.7 507 < 0.000010 0.033347 >3334.7 508 < 0.000010 0.043152 >4315.2 509 0.006300 0.229180 36^4 STO 0.000674 0.173870 257.8 511 < 0.000010 0.021592 >2159.2 512 < 0.000010 0.017338 >1733.8 513 < 0.000010 0.006462 >646.2 514 < 0.000010 0.010413 >1041.3 515 < 0.000010 0.139940 > 13994.0 516 < 0.000010 0.004823 >482.3 SIT < 0.000010 0.006077 >607.7 518 < 0.000010 0.002546 >254.6 519 0.000012 0.310940 25935.4 520 < 0.000010 0.015378 >1537.8 521 < 0.000010 0.004669 >466.9 522 < 0.000010 0.002079 >207.9 -229- 523 I < 0.000010 I 0.049444 I >4944.4 524 < 0.000010 0.022184 >2218.4 525 < 0.000010 0.018984 >1898.4 526 < 0.000010 0.004679 >467.9 527 < 0.000010 0.004219 >421.9 528 < 0.000010 0.003669 >366.9 529 < 0.000010 0.008284 >828.4 530 < 0.000010 0.076660 >7666.0 531 < 0.000010 0.012578 >1257.8 532 < 0.000010 0.009812 >981.2 533 < 0.000010 0.010443 >1044.3 534 < 0.000010 0.046039 >4603.9 535 < 0.000010 0.002505 >250.5 536 0.000025 0.022152 8861 538 < 0.000010 0.008001 >800.1 539 < 0.000010 0.040843 >4084.3 540 < 0.000010 0.001247 >124.7 541 < 0.000010 0.001382 >138.2 542 0.000023 0.124230 5359.8 543 < 0.000010 0.150470 >15047.0 544 < 0.000010 0.067003 >6700.3 545 < 0.000010 0.003566 >356.6 546 < 0.000010 0.006699 >669.9 547 0.000015 0.062949 4287.5 548 0.000014 0.028544 2111.7 549 < 0.000010 0.014820 >1482.0 550 0.000016 0.027218 1738.4 551 < 0.000010 0.016246 >1624.6 552 < 0.000010 0.010447 >1044.7 553 < 0.000010 0.013383 >1338.3 554 0.000034 0.057243 1674.6 555 < 0.000010 0.006298 >629.8 -230- 556 I 0.000034 I 0.091831 I 2730.2 557 0.000069 0.013166 r89!8 538 0.000064 0.349890 5442.9 539 < 0.000010 0.005630 >563.0 540 < 0.000010 0.034339 >3433.9 541 0.000167 0.054207 324.0 542 0.000328 0.025460 7X6 543 0.000033 0.075419 2287.2 544 < 0.000010 0.023459 >2345.9 545 0.0001749 0.13811 789.7 546 0.001144 0.106070 92?7 547 0.000017 0.077183 4600.5 548 < 0.000010 0.045096 >4509.6 549 < 0.000010 0.041883 >4188.3 550 < 0.000010 0.015566 >1556.6 551 0.000078 0.043348 558.9 552 0.000082 0.124230 1517.4 553 < 0.000010 0.124910 >12491.0 554 < 0.000010 0.104150 >10415.0 555 < 0.000010 0.147340 >14734.0 556 0.000027 0.162530 6025.7 557 0.000025 0.144860 5754.1 558 iid nd iid nd = not determined TABLE 2 shows the utility of compounds having Formula I to functionally inhibit anti-apoptotic Bcl-2 protein. It also suiprisingly demonstrates these compounds having comparatively less affinity for anti-apoptotic Bcl-xL protein, which in turn gives rise to high binding selectivity ratios (Bcl-xL Ki / Bcl-2 Ki) ranging from >2 to > 250,000. This selectivity for Bcl-2 protein is significantly greater than compounds previously disclosed in PCT US 2004/36770 and PCT US 2004/367911, as exemplified by ABT-737 in TABLE 2. For some compounds (e.g., 192 and 193), the assay did not detect any activity against either Bcl-2 or Bcl-XL under the conditions stated above in the experimental description for -231- the FRET assay . As those skilled in the art will appreciate, the upper and lower limits of detection in an assay are influenced by the assay conditions, and for the FRET assay specifically, by the concentration of the probe that is used. Since compounds represented by Examples 192 and 193 show Ki values that are greater than the limits of detection in the assay format used, it can be stated that their affinity for Bcl-2 and Bcl-XL is less than the upper limit of detection of the assays. However, they may still have affinity for one or both proteins, and the inventors expect that they also have selectivity for Bcl-2. Platelet Cell Viability Assay Platelet-rich plasma (PRP) (prepared in-house according to conventional techniques) was incubated with ABT-737 (4-(4-((4'-ch]oro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-(((lR)-3-(dimethylamino)-l-((phenylthio)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)benzamide) or compounds of the invention at various concentrations for five hours at 37°C. After the incubation, platelets were equilibrated to room temperature for 20 minutes and then an equal volume of Cell Titer Glo reagent (Promega Corporation) was added. Samples were mixed for two minutes and then allowed to equilibrate for an additional 10 minutes at room temperature. The luminescence generated from the samples was quantitated using an UL Analyst plate reader. IC50 values are concentrations of compound needed for 50% inhibition of cellular viability. FL5.12/Bcl-2 cell viability assay FL5.12 is an IL-3 dependent prolymphocytic murine cell line that undergoes apoptosis upon IL-3 withdrawal as a result of the upregulation of pro-apoptotic Bcl-2 proteins such as Bim and Puma. Stable overexpression of anti-apoptotic Bcl-2 protein (FL5.12/Bcl-2) protects against apoptosis induced by IL-3 withdrawal by sequestration of Bim and Puma. [Refs. Harada, etal. PNAS IQl, 15313 (2004); Certo, et.al. Cancer Cell 9,351 (2006).] The ability of compounds to kill FL5.12/Bcl-2 cells upon IL-3 withdrawal is a direct measure of the compounds' ability to inhibit anti-apoptotic Bcl-2 protein function. Wild type FL5.12/Bcl-2 overexpressing stable transfectants were cultured in RPMI-1640 supplemented with 2 mM L-glutamine, 10% FBS, 1 mM sodium pyruvate, 2 mM HEPES, 1% penicillin/streptomycin (Invitiogen), 57 pM P-ME, and 10% WEHI-3B conditioned medium (source of IL-3) and maintained at 37 °C containing 5% C02. 1x10^ cells/ml were washed 1 x PBS and resuspended in medium not supplemented with 10% WEHI-3B for 48 hrs prior to cytotoxicity assays. Cells were then treated for an additional 24 hrs in the presence of various concentrations of the indicated compounds. Cell viabiUty was -232- assessed by CeUTitre Glo assay (Promega Corp.) according to the manufacturer's recommendations. Data analysis was performed using GraphPad Prism 4.0 and results are shown in TABLE 3 below. TABLE 3. Cellular Activity I FL5.12/Bcl- I Canine I Selectivity 2 platelets Ratio (Platelet EC50/ EC50 FL5.12/Bcl-2 EC50 (pM) (pM) EC50) ABT- 737 0.025 0.282 11 18 0.123 29.69 241 21 Toi >50 >49 22 0.825 >50 >6l 23 L44 >50 >35 24 0.055 >50 >906 25 0.049 >50 >1020 26 0.035 >50 >1429 40 0.165 >50 >303 45 0.139 >50 >360 46 0.041 30 725 52 0.016 >50 >3164 53 OOn 18.325 1697 54 0.064 >50 >785 55 0.022 36 1614 56 0049 27 554 57 0.016 Tel 1077 68 0.044 >50 >1144 69 0.075 >50 >666 70 0.111 >50 >450 71 046 >50 >T07 -233- 72 0.154 >50 >325 73 014 23.22 166 74 0.008 16/71 1989 75 0.022 17?73 821 76 0.039 8^66 221 86 0.074 36.27 489 88 0.032 19.87 613 89 0.065 31.95 495 94 004 23.85 590 96 0.011 22.27 2043 97 0.013 iil 1052 98 0.004 17.94 4849 99 0.009 21.72 2440 100 0.015 31.25 2029 102 002 2021 996 103 0.014 31.35 2305 104 0.021 >50 >2392 105 0.013 3031 2262 106 0.009 15.24 1657 109 0.036 >50 >1404 120 0.319 >50 >157 121 O038 O309 8 122 O04 >50 >1259 123 0.087 l81 32 125 OOl 44.83 4719 126 0.031 >50 >1618 128 0.025 >50 >2000 129 0.021 >50 >2415 130 0197 >50 ^54 131 0.031 >50 >1597 132 0.042 >50 >1196 133 O02 0.095 5 -234- 134 0.048 4.72 98 135 0.042 4!55 108 136 0T9 >50 >263 137 0.281 >50 >178 138 0.029 17.75 616 139 0.046 38^5 841 140 IT3 >50 >23 141 0.076 >50 >66l 142 027 >50 >T85 143 0.199 >50 >251 144 0.046 40.02 864 145 0.004 121 730 146 0.152 21.97 145 147 0.009 17.62 1895 148 0071 l9?77 278 149 0.013 16.74 1298 150 0.006 19 509 151 0.049 3L4 642 152 0.009 l66 283 154 0.085 29 343 155 0.421 >50 >TT9 166 0.153 >50 >327 170 0.015 735 507 171 0.276 >50 >T81 172 0.194 >50 ^57 173 0.011 >50 >4587 174 0.011 193 1857 175 0.0062 M lid 176 O0585 ^d lid 177 0.01966 nd iid 178 0.0186 Hd M 179 0.02346 Hd ^ -235- 180 0.02047 nd nd I 181 0.03353 nd iid 182 0.01242 nd lid 183 0.03077 iid iid 184 0.02698 iid iid 185 0.06335 nd iid 186 0.02036 iid iid 187 0.34128 iid iid 188 0.02466 nd iid 189 0.01489 nd nd 190 0.02421 nd iid 191 0.01172 iid iid 192 >a5 iid iid 193 >a5 iid iid 194 0.02697 iid iid 195 0.01124 iid iid 196 0.01236 iid iid 197 0.00618 nd iid 198 iid iid iid 199 0.02854 iid iid 200 0.00629 nd iid 201 0.0174 iid iid 202 0.01383 iid iid 203 0.0223 iid iid 204 0.02738 nd iid 205 0.03753 iid iid 206 0.00501 iid iid 207 0.1199 iid iid 208 0.26403 iid iid 209 0.13896 nd iid 210 0.25691 iid iid 211 0.01713 iid iid -236- 212 >0.5 nd nd 213 0.43216 iid nd 214 0.01569 iid iid 215 0.11576 iid iid 216 0.03985 iid iid 217 0.02083 iid iid 218 0.033 iid nd 219 0.02296 iid iid 220 0.02403 iid iid 221 0.14872 iid iid 222 0.02366 iid iid 223 0.03713 iid iid 224 0.02116 iid iid 225 0.02989 nd iid 226 0.02301 iid nd 227 >a5 iid iid 228 >a5 iid iid 229 >0!5 iid iid 230 0.17755 iid iid 231 0.0509 iid iid 232 0.01228 iid iid 233 iid iid iid 234 iid iid iid 235 nd nd iid 236 iid nd iid 237 iid iid iid 238 0.05896 iid iid 239 0.01764 iid iid 240 0.20943 iid iid 241 nd nd iid 242 0.16457 nd iid 243 0.028 nd iid -237- 244 0.02025 nd nd 245 0.07244 nd nd 246 0.048 iid iid 247 0.01607 iid iid 248 0.04981 iid iid 249 0.0412 iid iid 250 0.07951 iid ' iid 251 0.07812 iid iid 252 0.00662 iid iid 253 0.00758 nd iid 254 0.01693 nd iid 255 >a5 iid iid 256 0.00889 iid nd 257 0.00934 iid iid 258 0.00911 iid iid 259 >a5 iid iid 260 0.05944 iid iid 261 0.01701 iid iid 262 0.17622 iid iid 263 0.02835 iid iid 264 0.02571 iid iid 265 0.24417 iid iid 266 0.01148 iid iid 267 0.05643 iid iid 7 268 0.06822 nd iid 269 iid iid iid 270 0.42893 iid iid 271 >a5 iid iid 272 0.19406 nd iid 273 0.07001 nd iid 274 0.15519 nd iid 275 0.03801 iid iid -238- 276 0.06218 nd nd 277 >a5 iid nd 278 0.15272 iid iid 279 0.01623 iid iid 280 0.24715 iid iid 281 0.06022 iid iid 282 0.09216 iid iid 283 >a5 nd iid 284 >a5 nd iid 285 >a5 iid iid 286 0.27896 iid iid 287 iid iid iid 288 0.06432 nd iid 289 0.02736 iid iid 290 0.04468 nd iid 291 0.05801 iid iid 292 0.06916 iid iid 293 0.06806 nd iid 294 0.05981 iid iid 295 0.04634 nd iid 296 0.18237 iid iid 297 0.01321 iid iid 298 0.01948 iid iid 299 0.07725 nd iid 300 0.06215 iid nd 301 0.05945 iid iid 302 0.03238 nd iid 303 >a5 iid iid 304 0.41529 iid iid 305 >a5 iid iid 306 0.00716 iid iid 307 >'a5 iid iid -239- 308 >0.5 nd nd 309 >a5 nd iid 310 0.00451 iid iid 311 0.0334 iid iid 312 0.01924 iid rid 313 0.08289 iid iid 314 0.24014 iid iid 315 7o3 iid iid 316 0.06749 iid iid 317 0.08309 iid iid 318 0.07695 nd iid 319 0.03141 iid iid 320 0.04158 nd iid 321 0.02909 iid iid 322 0.04445 nd iid 323 0.09208 nd iid 324 0.13417 iid iid 325 0.25639 iid iid 326 0.03509 iid iid 327 0.00657 iid iid 328 >a5 iid iid 329 0.12652 iid iid 330 >a5 iid iid 331 >a5 iid iid 332 >a5 iid iid 333 0.10932 iid iid 334 0.06592 iid iid 335 0.03897 iid iid 336 0.00749 iid iid 337 0.12389 nd iid 338 0.07113 iid iid 339 >"a5 iid iid -240- 340 >0.5 nd nd 341 >a5 iid iid 342 >a5 iid '' iid 343 0.05489 iid iid 344 0.07147 nd iid 345 >a5 iid iid 346 0.01747 iid iid 347 0.04681 iid iid 348 0.0872 iid iid 349 0.14571 iid iid 350 0.31119 iid iid 351 0.34452 iid iid 352 0.15632 iid iid 353 0.05828 iid iid 354 0.0056 iid iid 355 >a5 iid iid 356 >'a5 iid iid 357 >a5 nd iid 358 >a5 nd iid 359 >a5 nd iid 360 0.10622 nd iid 361 >a5 iid iid 362 0.17126 iid nd 363 0.08692 iid iid 364 0.18474 iid iid 365 >a5 iid iid 366 >0.5 iid iid 367 >^!5 iid iid 368 >a5 iid iid 369 >a5 iid iid 370 0.26334 iid iid 371 >a5 iid iid -241- 372 >0.5 nd nd 374 >a5 nd iid 375 >a5 nd iid 376 >a5 iid iid 377 0.08573 iid iid 378 >0.5 iid iid 379 >a5 iid iid 380 0.06849 nd iid 381 0.07185 iid iid 382 >a5 nd iid 383 >0l iid iid 384 0.10121 nd nd 385 0.05636 nd iid 386 0.15353 iid nd 387 0.08652 iid iid 388 0.08288 iid iid 389 0.02812 iid iid 390 0.04118 nd iid 391 >03 ai nd 392 iid iid iid 393 iid nd iid 394 iid nd iid 395 iid nd iid 396 >a5 nd iid 397 iid nd iid 398 0.33382 nd iid 399 >a5 iid nd 400 0.00847 iid iid 401 0.00538 iid iid 402 0.01336 nd iid 403 0.00292 nd iid 404 0.00234 iid iid -242- 405 0.01162 nd nd 406 0.02046 nd M 407 0.0081 iid iid 408 0.00239 iid iid 409 0.0012 iid iid 410 0.01386 iid nd 411 0.01145 iid iid 412 0.00948 iid iid 474 0.0934 iid iid 475 0.223 iid iid 477 >1.67 iid iid 478 >5l0 iid iid nd = not detennined TABLE 3 shows the utility of compounds having Formula I to functionally inhibit anti-apoptotic Bcl-2 protein in a cellular context. FL5.12 is an IL-3 dependent prolymphocytic murine cell line that undergoes apoptosis upon IL-3 withdrawal as a result of the upregulation of pro-apoptotic Bcl-2 family proteins such as Bim and Puma. Stable overexpression of anti-apoptotic Bcl-2 protein (FL5.12/Bcl-2) protects against apoptosis induced by 11^3 withdrawal by sequestration of Bim and Puma. (Refs. Harada, et.al. PNAS 2004,101,15313; Certo, et.al. Cancer Cell 2006,9, 351.) The ability of compounds to kill FL5.12/Bcl-2 cells upon IL-3 withdrawal is a direct measure of the compounds ability to inhibit anti-apoptotic Bcl-2 protein fiinction. Compounds of Formula I are very effective in killing FL5.12/Bcl-2 cells under IL-3 withdrawal as demonstrated by low EC50 values. Compounds of this invention bind to anti-apoptotic Bcl-2 proteins with high affinity and potently inhibit the function of anti-apoptotic Bcl-2 protein in a cellular context and are therefore expected to have utility in treatment of diseases during which anti-apoptotic Bcl-2 protein is expressed. The anti-apoptotic Bcl-xL protein has been disclosed elsewhere {Cell March 23, 2007,128,1173-1176.) to be the major regulator of the survival of circulating platelets in animals. Genetic mutations to Bcl-xL protein that decrease BcI-xL protein stability and half-life causes a decrease in platelet survival and life-span in mice bearing these mutations. A potent pharmacologic inhibitor of Bcl-xL, ABT-737, causes a rapid, concentration dependant decrease in circulating platelets following injection into C57BL/6 mice or in beagle canines -243- {Cell March 23,2007, 128, 1173-1176.; Cell Death Differ. May 2007; 14(5), 943-51). Thus, without being limited by theory, compounds of this invention that have reduced affinity for Bcl-xL can be expected to show lower levels of platelet apoptosis than previously reported compounds with higher Bcl-xL affinity. The effect of compounds on platelet survival can be directly evaluated ex vivo by examining the viability of isolated canine platelets in the presence of various concentrations of compound. The data in Table 3 shows that compounds of Formula I have significantly less to no effect on the viability of isolated canine platelets ex vivo (higher EC50 values) compared to compounds previously disclosed in PCT US 2(X)4/36770 and PCT US 2004/367911, as exemplified by ABT-737. Furthermore, the functional selectivity ratio (canine platelet EC50: FL5.12/Bcl-2 EC50) for compounds of Formula I ranges from 32 to 4849, which is significantly higher than that for compounds previously disclosed in PCT US 2004/36770 and PCT US 2004/367911, as exemplified by ABT-737. Because compounds having Formula I bind to anti-apoptotic Bcl-2 protein with comparatively lower binding to anti-apoptotic Bel- XL protein, the compounds would have utility as medicaments for the treatment of cancer and autoimmune and immune diseases with reduction of the side effect of thrombocytopenia (i.e., they would be circulating platelet-sparing). Involvement of Bel- XL in thrombocytopenia is disclosed in Cell March 23,2007, 128,1173-1176. As described herein and elsewhere, a potent inhibitor of Bel- XL, ABT-737, causes a dose-dependent decrease in circulating platelets following injection into C57BL/6 mice or in canines (Cell Death Differ. May 2007;14(5), 943-51). Compounds with reduced Bel- XL affinity exhibit substantially less to no decrease in circulating platelets. Thus, without being limited by theory, compounds of this invention that have reduced affinity for Bel- XL can be expected to show lower levels of platelet apoptosis than previously reported compounds with higher Bel- XL affinity. The EC50 data in TABLE 2 show the effects of administration of compounds of this invention, compared to ABT-737, on canine platelets. Involvement of Bcl-2 protein in bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer spleen cancer, and the like is described in commonly-owned PCT US 2004/36770, published as WO 2005/049593, and PCT US 2004/37911, published as WO 2005/024636. -244- Involvement of Bcl-2 proteins in immune and autoimmune diseases is described in Current Allergy and Asthma Reports 2003, 3, 378-384; British Journal of Haematology 2000, 110(3), 584-90; Blood 2000, 95(4), 1283-92; and New England Journal of Medicine 2004, 351(14), 1409-1418. Involvement of Bcl-2 protein in arthritis is disclosed in commonly-owned United States Provisional Patent Application Serial No. 60/988,479. Involvement of Bcl-2 protein in bone marrow transplant rejection is disclosed in commonly-owned United States Patent Application Serial No. 11/941,196 (now U.S. Published Application 20080182845A1). Overexpression of Bcl-2 protein correlates with resistance to chemotherapy, clinical outcome, disease progression, overall prognosis or a combination thereof in various cancers and disorders of the immune system. Cancers include, but are not limited to, hematologic and solid tumor types such as acoustic neuroma, acute leukemia, acute lymphoblastic leukemia, acute myelogenous leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal ceU carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer (including estrogen-receptor positive breast cancer), bronchogenic carcinoma, Burkitt's lymphoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, eiythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, gastric carcinoma, germ cell testicular cancer, gestational trophoblastic disease, glioblastoma, head and neck cancer, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer (including small cell lung cancer and non-small cell lung cancer), lymphangioendothelio-sarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, oligodendroglioma, oral cancer, osteogenic -245- sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, peripheral T-cell lymphoma, pinealoma, polycythemia vera, prostate cancer (including hormone-insensitive (refractory) prostate cancer), rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, testicular cancer (including germ cell testicular cancer), thyroid cancer, Waldenstrom's macroglobulinemia, testicular tumors, uterine cancer, Wilms' tumor and the like. It is also expected that compounds having Formula I would inhibit growth of cells expressing Bcl-2 protein derived from a pediatric cancer or neoplasm including embryonal rhabdomyosarcoma, pediatric acute lymphoblastic leukemia, pediatric acute myelogenous leukemia, pediatric alveolar rhabdomyosarcoma, pediatric anaplastic ependymoma, pediatric anaplastic large cell lymphoma, pediatric anaplastic medulloblastoma, pediatric atypical teratoid/rfiabdoid tumor of the central nervous system, pediatric biphenotypic acute leukemia, pediatric Buikitts lymphoma, pediatric cancers of Ewing's family of tumors such as primitive neuroectodermal rumors, pediatric diffuse anaplastic Wilm's tumor, pediatric favorable histology Wilm's tumor, pediatric glioblastoma, pediatric medulloblastoma, pediatric neuroblastoma, pediatric neuroblastoma-derived myelocytomatosis, pediatric pre-B-cell cancers (such as leukemia), pediatric psteosarcoma, pediatric rhabdoid kidney tumor, pediatric rhabdomyosarcoma, and pediatric T-cell cancers such as lymphoma and skin cancer and the like. Autoimmune disorders include acquired immimodeficiency disease syndrome (AIDS), autoimmune lymphoproliferative syndrome, hemolytic anemia, inflammatory diseases, and thrombocytopenia, acute or chronic immune disease associated with organ transplantation, Addison's disease, allergic diseases, alopecia, alopecia areata, atheromatous disease/arteriosclerosis, atherosclerosis, arthritis (including osteoarthritis, juvenile chronic arthritis, septic arthritis, Lyme arthritis, psoriatic arthritis and reactive arthritis), autoimmune bullous disease, abetalipoprotemia, acquired immunodeficiency-related diseases, acute immune disease associated with organ transplantation, acquired acrocyanosis, acute and chronic parasitic or infectious processes, acute pancreatitis, acute renal failure, acute rheumatic fever, acute transverse myelitis, adenocarcinomas, aerial ectopic beats, adult (acute) respiratory distress syndrome, AIDS dementia complex, alcoholic cinhosis, alcohol-induced hver injury, alcohol-induced hepatitis, allergic conjunctivitis, allergic contact dermatitis, allergic rtiinitis, allergy and asthma, allograft rejection, alpha-1- antitrypsin -246- deficiency, Alzheimer's disease, amyotrophic lateral sclerosis, anemia, angina pectoris, ankylosing spondylitis associated lung disease, anterior horn cell degeneration, antibody mediated cytotoxicity, antiphospholipid syndrome, anti-receptor hypersensitivity reactions, aortic and peripheral aneurysms, aortic dissection, arterial hypertension, arteriosclerosis, arteriovenous fistula, arthropathy, asthenia, asthma, ataxia, atopic allergy, atrial fibrillation (sustained or paroxysmal), atrial flutter, atrioventricular block, atrophic autoimmune hypothyroidism, autoimmune haemolytic anaemia, autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmune or lupoid hepatitis), autoimmune mediated hypoglycaemia, autoimmune neutropaenia, autoimmune thrombocytopaenia, autoimmune thyroid disease, B cell lymphoma, bone graft rejection, bone marrow transplant (BMT) rejection, bronchiolitis obliterans, bundle branch block, bums, cachexia, cardiac arrhythmias, cardiac stun syndrome, cardiac tumors, cardiomyopathy, cardiopulmonary bypass inflammation response, cartilage transplant rejection, cerebellar cortical degenerations, cerebellar disorders, chaotic or multifocal atrial tachycardia, chemotherapy associated disorders, chlamydia, choleosatatis, chronic alcoholism, chronic active hepatitis, chronic fatigue syndrome, chronic immune disease associated with organ transplantation, chronic eosinophilic pneumonia, chronic inflammatory pathologies, chronic mucocutaneous candidiasis, chronic obstructive pulmonary disease (COPD), chronic salicylate intoxication, colorectal common varied immunodeficiency (common variable hypogammaglobulinaemia), conjunctivitis, connective tissue disease associated interstitial lung disease, contact dermatitis, Coombs positive haemolytic anaemia, cor pulmonale, Creutzfeldt-Jakob disease, cryptogenic autoimmune hepatitis, cryptogenic fibrosing alveolitis, culture negative sepsis, cystic fibrosis, cytokine therapy associated disorders, Crohn's disease, dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever, dermatitis, dermatitis scleroderma, dermatologic conditions, dermatomyositis/polymyositis associated lung disease, diabetes, diabetic arteriosclerotic disease, diabetes mellitus, Difhise Lewy body disease, dilated cardiomyopathy, dilated congestive cardiomyopathy, discoid lupus erythematosus, disorders of the basal ganglia, disseminated intravascular coagulation, Down's Syndrome in middle age, drug-induced interstitial lung disease, drug-induced hepatitis, drug-induced movement disorders induced by drugs which block CNS dopamine, receptors, drug sensitivity, eczema, encephalomyelitis, endocarditis, endocrinopathy, enteropathic synovitis, epiglottitis, Epstein-Barr virus infection, erythromelalgia, extrapyramidal and cerebellar disorders, familial hematophagocytic lymphohistiocytosis, fetal thymus implant rejection, Friedreich's ataxia, functional peripheral arterial disorders, female infertility, fibrosis, fibrotic lung disease, fungal sepsis, gas -247- gangrene, gastric ulcer, giant cell arteritis, glomerular nephritis, glomerulonephritides, Goodpasture's syndrome, goitrous autoimmune hypothyroidism (Hashimoto's disease), gouty arthritis, graft rejection of any organ or tissue, graft versus host disease, gram negative sepsis, gram positive sepsis, granulomas due to intracellular organisms, group B streptococci (GBS) infection. Grave's disease, haemosiderosis associated lung disease, hairy cell leukemia, hairy cell leukemia, Hallerrorden-Spatz disease, Hashimoto's thyroiditis, hay fever, heart transplant rejection, hemachromatosis, hematopoietic malignancies (leukemia and lymphoma), hemolytic anemia, hemolytic uremic syndrome/thrombolytic thrombocytopenic purpura, hemorrhage, Henoch-Schoenlein purpurea. Hepatitis A, Hepatitis B, Hepatitis C, HIV infection/HIV neuropathy, Hodgkin's disease, hypoparathyroidism, Huntington's chorea, hyperkinetic movement disorders, hypersensitivity reactions, hypersensitivity pneumonitis, hyperthyroidism, hypokinetic movement disorders, hypothalamic-pituitary-adrenal axis evaluation, idiopathic Addison's disease, idiopathic leucopaenia, idiopathic pulmonary fibrosis, idiopathic thrombocytopaenia, idiosyncratic liver disease, infantile spinal muscular atrophy, infectious diseases, inflammation of the aorta, inflammatory bowel disease, insulin dependent diabetes mellitus, interstitial pneumonitis, iridocyclitis/uveitis/optic neuritis, ischemia-reperfusion injury, ischemic stroke, juvenile pernicious anaemia, juvenile rheumatoid arthritis, juvenile spinal muscular atrophy, Kaposi's sarcoma, Kawasaki's disease, kidney transplant rejection, legionella, leishmaniasis, leprosy, lesions of the corticospinal system, linear IgA disease, lipidema, liver transplant rejection, Lyme disease, lymphederma, lymphocytic infdtrative lung disease, malaria, male infertility idiopathic or NOS, malignant histiocytosis, malignant melanoma, meningitis, meningococcemia, microscopic vasculitis of the kidneys, migraine headache, mitochondrial multi-system disorder, mixed connective tissue disease, mixed connective tissue disease associated lung disease, monoclonal gammopathy, multiple myeloma, multiple systems degenerations (Mencel Dejerine-Thomas Shi-Drager and Machado-Joseph), myalgic encephalitis/Royal Free Disease, myasthenia gravis, microscopic vasculitis of the kidneys, mycobacterium avium intracellulaie, mycobacterium tuberculosis, myelodyplastic syndrome, myocardial infarction, myocardial ischemic disorders, nasopharyngeal carcinoma, neonatal chronic lung disease, nephritis, nephrosis, nephrotic syndrome, neurodegenerative diseases, neurogenic I muscular atrophies, neutropenic fever, Non-alcohoUc Steatohepatitis, occlusion of the abdominal aorta and its branches, occlusive arterial disorders, organ transplant rejection, orchitis/epidydimitis, orchitis/vasectomy reversal procedures, organomegaly, osteoarthrosis, osteoporosis, ovarian failure, pancreas transplant rejection, parasitic diseases, parathyroid transplant rejection, -248- Parkinson's disease, pelvic inflammatory disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, perennial rhinitis, pericardial disease, peripheral atherlosclerotic disease, peripheral vascular disorders, peritonitis, pernicious anemia, phacogenic uveitis, Pneumocystis carinii pneumonia, pneumonia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), post perfusion syndrome, post pump syndrome, post-MI cardiotomy syndrome, postinfectious interstitial lung disease, premature ovarian failure, primary biliary cirrhosis, primary sclerosing hepatitis, primary myxoedema, primary pulmonary hypertension, primary sclerosing cholangitis, primary vasculitis. Progressive supranucleo Palsy, psoriasis, psoriasis type 1, psoriasis type 2, psoriatic arthropafliy, pulmonary hypertension secondary to connective tissue disease, pulmonary manifestation of polyarteritis nodosa, post¬inflammatory interstitial lung disease, radiation fibrosis, radiation therapy, Raynaud's phenomenon and disease,, Refsum's disease, regular narrow QRS tachycardia, Reiter's disease, renal disease NOS, renovascular hypertension, reperfiision injury, restrictive cardiomyopathy, rheumatoid arthritis associated interstitial lung disease, rheumatoid spondylitis, sarcoidosis, Schmidt's syndrome, scleroderma, senile chorea. Senile Dementia of Lewy body type, sepsis syndrome, septic shock, seronegative arthropathies, shock, sickle cell anemia, Sjogren's disease associated lung disease, Sjorgren's syndrome, skin allograft rejection, skin changes syndrome, small bowel transplant rejection, sperm autoimmunity, multiple sclerosis (all subtypes), spinal ataxia, spinocerebellar degenerations, spondyloarthropathy, sporadic, polyglandular deficiency type I sporadic, polyglandular deficiency type II, Still's disease, streptococcal myositis, stroke, structural lesions of the cerebellum. Subacute sclerosing panencephalitis, sympathetic ophthalmia. Syncope, syphilis of the cardiovascular system, systemic anaphylaxis, systemic inflammatory response syndrome, systemic onset juvenile rheumatoid arthritis, systemic lupus erythematosus, systemic lupus erythematosus-associated lung disease, systemic sclerosis, systemic sclerosis-associated interstitial lung disease, T-cell or FAB ALL, Takayasu's disease/arteritis. Telangiectasia, Th2 Type and Thl Type mediated diseases, thromboangitis obliterans, thrombocytopenia, thyroiditis, toxicity, toxic shock syndrome, transplants, trauma/hemorrhage, type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), type B insulin resistance with acanthosis nigricans, type III hypersensitivity reactions, type IV hypersensitivity, ulcerative colitic arthropathy, ulcerative colitis, unstable angina, uremia, urosepsis, urticaria, uveitis, valvular heart diseases, varicose veins, vasculitis, vasculitic diffuse lung disease, venous diseases, venous thrombosis, ventricular fibrillation, vitiligo -249- acute liver disease, viral and fungal infections, vital encephalitis/aseptic meningitis, vital-associated hemaphagocytic syndrome, Wegener's granulomatosis, Wernicke-Korsakoff syndrome, Wilson's disease, xenograft rejection of any organ or tissue, yersinia and salmonella-associated arthropathy and the like. Schemes and Experimentals The following schemes are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention. Compounds of this invention may be made by synthetic chemical processes, examples of which are shown herein. It is meant to be understood that the order of the steps in the processes may be varied, that reagents, solvents and reaction conditions may be substituted for those specifically mentioned, and that vulnerable moieties may be protected and deprotected, as necessary. The following abbreviations have the meanings indicated. ADDP means 1,1'-(azodicarbonyl)dipiperidine; AD-mix-P means a mixture of (DHQD)2PHAL, K3Fe(CN)6, K2CO3, and K2SO4); 9-BBN means 9-borabicyclo(3.3.1)nonane; Boc means tert-butoxycarbonyl; (DHQD)2PHAL means hydroquinidine 1,4-phthalazinediyl diethyl ether; DBU means l,8-diazabicyclo(5.4.0)undec-7-ene; DIBAL means diisobutylaluminum hydride; DIEA means diisopropylethylamine; DMA? means N,N-dimethylaminopyridine; DMF means N,N-dimethylformamide; dmpe means l,2-bis(dimethylphosphino)ethane; DMSO means DMSO; dppb means l,4-bis(diphenylphosphino)-butane; dppe means 1,2-bis(diphenylphosphino)ethane; dppf means l,r-bis(diphenylphosphino)feniocene; dppm means l,l-bis(diphenylphosphino)mediane; EDAC-HCl means l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; Fmoc means fluorenylmethoxycarbonyl; HATU means 0-(7-azabenzotriazol- l-yl)-N,N'N'N'-tetramethyluronium hexafluorophosphate; HMPA means hexamethylphosphoramide; IPA means isopropyl alcohol; MP-BH3 means macroporous triethylammonium methylpolystyrene cyanoborohydride; TEA means triethylamine; TFA means trifluoroacetic acid; THF means tetrahydrofuran; NCS means N-chlorosuccinimide; NMM means N-methylmorphoUne; NMP means N-methylpyrrolidine; PPh3 means triphenylphosphine. -250- SCHEME 1 ^2R CO2R CO2R ro^H (^(R-)„ fjCR'"")- f\iR^'>'). (r>(R"^)„ Yd) S^-^ p(3) 0(4) Compounds of Formula (4) can be prepared as shown in SCHEME 1, and can be used as described in SCHEME 7 to prepare compounds of Formula (I), which are representative of the compounds of the present invention. Compounds of Formula (1) wherein R is alkyl, R"* is as described for substituents on R^^, and n is 1,2, or 3; can be converted to compounds of Formula (2) using R^^CH^MgX', wherein X' is a halide, in a solvent such as but not limited to ether or tetrahydrofuran. Compounds of Formula (3) can be prepared from compounds of Formula (2) using a strong base such as NaH and R^^'X^, wherein X^ is a halide and R'"" IS as described herein. Compounds of Formula (3), when treated with aqueous NaOH or LiOH.will provide compounds of Formula (4). SCHEME 2 COR J^ J?^^ ^^'" ? 9 9 R41 R"' As shown in SCHEME 2, compounds of Formula (5) can be reacted with compounds of Formula (6) and a reducing agent to provide compounds of Formula (7). Examples of reducing agents include sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, polymer supported cyanoborohydride, and the like. The reaction is typically performed in a solvent such as but not limited to methanol, tetrahydrofuran, and dichloromethane or mixtures thereof Compounds of Formula (8) can be prepared fix)m compounds of Formula (7) as described in SCHEME 1, and can be used as described in SCHEME 7 to prepare compounds of Formula (I). -251- SCHEME 3 Br CO2R j^3J CO2R R41-B(0H)2 CO2R CO2H [^(R"'\ X(io)^ r>(R'°°)n ^'^^ H>(R"^)" l^^^"^^" rt rt rt r'^T y(9) y (11) ^N^ (13) ^N^ (14) R3^ RSI J^S) X R41 R41 Compounds of Formula (9), when reacted with a compound a Fonnula (10) wherein X is a halide or triflate, and a base will provide a compound of Formula (11). Bases useful in the reaction include triethylamine, diisopropylethylamine and the like. Compounds of Formula (13), wherein R'*' is as described herein for substituents on R^', can be prepared fix)m compounds of Formula (11) and compounds of Formula (12) using Suzuki coupling conditions known to those skilled in the art and readily available in the literature. Compounds of Formula (14) can be prepared from compounds of Formula (13) as described in SCHEME 1, and can be used as described in SCHEME 7 to prepare compounds of Formula (I). SCHEME 4 (,5, (17) (18) (19) CO2R CO2H (5) (|\(R"^n (S'(R^"')n (20) (21) A, shown in SCHEME 4, compounds of Formula (17) can be prepared from compounds of Fonnula (15) and compounds of Formula (16), wherein R is alkyl and R'*' is as described herein, using Suzuki coupling conditions known to those skilled in the art and readily available in the literature. Compounds of Formula (17) can be reduced to compounds of -252- Formula (18) using a reducing agent such as LiAlFU in a solvent such as but not limited to diethyl ether or THF. Compounds of Formula (19) can be prepared from compounds of Fonnula (18) using Dess-Martin periodinane or Swem oxidation conditions known to those skilled in the art and readily available in the literature. Compounds of Formula (19) can be reacted with a compound of Fonnula (5) and a reducing agent to provide compounds of Formula (20). Examples of reducing agents include sodium borohydride, sodium cyanoborohydride, sodium triacetoxyborohydride, polymer supported cyanoborohydride, and the like. The reaction is typically performed in a solvent such as but not limited to methanol, tetrahydrofuran, 1,2-dichloroethane, and dichloromethane or mixtures thereof. Compounds of Formula (21) can be prepared from compounds of Formula (20) as described in SCHEME 1, and can be used as described in SCHEME 7to prepare compounds of Formula (I). SCHEME 5 CO2R CO2R r.30 P^" 1 (22) l„ (23) R37 R" ^ ' As shown in SCHEME 5, compounds of Formula (22), wherein R is alkyl, may be converted to compounds of Fonnula (23) by reacting the former, wherein X' is CI, Br, I, or CF3SO3-, and compounds of Fonnula R'°'^-0H and a catalyst, with or without a first base. Examples of catalysts include copper(I) trifluoromethanesulfonate toluene complex, PdCli, Pd(0Ac)2, and Pd2(dba)3. Examples of first bases include triethylamine, N,N-diisopropylethylamine, CS2CO3, Na2C03, K3PO4, and mixtures thereof. Compounds of Formula (22) may also be converted to compounds of Formula (23) by reacting the former, when X' is CI, F, or NO2, and compounds of Formula R''''^-0H with a first base. Examples of first bases include triethylamine, N,N-diisopropylethylamine, CS2CO3, Na2C03, K3PO4, and mixtures thereof. - 253 - SCHEME 6 I COgR V H U r™ ^N-v ^N. T 126) "xS —' ^'^ —' ^-^ -—- ^ ' (25) COgR COgH ^XJ (27) ^,,11^ (28) Compounds of Formula (18) can be reacted with mesyl chloride and a base such as but not limited to triethylamine, followed by N-t-butoxycarbonylpiperazine, to provide compounds of Formula (24). Compounds of Formula (25) can be prepared by reacting compounds of Formula (24) with triethylsilane and trifluoroacetic acid. Compounds of Formula (25) can be reacted with compounds of Formula (26) and HK2PO4 to provide compounds of Formula (27) in a solvent such as but not limited to dimethylsulfoxide. Compounds of Formula (28) can be prepared from compounds of Formula (27) as described in SCHEME 1, and can be used as described in SCHEME 7 to prepare compounds of Formula (I). SCHEME 7 r-1 .-1 (4). (8), (14), %P f , %'P f , (21): (23). O o n f oAK PAA'-^B^ \X,K (32) (33) (D ^^ shown in SCHEME 7, compounds of Formula (32), which can be prepared as described herein, may be converted to compounds of Formula (33) by reacting the former with ammonia. Compounds of Formula (33) may be converted to compounds of Formula (I) by -254- reacting the former and compounds of Formula (4), (8), (14), (21), (23), (28), or (38) and a coupling agent, with or without a first base. Examples of coupling agents include l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride, l,r-carbonyldiimidazole, and benzotriazol-1-yl-oxytripynolidinophosphonium hexafluorophosphate. Examples of first bases include triethylamine, N,N-diisopropylethylamine, 4-(dimethylamino)pyridine, and mixtures thereof. SCHEME 8 O (32) (33) ^'^ Compounds of Formula (33), prepared as described in SCHEME 7, can also be converted to compounds of Formula (I) by reacting the former and compounds of Formula (34) and a first base. Examples of first bases include but are not limited to sodium hydride, triethylamine, N,N-diisopropylethylamine, 4-(dimethylamino)pyridine, and mixtures thereof. SCHEME 9 H " 0 0 (35) N N (37) (38) As shown in SCHEME 9, compounds of Formula (35), wherein L is a bond, alkyl, O, S, S(0), S(0)2, NH, etc., can be reacted with compounds of Formula (36), to provide compounds of Formula (37). The reaction is typically performed at elevated temperatures in a solvent such as but not limited to dimethylsulfoxide, and may require the use of a base such as but not limited to potassium phosphate, potassium carbonate, and the like. Compounds of Formula (38) can be prepared from compounds of Formula (37) as described in SCHEME 1, and can be used as described in SCHEME 7 to prepare compounds of Formula (I). -255- SCHEME 10 O OH ?\ 9^ N ' " (40) (41) Compounds of Formula (39), wherein Y is as described herein for substituents on R^', can be prepared from compounds of Formula (39A) wherein X is a halide or triflate, and Y-B(0H)2 using Suzuki coupling conditions known to those skilled in the art and readily available in the literature. Compounds of Formula (39) can be reacted with lert-butyl piperazine-1-carboxylate and a reducing agent such as sodium triacetoxyborohydride to provide compounds of Formula (40). The reaction is typically performed in a solvent such as but not limited to methylene chloride. Compounds of Formula (41) can be prepared from compounds of Formula (40) by reacting the latter with R^^'X, wherein X is a haUde, and NaH in a solvent such as N,N-dimethylformamide, and then the resulting material can be treated with triethylsilane and trifluoroacetic acid in dichloromethane. Compoimds of Formula (41) can be used as described in Scheme 9 wherein CHiR^^ is as shown in Formula (41). SCHEME 11 R31 [ I ^ ^N^R50 ^ ^N-^R^O H R31'^R37 R^I-^RSV (42) (43) As shown in SCHEME 11, substituted piperazin-2-ones wherein R^" is alkyl, can be reacted with compounds of Formula (6a) and a reducing agent such as sodium triacetoxyborohydride in dichloromethane to provide compounds of Formula (42). Compounds of Formula (42) can be reduced to compounds of Formula (43) using a reducing agent such as but not limited to lithium aluminum hydride in a solvent such as but not limited to tetrahydrofuran. Compounds of Formula (43) can be used as described in Scheme 9 wherein CH2R^^ is as shown in Formula (43). -256- The following examples are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention. The exemplified compounds were named using ACD/ChemSketch Version 5.06 (05 June 2001, Advanced Chemistry Development Inc. .Toronto, Ontario), ACD/ChemSketch Version 12.01 (13 May 2009), or ChemDraw® Ver. 9.0.5 (CambridgeSoft, Cambridge, MA). Intermediates were named using ChemDraw® Ver. 9.0.5 (CambridgeSoft, Cambridge, MA). EXAMPLE 1 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-({ 3-nitro-4- [(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-phenoxybenzamide EXAMPLE lA tert-butyl 4-((4'-chlorobiphenyl-2-yI)methyI)piperazine- 1-carboxylate 4'-Chlorobiphenyl-2-carbaldehyde (EXAMPLE 27C) (4.1 g), tert-butyl piperazine-1-carboxylate (4.23 g), and sodium triacetoxyborohydride (5.61 g) in CH2CI2 (60 mL) were combined stirred for 24 hours. The reaction was quenched with methanol and poured into ether. The solution was washed with water and brine, concentrated, and chromatographed on silica gel with 2-25% ethyl acetate/hexanes. EXAMPLE IB l-((4'-chlorobiphenyI-2-yl)methyl)piperazine EXAMPLE lA (3.0 g) and triethylsilane (1 mL) were stirred in CH2CI2 (30 mL) and trifluoroacetic acid (30 mL) for 2 hours, and the reaction was concentrated, and then taken up in ether and concentrated again. The product was used without further purification. EXAMPLE IC methyl 4-fluoro-2-phenoxybenzoate Methyl 2-bromo-4-fluorobenzoate (1 g), phenol (0.565 g), cesium carbonate (1.96 g), copper(I) triflate toluene complex (0.087 g), and ethyl acetate (0.034 mL) in toluene (12 mL) was stirred at 110°C for 24 hours. The reaction was cooled and chromatographed on silica gel with 5% ethyl acetate/hexanes. -257- EXAMPLE ID methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-phenoxybenzoate EXAMPLE IC (630 mg), EXAMPLE IB , and K2CO3 (707 mg) were stirred in dimethylsulfoxide at 125°C for 5 hours. The reaction was cooled and chromatographed on silica gel with 10% ethyl acetate/hexanes. EXAMPLE IE 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-phenoxybenzoic acid EXAMPLE ID (600 mg) was stirred in 25 mL 2:1 dioxane/lM NaOH at 60°C for 24 hours. The solution was cooled and adjusted to pH 4 with NaH2P04 solution and concentrated HCl, and extracted with ethyl acetate. The extract was washed with brine and dried (Na2S04), filtered and concentrated. EXAMPLE IF 3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)benzenesulfonamide 4-Fluoro-3-nitrobenzenesulfonamide (2.18 g), (tetrahydropyran-4-yl)methylamine (1.14 g), and triethylamine (1 g) were stirred in tetrahydrofuran (30 mL) for 24 hours. The solution was diluted with ethyl acetate, washed with NaH2P04 solution and brine, and dried (Na2S04), filtered and concentrated. The product was triturated from ethyl acetate. EXAMPLE IG 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-({ 3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-phenoxyben2amide EXAMPLE IE (90 mg), EXAMPLE IF (45 mg), l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (65 mg), and 4-dimethylaminopyridine (22 mg) were stirred in CH2CI2 (4 mL) for 24 hours. The reaction was cooled and chromatographed on silica gel with 20-100% ethyl acetate/hexanes. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 11.55 (brs, IH), 8.63 (t, IH), 8.47 (d. IH), 7.75 (d, IH), 7.46 (m, 6H), 7.35 (m, 2H), 7.24 (m, 3H), 7.15 (d, IH), 6.99 (dd, IH), 6.82 (d, 2H), 6.75 (d, IH), 6.38 (d, IH), 3.86 (br d, 2H), 3.49 (m, 2H), 3.37 (br s, 2H), 3.15 (br s, 4H), 2.34 (br s, 4H), 1.91 (br s, 4H), 1.64 (br d. 2H), 1.29 (m, 3H). -258- EXAMPLE 2 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-phenoxy-N-( {4- [(tetrahydro- 2H-pyran-4-ylmethyI)amino]phenyl}sulfonyl)benzamide EXAMPLE 2A 4-((tetrahydro-2H-pyran-4-yl)methylamino)benzenesulfonamide 4-Aminobenzenesulfonamide (6.80 g), tetrahydropyran-4-carboxaldehyde (4.96 g), and sodium triacetoxyborohydride (16.74 g) in tetrahydrofuran (3(X) mL) and acetic acid (15 mL) were stirred in for 24 hours. The reaction was concentrated and taken up in ethyl acetate. TTie resulting solution was washed with water and brine, concentrated, and chromatographed on silica gel with 50% ethyl acetate/hexanes. EXAMPLE 2B 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-phenoxy-N-( {4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 2A for EXAMPLE IF in EXAMPLE IG. 'H NMR (500MHz, dimethylsulfoxide-de/DaO) 8 7.54 (d, IH), 7.46 (m, 8H), 7.36 (m, 4H), 7.24 (d, IH), 7.13 (dd, IH), 6.93 (d, 2H), 6.75 (d, IH), 6.55 (d, 2H), 6.30 (d, IH), 3.86 (dd, 2H), 3.36 (s, 2H), 3.28 (t, 2H), 3.10 (br s, 4H), 2.96 (d, 2H), 2.32 (br s, 4H), 1.76 (m, IH), 1.64 (d, 2H), 1.20 (m, 2H). EXAMPLE 3 2-(benzyloxy)-4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-l -yl} -N-( {3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl) sulfonyl)benzamide EXAMPLE 3A methyl 2-(benzyloxy)-4-fluorobenzoate Methyl 4-fluoro-2-hydroxybenzoate (2.00 g), benzyl bromide (1.54 mL), and cesium carbonate (4.60 g) in N,N-dimethylformamide (50 mL) were stirred for 24 hours. The reaction was taken up in ether and washed with 3x IM NaOH solution, and brine, then concentrated to give the pure product. -259- EXAMPLE 3B methyl 2-(benzyloxy)-4-(4-((4'-ch]orobiphenyl-2-yl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 3A for EXAMPLE IC in EXAMPLE ID. EXAMPLE 3C 2-(benzyloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 3B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 3D 2-(benzyloxy)-4- {4-[(4'-chloro-1,1 '-biphenyl-2-y l)methyl]piperazin-1 -yl} -N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 3C for EXAMPLE IE in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-dg) 6 10.90 (br s, IH), 8.66 (m, IH), 8.59 (s, IH), 7.82 (d, IH), 7.33-7.55 (m, 12H), 7.18-7.27 (m, 3H), 6.61 (s, IH), 6.56 (d, IH), 5.22 (s, 2H), 3.86 (br d, 2H), 3.40 (m, 2H), 3.31 (m, 8H), 2.34 (br s, 4H), 1.91 (br s, 2H), 1.64 (br d, 2H), 1.29 (m, 3H). EXAMPLE 4 4- (4- [(4'-chloro-1,1 '-biphenyl-2-y l)methyl]piperazin-1 -yl) -N-( {3-nitro-4- [(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-(2-phenylethoxy)benzamide EXAMPLE 4A methyl 4-fluoro-2-phenethoxybenzoate Methyl 4-fluoro-2-hydroxybenzoate (1.00 g) and phenethyl alcohol (0.64 mL) were added to triphenylphosphine (1.54 g) and diisopropylazodicarboxylate (1.04 mL) in tetrahydrofuran (20 mL) at 0**C, and the reaction was stirred at room temperature for 24 hours. The mixture was chromatographed on silica gel with 5% ethyl acetate/hexanes. EXAMPLE 4B methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-phenethoxybenzoate -260- The title compound was prepared by substituting EXAMPLE 4A for EXAMPLE IC in EXAMPLE ID. EXAMPLE 4C 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-phenethoxybenzoic acid The title compound was prepared by substituting EXAMPLE 4B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 4D 4- {4-[(4'-chloro-1,1 '-biphenyl-2-y l)methyl]piperazin-1 -yl} -N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(2-phenylethoxy)benzamide The title compound was prepared by substituting EXAMPLE 4C for EXAMPLE IE in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-de) 8 10.75 (br s, IH), 8.66 (m, 2H), 7.91 (d, IH), 7.47 (m, 6H), 7.20-7.40 (m, 8H), 6.53 (d, IH), 6.47 (s, IH), 4.35 (t, 2H), 4.03 (m, IH), 3.85 (br d, 2H), 3.38 (s, 2H), 3.25 (m, 8H), 3.13 (t, 2H), 2.36 (br s, 4H), 2.21 (br s, 2H), 1.62 (br d, 2H), 1.20 (m, 2H), 1.17 (m, IH). EXAMPLE 5 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -N-( {3-nitro-4- [(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(phenylthio)benzamide EXAMPLE 5A methyl 4-fluoro-2-(phenylthio)benzoate 5-Fluoro-2-(methoxycarbonyl)phenylboronic acid (1.00 g), 2-(phenylthio)isoindoline-L3-dione (0.86 g), and (2-hydroxy-3,5- diisopropylbenzoyloxy)copper (0.29 g) were stirred in dioxane (15 mL) at 50°C for 24 hours. The reaction mixture was chromatographed on silica gel with 5% ethyl acetate/hexanes. EXAMPLE 5B methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(phenylthio)benzoate The title compound was prepared by substituting EXAMPLE 5A for EXAMPLE IC in EXAMPLE ID. -261- EXAMPLE 5C 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(phenyltliio)benzoic acid The title compound was prepared by substituting EXAMPLE 5B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 5D 4- {4-[(4'-chloro-1,1 '-biphenyl-2-y l)methyl]piperazin-1 -yl} -N-( {3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-(phenylthio)benzamide The title compound was prepared by substituting EXAMPLE 5C for EXAMPLE IE in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-de) 8 11.95 (br s, IH), 8.59 (m, 2H), 7.93 (d, IH), 7.63 (d, IH), 7.15-7.50 (m, 14H), 6.73 (d, IH), 6.18 (s, IH), 3.82 (dd, 2H), 3.36 (m, 4H), 3.32 (m, 2H), 2.94 (br s, 4H), 2.30 (br s, 4H), 1.64 (m, IH), 1.61 (m, 2H), 1.25 (m, 2H). EXAMPLE 6 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -2-(phenylthio)-N-( {4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 5C for EXAMPLE IE and EXAMPLE 2A for EXAMPLE IF in EXAMPLE IG. 'H NMR (500MHz, dimethylsulfoxide-de/DzO) 57.65 (d, 2H), 7.55 (d, IH), 7.33-7.48 (m, 12H), 7.24 (m, 2H), 6.73 (d, IH), 6.66 (d, 2H), 6.17 (d, IH), 3.85 (dd, 2H), 3.34 (s, 2H), 3.26 (t, 2H), 2.98 (d, 2H), 2.92 (br s, 4H), 2.25 (br s, 4H), 1.78 (m, IH), 1.63 (d, 2H), 1.20 (m, 2H). EXAMPLE 7 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin- 1-yl} -N-( {4- [(3-morpholin-4- ylpropyl)amino]-3-nitrophenyl} sulfonyl)-2-(phenylthio)benzamide EXAMPLE 7A 4-(3-morpholinopropylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 3-(N-morpholinyl)-l-propylamine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. -262- EXAMPLE 7B 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-( {4- [(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(phenylthio)benzamide The title compound was prepared by substituting EXAMPLE 5C for EXAMPLE IE and EXAMPLE 7A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 8 10.20 (br s, IH), 8.69 (m, IH), 8.57 (d, IH), 7.95 (dd, 2H), 7.71 (m, IH), 7.31-7.51 (m, lOH), 7.12-7.26 (m, 3H), 6.68 (dd, IH), 6.07 (m, IH), 4.06 (s, 2H), 3.68 (m, 4H), 3.50 (m, 2H), 3.32 (m, 6H), 2.88 (m, 4H), 2.27 (m, 4H), 1.91 (m, 2H). EXAMPLE 8 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -N-( {3-nitro-4- [(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-(phenylsulfonyl)benzamide EXAMPLE 8A methyl 4-fluoro-2-(phenylsulfonyl)benzoate EXAMPLE 5A (0.30 g) and KMn04 (1.80 g) were stirred in acetic acid (40 mL) at 60°C for 24 hours. The reaction mixture was filtered through a plug of silica gel, concentrated, and chromatographed on silica gel with 50% ethyl acetate/hexanes. EXAMPLE 8B methyl 4-(4-((4'-ch]orobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(phenylsulfonyl)benzoate The title compound was prepared by substituting EXAMPLE 8A for EXAMPLE IC in EXAMPLE ID. EXAMPLE 8C 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(phenylsulfonyl)benzoic acid The title compound was prepared by substituting EXAMPLE 8B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 8D 4- {4-[(4'-chloro-1,1 '-biphenyl-2-y l)methyl]piperazin-1 -yl} -N-( {3-nitro-4- [(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-(phenylsulfonyl)benzamide -263- The title compound was prepared by substituting EXAMPLE 8C for EXAMPLE IE in EXAMPLE IG. ^H NMR (500MHz, dimethylsulfoxide-dg) 8 1L95 (br s, IH), 8.54 (s, IH), 8.41 (dd, IH), 7.90 (m, 2H), 7.82 (d, IH), 7.76 (d, IH), 7.66 (m, IH), 7.46 (m, 5H), 7.40 (m, 4H), 7.11 (m, 2H), 6.67 (dd, IH), 6.62 (m, IH), 4.36 (m, IH), 3.82 (dd, 2H), 3.39 (m, 6H), 3.19 (m, 6H), 2.37 (br s, 4H), 1.91 (m, IH), 1.63 (m, 2H), L26 (m, 2H). EXAMPLE 9 4- {4- [(4'-chloro-1,1 '-biphenyl-2-y l)methyl]piperazin-1 -yl) -N-( {3-nitro-4- [(tetrahydio-2H- pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-(phenylsulfinyl)benzamide EXAMPLE 9A methyl 4-fluoro-2-(phenylsulfinyl)benzoate OXONE® (Dupont) (5.60 g) was added portionwise over 1 hour to EXAMPLE 5A (LOO g) in a mixture of acetic acid (30 mL), water (30 mL) and CH2CI2 (20 mL), and the reaction was stirred for an additional 1 hour. The reaction mixture was taken up in ethyl acetate, washed with Na2S203 solution, water, and brine, concentrated, and chromatographed on silica gel with 5-25% ethyl acetate/hexanes. EXAMPLE 9B methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(phenylsulfmyl)benzoate The title compound was prepared by substituting EXAMPLE 9A for EXAMPLE IC in EXAMPLE ID. EXAMPLE 9C 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(phenylsuliinyl)benzoicacid The title compound was prepared by substituting EXAMPLE 9B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 9D 4- {4-[(4'-chloro-1,1 '-biphenyl-2-y l)methyl]piperazin-1 -yl) -N-( {3-nitro-4- [(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl) sulfonyl)-2-(phenylsulfmyl)benzamide The title compound was prepared by substituting EXAMPLE 9C for EXAMPLE IE in EXAMPLE IG. ^H NMR (500MHz, dimethylsulfoxide-d6/D20) 5 8.51 (s, -264- IH), 7.85 (dd, 2H), 7.64 (d, 2H), 7.48 (m, 8H), 7.32 (m, IH), 7.23 (m, IH), 7.14 (m, 4H), 6.97 (d, IH), 3.85 (dd, 2H), 3.35 (d, 2H), 3.34 (m, 6H), 3.27 (t, 2H), 2.74 (br s, 4H),1.93 (m, IH), 1.64 (d, 2H), 1.28 (m, 2H). EXAMPLE 10 2-benzyl-4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE lOA methyl 2-benzy]-4-fluoiobenzoate 5-Fluoro-2-(methoxycarbonyl)phenylboronic acid (1.00 g), benzyl bromide (0.50 mL), K2CO3 (1.75 g), and [l,r-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (PdCl2(dppf)) (0.17 g) were stirred in tetrahydrofuran (20 mL) at 60°C for 24 hours. The reaction mixture was chromatographed on silica gel with 2% ethyl acetate/hexanes. EXAMPLE lOB methyl 2-benzyl-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE lOA for EXAMPLE IC in EXAMPLE ID. EXAMPLE IOC 2-benzyl-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE lOB for EXAMPLE ID in EXAMPLE IE. EXAMPLE lOD 2-benzyl-4- {4-[(4'-chloro-1, r-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-( {3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE IOC for EXAMPLE IE in EXAMPLE IG. 'H NMR (500MHz, dimethylsulfoxide-de/DaO) 6 8.55 (d, IH), 7.90 (d, IH), 7.38-7.56 (m, lOH), 7.25 (m, 2H), 6.96 (d, 2H), 6.83 (s, 2H), 6.75 (d, IH), 4.06 (s, 2H), 3.85 (dd, 2H), 3.48 (s, 2H), 3.37 (d, 2H), 3.25 (t, 2H), 3.20 (br s, 4H), 2.44 (br s, 4H), 1.91 (m, IH), 1.63 (d, 2H), 1.29 (m, 2H). -265- EXAMPLE 11 2-benzyl-4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl }-N-({ 4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE IOC for EXAMPLE IE and EXAMPLE 2A for EXAMPLE IF in EXAMPLE IG. 'H NMR (SOOMHz, dimethylsulfoxide-de) 8 n.70 (br s, IH), 7.48 (m, 6H), 6.88 (m, 6H), 6.62 (m, 6H), 6.42 (dd, 2H), 3.83 (dd, 4H), 3.24 (m, 6H), 2.96 (m, 4H), L82 (m, 2H), L63 (m, 3H), L18(m,4H). EXAMPLE 12 2-benzyl-4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -N-( {4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE IOC for EXAMPLE IE and EXAMPLE 7A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 5 11.90 (br s, IH), 8.80 (m, IH), 8.54 (d, IH), 7.91 (dd, IH), 7.48 (m, 7H), 7.40 (d, 2H), 7.26 (d, 2H), 6.97 (dd, 2H), 6.86 (m, 2H), 6.76 (d, IH), 4.04 (m, 5H), 3.72 (m, 4H), 3.56 (m, 2H), 3.40 (m, 8H), 3.21 (m, 4H), 2.34 (m, 2H), 1.98 (m, 2H). EXAMPLE 13 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -N-( {3-nitro-4- [(tetrahydro-2H- pyran-4-ylmethyl)amino]pheny 1} sulfonyl)-2-(2-phenylethyl)benzamide EXAMPLE 13A methyl 4-fluoro-2-phenethylbenzoate Methyl 2-bromo-4-fluorobenzoate (1.00 g), (E)-styrylboronic acid (0.89 g), tetrakis(triphenylphosphine)palladium(0) (0.50 g), and K3PO4 (2.28 g) were stirred in dioxane (17 mL) at 90*C for 24 hours. The reaction mixture chromatographed on silica gel with 1-5% ethyl acetate/hexanes. The product in methanol (10 ml) was added to 20 wt% of fresh dry 5% Pd-C and stirred 4 days with H2 in a pressure bottle. The mixture was filtered through a nylon membrane and concentrated. -266- EXAMPLE 13B methyl 4-(4-((4'-chIorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-phenethylbenzoate The title compound was prepared by substituting EXAMPLE 13A for EXAMPLE IC in EXAMPLE ID. EXAMPLE 13C 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-phenethylbenzoic acid The title compound was prepared by substiuiting EXAMPLE 13B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 13D 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-N-(3 -nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)-2-phenethylbenzamide The title compound was prepared by substituting EXAMPLE 13C for EXAMPLE IE in EXAMPLE IG. 'H NMR (500MHZ, dimethylsulfoxide-dg/DzO) 8 8.62 (d, IH), 7.95 (d, IH), 7.91 (m, IH), 7.35-7.52 (m, 6H), 7.19 (m, 2H), 7.13 (m, 2H), 6.99 (m, 4H), 6.83 (d, lH),6.70(d, IH), 6.65 (s, IH), 3.80(m, 2H), 3.24(m, 2H),3.18 (t, 2H), 3.11 (brs, 4H), 2.91 (t, 2H), 2.48 (m, 2H), 2.38 (br s, 4H), 1.81 (m, IH), 1.54 (d, 2H), 1.23 (m, 2H). EXAMPLE 14 2-(benzylamino)-4- {4- [(4'-chloro-1, l'-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-( {3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 14A methyl 2-(benzylamino)-4-fluorobenzoate Methyl 2-amino-4-fluorobenzoate (0.90 g), benzaldehyde (0.54 mL), sodium triacetoxyborohydride (1.58 g) and acetic acid (0.3 mL) in CH2CI2 (20 mL) were stirred for 3 hours. The reaction was quenched with methanol, concentrated, and chromatographed on silica gel with 5% ethyl acetate/hexanes. EXAMPLE 14B methyl 2-(benzylamino)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)benzoate -267- The title compound was prepared by substituting EXAMPLE 14A for EXAMPLE IC in EXAMPLE ID. EXAMPLE 14C 2-(benzylamino)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)benzoic acid The title compound was prepared by substituting EXAMPLE 14B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 14D 2-(benzylamino)-4- {4-[(4'-chloro-1, r-biphenyl-2-yl)methyl]piperazin- 1-yl }-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 14C for EXAMPLE IE in EXAMPLE IG. 'H NMR (500MHZ, dimethylsulfoxide-dg/DzO) 5 8.58 (d, IH), 7.92 (d, IH), 7.87 (m, IH), 7.59 (d, 2H), 7.48 (m, 2H), 7.43 (m, 4H), 7.20-7.29 (m, 8H), 6.15 (d, IH), 4.32 (s, 2H), 3.85 (m, 2H), 3.49 (m, 2H), 3.33 (m, 2H), 3.26 (t, 2H), 3.12 (br s, 4H), 2.39 (br s, 4H), 1.90 (m, IH), 1.62 (d, 2H), 1.27 (m, 2H). EXAMPLE 15 2-anilino-4- {4-[(4'-chloro-l, r-biphenyl-2-yl)methyl]piperazin- 1-yl} -N-({ 3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl) sulfonyl)benzamide EXAMPLE 15A methyl 4-fluoro-2-(phenylamino)benzoate Methyl 2-bromo-4-fluorobenzoate (1.00 g), aniline (0.47 mL), palladium(n) acetate(0.048 g), 2,2'-bis(diphenylphosphino)-l,l'-binaphthyl (0.214 g) and CS2CO3 (2.08 g) in toluene (12 mL) were stirred at 90°C for 24 hours. The reaction was concentrated and chromatographed on silica gel with 5-50% ethyl acetate/hexanes. EXAMPLE 15B methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(phenylamino)benzoate The title compound was prepared by substituting EXAMPLE 15A for EXAMPLE IC in EXAMPLE ID. -268- EXAMPLE 15C 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(phenylamino)benzoic acid The title compound was prepared by substituting EXAMPLE 15B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 15D 2-anilino-4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methy l]piperazin-1 -yl) -N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 15C for EXAMPLE IE in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 11.55 (br s, IH), 8.56 (m, 2H), 7.92 (d, IH), 7.72 (d, IH), 7.47 (m, 6H), 7.25 (m, 4H), 7.12 (d, 2H), 6.95 (m, 2H), 6.53 (s, IH), 6.38 (dd, IH), 3.81 (dd, 2H), 3.37 (br s, 4H), 3.12 (br s, 4H), 2.41 (br s, 4H), 1.91 (m, IH), 1.61 (br d, 2H), 1.23 (m, 4H). EXAMPLE 16 2-anilino-4- {4-[(4'-chloro-1, r-biphenyl-2-yl)methyl]piperazin- 1-yl} -N-( {4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 15C for EXAMPLE IE and EXAMPLE 2A for EXAMPLE IF in EXMAPLE IG. 'H NMR (500MHz, dimethylsulfoxide-dft/DzO) 5 7.78 (d, IH), 7.52 (d, 2H), 7.47 (m, 6H), 7.36 (m, 3H), 7.27 (m. 3H), 7.11 (m, 2H), 6.90 (m, IH), 6.61 (s, IH), 6.53 (d, IH), 6.31 (d, IH), 4.46 (s, IH), 3.82 (m, 2H), 3.37 (s, 2H), 3.26 (t, 2H), 3.05 (br s, 4H), 2.93 (d, 2H), 2.37 (br s, 4H), 1.77 (m, IH), 1.63 (d, 2H), 1.20 (m, 2H). EXAMPLE 17 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin- 1-yl} -2-methoxy-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl) sulfonyl)benzamide EXAMPLE 17A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-methoxybenzoate Methyl 4-bromo-2-methoxybenzoic acid (700 mg), EXAMPLE IB (983 mg), K3PO4 (909 mg), tris(dibenzylideneacetone)dipalladium(0) (78 mg), and 2-(di-t-butylphosphino)biphenyl (102 mg) were stirred in 1,2-dimethoxyethane (10 mL) at 80°C for -269- 24 hours. The reaction mixture was chromatographed on sihca gel with 20-50% ethyl acetate/hexanes. EXAMPLE 17B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-methoxybenzoic acid The title compound was prepared by substituting EXAMPLE 17A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 17C 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin- 1-yl} -2-methoxy-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 17B for EXAMPLE IE in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-de) 8 10.81 (br s, IH), 8.64 (m, 2H), 7.96 (d, IH), 7.20-7.54(m, lOH), 6.52 (d, IH), 6.46 (s, IH), 3.90 (s, 3H), 3.40 (m, 4H), 3.27 (br s, 4H), 2.39 (br s, 4H), L91 (m, IH), 1.62 (br d, 2H), 1.27 (m, 4H). EXAMPLE 18 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-N-( {4- [(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-phenoxybenzamide EXAMPLE 18A methyl 4,4-dimethyl-2-(trifluoromethylsulfonyloxy)cyclohex-l-enecarboxylate To a suspension of hexane washed NaH (17 g) in dichloromethane (7(X) mL), 5,5-dimethyl-2-methoxycarbonylcyclohexanone (38.5 g) was added dropwise at 0°C. After stirring for 30 minutes, the mixture was cooled to -78°C and trifluoromethanesulfonic anhydride (40 mL) was added. The reaction mixture was warmed to room temperature and stirred for 24 hours. The organic layer was washed with brine, dried, and concentrated to give the product. EXAMPLE 18B methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enecarboxylate EXAMPLE 18A (62.15g), 4-chlorophenylboronic acid (32.24 g), CsF (64 g) and tetrakis(triphenylphosphine)palladium(0) (2g) in 2:1 1,2-dimethoxyethane/methanol (600 -270- mL) were heated to 70°C for 24 hours. The mixture was concentrated. Ether (4x 200 mL) was added and the mixture was filtered. The combined ether solution was concentrated to give the product. EXAMPLE 18C (2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methanol To a mixture of LiBH4 (13g), EXAMPLE 18B (53.8 g) and ether (400 mL), methanol (25 mL) was added slowly by syringe. The mixture was stirred at room temperature for 24 hours. The reaction was quenched with IN HCl with ice-cooling. The mixture was diluted with water and extracted by ether (3x lOOmL). The extracts were dried, and concentrated. The crude product was chromatogr^hed on silica gel with 0-30% ethyl acetate/hexanes. EXAMPLE 18D methyl 2-bromo-4-(piperazin- l-yl)benzoate The title compound was prepared by substituting piperazine for EXAMPLE IB and methyl 2-bromo-4-fluorobenzoate for EXAMPLE IC in EXAMPLE ID. EXAMPLE 18E methyl 2-bK)mo-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 - yl)benzoate MsCl (7.5 mL) was added via syringe to EXAMPLE 18C (29.3 g) and triethylamine (30 mL) in CH2CI2 (500 mL) at 0°C, and the mixture was stirred for 1 minute. EXAMPLE 18D (25 g) was added and the reaction was stirred at room temperature for 24 hours. The suspension was washed with brine, dried, and concentrated. The crude product was chromatographed on silica gel with 10-20% ethyl acetate/hexanes. EXAMPLE 18F methyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2- phenoxybenzoate EXAMPLE 18E (500 mg), phenol (195 mg), CS2CO3 (674 mg), 1-naphthoic acid (356 mg), copper (I) triflate-toluene complex (45 mg), ethyl acetate (0.016 mL), and 4A sieves (50 mg) in toluene (2 mL) was stirred at 105°C for 24 hours. The reaction was cooled -271- and taken up in ethyl acetate (100 mL) and water (40 mL). The layers were separated and the organic layer was washed with 2x NaaCOs solution and brine, dried, and concentrated. The crude product was chromatographed on silica gel with 20% ethyl acetate/hexanes. EXAMPLE 18G 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2- phenoxybenzoic acid The title compound was prepared by substituting EXAMPLE 18F for EXAMPLE ID in EXAMPLE IE. EXAMPLE 18H 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N-( {4-[(3-morpholin-4-ylpropyl)amino]-3-mtrophenyl}sulfonyl)-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 18G for EXAMPLE IE and EXAMPLE 7A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-dg) 5 11.10 (br s, IH), 8.76 (m, IH), 8.46 (d, IH), 7.76 (dd, IH), 7.50 (d, IH), 7.35 (d, 2H), 7.23 (d, 2H), 7.06 (dd, 2H), 6.99 (dd, IH), 6.81 (d, 2H), 6.74 (d, IH), 6.34 (s, IH), 3.62 (m, 4H), 3.46 (m, 2H), 3.13 (m, 4H), 2.76 (m, 2H), 2.48 (m, 2H), 2.22 (m, 6H), 1.97 (m, 2H), 1.82 (m, 2H), 1.40 (t, 2H), 1.06 (m, 7H), 0.94 (s, 3H). EXAMPLE 19 4-(4-{ [2-(4-chlorophenyl)-5,5-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N-( {4- [(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-phenoxybenzamide EXAMPLE 19A methyl 5,5-dimethyl-2-(tiifluoromethylsulfonyloxy)cyclohex-1 -enecarboxylate The title compound was prepared by substituting 4,4-dimethyl-2-methoxycaibonylcyclohexanone for 5,5-dimethyl-2-methoxycarbonylcyclohexanone in EXAMPLE 18A. EXAMPLE 19B methyl 2-(4-chIorophenyl)-5,5-dimethylcyclohex-l-enecarboxylate -272- The title compound was prepared by substituting EXAMPLE 19A for EXAMPLE 18A in EXAMPLE 18B. EXAMPLE 19C (2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-enyl)methanol The title compound was prepared by substituting EXAMPLE 19B for EXAMPLE 18B in EXAMPLE 18C. EXAMPLE 19D methyl 2-bromo-4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-enyl)methyl)piperazin-l- yl)benzoate The title compound was prepared by substituting EXAMPLE 19C for EXAMPLE 18C in EXAMPLE 18E. EXAMPLE 19E methyl 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2- phenoxybenzoate The title compound was prepared by substituting EXAMPLE 19D for EXAMPLE 18E in EXAMPLE 18F. EXAMPLE 19F 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex- l-enyl)methyl)piperazin-1 -yl)-2- phenoxybenzoic acid The title compound was prepared by substituting EXAMPLE 19E for EXAMPLE ID in EXAMPLE IE. EXAMPLE 19G 4-(4- {[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N-( {4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 19F for EXAMPLE IE and EXAMPLE 7A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 5 11.10 (br s, IH), 8.71(m, IH), 8.42 (d, IH), 7.73 (dd, IH), 7.53 (d, IH), 7.34 (d, 2H), 7.21 (dd, 2H), 7.10 (d, 2H), 6.96 (dd, IH), 6.78 (d, 2H), 6.70 (d, -273- IH), 6.32 (s, IH), 3.61 (m, 4H), 3.44 (m, 2H), 3.09 (m, 4H), 2.71 (m, 2H), 2.44 (m, 4H), 2.21 (m, 4H), 1.96 (m, 2H), 1.79 (m, 2H), 1.47 (t, 2H), 1.17 (m, 3H), 1.08 (m, 4H), 0.95 (s, 3H). EXAMPLE 20 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H- indazol-5-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide EXAMPLE 20A ethyl 2-(lH-indazol-5-yloxy)-4-fluorobenzoate Ethyl 2,4-difluorobenzoate (1.14 g), K3PO4 (1.30 g) and 5-hydroxyindazole (0.90 g) were stirred at 110°C in diglyme (12 mL) for 24 hours. The reaction was cooled and poured into ether. The solution was washed three times with IM NaOH solution, and brine, and dried. The solution was then concentrated, and the crude product was chromatographed on silica gel with 20% ethyl acetate/hexanes. EXAMPLE 20B tert-butyl4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazine-l- carboxylate The title compound was prepared by substituting N-t-butoxycarbonylpiperazine for EXAMPLE 18D in EXAMPLE 18E. EXAMPLE 20c 1 -((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazine This EXAMPLE was prepared by substituting EXAMPLE 20B for EXAMPLE lA in EXAMPLE IB. EXAMPLE 20D ethyl 2-( 1 H-indazol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoate EXAMPLE 20A (330 mg), EXAMPLE 20C (335 mg), and HK2PO4 (191 mg) were stirred in dimethylsulfoxide (5 mL) at 140°C for 24 hours. The reaction was diluted with ethyl acetate, washed three times with water, washed with brine, dried, and concentrated. The crude product was chromatogr^hed on silica gel with 30% ethyl acetate/hexanes. -274- EXAMPLE 20E 2-(lH-indazol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 20D for EXAMPLE ID in EXAMPLE IE. EXAMPLE 20F 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-5-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 20E for EXAMPLE IE and EXAMPLE 7A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 5 13.03 (br s, IH), 11.25 (br s, IH), 8.70 (m, IH), 8.48 (d, IH), 7.94 (dd, IH), 7.68 (dd, IH), 7.52 (m, 2H), 7.34 (d, 2H), 7.06 (m, 4H), 6.96 (dd, IH), 6.88 (d, IH), 6.23 (s, IH), 3.61 (m, 4H), 3.44 (m, 2H), 3.05 (m, 4H), 2.73 (m, 2H), 2.42 (m, 4H), 2.18 (m, 4H), 1.99 (m, 2H), 1.91 (d, 2H), 1.78 (m, 2H), 1.39 (t, 2H), 1.17 (m, 2H), 0.93 (s, 6H). EXAMPLE 21 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide EXAMPLE 21A 4-(l-methylpiperidin-4-ylamino)-3-nitiobenzenesulfonamide The title compound was prepared by substituting 4-amino-N-methylpiperidine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 21B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 20E for EXAMPLE IE and EXAMPLE 21A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 5 12.80 (br s, IH), 10.70 (br s, IH), 8.34 (s, IH), 8.02 (d, IH), 7.87 (d, IH), 7.70 (dd, IH), 7.55 (m, 2H), 7.36 (d, 2H), 7.06 (m, 2H), 6.95 (m, IH), -275- 6.72 (d, IH), 6.62 (d, IH), 6.24 (s, IH), 3.35 (m, 4H), 3.18 (m, 2H), 3.00 (m, 2H), 2.80 (m, 4H), 2.73 (m, 2H), 2.20 (m, 4H), 1.99 (m, 2H), 1.91 (s, 3H), 1.54 (m, IH), 1.41 (t, 2H), 1.22 (m, 2H), 1.09 (s, 6H). EXAMPLE 22 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(l,2,3,4-tetrahydroquinolin-6- yloxy)benzamide EXAMPLE 22A ethyl 4-fluoro-2-( 1,2,3,4-tetrahydroquinolin-6-yloxy)benzoate The title compound was prepared by substituting 5-hydroxy-l,2,3,4-tetrahydroquinoline for 5-hydroxyindazole in EXAMPLE 20A. EXAMPLE 22B ethyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(l,2,3,4-tetrahydroquinolin-6-yloxy)benzoate The title compound was prepared by substituting EXAMPLE 22A for EXAMPLE 20A in EXAMPLE 20D. EXAMPLE 22C 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(l,2,3,4-tetrahydroquinolin-6-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 22B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 22D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-N-( {4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(l,2,3,4-tetTahydroquinolin-6- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 22C for EXAMPLE IE and EXAMPLE 7A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 8 10.95 (br s, IH), 8.83 (m, IH), 8.60(d, IH), 7.90 (dd, IH), -276- 7.46 (d, IH), 7.35 (d, 2H), 7.21 (dd, 2H), 7.06 (d, 2H), 6.62 (m, 2H), 6.42 (d, IH), 6.11 (d, IH), 5.61 (br s, IH), 4.02 (m, IH), 3.61 (m, 4H), 3.48 (m, 2H), 3.17 (m, 2H), 3.07 (m, 4H), 2.74 (m, 2H), 2.63 (m, 2H), 2.44 (m, 4H), 2.19 (m, 4H), 1.97 (m, 4H), 1.79 (m, 4H), 1.41 (t, 2H), 1.17 (m,4H), 0.94 (s,6H). EXAMPLE 23 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)-2-( 1,2,3,4-tetrahydroquinolin-6- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 22C for EXAMPLE IE and EXAMPLE 21A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz. dimethylsulfoxide-de) 8 11.10 (br s, IH), 8.71(m, IH), 8.42 (d, IH), 7.73 (dd, IH), 7.53 (d, IH), 7.34 (d, 2H), 7.21 (dd, 2H), 7.10 (d, 2H), 6.96 (dd, IH), 6.78 (d, 2H), 6.70 (d, IH), 6.32 (s, IH), 3.61 (m, 4H), 3.44 (m, 2H), 3.09 (m, 4H), 2.71 (m, 2H), 2.44 (m, 4H), 2.21 (m, 4H), 1.96 (m, 2H), 1.79 (m, 2H), 1.47 (t, 2H), 1.17 (m, 3H), 1.08 (m, 4H), 0.95 (s, 3H). EXAMPLE 24 4-(4- {[4'-chloro-4-(pyrrolidin- 1-ylmethyl)-1,1 '-biphenyl-2-yl]methyl }piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 24A methyl 5-formyl-2-(trifluoromethylsulfonyloxy)benzoate Triflic anhydride (7.74 mL) was added to methyl 5-formyl-2-hydroxybenzoate (7.5 g) in 150 mL CH2CI2 at 0°C, and the reaction was stirred and allowed to warm to room temperature over 3 hours. The reaction was diluted with CH2CI2 (150 mL), washed with 3x brine, dried over Na2S04, and concentrated. The product was used without further purification. EXAMPLE 24B methyl 4'-chloro-4-formylbiphenyl-2-carboxylate EXAMPLE 24A (14.5 g), 4-chlorophenylboronic acid (6.88 g) CsF (12.2 g), and tetrakis(triphenylphosphine)palladium(0) were stirred at 70°C for 24 hours. The reaction -277- was cooled, filtered, and concentrated. The crude product was taken up in ethyl acetate (250 mL), washed with 3x IM NaOH, and brine, concentrated, and chromatographed on silica gel with 10% ethyl acetate/hexanes. EXAMPLE 24C methyl 4'-chloro-4-(pyrrolidin-1 -ylmethyl)biphenyl-2-carix)xylate The title compound was prepared by substituting EXAMPLE 24B for 4'- chlorobiphenyl-2-carboxaldehyde and pyrrolidine for tert-butyl piperazine-l-carboxylate in EXAMPLE lA. EXAMPLE 24D (4'-chloro-4-(pyrrolidin-l-ylmethyl)biphenyl-2-yl)methanol DffiAL in hexanes (IM, 5.9 mL) was added to EXAMPLE 24C (650 mg) in CH2CI2 (30 mL) at 0°C, and the reaction was stirred for 20 minutes. The reaction was quenched by the slow addition of methanol (2 mL), and IM NaOH (10 mL), and the resulting solution was extracted twice with ethyl acetate. The extracts were washed with brine, dried over Na2S04, and concentrated. The product was used without further purification. EXAMPLE 24E 4'-ch]oro-4-(pyrrolidin-1 -ylmethy])biphenyl-2-carbaldehyde Dess-Martin periodinane (1.30 g) was added to EXAMPLE 24D (770 mg) in CH2CI2 (30 mL) at room temperature and the reaction was stirred for 24 hours. The reaction mixture was concentrated and chromatographed on silica gel with 1% triethylamine in 25% ethyl acetate/hexanes. EXAMPLE 24F methyl 2-( 1 H-indo]-4-yloxy)-4-fluorobenzoate The title compound was prepared by substituting 4-hydroxyindole for 5-hydroxyindazole and methyl 2,4-difluorobenzoate for ethyl 2,4-difluorobenzoate in EXAMPLE 20A. EXAMPLE 24G tert-butyl 4-(3-( 1 H-indo]-4-yloxy)-4-(methoxycarbonyl)phenyl)piperazine-1 -carboxylate -278- The title compound was prepared by substituting EXAMPLE 24F for EXAMPLE 20A and tert-butyl piperazine-1-carboxylate for EXAMPLE 20C in EXAMPLE 20D. ; EXAMPLE 24H methyl 2-(lH-indol-4-yloxy)-4-(piperazin-l-yl)benzoate The title compound was prepared by substituting EXAMPLE 24G for EXAMPLE 1A in EXAMPLE IB. I EXAMPLE 241 methyl 2-(lH-indol-4-yloxy)-4-(4-((4'-chloro-4-(pyrrolidin-l-ylmethyl)biphenyl-2-yl)methyl)piperazin-1 -yI)benzoate The title compound was prepared by substituting EXAMPLE 24E for 4'-chlorobiphenyl-2 carboxaldehyde and EXAMPLE 24H for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 24J 2-(lH-indol-4-yloxy)-4-(4-((4'-chloro-4-(pyrrolidin-l-ylmethyl)biphenyl-2-yl)methyl)piperazin-l-yl)benzoic acid The title compound was prepared by substituting EXAMPLE 241 for EXAMPLE ID in EXAMPLE IE. EXAMPLE 24K 4-(4- {[4'-chloro-4-(pyrrolidin- 1-ylmethyl)-1,1 '-biphenyl-2-yl]methyI} piperazin- l-yl)-2-( 1H-indol-4-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 24J for EXAMPLE IE in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-de) 8 U.52 (br s, IH), 11.26 (s, IH), 10.68 (br s, IH), 8.61 (dd, IH), 8.49 (s, IH), 8.19 (br s, IH), 7.66 (d, 2H), 7.54 (m, 3H), 7.36 (m, 2H), 7.28 (s, IH), 7.24 (d, IH), 7.05 (d, IH), 6.95 (dd, IH), 6.75 (d, IH), 6.35 (m, 2H), 6.26 (s, IH), 4.38 (m, 3H), 3.85 (dd, 2H), 3.61 (m. 4H), 3.24 (m, 4H), 3.09 (m, 4H), 2.85 (m, 2H), 2.35 (m, 2H), 2.02 (m, 2H), 1.87 (m, 4H), 1.60 (m, 2H), 1.25 (m, 2H). -279- EXAMPLE 25 4.(4. {[4'-chloro-4-(2-pyrrolidin-1 -ylethyl)-1, l'-biphenyl-2-yl]methyl} piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 25A methyl 4'-ch]oro-4-(2-oxoethyl)biphenyl-2-carboxylate To a solution of (methoxymethy])diphenylphosphine oxide (1.62 g) in 40 mL tetrahydrofuran at -78°C, was added lithium diisopiopylamide (2M, 3.3 mL), and after stirring 3 minutes, EXAMPLE 24B (1.57 g) was added, and the solution was warmed to room temperature. NaH (230 mg), and 40 mL N,N-dimethylformamide were added, and the mixture was heated to 60°C for 1 hours. The reaction was cooled and poured into NaH2P04 solution. The resulting solution was extracted twice with ether, and the combined extracts were washed twice with water, and brine, and concentrated. The crude mixture of enol ethers was taken up in IM HCl (50 mL) and dioxane (50 mL), and stirred at 60°C for 3 hours. The reaction was cooled and poured into NaHC03 solution. The resulting solution was extracted twice with ether, and the combined extracts were washed with water, and brine, and concentrated. The product was used without further purification. EXAMPLE 25B methyl 4'-chloro-4-(2-(pyrrolidin-1 -yl)ethyl)biphenyl-2-caiboxylate The title compound was prepared by substituting EXAMPLE 25A for 4'- chlorobiphenyl-2-carboxaldehyde and pyrrolidine for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 25C (4'-chloro-4-(2-(pyrrolidin-1 -yl)ethyl)biphenyl-2-yl)methanol The title compound was prepared by substituting EXAMPLE 25B for EXAMPLE 24C in EXAMPLE 24D. EXAMPLE 25D 4'-chloro-4-(2-(pyrrolidin-1 -yl)ethyl)biphenyl-2-carbaldehyde -280- The title compound was prepared by substituting EXAMPLE 25C for EXAMPLE 24D in EXAMPLE 24E. EXAMPLE 25E methyl 2-(lH-indol-4-yloxy)-4-(4-((4'-chloro-4-(2-(pyrrolidin-l-yl)ethyl)biphenyl-2-yl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 25D for 4'-chlorobiphenyl-2 carboxaldehyde and EXAMPLE 24H for tert-butyl piperazine-l-carboxylate in EXAMPLE 1 A. EXAMPLE 25F 2-( lH-indol-4-yloxy)-4-(4-((4'-chloro-4-(2-(pynx)lidin-1 -yl)ethyl)biphenyl-2- yl)methyl)piperazin-l-yl)benzoic acid The title compound was prepared by substituting EXAMPLE 25E for EXAMPLE ID in EXAMPLE IE. EXAMPLE 25G 4-(4- {[4'-chloro-4-(2-pyrrolidin-1 -ylethyl)-1, r-biphenyl-2-yl]methyl} piperazin-1 -yl)-2-( 1H-indol-4-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-. ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 25F for EXAMPLE IE in EXAMPLE IG. ^H NMR (300MHz, dimethylsulfoxide-dg) 6 1L15 (s, IH), 8.47 (t, IH), 8.42 (s, IH), 7.68 (dd, IH), 7.58 (d, IH), 7.44 (m, 4H), 7.22 (m, 3H), 7.10 (d, IH), 6.92 (m, 2H), 6.68 (d, IH), 6.34 (d, IH), 6.26 (s, 2H), 3.87 (dd, 2H), 3.61 (m, 4H), 3.10-3.24 (m, IIH), 2.97 (m, 4H), 2.31 (m, 4H), 1.89 (m, 4H), 1.61 (m, 2H), 1.26 (m, 2H). EXAMPLE 26 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N-( {4- [(l-cyclopentylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzamide EXAMPLE 26A ethyl 2-(lH-indol-5-yloxy)-4-fluorobenzoate -281- The title compound was prepared by substituting 5-hydroxyindole for 5-hydroxyindazole in EXAMPLE 20A. EXAMPLE 26B ethyl 2-(lH-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 26A for EXAMPLE 20A in EXAMPLE 20D. EXAMPLE 26C 2-( 1 H-indol-5-y loxy)-4-(4-((2-(4-chIorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 26B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 26D 4-(l-cyclopentylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting l-cyclopentylpiperidin-4-amine for (tetrahydropyran-4-yl)methylanune in EXAMPLE IF. EXAMPLE 26E 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl jpiperazin- l-yI)-N-( {4- [(l-cyclopentyIpiperidin-4-yl)amino]-3-nitrophenyI}sulfonyl)-2-(lH-indol-5- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 26C for EXAMPLE IE and EXAMPLE 26D for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 5 11.13 (br s, IH), 8.52 (s, IH), 8.14 (d, IH), 7.80 (d, IH), 7.52 (d, IH), 7.35 (m, 4H), 7.04 (m, 4H), 6.80 (d, IH), 6.61 (d, IH), 6.36 (s, IH), 6.14 (s, IH), 5.76 (s, IH), 3.84 (m, 2H), 3.24 (m, 4H), 2.99 (m, 4H), 2.85 (m, 2H). 2.71 (m. 2H), 2.16 (m, 6H), 1.95 (m, 4H), 1.50-1.70 (m, 6H), 1.38 (m, 2H), 1.17 (m, 2H), 0.93 (s, 6H). -282- EXAMPLE 27 4.{4.[(4'.chloro-l,l'-biphenyl-2-yl)methyl]-3-isobutylpiperazin-l-yl}-N-({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxybenzamide EXAMPLE 27A methyl 2-bromo-4-methylpentanoate To concentrated HBr (48%) (20 mL) in water (214 mL), was added KBr (17.6 g, cooled to 0 °C, then sodium nitrite (5.2 g) all at once, then DL-leucine (5.2 g) in a few portions. The reaction was mechanically stirred at 0 °C for 1.5 hours, then extracted with 2 x 200 mL ethyl acetate. The combined organic layers were washed with brine and dried over Na2S04. After filtration and concentration, the resultant oil was dissolved in CHaCymethanol and treated with 2.0M (TMS)CHN2 in ether (30 mL) at room temperature for 10 minutes. The reaction was concentrated and then purified by flash chromatography using 97.5/2.5 hexane/ethyl acetate. EXAMPLE 27B 3-isobutylpiperazin-2-one EXAMPLE 27A (2.2 g) in ethanol (15 mL) was added dropwise over a period of 2.5 hours to a stirred refluxing solution of ethane-1,2-diamine (13.2 mL) in ethanol (60 mL). Heating was continued for another 2.5 hours, then NaOEt in ethanol was added (21% by wt, 4.0 mL) and heated for another 90 minutes. The reaction was then cooled and concentrated. After trituration with ether, the title compound was used without purification. EXAMPLE 27C 4'-chlorobiphenyl-2-carba]dehyde To 2-bromobenzaldehyde (2.3 ml) and tetrakis(triphenylphosphine)palladium(0) (0.35 g) in toluene (50 mL), was added 4-chlorophenylboronic acid (4.0 g) and 2M NaiCOs (70 ml). The mixture was heated under reflux for one hour. The reaction was cooled, diluted with water and extracted with ethyl acetate. The organic layer was washed with brine and the combined aqueous layers back-extracted with ethyl acetate. The combined organic layers were dried over Na2S04. The crude material was purified by flash chromatography using 97.5/2.5 hexane/ethyl acetate. -283- EXAMPLE 27D 4-((4'-chlorobiphenyl-2-yl)methyl)-3-isobutylpiperazin-2-one The title compound was prepared by substituting EXAMPLE 27B for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 27E l-((4'-chlorobiphenyl-2-yl)methyl)-2-isobutylpiperazine To a solution of EXAMPLE 27D in tetiahydrofuran (3.6 mL) was added borane-methyl sulfide complex (lOM in tetiahydrofuran) (0.24 mL). The reaction was heated under reflux for 16 hours, then cooled in an ice/water bath. Methanol (5 mL) was added carefully, and the mixture was stirred cold for 75 minutes. Then 4N HCl in dioxane (0.65 mL) was added and the reaction heated under reflux for 60 minutes. After cooling to room temperature, WNH4OH (2.6 mL) was added and the reaction was stirred for 15 minutes. Then the reaction was concentrated, redissolved in methanol, concentrated, redissolved in toluene and concentrated. The crude solids were slurried in CHCh/methanol, the solids were filtered off, and the filtrate concentrated to afford the title compound. EXAMPLE 27F methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)-3-isobutylpiperazin-l-yl)-2-phenoxybenzoate The title compound was prepared by substituting EXAMPLE 27E for EXAMPLE IB in EXAMPLE ID. EXAMPLE 27G 4-(4-((4'-ch]orobiphenyl-2-yI)methyl)-3-isobutylpiperazin-1 -yI)-2-phenoxybenzoic acid The title compound was prepared by substituting EXAMPLE 27F for EXAMPLE ID in EXAMPLE IE. EXAMPLE 27H 4- {4-[(4'-chloio-1, r-biphenyl-2-yl)methyl]-3-isobutylpiperazin-1 -yl} -N-( {3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxybenzamide EXAMPLE 27G (13 mg), EXAMPLE IF (7 mg), l-ethyl-3-[3- (dimethylamino)propyl]-carbodiimide hydrochloride (8 mg), and 4-dimethylaminopyridine (5 mg) were stirred in CH2CI2 (1 mL) for 24 hours. The product was purified by preparative -284- HPLC using a C18 column, 250 x 50 mm, lOp., and eluting with a gradient of 20-100% CH3CN vs. 0.1% trifluoroacetic aicd in water, giving the product as a trifluoroacetate salt. 'H NMR (300 MHz, dimethylsulfoxide-ds) 8 11.62 (br s, IH), 9.10 (br s, IH), 8.65 (t, IH), 8.47 (d, IH), 7.77 (dd, IH), 7.70 (br s, IH), 7.50 (m, 5H), 7.39 (m, 3H), 7.25 (m, 2H), 7.18 (d, IH), 7.01 (dd, IH), 6.83 (m, 2H), 6.76 (m, IH), 6.40 (br s, IH), 4.70 and 4.15 (both v br s, total IH), 3.85 (dd, 2H), 3.60 (v br s, IH), 3.32, 3.27, 3.24, 3.06 (all m, total 1 IH), 1.90 (m, IH), 1.62 (m, 3H), 1.30 (m, 4H), 0.70 (br m, 6H). EXAMPLE 28 4. {4-[(4'-chloro-1, l'-biphenyl-2-yl)methyl]piperazin- 1-yl} -N- {[4-(2,4-dioxo-3-azabicyclo[3.2.0]hept-3-yl)phenyl]sulfonyl} -2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE IE for EXAMPLE 27G and 4-(2,4-dioxo-3-azabicyclo[3.2.0]heptan-3-yl)bezenesuIfonamide for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 11.87 (br s, IH), 9.58 (br s, IH), 7.93 (d, 2H), 7.71 (br s, IH), 7.54 (m, 7H), 7.35 (m, 5H), 7.10 (dd, IH), . 6.89 (d, 2H), 6.78 (dd, IH), 6.42 (s, IH), 4.37 (br s, IH), 3.78 (br s, IH), 3.43 (m, 4H), 3.22, 3.00, 2.85 (all v br s, total 6H), 2.62 (m, 2H), 2.18 (m, 2H). EXAMPLE 29 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -N- {[4-(4-methyl-6-oxo-1,4,5,6-tetrahydiopyridazin-3-yl)phenyl]sulfonyl} -2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE IE for EXAMPLE 27G and 4-(4-methyl-6-oxo-l,4,5,6-tetrahydropyridazin-3-yl)bezenesulfonamide for EXAMPLE IF in EXAMPLE 27H. ^H NMR (300 MHz, dimethylsulfoxide-de) 5 11.87 (br s, IH), 11.20 (s, IH), 9.58 (br s, IH). 7.90 (d, 2H), 7.83 (d, 2H), 7.50 (m, 5H), 7.32 (m, 5H), 7.08 (dd, IH), 6.85 (d, 2H), 6.76 (dd, IH), 6.43 (s, IH), 4.38 (br s, IH), 3.80 (br s, IH), 3.60 (m, 2H), 3.40 (m, 2H), 3.21, 3.00,2.84 (all br s, total 6H), 2.75 (dd, IH), 2.28 (d, IH). 1.08 (d, 3H). EXAMPLE 30 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N- {[4-(3,3-dimethyl-2- oxoazetidin-1 -yl)pheny 1] sulfony 1) -2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE IE for EXAMPLE 27G and 4-(3,3-dimethyl-2-oxoazetidin-l-yl)bezenesulfonamide for EXAMPLE IF in EXAMPLE -285- 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 11.62 (br s, IH), 9.58 (br s, IH), 7.80 (d, 2H), 7.72 (br s, IH), 7.50 (m, 5H), 7.40 (m, 4H), 7.33 (m, 3H), 7.08 (dd, IH), 6.85 (d, 2H), 6.76 (dd, IH), 6.41 (s, IH), 4.38 (br s, IH), 3.77 (br s, IH), 3.58 (s, 2H), 3.45 (m, 2H), 3.21, 3.00, 2.84 (all br s, total 6H), 1.32 (s, 6H). EXAMPLE 31 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin- 1-yl} -N- {[4-(4-nitio-2H-1,2,3-triazol-2-yl)phenyl]sulfonyl) -2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE IE for EXAMPLE 27G and 4-(4-nitro-2//-l,2,3-triazol-2-yl)bezenesulfonaniide for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 6 11.98 (br s, IH), 9.58 (br s, IH), 9.11 (s, IH), 8.21 (d, 2H), 8.05 (d, 2H), 7.70 (br s, IH), 7.50 (m, 5H), 7.39 (m, 2H), 7.30 (m, IH), 7.24 (m, 2H), 7.00 (dd, IH), 6.82 (d, 2H), 6.78 (dd, IH), 6.43 (s, IH), 4.38 (br s, IH), 3.77 (br s, IH), 3.45 (m, 2H), 3.21.3.00,2.84 (all br s, total 6H). EXAMPLE 32 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl }-2-phenoxy-N- {[2-(2-piperidin-1 - ylethoxy)phenyl]sulfonyl} benzamide The title compound was prepared by substituting EXAMPLE IE for EXAMPLE 27G and 2-(2-(piperidin-l-yl)ethoxy)bezenesulfonamide for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.65 (br s, IH), 9.77 (br s, IH), 8.95 (br s, IH), 7.80 (dd, IH), 7.70 (br s, IH), 7.68 (m, IH), 7.50 (m, 5H), 7.36 (m, 5H), 7.23 (d, IH), 7.15 (m, 2H), 6.90 (d, 2H), 6.78 (dd, IH), 6.42 (s, IH), 4.40 (m, 3H), 3.80 (br s, IH), 3.40, 3.20 3.00,2.90 (all v br m, total 13H), 1.63 (m, 5H), 1.27 (v br s, IH). EXAMPLE 33 4-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl}-N-{[3-({[(l-ethylpyrrolidin-2-yl)methyl]amino }carbonyl)-4-methoxyphenyl]sulfonyl} -2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE IE for EXAMPLE 27G and A^-((l-ethylpyrrolidin-2-yl)methyl)-2-methoxy-5-sulfamoylbenzamide for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.75 (br s, IH), 9.70 (br s, IH), 9.25 (br s, IH), 8.62 (t, IH), 8.25 (d, IH), 7.90 (dd, IH), 7.70 (br s, IH), 7.50 (m, 5H), 7.40 (m, 2H), 7.10 (m, 5H), 7.09 (dd, IH), 6.85 (d, 2H), 6.76 (dd, IH), 6.40 (s, IH), 4.39 (br -286- s, IH), 3.96 (s, 3H), 3.77 (brs, IH), 3.60 (m, 4H), 3.55-2.80 (envelope, lOH), 2.12 (m, IH), 2.00 (m, IH), 1.85 (m, 2H), 1.23 (t, 3H). EXAMPLE 34 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-( 1 -n^hthyloxy)-N-( {3 -nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 34A methyl 2-bromo-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)benzoate The title compound was prepared by substituting methyl 2-bromo-4-fluorobenzoate for EXAMPLE IC in EXAMPLE ID. EXAMPLE 34B methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)pipcrazin-l-yl)-2-(naphthalen-l- yloxy)benzoate The title compound was prepared by substituting EXAMPLE 34A for EXAMPLE 18E and 1-naphthol for phenol in EXAMPLE 18F. EXAMPLE 34C 4-(4-((4'-chlon)biphenyl-2-yl)methyl)piperazin-l-yl)-2-(naphthalen-l-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 34B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 34D 4- {4- [(4'-chloro-1,1 *-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-( 1 -naphthyloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 34C for EXAMPLE 27G in EXAMPLE 27H. ^H NMR (300 MHz, dimethylsulfoxide-de) 8 11.82 (br s, IH), 9.50 (br s, IH), 8.58 (t, IH), 8.29 (d, IH), 8.18 (d, IH), 7.85 (d, IH), 7.70 (br s, IH), 7.50 (m, 8H), 7.38 (m, 4H), 7.20 (dd, IH), 6.82 (m, 2H), 6.55 (s, IH), 6.45 (d, IH), 4.38 (br s, IH), 3.85 (dd, 2H), 3.78 (br s, IH), 3.27 (m, 6H), 3.22, 3.02, 2.85 (all br s, total 6H), 1.84 (m, IH), 1.60 (m, 2H), 1.29 (m, 2H). -287- EXAMPLE 35 4.{4.[(4'.chloio-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl}-2-(2-naphthyloxy)-N-({3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide EXAMPLE 35A l-(difluoromethylsulfonyl)-2-fluorobenzene The title compound was prepared by substituting EXAMPLE 34A for EXAMPLE 18E and 2-naphthol for phenol in EXAMPLE 18F. EXAMPLE 35B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(naphthalen-2-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 35A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 35C 4- {4- [(4'-chloro-1,1 '-biphenyL2-yl)methyl]piperazin-1 -yl) -2-(2-n£^hthyloxy)-N-( {3 -nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 35B for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.80 (br s, IH), 9.55 (br s, IH), 8.50 (t, IH), 8.39 (d, IH), 7.83 (m, 2H), 7.69 (br s, IH), 7.64 (d, IH), 7.50 (m, 6H), 7.37 (ra, 5H), 7.18 (dd, IH), 7.00 (d, IH), 6.81 (dd, IH), 6.77 (d, IH), 6.56 (d, IH), 4.38 (br s, IH), 3.85 (dd, 2H), 3.78 (br s, IH), 3.27 (m, 6H), 3.22, 3.02,2.85 (all br s, total 6H), 1.84 (m, IH), 1.60 (m, 2H), 1.29 (m, 2H). EXAMPLE 36 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-( {4- [(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(2-naphthyloxy)benzamide The tide compound was prepared by substituting EXAMPLE 35B for EXAMPLE 27G and EXAMPLE 7A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-dfi) 5 11.80 (br s, IH), 9.61 (br s, 2H), 8.57 (t, IH), 8.40 (d, IH), 7.83 (m, 2H), 7.66 (m, 2H), 7.50 (m, 6H), 7.40 (m, 5H), 7.18 (dd, IH), 7.02 (d, IH), 6.81 (d, IH), 6.57 -288- (s, IH), 4.38 (br s, IH), 4.00 (m, 2H), 3.80 (br s, IH), 3.40 (m, 8H), 3.30-2.80 (envelope, lOH), 1.92 (m, 2H). EXAMPLE 37 4-{4.[(4'-chloK)-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl)-2-(2-naphthyloxy)-N-({4-[(tetrahydro-2H-pyran-4-ylmethy])amino]-3-[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 35B for EXAMPLE 27G and EXAMPLE 163A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, diraethylsulfoxide-de) 8 11.82 (br s, IH), 9.58 (br s, IH), 8.03 (d, IH), 7.90 (m, 2H), 7.70 (d, IH), 7.69 (br s, IH), 7.65 (dd, IH), 7.50 (m, 7H), 7.36 (m, 3H), 7.18 (m, 2H), 7.05 (d, IH), 6.81 (dd, IH), 6.75 (d, IH), 6.56 (d, IH), 4.38 (br s, IH), 3.83 (dd, 2H), 3.78 (br s, IH), 3.23 (m, 4H), 3.22, 3.02,2.85 (all br s, total 6H), 3.15 (m, 2H), 1.80 (m, IH), 1.55 (m, 2H), 1.22 (m, 2H). EXAMPLE 38 4- {4-[(4'-chloro-1,1 '-biphenyl-2-y l)methyl]piperazin- 1-yl) -N-( {3-nitio-4- [(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-(quinolin-7-yloxy)benzaniide EXAMPLE 38A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyI)piperazin-l-yl)-2-(quinolin-7- yloxy)benzoate The title compound was prepared by substituting EXAMPLE 34A for EXAMPLE 18E and quinolin-7-ol for phenol in EXAMPLE 18F. EXAMPLE 38B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(qutnolin-7-yloxy)benzoic acid The tide compound was prepared by substituting EXAMPLE 38A for EXAMPLE ID in EXAMPLE IE. -289- EXAMPLE 38C 4. {4.[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-l-yl} -N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4-y]methyl)amino]phenyl)sulfonyl)-2-(quinolin-7-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 38B for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 8.80 (d, IH), 8.48 (t, IH), 8.35 (d, IH), 8.32 (d, IH), 7.90 (d, IH), 7.74 (m, IH), 7.59 (m, 2H), 7.50 (m, 4H), 7.45 (dd, IH), 7.38 (d, 2H), 7.30 (m, 2H), 6.95 (d, IH), 6.86 (dd, IH), 6.83 (d, IH), 6.71 (d, IH), 4.38 (br s, IH), 3.85 (dd, 2H), 3.78 (br s, IH), 3.30-2.80 (envelope, 12H), 1.84 (m, IH), 1.60 (m,2H), 1.25(m,2H). EXAMPLE 39 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin- 1-yl )-N-({ 3-nitro-4-[(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl) sulfonyl)-2-(quinolin-6-yloxy)benzamide EXAMPLE 39A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(quinolin-6-yIoxy)benzoate The title compound was prepared by substituting EXAMPLE 34A for EXAMPLE 18E and quinolin-6-ol for phenol in EXAMPLE 18F. EXAMPLE 39B 4-(4-((4'-chloiobiphenyl-2-yl)methyI)piperazin-l-yI)-2-(quinolin-6-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 39A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 39C 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -N-({ 3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(quinoIin-6-yIoxy)benzamide The title compound was prepared by substituting EXAMPLE 39B for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 11.90 (br s, IH), 9.65 (br s, IH), 8.80 (d, IH), 8.46 (t, IH), 8.35 (d, IH), 7.90 (d, IH), 7.72 (m, IH), 7.50 (m, 6H), 7.45 (dd, IH), 7.37 (m, 4H), 7.02 (d, IH), 6.83 (dd, IH), 6.79 (d, IH), 6.63 (d, IH), 4.38 (br -290- s, IH), 3.85 (dd, 2H), 3.78 (br s, IH), 3.40-2.80 (envelope 12H), 1.87 (m, IH), 1.62 (m, 2H), 1.26 (m,2H). EXAMPLE 40 4.(4.[(4'.chloro-l,l'-biphenyI-2-yI)methyl]piperazin-l-yl}-2-(lH-indol-5-yloxy)-N-((3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzaraide EXAMPLE 40A 1 -(ttiisopiopylsilyl)-lH-iivdol-5-ol S-Benzyloxy-indole (1.0 g) was treated with NaH (135 mg) and triisopropylsilyl chloride (1.0 g) in tetrahydrofuran for 1 hour, purified by flash chromatography (98/2 ethyl acetate/hexanes), then debenzylated in ethanol (35 mL) using Pearlman's catalyst (0.19 g) and a hydrogen balloon. EXAMPLE 40B methyl 2-(lH-indol-5-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)benzoate The tide compound was prepared by substituting EXAMPLE 34A for EXAMPLE 18E and EXAMPLE 40A for phenol in EXAMPLE 18F. In this example, the crude material from the ether formation was desilylated using tetrabutyl ammonium fluoride in tetrahydrofuran/water 95/5 prior to purification. EXAMPLE 40C 2-(lH-indol-5-yloxy)-4-(4-((4'-chloiobiphenyl-2-yl)methyl)piperazin-l-yl)ben2oicacid The title compound was prepared by substituting EXAMPLE 40B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 40D 4-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methyllpiperazin-l-yl}-2-(lH-indol-5-yloxy)-N-({3-mtro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 40C for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.40 (br s, IH), 11.17 (s, IH), 9.50 (V br s, IH), 8.61 (t, IH), 8.57 (d, IH), 7.77 (dd, IH), 7.70 (br s, IH), 7.50 (m, 5H), 7.36 (m, 5H), 7.10 (s, IH), 7.08 (d, IH), 6.83 (dd, IH), 6.69 (dd, IH), 6.37 (m, IH), 6.21 (d, IH), 4.30 (br s, IH), 3.84 (dd, 2H), 3.70 (br s, IH). 3.30 (m, 6H), 3.20, 2.95, 2.80 (all br s, total 6H), 1.86 (m, IH), 1.60 (m, 2H), 1.25 (m, 2H). -291- EXAMPLE 41 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)niethy]]piperazin-1 -yl} -2-(isoquinolin-5-yloxy)-N-( {3- nitK)-4-[(tetrahydro-2H-pyran-4-ylmethyl)aniino]phenyl}sulfonyl)benzamide EXAMPLE 41A methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(isoquinolin-5- yloxy)benzoate The title compound was prepared by substituting EXAMPLE 34A for EXAMPLE 18E and isoquinolin-5-ol for phenol in EXAMPLE 18F. EXAMPLE 41B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(isoquinolin-5-yloxy)ben2oic acid The title compound was prepared by substituting EXAMPLE 41A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 41C 4- {4-[(4'-chloio-1, r-biphenyl-2-yl)methyl]piperazin- 1-yl) -2-(isoquinolin-5-yloxy)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 4 IB for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 1L90 (br s, IH), 9.55 (v br s, IH), 9.26 (s, IH), 8.47 (m, 2H), 8.14 (d, IH). 7.99 (d, IH), 7.65 (br s, IH), 7.60 (d, IH), 7.45 (m, 6H), 7.29 (m, 4H), 6.80 (m, 2H), 6.60 (m, 2H), 4.38 (br s, IH), 3.85 (dd, 2H), 3.78 (br s, IH), 3.24 (m, 6H), 3.22,3.00,2.85 (all br s, total 6H), 1.87 (m, IH), 1.62 (m, 2H), 1.26 (m, 2H). EXAMPLE 42 4-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl}-N-[(4-{[3-(dimethylamino)propyl]amino}-3-nitiophenyl)sulfonyl]-2-(isoquinolin-5-yIoxy)benzamide The title compound was prepared by substituting EXAMPLE 4 IB for EXAMPLE 27G and EXAMPLE 154A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, -292- dimethylsulfoxide-dfi) 8 11.90 (br s, IH), 9.38 (v br s, IH), 9.22 (s, IH), 8.54 (t, IH), 8.45 (d, IH), 8.16 (d, IH), 7.96 (d, IH), 7.62 (brs, IH), 7.56 (d, IH), 7.50 (d, IH), 7.45 (m, 5H), 7.29 (m, 4H), 6.80 (m, 2H), 6.60 (m, 2H), 4.23 (br s, IH), 3.78 (br s, IH), 3.40 (m, 2H), 3.35-2.80 (envelope, 8H), 3.08 (m, 2H), 2.72, 2.70 (both s, total 6H), 1.87 (m, 2H). EXAMPLE 43 4- {4-[(4'-chloio-1, r-biphenyl-2-yl)methyl]pipera2in-l -yl} -N-[(4- {[3-(dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(quinolin-6-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 39B for EXAMPLE 27G and EXAMPLE 154A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 11.96 (br s, IH), 9.38 (v br s, IH), 8.77 (dd, IH), 8.51 (t, IH), 8.35 (d, IH), 8.05 (d,lH), 7.90 (d, IH), 7.70 (brs, IH), 7.50 (m, 6H), 7.38 (m, 5H), 6.98 (d, IH), 6.83 (dd, IH), 6.79 (d, IH), 6.63 (d, IH), 4.38 (br s, IH), 3.78 (br s, IH), 3.42 (m, 2H), 3.35-2.80 (envelope, 8H), 3.15 (m, 2H), 2.81, 2.79 (both s, total 6H), 1.93 (m, 2H). EXAMPLE 44 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N- [(4- {[3-(dimethylaniino)pK)pyl]amino} -3-nitrophenyl)sulfonyl]-2-( lH-indol-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 40C for EXAMPLE 27G and EXAMPLE 154A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.40 (br s, IH), 11.18 (s, IH), 9.30 (v br s, IH), 8.66 (t, IH), 8.60 (d, IH), 7.85 (dd, IH), 7.52 (d, IH), 7.50 (m, 5H), 7.40 (m, 4H), 7.30 (br s, IH), 7.14 (s, IH), 7.10 (d, IH), 6.84 (dd, IH), 6.67 (dd, IH), 6.39 (m, IH), 6.20 (s, IH), 4.35 (br s, IH), 3.78 (br s, IH), 3.40 (m, 2H), 3.35-2.80 (envelope, 8H), 3.10 (m, 2H), 2.78,2.76 (both s, total 6H), 1.95 (m,2H). EXAMPLE 45 4-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl}-2-(lH-indol-4-yloxy)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide EXAMPLE 45A 1 -(triisopropylsilyl)-1 H-indol-4-ol -293- 4-Benzyloxy-indole (1.0 g) was treated with NaH (135 mg) and triisopropylsilyl cMoride (1.0 g) in tetrahydrofiiran for 1 hour, purified by flash chromatography (98/2 ethyl acetate/hexanes), then debenzylated in ethanol (35 mL) using Pearlman's catalyst (0.19 g) and a hydrogen balloon. EXAMPLE 45B methyl 2-(lH-indol-4-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)benzoate Tlie title compound was prepared by substituting EXAMPLE 34A for EXAMPLE 18E and EXAMPLE 45A for phenol in EXAMPLE 18F. Here the crude material from the ether formation was desilated using tetra-n-butylammonium fluoride in tetrahydrofuran/water 95/5 prior to purification. EXAMPLE 45C 2-( 1 H-indol-4-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 45B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 45D 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-( 1 H-indol-4-yloxy)-N-( {3-nitn)-4-[(tetrahydro-2H-pyran-4-ylmethyl)aminolphenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 45C for EXAMPLE 27G in EXAMPLE 27H. ^H NMR (300 MHz, dimethylsulfoxide-de) 5 11.50 (br s, IH), 11.24 (s, IH), 9.50 (v br s, IH), 8.61 (t, IH), 8.47 (d, IH), 7.70 (br s, IH), 7.64 (dd, IH), 7.50 (m, 5H), 7.30 (m, 4H), 7.15 (d, 2H), 7.04 (d, 2H), 6.92 (dd, IH), 6.75 (dd, IH), 6.33 (m, 2H), 6.23 (s, IH), 4.30 (br s, IH), 3.84 (dd, 2H), 3.70 (br s, IH), 3.30 (m, 6H), 3.20, 2.95, 2.80 (all br s, total 6H), 1.86 (m, IH), 1.60 (m, 2H), 1.25 (m, 2H). EXAMPLE 46 4-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl}-N-[(4-{[3-(dimethylamino)piiopy]]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 45C for EXAMPLE 27G and EXAMPLE 154A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, -294- dimethylsulfoxide-dfi) 8 11.50 (v br s, IH), 11.24 (s, IH), 9.30 (br s, IH), 8.66 (t, IH), 8.53 (d, IH), 7.85 (dd, IH), 7.55 (d, IH), 7.50 (m, 5H), 7.39 (m, 2H), 7.30 (m, 2H), 7.148 (d, IH), 7.10 (d, IH), 6.96 (dd, IH), 6.72 (dd, IH), 6.41 (d, IH), 6.32 (s, IH), 6.23 (s, IH), 4.35 (br s, IH), 3.78 (br s, IH), 3.40 (m, 2H), 3.35-2.80 (envelope, 8H), 3.10 (m, 2H), 2.78, 2.76 (both s, total 6H), 1.95 (m,2H). EXAMPLE 47 4.{4.[(4'.chloro-l,r-biphenyl-2-yl)methyl]piperazin-l-yl}-N-[(4-{[3- (dimethylainino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-6-yloxy)benzamide EXAMPLE 47A 1 -(triisopropylsilyl)-1 H-indol-6-ol 6-Benzyloxy-indole (1.0 g) was treated with NaH (135 mg) and triisopropylsilyl chloride (1.0 g) in tetrahydroftiran for 1 hour, purified by flash chromatography (98/2 ethyl acetate/hexanes), then debenzylated in ethanol (35 mL) using Pearlman's catalyst (0.19 g) and a hydrogen balloon. EXAMPLE 47B methyl 2-( 1 H-indol-6-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 34A for EXAMPLE 18E and EXAMPLE 47A for phenol in EXAMPLE 18F. In this example, the crude material from the ether formation was desilated using tetrabutyl ammonium fluoride in tetrahydrofuran/water 95/5 prior to purification. EXAMPLE 47C 2-( 1 H-indol-6-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 47B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 47D 4- {4-[(4'-chloro-1, r-biphenyl-2-yl)methyl]pipera2in-l -yl} -N-[(4- {[3- (dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-6-yloxy)benzamide -295- The title compound was prepared by substituting EXAMPLE 47C for EXAMPLE 27G and EXAMPLE 154A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 U.50 (vbr s, IH), ILOO (s, IH), 9.38 (brs, IH), 8.64 (t, IH), 8.58 (d, IH), 7.75 (dd, IH), 7.65 (br s, IH), 7.55 (d, IH), 7.50 (m, 5H), 7.39 (m, 2H), 7.30 (m, 2H), 7.00 (d, IH), 6.90 (s, IH), 6.70 (m, 2H), 6.42 (m, IH), 6.30 (s, IH), 4.35 (br s, IH), 3.78 (br s, IH), 3.40 (m, 2H), 3.35-2.80 (envelope. 8H), 3.10 (m, 2H), 2.78, 2.76 (both s, total 6H), 1.95(m,2H). EXAMPLE 48 4- {4-[(4'-chloio-1, r-biphenyl-2-yl)methyl]piperazin-1 -yl) -2-(isoquinolin-7-yloxy)-N-( {4- [(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl} sulfonyl)benzamide EXAMPLE 48A This EXAMPLE was prepared by substituting EXAMPLE 34A for EXAMPLE 18E and isoquinolin-7-ol for phenol in EXAMPLE 18F. EXAMPLE 48B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(isoquinolin-7-yloxy)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 48A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 48C 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-(isoquinolin-7-yloxy)-N-( {4-[(3-motpholin-4-ylpropyl)aniino]-3-nitrophenyl}sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 48B for EXAMPLE 27G and EXAMPLE 7A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dunethylsulfoxide-de) 8 11.98 (v br s, IH), 9.70 (v br s, 2H), 9.10 (s, IH), 8.56 (t, IH), 8.42 (d, IH), 8.13 (d, IH), 7.93 (d, IH), 7.81 (d, IH), 7.70 (br s, IH), 7.60 (m, 2H), 7.50 (m, 5H), 7.40 (d, 2H), 7.35 (m, IH), 7.14 (d, IH), 6.84 (m, 2H), 6.70 (d, IH), 4.38 (br s, IH), 4.00 (m, 2H), 3.80 (br s, IH), 3.40 (m, 4H), 3.30-2.80 (envelope, lOH), 3.20 (m, 4H), 1.92 (m, 2H). -296- EXAMPLE 49 4- {4-[(4'-chl0K)-1,1 •-biphenyl-2-yl)methyl]piperazin-1 -yl) -N- [(4- {[3-(dimethylamino)propyl]amino}-3-nitiophenyl)sulfonyl]-2-(isoquinolin-7-yloxy)benzaniide The title compound was prepared by substituting EXAMPLE 48B for EXAMPLE 27G and EXAMPLE 154A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 1L98 (v br s, IH), 9.40 (br s, 2H), 9.10 (s, IH), 8.56 (t, IH), 8.40 (d, IH), 8.13 (d, IH), 7.93 (d, IH), 7.81 (d, IH), 7.70 (br s, IH), 7.60 (m, 2H), 7.50 (m, 5H), 7.40 (d, 2H), 7.35 (m, IH), 7.14 (d, IH), 6.84 (m, 2H), 6.70 (d, IH), 4.38 (br s, IH), 3.78 (br s, IH), 3.42 (m, 2H), 3.35-2.80 (envelope, 8H), 3.15 (m, 2H), 2.81, 2.79 (both s, total 6H), 1.93 (m, 2H). EXAMPLE 50 4-(4-{[2-(4-chlorophenyl)-5,5-dimethyIcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitK)phenyl}sulfonyl)benzamide EXAMPLE 50A methyl 2-( lH-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 19D for EXAMPLE 34A in EXAMPLE 40B. EXAMPLE SOB 2-(lH-indol-5-yloxy)-4-(4-((2-(4-chloiophenyl)-5,5-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 50A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 50C 4-(4- {[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-( {4-[(3-morpholin-4-ylpropyl)amino]-3 -nitrophenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 50B for EXAMPLE 27G and EXAMPLE 7A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.98 (br s, IH), 11.20 (s, IH), 9.70 (v br s, IH), 9.35 (v br s, IH), -297- 8.71 (t, IH), 8.62 (d, IH), 7.86 (dd, IH), 7.54 (d, IH), 7.40 (m, 4H), 7.12 (m, 4H), 6.87 (dd, IH), 6.70 (dd, IH), 6.40 (m, IH), 6.20 (d, IH), 3.98 (m, 2H), 3.50, 3.40, 3.30 (all m, total 12H), 3.19 (m, 2H), 3.00 (m, 4H), 2.75 (br s, 2H), 2.23 (br m, 2H), 1.97 (br m, 2H), 1.43 (br t, 2H), 0.98 (s, 6H). EXAMPLE 51 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[3-(dimethylainino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-mdol-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 50B for EXAMPLE 27G and EXAMPLE 154A for EXAMPLE IF in EXAMPLE 27H. ^H NMR (300 MHz, dimethylsulfoxide-dfi) 8 11.42 (br s, IH), 11.20 (s, IH), 9.40 (v br s, IH), 9.30 (v br s, IH), 8.66 (t, IH), 8.61 (d, IH), 7.86 (dd, IH), 7.54 (d, IH), 7.40 (m, 4H), 7.18 (d, IH), 7.12 (m, 3H), 6.87 (dd, IH), 6.70 (dd, IH), 6.40 (s, IH), 6.20 (s, IH), 3.60 (br s, 2H), 3.50 (m, 4H), 3.35 (br s, 2H), 3.13 (m, 3H), 3.00 (br m, 2H), 2.78,2.77 (both s, total 6H), 2.70 (br s, IH), 2.12 (br m, 2H), 1.97 (m, 4H), 1.42 (br t, 2H), 0.97 (s, 6H). EXAMPLE 52 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 26C for EXAMPLE 27G and EXAMPLE 7A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.40 (br s, IH), 11.20 (s, IH), 9.60 (v br s, IH), 9.25 (v br s, IH), 8.70 (t, IH), 8.62 (d, IH), 7.86 (dd, IH), 7.54 (d, IH), 7.40 (m, 4H), 7.18 (d, IH), 7.13 (d, IH), 7.09 (d, 2H), 6.87 (dd, IH), 6.70 (dd, IH), 6.40 (m, IH), 6.20 (s, IH), 3.98 (m, 2H), 3.50, 3.40, 3.30 (aU m, total 12H), 3.19 (m, 2H), 3.00 (m, 4H), 2.75 (br s, 2H), 2.18 (br m, 2H), 2.00 (br m, 4H), 1.43 (br t, 2H), 0.96 (s, 6H). EXAMPLE 53 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl jpiperazin- l-yl)-N-[(4- {[3-(dimethylamino)propyl]amino)-3-nitTophenyl)sulfonyl]-2-(lH-indol-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 55B for EXAMPLE 27G and EXAMPLE 154A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.41 (br s, IH), 11.20 (s, IH), 9.35 (v br s, 2H), 8.66 (t, IH), 8.62 -298- (d, IH), 7.86 (dd, IH), 7.54 (d, IH), 7.40 (m, 4H), 7.18 (d, IH), 7.13 (d, IH), 7.09 (d, 2H), 6.87 (dd, IH), 6.70 (dd, IH), 6.40 (m, IH), 6.20 (s, IH), 3.50 (m, 4H), 3.35 (br s, 2H), 3.13 (m, 3H), 3.00 (br m, 2H), 2.78,2.77 (both s, total 6H), 2.70 (br s, IH), 2.20 (br m, 2H), 2.00 (m, 2H), 1.93 (m, 2H), 1.42 (br t, 2H), 0.97 (s, 6H). EXAMPLE 54 4-(4- {[2-(4-chIoiophenyl)-5,5-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H-indol-4-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitiophenyl}sulfonyl)benzamide EXAMPLE 54A methyl 2-(lH-indol-4-yloxy)-4-(4-((2-(4-ch]oTOphenyl)-5,5-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoate TTie title compound was prepared by substituting EXAMPLE 19D for EXAMPLE 34A in EXAMPLE 45B. EXAMPLE 54B 2-( 1 H-indol-4-yloxy)-4-(4-((2-(4-chloiDphenyl)-5,5-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 54A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 54C 4-(4- {[2-(4-chlorophenyl)-5,5-diraethyIcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( IH-indol-4-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sxilfonyl)benzamide The title compound was prepared by substituting EXAMPLE 54B for EXAMPLE 27G and EXAMPLE 7A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-d6)5ll.50(brs, IH), 11.27 (s, IH), 9.60 (v br s, IH), 9.20 (v br s, IH), 8.65 (t, IH), 8.55 (d, IH), 7.80 (dd, IH), 7.57 (d, IH), 7.40 (d, 2H), 7.30 (dd, IH), 7.12 (d, 2H), 7.10 (d, 2H), 7.00 (dd, IH), 6.73 (dd, IH), 6.46 (d.lH), 6.30 (s, IH), 6.23 (m, IH), 3.98 (m, 2H), 3.60, 3.50, 3.40 (all m, total 12H), 3.19 (m, 2H), 3.00 (m, 4H), 2.75 (br s, 2H), 2.23 (br m, 2H), 1.97 (br m, 4H), 1.43 (br t, 2H), 0.98 (s, 6H). -299- EXAMPLE 55 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H-indol-4-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide EXAMPLE 55A methyl 2-(lH-indol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 45A for phenol in EXAMPLE 18F. Here the crude material from the ether formation was desilated using tetrabutyl ammonium fluoride in tetrahydrofuran/water 95/5 prior to purification. EXAMPLE 55B 2-( 1 H-indol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 55A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 55C 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 -yl)-2-( 1H-indol-4-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 55B for EXAMPLE 27G and EXAMPLE 7A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-dfi) 8 11.50 (br s, IH), 11.25 (s, IH), 9.60 (v br s, IH), 9.20 (v br s, IH), 8.65 (t, IH), 8.55 (d, IH), 7.80 (dd, IH), 7.57 (d, IH), 7.40 (d, 2H), 7.30 (dd, IH), 7.20 (d, IH), 7.10 (m, 3H), 7.00 (dd, IH), 6.73 (dd, IH), 6.46 (d,lH), 6.30 (s, IH), 6.23 (m, IH), 3.98 (m, 2H), 3.60, 3.50, 3.40 (all m, total 12H), 3.19 (m, 2H), 3.00 (m, 4H), 2.75 (br s, 2H), 2.20 (br m, 2H), 2.00 (br m, 4H), 1.43 (br t, 2H), 0.98 (s, 6H). EXAMPLE 56 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[3-(dimethylamino)propyl]amino)-3-nitrophenyl)sulfonyl]-2-(lH-indol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 54B for EXAMPLE 27G and EXAMPLE 154A for EXAMPLE IF in EXAMPLE 27H. *H NMR (300 MHz, -300- climethylsulfoxide-d6)5ll.55(brs, IH), 11.27 (s, IH), 9.40 (v br s, IH), 9.35 (v br s, IH), 8.65 (t, IH), 8.55 (d, IH), 7.79 (dd, IH), 7.57 (d, IH), 7.40 (d, 2H), 7.30 (dd, IH), 7.20 (d, IH), 7.10 (m, 3H), 7.00 (dd, IH), 6.73 (dd, IH), 6.46 (d.lH), 6.30 (s, IH), 6.23 (m, IH), 3.50 (m, 4H), 3.35 (br s, 2H), 3.13 (m, 3H), 3.00 (br m, 2H), 2.78,2.77 (both s, total 6H), 2.70 (br s, IH), 2.22 (br m, 2H), 1.97 (m, 2H), 1.93 (m, 2H), 1.42 (br t, 2H), 0.97 (s, 6H). EXAMPLE 57 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N-[(4- {[3-(dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 55B for EXAMPLE 27G and EXAMPLE 154A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-d6) 8 11.50 (br s, IH), 11.25 (s, IH), 9.60 (v br s, IH), 9.20 (v br s, IH), 8.65 (t, IH), 8.55 (d, IH), 7.79 (dd, IH), 7.57 (d, IH), 7.40 (d, 2H), 7.30 (dd, IH), 7.20 (d, IH), 7.10 (m, 3H), 7.00 (dd, IH), 6.73 (dd, IH), 6.46 (d,lH), 6.30 (s, IH), 6.23 (m, IH), 3.50 (m, 4H), 3.35 (br s, 2H), 3.13 (m, 3H), 3.00 (br m, 2H), 2.78,2.77 (both s, total 6H). 2.70 (br s, IH), 2.20 (br m, 2H), 2.00 (m, 2H), 1.93 (m, 2H), 1.42 (br t, 2H), 0.97 (s, 6H). EXAMPLE 58 4-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl}-2-(lH-indol-4-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 45C for EXAMPLE 27G and EXAMPLE 7A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-dfi) 8 11.50 (br s, IH), 11.24 (s, IH), 9.50 (v br s, IH), 8.67 (t, IH), 8.52 (d, IH), 7.78 (dd, IH), 7.70 (br s, IH), 7.55 (d, IH), 7.50 (m, 4H), 7.38 (d, 2H), 7.30 (dd, 2H), 7.18 (d, IH), 7.08 (d, IH), 6.96 (dd, IH), 6.75 (dd, IH), 6.40 (d, IH), 6.33 (s, IH), 6.23 (s, IH), 4.38 (br s, IH), 4.00 (m, 2H), 3.80 (br s, IH), 3.40 (m, 4H), 3.30-2.80 (envelope, lOH), 3.20 (m, 4H), 1.95 (m, 2H). EXAMPLE 59 4-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl}-2-(lH-indol-5-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 40C for EXAMPLE 27G and EXAMPLE 7A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, -301- dimethylsulfoxide-d6)8ll.40(brs, IH), 11.19(s, IH), 9.60(vbrs, lH),8.69(t, IH), 8.60 (d, IH), 7.83 (dd, IH), 7.65 (br s, IH), 7.50 (m, 5H), 7.38 (m, 5H), 7.12 (m, 2H), 6.83 (dd, IH), 6.69 (dd, IH), 6.39 (m, IH), 6.20 (d, IH), 4.38 (br s, IH), 4.00 (m, 2H), 3.80 (br s, IH), 3.40 (m, 4H), 3.30-2.80 (envelope, lOH), 3.20 (m, 4H), 1.96 (m, 2H). EXAMPLE 60 4- {4-[(4'-chloro-1, r-biphenyl-2-yI)methyl]piperazin- 1-yl }-N-[(4-methoxyphenyl)sulfonyl]- 2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE IE for EXAMPLE 27G and 4-methoxybenzenesulfonamide for EXAMPLE IF in EXAMPLE 27H. 'H NMR (500MHz, dimethylsulfoxide-dfi) 8 11.57 (s, IH), 7.74 (d, 2H), 7.50 (m, 5H), 7.35 (m, 6H), 7.10 (t, IH), 7.02 (m, 2H), 6.87 (d, 2H), 6.75 (dd, IH), 6.41 (s, IH), 4.36 (m, 2H), 3.83 (s, 3H), 3.76 (m, 2H), 3.23 (m, 2H), 3.01 (m, 2H), 2.84 (m, 2H). EXAMPLE 61 4- {4-[(4'-chloro-l, r-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-[(4-methylphenyl)sulfonyl]-2- phenoxybenzamide The tide compound was prepared by substituting EXAMPLE IE for EXAMPLE 27G and 4-methylbenzenesulfonamide for EXAMPLE IF in EXAMPLE 27H. 'H NMR (500MHz, dimethylsulfoxide-ds) 8 11.64 (s, IH), 7.68 (d, 2H), 7.50 (m, 5H), 7.38 (m, 2H), 7.32 (m, 6H), 7.11 (t, IH), 6.87 (d, 2H), 6.75 (dd, IH), 6.41 (s, IH), 4.36 (m, 2H), 3.76 (m, 2H), 3.23 (m, 2H), 3.01 (m, 2H), 2.84 (m, 2H), 2.37 (s, 3H). EXAMPLE 62 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-( 1 H-indol-5-yloxy)-N-( {4-[(tetrahydro-2H-pyran-4-ylmethyI)amino]-3-[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 40C for EXAMPLE 27G and EXAMPLE 163A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300MHz, dimethylsulfoxide-de) 8 11.46 (s, IH), 11.16 (s, IH), 8.17 (d, IH), 7.88 (dd, IH), 7.68 (br s, IH), 7.50 (m, 5H), 7.36 (m, 6H), 7.13 (s, IH), 7.03 (d, IH), 6.84 (dd, IH), 6.68 (dd, IH), 6.39 (m, IH), 6.21 (br s, IH), 4.32 (s, 2H), 3.84 (dd, 2H), 3.25 (m, 7H), 2.93 (m, 4H), 1.84 (m, 2H), 1.54 (m, 2H), 1.24 (m, 2H). -302- EXAMPLE 63 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -2-( 1 H-indol-4-yloxy)-N-( {4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl ]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 45C for EXAMPLE 27G and EXAMPLE 163A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300MHZ, dimethylsulfoxide-de) 6 H.58 (s, IH), n.27 (s, IH), 8.12 (d, IH), 7.71 (m, 2H), 7.52 (m, 5H), 7.32 (m, 5H), 7.18 (d, IH), 6.96 (m, 2H), 6.74 (dd, IH), 6.36 (m, 2H), 6.26 (m, IH), 4.32 (s, 2H), 3.84 (dd, 2H), 3.25 (m, 7H), 2.93 (m, 4H), 1.84 (m, 2H), 1.54 (m, 2H), 1.24 (m, 2H). EXAMPLE 64 4-{4-[(4'-chloro-l,r-biphenyl-2-yl)methyl]piperazin-l-yl}-N-({4-{[3- (dimethylamino)propyl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 40C and EXAMPLE 170A for EXAMPLE 27G and EXAMPLE IF respectively, in EXAMPLE 27H. ^H NMR (300MHz, dimethylsulfoxide-de) 5 11.46 (brs, IH), 11.18 (s, IH), 8.21 (d, IH), 7.98 (dd, IH), 7.50 (m, 6H), 7.41 (m, 5H), 7.29 (br s, IH), 7.17 (s, IH), 7.08 (d, IH), 6.84 (dd, IH), 6.68 (dd, IH), 6.40 (m, IH), 6.18 (br s, IH), 4.32 (br s, 2H), 3.59 (m, 4H), 3.25 (m, 2H), 3.05 (m, 4H), 2.90 (m, 2H), 2.77 (d, 6H), 1.88 (m, 2H). EXAMPLE 65 4-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl}-2-(lH-indol-4-yloxy)-N-({4-[(3- moipholin-4-ylpropyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide EXAMPLE 65A 4-(3-morpholinopropylamino)-3-(trifluoromethylsulfonyl)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 159C and 3- morpholinopropan-l-amine for 4-fluoro-3-nitrobenzenesulfonamide and (tetrahydropyran-4- yl)methylamine respectively, in EXAMPLE IF. EXAMPLE 65B - 303 - 4- (4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -2-( 1 H-'indol-4-yloxy)-N-( {4- [(3 -morpholin-4-ylpropyl)anuno]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 40C and EXAMPLE 65A for EXAMPLE 27G and EXAMPLE IF respectively, in EXAMPLE 27H. 'H NMR (300MHz, dimetiiylsulfoxide-ds) 8 11.46 (br s, IH), 11.18 (s, IH), 8.18 (d, IH), 7.91 (m, IH), 7.50 (m, 6H), 7.41 (m, 5H), 7.30 (m, IH), 7.19 (d, IH), 7.08 (m, IH), 6.99 (m, IH), 6.72 (dd, IH), 6.48 (br s, IH), 6.25 (m, IH), 4.29 (br s, 2H), 4.01 (m, 2H), 3.59 (m, 2H), 3.41 (m, 4H), 3.05 (m, lOH), 2.58 (m, 2H), 1.91 (m, 2H). EXAMPLE 66 N-[(3-([chloro(difluoro)methyl]sulfonyl)-4-{I3- (dimethylaniino)propyl]amino }phenyl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-4-yloxy)benzamide EXAMPLE 66A (difluoromethyl)(2-fluorophenyl)sulfane Powdered NaOH (31.2 g), tris(2-(2-methoxyethoxy)ethyl)amine (5 mL) and 2-fluorobenzene thiol (33.6 mL) in benzene (400 mL) was saturated with chlorodifluoromethane, stirred at 80°C for 30 minutes and filtered through diatomaceous earth (Celite®). The filtrate was washed with saturated NaHCOj and the water layer was extracted with diethyl ether. The extracts were combined and dried (MgS04), filtered and concentrated. EXAMPLE 66B l-(difluoromethylsulfonyl)-2-fluorobenzene EXAMPLE 66A (46 g) in 1:1:2 CCVCHsCN/water (1.2L) at 25°C was treated with NaI04 (164.6 g) and RuCls-xHzO (534 mg), stirred for 18 hours, diluted with dichloromethane and filtered through diatomaceous earth (Celite®). The filtrate was washed with saturated NaHCOs and dried (Na2S04), filtered and concentrated. The concentrate was filtered through silica gel. EXAMPLE 66C l-(chlorodifluoromethylsulfonyl)-2-fluorobenzene -304- EXAMPLE 66B (25 g) and N-chlorosuccinimide (17.55 g) in tetrahydrofuran (690 mL) at -78°C was treated with lithium hexamethyldisilazide (178.5 mL) over 1 hour, stirred for 1 hour and quenched with ammonium chloride. The mixture was extracted with ethyl acetate, and the extract was washed with brine and dried (MgS04), filtered and concentrated. The concentrate was chromatographed on silica gel with 0-5% ethyl acetate/hexanes. EXAMPLE 66D 3-(chlorodifluoTC)methylsulfonyl)-4-fluorobenzene-l-sulfonyl chloride EXAMPLE 66C (44 g) in chloiosulfonic acid (36.7 mL) at 120°C was stirred for 18 hours, cooled to 25°C, pipetted onto crushed ice and extracted with ethyl acetate. The extract was washed with water and brine and dried (MgS04), filtered and concentrated. EXAMPLE 66E 3-(chlorodifluoromethylsulfonyl)-4-fluorobenzenesulfonamide EXAMPLE 66D (22 g) in isopropanol (690 mL) at -78°C was treated with aqueous ammonia (90 mL) over 1 hour, stirred for another hour, quenched with 6M HCl (300 mL), warmed to 25°C and concentrated. The concentrate was mixed with water and extracted with ethyl acetate. The extract was dried (MgS04), filtered and concentrated. The concentrate was recrystallized from hexanes/ethyl acetate. EXAMPLE 66F 3-(chlorodifluoromethylsulfonyl)-4-(3-(dimethyIamino)propylamino)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 66E and N,N-dimethylpropane-l,3-diamine for 4-fluoro-3-nitrobenzenesulfonamide and (tetrahydropyran-4-yl)methylamine respectively, in EXAMPLE IF. EXAMPLE 66G N-[(3-{[chloro(difluoro)methyl]sulfonyl}-4-{[3-(dimethylamino)propyl]amino }phenyl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-2-(lH-indol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 54B and EXAMPLE 66F for EXAMPLE 27G and EXAMPLE IF respectively, in EXAMPLE 27H. 'H NMR (300MHz, dimettiylsulfoxide-dg) 5 11.20 (s, IH), 8.28 (m,lH), 7.99 (m, IH), 7.55 (m, 2H), -305- 7.38 (m, 2H), 7.21 (m, 3H), 7.09 (d, 2H), 6.98 (m, IH), 6.71 (m, IH), 6.41 (m, 2H), 6.21 (m, IH), 3.57 (m, 2H), 3.28 (m, 4H), 2.84 (m, 6H), 2.67 (m, 5H), 2.19 (m, 2H), 2.02 (m, 2H), 1.77 (br s, 2H), 1.61 (m, 2H), 1.46 (m, 2H), 0.94 (s, 6H). EXAMPLE 67 N-[(3-{ [chloro(difluoro)methyl]sulfonyl} -4- {[3-(dimethylamino)propyl]amino }phenyl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazm-l-yl)-2-(lH-indol-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 26C and EXAMPLE 66F for EXAMPLE 27G and EXAMPLE IF respectively, in EXAMPLE 27H. 'H NMR (300MHz, dimethylsulfoxide-de) 8 11.20 (s, IH), 8.28 (m,lH), 8.05 (m, IH), 7.99 (m, IH), 7.55 (m, 2H), 7.38 (m, 2H), 7.21 (m, 3H), 7.09 (d, 2H), 6.98 (m, IH), 6.71 (m, IH), 6.41 (m, 2H), 6.21 (m, IH), 3.57 (m, 2H), 3.28 (m, 4H), 3.05 (m, 2H), 2.96 (m, 2H), 2.88 (s, 3H), 2.78 (m, 2H), 2.68 (m, 3H), 2.19 (m, 2H), 2.01 (br s, 2H), 1.72 (m, 2H), 1.45 (m, 2H), 0.93 (s, 6H). EXAMPLE 68 2-( 1 H-indol-4-yloxy)-4-(4- {[2-(4-methoxyphenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N-( {3-nitro-4-[(3-pyrrolidin-1 - ylpropyl)aniino]phenyl} sulfonyl)benzamide EXAMPLE 68A (2-bromo-4,4-dimethylcyclohex-1 -enyl)methanol N,N-dimethylformamide (18.41 ml) was taken up in chloroform (64 ml) and the resulting solution was cooled in an ice bath. Phosphorus tribromide (20.18 ml) was added dropwise over 15 minutes. The resulting suspension was then heated to 70 °C for 30 minutes. A solution of 3,3-dimethylcyclohexanone (10 g) in chloroform (21 ml) was added dropwise over 30 minutes. The mixture was stirred at 70 °C for another 2 hours. The mixture was then allowed to cool to room temperature. The solution was cautiously poured over ice. Solid sodium bicarbonate was added to neutralize acid. The mixture was extracted three times with ether, and the extracts were washed with water and brine and dried (MgS04). The solvent was removed under vacuum, and the crude material was flushed through a silica plug with ether as the eluent. After concentration, the crude material was dissolved in methanol. -306- Sodium borohydride (1.757 g) was added cautiously. The resulting mixture was stirred at room temperature overnight, and diluted with ethyl acetate. The mixture was washed with water and brine and dried (MgS04). The solvent was removed under vacuum, and the residue was purified by flash chromatography eluting with 20% ethyl acetate in hexanes to 100% ethyl acetate. EXAMPLE 68B methyl 2-(lH-indol-4-yloxy)-4-(piperazin- l-yl)benzoate The title compound was prepared by substituting EXAMPLE 24F and piperazine for EXAMPLE IC and EXAMPLE IB respectively, in EXAMPLE ID. EXAMPLE 68C methyl 2-(lH-indol-4-yloxy)-4'(4-((2-bromo-4,4-dimethylcyclohex-l-enyl)methyl)piperazin- l-yl)benzoate The title compound was prepared by substituting EXAMPLE 68A and EXAMPLE 68B for EXAMPLE 18C and EXAMPLE 18D respectively, in EXAMPLE 18E. EXAMPLE 68D methyl 2-(lH-indol-4-ylos^y)-4-(4-((2-(4-methoxyphenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoate EXAMPLE 68C (142mg), 4-methoxyphenylbon)nic acid (45.6 mg), bis(triphenylphosphine)palladium(n) dichloride (8.7 mg), and cesium fluoride (114 mg) were combined in dimethoxyethane (0.9 mL) and methanol (0.4 mL) and heated to 90°C for 2 hours. The reaction mixture was diluted with ethyl acetate and poured into water. The organic layer was washed with water and with brine, dried (MgS04), filtered, and concentrated. The resulting solid was triturated with methanol, and filtered. EXAMPLE 68E 2-(lH-indol-4-yloxy)-4-(4-((2-(4-methoxyphenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 68D for EXAMPLE ID in EXAMPLE IE. -307- EXAMPLE 68F 3-nitro-4-(3-(pyrrolidm-l-yl)propylamino)benzenesulfonamide The title compound was prepared by substituting 3-(pyrrolidin-l-yl)propan-l-amine for (tetrahydropyran-4-yl)methylamina in EXAMPLE IF. EXAMPLE 68G 2-(lH-indol-4-yloxy)-4-(4-{[2-(4-methoxyphenyl)-4,4-dimethylcyclohex-l-en-l-yljmethyl }piperazin-1 -yl)-N-({ 3-nitro-4-[(3-pyrrolidin-1 -ylpropyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 68E and EXAMPLE 68F for EXAMPLE 27G and EXAMPLE IF respectively, in EXAMPLE 27H. 'H NMR (300MHZ, dimethylsulfoxide-de) 8 11.56 ( brs, IH), 11.26 (s, IH), 8.66 (t, IH), 8.53 (d, IH), 7.78 (dd, IH), 7.56 (d, IH), 7.29 (t, IH), 7.19 (d, IH), 7.10 (d, IH), 6.98 (m, 3H), 6.88 (m, 2H), 6.74 (m, IH), 6.43 (d, IH), 6.36 (br s, IH), 6.23 (m, IH), 3.73 (s, 3H), 3.62 (m, 2H), 3.52 (m, 4H), 3.22 (m, 4H), 2.99 (m, 4H), 2.18 (m, 2H), 1.99 (m, 6H), 1.84 (m, 2H), 1.45 (m, 2H), 1.23 (m, 2H), 0.94 (s, 6H). EXAMPLE 69 4-[4-({4,4-dimethyl-2-[4-(trifluoromethyl)phenyl]cyclohex-l-en-l-yl}methyl)piperazin-l- yl]-2-(lH-indol-4-yloxy)-N-({3-nitro-4-[(3-pyrrolidin-l- ylpropyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 69A methyl 2-(lH-indol-4-yloxy)-4-(4-((4,4-dimethyl-2-(4-(trifluoromethyl)phenyl)cyclohex-l- eny l)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting 4-(trifluoromethyl)phenylboronic acid for 4-methoxyphenylboronic acid in EXAMPLE 68D. EXAMPLE 69B 2-(lH-indol-4-yloxy)-4-(4-((4,4-dimethyl-2-(4-(trifluoromethyl)phenyl)cyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 69A for EXAMPLE ID in EXAMPLE IE. -308- EXAMPLE 69C 4-[4-( {4,4-dimethyl-2- [4-(trifluoromethyl)phenyl]cyclohex-1 -en-1 -yl) methyl)piperazin-1 -yl]-2-(lH-indol-4-yloxy)-N-({3-nitio-4-[(3-pyniolidin-l-ylpropyl)aniino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 69B and EXAMPLE 68F for EXAMPLE 27G and EXAMPLE IF respectively, in EXAMPLE 27H. 'H NMR (300MHz, dimethylsulfoxide-dfi) 8 n.55 (br s, IH), 11.26 (s, IH), 8.66 (t, IH), 8.53 (d, IH), 7.78 (m, IH), 7.67 (m, 2H), 7.56 (m, IH), 7.29 (m, 3H), 7.19 (d, IH), 7.10 (d, IH), 6.98 (m, IH), 6.72 (m, IH), 6.46 (m, IH), 6.36 (br s, IH), 6.23 (m, IH), 3.62 (m, 4H), 3.52 (m, 4H), 3.18 (m, 4H), 3.02 (m, 4H), 2.19 (m, 2H), 2.02 (m, 6H), L82 (m, 2H), 1.47 (m, 2H), 0.94 (s, 6H). EXAMPLE 70 4-[4-( {4,4-dimethyl-2-[4-(trifluoromethoxy)phenyl]cyclohex-1 -en-1 -yl} methyl)piperazin-1 - yl]-2-(lH-indol-4-yloxy)-N-({3-nitro-4-[(3-pyrrolidin-l- ylpiopyI)amino]phenyl} sulfonyl)benzamide EXAMPLE 70A methyl 2-( lH-indol-4-yloxy)-4-(4-((4,4-dimethyl-2-(4-(trifluoromethoxy)phenyl)cyclohex-1 - enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting 4-(trifluoromethoxy)phenylboronic acid for 4-methoxyphenylboronic acid in EXAMPLE 68D. EXAMPLE 70B 2-( 1 H-indol-4-yloxy)-4-(4-((4,4-dimethyl-2-(4-(trifluoromethoxy)phenyl)cyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 70A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 70C -309- 4- [4-( {4,4-dimethyl-2-[4-(trifluoromethoxy)phenyl]cyclohex-1 -en-1 -yl) methyl)piperazin-1 -yl]-2-( 1 H-indol-4-yloxy)-N-( {3-nitro-4- [(3-pynolidin-1-ylpropyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 70B and EXAMPLE 68F for EXAMPLE 27G and EXAMPLE IF respectively, in EXAMPLE 27H. 'H NMR (300MHz, dimethylsulfoxide-de) 5 11.56 (br s, IH), 11.26 (s, IH), 8.66 (t, IH), 8.54 (d, IH), 7.80 (m, IH), 7.63 (m, 2H), 7.56 (m, 3H), 7.29 (m, 2H), 7.19 (m, 2H), 6.98 (m, IH), 6.72 (m, IH), 6.46 (m, IH), 6.23 (m, IH), 3.62 (m, 4H), 3.52 (m, 4H), 3.18 (m, 4H), 3.02 (m, 4H), 2.19 (m, 2H), 2.02 (m, 6H), 1.82 (m, 2H), 1.47 (m, 2H), 0.94 (s, 6H). EXAMPLE 71 4- [4-({ 4,4-dimethyl-2- [3-(trifluoronaethyl)phenyl]cyclohex-1 -en-1 -yl) methyl)piperazin-1 - yl]-2-(lH-indoI-4-yloxy)-N-({3-nitT0-4-[(3-pyrrolidin-l- ylpropyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 71A methyl 2-(lH-indol-4-yloxy)-4-(4-((4,4-dimethyl-2-(3-(trifluoromethyl)phenyl)cyclohex-l- enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting 3-(trifluoromethyl)phenylboronic acid for 4-methoxyphenylboronic acid in EXAMPLE 68D. EXAMPLE 71B 2-(lH-indol-4-yloxy)-4-(4-((4,4-dimethyl-2-(3-(trifluoromethyl)phenyl)cyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 71A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 71C 4- [4-( {4,4-dimethyl-2- [3-(trifluoromethyl)phenyl]cyclohex-1 -en-1 -yl} methyl)piperazin-1 - yl]-2-( lH-indol-4-yloxy)-N-( {3-nitro-4-[(3-pyrrolidin-1 - ylpropyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 7 IB and EXAMPLE 68F for EXAMPLE 27G and EXAMPLE IF respectively, in EXAMPLE 27H. 'H NMR -310- (300MHz, dimethylsulfoxide-d6) 8 11.55 (br s, IH), 11.26 (s, IH), 8.65 (t, IH), 8.54 (d, IH), 7.80 (dd, IH), 7.63 (m, 2H), 7.56 (m, 3H), 7.38 (m, 2H), 7.29 (t, IH), 7.19 (d, IH), 7.11 (d, IH), 6.98 (t, IH), 6.72 (m, IH), 6.46 (m, IH), 6.31 (m, IH), 6.23 (m, IH), 3.58 (m, 7H), 3.18 (m, 4H), 3.02 (m, 4H), 2.19 (m, 3H), 2.02 (m, 6H), 1.82 (m, 2H), 1.47 (m, 2H), 0.96 (s, 6H). EXAMPLE 72 4-(4- {[2-(3-fluorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H-indol-4-yloxy)-N-({3-nitro-4-[(3-pyrrolidin-l-ylpropyl)aniino]phenyl}sulfonyl)benzamide EXAMPLE 72A methyl 2-(lH-indol-4-yloxy)-4-(4-((2-(3-fluorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1-yl)benzoate The title compound was prepared by substituting 3-fluorophenylboronic acid for 4-methoxyphenylboionic acid in EXAMPLE 68D. EXAMPLE 72B 2-(lH-indol-4-yloxy)-4-(4-((2-(3-fluorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 72A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 72C 4-(4- {[2-(3-fluorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin-1 -yl)-2-( 1H-indol-4-yloxy)-N-({3-nitro-4-[(3-pynolidin-l-ylpiDpyl)amino]phenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 72B and EXAMPLE 68F for EXAMPLE 27G and EXAMPLE IF respectively, in EXAMPLE 27H. 'H NMR (300MHz, dimethylsulfoxide-de) 8 11.55 (br s, IH), 11.26 (s, IH), 8.65 (t, IH), 8.54 (d, IH), 7.80 (m, IH), 7.63 (m, 2H), 7.56 (m, 3H), 7.38 (m, 2H), 7.29 (t, IH), 7.19 (d, IH), 7.11 (d, IH), 6.98 (m, IH), 6.72 (m, IH), 6.46 (m, IH), 6.31 (m, IH), 6.23 (m, IH), 3.58 (m, 7H), 3.18 (m, 4H), 3.02 (m, 4H), 2.19 (m, 3H), 2.02 (m, 6H), 1.82 (m, 2H), 1.47 (m, 2H), 0.96 (s, 6H). -311- EXAMPLE 73 4-(4- {[2-(4-fluorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin-1 -yl)-2-( 1H-indol-4-yloxy)-N-({3-nitro-4-[(3-pynolidin-l-ylpropyl)amino]phenyl}sulfonyI)benzamide EXAMPLE 73A methyl 2-(lH-indol-4-yloxy)-4-(4-((2-(4-fluorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting 4-fluoiDphenylboronic acid for 4-methoxyphenylboronic acid in EXAMPLE 68D. EXAMPLE 73B 2-( lH-indol-4-yioxy )-4-(4-((2-(4-fluorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 73A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 73C 4-(4-{ [2-(4-fluorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl )piperazin-1 -yl)-2-(l H-indol-4-yloxy)-N-({3-nitto-4-[(3-pyrroUdin-l-ylpropyl)amino]phenyl}sulfonyl)benzamide TTie title compound was prepared by substituting EXAMPLE 73B and EXAMPLE 68F for EXAMPLE 27G and EXAMPLE IF respectively, in EXAMPLE 27H. 'H NMR (300MHz, dimethylsulfoxide-de) 8 11.56 (br s, IH), 11.26 (s, IH), 8.66 (t, IH), 8.54 (d, IH), 7.80 (m, IH), 7.63 (m, 2H), 7.56 (m, 3H), 7.29 (m, 2H), 7.19 (m, 2H), 6.98 (m, IH), 6.72 (m, IH), 6.46 (m, IH), 6.23 (m, IH), 3.62 (m, 4H), 3.52 (m, 4H), 3.18 (m, 4H), 3.02 (m, 4H), 2.19 (m, 2H), 2.02 (m, 6H), 1.82 (m, 2H), 1.47 (m, 2H), 0.94 (s, 6H). EXAMPLE 74 N-({3-{[chloro(difluoro)methyl]sulfonyl)-4-[(l-methylpiperidin-4- yl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-indol-5-yloxy)benzamide -312- EXAMPLE 74A 3-(chlorodifluoromethylsulfonyl)-4-(l-methylpiperidin-4-ylamino)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 66E and 1-methylpiperidin-4-anune for 4-fluon>-3-nitrobenzenesulfonamide and (tetrahydropyran-4-yl)methylamine respectively, in EXAMPLE IF. EXAMPLE 74B N-({3-([chloro(difluoro)methyl]sulfonyl}-4-[(l-methylpiperidin-4-yl)amino]phenyl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl}piperazin-l-yl)-2-(lH-indol-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 26C and EXAMPLE 74A for EXAMPLE IE and EXAMPLE IF respectively, in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-d6) 8 11.07 (s, IH), 8.11 (d, IH), 7.89 (dd, IH), 7.50 (d, IH), 7.34 (m, 4H), 7.05 (m, 3H), 6.96 (d, IH), 6.78 (dd, IH), 6.60 (m, 2H), 6.36 (s, IH), 6.13 (d, IH), 3.67 (m, IH), 2.97 (m, 6H), 2.71 (s, 2H), 2.59 (m, 2H), 2.46 (s, 3H), 2.16 (m, 6H), 1.98 (m, 4H), 1.55 (ra, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 75 4-(4- {[2-(4-chlorophenyl)cyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-2-( 1 H-indol-5-yloxy)- N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide EXAMPLE 75A methyl 2-(lH-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)cyclohex-l-enyl)methyl)piperazin-l- yl)benzoate The title compound was prepared by substituting EXAMPLE 149D and EXAMPLE 150A for4'-chlorobiphenyl-2-carboxaldehyde and tert-butylpiperazine-l-carboxylate respectively, in EXAMPLE lA. EXAMPLE 75B 2-( lH-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)cyclohex-1 -enyl)methyl)piperazin-1 - yl)benzoic acid The title compound was prepared by substituting EXAMPLE 75A for EXAMPLE ID in EXAMPLE IE. -313- EXAMPLE 75C 4-(4- {[2-(4-chlorophenyl)cyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( 1 H-indol-5-yloxy)-N-( {4-[(l -methylpiperidin-4-yl)amino]-3-nittophenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 75B and EXAMPLE 21A for EXAMPLE IE and EXAMPLE IF respectively, in EXAMPLE IG. *H NMR (300MHz, dimethylsulfoxide-de) 8 11.07 (s, IH), 8.52 (d, IH), 8.12 (d, IH), 7.79 (dd, IH), 7.52 (d, IH), 7.34 (m, 4H), 7.05 (m, 4H), 6.79 (dd, IH), 6.59 (dd, IH), 6.36 (s, IH), 6.13 (d, IH), 3.72 (m, IH), 2.97 (m, 6H), 2.69 (s, 2H), 2.59 (m, 2H), 2.46 (s, 3H), 2.16 (m, 6H), 2.11 (m, 2H), 1.98 (m, 2H), 1.70 (m, 2H), 1.62 (m, 4H). EXAMPLE 76 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-( {4-[( l-methylpiperidin-4-yl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide EXAMPLE 76A 4-(l-methylpiperidin-4-ylamino)-3-(trifluoromethylsulfonyl)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 159C and 1-methylpiperidin-4-amine for 4-fluoro-3-nitrobenzenesulfonamide and (tetrahydropyran-4-yl)methylamine respectively, in EXAMPLE IF. EXAMPLE 76B 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH-indol-5-yloxy)-N-( {4-[( l-methylpiperidin-4-yl)amino]-3-[(trifluororaethyl)sulfonyl]phenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 26C and EXAMPLE 76A for EXAMPLE IE and EXAMPLE IF respectively, in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 611.08 (s, IH), 8.11 (d, IH), 7.89 (dd, IH), 7.50 (d, IH), 7.34 (m, 4H), 7.05 (m, 3H), 6.98 (d, IH), 6.78 (dd, IH), 6.60 (m, 2H), 6.36 (t, IH), 6.13 (d, IH), 3.67 (br s, IH), 2.97 (m, 6H), 2.71 (s, 3H), 2.63 (m, IH), 2.47 (s, 3H), 2.17 (m, 6H), 1.98 (m, 4H), 1.60 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H). -314- EXAMPLE 77 4.{4.[(4'.chloro-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H- pyran-4-ylinethyl)amino]phenyl) sulfonyl)-2-(phenoxymethyl)benzamide EXAMPLE 77A 5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazm-l-yl)isobenzofuran-l(3H)-one 5-bromoisobenzofuran-l(3H)-one (400 mg), EXAMPLE IB (646 mg), and potassium phosphate tribasic (558 mg) were added to 1,2-dimethoxyethane (10 mL). The solution was degassed under vacuum and flushed with nitrogen three times. Tris(dibenzylideneacetone)dipalladium(0) (51.6 mg) and 2-(di-tert-butylphosphino)biphenyl (67.2 mg) were added and the solution was heated to 80°C for 16 hours. The solution was cooled, filtered, concentrated, and purified by flash column chromatography on silica gel with 30% ethyl acetate in hexanes. EXAMPLE 77B 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(hydroxymethyl)benzoic acid EXAMPLE 77A (256 mg) and lithium hydroxide monohydrate (154 mg) were added to 1,4-dioxane (4 mL) and water (1 mL). The solution was heated to 65°C for 16 hours, cooled, concentrated under vacuum, and purified by flash column chromatography on silica gel with ethyl acetate. The solution was subsequently dried with anhydrous sodium sulfate to afford crude product of sufficient purity for subsequent use. EXAMPLE 77C methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(hydroxymethyl)benzoate Trimethylsilyldiazomethane (2M solution in diethyl ether, 0.214 mL) was added to EXAMPLE 77B (170 mg) dissolved in ethyl acetate (2 mL) and methanol (2 mL). The solution was mixed for 5 minutes after which the solvent was removed under vacuum to afford crude product of sufficient purity for subsequent use. EXAMPLE 77D methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(phenoxymethyl)ben2oate Triphenylphosphine (93 mg) was added to tetrahydrofiiran (3 mL) and cooled to 0°C. Diethylazodicaiboxylate (40% solution, 0.161 mL) was added, and the solution was stirred at 0°C for 15 minutes. Phenol (33.3 mg) and EXAMPLE 77C (145 mg) were added, -315- and the solution was allowed to warm to room temperature and mix for 16 hours. The solution was concentrated on vacuum and purified by flash column chromatography on silica gel with 30% ethyl acetate (hexanes) increasing to 50% ethyl acetate (hexanes). EXAMPLE 77E 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(phenoxymethyl)benzoic acid The title compound was prepared by substituting EXAMPLE 77D for EXAMPLE 77A in EXAMPLE 77B. EXAMPLE 77F The title compound was prepared by substituting EXAMPLE 77E for EXAMPLE IE in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 8.52 (m, 2H), 7.88 (dd, IH), 7.84 (d, IH), 7.50 (m, 2H), 7.48 (s, 3H), 7.37 (m, 2H), 7.26 - 7.10 (m, 4H), 7.01 (s, IH), 6.87 (t, IH), 6.83 - 6.75 (m, 3 H), 5.22 (broad s, 2H), 3.84 (dd, 2H), 3.41 - 3.10 (m, lOH), 2.39 (broad s, 4H), 1.89 (m, IH), 1.60 (m, 2H), 1.32 - 1.18 (m, 2H). EXAMPLE 78 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-( {4-[(3-morpholin-4- ylpropyl)amino]phenyl} sulfonyl)-2-phenoxybenzamide EXAMPLE 78A N-(4-sulfamoylphenyl)acrylamide 4-aminobenzenesulfonamide (1.00 g) and pyridine (1.41 mL) were added to 1,4-dioxane (30 mL). Acryloyl chloride (0.49 mL) was added dropwise and the solution was stirred for 3 hours at room temperature. IM HCl was added, and the solution extracted with ethyl acetate. The extracts were dried using brine and anhydrous sodium sulfate and the solvent was removed to afford crude product of sufficient purity for subsequent use. EXAMPLE 78B 3-morpholino-N-(4-suIfamoylphenyl)propanainide EXAMPLE 78A (359 mg) and morpholine (1.38 mL) were added to acetonitrile (10 mL) and N,N-dimethylformamide (1 mL) and mixed at room temperature for 16 hours. -316- The solution was concentrated on vacuum, and purified by flash column chromatography on silica gel with 5% methanol in dichloromethane. EXAMPLE 78C 4-(3-morpholinopropylamino)benzenesulfonamide EXAMPLE 78B (268 mg) was added to tetrahydrofuran (4 mL). Borane (IM in tetrahydrofuran, 4.28 mL) was added slowly, and the solution was mixed at room temperature for 16 hours. The reaction was quenched slowly with methanoL N,N-diisopropylethylamine resin (3.42 mmol amine) was added and the solution was mixed at room temperature for 15 minutes. The solution was filtered, concentrated on vacuum, and purified by flash column chromatography on silica gel with 10% methanol in ethyl acetate. EXAMPLE 78D 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin- 1-yl} -N-( {4- [(3-morpholin-4-ylpropyl)amino]phenyl} sulfonyl)-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 78C for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 8 10.98 (broad s, IH), 7.51 -7.44 (m, 9H), 7.40 - 7.31 (m, 3H), 7.26 - 7.21 (m, IH), 7.13 (tt, IH), 6.94 (dd, 2H), 6.75 (dd, IH), 6.66 (t, IH), 6.54 (d, 2H), 6.32 (d, IH), 3.57 (t, 4H), 3.35 (m, 2H), 3.16 - 3.04 (m, 6H), 2.35 (m, lOH), 1.60 (m, 2H). EXAMPLE 79 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-({ 3-nitro-4- [(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-(pyridin-3-yloxy)benzamide EXAMPLE 79A methyl 4-bromo-2-fluorobenzoate 4-Bromo-2-fluorobenzoic acid (5.(X) g) was added to ethyl acetate (35 mL) and methanol (35 mL). Trimethylsilyldiazomethane (2M solution in diethyl ether, 12.56 mL) was added slowly and the solution was mixed at room temperature for 30 minutes. The solvent was removed under vacuum, and the crude material was dissolved in ethyl acetate. The solution was extracted with 0.5M sodium hydroxide and dried with brine then anhydrous -317- sodium sulfate. After filtration, the solvent was removed under vacuum to afford crude product of sufficient purity for subsequent use. EXAMPLE 79B methyl 4-bromo-2-(pyridin-3-yloxy)benzoate EXAMPLE 79A (500 mg), pyridine-3-ol (204 mg), and potassium caibonate (385 mg) were added to N,N-dimethylacetamide (18 mL) and the mixture was heated to 145°C for 2 hours and then at 130°C for 16 hours. The solution was cooled, added to water (1(X) mL), extracted with 70% ethyl acetate in hexanes, and dried with anhydrous sodium sulfate. After filtration, the solution was concentrated under vacuum and purified by flash column chromatography on silica gel with 50-70% ethyl acetate in hexanes. EXAMPLE 79C methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(pyridin-3-yloxy)benzoate EXAMPLE 79B (367 mg), EXAMPLE IB (410 mg), and potassium phosphate tribasic (379 mg) were added to 1,2-dimethoxyethane (6 mL). The solution was degassed under vacuum and flushed with nitrogen three times. Tris(dibenzyUdeneacetone)dipalladium(0) (32.7 mg) and 2-(di-tert-butylphosphino)biphenyl (42.6 mg) were added and the solution was heated to 80°C for 16 hours. The solution was cooled, filtered, concentrated, and purified by flash column chromatography on silica gel with 50-70% ethyl acetate in hexanes. EXAMPLE 79D 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(pyridin-3-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 79C for EXAMPLE ID in EXAMPLE IE. EXAMPLE 79E 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-( {3-nitro-4- [(tetrahydro-2H-pyTan-4-ylmethyl)amino]phenyl} sulfonyl)-2-(pyridin-3-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 79D for EXAMPLE IE in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 8 11.72 (broad s, IH), 8.64 (t, IH), 8.46 (d, IH), 8.15 (t, 2H), 7.75 (dd, IH), 7.52 - 7.44 (m, 6H), 7.37 (m, 2H), 7.26 - 7.10 -318- (m, 4H), 6.79 (dd, IH), 6.50 (d, IH), 3.87 (dd, 2H), 3.40 (s, 2H), 3.38 - 3;24 (m, 4H), 3.19 (broad s, 4H), 2.37 (broad s, 4H), 1.92 (m, IH), 1.65 (d, 2H), 1.28 (m, 2H). EXAMPLE 80 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-(pyridin-3-yloxy)-N-( {4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl) sulfonyl)benzaniide The title compound was prepared by substituting EXAMPLE 79D for EXAMPLE IE and EXAMPLE 2A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-dfi) 8 11.34 (s, IH), 8.27 (dd, 2H), 7.51 - 7.44 (m, 8H), 7.41 - 7.29 (m, 3H), 7.27 - 7.19 (m, 2H), 6.78 (dd, IH), 6.72 (t, IH), 6.56 (d, 2H), 6.44 (d, IH), 3.86 (dd, 2H), 3.36 (s, 2H), 3.29 - 3.22 (m, 2H), 3.16 (m, 4H), 2.96 (t, 2H), 2.34 (m, 4H), 1.77 (m, IH), 1.66 (d, 2H), 1.21 (m, 2H). EXAMPLE 81 4-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methy]]piperazin-l-yl}-N-{[4-({(lR)-3-(dimethylamino)- 1 - [(phenylthio)methyl]propyl} amino)-3-nitrophenyl]sulfonyl} -2-phenoxybenzaniide EXAMPLE 81A (R)-tert-butyl3-(((9H-fluoren-9-yl)methoxy)carbonyIamino)-4-hydroxybutanoate Fmoc-D-Asp(OtBu)-OH (9.0g) and MA^-diisopropylethylamine (4.6 mL) were added to tetrahydrofuran (100 mL) and cooled to -40 °C. Isobutyl cMoroformate (3.1 mL) was added, and the solution was gradually warmed to 0°C over 30 minutes. The solution was cooled to -20 °C, and to it was carefully added sodium borohydride (1.64 g, 43.6 mmol) and methanol (10 mL). The solution was gradually warmed to room temperature over two hours, diluted with ethyl acetate (200 mL), washed with water (100 mL) and brine (50 mL), dried with anhydrous magnesium sulfate, filtered, and concentrated to afford crude product of sufficient purity for subsequent use. EXAMPLE 81B (R)-tert-butyl3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-(phenylthio)butanoate Tri-n-butylphosphine (90 |J,L) and l,r-(azodicarbonyl)dipiperidine (91 mg) were added to tetrahydrofuran (4 mL), treated with EXAMPLE 81A (90 mg) and thiophenol (21 -319- mg), and stirred at room temperature for 18 hours. The solution was concentrated and purified by flash colunm chromatography on silica gel with 50% ethyl acetate in hexanes. EXAMPLE 81C (R)-tert-butyl3-(2-nitro-4-sulfamoylphenylamino)-4-(phenylthio)butanoate EXAMPLE 81B (600 mg), 4-fluoro-3-nitrobenzenesulfonamide (298 mg), and A^,A^-diisopropylethylamine (3 mL) were added to N,N-dimethylformamide (3 mL) and stirred at 60°C for 12 hours. The reaction mixture was diluted with ethyl acetate (I(X) mL), washed with water (45 mL) and brine (10 mL), dried with anhydrous magnesium sulfate, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel with 30% ethyl acetate in dichloromethane. EXAMPLE 8ID (R)-3-(2-nitro-4-sulfamoylphenylamino)-4-(phenylthio)butanoic acid EXAMPLE 81C (468 mg) and 4 M HCl in 1,4-dioxane (10 mL) were stirred at SOT for 5 hours. The solution was concentrated to give the crude product of sufficient purity for subsequent use. EXAMPLE 8 IE (R)-N,N-dimethyl-3-(2-nitro-4-sulfamoylphenylamino)-4-(phenylthio)butanamide The tide compound was prepared by substituting EXAMPLE 8 ID for EXAMPLE IE and dimethylamine (2M in tetrahydrofuran) for EXAMPLE IF in EXAMPLE IG. EXAMPLE 8 IF (R)-4-(4-(dimethylamino)-l-(phenylthio)butan-2-ylamino)-3-nittobenzenesulfonamide To EXAMPLE 81E (4.06 g) was added borane (1 M in tetrahydrofuran, 20.0 mL). The solution was stirred at room temperature for 16 hours. The reaction was quenched slowly with methanol (5.0 mL) and concentrated aqueous HCl (2.0 mL) was added. The solution was stirred at 80°C for three hours, cooled to room temperature, carefully basified with 4 M sodium carbonate, diluted with ethyl acetate (150 mL), washed with water (50 mL) and brine (10 mL), dried with anhydrous magnesium sulfate, and filtered. The solution was concentrated and purified by flash column chromatography on silica gel with 20% methanol in dichloromethane. -320- EXAMPLE 8IG 4- {4-[(4'-chIoro-1,1 '-biphenyl-2-yl)methy]]piperazin-1 -y 1} -N- {[4-( {(lR)-3 -(dimethylamino)-l-[(phenylthio)methyl]propyl}amino)-3-nitrophenylJsulfonyl}-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 81F for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-dg) 8 8.33 (d, IH), 8.28 (d, IH), 7.61 (dd, 2H), 7.50 - 7.43 (m, 4H), 7.37 - 7.14 (ra, IIH), 6.90 (t, IH), 6.84 (d, IH), 6.71 (d, 2H), 6.70 (dd, IH), 6.32 (d, IH), 4.06 (m, IH), 3.36 (s, 2H), 3.33 - 3.30 (m, 2H), 3.08 (t, 4H), 2.86 (m, 2H), 2.53 (s, 6H), 2.35 (t, 4H), 2.04 (m, 2H). EXAMPLE 82 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin- 1-yl} -N-( {3-nitro-4- [(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-(pyridin-4-yloxy)benzamide EXAMPLE 82A methyl 4-bromo-2-(pyridin-4-yloxy)benzoate EXAMPLE 79A (800 mg), pyridine-4-ol (359 mg), and potassium carbonate (617 mg) were added to N,N-dimethylacetamide (20 mL) and the mixture was heated to 125°C for 16 hours. The solution was concentrated on vacuum at 48°C and purified by flash column chromatography on silica gel with 20% methanol in dichloromethane. EXAMPLE 82B methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(pyridin-4-yloxy)benzoate The title compound was prepared by substituting EXAMPLE 82A for EXAMPLE 79B in EXAMPLE 79C. EXAMPLE 82C 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-(pyridin-4-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 82B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 82D 4- {4-[(4'-chloro-1, l'-biphenyl-2-y l)methyl]piperazin-1 -yl) -N-({ 3-nitro-4- [(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(pyridin-4-yloxy)benzamide -321- The title compound was prepared by substituting EXAMPLE 82C for EXAMPLE IE in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 8.40 (t, IH), 8.37 (d, IH), 7.76 (dd, IH), 7.65 (d, IH), 7.54 - 7.48 (m, IH), 7.47 (s, 3H), 7.42 - 7.35 (m, 5H), 7.27 - 7.23 (m, IH), 7.06 (dd, IH), 6.92 (dd, IH), 6.88 (d, IH), 5.91 (d, 2H), 3.85 (dd, 2H), 3.39 (s, 2H), 3.34 - 3.25 (m, 4H), 3.19 (broad, s, 4H), 2.39 (broad s, 4H), 1.92 (in, IH), 1.65 (d, 2H), 1.27 (m, 2H). EXAMPLE 83 4- {4-[(4'-chloro-1, r-biphenyl-2-yl)methyl]piperazin-1 -yl ] -N-( {4- [(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(pyridin-3-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 79D for EXAMPLE IE and EXAMPLE 7A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 68.73 (t, IH), 8.43 (d, IH), 8.12 (t, 2H), 7.73 (dd, IH), 7.55 (d, IH), 7.51 - 7.44 (m, 4H), 7.37 (m, 2H), 7.25 - 7.17 (m, 3H), 7.07 (d, 2H), 6.78 (dd, IH), 6.47 (d, IH), 3.65 (t, 4H), 3.47 (q, 2H), 3.38 (s, 2H), 3.28 (m, 2H), 3.17 (br s, 4H), 2.57 (br s, 4H), 2.36 (br s,4H), 1.84 (m,2H). EXAMPLE 84 4-(4-[(4'-chloro-l,r-biphenyl-2-yl)methyl]piperazin-l-yl}-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(pyridin-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 82C for EXAMPLE IE and EXAMPLE 7A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 5 8.55 (t, IH), 8.37 (d, IH), 7.77 (dd, IH), 7.65 (d, IH), 7.54 - 7.43 (m, 5H), 7.42 - 7.32 (m, 4H), 7.26 - 7.22 (m, IH), 7.01 (d, IH), 6.91 (dd, IH), 6.66 (d, IH), 5.90 (d, 2H), 3.60 (t, 4H), 3.43 (q, 2H), 3.39 (s, 2H), 3.18 (br s, 4H), 2.38 (m, lOH), 1.80 (t, 2H). EXAMPLE 85 4- {4-[(4'-chloro-1, r-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-[(4- {[2-(4-methylpiperazin-l - yl)ethyl]aniino}-3-nitrophenyl)sulfonyl]-2-phenoxybenzamide EXAMPLE 85A 4-(2-(4-methylpiperazin-l-yl)ethylamino)-3-nitrobenzenesulfonamide -322- The title compound was prepared by substituting 2-(4-methylpiperazin-l-yl)ethanamine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 85B 4-{4-[(4'-chloro-l,r-biphenyl-2-yl)methyl]piperazin-l-yl}-N-[(4-{I2-(4-methylpiperazin-l-yl)ethyl]amino)-3-nitrophenyl)sulfonyl]-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 85A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-de) 6 8.61 (t, IH), 8.40 (d, IH), 7.72 (dd, IH), 7.57 (d, IH), 7.51 - 7.44 (m, 5H), 7.36 (m, 2H), 7.26 - 7.15 (m, 3H), 6.95 (t, 2H), 6.75 (dd, 2H), 6.71 (dd, IH), 6.34 (d, IH), 3.45 (q, 2H), 3.36 (s, 2H), 3.34 (m, 2H), 3.10 (t, 4H), 2.79 (broad s, 4H), 2.68 (t, 2H), 2.60 (broad s, 2H), 2.49 (s, 3H), 2.35 (t, 4H). EXAMPLE 86 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)raethyl]piperazin-1 -yl} -N- [(4- {[3-(4-methylpiperazin-1 - yl)propyl]amino}-3-nitrophenyl)sulfonyl]-2-phenoxybenzamide EXAMPLE 86A 4-(3-(4-methylpiperazin-1 -yl)propylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 3-(4-methylpiperazin-l-yl)propan-l-amine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 86B 4-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl)-N-[(4-{[3-(4-methylpiperazin-l-yl)propyl]amino} -3-mtrophenyl)sulfonyl]-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 86A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 8 8.57 (t, IH), 8.38 (d, IH), 7.71 (dd, IH), 7.59 (d, IH), 7.50 - 7.44 (m, 5H), 7.36 (m, 2H), 7.27 - 7.15 (m, 3H), 6.98 (d, 2H), 6.91 (t, IH), 6.73 (dd, 2H), 6.70 (dd, 2H), 6.33 (d, IH), 3.43 (q, 2H), 3.36 (s, 2H), 3.34 (m, 2H), 3.09 (t, 4H), 2.82 (broad s, 4H), 2.56 (broad s, 2H), 2.49 (s, 3H), 2.35 (t, 4H), 1.79 (t,2H). -323- EXAMPLE 87 4-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl}-N-({4-[[3- (dimethylamino)propyl](methyl)anuno]-3-nitrophenyl}sulfonyl)-2-phenoxybenzamide EXAMPLE 87A 4-((3-(dimethylamino)piopyl)(methyl)amino)-3-nitiobenzenesulfonamide The title compound was prepared by substituting N',N\N^-trimethylpropane-l,3-diamine for 3-(pyrrolidin-l-yl)propan-l-amine in EXAMPLE 68F. EXAMPLE 87B 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-( {4-[[3 -(dimethylamino)propyl](methyl)amino]-3-nitrophenyl}sulfonyl)-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 87A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-ds) 8 8.01 (d, IH), 7.68 (dd, IH), 7.63 (d, IH), 7.51 - 7.44 (m, 5H), 7.36 (m, 2H), 7.26 - 7.13 (m, 3H), 6.93 (t, IH), 6.83 (m, IH), 6.74 (dd, 2H), 6.69 (dd, IH), 6.32 (d, IH), 3.46 (q, 2H), 3.36 (s, 2H), 3.08 (t, 4H), 2.83 (t, 2H), 2.77 (s, 3H), 2.60 (s, 6H), 2.36 (t, 4H), 1.86 (m, 2H). EXAMPLE 88 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -N-[(4- {[(1 -methylpiperidin-4- yl)methyl]amino} -3-nitrophenyl)sulfonyl]-2-phenoxybenzamide EXAMPLE 88A 4-((l-methylpiperidin-4-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting (l-methylpiperidin-4-yl)methanamine for 3-(pyTrolidin-l-yl)propan-l-amine in EXAMPLE 68F. EXAMPLE 88B 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin- 1-yl) -N-[(4- {[(1 -methylpiperidin-4-yl)methyl]amino} -3-nitrophenyl)sulfonyl]-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 88A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-ds) 8 8.44 (t, IH), 8.35 (d, IH), - 324 - 7.79 (dd, IH), 7.62 (d, IH), 7.51 - 7.45 (m, 5H), 7.36 (m, 2H), 7.25 - 7.14 (m, 3H), 6.99 (d, IH), 6.89 (t, IH), 6.71 (d, 2H), 6.68 (dd, IH), 6.31 (d, IH). 3.36 (s, 2H), 3.34 (m, 4H), 3.07 (t, 4H), 2.73 (m, 2H), 2.62 (s, 3H), 2.36 (t, 4H), 1.90 - 1.82 (m, 3H), 1.47-1.31 (m, 2H). EXAMPLE 89 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-( {4-[( 1 -methylpiperidin-4-yl)anuno]-3-nitrophenyl} sulfonyl)-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 21A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 6 8.38 (t, IH), 8.09 (d, IH), 7.73(m, IH), 7.59 (d, IH), 7.52 - 7.44 (m, 5H), 7.36 (m, 2H), 7.26 - 7.22 (m, IH), 7.17 (t, IH), 7.05 (d, IH), 6.90 (t, IH), 6.83 (m, IH), 6.72 (d, 2H), 6.70 (dd, IH), 6.33 (d, IH), 3.36 (q, 2H), 3.36 (s, 2H), 3.24 - 3.12 (m, 2H), 3.09 (t, 4H), 2.80 (m, IH), 2.59 (s, 3H), 2.36 (t, 4H), 2.08 (m, 2H), 1.77 (m, 2H). EXAMPLE 90 4-{4-[(4'-chloro-l, r-biphenyl-2-yl)methyl]piperazin-1-yl}-N-[(3-cyano-4-([3- (dimethylamino)propyl]amino}phenyl)sulfonyl]-2-phenoxybenzamide EXAMPLE 90A 3-cyano-4-fluorobenzenesulfonamide Concentrated ammonium hydroxide (28% solution in water, 3.17 mL) was cooled to 0''C and 3-cyano-4-fluorobenzene-l-sulfonyl chloride (1.00 g) was added. The solution was mixed at 0°C for four minutes. 4M HCl (10 mL) was added slowly and the solution was extracted with ethyl acetate. The extract was dried on brine and anhydrous sodium sulfate and the solvent removed under vacuum. EXAMPLE 90B 3-cyano-4-(3-(dimethylamino)propylamino)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 90A for 4-chloro-3-nitrobenzenesulfonamide and N\N'-dimethylpropane-l,3-diamine for 3-(pyrrolidin-l-yl)propan-l-amine in EXAMPLE 68F. -325- EXAMPLE 90C 4-{4-[(4'-chloro-l,r-biphenyl-2-yl)methyl]piperazin-l-yl}-N-[(3-cyano-4-{[3- (dimethylatnino)propyl]amino}phenyl)sulfonyl]-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 90B for EXAMPLE IF in EXAMPLE IG. *H NMR (300MHz, dimethylsulfoxide-de) 5 7.67 (s, IH), 7.66 (dd, IH), 7.59 (d, IH), 7.51 - 7.44 (m, 5H), 7.36 (m, 2H), 7.28 - 7.20 (m, 3H), 6.98 (t, 2H), 6.77 (dd, 2H), 6.70 (d, 2H), 6.33 (d, IH), 3.36 (s, 2H), 3.27 (q, 2H), 3.09 (t, 4H), 2.82 (t, 2H), 2.54 (s, 6H), 2.35 (t, 4H), L82 (m, 2H). EXAMPLE 91 4- {4-[(4'-chloro-1,1 '-biphenyl-2-y l)methyl]piperazin-1 -yl) -N-( {3-nitro-4- [(3-pyrrolidin-1 -ylpropyl)amino]phenyl}sulfonyl)-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 68F for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 8 8.49 (t, IH), 8.37 (d, IH), 7.72 (dd, IH), 7.62 (d, IH), 7.50 - 7.43 (m, 5H), 7.35 (m, 2H), 7.26 - 7.14 (m, 3H), 6.97 (d, IH), 6.90 (t, IH), 6.72 (d, 2H), 6.69 (dd, IH), 6.31 (d, IH), 3.47 (q, 2H), 3.36 (s, 2H), 3.20 (m, 2H), 3.07 (broad s, 8H), 2.35 (broad s, 4H), 1.95 - 1.83 (m, 6H). EXAMPLE 92 4.{4.[(4'.chloro-l,l'-biphenyl-2-yl)methyl]piperazin-l-yI}-N-{[4-{[3- (dimethylamino)propyl]amino}-3-(trifluoromethyl)phenyl]sulfonyl)-2-phenoxybenzamide EXAMPLE 92A 4-fluoro-3-(trifluoromethyl)benzenesulfonamide The title compound was prepared by substituting 4-fluoro-3-(trifluoromethyl)benzene-l-sulfonyl chloride for 3-cyano-4-fluorobenzene-l-sulfonyl chloride in EXAMPLE 90A. EXAMPLE 92B 4-(3-(dimethylamino)propylamino)-3-(trifluoromethyl)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 92A for 4-fluoro-3-nitrobenzenesulfonamide and N',N'-dimethylpropane-l,3-diamine for tetrahydropyran-4-yl)methylamine in EXAMPLE IF -326- EXAMPLE 92C 4-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl}-N-{[4-{l3-(dimethylaniino)propyl]amino)-3-(trifluoromethyl)phenyl]sulfonyl}-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 92B for EXAMPLE IF in EXAMPLE IG. ^H NMR (300MHz, dimethylsulfoxide-de) 6 7.77 (s, IH), 7.68 (dd, IH), 7.57 (d, IH), 7.51 - 7.45 (m, 5H), 7.36 (m, 2H), 7.29 - 7.21 (m, 3H), 6.99 (t, IH), 6.82 - 6.68 (m, 5H), 6.32 (d, IH), 3.36 (s, 2H), 3.28 (q, 2H), 3.09 (t, 4H), 2.73 (m, 2H), 2.48 (s, 6H), 2.35 (t, 4H), 1.79 (m, 2H). EXAMPLE 93 4-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl}-N-{[4-({3- [isopropyl(methyl)amino]propyl} amino)-3 -nitrophenyl]sulfonyl} -2-phenoxybenzamide EXAMPLE 93A tert-butylmethyl(3-(2-nitro-4-sulfamoylphenylamino)propyl)carbamate The title compound was prepared by substituting teit-butyl 3-aminopropyl(methyl)caibamate for 3-(pyrrolidin-l-yl)propan-l-amine in EXAMPLE 68F. EXAMPLE 93B tert-butyl 3-(4-(N-(4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-phenoxybenzoyl)sulfamoyl)-2-nitrophenylamino)propyl(methyl)caibamate The title compound was prepared by substituting EXAMPLE 93A for EXAMPLE IF in EXAMPLE IG. EXAMPLE 93C 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)-N-(4-(3-(methylamino)propylamino)-3-nitrophenylsulfonyl)-2-phenoxybenzamide EXAMPLE 93B (112 mg) and triethylsilane (0.082 mL) were added to dichloromethane (2 mL). Trifluoroacetic acid (0.198 mL) was added, the solution stirred at room temperature for one hour, and the solvent removed under vacuum. -327- EXAMPLE 93D 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin- 1-yl} -N- {[4-({ 3-[isopropyl(niethyl)amino]propyl]amino)-3-nitrophenyl]sulfonyl}-2-phenoxybenzamide EXAMPLE 93C (128 mg), acetone (0.014 mL), and sodium cyanoborohydride resin (2.15 mmol/g, 66 mg) were added to tetrahydiofuran (0.9 mL) and acetic acid (0.3 mL), and the soltuion was stirred at room temperature for 16 hours. More acetone (0.014 mL), and sodium cyanoborohydride resin (66 mg) were added, and the solution was stirred for 24 hours. The solution was purified by flash column chromatography on silica gel with 1% acetic acid and 10% methanol in dichloromethane. 'H NMR (300MHZ, dimethylsulfoxide-d^) 8 11.93 (broad s, 3H), 8.53 (broad s, IH), 8.40 (d, IH), 7.75 (dd, IH), 7.60 (d, IH), 7.51 -7.45 (m, 5H), 7.36 (m, 2H), 7.25 - 7.16 (m, 3H), 7.02 (d, IH), 6.92 (t, IH), 6.74 (d, 2H), 6.70 (dd, IH), 6.32 (d, IH), 3.47 (m, 4H), 3.36 (s, 2H), 3.09 (t, 4H), 3.01 (broad s, 2H), 2.58 (s, 3H), 2.35 (t, 4H), 1.94 (m, IH), 1.18 - 1.14 (m, 6H). EXAMPLE 94 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-( {4- [3- (dimethyIamino)propoxy]-3-nitiophenyl}sulfonyl)-2-phenoxybenzamide EXAMPLE 94A 4-(3-(dimethylamino)pTopoxy)-3-nitrobenzenesulfonamide Triphenylphosphine (1.398 g) was added to tetrahydrofuran (20 mL) and cooled to 0°C. Diethylazodicaiboxylate (40% solution, 2.428 mL) was added, and the solution was stirred for at 0°C for 15 minutes. 4-Hydroxy-3-nitrobenzenesulfonamide (1.163 g) and 3-(dimethylamine)propan-l-ol (0.567 mL) were added, and the solution was allowed to warm to room temperature and stir for 16 hours. Solvent was removed under vacuum and the material recrystallized using 20% methanol (dichloromethane). The recrystallized solid was washed with dichloromethane, dissolved in methanol / dichloromethane, treated with triethylamine (0.13 mL, 0.924 mmol), and purified by flash column chromatography on silica gel with 10-20% methanol in dichloromethane. EXAMPLE 94B 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yI)methyl]piperazin-1 -yl} -N-( {4- [3- (dimethylamino)propoxy]-3-nitrophenyl} sulfonyl)-2-phenoxybenzamide -328- The title compound was prepared by substituting EXAMPLE 94A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 8.06 (d, IH), 7.84 (dd, IH), 7.65 (d, IH), 7.52 - 7.45 (m, 5H), 7.36 (m, 2H), 7.26 - 7.22 (m, 2H), 7.18 (td, 2H), 6.89 (t, IH), 6.69 (d, IH), 6.68 (d, 2H), 6.32 (d, IH), 4.25 (t, 2H), 3.36 (s, 2H), 3.13 (t, 2H), 3.08 (t, 4H), 2.75 (s, 6H), 2.36 (t, 4H), 2.11 (m, 2H). EXAMPLE 95 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(4-{[2-(4-methylpiperazin-l-yl)ethyl]amino}-3- nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 26C for EXAMPLE IE and EXAMPLE 85A for EXAMPLE IF in EXAMPLE IG. ^H NMR (300MHz, dimethylsulfoxide-dfi) 8 11.10 (s, IH), 8.67 (t, IH), 8.53 (d, IH), 7.78 (dd, IH), 7.52 (d, IH), 7.39 - 7.31 (m, 4H), 7.08 - 7.02 (m, 3H), 6.94 (d, IH), 6.80 (dd, IH), 6.61 (dd, IH), 6.36 (t, IH), 6.14 (d, IH), 3.42 (q, 2H), 2.99 (t, 4H), 2.71 (s, 2H), 2.70 - 2.48 (m, lOH), 2.39 (s, 3H), 2.16 (m, 6H), 1.95 (s, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 96 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-[(4-{I3-(4-methylpiperazin-l-yl)propyl]amino}-3-nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 26C for EXAMPLE IE and EXAMPLE 86A for EXAMPLE IF in EXAMPLE 10. 'H NMR (300MHz, dimethylsulfoxide-de) 5 11.09 (s, IH), 8.62 (t, IH), 8.51 (d, IH), 7.76 (dd, IH), 7.53 (d, IH), 7.38 - 7.31 (m, 4H), 7.05 (s, IH), 7.02 (d, 2H), 6.96 (d, IH), 6.79 (dd, IH), 6.60 (dd, IH), 6.35 (t, IH), 6.14 (d, IH), 3.40 (q, 2H), 2.98 (t, 4H), 2.71 (s, 2H), 2.67 (broad s, 4H), 2.55 - 2.40 (m, 6H), 2.39 (s, 3H), 2.16 (m, 6H), 1.95 (s, 2H), 1.77 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 97 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl Jpiperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-({3-nitiD-4-[(3-pyTTOlidin-l-ylpropyl)aminoJphenyl}sulfonyl)benzamide -329- The title compound was prepared by substituting EXAMPLE 26C for EXAMPLE IE and EXAMPLE 68F for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-dfi) 5 IL06 (s, IH), 8.58 (t, IH), 8.49 (d, IH), 7.77 (dd, IH), 7.54 (d, IH), 7.36 - 7.31 (m, 4H), 7.06 - 7.01 (m, 3H), 6.95 (d, IH), 6.76 (dd, IH), 6.57 (dd, IH), 6.35 (t, IH), 6.14 (d, IH), 3.44 (q, 2H), 2.97 (broad s, lOH), 2.71 (s, 2H), 2.16 (m, 6H), 1.95 (s, 2H), 1.90 - 1.80 (m, 6H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 98 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl ]methyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 26C for EXAMPLE IE and EXAMPLE 21A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-dfi) 8 11.08 (s, IH), 8.51 (d, IH), 8.13 (d, IH), 7.78 (dd, IH), 7.52 (d, IH), 7.37 - 7.31 (m, 4H), 7.06 - 7.00 (m, 4H), 6.79 (dd, IH), 6.59 (dd, IH), 6.35 (t, IH), 6.14 (d, IH), 3.73 (m, IH), 3.05 - 2.95 (m, 6H), 2.71 (s, 2H), 2.60 (m, 2H), 2.48 (s, 3H), 2.16 (m, 6H), 2.01 (m, 2H), 1.95 (s, 2H), 1.70 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 99 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-[(4-{[3-(4-raethylpiperazin-1-yOpropylJamino} -3- nitrophenyl)sulfonyl]benzamide The tide compound was prepared by substituting EXAMPLE 55B for EXAMPLE IE and EXAMPLE 86A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-dfi) 8 11.16 (s, IH), 8.59 (t, IH), 8.45 (d, IH), 7.72 (dd, IH), 7.55 (d, IH), 7.34 (d, 2H), 7.23 (t, IH), 7.12 (d, IH), 7.02 (d, 2H), 6.95 (d, IH), 6.94 (t, IH), 6.64 (dd, IH), 6.34 (d, IH), 6.23 (m, 2H), 3.41 (q, 2H), 2.98 (t, 4H), 2.71 (broad s, 6H), 2.52 - 2.42 (m, 6H), 2.41 (s, 3H), 2.15 (m, 6H), 1.95 (s, 2H), 1.77 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 100 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [3-(dimethylamino)propoxy]-3-nitrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzaniide The title compound was prepared by substituting EXAMPLE 26C for EXAMPLE IE and EXAMPLE 94A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, -330- dimethylsulfoxide-dfi) 511.03 (s, IH), 8.23 (d, IH), 7.91 (dd, IH), 7.56 (d. IH), 7.36 - 7.29 (m, 4H), 7.19 (d, IH), 7.05 (d, 2H), 6.97 (s, IH), 6.73 (dd, IH), 6.57 (dd, IH), 6.33 (t, IH), 6.15 (d, IH), 4.23 (t, 2H), 3.04 (m, 2H), 2.96 (t, 4H), 2.72 (s, 2H), 2.67 (s, 6H), 2.22 - 2.02 (m, 8H), 1.95 (s, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 101 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( IH-indol-4-yloxy)-N-[(4- {I2-(4-methylpiperazin-1 -yl)ethyl]ammo} -3-nitrophenyI)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 55B for EXAMPLE IE and EXAMPLE 85A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsuIfoxide-d6) 6 11.18 (s, IH), 8.64 (t, IH), 8.47 (d, IH), 7.73 (dd, 2H), 7.56 (d, IH), 7.34 (d, 2H), 7.24 (t, IH), 7.04 (d, 2H), 6.96 (d, IH), 6.94 (d, IH), 6.65 (dd, IH), 6.37 (d, IH), 6.23 (m, 2H), 3.43 (q, 2H), 2.99 (t, 4H), 2.71 (s, 2H), 2.65 (m, 6H). 2.56 (in, 4H), 2.42 (s, 3H), 2.15 (m, 6H), 1.95 (s, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 102 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H-indol-4-yloxy)-N-({3-nitro-4-[(3-pyrrolidin-l-ylpropyl)amino]phenyl)sulfonyl)benzamide The title conywund was prepared by substituting EXAMPLE 55B for EXAMPLE IE and EXAMPLE 68F for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-dfi) 8 11.14 (s, IH), 8.54 (t, IH), 8.44 (d, IH), 7.76 (dd, IH), 7.59 (d, IH), 7.34 (d, 2H), 7.22 (t, IH). 7.10 (d, IH), 7.05 (d, 2H), 6.98 - 6.89 (m, 2H), 6.62 (dd, IH), 6.33 (d, IH), 6.23 (t, IH), 6.21 (d, IH), 3.44 (q, 2H), 3.10 - 2.91 (m, lOH), 2.71 (s, 2H), 2.16 (m, 6H), 1.95 (s, 2H), 1.92 - 1.79 (m, 6H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 103 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 55B for EXAMPLE IE and EXAMPLE 21A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 6 11.14 (s, IH), 8.44 (d, IH), 8.11 (d, IH), 7.75 (dd, IH), 7.56 (d, IH), -331- 7.34 (d, 2H), 7.23 (t, IH), 7.11 (d, IH), 7.04 (d, 2H), 7.03 (d, IH), 6.93 (t, IH), 6.64 (dd, IH), 6.34 (d, IH), 6.22 (m, 2H), 3.73 (m, IH), 3.08 - 2.93 (m, 6H), 2.71 (s, 2H), 2.70 - 2.56 (m, 2H), 2.48 (s, 3H), 2.16 (m, 6H), 2.02 (m, 2H), 1.95 (s, 2H), 1.70 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 104 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-[(4-{[(l-methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamide TTie title compound was prepared by substituting EXAMPLE 26C for EXAMPLE IE and EXAMPLE 88A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 10.99 (s, IH), 8.39 (d, IH), 8.32 (t, IH), 7.65 (dd, IH), 7.54 (d, IH), 7.34 (d, 2H), 7.30 - 7.26 (m, 2H), 7.05 (d, 2H), 6.92 (d, IH), 6.81 (d, IH), 6.70 (dd, IH), 6.53 (dd, IH), 6.30 (t, IH), 6.15 (d, IH), 3.28 - 3.19 (m, 2H), 2.93 (t, 4H), 2.83 (m, 2H), 2.71 (s, 2H), 2.68 - 2.50 (m, 2H), 2.54 (s, 3H), 2.24 - 2.10 (m, 6H), 1.95 (broad s, 2H), 1.68 (d, 2H), 1.59 (m, IH), 1.38 (t, 2H), 1.32 - 1.17 (m, 2H), 0.92 (s, 6H). EXAMPLE 105 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H-indol-4-yloxy)-N-[(4- {[(1 -niethylpiperidin-4-yl)methyl]amino) -3-nitrophenyl)sulfonyl]benzaniide The title compound was prepared by substituting EXAMPLE 55B for EXAMPLE IE and EXAMPLE 88A for EXAMPLE IF in EXAMPLE IG. ^H NMR (300MHz, dimethylsulfoxide-dfi) 5 11.11 (s, IH), 8.44 (t, IH), 8.41 (d, IH), 7.74 (dd, IH), 7.59 (d, IH), 7.34 (d, 2H), 7.21 (t, IH), 7.11 - 7.02 (m, 3H), 6.98 - 6.90 (m, 2H), 6.61 (dd, IH), 6.31 (d, IH), 6.23 (t, IH), 6.20 (d, IH), 3.20 (m, 2H), 2.95 (t, 4H), 2.71 (s, 2H), 2.62 - 2.49 (m, 4H), 2.55 (s, 3H), 2.16 (m, 6H), 1.95 (s, 2H), 1.86 - 1.78 (m, 3H), 1.42 - 1.31 (m, 4H), 0.92 (s, 6H). EXAMPLE 106 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4-[3- (dimethylaniino)propoxy]-3-nitiophenyl}sulfonyl)-2-(lH-indol-4-yloxy)benzamide -332- The title compound was prepared by substituting EXAMPLE 55B for EXAMPLE IE and EXAMPLE 94A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-dc) 8 ILIO (s, IH), 8.16 (d, IH), 7.90 (dd, IH), 7.61 (d, IH), 7.35 (d, 2H), 7.24 - 7.19 (m, 2H), 7.10 - 7.01 (m, 3H), 6.91 (t, IH), 6.60 (dd, IH), 6.28 (d, IH), 6.23 (t, IH), 6.20 (d, IH), 4.23 (t, 2H), 3.03 (t, 2H), 2.95 (t, 4H), 2.72 (s, 2H), 2.67 (s, 6H), 2.17 (m, 6H), 2.07 (m, 2H), 1.95 (s, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 107 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N- {[4-(4-methylpiperazin-1 -yl)-3-nitrophenyl]sulfonyl} benzamide EXAMPLE 107A 4-(4-methylpiperazin- l-yl)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 1-methylpiperazine for 3-(pyrrolidin-l-yl)propan-l-amine in EXAMPLE 68F. EXAMPLE 107B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-{[4-(4-methylpiperazin-l-yl)-3-nitrophenyl]sulfonyl}benzaniide The title compound was prepared by substituting EXAMPLE 26C for EXAMPLE IE and EXAMPLE 107A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-d6) 811.21 (s, IH), 8.18 (d, IH), 7.77 (dd, IH), 7.57 (d, IH), 7.34 (d. 2H), 7.26 (t, IH), 7.22 (d, IH), 7.16 (d, IH), 7.07 - 7.02 (m, 2H), 6.96 (t, IH), 6.87 (dd, IH), 6.39 (d, IH), 6.25 (m, 2H), 3.16 (m, 4H), 3.01 (t, 4H), 2.73 (s, 2H), 2.66 (broad s, 4H), 2.39 (s, 3H), 2.18 (m, 6H), 1.95 (s, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 108 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-[(3-nitro-4-{[l-(2,2,2-trifluoroethyl)piperidin-4- yljamino} phenyl)sulfonyl]benzamide EXAMPLE 108A 3-nitro-4-(l-(2,2,2-trifluoroethyl)piperidin-4-ylamino)benzenesulfonamide -333- 4-chloro-3-nitrobenzenesulfonamide (1.300 g), l-(2,2,2-trifluoroethyl)piperidin-4-amine hydrochloride (1.201 g), and triethylamine (2.30 mL) were added to 1,4-dioxane (50 mL) and water (5 mL) and heated at 90°C for 16 hours. The solution was concentrated on vacuum and purified by flash column chromatography on silica gel with ethyl acetate increasing to 5% methanol in ethyl acetate. EXAMPLE 108B 4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( 1H-indol-4-yloxy)-N-[(3-nitro-4-{[l-(2,2,2-trifluoroethyl)piperidin-4-yl]amino}phenyl)sulfonyl]benzamide This EXAMPLE was prepared by substituting EXAMPLE 55B for EXAMPLE IE and EXAMPLE 108A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-dfi) 6 11.24 (s, IH), 8.50 (d, IH), 8.25 (d, IH), 7.71 (dd, IH), 7.52 (d, IH), 7.34 (d, 2H), 7.27 (t, IH), 7.17 (d, IH), 7.11 (d, IH), 7.04 (d, 2H), 6.97 (t, IH), 6.71 (dd, IH), 6.43 (d, IH), 6.28 (d, IH), 6.24 (t, IH), 3.68 (m, IH), 3.23(q, 2H), 3.06 (broad s, 4H), 2.95 -2.87 (m, 2H), 2.78 - 2.71 (m, 2H), 2.58 (t, 2H), 2.25 - 2.11 (m, 6H), 1.98 - 1.85 (m, 4H), 1.64 (m, 2H), 1.39 (t, 2H), 0.92 (s, 6H). EXAMPLE 109 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N- {[4- ({[4-(dimethylamino)-1 -methylpiperidin-4-yl]methyl) amino)-3-nitrophenyl]sulfonyl} -2-( IH- indol-5-yloxy)benzamide EXAMPLE 109A 4-((4-(dimethylamino)-l-melhylpiperidin-4-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 4-(aminomethyl)-N,N,l-trimethylpiperidin-4-amine for l-(2,2,2-trifluoroethyl)piperidin-4-amine hydrochloride in EXAMPLE 108A. EXAMPLE 109B 4-(4-{[2-(4-chlorophenyl)-4,4-diraethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-{[4- ({[4-(dimethylamino)-1 -methylpiperidin-4-yl]methyl} amino)-3-nitropheny l]sulfonyl} -2-( IH- indol-5-yloxy)benzamide - 334 - The title compound was prepared by substituting EXAMPLE 26C for EXAMPLE IE and EXAMPLE 109A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 1L06 (s, IH), 8.56 (broad s, IH), 8.50 (d, IH), 7.81 (dd, IH), 7.54 (d, IH), 7.36 - 7.31 (m, 4H), 7.08 - 7.02 (m, 4H), 6.77 (dd, IH), 6.57 (dd, IH), 6.34 (t, IH), 6.13 (d, IH), 3.50 (d, 2H), 3.04 (m, 2H), 2.96 (t, 4H), 2.87 (m, 2H), 2.71 (s, 2H), 2.58 (s, 3H), 2.28 (s, 6H), 2.16 (m, 6H), 1.98 (m, 2H), 1.95 (s, 2H), 1.65 - 1.54 (m, 2H), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 110 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-(2,3-dihydro-1,4-benzodioxin- 5-yloxy)-N-({3-nitro-4-[(tetrahydio-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)benzamide EXAMPLE llOA methyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin- l-yl)-2-(2,3-dihydrobenzo[bl[ 1,4]dioxin-5-yloxy)benzoate The title compound was prepared by substituting EXAMPLE 34A for EXAMPLE 18E and 2,3-dihydrobenzo[b][l,4]dioxin-5-ol for phenol in EXAMPLE 18F. EXAMPLE HOB 4-(4-((4'-ch]orobiphenyl-2-yl)methyl)piperazin-l-yl)-2-(2,3-dihydrobenzo[b][l,4]dioxin-5- yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 1 lOA for EXAMPLE ID in EXAMPLE IE. EXAMPLE HOC 4-{4-[(4'-chloro-l,r-biphenyl-2-yl)methyl]piperazin-l-yl}-2-(2,3-dihydro-l,4-benzodioxin- 5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyI}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 1 lOB for EXAMPLE IE in EXAMPLE IG. 'H NMR (300 MHz. dimethylsulfoxide-de) 8ppm H.40 (s, 1 H), 8.65 (t, 1 H), 8.55 (d, 1 H), 7.83 (dd, 1 H), 7.46 (m, 6 H), 7.36 (m, 2 H), 7.23 (m, 2 H), 6.77 (d, 1 H), 6.70 (dd, 1 H), 6.42 (m, 2 H). 6.27 (d, 1 H), 4.20 (s, 4 H), 3.85 (dd, 2 H), 3.37 (m, 4 H), 3.25 (m, 2 H), 3.13 (m, 4 H), 2.35 (m, 4 H), 1.90 (m, 1 H), 1.62 (dd, 2 H), 1.27 (m, 2 H). -335- EXAMPLE 111 5- {4-[(4'-chloro-1,1 '-biphenyl-2-y l)methyl]piperazin-1 -yl} -N-( {3-nitro-4- [(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl} sulfonyl)-1,1 '-biphenyl-2-carboxamide EXAMPLE 111 A methyl 5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)biphenyl-2-carboxylate EXAMPLE 34A (100 mg, 0.2 mmol) in tetrahydrofuran (1.5 mL) was treated with phenylboronic acid (36.6 mg, 0.3 mmol), tris(dibenzylideneacetone)dipalladium(0) (9.2 mg, 0.01 mmol), tri-tert-butylphosphonium tetrafluoroborate (5.8 mg, 0.02 mmol) and cesium fluoride (91 mg, 0.6 mmol), flushed with nitrogen and stirred overnight at ambient temperature. The reaction mixture was diluted with ethyl acetate, washed with water and brine, dried (MgS04), filtered and concentrated. The concentrate was purified by column chromatography on silica gel eluting with a gradient of 0 to 3% methanol in CH2CI2 to give the product. EXAMPLE 11 IB 5-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-l-yl)biphenyl-2-carboxylicacid The title compound was prepared by substituting EXAMPLE 111A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 11IC 5-{4-[(4'-chloro-1, r-biphenyl-2-yl)methyl]piperazin-1-yl}-N-( {3-nit^o-4-[(tet^ahyd^o-2H-pyran-4-ylmethyl)amino]phenyl ) sulfonyl)-l, 1 '-biphenyl-2-carboxamide The title compound was prepared by substituting EXAMPLE 11 IB for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-dg) S ppm 12.09 (s, IH), 8.72 (t, IH), 8.46 (d, IH). 7.79 (m, 2H), 7.52 (m, 4H), 7.35 (dd, 5H), 7.16 (m, IH), 7.04 (m, 4H), 6.91 (dd, IH), 6.78 (m, IH), 4.39 (m, IH), 3.88 (m, 3H), 3.42 (m, 4H), 3.27 (m, 4H), 2.96 (m, 4H), 1.95 (m, IH), 1.67 (m, 2H), 1.31 (m, 2H). EXAMPLE 112 5-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl}-N-[(4-{[3- (dimethylamino)propyl]amino) -3 -nitrophenyl)sulfonyl]-1,1 '-biphenyl-2-carboxamide -336- The title compound was prepared by substituting EXAMPLE 11 IB for EXAMPLE 27G and EXAMPLE 154A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (300 MHz, dimethylsulfoxide-de) 8ppm 12.09 (s, IH), 8.74 (t, IH), 8.47 (d, IH), 7.83 (dd, IH), 7.70 (m, IH). 7.40 (m, 8H), 7.27 (m, IH), 7.20 (m, IH), 7.07 (m, 4H), 6.91 (dd, IH), 6.77 (m, IH), 4.39 (m, IH), 3.87 (m, IH), 3.55 (m, 4H), 3.26 (m, 2H), 3.16 (m, 4H), 3.03 (m, 2H), 2.80 (m, 6H), 1.98(m,2H). EXAMPLE 113 4-[4-( {4'-chloro-4-[2-(dimethylaniino)ethoxy ]-1,1 '-biphenyl-2-yl} methyl)piperazin-1 -yl] -N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-2-phenoxybenzamide EXAMPLE 113A methyl 2-phenoxy-4-(piperazin- l-yl)benzoate The title compovmd was made by substituting piperazine for EXAMPLE IB in EXAMPLE ID. EXAMPLE 113B methyl 4-(4-(2-bromo-5-hydroxybenzyl)piperazin- l-yl)-2-phenoxybenzoate The title compound was made by substituting 2-bromo-5-hydroxybenzaldehyde for 4'-chlorobipheny]-2-carboxaldehyde and EXAMPLE 113A for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 113C methyl 4-(4-(2-bromo-5-(2-(dimethylamino)ethoxy)benzyl)piperazin-1 -yl)-2- phenoxybenzoate A mixture of EXAMPLE 113B (170 mg), 2-chloro-N,N-dimethylethanamine hydrochloride salt (80 mg) and cesium carbonate (278 mg) was suspended in anhydrous N,N-dimethylformamide (3 mL). The reaction mixture was heated at SO'C overnight. The reaction mixture was cooled to room temperature and diluted with ethyl acetate. The organic phase was washed with water and brine, and dried over anhydrous Na2S04. The solvent was removed under vacuum to afford an oily residue which was used in the next step without further purification. -337- EXAMPLE 113D methyl 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxybenzoate The tiUe compound was made by substituting EXAMPLE 113C for EXAMPLE 68C and 4-chlorophenylboronic acid for 4-methoxyphenylboionic acid in EXAMPLE 68D. EXAMPLE 113E 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxybenzoic acid The title compound was made by substituting EXAMPLE 113D for EXAMPLE ID in EXAMPLE IE. EXAMPLE 113F 4-[4-({4'-chloro-4- [2-(dimethylamino)ethoxy]-1,1 '-biphenyl-2-yl} methyl)piperazin- l-yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-2-phenoxybenzamide The title compound was made by substituting EXAMPLE 113E for EXAMPLE IE in EXAMPLE 27H. 'H NMR (400MHZ, dimethylsulfoxide-de) 8 11.69 (br s, IH), 9.87 (br s, IH), 8.63 (t, IH), 8.46 (d, IH), 7.75 (dd, IH), 7.50 (m, 3H), 7.34-7.23 (m, 6H), 7.14 (m, 2H), 6.98 (m, IH), 6.78 (m, 3H), 6.44 (d,'lH), 4.37 (t, 2H), 3.86 (m, 2H), 3.60-3.41 (m, lOH), 3.34 (t, 4H), 3.28(m, 2H), 2.89 (s, 6H), 1.91 (m, IH), 1.62 (m, 2H), 1.28 (m, 2H). EXAMPLE 114 4-(4-{[4'-chloro-4-(3-piperidin-l-ylpropoxy)-l,r-biphenyl-2-yl]methyl}piperazin-l-yl)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyI} sulfonyl)-2-phenoxybenzamide EXAMPLE 114A methyl 4-(4-(2-bromo-5-(3-(piperidin- l-yl)propoxy)benzyl)piperazin- l-yl)-2- phenoxybenzoate The title compound was made by substituting l-(3-chloropropyl)piperidine hydrochloride salt for 2-chloro-N,N-dimethylethanamine hydrochloride salt in EXAMPLE 113C. -338- EXAMPLE 114B methyl 4-(4-((4'-cWoro-4-(3-(piperidin- l-yI)piopoxy)biphenyl-2-yl)methyl)piperazin- l-yl)-2- phenoxybenzoate The title compound was made by substituting EXAMPLE 114A for EXAMPLE 68C and 4-chlorophenylboronic acid for 4-methoxyphenylboronic acid in EXAMPLE 68D. EXAMPLE 114C 4-(4-((4'-chIoro-4-(3-(piperidin-l-yl)propoxy)biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxybenzoic acid The title compound was made by substituting EXAMPLE 114B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 114D 4-(4- {[4'-chloro-4-(3-piperidin-1 -ylpropoxy)-1,1 '-biphenyl-2-yl]methyl }piperazin-1 -yl)-N-({3-nitro-4-I(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxybenzamide The title compound was made by substituting EXAMPLE 114C for EXAMPLE IE in EXAMPLE 27H. "H NMR (400MHZ, dimethylsulfoxide-de) 8 11.69 (br s, IH), 9.18 (br s, IH), 8.63 (t, IH), 8.46 (d, IH). 7.75 (dd, IH), 7.50 (m, 3H), 7.33-7.21 (m, 6H), 7.15 (d, 2H), 6.98 (m, IH), 6.78 (m, 3H), 6.44 (d, IH), 4.11 (t, 2H), 3.87 (dd, 2H), 3.60-3.38 (m, lOH), 3.34 (m, 4H), 3.25 (m, 4H), 2.92 (m, 2H), 2.17 (m, 2H), 1.85 (m, 3H), 1.64 (m, 6H), 1.29 (m, 2H). EXAMPLE 115 4-(4- {[4'-chloro-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yI]methyl jpiperazin-1 -yl)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxybenzamide EXAMPLE 115A methyl 4-(4-(2-bromo-5-(2-morpholinoethoxy)benzy l)piperazin-1 -yl)-2-phenoxybenzoate The title compound was made by substituting 4-(2-chloroethyl)morpholine hydrochloride salt for 2-chloro-N,N-dimethylethanamine hydrochloride salt in EXAMPLE 113C. -339- EXAMPLE 115B methyl 4-(4-((4'-chloio-4-(2-morpholinoethoxy)biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxybenzoate The title compound was made by substituting EXAMPLE USA for EXAMPLE 68C and 4-chlorophenylboronic acid for 4-methoxyphenylboronic acid in EXAMPLE 68D. EXAMPLE use 4.(4.((4'.chloro-4-(2-morpholinoethoxy)biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxybenzoic acid The title compound was made by substituting EXAMPLE 115B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 115D 4-(4-{[4'-chloro-4-(2-morpholin-4-ylethoxy)-l,r-biphenyl-2-yl]methyl)piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-phenoxybenzamide The title compound was made by substituting EXAMPLE 115C for EXAMPLE IE in EXAMPLE 27H. 'H NMR (400MHZ, dimethylsulfoxide-de) 6 11.66 (br s, IH), 8.63 (t, IH), 8.46 (d, IH), 7.75 (dd, IH), 7.50 (m, 3H), 7.31 (m, 4H), 7.23 (m, 2H), 7.15 (m, 2H), 6.98 (m ,1H), 6.78 (m, 3H), 6.44 (d, IH), 4.41 (m, 2H), 3.87 (m, 6H), 3.60-3.38 (m, 12H), 3.36-3.25 (m, 8H), 1.91 (m, IH), 1.64 (m, 2H), 1.29 (m, 2H). EXAMPLE 116 4-[4-({4'-chloro-4-[3-(dimethylamino)propoxy]-l,r-biphenyl-2-yl)methyl)piperazin-l-yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-phenoxybenzamide EXAMPLE 116A methyl 4-(4-(2-bromo-5-(3-(dimethylamino)propoxy)benzyl)piperazin-l-yl)-2- phenoxybenzoate The title compound was made by substituting 3-chloro-N,N-dimethyIpropan-l-amine hydrochloride salt for 2-chloro-N,N-dimethylethanamine hydrochloride salt in EXAMPLE 113C. -340- EXAMPLE 116B methyl 4-(4-((4'-chloro-4-(3-(dimethylamino)propoxy)biphenyl-2-yl)methyl)piperazin-l-yl)- 2-phenoxybenzoate The title compound was made by substituting EXAMPLE 116A for EXAMPLE 68C and 4-chIorophenylboTonic acid for 4-methoxyphenylboronic acid in EXAMPLE 68D. EXAMPLE 116C 4-(4-((4'-chloro-4-(3-(dimethylamino)propoxy)biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxybenzoic acid The title compound was made by substituting EXAMPLE 116B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 116D 4-[4-({4'-chloro-4-f3-(dimethylamino)propoxy]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxybenzamide The title compound was made by substituting EXAMPLE 116C for EXAMPLE IE in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-d^) 5 11.64 (br s, IH), 9.52 (br s, IH), 8.63 (t, IH), 8.47 (d, IH), 7.75 (dd, IH), 7.50 (m, 3H), 7.34 (m, 2H), 7.23 (m, 4H), 7.14 (d, IH), 6.98 (m, 2H), 6.78 (m, 3H), 6.42 (s, IH), 4.09 (t, 2H), 3.86 (m, 2H), 3.50-3.36 (m, 8H), 3.28 (m, 8H), 2.83 (s, 6H), 2.12 (m, 2H), 1.91 (m, IH), 1.62 (m, 2H), 1.29 (m, 2H). EXAMPLE 117 4-(4-{[4'-chloro-4-(2-morpholin-4-ylethoxy)-l,r-biphenyl-2-yl]methyl}piperazin-l-yl)-2-phenoxy-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide The title compound was made by substituting EXAMPLE 115C for EXAMPLE 27G and EXAMPLE 163A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-de) 8 8.11 (d, IH), 7.86 (dd, IH), 7.49 (m, 3H), 7.36-7.26 (m, 7H), 7.10 (m, 3H), 6.84 (d, 2H), 6.77 (dd, IH), 6.41 (s, IH), 4.38 (m, 2H), 3.84 (m, 4H), 3.55 (m, 2H), 3.50-3.30 (m, lOH), 3.28 (m, 8H), 3.20 (m, 2H), 1.86 (m, IH), 1.55 (m, 2H), 1.26 (m, 2H). EXAMPLE 118 -341- 4-(4- {[4'-chloro-4-(3-piperidin-1 -ylpropoxy)-1,1 '-biphenyl-2-yl]methyl) piperazin- l-yl)-2-phenoxy-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)ainino]-3-[(trifluoromethyl)sulfonyl]phenyI} sulfonyI)benzamide The title compound was made by substituting EXAMPLE 114C for EXAMPLE 27G and EXAMPLE 163A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (400MHZ, dimethyisulfoxide-d6) 8 n.65 (br s, IH), 9.06 (br s, IH), 8.11 (d, IH), 7.86 (dd, IH), 7.49 (m, 3H), 7.36-7.20 (m, 7H), 7.06 (m, 3H), 6.83 (d, 2H), 6.76 (dd, IH), 6.41 (s, IH), 4.10 (t, 2H), 3.85 (dd, 2H), 3.40-3.05 (m, 16H), 2.90 (m, 2H), 2.15 (m, 2H), 1.84 (m, 3H), 1.60 (m, 6H), 1.41 (m, 2H), 1.26 (m, 2H). EXAMPLE 119 4- [4-( {4'-chloro-4- [3 -(dimethylamino)propoxy ] -1,1 '-bipheny 1-2-yl} methyl)piperazin-1 -yl] -2-phenoxy-N-({4-[(tetrahydio-2H-pyran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide The title compound was made by substituting EXAMPLE 116C for EXAMPLE 27G and EXAMPLE 163A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-dfi) 8 8.11 (d, IH), 7.86 (dd, IH), 7.49 (m, 3H), 7.36-7.26 (m, 7H), 7.06 (m, 3H), 6.84 (d, 2H), 6.76 (dd, IH), 6.41 (d, IH), 4.09 (t, 2H), 3.84 (dd, 2H), 3.50-3.24 (m, 14H), 3.10 (m, 2H), 2.83 (s, 6H), 2.12 (m, 2H), 1.86 (m, IH), 1.55 (m, 2H), 1.26 (m, 2H). EXAMPLE 120 4- [4-( {4'-chloro-4- [2-(dimethylamino)ethoxy]-1,1 '-biphenyl-2-yl} methyl)piperazin-1 -yl]-2-phenoxy-N-({4-[(tetrahydio-2H-pyran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl) sulfonyl)benzamide The title compound was made by substituting EXAMPLE 113E for EXAMPLE 27G and EXAMPLE 163A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-dfi) 8 11.75 (br s, IH), 9.90 (br s, IH), 8.10 (d, IH), 7.85 (dd, IH), 7.49 (m, 3H), 7.38-7.25 (m, 7H), 7.11 (d, 2H), 7.03 (m, IH), 6.82 (d, 2H), 6.77 (dd, IH), 6.44 (s, IH), 4.37 (t, 2H), 3.85 (m, 6H), 3.55 (m, 2H), 3.29 (m, 8H), 3.10 (m, 2H). 2.89 (s, 6H), 1.86 (m, IH), 1.55 (m, 2H), 1.24 (m, 2H). EXAMPLE 121 -342- 4-[4-( {4'-chloro-4-[2-(dimethylaniino)ethoxy]-1,1 '-biphenyl-2-yl} methyl)piperazin-1 -yl]-N-({3-nitro-4-[(3-pyTroIidin-1 -ylpiopyl)amino]phenyl} sulfonyl)-2-phenoxybenzanude The title compound was made by substituting EXAMPLE 113E for EXAMPLE 27G and EXAMPLE 68F for EXAMPLE IF in EXAMPLE 27H. 'H NMR (400MHZ, dimethylsulfoxide-d6) 5 U.70 (br s, IH), 9.95 (br s, IH), 9.73 (br s, IH), 8.69 (t, IH), 8.49 (d, IH), 7.79 (dd, IH), 7.50 (m, 3H), 7.34 (m, 2H), 7.23 (m, 3H), 7.16 (d, IH), 7.09 (m, IH), 7.00 (m, IH), 6.82 (d, 2H), 6.77 (dd, IH), 6.42 (s, IH), 4.37 (m, 2H), 3.70 (m, 6H), 3.54 (m, 8H), 3.21 (m, 4H), 3.19 (m, 2H), 2.88 (s, 6H), 1.97 (m, 4H), 1.85 (m, 2H). EXAMPLE 122 4-[4-( {4'-chloro-3- [2-(dimethylamino)ethoxy]-1,1 '-biphenyl-2-yl} methyl)piperazin- l-yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxybenzamide EXAMPLE 122A methyl 4-(4-(2-bromo-6-hydroxybenzyl)piperazin-1 -yl)-2-phenoxybenzoate The title compound was made by substituting 2-bromo-6-hydroxybenzaIdehyde for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE113A for tert-butyl piperazine-l-carboxylate in EXAMPLE lA. EXAMPLE 122B methyl 4-(4-((4'-chloio-3-hydroxybiphenyl-2-yl)methyl)piperazin-l-yl)-2-phenoxybenzoate The title compound was made by substituting EXAMPLE 122A for EXAMPLE 68C and 4-chlorophenylboronic acid for 4-methoxyphenylboronic acid in EXAMPLE 68D. EXAMPLE 122C methyl 4-(4-((4*-chloro-3-(2-(dimethylamino)ethoxy)biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxybenzoate EXAMPLE i22B (100 mg) and 2-chloro-N,N-dimethylethanamine hydrochloride salt (30 mg) was dissolved in mixed solvent of dichloromethane (1.5 mL) and 50% sodium hydroxide aqueous solution (0.5 mL), followed by addition of tetrabutylammonium iodide (15 mg). The reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with ethyl acetate, and washed with water and brine. The organic phase -343- was dried over Na2S04 and concentrated. Flash column purification was performed with 0-5% methanol/dichloromethane to afford the product. EXAMPLE 122D 4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxybenzoic acid The title compound was made by substituting EXAMPLE 122C for EXAMPLE ID in EXAMPLE IE. EXAMPLE 122E 4-[4-({4'-chloro-3-[2-(dimethylamino)ethoxy]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-phenoxybenzamide The title compound was made by substituting EXAMPLE 122D for EXAMPLE IE in EXAMPLE 27H. 'H NMR (400MHZ, dimethylsulfoxide-dg) 8 10.20 (br s, IH), 9.46 (br s, IH), 8.65 (t, IH), 8.47 (d, IH), 7.78 (d, IH), 7.75(dd, IH), 7.52 (m, 4H), 7.38 (m, 3H), 7.23 (m, 3H), 7.12 (m, IH), 6.98 (m, 2H), 6.78 (d, 2H), 6.76 (dd, IH), 6.43 (s, IH), 4.43 (m, 2H), 3.87 (m, 2H), 3.62 (m, 4H), 3.35-3.15 (m, 12H), 2.90 (s, 6H), L90 (m, IH), L62 (m, 2H), 1.27 (m, 2H). EXAMPLE 123 4-[4-( {4'-chloro-3-[2-(dimethylamino)ethoxy]-1,1 '-biphenyl-2-yl} methyl)piperazin- l-yl]-N-({3-nitTO-4-[(3-pyrrolidin-1 -ylpropyl)amino]phenyl} sulfonyl)-2-phenoxybenzamide The title compound was made by substituting EXAMPLE 122C for EXAMPLE IE and EXAMPLE 68F for EXAMPLE IF in EXAMPLE IG. 'H NMR (400MHz, dimethylsulfoxide-de) 8 10.01 (br s, IH), 9.63 (br s, IH), 9.32 (br s, IH), 8.69(t, IH), 8.49 (d, IH), 7.80 (dd, IH), 7.52 (m, 4H), 7.38 (m, 2H), 7.25 (m, 3H), 7.15 (d, IH), 7.01 (m, IH), 6.95 (m, IH), 6.81 (d, 2H), 6.76 (m, IH), 6.41 (s, IH), 4.43 (m, 4H), 3.56-3.51 (m, 8H), 3.20 (m, 4H), 3.10 (m, 6H), 2.91 (s, 6H), 1.98 (m, 4H), 1.85 (m, 2H). EXAMPLE 124 4-[4-({4'-chloro-3-[2-(dimethylamino)ethoxy]-l,r-biphenyl-2-yI}methyl)piperazin-l-yl]-2- phenoxy-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide -344- The title compound was made by substituting EXAMPLE 122C for EXAMPLE 27G and EXAMPLE 163A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (400MHZ, dimethylsulfoxide-d6) 8 UJl (br s, IH), 9.89 (br s, IH), 9.14 (br s, IH), 8.1 l(d, IH), 7.86 (dd, IH), 7.52 (m, 4H), 7.38 (m, 2H), 7.29 (m, 3H), 7.20 (m, IH), 7.11 (d, IH), 7.05 (m, IH), 6.95 (m, IH), 6.83 (d, 2H), 6.76 (dd, IH), 6.40 (s, IH), 4.41 (m, 2H), 3.85 (m, 2H), 3.59 (m, 4H), 3.44 (ra, 2H), 3.28 (m, 8H), 3.06 (m, 2H), 2.91 (s, 6H), 1.84 (m, IH), 1.55 (m, 2H), 1.26 (m, 2H). EXAMPLE 125 4- [4-( {4'-chloro-4- [2-(dimethylamino)ethoxy]-1,1 '-biphenyl-2-yl} methyl)piperazin-1 -yl]-2- (lH-indol-4-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 125A 4'-chloro-4-hydroxybipheny]-2-cart>aldehyde The title compound was made by substituting 2-bromo-5-hydroxybenzaldehyde for EXAMPLE 68C and 4-chlorophenylboronic acid for 4-methoxyphenylboronic acid in EXAMPLE 68D. EXAMPLE 125B 4'-chloro-4-(2-(dimethylamino)ethoxy)biphenyl-2-caibaldehyde The title compound was made by substituting EXAMPLE 125A for EXAMPLE 122B in EXAMPLE 122C. EXAMPLE 125C methyl 2-(lH-indol-4-yloxy)-4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)biphenyl-2- yl)methyl)piperazin-1 -yl)benzoate The title compound was made by substituting EXAMPLE 125B for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 683 for tert-butyl piperazine-1-carboxylate in EXAMPLE 1 A. EXAMPLE 125D -345- 2-(lH-indol-4-yloxy)-4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)biphenyl-2- yl)methyl)piperazin-l-yl)benzoic acid The title compound was made by substituting EXAMPLE 125C for EXAMPLE ID in EXAMPLE IE. EXAMPLE 125E 4.[4.({4'^hloro-4-[2-(dimethylamino)ethoxy]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-2-(1 H-indol-4-yloxy)-N-({ 3-nitro-4- [(tetrahydro-2H-pyran-4-yImethyl)amino]phenyI} suIfonyl)benzamide The title compound was made by substituting EXAMPLE 125D for EXAMPLE IE in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-d6) 8 11.46 (br s, IH), 11.25 (s, IH), 9.80 (br s, IH), 8.60 (t, IH), 8.48(d, IH), 7.65 (dd, IH), 7.55 (d, IH), 7.46 (d, 2H), 7.28 (m, 5H), 7.15 (d, IH), 7.10 (m, IH), 7.04 (d, IH), 6.94 (m, IH), 6.73 (dd, IH), 6.36 (m, 2H), 6.26 (m, IH), 4.35 (t, 2H), 3.85 (m, 6H), 3.54 (m, 4H), 3.31 (m, 6H), 3.06 (m, 2H), 2.88 (s, 6H), 1.88 (m, IH), 1.60 (m, 2H), 1.28 (m, 2H). EXAMPLE 126 4-[4-({4'-chloro-4-[2-(dimethylamino)ethoxy]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-2- (lH-indo]-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 126A methyl 2-(lH-indol-5-yloxy)-4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)biphenyl-2- yl)methyl)piperazin-1 -yl)benzoate The tide compound was made by substituting EXAMPLE 125B for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 150A for tert-butyl piperazine-l-carboxylate in EXAMPLE lA. EXAMPLE 126B 2-(lH-indol-5-yloxy)-4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)biphenyl-2- yl)methyl)piperazin- l-yl)benzoic acid The title compound was made by substituting EXAMPLE 126A for EXAMPLE ID in EXAMPLE IE. -346- EXAMPLE 126C 4.[4-({4'-chloro-4-[2-(dimethylamino)ethoxy]-l,r-biphenyl-2-yl}melhyl)piperazin-l-yI]-2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-y]methyl)amino]phenyl} sulfonyl)ben2amide The title compound was made by substituting EXAMPLE 126B for EXAMPLE IE in EXAMPLE 27H. 'H NMR (400MHZ, dimethylsulfoxide-de) 8 n.35 (br s, IH), ILl? (s, IH), 9.85 (br s, IH), 8.61 (t, IH) 8.57(d, IH), 7.77 (dd, IH), 7.54 (d, IH), 7.46 (d, 2H), 7.38 (m, 2H), 7.30 (m, 4H), 7.09 (m, 3H), 6.84 (dd, IH), 6.69 (dd, IH), 6.36 (m, IH), 6.26 (m, IH), 4.35 (t, 2H), 3.85 (m, 6H), 3.54 (m, 4H), 3.31 (m, 6H), 3.06 (m, 2H), 2.88 (s, 6H), 1.88 (m, IH), 1.60 (m, 2H), 1.28 (m, 2H). EXAMPLE 127 4-(4- {[4'-chloro-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl]methyl} piperazin-1 -yl)-2- (lH-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethy l)amino]pheny 1} sulfony l)benzamide EXAMPLE 127A 4'-chloro-4-(2-morpholinoethoxy)biphenyl-2-caibaldehyde The title compound was made by substituting EXAMPLE 125A for EXAMPLE 122B in and 4-(2-chloroethyl)moipholine hydrochloride salt for 2-chloro-N,N-dimethylethanamine hydrochloride salt EXAMPLE 122C. EXAMPLE 127B methyl 2-(lH-indol-5-yloxy)-4-(4-((4'-chloro-4-(2-morpholinoethoxy)biphenyI-2-yl)methyl)piperazin-1 -yl)benzoate The title compound was made by substituting EXAMPLE 127A for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 150A for tert-butyl piperazine-l-carboxylate in EXAMPLE lA. EXAMPLE 127C 2-(lH-indol-5-yloxy)-4-(4-((4'-chloro-4-(2-morpholinoethoxy)biphenyl-2- yl)methyl)piperazin-l-yl)benzoic acid -347- The title compound was made by substituting EXAMPLE 127Bfor EXAMPLE ID in EXAMPLE IE. EXAMPLE 127D 4.(4. {[4'-chloro-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl]methyl} piperazin-1 -yl)-2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was made by substituting EXAMPLE 127C for EXAMPLE IE in EXAMPLE 27H. 'H NMR (400MHZ, dimethylsulfoxide-de) 8 11.35 (br s, IH), 11.17 (s, IH), 8.61 (t, IH), 8.57 (d, IH), 7.77 (dd, IH), 7.54 (d, IH), 7.46 (d, 2H), 7.38 (m, 2H), 7.29 (m, 4H), 7.09 (m, 3H), 6.84 (dd, IH), 6.69 (dd, IH), 6.36 (m, IH), 6.26 (d, IH), 4.39 (t, 2H), 3.85 (m, 6H), 3.54 (m, lOH), 3.31 (m, 8H), 3.06 (m, 2H), 1.88 (m, IH), 1.60 (m, 2H), 1.27 (m,2H). EXAMPLE 128 4-[4-( {4'-ch]oro-3-[2-(dimethylamino)ethoxy]-1, r-biphenyl-2-yl }methyl)piperazin-l -yl]-2- (lH-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 128A 4'-chloro-3-hydroxybiphenyl-2-carbaIdehyde The title compound was made by substituting 2-bromo-6-hydroxybenzaldehyde for EXAMPLE 68C and 4-chlorophenylboronic acid for 4-methoxyphenylboronic acid in EXAMPLE 68D. EXAMPLE 128B 4'-chloro-3-(2-(dimethylamino)ethoxy)biphenyl-2-carbaldehyde The title compound was made by substituting EXAMPLE 128A for EXAMPLE 122B in EXAMPLE 122C. EXAMPLE 128C methyl 2-( 1 H-indol-4-yIoxy)-4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)bipheny]-2- yl)methyl)piperazin-l-yl)benzoate -348- The title compound was made by substituting EXAMPLE 128B for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 68B for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 128D 2-(lH-indol-4-yloxy)-4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)biphenyl-2- yl)methyl)piperazin-l-yl)benzoic acid The title compound was made by substituting EXAMPLE 128C for EXAMPLE ID in EXAMPLE IE. EXAMPLE 128E 4-[4-({4'-chloro-3-[2-(dimethylamino)ethoxy]-Ll'-biphenyl-2-yl}methyl)piperazin-l-yl]-2-(lH-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-y Imethy l)amino]pheny 1} sulfonyl)benzamide The title compound was made by substituting EXAMPLE 128D for EXAMPLE IE in EXAMPLE 27H. 'H NMR (400MHZ, dimethylsulfoxide-dg) 5 11.15 (s, IH), 8.47 (t, IH) 8.45 (d, IH), 7.68 (dd, IH), 7.57 (d, IH), 7.50 (d, 2H). 7.42 (d, 2H), 7.32 (m, IH), 7.24 (m, IH), 7.12 (d, IH), 7.05 (d, IH), 6.94 (m, 2H), 6.84 (d, IH), 6.66 (dd, IH), 6.35 (d, IH), 6.25 (m, 2H), 4.17 (t, 2H), 3.85 (m, 2H), 3.54 (m, lOH), 3.40 (m, 6H), 3.30 (s, 6H), 3.02 (m, 2H), 2.96 (m, 4H), 2.28 (m, 4H), 1.88 (m, IH), 1.60 (m, 2H), 1.28 (m, 2H). EXAMPLE 129 4-[4-({4'-chloro-3-[2-(dimethylamino)ethoxy]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-2- (lH-indol-5-yloxy)-N-({3-nitro-4-I(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl) sulfonyl)benzamide EXAMPLE 129A methyl 2-(lH-indol-5-yloxy)-4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)biphenyl-2- yl)methyl)piperazin-1 -yl)benzoate The title compound was made by substituting EXAMPLE 128B for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 150A for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. -349- EXAMPLE 129B 2-(lH-indol-5-yloxy)-4-(4-((4'-chloro-3-(2-(diniethylamino)ethoxy)biphenyl-2- yl)methyl)piperazin- l-yl)benzoic acid The title compound was made by substituting EXAMPLE 129A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 129C 4.[4-( {4'-ch]oro-3-[2-(dimethy]amino)ethoxy]-1, r-biphenyl-2-yl }methyl)piperazin-l-yl]-2-(1 H-indol-5-yloxy)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was made by substituting EXAMPLE 129B for EXAMPLE IE in EXAMPLE 27H. 'H NMR (400MHZ, dimethylsulfoxide-d^) 8 1L38 (br s, IH), 1L19 (s, IH), 10.00(br s, IH), 8.61 (t, IH) 8.58 (d, IH), 7.79 (dd, IH), 7.53 (m, 4H), 7.39 (m, 4H), 7.19 (m. IH), 7.11 (m, 2H), 6.93 (d, IH), 6.84 (dd, IH), 6.69 (dd, IH), 6.39 (m, IH), 6.19 (d, IH), 4.40 (m, 2H), 3.85 (m. 8H), 3.58 (m, 2H), 3.27 (m, 6H), 3.06 (m, 2H), 2.89 (s, 6H), 1.89 (m, IH), 1.60 (m, 2H), 1.27 (m, 2H). EXAMPLE 130 4-(4- {[4'-chloro-4-(2-morpholin-4-ylethoxy)-1, r-biphenyl-2-yl]methyl} piperazin-1 -yl)-2- (lH-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 130A methyl 2-(lH-indol-4-yloxy)-4-(4-((4'-chloro-4-(2-morpholinoethoxy)biphenyl-2-y l)methyl)piperazin-1 -yl)benzoate The title compound was made by substituting EXAMPLE 127A for 4'-chIorobiphenyl-2-carboxaIdehyde and EXAMPLE 68B for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 130B 2-(lH-indol-4-yIoxy)-4-(4-((4'-chIoro-4-(2-morpholinoethoxy)biphenyl-2- yl)methyl)piperazin- l-yl)benzoic acid -350- The title compound was made by substituting EXAMPLE 130A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 130C 4-(4- {[4'-chloro-4-(2-morpholin-4-ylethoxy)-1, r-biphenyl-2-yl]methyl} piperazin-1 -yl)-2-(lH-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-y]methyl)amino]phenyl} sulfonyl)benzamide The title compound was made by substituting EXAMPLE 130B for EXAMPLE IE in EXAMPLE 27H. 'H NMR (400MHZ, dimethylsulfoxide-de) 5 1 L47(br s, IH), n.23 (s, IH), 8.59 (t, IH) 8.47 (d, IH), 7.63 (dd, IH), 7.54 (d, IH), 7.47 (d, 2H), 7.27 (m, 6H), 7.13 (m, 2H), 7.03 (m, IH), 6.93 (m, IH), 6.74 (dd, IH), 6.35 (m, IH), 6.24 (m, IH), 4.39 (t, 2H), 3.85 (m, 6H), 3.54 (m, lOH), 3.26 (m, lOH), L88 (m, IH), L59 (m, 2H), L27 (m, 2H). EXAMPLE 131 4-(4- {[4'-chloro-3-(2-morphoIin-4-ylethoxy)-1,1 '-biphenyl-2-yl]methyl} piperazin-1 -y I)-2- (1 H-indol-4-yloxy)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfony l)benzamide EXAMPLE 131A 4'-chloro-3-(2-morpholinoethoxy)biphenyl-2-carbaldehyde The tiUe compound was made by substituting EXAMPLE 128A for EXAMPLE 122B and 4-(2-chloroethyl)morpholine hydrochloride salt for 2-chloro-N,N-diemthylethanamine hydrochloride salt in EXAMPLE 122C. EXAMPLE 13 IB methyl 2-( 1 H-indol-4-yloxy)-4-(4-((4'-chloro-3-(2-morpholinoethoxy)biphenyl-2-yl)methyl)piperazin-1 -yl)benzoate The title compound was made by substituting EXAMPLE 131A for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 68B for tert-butyl piperazine-l-carboxylate in EXAMPLE lA. -351- EXAMPLE 13IC 2-(lH-indol-4-yloxy)-4-(4-((4'-chloro-3-(2-morpholinoethoxy)biphenyl-2-yl)methyl)piperazin-l-yl)benzoic acid The title compound was made by substituting EXAMPLE 131B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 13 ID 4.(4- {[4'-chloro-3-(2-morpholin-4-ylethoxy)-1,1 '-bipheny l-2-yl]methyl} piperazin-1 -yl)-2-(lH-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was made by substituting EXAMPLE 131C for EXAMPLE IE in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-dg) 511.49 (br s, 1H), 11.25 (s, IH), 8.59 (t, IH), 8.50 (d, IH), 7.68 (dd, IH), 7.52 (m, 4H), 7.34 (d, 2H), 7.28 (m, IH), 7.18 (m, 2H), 7.06 (d, IH), 6.94 (m, 2H), 6.73 (dd, IH), 6.40 (d, IH), 6.33 (d, IH), 6.24 (m, IH), 4.43(t, 2H), 3.85 (m, lOH), 3.61 (m, 6H), 3.27 (m, 8H), 3.02 (m, 2H), 1.88 (m, IH), 1.60 (m, 2H), 1.28 (m, 2H). EXAMPLE 132 4-(4- {[4'-chloro-3-(2-morpholin-4-ylethoxy)-1, r-biphenyl-2-yl]methyl) piperazin-1 -yl)-2- (1 H-indo]-5-yloxy)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyI)amino]phenyl) sulfonyl)benzamide EXAMPLE 132A methyl 2-(lH-indol-5-yloxy)-4-(4-((4'-chloro-3-(2-morpholinoethoxy)biphenyl-2-y l)methy l)piperazin-1 -yl)benzoate The title compound was made by substituting EXAMPLE 131A for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 150A for tert-butyl piperazine-1-caiboxylate in EXAMPLE lA. EXAMPLE 132B 2-(lH-indol-5-yloxy)-4-(4-((4'-chloro-3-(2-morpholinoethoxy)biphenyl-2- yl)methyl)piperazin-l-yl)benzoic acid -352- The title compound was made by substituting EXAMPLE 132A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 132C 4.(4. {[4'-chloro-3-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl]methyl jpiperazin-1 -yl)-2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was made by substituting EXAMPLE 132B for EXAMPLE IE in EXAMPLE 27H. 'H NMR (400MHZ, dimethylsulfoxide-de) 8 11.34 (br s, IH), 11.17 (s, IH), 8.60 (t, IH), 8.58 (d, IH), 7.79 (dd, IH), 7.50 (m, 4H), 7.39 (m, 4H), 7.19 (d, IH), 7.14 (d, IH), 7.09 (d, IH), 6.93 (d, IH), 6.84 (dd, IH), 6.69 (dd, IH), 6.39 (m, IH), 6.19 (d, IH), 4.40 (m, 2H), 3.85 (m, 6H), 3.48 (m, 8H), 3.27 (m, lOH), 3.06 (m, 2H), 1.89 (m, IH), 1.60 (m, 2H), 1.27(m, 2H). EXAMPLE 133 4-[4-({4'-chloro-4-[2-(dimethylamino)ethoxy]-l,r-biphenyl-2-yl)methyl)piperazin-l-yl]-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-phenoxybenzamide The tide compound was made by substituting EXAMPLE 113D for EXAMPLE 27G and EXAMPLE 21A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-de) 5 8.34 (d, IH), 8.05 (d, IH), 7.69 (dd, IH), 7.59 (d, IH), 7.42 (m, 4H), 7.14 (m, 3H), 7.09 (d, IH), 6.98 (d, IH), 6.92 (dd, IH), 6.87 (m, IH), 6.84 (m, 3H), 6.30 (d, IH), 4.16 (t, 2H), 3.07 (m, 6H), 2.95 (m, 4H), 2.56 (m, 2H), 2.45 (s, 3H), 2.35 (m, 4H), 2.03 (m, 2H), 1.68 (m, 2H). EXAMPLE 134 4-[4-({4'-chloro-3-[2-(dimethylamino)ethoxy]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(3-pyrrolidin-l-ylpropyl)amino]phenyl) sulfonyl)benzamide The title compound was made by substituting EXAMPLE 129B for EXAMPLE 27G and EXAMPLE 68F for EXAMPLE IF in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-de) 6 11.34 (br s, IH), 11.17 (s, IH), 9.65 (br s, IH), 8.63 (t, IH), 8.60 (d, IH), 7.86 (dd, IH), 7.53 (d, 2H), 7.41 (m, 6H), 7.15 (m, 3H), 6.92 (m, IH), 6.84 (dd, IH), -353- 6.66 (dd, IH), 6.38 (m, IH), 6.16 (d, IH), 4.37 (m, 2H), 3.50 (m, 12H), 3.17 (m, 4H), 2.97 (m, 4H), 2.88 (s, 6H), 1.95 (m, 4H), 1.85 (m, 2H). EXAMPLE 135 4.[4-({4'-chloro-4-[2-(dimethylammo)ethoxy]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(3-pyiTolidin-l-ylpropyl)amino]phenyl} sulfonyl)benzamide Tlie title compound was made by substituting EXAMPLE 126B for EXAMPLE 27G and EXAMPLE 68F for EXAMPLE IF in EXAMPLE 27H. 'H NMR (4(X)MHZ, dimethylsulfoxide-de) 8 11.29 (br s, IH), 11.16 (s, IH), 9.56 (br s, IH), 8.63 (t, IH), 8.60 (d, IH), 7.85 (dd, IH), 7.53 (d, IH), 7.41 (m, 4H), 7.32 (m, 3H), 7.24 (m, IH), 7.12 (m, 3H), 6.84 (dd, IH), 6.66 (dd, IH), 6.38 (m, IH), 6.18 (d, IH), 4.33 (t, 2H), 3.50 (m, 12H), 3.17 (m, 4H), 2.97 (m, 4H), 2.86 (s, 6H), 1.95 (m, 4H), 1.85 (m, 2H). EXAMPLE 136 4-(4- {[4'-chloro-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl]methyl) piperazin-1 -yl)-2-(lH-indol-5-yloxy)-N-({ 3-nitro-4-[(3-pyrrolidin-1-ylpropyl)amino]phenyl ] sulfonyl)benzamide The title compound was made by substituting EXAMPLE 127C for EXAMPLE 27G and EXAMPLE 68F for EXAMPLE IF in EXAMPLE 27H. ^H NMR (400MHz, dimethylsulfoxide-dfi) 8 11.29 (br s, IH), 11.16 (s, IH), 9.54 (br s, IH), 8.63 (t, IH), 8.60 (d, IH), 7.85 (dd, IH), 7.53 (d, IH), 7.45 (d, 2H), 7.38 (m, 2H), 7.31(d, 2H), 7.23 (m, 2H), 7.12 (m, 3H), 6.84 (dd, IH), 6.66 (dd, IH), 6.38 (m, IH), 6.18 (d, IH), 4.36 (t, 2H), 3.82 (m, 4H), 3.50 (m, 8H), 3.17 (m, lOH), 2.98 (m, 4H), 1.95 (m, 6H), 1.85 (m, 2H). EXAMPLE 137 4- [4-( {4'-chloro-4- [2-(dimethylamino)ethoxy]-1,1 '-biphenyl-2-yl} methyl)piperazin-1 -yl]-N- [(3-nitro-4-{[l-(2,2,2-trifluoroethyl)piperidin-4-yl]amino}phenyl)sulfonyl]-2- phenoxybenzamide The title compound was made by substituting EXAMPLE 113E for EXAMPLE 27G and EXAMPLE 108A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-de) 8 11.71 (br s, IH), 9.81 (br s, IH), 8.46(d, IH), 8.29 (d, IH), 7.75 (dd, IH), 7.50 (m, 3H), 7.30 (m, 4H), 7.21(m, 3H), 7.10 (m, IH), 6.97 (m, IH), 6.77 (m, 3H), 6.43 -354- (s, IH), 4.36 (t, 2H), 3.72 (m, 2H), 3.58 (m, 4H), 3.23 (m, 6H), 2.95 (m, 4H), 2.89 (s, 6H), 2.60 (m, 2H), 1.92 (m, 2H), 1.68 (m, 2H). EXAMPLE 138 4.(4-{[4'-chloro-4-(2-pyrrolidin-l-ylethoxy)-l,l'-biphenyl-2-yl]methyl}piperazin-l-yl)-N- ({3 -nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl) sulfonyl)-2-phenoxybenzamide EXAMPLE 138A methyl 4-(4-((4'-chloro-4-hydroxybiphenyl-2-yl)methyl)piperaan-l-yl)-2-phenoxybenzoate The title compound was made by substituting EXAMPLE 113B for EXAMPLE 68C and 4-chlorophenylboronic acid for 4-methoxyphenylboronic acid in EXAMPLE 68D. EXAMPLE 138B methyl 4-(4-((4'-chloro-4-(2-(pyirolidin-1 -yl)ethoxy)biphenyI-2-yl)methyl)piperazin-1 -yl)-2- phenoxybenzoate The title compound was made by substituting EXAMPLE 138A for EXAMPLE 113B and l-(2-chloroethyl)pyrro]idine HCl salt for 2-chloro-N,N-dimethylethanamine hydrochloride salt in EXAMPLE 113C. EXAMPLE 138C 4-(4-((4'-ch]oro-4-(2-(pyrrolidin-1 -yl)ethoxy)biphenyl-2-yl)methyl)piperazin-1 -yl)-2- phenoxybenzoic acid The title compound was made by substituting EXAMPLE 1383 for EXAMPLE ID in EXAMPLE IE. EXAMPLE 138D 4-(4-{[4'-chloro-4-(2-pyrrolidin-l-ylethoxy)-l,r-biphenyl-2-yl]methyl)piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino Jphenyl) sulfony])-2-phenoxybenzamide The title compound was made by substituting EXAMPLE 138C for EXAMPLE IE in EXAMPLE 27H. 'H NMR (400MHz. dimethylsulfoxide-d6) 5 11.64 (br s, IH), 9.98 (br s, IH), 8.62(d, IH), 8.47 (d, IH), 7.75(dd, IH), 7.50 (m, 3H), 7.26 (m, 6H), 7.14 (m, 2H), 6.99 (m, IH), 6.81 (d, 2H), 6.77 (dd, IH), 6.43 (d, IH), 4.36 (t, 2H), 3.86 (dd, 2H), 3.62 (m, 8H), 3.28 (m, 8H), 3.10 (m, 4H), 2.04 (m, 2H), 1.90(m, 3H), 1.65 (m, 2H), 1.29 (m, 2H). -355- EXAMPLE 139 4.[4.( {4'-chloro-4- [2-(diisopropylammo)ethoxy]-1,1 '-biphenyl-2-yl} methyl)piperazin-1 -yl]- N-( {3-nitro-4-[(tetiahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2- phenoxybenzamide EXAMPLE 139 A methyl 4-(4-((4'-chloro-4-(2-(diisopropylamino)ethoxy)biphenyl-2-yl)methyl)piperazin-1 -yl)- 2-phenoxyben2oate The title compound was made by substituting EXAMPLE 138A for EXAMPLE 113B and 2-diisopropylaminoethyl chloride hydrochloride salt for 2-chloro-N,N-dimethylethanamine hydrochloride salt in EXAMPLE 113C. EXAMPLE 139B 4-(4-((4'-chloro-4-(2-(diisopropylamino)ethoxy)biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxybenzoic acid The title compound was made by substituting EXAMPLE 139A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 139C 4-[4-({4'-chloro-4-[2-(diisopropylamino)ethoxy]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]- N-( {3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2- phenoxybenzamide The title compound was made by substituting EXAMPLE 139B for EXAMPLE IE in EXAMPLE 27H. 'H NMR (400MHZ, dimethylsulfoxide-de) 8 11.65 (br s, IH), 8.75 (br s, IH), 8.62 (d, IH), 8.47 (d, IH), 7.75 (dd, IH), 7.50 (m, 3H), 7.31 (m, 4H), 7.23 (m, 2H), 7.13 (m, 2H), 6.99 (m, IH), 6.79 (m, 3H), 6.44 (m, IH), 4.31 (t, 2H), 3.86 (dd, 2H), 3.62 (m, lOH), 3.28 (m, 6H), 1.91(m, IH), 1.62 (m, 2H), 1.32(m, 14H). EXAMPLE 140 4-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methyl]piperazin-l-yl}-2-(2,3-dihydro-lH-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide A suspension of EXAMPLE 40D (22.57 mg) and sodium cyanoborohydride (25 mg) in acetic acid (5 ml) was stirred at room temperature for 2 hours. The product was -356- partitioned between dichloromethane and water. The organic layer was separated, dried over Na2S04, and concentrated. The crude product was purified by RP HPLC (C8, 30 -100 acetonitrile/water/0.1%trifluoroacetic acid). 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.56 (s, IH), 9.60 (s, IH), 8.66 (t, IH), 8.57 (d, IH), 7.85 (dd, IH), 7.71 (s, IH), 7.46 - 7.60 (m, 5H), 7.29 - 7.42 (m, 3H), 7.25 (d, IH), 6.95 (s, IH), 6.82 (s, IH), 6.73 (d, IH), 6.36 (s, IH), 4.32 (bs, 2H), 3.85 (dd, 4H), 3.59 (t, 4H), 3.35 (t, 2H), 3.27 (t, 2H), 3.02 (t, 4H), 1.80 -1.99 (m, IH), 1.62 (d, 2H), 1.15 - 1.36 (m, 2H). EXAMPLE 141 4-(4- {[2-(4-chlorophenyl)cyclohept-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)- N-( {3-nitro-4-[(3-pyrrolidin-1 -ylpropyl)amino]phenyl} su]fonyl)benzamide EXAMPLE 141A (Z)-methyl 2-(trifluoromethylsulfonyloxy)cyclohept-1 -enecaiboxylate The title compound was prepared by substituting methyl 2-oxocycloheptanecarboxylate for 5,5-dimethyl-2-methoxycarbonylcyclohexanone in EXAMPLE 18A. EXAMPLE 141B (Z)-methyl2-(4-chlorophenyl)cyclohept-l-enecarboxylate The title compound was prepared by substituting EXAMPLE 141A for EXAMPLE 18A in EXAMPLE 18B. EXAMPLE 141C (Z)-(2-(4-chloiophenyl)cyclohept-1 -enyl)methanol The title compound was prepared by substituting EXAMPLE 14IB for EXAMPLE 18B in EXAMPLE 18C. EXAMPLE 141D (Z)-2-(4-chlorophenyl)cyclohept-l-enecaibaldehyde The title compound was prepared by susbstituting EXAMPLE 141C for EXAMPLE 143C in EXAMPLE 143D. -357- EXAMPLE 141E (Z)-ethyl2-(lH-indol-4-yloxy)-4-(4-((2-(4-chlorophenyl)cyc]ohept-l-eny])methyl)piperazih- l-yl)benzoate The title compound was prepared by substituting EXAMPLE 141D for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 68B for tert-butyl piperazine-1-carboxylate in EXAMPLE I A. EXAMPLE 14 IF (Z)-2-(lH-indol-4-yloxy)-4-(4-((2-(4-chlorophenyl)cyclohept-l-enyl)methyl)piperazin-l- yl)benzoic acid The title compound was prepared by substituting EXAMPLE 141E for EXAMPLE 143E in EXAMPLE 143F. EXAMPLE 141G 4-(4-{[2-(4-chloiophenyl)cyclohept-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-({3-nittx)-4-[(3-pyirolidin-l-ylpropyl)amino]phenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 141F for EXAMPLE IE and EXAMPLE 68F for EXAMPLE IF in EXAMPLE IG. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 11.45 (m, IH), 10.03 (m, IH), 8.58 (m, 2H), 8.30 (m, IH), 7.26 (m, IIH), 6.25 (m, 2H), 3.14 (m, 12H), 2.73 (m, 5H), 1.94 (m, 12H), 1.54 (m, 5H). EXAMPLE 142 4-(4- {[2-(4-chlorophenyl)cyclooct-1 -en-1 -yl]methyl )piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)- N-( {3-nitro-4-[(3-pyrrolidin-1 -ylpropy l)amino]phenyl} sulfonyl)benzamide EXAMPLE 142A (Z)-ethyl 2-(trifluoromethylsulfonyloxy)cyclooct-1 -enecaiboxylate The title compound was prepared by substituting ethyl 2- oxocyclooctanecarboxylate for 5,5-dimethyl-2-methoxycarbonylcyclohexanone in EXAMPLE 18 A. EXAMPLE 142B (Z)-ethyl 2-(4-chlorophenyl)cyclooct-1 -enecarboxylate -358- The title compound was prepared by substituting EXAMPLE 142 A for EXAMPLE 18A in EXAMPLE 18B. EXAMPLE 142C (Z)-(2-(4-chlorophenyl)cyclooct-1 -enyl)methanol The title compound was prepared by substituting EXAMPLE 142B for EXAMPLE 18B in EXAMPLE 18C. EXAMPLE 142D (Z)-2-(4-chloiophenyl)cyclooct-1 -enecarbaldehyde The title compound was prepared by substituting EXAMPLE 142C for EXAMPLE 143C in EXAMPLE 143D. EXAMPLE 142E (Z)-ethyl 2-( 1 H-indoI-4-yloxy)-4-(4-((2-(4-chlorophenyl)cycIooct-1 -enyl)methyl)piperazin- l-yl)benzoate The title compound was prepared by substituting EXAMPLE 142D for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 688 for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 142F (Z)-2-( lH-indol-4-yloxy)-4-(4-((2-(4-chlorophenyl)cyclooct-1 -enyl)methyl)piperazin-1 - yl)benzoic acid The title compound was prepared by substituting EXAMPLE 142E for EXAMPLE 143E in EXAMPLE 143F. EXAMPLE 142G 4-(4- {[2-(4-chlorophenyl)cyclooct-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)-N-( {3-nitro-4-I(3-pyrrolidin-1 -ylpropy l)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 142F for EXAMPLE IE and EXAMPLE 68F for EXAMPLE IF in EXAMPLE IG. 'H NMR (300 MHz, dimethylsulfoxide-d6) 8 11.51 (m, IH), 10.01 (m, IH), 8.58 (m, 2H), 7.26 (m, 12H), 6.35 (m, 2H), 3.14 (m, 13H), 2.73 (m, 5H), 1.88 (m, 7H), 1.45 (m, lOH). -359- EXAMPLE 143 4-(4-{[2-(4-chloiDphenyl)cyclopent-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-4-yloxy)- N-( {3-nitro-4-[(3-pyrrolidin-1 -ylpropy l)amino]phenyl} sulfonyl)benzamide EXAMPLE 143 A ethyl 2-(trifluoromethylsulfonyloxy)cyclopent-1 -enecaiboxylate The title compound was prepared by substituting ethyl 2-oxocyclopentanecarboxylate for 5,5-dimethyl-2-methoxycaibonylcyclohexanone in EXAMPLE 18A. EXAMPLE 143B ethyl 2-(4-chlorophenyl)cyclopent-l-enecarboxylate The title compound was prepared by substituting EXAMPLE 143A for EXAMPLE 18A in EXAMPLE 18B. EXAMPLE 143C (2-(4-chlorophenyl)cyclopent-1 -enyl)methanol The title compound was prepared by substituting EXAMPLE 143B for EXAMPLE 18B in EXAMPLE 18C. EXAMPLE 143D 2-(4-chlorophenyl)cyclopent-1 -enecarbaldehyde To a solution of oxalyl chloride (l.lg) in dichloromethane (30 ml) at -78°C was added dimethylsulfoxide (6.12 ml). The mixture was stirred at -78°C for 30 minutes, and then a solution of EXAMPLE 143C (1.2 g) in dichloromethane (10 ml) was added. The mixture was stirred at -78°C for 2 hours before the addition of triethylamine (10 ml). The mixture was stirred overnight and the temperature was allowed to rise to room temperature. The mixture was diluted with ether (300 ml) and washed with water, brine and dried over Na2S04. Evaporation of solvent and column purification (5% ethyl acetate in hexane) to give the product. -360- EXAMPLE 143E ethyl 2-( 1 H-indol-4-yloxy)-4-(4-((2-(4-ch]orophenyl)cyclopent-1 -eny])methyl)pipera2in-1 - yl)benzoate The title compound was prepared by substituting EXAMPLE 143D for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 68B for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 143F 2-( 1 H-indol-4-yloxy)-4-(4-((2-(4-chlorophenyl)cyclopent-1 -enyl)methyl)piperazin-1 - yl)benzoic acid To a solution of EXAMPLE 143E (254 mg) in tetrahydrofiiran (4 ml), methanol (2 ml) and water (2 ml) was added LiOH-H20 (126 mg). The mixture was stirred overnight. The mixture was then neutralized with 5% HCl and diluted with ethyl acetate (200 ml). After washing with brine, it was dried over Na2S04. Evaporation of solvent gave the product, EXAMPLE 143G 4-(4- {[2-(4-chlorophenyl)cyclopent-1 -en-1 -yl]methyl }piperazin-1 -yI)-2-(l H-indol-4-yloxy)-N-( {3-nitro-4-[(3-pyrrolidin-1 -ylpropyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 143F for EXAMPLE IE and EXAMPLE 68F for EXAMPLE IF in EXAMPLE IG. 'H NMR (300 MHz, dimethylsulfoxide-d6) 8ppm 11.41 (m, IH), 10.19 (m, IH), 8.58 (m, 2H), 7.26 (m, 14H), 6.33 (m, 2H), 3.80 (m, 4H), 3.13 (m, 12H), 2.69 (m, 5H), 1.95 (m, 7H). EXAMPLE 144 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclopent-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-( {4-[( 1 -methylpiperidin-4-yl)amino]-3-nitrophenyl }su]fonyl)benzamide EXAMPLE 144A methyl 4,4-dimethyl-2-oxocyclopentanecarboxylate This compound was prepared according to WO 2006/035061 (page 53). EXAMPLE 144B methyl 4,4-dimethyl-2-(trifluoromethylsulfonyloxy)cyclopent-l-enecarboxylate -361- The title compound was prepared by substituting ethyl 2-oxocyclopentanecarboxylate for 5,5-dimethyl-2-methoxycarbonylcyclohexanone in EXAMPLE 18A. EXAMPLE 144C ethyl 2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -enecarboxylate The title compound was prepared by substituting EXAMPLE 144B for EXAMPLE 18A in EXAMPLE 18B. EXAMPLE 144D (2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -enyl)methanol The title compound was prepared by substituting EXAMPLE 144C for EXAMPLE 18B in EXAMPLE 18C. EXAMPLE 144E 2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -enecaibaldehyde The title compound was prepared by substituting EXAMPLE 144D for EXAMPLE 143C in EXAMPLE 143D. EXAMPLE 144F ethyl 2-(lH-indol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclopent-l-enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 144E for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 68B for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 144G 2-( 1 H-indol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 144F for EXAMPLE 143E in EXAMPLE 143F. -362- EXAMPLE 144H 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H-mdol-4-yloxy)-N-({4-[(l-methylpiperidin-4-yl)aniino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 144G for EXAMPLE IE and EXAMPLE 21A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300 MHz, dimethylsuIfoxide-d6) 5 n.59 (m, IH), 1L25 (s, IH), 9.53 (m, IH), 8.50 (d, IH), 8.16 (d, IH), 8.16 (d, IH), 7.80 (m, IH), 7.56 (d, IH), 7.26 (m, 7H), 6.95 (m, IH), 6.77 (dd, IH), 6.41 (m, 2H), 6.23 (s, IH), 2.87 (m, lOH), 2.28 (m, 12H), 1.11 (m, 6H). EXAMPLE 145 4-(4-.{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-(lH-indol-4-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 145A methyl 6,6-dimethyl-4-oxotetrahydro-2H-pyran-3-caiboxylate To a suspension of hexane-washed NaH (0.72 g, 60%) in tetrahydrofuran (30 ml) was added a solution of 2,2-dimethyldihydro-2H-pyran-4(3H)-one (2.0 g) in tetrahydrofuran (20 ml). The suspension was stirred for 30 minutes. The dimethylcarbonate (6.31 ml) was added dropwise by syringe. The mixture was heated to reflux for 4 hours. The mixture was acidified with 5% HCl and extracted with dichloromethane (3x 100ml) and washed with water, brine and dried over Na2S04. After evaporation, the crude product was loaded on a column and eluted with 10% ethyl acetate in hexane to give the product. EXAMPLE 145B methyl 6,6-dimethyl-4-(trifluoromethylsulfonyloxy)-5,6-dihydro-2H-pyran-3-carboxylate The title compound was prepared by substituting EXAMPLE 145A for 5,5-dimethy]-2-methoxycarbonylcyclohexanone in EXAMPLE 18A. EXAMPLE 145C methyl 4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-carboxylate The title compound was prepared by substituting EXAMPLE 145B for EXAMPLE 18A in EXAMPLE 18B. -363- EXAMPLE 145D (4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methanol The title compound was prepared by substituting EXAMPLE 145C for EXAMPLE 18B in EXAMPLE 18C. EXAMPLE 145E 4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-carbaldehyde The title compound was prepared by substituting EXAMPLE 145D for EXAMPLE 143C in EXAMPLE 143D. EXAMPLE 145F ethyl 2-(lH-indol-4-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3- yl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 145E for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 68B for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 145G 2-(lH-indol-4-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin- l-yl)benzoic acid The title compound was prepared by substituting EXAMPLE 145F for EXAMPLE 143E in EXAMPLE 143F. EXAMPLE 145H 4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyTan-3-yl]methyl Ipiperazin-1 -yl)- 2-(lH-indol-4-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzanude The title compound was prepared by substituting EXAMPLE 145G for EXAMPLE IE and EXAMPLE 21A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300 MHz, dimethylsulfoxide-d6) 8 11.56 (m, IH), 1L26 (s, IH), 9.52 (m. IH), 8.51 (m, IH), 8.16 (d, IH), 7.80 (dd, IH), 7.55 (d, IH), 7.41 (d, 2H), 7.28 (t, IH), 7.17 (m, 4H), 6.96 (m, 2H), -364- 6.74 (d, IH), 6.39 (m, 2H), 6.23 (s, IH), 4.18 (s, 2H), 3.85 (m, 3H), 2.93 (m, lOH), 2.10 (m, 7H), 1.22 (s, 6H). EXAMPLE 146 4-(4- {[2-(4-chlorophenyl)cyclooct-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indol-4-y loxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzaniide The title compound was prepared by substituting EXAMPLE 142F for EXAMPLE IE and EXAMPLE 21A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300 MHz, dimethylsulfoxide-d6) 8 11.59 (s, IH), 11.25 (s, IH), 9.36 (m, 2H), 8.50 (d, IH), 8.16 (d, IH), 7.79 (dd, IH), 7.55 (d, IH), 7.40 (d, 2H), 7.28 (m, IH), 7.14 (m, 5H), 6.96 (t, IH), 6.74 (dd, IH), 6.38 (m, 2H), 6.23 (s, IH), 2.91 (m, 14H), 2.27 (m, 6H), 1.49 (m, IIH). EXAMPLE 147 4-(4-{[2-(4-chlorophenyl)cyclohept-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}suIfonyI)benzamide The title compound was prepared by substituting EXAMPLE 141F for EXAMPLE IE and EXAMPLE 21A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300 MHz, dimethylsulfoxide-d6) 5 11.60 (s, IH), 11.26 (s, IH), 9.32 (m, 2H), 8.51 (m, IH), 8.16 (d, IH), 7.79 (m, IH), 7.55 (d, IH), 7.39 (d, 2H), 7.29 (t, IH), 7.14 (m, 4H), 6.97 (t, IH), 6.75 (dd, IH), 6.40 (m, 2H), 6.22 (s, IH), 2.94 (m, 17H), 2.27 (m, 4H), 1.80 (m, 4H), 1.55 (m, 5H). EXAMPLE 148 4-(4- {[2-(4-chlorophenyl)cyclopent-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( lH-indol-4-yloxy)-N-( {4- [(1 -methy lpiperidin-4-y 1) amino] -3 -nitropheny 1} sulfony l)benzamide The title compound was prepared by substituting EXAMPLE 143F for EXAMPLE IE and EXAMPLE 21A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300 MHz, dimethy]su]foxide-d6) 8 11.60 (s, IH), 11.26 (s, IH), 9.47 (m, 2H), 8.51 (m, IH), 8.16 (d, IH), 7.77 (m, IH), 7.56 (d, IH), 7.43 (d, 2H), 7.20 (m, 6H), 6.96 (t, IH), 6.77 (dd, IH), 6.41 (m, 2H), 6.24 (s, IH), 2.93 (m, 17H), 2.01 (m, 8H). -365- EXAMPLE 149 4-(4- {[2-(4-chlorophenyl)cyclohex-1 -en-1 -yl]methyl} piperazin-1 -yI)-2-( 1 H-indol-4-yloxy)- N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide EXAMPLE 149A ethyl 2-(trifluoromethylsulfonyloxy)cyclohex-1 -enecarboxy late The title compound was prepared by substituting ethyl 2-oxocyclohexanecarboxylate for 5,5-dimethyl-2-methoxycarbonylcyclohexanone in EXAMPLE 18A. EXAMPLE 149B ethyl 2-(4-chlorophenyl)cyclohex-1 -enecaiboxylate The title compound was prepared by substituting EXAMPLE 149A for EXAMPLE 18A in EXAMPLE 18B. EXAMPLE 149C (2-(4-chlorophenyl)cyclohex-1 -enyl)methanol The title compound was prepared by substituting EXAMPLE 149B for. EXAMPLE 18B in EXAMPLE 18C. EXAMPLE 149D 2-(4-chlorophenyl)cyclohex-1 -enecarbaldehyde The title compound was prepared by substituting EXAMPLE 149C for EXAMPLE 143C in EXAMPLE 143D. EXAMPLE 149E ethyl 2-(lH-indol-4-yloxy)-4-(4-((2-(4-chlorophenyl)cyclohex-l-enyl)methyl)piperazin-l- yl)benzoate The title compound was prepared by substituting EXAMPLE 149D for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 68B for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. -366- EXAMPLE 149F 2-( lH-indol-4-yloxy)-4-(4-((2-(4-chlorophenyl)cyclohex-1 -enyl)methyl)piperazin-1 - yl)benzoic acid The title compound was prepared by substituting EXAMPLE 149E for EXAMPLE 143E in EXAMPLE 143F. EXAMPLE 149G 4-(4-{[2-(4-chlorophenyl)cyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 149F for EXAMPLE IE and EXAMPLE 21A for EXAMPLE IF in EXAMPLE IG. ^H NMR (300 MHz, dimethylsulfoxide-d6) 8 11.14 (s, IH), 8.44 (d, IH), 8.10 (d, IH), 7.74 (dd, IH), 7.56 (d, IH), 7.34 (d, 2H), 7.23 (m, IH), 7.01 (m, 5H), 6.63 (dd, IH), 6.34 (d, IH), 6.22 (m, 2H), 3.74 (m, IH), 3.03 (m, 7H), 2.67 (m, 5H), 2.07 (m, IIH), 1.67 (m, 7H). EXAMPLE 150 4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)- 2-(lH-indol-5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 150A methyl 2-(lH-indol-5-yloxy)-4-(piperazin-l-yl)benzoate The title compound was prepared by substituting EXAMPLE 26A for EXAMPLE IC and piperazine for EXAMPLE IB in EXAMPLE ID. EXAMPLE 150B methyl 2-(lH-indol-5-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran- 3-yl)methyl)piperazin- l-yl)benzoate The title compound was prepared by substituting EXAMPLE 145E for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 150A for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. -367- EXAMPLE 150C 2-(lH-indol-5-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)pipera2in-l-yl)benzoic acid The title compound was prepared by substituting EXAMPLE 150B for EXAMPLE 143E in EXAMPLE 143F. EXAMPLE 150D 4-(4- {[4-(4-chloiophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl} piperazin-1 -yl)- 2-(lH-indol-5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)aniino]-3- nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 150C for EXAMPLE IE and EXAMPLE 21A for EXAMPLE IF in EXAMPLE IG. ^H NMR (300 MHz, dimethylsulfoxide-d6) S 11.00 (s, IH), 8.42 (d, IH), 8.07 (d, IH), 7.67 (dd, IH), 7.52 (d, IH), 7.37 (d, 2H), 7.29 (m, IH), 7.14 (d, 2H), 6.93 (d, IH), 6.86 (d, IH), 6.72 (dd, IH), 6.55 (dd, IH), 6.31 (s, IH), 6.15 (d, IH), 5.85 (m, 3H), 4.11 (s, 2H), 3.00 (m, 8H), 2.82 (s, 2H), 2.73 (m, 3 H), 2.23 (m, 8H), 1.57 (m, 2H), 1.18 (s, 6H). EXAMPLE 151 4-(4- {[2-(4-chlorophenyl)cyclohept-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indol-5 -yloxy)- N-( {4-[(l -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide EXAMPLE 151A (Z)-methyl2-(lH-indol-5-yloxy)-4-(4-((2-(4-chloiophenyl)cyclohept-l-enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 141D for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 150A for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 15 IB (Z)-2-( 1 H-indol-5-yloxy)-4-(4-((2-(4-chloropheny l)cyclohept-1 -enyl)methyl)piperazin-1 - yl)benzoic acid The title compound was prepared by substituting EXAMPLE 151A for EXAMPLE 143E in EXAMPLE 143F. -368- EXAMPLE 15IC 4-(4-{[2-(4-chlorophenyl)cyclohept-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5-yloxy)-N-({4-[(l-raethylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 15IB for EXAMPLE IE and EXAMPLE 21A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300 MHz, dimethylsulfoxide-d6) 8 11.06 (s, IH), 8.48 (d, IH), 8.11 (d, IH), 7.74 (dd, IH), 7.52 (d, IH), 7.33 (m, 4H), 7.01 (m, 4H), 6.76 (dd, IH), 6.58 (dd, IH), 6.34 (s, IH), 6.14 (d, IH), 5.75 (s, IH), 3.69 (m, IH), 2.96 (m, 6H), 2.71 (m, 2H), 2.36 (m, 8H). 2.21 (s, 5H), 1.98 (m, 2H), 1.63(m,8H). EXAMPLE 152 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N-( {4- [(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-phenoxybenzamide This compound was made by substituting EXAMPLE 18G for EXAMPLE IE and EXAMPLE 21A for EXAMPLE IF in EXAMPLE IG. 'H NMR (400 MHz, dimethylsulfoxide-de) 5 8.43 (m, IH) 8.18 (d, IH) 7.82 (dd, IH) 7.52 (d, IH) 7.40 (m, 2H) 7.22 (m, 3H) 7.11 (m, 2H) 7.01 (t, IH) 6.79 (m, 3H) 6.45 (d, IH) 3.06 (m, 14H) 2.20 (m, 4H) 2.04 (s, 3H) 1.85 (m, 2H) 1.47 (m, 2H) 0.96 (s, 6H). EXAMPLE 153 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N- [(4- {[2- (dimethylanuno)ethyl]amino}-3-nitrophenyl)sulfonyl]-2-phenoxybenzamide EXAMPLE 153A 4-(2-(dimethylamino)ethylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting N,N-dimethylethylenediamine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 153B 4- {4-[(4'-chloro-1, l'-biphenyl-2-yl)methyl]piperazin-1 -yl} -N- [(4- {[2- (dimethylamino)ethyl]amino}-3-nitrophenyl)sulfonyl]-2-phenoxybenzamide -369- The title compound was prepared by substituting EXAMPLE 153 A for EXAMPLE IF and EXAMPLE IE for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (500MHz, dimethylsulfoxide-d6) 8 11.75 (br s, IH), 9.78 (br s, IH), 9.44 (br s, IH), 8.66 (t, IH), 8.49 (d, IH), 7.83 (d, IH), 7.70 (m, 2H), 7.51 (m, 4H), 7.38 (d, 2H), 7.33 (m, IH), 7.24 (d, 2H), 7.18 (d, IH), 7.02 (dd, IH), 6.81 (d, 2H), 6.76 (d, IH), 6.44 (s, IH), 4.30 (m, IH), 3.83 (m, 4H), 3.31 (m, 6H), 3.15 (m, 2H), 3.04 (m, 2H), 2.85 (s, 6H). EXAMPLE 154 4- {4.[(4'K;hloro-1, l'-biphenyl-2-yl)methyl]piperazin- 1-yl} -N-[(4- {[3- (dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-phenoxybenzamide EXAMPLE 154A 4-(3-(dimethylamino)propylamino)-3-nitrobenzenesulfonaniide The title compound was prepared by substituting N,N-dimethyl-l,3-ptopanediamine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 154B 4- {4-[(4'-chloro-1, l'-biphenyl-2-yl)methyl]piperazin-l-yl} -N- [(4- {[3-(dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 154A for EXAMPLE IF and EXAMPLE IE for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-de) 8 11.68 (br s, IH), 9.38 (br s, IH), 8.66 (t, IH), 8.49 (d, IH), 7.80 (d, IH), 7.68 (m, 2H), 7.51 (m, 4H), 7.38 (d, IH), 7.33 (m, 2H), 7.24 (d, 2H), 7.16 (d, IH), 7.02 (dd, IH), 6.81 (d, 2H), 6.76 (d, IH), 6.43 (s, IH), 4.25 (m, IH), 3.50 (m, 4H), 3.30 (m, 4H), 3.12 (m, 6H), 2.78 (s, 6H), 1.95 (m, 2H). EXAMPLE 155 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -N-( {4- [(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl} sulfonyl)-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 7A for EXAMPLE IF and EXAMPLE IE for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-dfi) 8 11.70 (br s, IH), 9.72 (br s, IH), 8.68 (t, IH), 8.49 (d, IH), 7.81 (d, IH), 7.70 (m, 2H), 7.51 (m, 4H), 7.37 (d, 2H), 7.33 (m, IH), 7.24 (d, 2H), 7.15 -370- (d, IH), 7.03 (dd, IH), 6.81 (d, 2H), 6.76 (d, IH), 6.44 (s, IH), 4.24 (m, IH), 3.97 (m, 2H), 3.63 (m, 4H), 3.28 (m, 4H), 3.18 (m, 4H), 3.06 (m, 4H), 2.88 (m, 4H), 1.99 (m, 2H). EXAMPLE 156 4- {4-[(4' -chloro-1, r-biphenyl-2-yl)methyl]piperazin-l -yl} -N- [(4- {[4- (dimethylamino)butyl]amino}-3-nitrophenyl)sulfonyl]-2-phenoxybenzamide EXAMPLE 156A 4-(4-(dimethylamino)butylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting N,N-dimethy 1-1,4-butanediamine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 156B 4- {4-[(4'-chloro-1, l'-biphenyl-2-yl)methyl]piperazin-1 -yl} -N- [(4- {[4-(dimethylamino)butyl]amino}-3-nitrophenyl)sulfonyl]-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 156A for EXAMPLE IF and EXAMPLE IE for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-de) 8 11.70 (br s, IH), 9.34 (br s, IH), 8.63 (t, IH), 8.48 (d, IH), 7.79 (d, IH), 7.70 (m, 2H), 7.51 (m, 4H), 7.39 (d, 2H), 7.33 (m, IH), 7.24 (d, 2H), 7.12 (d, IH), 7.01 (dd, IH), 6.80 (d, 2H), 6.75 (d, IH), 6.44 (s, IH), 4.28 (m, IH), 3.83 (m, 4H), 3.45 (m, lOH), 3.10 (m, 4H), 2.85 (s, 6H), 1.66 (m, 4H). EXAMPLE 157 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -N- [(3-nitro-4- {[ 1 -(phenylsulfonyl)piperidin-4-yl]amino}phenyl)sulfonyl]-2-phenoxybenzamide EXAMPLE 157A tert-butyl 4-(2-nitro-4-sulfamoylphenylamino)piperidine-1 -carboxylate The title compound was prepared by substituting l-Boc-4-aminopiperidine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 157B 3-nitro-4-(piperidin-4-ylamino)benzenesulfonamide -371- The title compound was prepared by substituting EXAMPLE 157A for EXAMPLE lA in EXAMPLE IB. EXAMPLE 157C 3-nitro-4-(l-(phenylsulfonyl)piperidin-4-ylamino)benzenesulfonamide A mixture of EXAMPLE 157B (84 mg), benzenesulfonyl chloride (46 mg), and triethylamine (101 mg) in CH2CI2 (2 mL) was stirred for 1 hours. The product was chromatographed on silica gel with 25% ethyl acetate/hexanes. EXAMPLE 157D 4- {4-[(4'-chloio-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -N-[(3-nitro-4- {[ 1 -(phenylsulfonyl)piperidin-4-yl]amino}phenyl)sulfonyl]-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 157C for EXAMPLE IF and EXAMPLE IE for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-ds) 8 11.68 (br s, IH), 9.65 (br s, IH), 8.42 (s, IH), 8.19 (d, IH), 7.78 (m, 2H), 7.70 (m, 4H), 7.51 (m, 5H), 7.37 (m, 3H), 7.19 (m, 3H), 6.94 (dd, IH), 6.75 (m, 3H), 6.44 (s, IH), 4.28 (m, IH), 3.73 (m, 4H), 3.50 (m, 4H), 3.17 (m, 2H), 3.03 (m, 2H), 2.86 (m, 2H), 1.99 (m, 2H), 1.74 (m, 2H). EXAMPLE 158 4-{4-[(4'-chloro-l,r-biphenyl-2-yl)methyl]piperazin-l-yl)-N-[(3-nitro-4-{[l-(quinolin-8- ylsulfonyl)piperidin-4-yl]amino} phenyl)sulfonyl]-2-phenoxybenzamide EXAMPLE 158A 3-nitro-4-(l-(quinolin-8-ylsulfonyl)piperidin-4-ylamino)benzenesulfonamide The title compound was prepared by substituting quinoline-8-sulfonyl chloride for benzenesulfonyl chloride in EXAMPLE 157C. EXAMPLE 158B 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-[(3-nitro-4-{ [ 1 -(quinolin-8-ylsulfonyl)piperidin-4-yl]amino}phenyl)sulfonyl]-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 158A for EXAMPLE IF and EXAMPLE IE for EXAMPLE 27G in EXAMPLE 27H. 'H NMR -372- (400MHz, dimethylsulfoxide-dfi) 5 11.66 (br s, IH), 9.10 (dd, IH), 8.55 (s, IH), 8.41 (m, 2H), 8.32 (d, IH), 8.20 (d, IH), 7.78 (dd, 2H), 7.72 (d, 2H), 7.48 (m, 4H), 7.39 (dd, 2H), 7.33 (m, IH), 7.17 (m, 3H), 6.95 (dd, IH), 6.76 (m, 3H), 6.42 (s, IH), 4.35 (m, IH), 3.90 (d, 2H), 3.77 (m, 2H), 3.34 (m, 6H), 2.99 (m, 4H), 1.97 (m, 2H), 1.65 (m, 2H). EXAMPLE 159 4- {4-[(4'-chloro-1, r-biphenyl-2-yl)methyl]piperazin-l -yl} -2-phenoxy-N-( {4- {[ 1 - (phenylsulfonyl)piperidin-4-yl]amino} -3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzaniide EXAMPLE 159A (2-fluorophenyl)(trifluoromethyl)sulfane Methyl viologen hydrochloride (1.17 g) in N,N-dimethylformamide (80 itiL) at 25°C was saturated with trifluoromethyl iodide, treated with 2-fluorobenzenethiol (9.7 mL) and triethylamine (20 mL), stirred for 24 hours, diluted with water (240 mL) and extracted with diethyl ether. The extract was washed with IM NaOH, saturated ammonium chloride and brine and concentrated. EXAMPLE 159B l-fluoro-2-(trifluoromethylsulfonyl)benzene EXAMPLE 159A (17.346 g) in 1:1:2 carbon tetrachloride:acetonitrile:water (800 mL) at 25°C was treated with sodium periodate (56.8 g) and ruthenium(III) chloride hydrate (183 mg), stirred for 18 hours, diluted with dichloromethane (100 mL) and filtered through diatomaceous earth (Celite®). The filtrate was washed with saturated sodium bicarbonate and extracted with dichloromethane. The extract was washed with brine and dried (MgS04), filtered and concentrated. The concentrate was filtered through silica gel. EXAMPLE 159C 4-fluoro-3-(trifluoromethylsulfonyl)benzenesulfonamide EXAMPLE 159B (37.3 g) in chlorosulfonic acid (32.8 mL) at 120°C was stirred for 18 hours, cooled to 25°C and pipetted onto crushed ice. The mixture was extracted with ethyl acetate, and the extract was washed with water and brine and dried (MgS04), filtered and concentrated. The crude product was taken up in isopropanol (706 mL) at -78°C, treated with -373- ammonium hydroxide (98 mL) over 1 hour, stirred for 1 hour, quenched with 6M HCl (353 mL), warmed to 25°C and concentrated. The concentrate was mixed with water and extracted with ethyl acetate. The extract was dried over MgS04, filtered and concentrated. The concentrate was recrystallized from ethyl acetate/hexane. EXAMPLE 159D tert-butyl 4-(4-sulfamoyl-2-(trifluoromethylsulfonyl)phenylaniino)piperidine-1 -carboxylate The title compound was prepared by substituting l-Boc-4-aminopiperidine for (tetrahydropyran-4-yl)methylamine and EXAMPLE 159C for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE IF. EXAMPLE 159E 4-(piperidin-4-ylamino)-3-(trifluoromethylsulfonyl)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 159D for EXAMPLE lA in EXAMPLE IB. EXAMPLE 159F 4-(l-(phenylsulfonyl)piperidin-4-ylamino)-3-(trifluoromethylsulfonyl)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 159E for EXAMPLE 157B in EXAMPLE 157C. EXAMPLE 159G 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-phenoxy-N-( {4- {[ 1 -(phenylsulfonyl)piperidin-4-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 159F for EXAMPLE IF and EXAMPLE IE for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-de) 511.72 (br s, IH), 9.70 (br s, IH), 8.07 (s, IH), 7.67-7.82 (m, 7H), 7.52 (d, 2H), 7.47 (d, 2H), 7.36 (m, 3H), 7.24 (dd, 2H), 7.14 (d, IH), 7.01 (m, IH), 6.78 (d, 2H), 6.72 (m, 2H), 6.44 (d, IH), 4.27 (m, IH), 3.73 (m, 4H), 3.46 (m, 4H), 3.17 (m, 2H), 3.03 (m, 2H), 2.87 (m, 2H), 1.97 (m, 2H), 1.64 (m, 2H). -374- EXAMPLE 160 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-phenoxy-N-( {4- {[ 1 -(quinolin-8-ylsulfonyl)piperidin-4-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide EXAMPLE 160A 4-(l-(quinolin-8-ylsulfonyl)piperidin-4-ylamino)-3-(trifluoromethylsulfonyl)benzenesulfonamide The title compound was prepared by substituting EXAMPLE I59E for EXAMPLE 157B and quinoline-8-sulfonyl chloride for benzenesulfonyl chloride in EXAMPLE 157C. EXAMPLE 160B 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-phenoxy-N-( {4- {[ 1 -(quinolin-8-ylsulfonyl)piperidin-4-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 160A for EXAMPLE IF and EXAMPLE IE for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-de) 8 11.74 (br s, IH), 9.50 (br s, IH), 9.08 (dd, IH), 8.55 (s, IH), 8.39 (d, IH), 8.33 (d, IH), 8.06 (s, IH). 7.82 (dd, 2H), 7.70 (m, IH), 7.50 (m, 3H), 7.40 (dd, 2H), 7.33 (m, IH), 7.21 (m, 2H), 7.08 (m, 2H), 6.99 (dd, IH), 6.95 (s, IH), 6.78 (d, IH), 6.73 (m, 2H), 6.42 (s, IH), 4.35 (m, IH), 3.75 (m, 4H), 3.34 (m, 6H), 3.05 (m, 4H), 1.93 (m, 2H), 1.55 (m, 2H.. EXAMPLE 161 4-{ 4-[(4'-chloro-1, r-biphenyl-2-yl)methyl]piperazin- 1-yl} -N-[(4- {[(1 S)-3-(dimethylamino)- l-thien-2-ylpropyl]amino}-3-nitrophenyl)sulfonyl]-2-phenoxybenzamide EXAMPLE 161A (S)-3-(benzyloxycarbonylamino)-3-(thiophen-2-yl)propanoic acid (S)-3-amino-3-(thiophen-2-yl)propanoic acid (0.894 g) and benzyloxycarbonyl chloride 0.980 g) were stirred in 2M NaOH (8 mL) and dioxane (26 mL) at 0°C for 24 hours. The reaction mixture was acidified with concentrated aqueous HCl, extracted twice with ethyl acetate, and the extracts were dried over MgS04, filtered, concentrated, and chromatographed on silica gel with 50% ethyl acetate/hexanes. -375- EXAMPLE 161B (S)-benzyl 3-(dimethylanuno)-3-oxo- l-(thiophen-2-yl)propylcarbamate The title compound was prepared by substituting EXAMPLE 161A for EXAMPLE IE and dimethylamine for EXAMPLE IF in EXAMPLE IG. EXAMPLE 161C (S)-N' ,N'-dimethyI-3-(thiophen-2-yl)propane-1,3-diamine A solution of EXAMPLE 161B (400 mg) and borane in tetrahydrofuran (IM, 2.5 mL) in tetrahydrofuran (6 mL) was stirred for 24 hours. The reaction was quenched with methanol, taken up in pH 7 buffer solution, and extracted three times with ethyl acetate. The combined extracts were washed with brine and concentrated. The crude product was taken up in HBr in acetic acid (1.1 mL) and stirred for 2 hours. The reaction was poured into CH2CI2 (50 mL) and washed with IM NaOH solution. The organic layer was dried over Na2S04, and concentrated. EXAMPLE 161D (S)-4-(3-(dimethylamino)-l-(thiophen-2-yl)propylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 161C for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 161E 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-[(4- {[(1 S)-3-(dimethylamino)-l-thien-2-ylpropyl]amino}-3-nitrophenyl)sulfonyl]-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 161D for EXAMPLE IF and EXAMPLE IE for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-d6/D20) 8 11.72 (br s, IH), 9.51 (br s, IH), 8.60 (d, IH), 8.48 (s, IH), 7.75 (d, IH), 7.70 (m, IH), 7.51 (m, 4H), 7.38 (d, 2H), 7.32 (m, IH), 7.25 (d, IH), 7.16 (m, 3H), 7.06 (d, IH), 6.92 (m, IH), 6.75 (d, 3H), 6.44 (d, IH), 5.31 (m, IH), 4.30 (m, IH), 3.54 (m, 8H), 3.20 (m, 2H), 3.07 (m, 2H), 2.80 (s, 6H), 2.35 (m, 2H). -376- EXAMPLE 162 4- {4- [(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-( {3 -nitro-4-[(thien-2- ylmethyl)amino]phenyl} sulfonyl)-2-phenoxybenzamide EXAMPLE 162A 3-nitro-4-(thiophen-2-ylmethylamino)benzenesulfonamide The title compound was prepared by substituting 2-thiophenemethylamine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 162B 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-( {3-nitro-4-[(thien-2-ylmethyl)amino]phenyl} sulfonyl)-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 162B for EXAMPLE IF and EXAMPLE IE for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-dfi/DzO) 5 11.67 (br s, IH), 9.55 (brs, IH), 9.11 (t, IH), 8.47 (s, IH), 7.70 (m, 2H), 7.51 (m, 4H), 7.38 (d, 2H), 7.33 (m, IH), 7.15 (m, 4H), 7.02 (d, IH), 6.94 (m, IH), 6.74 (d, 3H), 6.44 (d, IH), 4.87 (m, 2H), 4.37 (m, IH), 3.34 (m, 8H), 3.03 (m, 2H). EXAMPLE 163 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -2-phenoxy-N-( {4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl)benzamide EXAMPLE 163A 4-((tetrahydro-2H-pyran-4-yl)methylamino)-3-(trifluon)methylsulfonyl)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 159C for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE IF. EXAMPLE 163B 4- {4- [(4'-chloro-1,1 '-biphenyl-2-y l)methyl]piperazin-1 -yl} -2-phenoxy-N-( {4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]-3-[(trifIuoromethyl)sulfonyl]phenyl}sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 163 A for EXAMPLE IF and EXAMPLE IE for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-de) 6 11.71 (br s, IH), 8.10 (d, IH), 7.86 (d, IH), 7.10 (m, IH), -377- 7.50 (m, 4H), 7.37 (m, 2H), 7.27 (m, 3H), 7.08 (m, IH), 7.03 (dd, IH), 6.95 (d, IH), 6.82 (d, IH), 6.76 (d, IH), 6.43 (s, IH), 4.35 (m, IH), 3.84 (dd, 2H), 3.35 (m, 8H), 3.22 (m, 2H), 3.03 (m, 2H), 2.86 (m, 2H), 1.86 (m, IH), 1.55 (m, 2H), 1.26 (m, 2H). EXAMPLE 164 4- {4-[(4'-chloro-1,1 '-biphenyI-2-yl)methyl]piperazin-1 -yl} -N-[(3-nitro-4- {[2-( 1H-1,2,3- triazol-l-yl)ethyl]amino}phenyl)sulfonyl]-2-phenoxybenzamide EXAMPLE 164A 4-(2-hydroxyethylamino)-3-nitn)benzenesulfonamide The title compound was prepared by substituting 2-aminoethanol for (tetrahydiopyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 164B 4-(2-(tert-butyldimethylsilyloxy)ethylamino)-3-nitrobenzenesulfonamide EXAMPLE 164A (131 mg), t-butyldimethylsilyl chloride (75 mg) and imidazole (68 mg) were stirred in CH2CI2 (17 mL) for 24 hours. The reaction mixture was chromatographed on silica gel with 10% ethyl acetate/hexanes. EXAMPLE 164C N-(4-(2-(tert-butyldimethylsilyloxy)ethylamino)-3-nitrophenyIsulfonyl)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1 -yl)-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 164B for EXAMPLE IF in EXAMPLE IG. EXAMPLE 164D 2-(4-(N-(4-(4-((4'-chlorobiphenyl-2-yl)methyl)pipera2in-l-yl)-2-phenoxybenzoyl)sulfamoyl)-2-mtrophenylaraino)ethyl4-methylbenzenesulfonate EXAMPLE 164C (150 mg) and concentrated aqueous HCl (0.020 mL) were stirred in tetrahydrofuran (1 mL) and methanol (1 mL) for 1 hours. The mixture was filtered through a short silica gel column. The product was taken up in CH2CI2 (1 mL) and to it was added triethylamine (0.074 mL) and p-toluenesulfonic anhydride (58 mg) and the reaction was stirred for 24 hours. The reaction mixture was chromatographed on silica gel with 10% ethyl acetate/hexanes. -378- EXAMPLE 164E 4-{4-[(4'-chloro-l,l'-biphenyl-2-yl)methyl]piperazm-l-yl)-N-[(3-nitro-4-{[2-(lH-l,2,3-triazol-l-yl)ethyl]amino}phenyl)sulfonyl]-2-phenoxybenzamide EXAMPLE 164D (30 mg), 1,2,3-triazole (7 mg) and cesium carbonate (55 mg) were stirred in N.N-dimethylformamide (0.2 mL) for 24 hours. The reaction was quenched with ammonium chloride, and was extracted twice with ethyl acetate. The combined organic layers were dried over MgS04, filtered, and concentrated. The product was purified by preparative HPLC using a C18 column, 250 x 50 mm, 10|i, and eluting with a gradient of 20-100% CH3CN vs. 0.1% trifluoroacetic aicd in water, giving the product as a trifluoroacetate salt. 'H NMR (500MHZ, dimethylsulfoxide-de) 5 11.75 (br s, IH), 9.62 (br s, IH), 8.66 (dd, IH), 8.44 (d, IH), 8.18 (s, IH), 7.72 (m, 3H), 7.51 (m, 5H), 7.36 (m, 3H), 7.19 (dd, 2H), 7.06 (m, IH), 6.93 (dd, IH), 6.75 (d, 2H), 6.45 (s, IH), 4.70 (t, 2H), 3.93 (dt, 2H), 3.61 (m, 4H), 3.22 (m, 2H), 3.01 (m, 2H), 2.84 (m, 2H). EXAMPLE 165 4. {4-[(4'-chloro-1, l'-biphenyl-2-yl)methyl]piperazin-1 -yl} -N-[(3-nitro-4- {[2-(2H-1,2,3-triazol-2-yl)ethyl]amino}phenyl)sulfonyl]-2-phenoxybenzamide The title compound was prepared in the same reaction as that for EXAMPLE 164E. 'H NMR (500MHz, dimethylsulfoxide-de) 8 11.75 (br s, IH), 9.70 (br s, IH), 8.67 (dd, IH), 8.42 (s, IH), 7.80 (s, IH), 7.75 (m, IH), 7.68 (d, 2H), 7.51 (m, 5H), 7.37 (m, 3H), 7.18 (dd, 2H), 6.97 (m. IH), 6.92 (dd, IH), 6.75 (d, 2H), 6.46 (s, IH), 4.76 (t, 2H), 3.93 (dt, 2H), 3.67 (m, 4H), 3.22 (m, 2H), 3.03 (m, 2H), 2.84 (m, 2H). EXAMPLE 166 4-{4.[(4'-chloro-l,l'-biphenyl-2-yl)raethyl]piperazin-l-yl}-N-[(4-{[3-(dimethylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(2-naphthyloxy)benzamide The title compound was prepared by substituting EXAMPLE 35B for EXAMPLE 27G and EXAMPLE 154A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-dfi) 8 11.83 (br s, IH), 9.46 (br s, IH), 8.53 (t, IH), 8.40 (s, IH), 7.81 (d, 2H), 7.71 (m, IH), 7.63 (m, 2H), 7.51 (m, 5H), 7.37 (m, 4H), 7.17 (d, IH), 7.03 (s, IH), 6.82 (d, 2H), 6.57 (d, IH), 4.27 (m, IH), 3.62 (m, 6H), 3.39 (m, 2H), 3.09 (m, 2H), 2.80-3.25 (m, 6H), 2.79 (s, 6H), 1.91 (m, 2H). -379- EXAMPLE 167 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin- 1-yl} -N-[(3-nitro-4- {[2-(2-oxopyridin-l(2H)-yl)ethyllamino}phenyl)sulfonyl]-2-phenoxybenzamide The title compound was prepared by substituting pyridin-2-ol for 1,2,3-triazole in EXAMPLE 164E. 'H NMR (400MHZ, dimethylsulfoxide-ds) 5 11.70 (br s, IH), 9.65 (br s, IH), 8.75 (t, IH), 8.44 (d, IH), 7.72 (d, 2H), 7.64 (d. IH), 7.51 (m, 5H), 7.37 (m, 3H), 7.20 (m, 3H), 6.95 (t, IH), 6.77 (d, 3H), 6.46 (s, IH), 6.41 (d, IH), 6.21 (t, IH), 4.31 (m, IH), 4.17 (t, 2H), 3.74 (dt, 2H), 3.60 (m, 6H), 3.20 (m, 2H), 3.03 (m, 2H), 2.87 (m, 2H). EXAMPLE 168 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin- 1-yl} -N-[(3-nitro-4- {[2-(pyridin-2-yloxy)ethyl]amino}phenyl)sulfonyl]-2-phenoxybenzamide The title compound was prepared by substituting pyridin-2-ol for 1,2,3-triazole in EXAMPLE 164E. ^H NMR (400MHz, dimethylsulfoxide-de) 5 11.71 (br s, IH), 9.65 (br s, IH), 8.84 (t, IH), 8.44 (d, IH), 8.19 (d, IH), 7.74 (m, 3H), 7.51 (m, 5H), 7.37 (m, 3H), 7.20 (m, 3H), 7.00 (dd, IH), 6.92 (t, IH), 6.83 (d, IH), 6.76 (m, 2H), 6.45 (d, IH), 4.56 (t, 2H), 4.31 (m, IH), 3.81 (dt, 2H), 3.71 (m, 6H), 3.23 (m, 2H), 3.04 (m, 2H), 2.89 (m, 2H). EXAMPLE 169 4- {4-[(4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -N-( {3-nitro-4- [(2-pyridin-4- ylethyl)amino]phenyl} sulfonyl)-2-phenoxybenzamide EXAMPLE 169A 3-nitro-4-(2-(pyridin-4-yl)ethylamino)benzenesulfonamide The title compound was prepared by substituting 2-(pyiidin-4-yl)ethanamine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IE. EXAMPLE 169B 4-{4-[(4'-chloro-1, r-biphenyl-2-yl)methyl]piperazin-1-yl)-N-( {3-nitio-4-[(2-pyridin-4-ylethyl)ainino]phenyl}sulfonyl)-2-phenoxybenzamide The title compound was prepared by substituting EXAMPLE 169A for EXAMPLE IF and EXAMPLE IE for EXAMPLE 27G in EXAMPLE 27H. 'H NMR -380- (400MHz, dimethylsulfoxide-dfi) 8 11.71 (br s, IH), 9.70 (br s, IH), 8.69 (d, IH), 8.61 (t, IH), 8.46 (s, IH), 7.79 (dd, IH), 7.72 (d, 3H), 7.51 (m, 5H), 7.37 (d, 2H), 7.32 (d, IH), 7.21 (m, 3H), 6.95 (t, IH), 6.78 (d, 2H), 6.75 (d, IH), 6.44 (d, IH), 4.23 (m, IH), 3.76 (dt, 2H), 3.63 (m, 4H), 3.13 (t, 2H), 2.76-3.24 (m, 6H). EXAMPLE 170 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N-( {4-{[3-(dimethylainino)piopyl]amino}-3-[(trifluoromethyl)sulfonyl]phenyI}sulfonyl)-2-(lH- indol-5-yloxy)benzaniide EXAMPLE 170A 4-(3-(dimethylamino)piopylamino)-3-(trifluoromethylsulfonyl)benzenesulfonamide The title compound was prepared by substituting N,N-dimethyl-l,3-propanediamine for (tetiahydropyran-4-yl)methylamine and EXAMPLE 159C for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE IF. EXAMPLE 170B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N-( {4-{[3-(dimethylamino)propyI]amino} -3- [(trifluoromethyl)sulfonyI]phenyl} sulfonyl)-2-( IH- indol-5-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 170A for EXAMPLE IF and EXAMPLE 26C for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-de) 6 11.42 (br s, IH), 11.17 (s, IH), 9.37 (br s, IH), 8.22 (d, IH), 7.98 (d, IH), 7.52 (d, IH), 7.35-7.45 (m, 4H), 7.19 (d, IH), 7.08 (m, 3H), 6.85 (dd, IH), 6.67 (dd, IH), 6.40 (d, IH), 6.19 (d, IH), 3.55 (m, 8H), 3.04 (m, 4H), 2.77 (s, 6H), 2.72 (m, 2H), 2.17 (m, 2H), 2.00 (m, 2H), 1.88 (m, 2H), 1.44 (m, 2H), 0.93 (s, 6H). EXAMPLE 171 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-N- {[4- {[3-(dimethylamino)pK)pyl]aniino}-3-(trifluoromethyl)phenyl]sulfonyl)-2-(lH-indol-5- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 26C for EXAMPLE 27G and EXAMPLE 92B for EXAMPLE IF in EXAMPLE 27H. 'H NMR -381- (400MHz, dimethylsulfoxide-dfi) 8 11.19 (br s, IH), 9.33 (br s, IH), 7.94 (d, IH), 7.85 (d, IH), 7.54 (d, IH), 7.35-7.45 (m, 4H), 7.20 (d, IH), 7.07 (d, 2H), 6.88 (dd, 2H), 6.67 (dd, IH), 6.58 (m,-lH), 6.41 (s, IH), 6.18 (s, IH), 3.57 (m, 6H), 3.33 (m, 2H), 3.09 (m, 2H), 3.04 (m, 2H), 2.77 (s, 6H), 2.74 (m, 2H), 2.17 (m, 2H), 2.00 (m, 2H), 1.87 (m, 2H), 1.44 (m, 2H), 0.93 (s, 6H). EXAMPLE 172 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N- [(3 - cyano-4-{[3-(dimethylamino)propyl]amino}phenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 26C for EXAMPLE 27G and EXAMPLE 90B for EXAMPLE IF in EXAMPLE 27H. ^H NMR (400MHz, dimediylsulfoxide-ds) 811.19 (br s, IH), 9.38 (br s, IH), 7.98 (s, IH), 7.81 (d, IH), 7.55 (d, IH), 7.35-7.45 (m, 4H), 7.20 (s, IH), 7.16 (t, IH), 7.07 (d, 2H), 6.86 (dd, 2H), 6.68 (dd, IH), 6.41 (s, IH), 6.18 (s, IH), 3.57 (m, 6H), 3.31 (m, 2H), 3.09 (m, 2H), 3.04 (m, 2H), 2.77 (s, 6H), 2.74 (m, 2H), 2.17 (m, 2H), 2.00 (m, 2H), 1.87 (m, 2H), 1.44 (m, 2H), 0.93 (s, 6H). EXAMPLE 173 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-2-(l H- indol-5-yloxy)-N-({ 3-nitro-4-[( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide EXAMPLE 173A tert-butyl l-(tetrahydro-2H-pyran-4-yl)piperidin-4-ylcarbamate A mixture of tert-butyl piperidin-4-ylcarbamate (45 g) and dihydro-2H-pyran-4(3H)-one (24.74 g) in dichloromethane (KXX) mL) was treated with sodium triacetoxyborohydride (61.9 g), stirred at room temperature for 16 hours, washed with IM sodium hydroxide and dried with anhydrous sodium sulfate, filtered and concentrated. The concentrate was flash column chromatographed on silica gel with 10-20% methanol/dichloromethane. -382- EXAMPLE 173B 1 -(tetrahydro-2H-pyran-4-yl)piperidin-4-amine A solution of EXAMPLE 173A (52.57 g) in dichloromethane (900 mL) was treated with 4M HCl (462 mL), mixed vigorously at room temperature for 16 hours and concentrated. EXAMPLE 173C 3-nitro-4-( 1 -(tetrahydro-2H-pyran-4-yl)piperidin-4-ylamino)benzenesulfonamide A mixture of EXAMPLE 173B (22.12 g), water (43 mL), and triethylamine (43.6 mL) in 1,4-dioxane (300 mL) was stirred at room temperature until EXAMPLE 173B completely dissolved. The solution was then treated with 4-chloro-3-nitrobenzenesulfonamide, heated at 90°C for 16 hours, cooled and concentrated. 10% methanol in dichloromethane was added, and the solution was stirred vigorously at room temperature until a fine suspension existed and the mixture was filtered. EXAMPLE 173D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide A mixture of EXAMPLE 26C (3.95 g), EXAMPLE 173C (2.66 g), l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (2.66 g), and 4-dimethylaminopyridine (0.846 g) in dichloromethane (70 mL) and acetonitrile (20 mL) was stirred at 35°C for 24 hours, cooled and chromatographed on silica gel with 0-10% methanol in ethyl acetate, then 10% methanol in 1:1 ethyl acetate/dichloromethane. The combined fractions were concentrated, dissolved in of 5% methanol/ethyl acetate (1.5L), and the solution was washed with saturated NaH2P04 solution and brine and dried over Na2S04, filtered, concentrated to 300 mL, cooled, and filtered. The remaining solution was concentrated partway and filtered again to isolate more product. 'H NMR (300MHZ, dimethysulfoxide-de) 811.17 (brs, IH), 10.70 (br s, IH), 8.60 (d, IH), 8.20 (br d, IH), 7.88 (dd, IH), 7.50 (d, IH), 7.39 (m, 2H), 7.33 (d, 2H), 7.16 (m, 2H), 7.03 (d, 2H), 6.85 (dd, IH), 6.65 (dd, IH), 6.39 (s, IH), 6.14 (s, IH), 3.97 (m, 4H), 3.44 (m, 4H), 3.04 (m, 6H), 2.75 (m, 2H), 2.14 (m, 8H), 1.95 (m, 6H), 1.66 (m, 2H), 1.38 (t, 2H), 0.92 (s, 6H). -383- EXAMPLE 174 4-(4- {[2-(4-chlorc)phenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin-1 -yl)-2-( IH-indol-5-yloxy)-N-( {4-[(4-methylpiperazin- l-yl)amino]-3-nitrophenyl) sulfonyl)benzamide EXAMPLE 174A 4-(4-niethylpiperazin-1 -ylamino)-3-nitrobenzenesulfonamide A mixture of 4-chloro-3-nitrobenzenesulfonamide (1 g), 4-methylpiperazin-l-amine dihydrochloride (1 g) and N\N',N^JV^-tetraniethylethane-l^-diamine (3 mL) in dioxane (10 mL) was refluxed for 12 hours, cooled to ambient temperature and filtered. The filtrate was added to a silica gel column (Analogix, SF65-200g) and purified by eluting with 1-5% methanol/dichloromethane). EXAMPLE 174B 4-(4- {[2-(4-chloK)phenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl}sulfonyl)benzamide A mixture of EXAMPLE 26C (0.108 g), EXAMPLE 174A (64 mg), l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (0.08 g) and 4-dimethylaminopyridine (0.08 g) in dichloromethane (3 mL) was stirred at ambient temperature overnight and concentrated. The concentrate was added to a preparative HPLC column and eluted with 20-1(X)% acetonitrile/water with 0.1% trifluoroacetic aicd. The trifluoroacetic aicd salt solution was neutralized with NaHCOj and extracted with dichloromethane. This solution was washed with saturated NaHCOs, dried over Na2S04, and filtered and concentrated. 'H NMR (500 MHz, dimethysulfoxide-de) 8 11.14 (s, IH), 9.17 (s, IH), 8.52 (s, IH), 7.83 (m, IH), 7.53 (m, 2H), 7.36 (m, 4H), 7.12 (s, IH), 7.03 (d, 2H), 6.83 (m, IH), 6.62 (m, IH), 6.38 (s, IH), 6.13 (m, IH), 5.76 (s, 2H), 2.85 (m, 12H), 2.35 (m, 4H), 2.14 (m, 6H), 1.94 (m, 2H), 1.38 (m, 2H), 0.92 (s, 6H). EXAMPLE 175 4-{4-[l-(4'-chloro-l,l'-biphenyl-2-yl)ethyl]piperazin-l-yl}-2-(lH-indol-4-yloxy)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide EXAMPLE 175A l-(4'-chlorobiphenyl-2-yl)ethanone -384- A mixture of l-(2-bromophenyl)ethanone (3.1 g, 15.57 nimol)4-chlorophenylboronic acid (2.92 g), (Ph3P)2PdCl2 (bis(triphenylphosphine)palladium(II) dichloride) (1.202 g) and Na2C03 (3.30 g) in dimethoxyethane-ethanol-water (7:2:3, 50 mL) was heated at 100°C for 3 hours and concentrated. The concentrate was suspended in dichloromethane (30 mL) and the insoluble material was removed by filtration. The filtrate was loaded onto a silica gel column, eluted with 0% - 50% dichloromethane in hexane to provide the title compound. EXAMPLE 175B tert-butyl4-(l-(4'-chlorobiphenyl-2-yl)ethyl)piperazine-l-carboxylate EXAMPLE 175A (1.9 g) was dissolved in dichloromethane (3 mL) and titanium(IV) chloride (9.06 mL, 9.06 mmol) was added. The solution was cooled to 0°C and tert-butyl piperazine-1-carboxylate (3.07 g) was added. The resulting mixture was stirred at ambient temperature for 3 hours and NaCNBHs (0.828 g) in methanol (5 mL) was added. The resulting mixture was stirred at room temperature overnight and neutralized by aqueous NaOH, and then concentrated. To the concentrate was added ethyl acetate and the insoluble material was filtered off. The organic layer was washed with water and concentrated. The concentrate was dissolved in a mixture of methanol-trifluoroacetic aicd-dimethysulfoxide, loaded onto a reverse phase CIS column, and eluted with 0 - 80% acetonitrile in 0.1% trifluoroacetic aicd water over 70 minutes. EXAMPLE 175C 1 -(1 -(4'-chlorobiphenyl-2-yl)ethyl)piperazine To a solution of EXAMPLE 175B (650mg) in dichloromethane (6 mL) was added trifluoroacetic aicd (6 mL) at 0°C. The reaction mixture was stirred at 0°C for 50 minutes and concentrated. The concentrate was dissolved in dichloromethane, washed with aqueous NaHCOs and the organic layer was dried over Na2S04, and concentrated. EXAMPLE 175D ethyl 2-(lH-indol-4-yloxy)-4-(4-(l-(4'-chlorobiphenyl-2-yl)ethyl)piperazin-l-yl)benzoate EXAMPLE 175C (193mg) and ethyl 2-(lH-indol-4-yloxy)-4-fluorobenzoate (211 mg) in dimethysulfoxide (15 mL) was treated with potassium hydrogen phosphate (168 mg) at 135''C overnight and cooled. The reaction mixture was dUuted with dichloromethane and washed with water. The organic layer was concentrated. The concentrate was dissolved in -385- dichloromethane, loaded onta a silica gel column, eluted with 0%-10% 10 M ammonia methanol in dichloromethane. EXAMPLE 175E 2-(lH-indol-4-yloxy)-4-(4-(l-(4'-chlorobiphenyl-2-yl)ethyl)piperazin-l-yl)benzoicacid EXAMPLE 175D (200mg) in tetrahydrofiiran (10 mL) and methanol (10 mL) was treated with 10% NaOH (3 mL) at 50°C overnight and neutralized with HCl. The mixture was concentrated and the concentrate was taken up in water and extracted with dichloromethane. The organic layer was dried over Na2S04 and concentrated. EXAMPLE 175F 4-(4-(l-(4'-chloro-l,r-biphenyl-2-yl)ethyl)piperazin-l-yl)-2-(lH-indol-4-yloxy)-A^-((3-nitro-4-((tetrahydio-2//-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide To a mixture of EXAMPLE 175E (66 mg), 3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)benzenesulfonamide (75 mg) and 4-dimethylaminopyridine (58.4 mg) in dichloromethane (5 mL) was added l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (45.8 mg). The mixture was stirred at ambient temperature overnight and concentrated. The concentrate was purified by RP HPLC (10-70% acetonitrile in 0.1% trifluoroacetic aicd water / 70 minutes). The desired fractions were concentrated to remove acetonitrile and the concentrate was diluted with dichloromethane and neutralized with aqueous NaHC03. The dichloromethane layer was dried over Na2S04 and concentrated to provide the title compound. 'H NMR (500 MHz, dimethysulfoxide-d^) 5 ppm 11.31 (1 H, s), 11.25 (1 H, s), 8.62 (1 H, t), 8.50 (1 H, d), 7.68 (1 H, dd), 7.53 (2 H, d), 7.46 (2 H, d), 7.37 (1 H, t), 7.24 - 7.31 (4 H, m), 7.17 (1 H, d), 7.12 (1 H, dd), 7.07 (1 H, d), 6.96 (1 H, t), 6.69 (1 H, dd), 6.42 (1 H, d), 6.26 (2 H, s), 3.85 (2 H, dd), 3.21 - 3.33 (5 H, m), 3.01 (4 H, s), 2.29 -2.39 (2 H, m), 2.15 - 2.22 (2 H, m), 1.83 - 1.94 (1 H, m), 1.57 - 1.68 (2 H, m), 1.22 - 1.31 (2 H,m), l.I7(3H,d). EXAMPLE 176 N-[(4- {[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino} -3-nitrophenyl)sulfonyl]-4-(4- {[2- (4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-4- yloxy)benzamide -386- EXAMPLE 176A 4-((4-aminotetrahydro-2H-pyran-4-yl)methylamino)-3-nitrobenzenesulfonaniide A mixture of 4-chloro-3-nitrobenzenesulfonamide, 4-(arainomethyl)tetrahydro-2H- pyran-4-amine bis-hydrochloric acid salt and triethylamine in dioxane (10 mL) was heated at 110 °C overnight. After cooling, the reaction mixture was diluted with water (10 mL), and the solid was filtered to give the title compound. EXAMPLE 176B Ar-((4-(((4-aminotetrahydro-2//-pyran-4-yl)methyl)amino)-3-mtrophenyl)sulfonyl)-4-(4-((2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl)methyl)piperazin-1 -yl)-2-( lff-indol-4- yloxy)benzamide This EXAMPLE was prepared by substituting EXAMPLE 55B for EXAMPLE IF and EXAMPLE 176A (4-aminotetrahydro-2H-pyran-4-yl)methylamino)-3-nitrobenzenesulfonamide) for EXAMPLE IG in EXAMPLE IH. 'H NMR (500MHz, dimethysulfoxide-dfi) 5 11.15 (s, IH), 8.51 (s, IH), 8.45 (d, J = 2.14 Hz, IH), 7.70 (dd, J = 9.0, 1.98 Hz, IH), 7.59 (d, J = 8.85 Hz, IH), 7.34 (d, J = 8.24 Hz, 2H), 7.22 (t, J = 2.59 Hz, IH), 7.11-7.12 (m, 2H), 7.04 (d, J = 8.54 Hz, 2H), 6.93 (t, J = 7.78 Hz, IH), 6.62 (dd, J = 9.0,1.98 Hz, IH), 6.34 (d, J = 7.63 Hz, IH), 6.20-6.23 (m, 2H), 3.55-3.70 (m, 6H), 2.96 (m, 3H), 2.71 (s, 2H), 2.16 (m, 6H), 1.95 (m, 2H), 1.70-1.74 (m, 2H), 1.55-1.59 (m, 2H), 1.37-1.39 (m, 2H), 0.92 (s, 6H). EXAMPLE 177 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide A mixture of EXAMPLE 26C (2.85 g, 10 mmol), EXAMPLE IF (1.577 g, 5 mmol), l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (1.917 g, 10 mmol), 4-(dimethylamino)pyridine (1.222 g, 10 mmol), and triethyl amine (2.8 mL, 20 mmol) was treated with CH2CI2 (20 mL) and N,N-dimethylfonnamide (2 mL). The reaction mixture was stirred over night. The solvent was removed, and the residue was partitioned between water and ethyl acetate. The organic layers were washed with 1 % HCl twice, then with sat NaHC03, brine, dried, filtered, and concentrated The residue was purified by reverse phase HPLC on a C18 column using a gradient of 40-60% acetonitrile/0.1% TFA in water to give -387- the title compound as the trifluoroacetate salt. The TFA salt was dissolved in dichloromethane (6 ml) and washed with 50% aqueous NaHCOs. The organic layer was dried over anhydrous Na2S04 and concentrated to give the title compound. 'H NMR (300MHz, dimethylsulfoxide-d6) 6 11.18 (s, 2H), 8.59-8.64 (m, 2H), 7.80 (dd, IH), 7.52 (d, IH), 7.39-7.42 (m, 2H), 7.33 (d, 2H), 7.16 (d, IH), 7.10 (d,lH), 7.03 (d, 2H), 6.8 (dd, IH), 6.65 (dd, IH), 6.40 )s, IH), 6.14 (d, IH), 3.85 (dd, 2H), 3.24-3.32 (m, 4H), 3.03 (s, 3H), 2.73 (s, 2H), 2.12-2.17 (m, 5H), 1.68-1.94 (m, 3H), 1.61 (d, 2H), 1.37 (t, 2H), 1.24-1.27 (m, 2H), 0.92 (s,6H). EXAMPLE 178 Trans-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2- (lH-indol-5-yloxy)-N-( {4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide EXAMPLE 178A Trans-4-(4-morpholinocyclohexylamino)-3-nitrobenzenesulfonamide This EXAMPLE was prepared by substituting 4-amino-N-morpholinylpiperidine for l-(tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 178B Trans-4-(4- {[2-(4-chlorDphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-(lH-indol-5-yloxy)-N-( {4-[(4-moipholin-4-ylcyclohexy])amino]-3-nitrophenyl} suIfonyl)benzamide The title compound was prepared as in EXAMPLE 177 by replacing EXAMPLE IF with EXAMPLE 178A. 'H NMR (500 MHz, pyridine-rfj) 5 12.29 (s, IH), 9.29 (d, 7=2.1 Hz, IH), 8.37 (d, y=7.6 Hz, IH), 8.32 (dd, 7=9.3, 2.3 Hz, IH), 8.18 (d, 7=8.8 Hz, IH), 7.52 - 7.57 (m, 2H), 7.39 - 7.47 (m, 3H), 7.10 (dd, 7=8.7, 2.3 Hz, IH), 7.05 - 7.08 (m, 2H), 6.90 (d, 7=9.5 Hz, IH), 6.74 (dd, 7=9.0, 2.3 Hz, IH), 6.59 - 6.63 (m, IH), 6.55 (d, 7=2.4 Hz, IH), 3.72 -3.78 (m, 4H), 3.33 - 3.43 (m, IH), 2.99 - 3.09 (m, 4H), 2.76 (s, 2H), 2.46 - 2.54 (m, 4H), 2.16 - 2.29 (m, 3H), 2.09 - 2.14 (m, 4H), 2.05 (d, 7=11.9 Hz, 2H), 1.97 (d, 7=1.8 Hz, 2H), 1.87 (d, 7=11.6 Hz, 2H), 1.19 - 1.42 (m, 6H), 0.93 (s, 6H). -388- EXAMPLE 179 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)benzamide EXAMPLE 179A 4-(2-methoxyethylamino)-3-nitrobenzenesulfonan(iide This EXAMPLE was prepared by substituting 2-methoxyethylamine for 1-(tetrahydropyran-4-yl)methylaniine in EXAMPLE IF. EXAMPLE 179B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)benzamide The title compound was prepared as in EXAMPLE 177 by replacing EXAMPLE IF with EXAMPLE 179A. 'H NMR (400 MHz, DMSO- de) 8 11.20 (br. s, IH) 11.15 (s, IH) 8.59 (m, 2H) 7.81 (dd, IH) 7.50 (d, IH) 7.36 (m, 4H) 7.08 (m, 4H) 6.85 (dd, IH) 6.65 (dd, IH) 6.38 (m, IH) 6.14 (m, IH) 3.58 (ra, 4H) 3.30 (s, 3H) 3.03 (m, 4H) 2.73 (s, 2H) 2.15 (m, 6H) 1.96 (s, 2H) 1.38 (t, 2H) 0.92 (s. 6H). EXAMPLE 180 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(3-nitro-4-{[(3S)-tetrahydTO-2H-pyran-3- ylmethyl]amino) phenyl)sulfonyl]benzamide EXAMPLE 180A (R)-3-nitrD-4-((tetrahydro-2H-pyran-3-yl)methylamino)benzenesulfonamideand(S)-3-nitro-4-((tetrahydro-2H-pyran-3-yl)methylamino)benzenesulfonamide This EXAMPLE was prepared by substituting (tetrahydro-2H-pyran-3-yl)methanainine for l-(tetrahydropyran-4-yl)methylainine in EXAMPLE IF. EXAMPLE 180B (S)-3-nitro-4-((tetrahydro-2H-pyran-3-yl)methylamino)benzenesulfonamide The racemic mixture of EXAMPLE 180A was resolved by chiral SEC on an AD column (21mm i.d.x 250 mm in length) using a gradient of 10-30% 0.1% diethylamine -389- methanol in CO2 over 15 min (oven temperature: 40°C; flow rate: 40mL/min) to provide the title compound. EXAMPLE 180C (R)-3-nitro-4-((tetrahydro-2H-pyran-3-yl)methylamino)benzenesulfonamide The racemic mixture of EXAMPLE 180A was resolved by chiral SFC on an AD column (21mm i.d.x 250 mm in length) using a gradient of 10-30% 0.1% diethylamine methanol in CO2 over 15 min (oven temperature: 40''C; flow rate: 40mL/min) to provide the title compound. EXAMPLE 180D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-pyran-3-ylmethyl]amino}phenyl)sulfonyl]benzamide The title compound was prepared as in EXAMPLE 177 by replacing EXAMPLE IF with EXAMPLE 180B. 'H NMR (400 MHz, DMSO-dg) 811.17 (s, 2 H), 8.53 - 8.65 (m, 2 H), 7.80 (d, 1 H), 7.51 (d, 1 H), 7.38 - 7.44 (m, 2 H), 7.33 (d, 2 H), 7.15 (s, 1 H), 7.02 - 7.09 (m, 3 H), 6.82 - 6.92 (m, 1 H), 6.65 (d, 1 H), 6.39 (s, 1 H), 6.14 (s, 1 H), 3.68 - 3.82 (m, 2 H), 3.22 - 3.32 (m, 2 H), 3.13 - 3.22 (m, 1 H), 3.03 (s, 4 H), 2.72 (s, 2 H), 2.09 - 2.23 (m, 6 H), 1.78 -1.98 (m, 4 H), 1.56 -1.66 (m, 1 H), 1.43 - 1.51 (m, 1 H), 1.37 (t, 2 H), 1.22 - 1.33 (m, 1 H), 0.92 (s, 6 H). EXAMPLE 181 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N-[(3-nitro-4- {[(3R)-tetrahydro-2H-pyran-3-ylmethyl]amino}phenyl)sulfonyl]benzamide The title compound was prepared as in EXAMPLE 177 by replacing EXAMPLE IF with EXAMPLE 180C. 'H NMR (400 MHz, DMSO-dg) 611.17 (s, 2 H), 8.53 - 8.65 (m, 2 H), 7.80 (d, 1 H), 7.51 (d, 1 H), 7.38 - 7.44 (m, 2 H), 7.33 (d, 2 H), 7.15 (s, 1 H), 7.02 - 7.09 (m, 3 H), 6.82 - 6.92 (m, 1 H), 6.65 (d, 1 H), 6.39 (s, 1 H), 6.14 (s, 1 H), 3.68 - 3.82 (m, 2 H), 3.22 - 3.32 (m, 2 H), 3.13 - 3.22 (m, 1 H), 3.03 (s, 4 H), 2.72 (s, 2 H), 2.09 - 2.23 (m, 6 H), 1.78 -1.98 (m, 4 H), 1.56 -1.66 (m, 1 H), 1.43 - 1.51 (m, 1 H), 1.37 (t, 2 H), 1.22 -1.33 (m, 1 H), 0.92 (s, 6 H). -390- EXAMPLE 182 4-(4.{[4-(4.chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2-(lH-mdol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared as in EXAMPLE 177 by replacing EXAMPLE 26C with EXAMPLE 150C. 'H NMR (400 MHz, DMSO-de) 8 11.20 (br s, IH), 11.17(s, IH), 8.63 (t, 1 H), 8.59 (d, 1 H), 7.79 (dd, 1 H), 7.51 (d, 1 H), 7.36 (m, 3 H), 7.13 (m, 2 H), 6.86 (dd, 1 H), 6.66 (dd, 1 H), 6.39 (s, I H). 6.15 (d, 1 H), 4.10 (s, 2 H), 3.85 (m, 3 H), 3.50 (m, 2 H), 3.42 (m, 2 H), 3.24 (m, 4 H), 3.02 (m, 4 H), 2.82 (m, 2 H), 2.16 (m, 2 H), 1.61 (m, 3 H), 1.25 (m, 4 H), 1.17 (s, 6 H). EXAMPLE 183 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N- [(4- {[(4-hydroxy- l-methylpiperidin-4-yl)methyl]amino} -3-nitrophenyl)sulfonyl]-2-( lH-indol-5- yloxy)benzamide EXAMPLE 183A 4-((4-hydroxy-l-methylpiperidin-4-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting 4-(aminomethyl)-l-methylpiperidin-4-ol for (tetrahydrDpyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 183B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N- [(4- {[(4-hydroxy-1 -methylpiperidin-4-yl)methyl]amino }-3-nitrophenyl)sulfonyl]-2-( lH-indol-5- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 183A for EXAMPLE IF in EXAMPLE 177. 'H NMR (500MHz, dimethylsulfoxide-de) 8 11.04 (s, IH), 8.46-8.48 (m, 2H), 7.92 (s, IH), 7.74 (d, IH), 7.54 (d, IH), 7.32-7.34 (m, 5H), 6.97-7.05 (m, 5H), 6.74-6.76 (m, IH), 6.55-6.57 (m, IH), 6.33 (s, IH), 6.13 (d, IH), 5.10 (s, IH), 3.14-3.17 (m, 2H), 2.95 (br, 5H), 2.71 (br, 2H), 2.14-2.17 (m, 6H), 1.95 (br s, 2H), 1.70 (br, 4H), 1.36-1.39 (m, 2H), 1.24-1.26 (m, 2H), 0.92 (s, 6H). -391- EXAMPLE 184 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-3-fluoro- 2-(lH-indol-5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- mt3X>pheny 1) sulfony l)benzamide EXAMPLE 184A ethyl 2-(lH-indol-5-yloxy)-3,4-difluorobenzoate The title compound was prepared by substituting ethyl 2,3,4-trifluorobenzoate for ethyl 2,4-difluorobenzoate and 5-hydroxyindole for 5-hydroxyindazole in EXAMPLE 20A. EXAMPLE 184B ethyl 2-(lH-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-3-fluorobenzoate The title compound was prepared by substituting EXAMPLE 184A for EXAMPLE 20A in EXAMPLE 20D. EXAMPLE 184C 2-(lH-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-3-fluorobenzoic acid The title compound was prepared by substituting EXAMPLE 184B for EXAMPLE ID in EXAMPLE IE. EXAMPLE 184D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-3-fluoro- 2-(lH-indol-5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 184C for EXAMPLE IE and EXAMPLE 21A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 5 10.98 (br s, IH), 8.35 (d, IH), 7.98 (dd, IH), 7.59 (dd, IH), 7.35 (m, 3H), 7.28 (t, IH), 7.21 (d, IH), 7.06 (d, 2H), 6.78 (m, 2H), 6.67 (m, 2H), 6.22 (s, IH), 3.74 (dd, 2H), 3.39 (m, 4H), 3.06 (m, 3H), 2.97 (m, 4H), 2.79 (m, 2H), 2.73 (s, 3H), 2.29 (m, 2H), 2.18 (m, 2H), 2.05 (m, 2H), 1.81 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). -392- EXAMPLE 185 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-3-fluoro-2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)aniino]phenyl} sulfonyl)benzanude The title compound was prepared by substituting EXAMPLE 184C for EXAMPLE IE and EXAMPLE 173C for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 8 10.98 (br s, IH), 8.33 (d, IH), 8.02 (dd, IH), 7.50 (dd, IH), 7.35 (m, 3H), 7.26 (t, IH), 7.19 (d, IH), 7.06 (d, 2H), 6.77 (dd, 2H), 6.67 (m, 2H), 6.22 (s, IH), 3.90 (dd, 2H), 3.57 (m, 5H), 3.30 (dd, 2H), 3.06 (m, 3H), 2.94 (m, 4H), 2.78 (m, 2H), 2.27 (m, 4H), 2.18 (m, 2H), 1.98 (m, 4H), 1.80 (m, 2H), 1.55 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 186 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 -yl)-N-[(4- {[(4-hydroxy-1 -methylpiperidin-4-yl)methyl]aniino} -3-nitrophenyl)sulfonyl]-2-( lH-indol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 183A for EXAMPLE IF and EXAMPLE 55B for EXAMPLE 26C in EXAMPLE 177. 'H NMR (500MHz, dimethylsulfoxide-ds) 6 11.12 (s, IH), 8.49 (s, IH), 8.42 (s, IH), 7.73-7.75 (m, IH), 7.58 (d, IH), 7.34 (d, 2H), 7.22 (s, IH), 7.09 (d, IH), 7.01-7.05 (m, 3H), 6.92 (t, IH), 6.61-6.62 (m, IH), 6.31 (d, IH), 6.23 (s, IH), 6.20 (s, IH), 5.16 (s, IH), 4.05 (s, 3H), 2.95 (br s, 6H), 2.71 (br s, 2H), 2.62 (br, 3H), 2.16 (br s, 6H), 1.95 (br s, 2H), 1.72 (br, 4H), 1.37-1.39 (m, 2H), 0.92 (s, 6H). EXAMPLE 187 N-[(4-{[(3S,4R)-l-benzyl-3-hydroxypiperidin-4-yl]amino)-3-mtn)phenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5- yloxy)benzamide EXAMPLE 187A 2-(lH-indol-5-yloxy)-N-(4-chloro-3-nitrophenylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzamide -393- The title compound was prepared by substituting 4-chloro-3-nitrobenzenesulfonamide for EXAMPLE IF and EXAMPLE 26C for EXAMPLE IE in EXAMPLE IG. EXAMPLE 187B N.[(4. {[(3S,4R)- l-benzyl-3-hydroxypiperidin-4-yl]amino} -3-nitn)phenyl)sulfonyl]-4-(4- {[2- (4-chloiophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5- yloxy)benzamide A mixture of EXAMPLE 187A (0.158 g), (3S,4R)-4-amino-l-benzylpiperidin-3-ol, hydrochloric acid (0.049 g), and trlethylamine (0.1 mL) in dioxane (2 mL) was heated at 100 °C overnight. The solvent was removed, and the residue was re-dissolved in 1:1 methanol:dimethylsulfoxide (3 mL). It was then purified by reverse phase Prep HPLC. The residue was purified by reverse phase HPLC on a CIS column using a gradient of 20-80% acetonitrile/0.1% TEA in water. The desired fractions were collected, and the organic solvent was partially removed under reduced pressure. The resulting mixture was treated with saturated aqueous NaHCOj mixture. It was then extracted with ethyl acetate three times. The combined organic layers were washed with brine, dried (MgS04), filtered, and concentrated to give the desired product. 'H NMR (500MHZ, dimethylsulfoxide-d^) S 11.14 (s, IH), 8.69 (d, IH), 8.14 (d, IH), 7.77 (dd, IH), 7.51 (d, IH), 7.29-7.41 (m, 9H), 7.10-7.13 (m, IH), 7.13 (d, 2H), 6.84 (dd, IH), 6.63 (dd, IH), 6.38 (s, IH), 6.13 (d, IH), 5.21-5.22 (br s, IH), 3.82 (m, 2H), 3.62 (br s, 2H), 3.01 (br s, 4H), 2.71-2.82 (m , 4H), 2.12-2.15 (m, 7H), 1.94 (br s, 2H), 1.81 (br s, 2H), 1.36-1.39 (m, 2H), 0.92 (s, 6H). EXAMPLE 188 N-[(4-{[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino}-3-nitrophenyl)suIfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indoI-5- yloxy)benzamide The title compound was prepared by substituting 4-(aniinomethyl)tetrahydro-2H-pyran-4-amine for (3S,4R)-4-amino-l-benzylpiperidin-3-ol hydrochloric acid in EXAMPLE 187B. 'H NMR (500MHz, dimethylsulfoxide-ds) 5 11.08 (s, IH), 8.60 (br s, IH), 8.51 (d, IH), 7.80 (dd, IH), 7.54 (d, IH), 7.32-7.36 (m, 4H), 7.12 (d, IH), 7.03-7.05 (m, 3H), 6.77 (dd, IH), 6.58 (dd, IH), 6.35 (s, IH), 6.13 (d, IH), 3.61-3.70 (m, 4H), 3.53 (br s, 2H), -394- 2.97 (br, 4H), 2.71 (br, 2H), 2.16 (br s, 6H), 1.94 (br s, 2H), 1.67-1.72 (m, 2H), 1.52-1.57 (m, 2H), 1.36-1.39 (m, 2H), 0.92 (s, 6H). EXAMPLE 189 4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(4-{[l-(2-methoxyethyl)piperidin-4-yl]amino}-3- nitrophenyl)sulfonyl]benzamide EXAMPLE 189A 4-[l-(2-methoxy-ethyl)-piperidin-4-ylaniino]-3-nitro-benzenesulfonamide l-(2-Methoxy-ethyl)-piperidin-4-ylamine (2.01 g) and triethylamine (3.24 mL, 2.35 g) were added to 1,4-dioxane (60 mL). 4-Chloro-3-nitrobenzenesulfonamide (2.50 g) was added, and the mixture was heated to 90°C for 16 hours. The mixture was cooled and the material purified by flash column chromatography on silica gel using 10% methanol in dichloromethane. EXAMPLE 189B 4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( 1H-indol-5-yloxy)-N- [(4- {[ 1 -(2-methoxyethyl)piperidin-4-yl]amino} -3-nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 26C for EXAMPLE IE and EXAMPLE 189A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-dfi) 5 11.12 (brs, IH), 8.52 (d, IH), 8.18 (d, IH), 7.76 (dd, IH), 7.51 (d, IH), 7.39-7.31 (m, 4H), 7.08-7.05 (m, 4H), 6.80 (dd, IH), 6.61, (dd, IH), 6.36 (t, IH), 6.14 (d, IH), 3.70 (m, IH), 3.50 (t, 2H), 3.27 (s, 3H), 2.99 (m, 6H), 2.71 (br s, 4H), 2.16 (m, 6H), 2.02-1.90 (m, 6H), 1.65 (m, 2H), 1.37 (t, 2H), 0.92 (s, 6H). EXAMPLE 190 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-2-( IH-indol-4-yloxy)-N-( {4-[(4-methylpiperazin-1 -yl)amino]-3-nitrophenyl) sulfonyI)benzamide The title compound was prepared by substituting EXAMPLE 174A for EXAMPLE IF and EXAMPLE 55B for EXAMPLE 26C in EXAMPLE 177. ^H NMR (400 MHz, dimethylsulfoxide-ds) 8 11.21 (br s, IH), 9.14 (s, IH), 8.45 (d, IH), 7.71 (dd, IH), 7.52 (m, 2H), 7.34 (m, 2H), 7.26 (m, IH), 7.15 (d, IH), 7.04 (m, 2H), 6.95 (t, IH), 6.67 (m, IH), -395- 6.38 (d, IH), 6.25 (m, 2H), 3.01 (m, 4H), 2.87 (m, 5H), 2.72 (m, 2H), 2.33 (m, 4H), 2.15 (m, 6H), 1.95 (s, 2H), 1.39 (m, 2H), 0.92 (s, 6H). EXAMPLE 191 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4-{[ 1 -(2-hydroxyethyl)piperidin-4-yl]amino} -3-nitrophenyl)sulfonyl]-2-(l H-indol-4- yloxy)benzamide EXAMPLE 191A tert-butyl4-(4-(N-(2-(lH-indol-4-yloxy)-4-(-4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-eny])methyl)piperazin- l-yl)benzoyl)sulfamoyl)-2-nitrophenylaniino)piperidine-1 -carboxylate The title compound was prepared by substituting EXAMPLE 55B for EXAMPLE IE and EXAMPLE 157A for EXAMPLE IF in EXAMPLE IG, except 5-7% methanol in CH2CI2 was used for the chromatography. EXAMPLE 191B 2-(lf?-indol-4-yloxy)-N-(4-(l-(2-(ferr-butyldimethylsilyloxy)ethyl)piperidin-4-ylamino)-3-nitrophenylsulfonyl)-4-(-4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1-yl)benzamide EXAMPLE 191A (400 mg) was dissolved in CH2CI2 (2.5 mL) and AN HCl in dioxane (2.5 mL), then stirred at room temperature for 30 minutes. The reaction was concentrated and then partitioned between CH2CI2 and saturated aqueous NaHCOs. The organic layer was washed with brine and dried over Na2S04. After filtration and concentration the resultant crude amine was slurried in CH2CI2 (2.5 mL) and {tert-butyldimethylsilyloxy)acetaldehyde (73 mg) was added. After stirring for 15 minutes, sodium triacetoxyborohydride (4(X) mg) was added and the reaction was stirred at room temperature overnight. The reaction was diluted with CH2CI2 and washed with saturated aqueous NaHCOs The organic layer was washed with brine and dried over Na2S04. The product was purified using column chromatography using 1.0-2.5 % methanol in CH2CI2 -396- EXAMPLE 191C 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N- [(4- {[ 1 -(2-hydroxyethyl)piperidin-4-yl]amino) -3-nitrophenyl)sulfonyl]-2-(l H-indol-4- yloxy)benzamide EXAMPLE 19IB (46 mg) was dissolved in tetrahydrofuran (0.8 mL), then l.OM tetrabutyl ammonium fluoride in 95/5 tetrahydrofuran/H20 (0.075 mL) was added and the reaction stirred at room temperature overnight. The reaction was concentrated and purified with column chromatography using 2-6 % methanol in CH2a2. 'H NMR (500MHz, dimethylsulfoxide-de) 5 11.15 (br s, IH), 8.44 (d, IH), 8.13 (br d, IH), 7.74 (dd, IH), 7.55 (d, IH), 7.33 (d, 2H), 7.23 (s, IH), 7.11 (d, IH), 7.03 (m, 3H), 6.93 (dd, IH), 6.64 (d, IH), 6.33 (d, IH), 6.23 (s, IH), 6.22 (s, IH), 3.75 (br s, IH), 3.61 (br s, 2H), 3.40 (br s, 2H), 3.10 (br s, 2H), 2.98 br s, 4H), 2.78 (br s, 2H), 2.71 (s, 2H), 2.16 (br m, 6H), 2.00 (br d, 2H), 1.95 (s, 2H), 1.72 (br s, 2H), 1.38 (t, 2H), 0.92 (s, 6H). EXAMPLE 194 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl Jpiperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N- [(4- {[ 1 -(2-methoxyethyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 55B for EXAMPLE IE and EXAMPLE 189A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-ds) 811.19 (br s, IH), 8.46 (d, IH), 8.17 (d, IH), 7.72 (dd, IH), 7.55 (d, IH), 7.35 (d, 2H), 7.25 (t, IH), 7.12 (d, IH), 7.07-7.02 (m, 3H), 6.94 (t, IH), 6.66, (dd, IH), 6.36 (d, IH), 6.24 (m, 2H), 3.73 (m, IH), 3.52 (t, 2H), 3.27 (s, 3H), 3.00 (m, 6H), 2.79 (m, 2H), 2.72 (br s, 2H), 2.16 (m, 6H), 2.04-1.93 (m, 6H), 1.68 (m, 2H), 1.37 (t, 2H), 0.92 (s, 6H). EXAMPLE 195 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcycIohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N- [(4- {[l-(3-hydroxypropyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide EXAMPLE 195A 4-(l-(3-(tert-butyldimethylsilyloxy)propyl)piperidin-4-ylamino)-3-nitrobenzenesulfonamide -397- A mixture of EXAMPLE 157B (300 mg), (3-bromopropoxy)(tert-butyl)dimethylsilane (304 mg) and cesium carbonate (967 mg) was suspended in anhydrous N,N-dimethylformamide (5 mL). The reaction mixture was heated at TO'C overnight. The reaction mixture was cooled to room temperature and diluted with ethyl acetate. The organic phase was washed with water, brine, dried over anhydrous sodium sulfate, and concentrated. The crude material was purified using flash column purification with 3-10% methanol/dichloromethane to afford the title compound. EXAMPLE 195B 2-(lH-indol-4-yloxy)-N-(4-(l-(3-(tert-butyldimethylsilyloxy)propyl)piperidin-4-ylamino)-3- nitrophenylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1 -yl)benzamide The title compound was prepared by substituting EXAMPLE 55B for EXAMPLE IE and EXAMPLE 195A for EXAMPLE IF in EXAMPLE IG. EXAMPLE 195C 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N- [(4- {[l-(3-hydroxypropyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide A mixture of EXAMPLE 195B (180 mg ) in anhydrous tetrahydrofuran (ImL) and tetrabutyl ammonium fluoride (0.5 mL IM in tetrahydrofuran) was stirred at room temperature for 2 hours. The solvent was removed under vacuum. The residue was purified by reverse phase HPLC on a C18 colunon using a gradient of 40-70% acetonitrile/0.1% trifluroacetic acid in water to give the title compound as the trifluoroacetate salt. The trifluToacetic acid salt was dissolved in dichloromethane (6 ml) and washed with 50% aqueous NaHCOj. The organic layer was dried over anhydrous Na2S04, filtered, and concentrated to give the title compound. 'H NMR (400MHZ, dimethylsulfoxide-de) 5 11.16 (s, IH), 8.43 (d, IH), 8.10 (m, IH), 7.74 (dd, IH), 7.57 (d, IH), 7.34 (d, 2H), 7.23 (m, IH), 7.10 (m, IH), 7.02 (m, 3H), 6.93 (m, IH), 6.65 (dd, IH), 6.34 (d, IH), 6.22 (m, 2H), 3.74 (m, 2H), 3.47 (m, 4H), 3.14 (m, 2H), 2.97 (m, 4H), 2.74 (m, 4H), 2.60 (m, IH), 2.17 (m, 4H), 1.97 (m, 4H), 1.69 (m, 4H), 1.40 (m, 2H), 0.93 (s, 6H). -398- EXAMPLE 196 4-[4-({4'-cMoro-3-[3-(dimethylamino)propyl]-l,r-biphenyl-2-yl}niethyl)piperazm-l-yl]-2- (lH-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- y Imethy l)amino]phenyl) sulfony l)benzamide EXAMPLE 196A 4'-ch]oro-3-hydroxybiphenyl-2-carbaldehyde The title compound was prepared as described in EXAMPLE 175 A by replacing l-(2-bromophenyl)ethanone with 2-bromo-6-hydroxybenzaldehyde. EXAMPLE 196B tert-butyl 4-((4'-chloro-3-hydroxybiphenyl-2-yl)methyl)piperazine-1 -carboxylate The title compound was prepared as described in EXAMPLE lA by replacing 4'-chlorobiphenyl-2-carboxaldehyde with EXAMPLE 196A. EXAMPLE 196C tert-butyl 4-((4'-chloro-3-(trifluoromethylsulfonyloxy)biphenyl-2-yl)methyl)piperazine-1 - carboxylate To a mixture of EXAMPLE 196B (390 mg) in pyridine (5 ml) at 0°C was added dropwise trifluoromethanesulfonic anhydride (0.326 ml). The reaction mixture was stirred in an ice bath for 1 hour and diluted with ethyl acetate. The resulting mixture was washed with brine extensively and the organic layer was dried over Na2S04, filtered, and concentrated to provide the title compound. EXAMPLE 196D tert-butyl 4-((4'-chloro-3-(3-(dimethylamino)prop-l-ynyl)biphenyl-2-yl)methyl)piperazine-l- carboxylate To a mixture of EXAMPLE 196C (380 mg), N,N-dimethylprop-2-yn-l-amine (0.227 ml), tetrakis(triphenylphosphine)palladium(0) (123 mg) and triethylamine (0.492) in N,N-dimethylformamide (1.5 ml) was added copper(I) iodide (27.1 mg) and 'BuNI (394 mg). The reaction mixture was heated at lOCfC for 4 hours, cooled and diluted with ethyl acetate. The organic layer was dried over Na2S04 and concentrated. The residue was purified by flash chromatography, eluting with a mixture of methanol, dichloromethane and triethyl amine to provide the title compound. -399- EXAMPLE 196E tert-butyl 4-((4'-chloro-3-(3-(climethylamino)propyl)biphenyl-2-yl)methyl)piperazine-1 - carboxylate EXAMPLE 196D (200 mg) in methanol (8 ml) was treated with platinum(IV) oxide (29.1 mg) under H2 atmosphere overnight. The insoluble material was filtered off and the filtrate was concentrated to provide the title compound. EXAMPLE 196F 3-(4'-chloro-2-(piperazin-1 -ylmethyl)biphenyl-3-yl)-N,N-dimethylpropan-1 -amine The title compound was prepared as described in EXAMPLE 175C by replacing EXAMPLE 175B with EXAMPLE 196E. EXAMPLE 196G ethyl 2-(lH-indol-4-yloxy)-4-(4-((4'-chloro-3-(3-(dimethylamino)propyl)biphenyl-2-yl)methyl)piperazin-1 -yl)benzoate The title compound was prepared as described in EXAMPLE 175D by replacing EXAMPLE 175C with EXAMPLE 196F. EXAMPLE 196H 2-(lH-indol-4-yloxy)-4-(4-((4'-chloro-3-(3-(dimethylamino)propyl)biphenyl-2-yl)methyl)piperazin-l-yl)benzoic acid The title compound was prepared as described in EXAMPLE 175E by replacing EXAMPLE 175D with EXAMPLE 196G. EXAMPLE 1961 4-[4-({4'-chloro-3-[3-(dimethylamino)propyl]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-2-(lH-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-y lmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared as described in EXAMPLE 175F by replacing EXAMPLE 175E with EXAMPLE 196H. 'H NMR (500 MHz, dimethylsulfoxide-dg) 6 11.11 (s, IH), 8.38 - 8.44 (m, 2H), 7.68 (dd, IH), 7.56 (d, IH). 7.44 (d, 2H), 7.19 - 7.29 (m, 5H), 7.07 (d, IH), 6.99 (dd, IH), 6.87 - 6.93 (m, 2H), 6.59 (dd, IH), 6.26 (d, IH), 6.23 (s, -400- IH), 6.19 (d, IH), 3.84 (dd, 2H), 3.22 - 3.29 (m, 4H), 2.87 (s, 6H), 2.69 - 2.75 (m, 2H), 2.59 (s, 5H), 2.14 (s, 4H), 1.83 -1.92 (m, 3H), 1.56 -1.65 (m, 2H), 1.19 - 1.31 (m, 4H), 0.81 -0.90 (m, IH) EXAMPLE 197 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethy]cyclohex-l -en- l-yl]methyl }piperazin-1 -yl)-N-[(4- {[l-(3-hydioxypiopyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide EXAMPLE 197A 2-(lH-indol-5-yloxy)-N-(4-(l-(3-(tert-butyldimethylsilyloxy)propyl)piperidin-4-ylamino)-3- nitiophenylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1 -y l)benzamide The title compound was prepared by substituting EXAMPLE 26C for EXAMPLE IE and EXAMPLE 195A for EXAMPLE IF in EXAMPLE IG. EXAMPLE 197B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N- [(4- {[l-(3-hydroxypropyl)piperidin-4-yIlamino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 197A for EXAMPLE 195B in EXAMPLE 195C. 'H NMR (400MHZ. dimethylsulfoxide-ds) 5 11.07 (bs, IH), 8.50 (d, IH), 8.14 (d,, IH), 7.75 (dd, IH), 7.52 (d, IH), 7.34 (m, 4H), 7.02 (m, 4H), 6.78 (dd, IH), 6.59 (dd, IH), 6.34 (m, IH), 6.14 (d, IH), 3.46 (m, 4H), 3.16 (m, 2H), 2.98 (m, 4H). 2.68 (m, 4H), 2.60 (m, IH), 2.16 (m, 6H), 1.97 (m, 4H), 1.68 (m, 4H), 1.38 (t, 2H), 0.93 (s, 6H). EXAMPLE 198 4- {4-[(4'-chloro-4-moipholin-4-yl-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-(l H-indol-4-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 198A tert-butyl 4-((4'-chloro-4-hydroxybiphenyI-2-yl)methyl)piperazine-1 -carboxylate -401- The title compound was prepared by substituting EXAMPLE 125A for 4'-chlorobiphenyl-2-carboxaldehyde in EXAMPLE lA. EXAMPLE 198B tert-butyl 4-((4'-chloro-4-(trifluoromethylsulfony loxy)biphenyl-2-yl)methyl)piperazine-1 - carboxylate A mixture of EXAMPLE 198A (3.0 g), trifluoromethanesulfonic anhydride (3.14 g) in anhydrous pyridine (50 mL) mixture was stirred at room temperature overnight. Tlie reaction mixture was diluted with ethyl acetate. The organic phase was washed with water, brine, dried over anhydrous sodium sulfate and concentrated. The residue was used in the next step without further purification. EXAMPLE 198C tert-butyl 4-((4'-chloK)-4-morpholinobiphenyl-2-yl)methyl)piperazine-1 -carboxylate A suspension of EXAMPLE 198B (5(X) mg), morpholine (80 mg), palladium (II) acetate (22 mg), biphenyl-2-yldi-tert-butylphosphine (50 mg) and cesium carbonate (427 mg) in anhydrous tetrahydrofuran (6 mL) was heated at 50*0 overnight. The reaction mixture was cooled to room temperature and diluted with ethyl acetate. The organic phase was washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated. The crude material was purified by flash column purification with 30-50% ethyl acetate/hexane to afford the title compound. EXAMPLE 198D 4-(4"-chloro-2-(piperazin-1 -ylmethyl)biphenyl-4-yl)morpholine The title compound was prepared by substituting EXAMPLE 198C for EXAMPLE lA in EXAMPLE IB. EXAMPLE I98E methyl 2-(lH-indol-4-yloxy)-4-(4-((4'-chloro-4-morpholinobiphenyl-2-yl)methyl)piperazin- l-yl)benzoate The title compound was prepared by substituting EXAMPLE 24F for EXAMPLE 20A and EXAMPLE 198D for EXAMPLE 20C in EXAMPLE 20D. -402- EXAMPLE 198F 2-(lH-indol-4-yloxy)-4-(4-((4'-chloro-4-morpholinobiphenyl-2-yl)methyI)piperazin-l- yl)benzoic acid The title compound was prepared by substituting EXAMPLE 198E for EXAMPLE ID in EXAMPLE IE. EXAMPLE 198G 4. {4-[(4'-chloro-4-morpholin-4-yl-1,1 '-biphenyl-2-yl)methyl]piperazin- 1-yl} -2-( 1 H-indol-4-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzainide The title compound was prepared by substituting EXAMPLE 198F for EXAMPLE 26C in EXAMPLE 177. 'H NMR (400MHZ, dimethylsulfoxide-de) 6 11.26 (bs, IH), 8.63 (t, IH), 8.49 (d, IH), 7.66 (dd, IH), 7.54 (d, IH), 7.40 (m, 4H), 7.29 (m, IH), 7.02 (m, 6H), 6.73 (dd, IH), 6.39 (d, IH), 6.30 (m, 2H), 3.85 (dd, 2H), 3.74 (m, 4H), 3.24 (m, 6H), 3.10 (m, 8H), 2.29 (m, 4H), 1.89 (m, IH), 1.63 (m, 2H), 1.28 (m, 2H). EXAMPLE 199 4-[4-( {4'-chloro-3-[2-(dimethylamino)ethoxy]-1, r-biphenyl-2-yl} methyl)piperazin-1-yl]-2- (lH-indol-4-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino Jphenyl} sulfonyI)benzamide EXAMPLE 199A tert-butyl 4-((4'-ch]oro-3-hydre>xybiphenyl-2-yl)methyl)piperazine-1 -carboxylate The title compound was prepared as described in EXAMPLE 1A by replacing EXAMPLE 27C with EXAMPLE 196A. EXAMPLE 199B tert-butyl 4-((4'-chloro-3-(2-(dimethylamino)ethoxy)biphenyl-2-yl)methyl)piperazine-l- carboxylate To a mixture of EXAMPLE 199A (1.5 g) in N,N-dimethylformamide (20 ml) was added 60% sodium hydride (0.596 g). The mixture was stirred at room temperature for 30 minutes and dimethylaminoethyl chloride hydrochloride salt (1.073 g) was added. After the resulting mixture was stirred overnight, additional 60% sodium hydride (0.596 g) and dimethylaminoethyl chloride hydrochloride salt (1.073 g) were added. The reaction mixture -403- was further stirred overnight, diluted with ethyl acetate and washed with water, saturated NaHCOs and brine. The organic layer was dried over Na2S04, filtered, and concentrated to provide the title compound. EXAMPLE 199C 2-(4'-chloro-2-(piperazin-1 -ylmethyl)biphenyl-3 -yloxy)-N,N-dimethylethanamine To a mixture of EXAMPLE 199B (2 g) in dichloromethane (10 ml) was added trifluroacetic acid (10 ml) at 0°C. The reaction mixture was stirred at room temperature for 30 minutes and concentrated. The residue was loaded onto a C18 column, and eluted with 0-50% 0.1% trifluroacetic acid/water in acetonitrile. The title compound was obtained as a trifluroacetic acid salt. EXAMPLE 199D ethyl 2-(lH-indol-4-yloxy)-4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)biphenyl-2-yl)methyl)pipeTazin-1 -yl)benzoate The title compound was prepared as described in EXAMPLE 175D by replacing EXAMPLE 175C with EXAMPLE 199C. EXAMPLE 199E 2-(lH-indol-4-yloxy)-4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)biphenyl-2-yI)methyl)piperazin-l-yl)benzoic acid The title compound was prepared as described in EXAMPLE I75E by replacing EXAMPLE 175D with EXAMPLE 199D. EXAMPLE 199F 4-[4-({4'-chloro-3-[2-(dimethylamino)ethoxy]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-2-(lH-indol-4-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl) sulfonyl)benzamide The title compound was prepared as described in EXAMPLE 175F by replacing EXAMPLE 175E and EXAMPLE IF with EXAMPLE 199E and EXAMPLE 173C, respectively. 'H NMR (500 MHz, dimethylsulfoxide-de) 5 11.13 (s, IH), 8.41 (d, IH), 8.12 (d, IH), 7.70 (dd, IH), 7.58 (d, IH), 7.52 (d, 2H), 7.43 (d, 2H), 7.31 (t, IH), 7.22 (t, IH), 7.06 (dd, 2H), 6.89 - 6.97 (m, 2H), 6.84 (d, IH), 6.64 (dd, IH), 6.30 (d, IH), 6.24 (dd, 2H), 4.14 (t, -404- 2H), 3.90 (dd, 2H), 3.53 - 3.73 (m, 2H), 3.22 - 3.32 (m, 4H), 2.93 (s, 6H), 2.34 - 2.46 (m, 7H), 2.29 (s, 5H), 1.97 (d, 2H), 1.73 (d, 2H), 1.41 - 1.62 (m, 4H). EXAMPLE 201 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl }piperazin- l-yl)-N-[(4- {[4-(diethylamino)cyclohexyl]amino} -3-nitrophenyl)sulfonyl]-2-( lH-indol-5- yloxy)benzamide EXAMPLE 201A 4-(4-(diethylamino)cyclohexylamino)-3-nitrobenzenesulfonaraide The title compound was prepared by substituting N\N'-diethylcyclohexane-1,4-diamine for l-(2-methoxy-ethyl)-piperidin-4-ylamine in EXAMPLE 189A. EXAMPLE 20 IB 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl Jpiperazin-1 -yl)-N- [(4- {[4-(diethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 26C for EXAMPLE IE and EXAMPLE 201A for EXAMPLE IF in EXAMPLE IG. 'H NMR (500 MHz, pyridine-ds) 8 ppm 12.28 (s, IH), 9.29 (d, IH). 8.29 - 8.38 (m, 2H), 8.19 (d, IH), 7.52 -7.57 (m, 2H), 7.40 - 7.47 (m, 3H), 7.10 (dd, IH), 7.06 (d, 2H), 6.92 (d, IH), 6.74 (dd, IH), 6.61 (s, IH), 6.55 (d, IH), 3.31 - 3.42 (m, IH), 3.00 - 3.08 (m, 4H), 2.76 (s, 2H), 2.54 - 2.61 (m, IH), 2.51 (q, 4H), 2.21 - 2.28 (m, 2H), 2.08 - 2.15 (m, 4H), 2.04 (d, 2H), 1.97 (s, 2H), 1.81 (d, 2H), 1.38 (t, 2H), 1.29 -1.36 (m, 2H), 1.17 -1.28 (m, 2H), 1.05 (t, 6H), 0.93 (s, 6H). EXAMPLE 202 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl jpiperazin- l-yl)-N-[(4- {[4-(dimethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide EXAMPLE 202A 4-(4-(dimethylamino)cyclohexylamino)-3-nitrobenzenesulfonamide -405- The title compound was prepared by substituting N',N'-dimethylcyclohexane-1,4-diamine for l-(2-methoxy-ethy])-piperidin-4-ylamine in EXAMPLE 189A. EXAMPLE 202B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N- [(4- {[4-(dimethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 55B for EXAMPLE IE and EXAMPLE 202A for EXAMPLE IF in EXAMPLE IG. 'H NMR (500 MHz, pyridine-ds) 8ppm 12.45 (s, IH), 9.21 (d, IH), 8.33 (d, IH), 8.27 (dd, IH), 8.18 (d, IH), 7.48 (t, IH), 7.45 (d, 2H), 7.40 (d, IH), 7.11 (t, IH), 7.08 (d, 2H), 6.87 (d, IH), 6.72 -6.81 (m, 3H), 6.67 (d, IH), 3.31 - 3.41 (m, IH), 3.00 - 3.06 (m, 4H), 2.77 (s, 2H), 2.31 (s, 6H). 2.25 (t, 2H), 2.20 - 2.25 (m, IH), 2.10 - 2.16 (m, 4H). 2.00 - 2.07 (d, 2H), 1.97 (s, 2H), 1.88 (d, 2H), 1.39 (t, 3H), 1.34 (d, 2H), 1.15 -1.28 (m, 4H), 0.94 (s, 6H). EXAMPLE 203 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N- [(4- {[4-(diethylamino)cyclohexyl]amino)-3-nitiophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 55B for EXAMPLE IE and EXAMPLE 201A for EXAMPLE IF in EXAMPLE IG. 'H NMR (500 MHz, pyridine-ds) 612.44 (s, IH), 9.21 (d. IH), 8.34 (d, IH), 8.28 (dd, IH), 8.18 (d, IH), 7.47 - 7.50 (m, IH), 7.45 (d, 2H), 7.40 (d, IH), 7.11 (t, IH), 7.08 (d, 2H), 6.90 (d, IH), 6.73 -6.81 (m, 3H), 6.67 (d, IH), 3.32 - 3.40 (m, IH), 2.99 - 3.06 (m, 4H), 2.76 (s, 2H), 2.52 - 2.60 (m, IH), 2.49 (q, 4H), 2.25 (t, 2H), 2.09 - 2.16 (m, 4H), 2.04 (d, 2H), 1.97 (s, 2H), 1.79 (d, 2H), 1.29 - 1.42 (m, 4H), 1.16 - 1.28 (m, 2H), 1.04 (t, 6H), 0.92 - 0.95 (m, 6H). EXAMPLE 204 Trans-4-(4-{[2-(4-chloiophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2- (lH-indol-4-yloxy)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl) sulfony])benzamide -406- EXAMPLE 204A trans-4-(4-morpholinocyclohexylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting trans-4-morpholinocyclohexanamine for l-(2-methox.y-ethyl)-piperidin-4-ylamine in EXAMPLE 189A. EXAMPLE 204B trans-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2- (lH-indol-4-yloxy)-N-({4-[(4-morpholin-4-ylcyclohexyl)ainino]-3- nitrophenyl ] sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 55B for EXAMPLE IE and EXAMPLE 204A for EXAMPLE IF in EXAMPLE IG. 'H NMR (500 MHz, pyridine-ds) 8 12.45 (s, IH), 9.21 (d, IH), 8.36 (d, IH), 8.26 (dd, IH), 8.16 (d, IH), 7.47 - 7.51 (m, IH), 7.45 (d, IH), 7.40 (d, IH), 7.12 (t, IH), 6.87 (d, IH), 6.73 - 6.81 (m, 3H), 6.68 (d, IH), 3.71 - 3.78 (m, 2H), 3.33 - 3.42 (m, IH), 3.00 - 3.06 (m, 4H), 2.76 (s, 2H), 2.44 - 2.52 (m, 4H), 2.25 (t, 2H), 2.16 - 2.23 (m, 2H), 2.09 - 2.16 (m, 4H), 2.06 (d, 2H), 1.97 (s, 2H), 1.86 (s, 2H), 1.39 (t, 2H), 1.17 - 1.35 (m, 6H), 0.94 (s, 6H). EXAMPLE 205 4-[4-({4'-chloro-3-[2-(dimethylamino)ethoxy]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-2-(lH-indol-4-yloxy )-N-( {4- [(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl) sulfonyl)benzamide The title compound was prepared as described in EXAMPLE 177 by replacing EXAMPLE 26C and EXAMPLE IF with EXAMPLE 199E and EXAMPLE 21A, respectively. 'H NMR (500 MHz, dichloromethane-da) 5 8.70 (d, IH), 8.56 (s, IH), 8.40 (d, IH), 7.95 (dd, IH), 7.91 (d, IH), 7.46 (d, 2H), 7.24 - 7.35 (m, 5H), 7.15 (t, IH), 6.90 (dd, 2H), 6.83 (d, IH), 6.75 (d, IH), 6.60 (dd, IH), 6.41 (d, IH), 6.19 (d, IH), 4.05 (t, 2H), 3.58 (s, IH), 3.32 (s, 2H), 2.95 - 3.02 (m, 4H), 2.66 - 2.80 (m, 4H), 2.30 - 2.35 (m, 4H), 2.24 -2.29 (m, 9H), 2.15 - 2.23 (m, 2H), 2.05 (d, 2H), 1.63 - 1.73 (m, 2H) EXAMPLE 206 4-{4-[I-(4'-chloro-l,l'-biphenyl-2-yl)ethyl]piperazin-l-yl}-2-(lH-indol-4-yloxy)-N-({4-[(l- methylpiperidin-4-yl)amino]-3-nitrophenyljsulfonyl)benzamide -407- The title compound was prepared as described in EXAMPLE 177 by replacing EXAMPLE 26C and EXAMPLE IF with EXAMPLE 175E and EXAMPLE 21A, respectively. 'H NMR (400 MHz, dichloromethane-di) 8 8.70 (d, IH), 8.51 (s, IH), 8.40 (d, IH), 7.94 (dd, IH), 7.90 (d, IH), 7.54 (d, IH), 7.33 (t, 4H), 7.21 - 7.27 (m, 2H), 7.10 - 7.19 (m, 4H), 6.91 (d, IH), 6.73 (d, IH), 6.55 - 6.60 (m, IH), 6.41 (s, IH), 6.16 (d, IH), 3.52 -3.63 (m, IH), 3.36 (q, IH), 2.96 - 3.07 (m, 4H), 2.72 - 2.79 (m, 2H), 2.33 - 2.41 (m, 2H), 2.27 (s, 3H), 2.14 - 2.27 (m, 4H), 2.00 - 2.09 (m, 2H), 1.63 -1.74 (m, 2H), 1.19 (d, 3H). EXAMPLE 207 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl}piperazin- l-yl)-N-{ [4-({[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl) amino)-3-nitropheny l]sulfonyl} -2- (lH-indol-5-yloxy)benzamide The title compound was prepared by substituting 4-(aminomethyl)-N,N-dimethyltetrahydro-2H-pyran-4-aminefor(3S,4R)-4-amino-l-benzylpiperidin-3-ol, hydrochloric acid in EXAMPLE 187B. 'H NMR (500MHz, dimethylsulfoxide-de) 8 11.17 (s, IH), 8.84 (br s, IH), 8.59 (d, IH), 7.84 (dd, IH), 7.51 (d, IH), 7.39-7.43 (m, 2H), 7.33 (d, 2H), 7.17-7.21 (m, 2H), 7.03 (d, 2H), 6.89 (dd, Hz, IH), 6.64 (d, IH), 6.40 (s, IH), 6.13 (d, IH), 3.72-3.75 (m, 2H), 3.34-3.57 (m, 4H), 3.02 (br, 4H), 2.71 (br, 2H), 2.27 (s, 6H), 2.16 (br s, 6H), 1.94 (br s, 2H), 1.78-1.85 (m, 2H), 1.36-1.39 (m, 2H), 0.92 (s, 6H). EXAMPLE 208 N-({4-[(2-aminocyclohexyl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4- dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5-yloxy)benzamide EXAMPLE 208A The title compound was prepared by substituting tert-butyl 2-aminocyclohexylcatbamate for (3S,4R)-4-amino-l-benzylpiperidin-3-ol, hydrochloric acid in EXAMPLE 187B. EXAMPLE 208B N-({ 4-[(2-aminocyclohexyl)amino]-3-nitrophenyl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5-yloxy)benzamide EXAMPLE 208A (0.1 g) in dimethylsulfoxide (4 mL) was heated under microwave conditions (200 °C, 1 hour). The residue was purified by reverse phase HPLC on -408- a CI8 column using a gradient of 30-70% acetonitrile/0.1% TFA in water. The desired fractions were collected, and the organic solvent was partially removed under reduced pressure. The resulting mixture was treated with saturated aqueous NaHCOa mixture. It was then extracted with ethyl acetate three times. The combined organic layers were washed with brine, dried (MgS04), filtered, and concentrated to give the title compound. 'H NMR (500MHz, dimethylsulfoxide-de) 6 11.02 (s, IH), 8.45 (s, IH), 8.05 (d, IH), 7.79-7.81 (m, IH), 7.56 (d, IH), 7.30-7.34 (m, 4H), 6.98-7.06 (m, 4H), 6.73 (d, IH), 6.54 (dd, IH), 6.33 (s, IH), 6.11 (d, IH), 3.64-3.70 (m, IH), 2.93 (br, 4H), 2.71 (br, 2H), 2.14-2.16 (br s, 6H), 1.95 (br s, 2H), 1.67-1.73 (m, 2H), 1.36-1.39 (m, 2H), 0.92 (s, 6H). EXAMPLE 209 4-[4-( {4'-chloro-4- [3-(dlmethylamino)prop-1 -ynyl]-1,1 '-biphenyl-2-yl) methyl)piperazin-1 - yl]-2-(lH-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 209A tert-butyl 4-((4'-chloro-4-(3-(dimethylamino)prop-1 -ynyl)biphenyl-2-yl)methyl)piperazine-1 - carboxylate A suspension of EXAMPLE 198B (800 mg), N,N-dimethylprop-2-yn-l-amine (373 mg), copperonate mixture, and the organic layer was dried with anhydrous sodium sulfate. The material was purified by flash column chromatography on silica gel using 30% ethyl acetate (in hexanes) increasing to 40% ethyl acetate (in hexanes). EXAMPLE 400C 2-(lH-Indazol-4-yloxy)-4-piperazin-l-yl-benzoic acid methyl ester EXAMPLE 400B (2.00 g) and piperazine (2.71 g) were added to dimethylsulfoxide (60 mL) and heated to 100°C for one hour. The mixture was cooled, addded to dichloromethane, washed with water twice, washed with a saturated aqueous sodium bicarbonate mixture, and dried on anhydrous sodium sulfate. After filtration, the solvent was removed under vacuum. EXAMPLE 400D 4- {4-[2-(4-Chloro-phenyl)-4,4-dimethyl-cyclohex-1 -enylmethyl]-piperazin-1 -yl} -2-( 1H-indazol-4-yloxy)-benzoic acid methyl ester The title compound was prepared by substituting EXAMPLE 218A for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 40(X]; for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 400E 4- {4-[2-(4-ChIoro-pheny l)-4,4-dimethyl-cyclohex-1 -enylmethylj-piperazin-1 -yl} -2-( 1H- indazol-4-yloxy)-benzoic acid -523- The title compound was prepared by substituting EXAMPLE 4000 for EXAMPLE ID in EXAMPLE IE. EXAMPLE 4(X)F 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcycloliex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H-indazol-4-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE IE in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 13.09 (s, IH). 8.56 (t, IH), 8.38 (d, IH), 7.80 (s, IH), 7.56 (dd, IH), 7.53 (d, IH), 7.36 (d, 2H), 7.16-7.05 (m, 4H), 6.99 (d, IH), 6.80 (dd, IH), 6.52 (d, IH), 6.19 (dd, IH), 3.87 (dd, 2H), 3.25-3.12 (m, 6H), 2.78 (m, 2H), 2.30-2.16 (m, 6H), 1.97 (br s, 2H), 1.90 (m, IH), 1.63 (m, 2H), 1.53 (m, IH), 1.40 (t, 2H), 1.29 (m, 3H), 0.94 (s, 6H). EXAMPLE 401 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide EXAMPLE 401A N-[(4-chloro-3-nitrophenyl)suIfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-l-yl]methyl)piperazin-l-yl)-2-(lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE IE and 4-chloro-3-nitiobenzenesulfonamide for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 5 13.04 (s, IH), 8.17 (br s, IH), 7.75 (s, IH), 7.73 (d, IH), 7.66-7.61 (m, 2H). 7.38 (d, 2H), 7.11-7.01 (m, 4H), 6.79 (dd, IH), 6.54 (d, IH), 6.10 (dd, IH), 3.38-3.05 (m, 8H), 2.73 (br s, 2 H), 2.19 (m, 2H), 2.00 (br s, 2H), 1.44 (t, 2H), 0.95 (s, 6H). EXAMPLE 40 IB 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide -524- The title compound was prepared by substituting EXAMPLE 173B for l-(2-methoxy-ethyl)-piperidin-4-ylamine and EXAMPLE 401A for 4-ch]oro-3-nitrobenzenesulfonamide in EXAMPLE 189A. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 13.05 (br s, IH), 8.35 (d, IH), 8.13 (d, IH), 7.78 (s, IH), 7.61-7.52 (m, 2H), 7.35 (d, 2H), 7.11-7.03 (m, 4H), 6.98 (d, IH), 6.77 (dd, IH), 6.48 (d, IH), 6.18 (m, IH), 3.69-3.52 (m, 4H), 3.12 (m, 6H), 2.76 (br s, 2H), 2.67 (m, 4H), 2.28-2.16 (m, 6H), 2.09-2.01 (m, 2H), 1.97 (br s, 2H). 1.95 (m, 2H), 1.50-1.38 (m, 6H), 0.93 (s, 6H). EXAMPLE 402 Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yI)-2-(lH-indazol-4-yloxy)-N-({4-[(4-moipholin-4-ylcyclohexyl)amino]-3-nitrophenyl} sulfonyl)benzainide The title compound was prepared by substituting trans-4-morpholin-4-yl-cyclohexylamine for l-(2-methoxy-ethyl)-piperidin-4-ylaniine and EXAMPLE 401A for 4-chloio-3-nitrobenzenesulfonamide in EXAMPLE 189A. 'H NMR (300MHz, dimethylsulfoxide-d6) S 13.02 (br s, IH), 8.35 (d, IH), 8.12 (m, IH), 7.75 (s, IH), 7.65-7.55 (m, 2H), 7.35 (d, 2H). 7.10-7.03 (m, 4H), 6.97 (m, IH), 6.76 (dd, IH), 6.44 (m, IH), 6.17 (t, IH), 3.95 (m, 2H), 3.77 (m, IH), 3.62 (m, IH), 3.10 (m, 6H), 2.75 (br s, 2H), 2.28-2.14 (m, 8H), 2.06 (m, 2H), 1.97 (br s, 2H), 1.85 (m, 2H), 1.71 (m, 2H), 1.55 (m, 4H), 1.40 (t, 2H), 0.93 (s, 6H). EXAMPLE 403 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yI]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 403A methy 4-fluoro-2-(3-fluoro-2-nitophenoxy)benzoate To a solution of methyl 4-fluoro-2-hydroxybenzoate (3.0 g) in tetrahydrofuran (65 mL) was added potassium t-butoxide (1.979 g) portion wise. The resulting solution was stirred at ambient temperature for 30 minutes and a solution of l,3-difluoro-2-nitrobenzene (2.338 g) in tetrahydrofuran (15 mL) was added dropwise. After 1 hour, the reaction was heated at reflux for 18 hours. The reaction was quenched with water (10 mL), diluted with -525- brine (75 mL) and extracted with methylene chloride (2x 75 mL). The erode product was isolated by concentration and purified on silica gel, eluted with a 10, 20, 50 % ethyl acetate in hexane step gradient to provide the title compound. EXAMPLE 403B methyl 2(3-(bis(4-methoxyphenyl)methylamino)-2-mitrophenoxy)-4-fluorobenzoate To a solution of EXAMPLE 403A (3.82 g) and bis(4-methoxyphenyl)methanamine (4.51 g) in N-methyl-2-pyrrolidinone (65 mL) was added N-ethyl-N-isopropylpropan-2-amine (4.30 mL) and the mixture was heated at 100 ° C for 24 hours. The crude product, isolated by concentration, was purified on silica gel, and was eluted with a 10, 25, and 65 % ethyl acetate in hexane step gradient to provide the title compound. EXAMPLE 403C methyl 2-(2-amino-3-(bis(4-methoxyphenyl)methylamino)phenoxy)-4-fluorobenzoate To a solution of EXAMPLE 403B (2.76 g) in tetrahydrofuran (125 mL) in a stainless steel pressure bottle was added nickel catalyst (2.76 g). The mixture was stirred for 1 hour under hydrogen at 30 psi and ambient temperature. The mixture was filtered though a nylon membrane to remove the catalyst, and concentrated to give the product. EXAMPLE 403D methyl 2-(l-(bis(4-methoxyphenyl)methyl)-lf/-benzo[rf]imidazol-4-yloxy)-4-fluorobenzoate To a solution EXAMPLE 403C (1.25 g) in diethyl orthoformate (30 mL) was added concentrated hydrochloric acid (0.75 mL). The mixture was stirred for 18 hours, quenched by the slow addition of 50% saturated aqueous sodium carbonate solution (100 mL) and extracted with ethyl acetate (2 x 100 mL). The crude product was isolated by concentration and purified on silica gel, and was eluted with a 25, 50, and 70% ethyl acetate in hexane step gradient to provide title compound. EXAMPLE 403E methyl 2-(l-(bis(4-methoxyphenyl)methyl)-l/f-benzo[cf|imidazol-4-yloxy)-4-(piperazin-l- yl)benzoate A solution of EXAMPLE 403D (500 mg), and piperazine (420 mg) in dimethylsulfoxide (9 mL) was heated at 1(X) °C for 3 hours. The crude product was isolated by concentration and, following an aqueous work up, it was purified on silica gel, and was -526- eluted with a 5 and 10% methanol in methylene chloride step gradient to provide the title compound. EXAMPLE 403F methyl 2-(l-(bis(4-methoxyphenyl)methyl)-lff-benzo[d]imidazol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)benzoate To a solution of EXAMPLE 403E (430 mg) and EXAMPLE 218A (259 mg) in dichloromethane (13 mL) was added sodium triacetoxyborohydride (323 mg) portionwise. After stiiring 42 hours, the reaction was quenched slowly with saturated aqueous sodium bicarbonate solution (80 mL) and extracted with methylene chloride (2 X 70 mL). The crude product was isolated by concentration and purified on silica gel, and was eluted with a 0, 2, 10% methanol in methylene chloride step gradient to provide the title compound. EXAMPLE 403G 2-(l-(bis(4-methoxyphenyl)methyl)-l//-benzo[d]imidazol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-enyl)methyl)piperazin-1 -yl)benzoic acid To a solution of EXAMPLE 403F (545 mg) in a mixture of methanol (7.50 mL) and tetrahydrofuran (7.50 mL) was added a solution of sodium hydroxide (269 mg) in water (3.0 mL). The reaction mixture was heated at 50° C for 18 hours and then concentrated. The residue was mixed with water (100 mL) and the pH was adjusted to ca. 7 with IM aqueous hydrochloric acid. TTie mixture was extracted with 10 % methanol in methylene chloride (10 X 50 mL), and the combined organic layers were concentrated to provide the title compound. EXAMPLE 403H 2-(l-(bis(4-methoxyphenyl)methyl)-l//-benzo[(f|imidazol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-7V-(3-mtro-4- ((tetrahydro-2f/-pyran-4-yl)methylamino)phenylsulfonyl)benzamide To a solution of EXAMPLE 403G (200 mg), EXAMPLE IF (99 mg), triethylamine (0.122 mL), N,N-dimethylpyridin-4-amine (77 mg) in a mixture of dichloromethane (8 mL) and N, N-dimethylformamide (1 mL) was added N'-((ethylimino)methylene)-N^,N^-dimethylpropane-l,3-diamine hydrochloric acid (96 mg). The reaction mixture was stirred 18 hours and then concentrated. The crude product was purified on silica gel eluted with an 80 and 100 % ethyl acetate in hexane step gradient to provide the title compound. -527- EXAMPLE 4031 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide A solution of EXAMPLE 403H (174 mg) and dichloromethane (25 mL) was cooled in an ice bath and 2,2,2-trifluoroacetic acid (25 mL) was added slowly dropwise. The reaction mixture was stirred 30 minutes under nitrogen and the ice bath was removed. The reaction was stirred 18 hours and then concentrated. The crude product was purified by reverse phase chomatography with anomonium acetate buffer in acetonitrile to give the title compound. 'H NMR (400 MHz, pyridine-ds) 8 9.30 (d, IH), 8.69 (t, IH), 8.59 (s, IH), 8.42 (dd, IH), 7.99 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.26 (m, IH), 7.18 (m, IH), 7.06 (d, 2H), 6.94 (d, IH), 6.72 - 6.66 (m, 2H), 5.53 (m, 2H), 3.98 (m, 2H), 3.32 (m, 2H), 3.18 (t, 2H), 2.03 (m, 4H), 2.76 (s, 2H), 2.25 (m, 2H), 2.13 (m, 4H), 1.97 (s, 2H), 1.83 (m, IH), 1.60 (m, 2H), 1.40 -1.29 (m, 4H), 0.94 (s, 6H). EXAMPLE 404 N-({ 5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide EXAMPLE 404A 5-chloro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 387A for EXAMPLE 329A and EXAMPLE 306C for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 329B. EXAMPLE 404B N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl)sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -y l]methyl }piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 404A for EXAMPLE IF and EXAMPLE 400E for EXAMPLE 26C in EXAMPLE 177. 'H NMR (500MHz, dimethylsulfoxide-dfi) 6 13.09 (s, IH), 8.27 (d, IH), 7.88 (d, IH), 7.80 (s, IH), 7.60 (d, IH), 7.37 (d, 2H), 7.03-7.10 (m, 4H), 6.79 (dd, IH), 6.53 (d, IH), 6.13 (d, IH), 4.50 -528- (d, 2H), 3.76-3.81 (m, 2H), 3.57-3.63 (m, 2H), 3.04 (brs, 4H), 2.84 (br s, 2H), 2.18 (m, 2H), 1.82-1.92 (m, 4H), 1.42 (t, 2H), 0.94 (s, 6H). EXAMPLE 405 N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl)sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l -en-1 -yl]methyl }piperazin-1 -yl)-2-( lH-indol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 404A for EXAMPLE IF and EXAMPLE 55B for EXAMPLE 26C in EXAMPLE 177. ^H NMR (500MHz, dimethylsulfoxide-de) 5 11.21 (s, IH), 8.43 (d, IH), 8.06 (d, IH), 7.55 (d, IH), 7.34 (d, 2H), 7.27 (t, IH), 7.13 (d, IH), 7.04 (d, 2H), 6.93 (t, IH), 6.69 (dd, IH), 6.36 (d, IH), 6.28 (d, IH), 6.26 (d, IH), 4.51 (d, 2H), 3.73-3.79 (m, 2H), 3.55-3.61 (m, 2H), 3.08 (br s, 4H), 2.86 (br s, 2H), 2.31 (br s, 2H), 2.18 (m, 2H), 1.95 (s, 2H), 1.79-1.90 (m, 4H), 1.36 (t, 2H), 0.92 (s, 6H). EXAMPLE 406 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N-( {5- cyano-6-[(4-fluorotetrahydK)-2H-pyTan-4-yl)n)ethoxy]pyTidin-3-yl}siilfonyl)-2-(lH-indazol- 4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 385B for EXAMPLE IF and EXAMPLE 400E for EXAMPLE 26C in EXAMPLE 177. 'H NMR (500MHz, dimethylsulfoxide-dfi) 8 13.03 (s, IH), 8.48 (d, IH), 8.17 (s, IH), 7.74 (s, IH), 7.63 (d, IH), 7.37 (d, 2H), 7.00-7.08 (m, 4H), 6.77 (dd, IH), 6.51 (s, IH), 6.07 (d, IH), 4.55 (d, 2H), 3.77-3.81 (m, 2H), 3.58-3.63 (m, 2H), 3.20 (br s, 4H), 2.19 (br s, 2H), 1.99 (s, 2H), 1.85-1.92 (m, 4H), 1.42 (t, 2H), 0.94 (s, 6H). EXAMPLE 407 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]metiiyl }piperazin-1 -yl)-N-[(4- {[(3R)-1 -(2,2-difluoroethyl)pyrrolidin-3-yl]amino} -3- nitrophenyl)sulfonyl]benzaniide EXAMPLE 407A (R)-tert-butyl l-(2,2-difluoroethyl)pyrrolidin-3-ylcarbamate -529- To a solution of (R)-tert-butyl pyrrolidin-3-ylcarbamate (500 mg), l,l-difluoro-2-iodoethane (618 mg) in N,N-dimethylformamide (6 mL) was added N-ethyl-N-isopropylpropan-2-aniine (1,403 mL) and the reaction stirred for 72 hours at 70 "C. The reaction mixture was concentrated and the crude product was purified on a silica gel and was eluted with a 0, 2, and 5 % methanol in methylene chloride step gradient to provide the title compound. EXAMPLE 407B (/?)-l-(2,2-difluoroethyl)pynolidin-3-amine To a solution of EXAMPLE 407A (525 mg) in a mixture of dichloromethane (3 mL) and methanol (2.0 mL) was added hydrogen chloride, 4M in dioxane (5.24 mL). The reaction was stirred for 3 hours, and concentrated to provide die title compound. EXAMPLE 407C (^)-4-(l-(2,2-difluoioethyl)pyrrolidin-3-ylamino)-3-nitrobenzenesulfonamide To a solution of EXAMPLE 407B (468 mg) in tetrahydrofiiran (20 mL), N-ethyl-N-isopropylpropan-2-amine (2.193 mL) and N,N-dimethylfonnamide (2 mL) was added 4-fluoro-3-nitK)benzenesulfonamide (473 mg) and the reaction mixture was stirred 72 hours. The crude product was isolated by concentration and was purified on silica gel, and was eluted with a 0.5,2.5, and 5 % methanol in methylene chloride step gradient to obtain the title compound. EXAMPLE 407D (/?)-2-(l-(bis(4-methoxyphenyl)methyl)-l/:/-benzo[t/]imidazol-4-yloxy)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l- nitrophenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 407C for EXAMPLE IF in EXAMPLE 403H. EXAMPLE 407E 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4-{[(3R)-l-(2,2-difluoroethyl)pynolidin-3-yl]amino}-3- nitrophenyl)sulfonyl]ben2amide -530- The title compound was prepared by substituting EXAMPLE 407D for EXAMPLE 403H in EXAMPLE 403L 'H NMR (400 MHz, pyridine-ds) 8 9.26 (d, IH), 8.60 - 8.55 (ni, 2H), 8.39 (m, IH), 7.99 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.25 (m, IH), 7.17 (m, IH), 7.06 (d, 2H), 6.86 (d, IH), 6.72 - 6.69 (m, 2H), 6.00 - 6.33 (m, IH), 5.27 (m, 2H), 4.09 (m, IH), 3.03 (m, 4H), 2.96 - 2.86 (m, 4H), 2.81 - 2.74 (m, 3H), 2.48 (m, IH), 2.26 (m, 3H), 2.13 (m, 4H), 1.97 (s, 2H), 1.67 (m, IH), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 408 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl) sulfonyl)benzaniide EXAMPLE 408A 2-(l-(bis(4-methoxyphenyl)methyl)-l//-benzo[rf]imidazol-4-yloxy)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-^-(4-((4- fluorotetrahydro-2//-pyran-4-yl)methoxy)-3-nitorophenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 306D for EXAMPLE IF in EXAMPLE 403H. EXAMPLE 408B 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 408A for EXAMPLE 403H in EXAMPLE 4031. 'H NMR (400 MHz, pyridine-dj) 8 9.01 (d, IH), 8.57 (m, 2H), 7.99 (d, IH), 7.53 (d, IH), 7.44 (d, 2H), 7.25 (m, IH), 7.21 (m, IH), 7.12 (d, IH), 7.07 (d, 2H), 6.73 - 6.70 (m, 2H), 5.35 (m, 2H), 4.36 (s, IH), 4.31 (s, IH), 3.88 (m, 2H), 3.78 (m, 2H), 3.05 (ra, 4H), 2.77 (s, 2H), 2.26 (m, 2H), 2.15 (m, 4H), 2.07 - 192 (m, 6H), 1.39 (t, 2H), 0.94 (s, 6H). EXAMPLE 409 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N- [(4- {[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indazol- 4-yloxy)benzamide -531- EXAMPLE 409A (4-fluorotetrahydio-2H-pyran-4-yl)methylmethanesulfonate A mixture of EXAMPLE 306C (L4 g), methanesulfony] chloride (L054 mL), ttiethylamine (2.99 mL), and 4-(dimethylamino)pyridine (0.051 g) in CH2CI2 (20 mL) was stirred at 0 "C for 2 hours, concentrated and chromatographed on silica gel with 30% ethyl acetate in hexanes as eluent to give the product. EXAMPLE 409B 2-((4-fluorotetrahydro-2H-pyran-4-yl)methyl)isoindoline-1,3-dione A mixture of EXAMPLE 409A (1.8 g) and potassium phthalimide (2.356 g) in N,N-dimethylformamide (30 mL) was heated at 150 "C overnight, diluted with ethyl acetate, washed with water and brine, dried (MgS04), filtered, concentrated and chromatographed on silica gel with 30% ethyl acetate in hexanes as eluent to give the product. EXAMPLE 409C (4-fluorotetrahydro-2H-pyran-4-yl)methanamine A mixture of EXAMPLE 409B (1.4 g) and hydrazine (1.548 mL) in ethanol (40 mL) was heated at 70 °C overnight, cooled to room temperature, slurried with CH2CI2 (200 mL) and the solid removed by filtration. The filtrate was concentrated and chromatographed on silica gel with 100:5:1 ethyl acetate/methanol/NHjOH as eluent to give the product. EXAMPLE 409D 4-((4-fluorotetrahydro-2H-pyran-4-yl)methylamino)-3-nitrobenzenesulfonamide A mixture of 4-fluoro-3-nitrobenzenesulfonamide (0.44 g), EXAMPLE 409C (0.266 g), and triethylamine (1.11 mL) in tetrahydrofiiran (10 mL) was heated at 70 °C overnight, diluted with ethyl acetate, washed with water and brine, dried (MgS04), filtered, concentrated and chromatographed on silica gel with 50% ethyl acetate in hexanes as eluent to give the product. EXAMPLE 409E 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino} -3-nitrophenyl)sulfonyl]-2-( IH-indazol- 4-yloxy)benzamide -532- The title compound was prepared by substituting EXAMPLE 409D for EXAMPLE IF and EXAMPLE 4(X)E for EXAMPLE 26C in EXAMPLE 177. 'H NMR (500MHz, dimethylsulfoxide-dg) 6 13.09 (s, IH), 8.59 (t, IH), 8.37 (d, IH), 7.80 (s, IH), 7.59 (dd, IH), 7.37 (d, 2H), 7.04-7.13 (m, 5H), 6.79 (dd, IH), 6.51 (d, IH), 6.18 (d, IH), 3.70-3.79 (m, 4H), 3.50-3.56 (m, 2H), 3.15 (br s, 4H), 2.78 (br s, 2H), 2.32 (br s, 4H), 2.17 (br s, 2H), 1.97 (s, 2H), 1.75-1.83 (m, 4H), 1.40 (t, 2H), 0.93 (s, 6H). EXAMPLE 410 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-N- {[6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2- (lH-indazol-4-yloxy)benzamide EXAMPLE 410A 5 -nitro-3 -(trifluoromethyl)pyridin-2-ol 3-(Trifluoromethyl)pyridin-2-ol (2.3 g) was added to concentrated sulfuric acid (15 mL) at 0 °C. Tlie mixture was stirred at 0 °C for 5 minutes. To this solution was added nitric acid (fuming) (6 mL) dropwise over 5 minutes. The reaction mixture was stirred at room temperature for 2 hours, and was heated at 50 °C for 3 hours. After cooling, the reaction mixture was poured into ice (200 g), and the mixture was extracted with ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated under reduced pressure to give the title compound. EXAMPLE 410B 2-chloro-5-nitro-3-(trifluoromethyl)pyridine A mixture of EXAMPLE 410A (1.69 g), phosphorus pentachloride (2.03 g), and phosphoryl trichloride (0.97 mL) was heated at 90 °C for 3 hours. After cooling, the reaction mixture was poured into ice, and extracted with ethyl acetate three times. The extract was washed with brine, dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with 1:9 ethyl acetate\hexanes to give the title compound. -533- EXAMPLE 410C A mixture of iron (1.5 g) and anunonium chloride (2.38 g) in water (40 niL) was stirred at room temperature for 5 minutes. To this suspension was added EXAMPLE 410B in methanol (40 mL). The reaction mixture was stirred at room temperature for 1 hour. Additional iron (1.8 g) was added to the reaction mixture, and it was stirred for another 3 hours. The solid from the reaction mixture was filtered off, and the filtrate was partitioned between water and ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with 1:4 ethyl acetate\hexanes to give the title compoimd. EXAMPLE 410D 6-chloro-5-(trifluoromethyl)pyridine-3-sulfonyl chloride Under ice-cooling, thionyl chloride (4 mL) was added dropwise over 20 minutes to water (27 mL). The mixture was stirred overnight for 12 hours to give a SO2 containing solution. Separately, EXAMPLE 410C (1.14 g) in dioxane (5 mL) was added to concentrated HCl (20 mL) at 0 °C. The solution was stirred for 5 minutes. To this mixture was added sodium nitrite (0.44 g) in water (6 mL) dropwise at 0 °C. The solution stirred at 0 "C for three hours. Diffing this time, any solids formed were crushed with a glass rod to make sure that EXAMPLE 4 IOC was completely reacted. To the SO2 containing solution was added copper(I) chloride (0.115 g). Then, to this solution was added the diazotized EXAMPLE 4 IOC at 0 °C. The solution was stirred for 30 minutes. The reaction mixture was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel eluting with 1:20 ethyl acetateNhexanes to give the title compound. EXAMPLE 4 lOE 6-chloro-5-(trifluoromethyl)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 410D for 5-bromo-6-chloropyridine-3-sulfonyl chloride in EXAMPLE 329A. -534- EXAMPLE 410F The title compound was prepared by substituting EXAMPLE 410E for EXAMPLE 329A and EXAMPLE 306C for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 329B. EXAMPLE 410G 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin- l-yl)-N- {[6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2- (1 H-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 410F for EXAMPLE IF and EXAMPLE 400E for EXAMPLE 26C in EXAMPLE 177. 'H NMR (500MHz, dimethylsulfoxide-ds) 8 13.05 (s, IH), 8.59 (s, IH), 8.17 (d, IH), 7.76 (s, IH), 7.62 (d, IH), 7.37 (d, 2H), 7.00-7.08 (m, 4H), 6.78 (dd, IH), 6.51 (s, IH), 6.11 (d, IH), 4.56 (d, 2H), 3.77-3.80 (m, 2H), 3.57-3.62 (m, 2H), 3.18 (br s, 2H), 2.32 (br s, 4H), 2.18 (br s, 2H), 1.99 (s, 2H), 1.81-1.90 (m, 4H), 1.42 (t, 2H), 0.94 (s, 6H). EXAMPLE 411 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin-1 -yl)-N- [(4-{[(4-cyclopn)pylmorphohn-2-yl)methyl]amino} -3-nitrophenyl)sulfonyl]-2-( lH-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE IE and EXAMPLE 432A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-d6) 5 13.09 (s, IH), 8.57 (m, IH), 8.37 (d, IH), 7.81 (s. IH), 7.56 (dd, IH), 7.52 (d, IH), 7.38-7.31 (m, 3H), 7.11-7.07 (m, 3H), 6.97 (d, IH), 6.80 (dd, IH), 6.52 (d, IH), 6.17 (d, IH), 3.84 (d, IH), 3.24-3.10 (m, 6H), 2.93 (d, 2H), 2.76 (m, 2H), 2.73 (s, 2H), 2.34-2.10 (m, 8H), 1.97 (bs, 2H), 1.67 (m, IH), 1.40 (t, 2H), 0.93 (s, 6H), 0.47-0.26 (m, 4H). EXAMPLE 412 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N- [(4- {[(4,4-difluorocyclohexyl)methyl]amino}-3-nitrophenyl)suIfonyl]-2-(lH-indazol-4- yloxy)benzamide EXAMPLE 412A tert-butyl(4,4-difluorocyclohexyl)methylcarbamate -535- Tert-butyl (4-oxocyclohexyl)methylcarbamate (5 g) and diethylaminosulfur trifluoride (7.45 g) were stirred in dichloromethane (100 mL) for 24 hours. The mixture was quenched with pH 7 buffer (100 niL), and poured into ether (400 mL). The resulting solution was separated, and the organic layer was washed twice with water, and once with brine, and then concentrated to give the crude product and fluoroolefm in a 3:2 ratio. The crude product was taken up in tetrahydrofuran (70 mL) and water (30 mL), and N-methylmorpholine-N-oxide (1.75 g), and OSO4 (2.5 wt % solution in t-butanol) were added, and the mixture was stirred for 24 hours. Na2S203 (10 g) was then added, and the mixture was stirred for 30 minutes. The nnixture was then diluted with ether (300 mL), and the resulting solution was separated, and rinsed twice with water, and once with brine, and concentrated. The crude product was chromatographed on silica gel using 5-10% ethyl acetate in hexanes to give the tide compound. EXAMPLE 412B (4,4-difluorocyclohexyl)methanamine A solution of EXAMPLE 412A (3 g) in dichloromethane (35 mL), trifluroacetic acid (15 mL), and triethylsilane (1 mL) was stirred for 2 hours. The solution was concentrated, then concentrated from toluene, and left on high vacuum for 24 hours. The semi-solid was taken up in ether/hexane and filtered to give the product as its trifluroacetic acid salt. EXAMPLE 412C 4-((4,4-difluorocyclohexyl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 412B for l-(2-methoxy-ethyl)-piperidin-4-ylamine in EXAMPLE 189A. EXAMPLE 412D 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl }piperazin- l-yl)-N-[(4- {[(4,4-difluorocyclohexyl)methyl]amino}-3-nitrophenyI)sulfonyl]-2-(lH-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE IE and EXAMPLE 412C for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-d6) 5 13.16 (s, IH), 11.70 (br s, IH), 8.65 (m, IH), 8.44 (d, IH), 7.87 (d, IH), 7.61 (dd, 2H), 7.41 (d, 2H), 7.02-7.20 (m, 4H), 6.88 (dd, IH), 6.58 (d, IH), 6.26 (dd, -536- IH), 3.22 (m, 4H), 2.86 (m, 2H), 2.20-2.35 (m, 7H), 2.14 (s, 2H), 2.10 (m, 2H), 2.03 (m, 2H), 1.91 (m, 2H), 1.87 (m, 2H), 1.46 (m, 2H), 1.27-1.39 (m, 3H), 1.00 (s, 6H). EXAMPLE 413 N-[(5-chloro-6-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}pyridin-3-yl)sulfonyl]-4- (4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide EXAMPLE 413A The title compound was prepared by substituting EXAMPLE 387A for 4-fluoro-3-nitrobenzenesulfonamide and EXAMPLE 409C for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 413B N-[(5-chloro-6- {[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino }pyridin-3-yl)sulfonyl]-4- (4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]niethyl} piperazin-1 -yl)-2-(l H- indazol-4-yloxy)benzaniide The title compound was prepared by substituting EXAMPLE 413A for EXAMPLE IF and EXAMPLE 400E for EXAMPLE 26C in EXAMPLE 177. 'H NMR (500MHz, dimethylsulfoxide-d6) 8 13.14 (s, IH), 8.19 (d, IH), 7.87 (s, IH), 7.60 (d, IH), 7.56 (d, IH), 7.36 (d, 2H), 7.31 (br s, IH), 7.08-7.17 (m, 2H), 7.06 (d, 2H), 6.80 (dd, IH), 6.53 (d, IH), 6.20 (d, IH), 3.70-3.78 (m, 4H), 3.43-3.54 (m, 2H), 3.18 (br s, 4H), 2.81 (s, 2H), 2.26 (br s, 4H), 2.17 (br s, 2H), 1.97 (s, 2H), 1.64-1.80 (m, 4H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 414 Trans-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin-l -yl)-2-( 1 H-indazol-4- yloxy)benzanude EXAMPLE 414A Cis-(4-methoxycyclohexyl)methanolandTrans-(4-methoxycyclohexyl)methanol -537- Ethyl 4-methoxycycloh6xanecarboxylate (1 g) in tetrahydrofuran (10 mL) was treated with 1.0 N LiAlILi in THF (2 mL) at 0°C. The mixture was stirred for 2 hours. The reaction was quenched with water (0.6 mL) followed by 2.0 N aqueous NaOH (0.2 mL). The mixture was stirred for another 20 minutes, and the solid was filtered off. The filtrate was taken up in ethyl acetate, washed with brine, dried over MgS04, filtered, and concentrated to give the title compound as a mixture of cis and trans isomers. EXAMPLE 414B 5-chloro-6-((trans-4-niethoxycyclohexyl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 387A for EXAMPLE 329A and EXAMPLE 414A for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 329B. TTie trans isomer was isolated by flash column chromatography on silica gel. EXAMPLE 414C Trans-N-({ 5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 414B for EXAMPLE IF and EXAMPLE 400E for EXAMPLE 26C in EXAMPLE 177. 'H NMR (500MHz, dimethylsulfoxide-de) 5 13.10 (s, IH), 8.27 (d, IH), 7.85 (d, IH), 7.80 (s. IH), 7.59 (d, IH), 7.36 (d, 2H), 7.03-7.10 (m, 4H), 6.79 (dd, IH), 6.53 (d, IH), 6.14 (d, IH), 4.19 (d, 2H), 3.24 (s, 3H), 3.20 (m, 4H), 3.07-3.10 (m, 2H), 2.93 (br s, 2H), 2.39 (s, 4H), 2.18 (s, 2H), 1.98-2.02 (m, 4H), 1.70-1.86 (m, 3H), 1.42 (t, 2H), 1.08-1.17 (m, 4H), 0.94 (s, 6H). EXAMPLE 415 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-{[4-({[4-(2,2-difluoroethyl)moipholin-2-yl]methyl}amino)-3- nitrophenyl]sulfonyl} benzamide -538- EXAMPLE 415 A /err-Butyl2-((2-nitro-4-sulfamoylphenylamino)methyl)morpholine-4-carboxylate TTiis EXAMPLE was prepared by substituting tert-butyl 2-(aminomethyl)morpholine-4-carboxylate for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 415B 4-(morpholin-2-ylmethylamino)-3-nitrobenzenesulfonamide A solution of EXAMPLE 415A (0.8 g) in methylene chloride (10 mL) and trifluoroacetic acid (10 mL) was stirred at room temperature for 2 hours. The solvents were ev^wrated and the residue was triturated with diethyl ether. The resulting solid was dissolved in 5% aqueous sodium carbonate solution (20 mL). The solution was evaporated to dryness and the resulting soUd was triturated with a solution of 10% methanol in dichloromethane several times. Evaporation of the organic solution gave the title compound. EXAMPLE 4I5C 4-((4-(2,2-difluoroethyl)morpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide To a solution of EXAMPLE 415B (633 mg) in anhydrous ^.^-dimethylformamide (10 mL) was added sodium carbonate (254 mg) and 2, 2-difluoroethyl iodide (422 mg). After stirring at 110*^ for 48 hours, the mixture was concentrated. The residue was mixed with water (20 mL) and extracted with ethyl acetate. The crude product was purified on a silica gel column eluting with 10% methanol in methylene chloride to give the title compound. EXAMPLE 415D 2-( l//-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl }piperazin- l-yl)-yV- {[4-( {[4-(2,2-difluoroethyl)morpholin-2-yl]methyl} amino)-3- nitrophenyl]sulfonyl) benzamide This EXAMPLE was prepared by substituting EXAMPLE 415C for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500MHz, pyridine-ds) 5 9.26 (d, IH), 8.87 (t, IH), 8.57 (s, IH), 8.37 (dd, IH), 7.99 (d, IH), 7.53 (d, IH), 7.43 (d, 2H). 7.25 (m, 2H), 7.17 (d, IH), 7.06 (d, 2H), 6.96 (d, IH), 6.72-6.69 (m, 2H), 6.31, 6.20, 6.09 (tt, IH), 3.90 (m, IH), 3.86 (d, IH), 3.68 (dt, IH), 3.54-3.41 (m, 2H), 3.03 (m, 4H), 2.97 (d, IH), 2.83-2.75 (m, 4H), 2.69 (d, IH), 2.35 (dt, IH), 2.27-2.23 (m, 3H), 2.14 (m, 4H), 1.97 (s, 2H), 1.38 (t, 2H), 0.94 (s, 6H). -539- EXAMPLE 416 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-N-( {5- fluoro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridm-3-yl}sulfonyl)-2-(lH-indazol- 4-yloxy)benzamide EXAMPLE 416A 5-bromo-3-fluoro-2-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridine The title compound was prepared by substituting EXAMPLE 306C for (tetrahydro-2H-pyran-4-yl)methanol and 5-bromo-2,3-difluoropyridine for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE 279A. EXAMPLE 416B tert-butyl5-fluoro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridin-3-ylcarbamate EXAMPLE 416A (0.658 g), tert-butyl carbamate (0.300 g), palladium(n) acetate (0.024 g), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.093 g) and cesium carbonate (1.044 g) were combined in a 20-mL vial with dioxane (10.7 ml). The vial was flushed with nitrogen, capped and stirred at 100 °C overnight. The reaction mixture was diluted with ethyl acetate, washed with water and brine, dried (MgS04), filtered, concentrated and chromatographed on silica gel with 20% ethyl aceate in hexanes as eluent. EXAMPLE 416C 5-fluoro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonyl chloride Under ice-cooling, thionyl chloride (1.563 mL) was added dropwise over 20 minutes to water (9 mL). The mixture was stirred for 12 hours to give a SOz-containing solution. Separately, EXAMPLE 416B (0.295 g) was added to a mixture of dioxane (3.2 mL) and concentrated HCl (8 ml) at 0 "C. The solution was stirred for 15 minutes, treated with a solution of sodium nitrite (0.065 g) in water (2 mL) dropwise at 0 "C and stirred at 0 °C for three hours. The SOi-containing solution was cooled to 0 °C, treated sequentially widi copper(I) chloride (0.042 g) and the diazotized mixture, and stirred for 30 minutes. The reaction mixture was then extracted with ethyl acetate and the organic layer was dried (MgS04), filtered and concentrated. The concentrate was chromatographed on silica gel with 5-10% ethyl aceate in hexanes as eluent. -540- EXAMPLE 416D 5-fluoro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridme-3-sulfonaraide EXAMPLE 416C (0.08 g,) in isopropanol (2 mL) at 0 °C was treated with ammonium hydroxide (L70 mL) and stirred overnight. The reaction mixture was concentrated to dryness, slurried in water, filtered, rinsed with water and dried under vacuum to provide the tide compound. EXAMPLE 416E 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N-( {5- fluoro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl)sulfonyl)-2-(lH-indazol- 4-yloxy)benzamide The tide compound was prepared by substituting EXAMPLE 400E for EXAMPLE 26C and EXAMPLE 416D for EXAMPLE IF in EXAMPLE 177. ^H NMR (400 MHz, PYRIDINE-d5) 8 14.67 (s, IH), 8.84 (d, IH), 8.38 (d, IH), 8.06 (d, IH), 8.00 (dd, IH), 7.46 (m, 2H), 7.35 (d, IH), 7.12 (m, 3H), 6.87 (m, 2H), 6.47 (d, IH), 4.56 (d, 2H), 3.80 (m, 4H), 3.18 (m, 4H), 2.83 (s, 2H), 2.31 (t, 2H), 2.24 (m, 4H), 1.99 (s, 2H), 1.86 (m, 4H), 1.41 (t, 2H), 0.96 (s, 6H). EXAMPLE 417 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yljmethyl }piperazin-l-yl)-N-( {3-nitro-4-[(l-tet^ahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl } sulfonyl)benzamide EXAMPLE 417A 2-( l-(bis(4-methoxyphenyl)methyl)-1 ff-benzo[rfIimidazol-4-yloxy)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-A'-(3-nitro-4-(l- (tetrahydro-2H-pyran-4-yl)piperidin-4-ylamino)phenylsulfonyl)benzamide TTie title compound was prepared by substituting EXAMPLE 173C for EXAMPLE IF in EXAMPLE 403H. -541- EXAMPLE 417B 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1-yl]methyl}piperazin-l-yl)-N-({3-nitio-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 417A for EXAMPLE 403H in EXAMPLE 403L 'H NMR (500 MHz, pyridine-ds) 5 9.27 (m, IH), 8.59 (s, IH), 8.47 (d, IH), 8.43 (d, IH), 8.01 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.24 (m, IH), 7.18 (m, IH), 7.07 (d, 2H), 6.96 (d, IH), 6.70 (m, 2H), 5.34 (m, 2H), 4.03 (m, 2H), 3.53 (m, IH), 3.31 (m, 2H), 3.03 (m, 4H), 2.82 (m, 2H), 2.76 (s, 2H), 2.42 (m, IH), 2.32 (m, 2H), 2.26 - 2.19 (m, 2H), 2.14 (m, 4H), 1.98 (m, 4H), 1.67 - 1.52 (m, 6H), 1.38 (m, 2H), 0.94 (s, 6H). EXAMPLE 418 2-( lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(l-methylpiperidiii-4-yl)amino]-3- nittophenyl} sulfonyl)benzamide EXAMPLE 418A 2-(I-(bis(4-methoxyphenyl)methyl)-lH-benzo[J]imidazol-4-yloxy)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-l -yl)-iV-(4-( 1 -methylpiperidin- 4-ylamino)-3-nitrophenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 21A for EXAMPLE IF in EXAMPLE 403H. EXAMPLE 418B 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl }piperazin-1 -yl)-N-( {4-[( 1 -methylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 418A for EXAMPLE 403H in EXAMPLE 403L 'H NMR (500 MHz, pyridine-ds) 5 9.25 (m, IH), 8.58 (s, IH), 8.42 (m, 2H), 8.02 (d, IH), 7.52 (d, IH), 7.43 (d, 2H), 7.23 (m, IH), 7.14 (d, IH), 7.07 (d, 2H), 6.92 (d, IH), 6.70 (m, 2H), 5.52 (m, 2H), 3.50 (m, IH), 3.03 (m, 4H), 2.77 (s, 2H), 2.68 (m, 2H), 2.25 (m, 2H), 2.20 (s, 3H), 2.14 (m, 6H), 1.97 - 1.90 (m, 4H), 1.67 (m, 2H), 1.38 (t,2H), 0.94 (s,6H). -542- EXAMPLE 419 N-[(5-chloro-6-{[l-(cyanomethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indazol-4-yloxy)benzamide EXAMPLE 419A tert-butyl 4-fluoro-4-(hydroxymetiiy l)piperidine-1 -carboxylate 1-Tert-butyl 4-ethyl 4-fluoropiperidine-l,4-dicarboxylate (LO g) in tetrahydrofuran (10 mL) at 0 °C was treated with a 1 N solution of LiAlH4 in tetrahydrofuran (2.54 mL), stirred for 2 hours at room temperature, treated sequentially dropwise with water (0.2 mL) and a 2 N aqueous solution of NaOH (0.6 mL), and stirred for 1 hour. The solid was removed by fdtration through a pad of diatomaceous earth rinsing with ethyl acetate. The filtrate was washed with water and brine, dried (MgS04), filtered and concentrated to give the tide compound. EXAMPLE 419B tert-butyl 4-((3-chloro-5-sulfamoylpyridin-2-yloxy)methyl)-4-fluoropiperidine-l-carboxylate The dtle compound was prepared by substituting EXAMPLE 419A for (tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 387A for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE 279 A. EXAMPLE 419C 5-chloro-6-((4-fluoropiperidin-4-yl)methoxy)pyridine-3-sulfonamide, 2«trifluoroaceticacid salt The title compound was prepared by substituting EXAMPLE 419B for EXAMPLE lA in EXAMPLE IB. EXAMPLE 419D 5-chloro-6-((l-(cyanomethyl)-4-fluoropiperidin-4-yl)methoxy)pyridine-3-sulfonamide EXAMPLE 419C (0.166 g) in acetonitrile (3.00 mL) was treated with 2-chloroacetonitrile (0.027 g) and sodium carbonate (0.064 g), heated at 60 °C overnight, cooled to room temperature and chromatographed on silica gel with 0 to 3% methanol in -543- CH2CI2 as eluent. The obtained solid was slurried in water, filtered, rinsed with water and diethyl ether, and dried in a vacuum oven at 80 °C to provide the title compound EXAMPLE 419E N- [(5-chloro-6- {[ I -(cyanomethyl)-4-fluoropiperidin-4-yl]methoxy }pyridin-3-yl)sulfonyl]-4- (4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-(l H- indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE 26C and EXAMPLE 419D for EXAMPLE IF in EXAMPLE 177. 'H NMR (400 MHz, PYRIDINE-ds) 6 14.70 (s, IH), 8.91 (d, IH), 8.39 (d, 2H), 8.10 (d, IH), 7.46 (m, 2H), 7.35 (d, IH), 7.11 (m, 3H), 6.87 (m, 2H), 6.50 (d, IH), 4.49 (d, 2H), 3.72 (s, 2H), 3.17 (m, 4H), 2.82 (s, 2H), 2.72 (m, 4H), 2.31 (m, 2H), 2.23 (m, 4H), 2.06 (m, 2H), 1.99 (s, 2H), 1.89 (m, 2H), 1.41 (t,2H), 0.96 (s,6H). EXAMPLE 420 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- {[5- chloro-6-(tetrahydrofiiran-3-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-indazol-4- yloxy)benzamide EXAMPLE 420A 5-chloro-6-((tetrahydrofuran-3-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 387A for EXAMPLE 329A and (tetrahydrofuran-3-yl)methanol for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 329B. EXAMPLE 420B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N- {[5- chloro-6-(tetrahydrofuran-3-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 420B for EXAMPLE IF and EXAMPLE 400E for EXAMPLE 26C in EXAMPLE 177. 'H NMR (500MHz, dimethylsulfoxide-de) 5 13.07 (s, IH), 8.25 (d, IH), 7.85 (d, IH), 7.79 (s, IH), 7.60 (d, IH), 7.36 (d, 2H), 7.03-7.09 (m, 4H), 6.78 (dd, IH), 6.51 (d, IH), 6.13 (dd, IH), -544- 4.25-4.37 (m, 2H), 3.77-3.81 (m, 2H), 3.64-3.70 (m, 2H), 3.54-3.57 (m, 2H), 3.17 (br s, 4H), 2.89 (br s, 2H), 2.68-2.71 (m, IH), 2.33 (m, 3H), 2.16-2.18 (m, 2H), 1.98-2.01 (m, 3H), 1.66-1.71 (m, IH), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 421 Trans-N-({5-chloro-6-[(4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4- y]oxy)benzamide EXAMPLE 421A 6-((trans-4-(tert-butyldimethylsilyloxy)cyclohexyl)methoxy)-5-chloropyridine-3-sulfonamide The tide compound was prepared by substituting EXAMPLE 387A for EXAMPLE 329A and trans-4-(tert-butyldimethylsilyloxy)cyclohexylmethanol, synthesized according to the procedure reported in WO 2008/124878 (Page 100), for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 329B. EXAMPLE 421B Trans-N-( {5-chloro-6-[(4-hydroxycyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 421A for EXAMPLE IF and EXAMPLE 400E for EXAMPLE 26C in EXAMPLE 177, after removal of the fert-butyldimethylsilyl group with trifluoroacetic acid. 'H NMR (500MHz, dimethylsulfoxide-de) 8 13.12 (s, IH), 8.29 (d, IH), 7.88 (d, IH), 7.84 (s, IH), 7.40 (d, 2H), 7.07-7.13 (m, 4H), 6.83 (dd, IH), 6.56 (s, IH), 6.17 (d, IH), 4.58 (d, IH), 4.21 (d, 2H), 3.22 (br s, 4H), 2.36-2.40 (m, 3H), 2.20-2.24 (m, 2H), 2.02-2.03 (m, 2H), 1.75-1.89 (m, 5H), 1.45 (t, 2H), 1.11-1.21 (m, 4H), 0.98 (s, 6H). EXAMPLE 422 N-[(5-chloK)-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol- 4-yloxy)benzamide - 545 - EXAMPLE 422A (R)-tert-butyl3-(3-chloro-5-sulfamoylpyridin-2-yloxy)pynolidine-l-carboxylate The title compound was prepared by substituting (R)-tert-butyl 3-hydroxypyrrolidine-1-carboxylate for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 387B. EXAMPLE 422B (R)-5-chloro-6-(pynolidin-3-yloxy)pyridine-3-sulfonamideHydrochloridesalt EXAMPLE 422A (480 mg) was dissolved in anhydrous tetrahydrofuran (10 mL) followed by addition of hydrogen chloride in dioxane solution (4M, 2.5 mL). The reaction mixture was stirred at room temperature overnight. The solvent was removed under vacuum to provide the title compound. EXAMPLE 422C (R)-5-chloro-6-(l-(2,2-difluoroethyl)pyrrolidin-3-yloxy)pyridine-3-sulfonamide A reaction mixture of EXAMPLE 422B (353 mg), l,l-difluoro-2-iodoethane (268 mg) and NaiCOs (283 mg) in N,N-dimethylfonnamide (10 mL) was heated at 80°C overnight. The reaction mixture was cooled to room temperature and diluted with ethyl acetate. The organic phase was washed with water and brine, dried over anhydrous sodium sulfate, and concentrated. The crude material was purified with 2.5-3% methanol/dichloromethane to afford the title compound. EXAMPLE 422D N-[(5-chloro-6-{I(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( 1 H-indazol- 4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE 26C and EXAMPLE 422C for EXAMPLE IF in EXAMPLE 177. 'H NMR (400MHZ, dimethylsulfoxide-de) 5 12.98 (s, IH), 8.17 (d, IH), 7.80 (d, IH), 7.73 (s, IH), 7.66 (d, IH), 7.35 (d, 2H), 7.05 (m, 4H), 6.73 (m, IH), 6.41 (d, IH), 6.10 (m, 2H), 5.37 (m, IH), 2.92 (m, 1 IH), 2.56 (m, 2H), 2.24 (m, 7H), 1.99 (m, 2H), 1.82 (m, IH), 1.39 (m, 2H), 0.93 (s, 6H). -546- EXAMPLE 423 2-(lH-benzimidazol-4-yloxy)-N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycyl)morpholin-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl ] methyl} piperazin-1 -yl)benzamide EXAMPLE 423A (5)-/ert-Butyl2-((3-chloro-5-sulfamoylpyridin-2-yloxy)methyl)morpholine-4-carboxylate This EXAMPLE was prepared by substituting (S)-tert-buty\ 2-(hydroxymethyl)morpholine-4-carboxylate for 4-hydroxymethyl-tetrahydropyran in EXAMPLE 387B. EXAMPLE 423B (iS)-5-chloro-6-(morphoUn-2-ylmethoxy)pyridine-3-sulfonamide This EXAMPLE was prepared by substituting EXAMPLE 423A for EXAMPLE 415A in EXAMPLE 4158. EXAMPLE 423C (5)-5-chloro-6-((4-(2-(dimethylaniino)acetyl)morpholin-2-yl)methoxy)pyridine-3- sulfonamide To a solution of EXAMPLE 423B (0.32 g) in anhydrous N,N-dimethylformamide (10 mL) was added sodium carbonate (0.165 g) and 2-(dimethylamino)acetyl chloride hydrochloride (0.40 g). After stirred at ambient temperature overnight, the mixture was concentrated to dryness. The residue was mixed with 5% aqueous Na2C03 (20 mL) and extracted with ethyl acetate. The crude product was purified on a silica gel column eluting with 10% methanol in dichloromethane saturated with ammonia to give the title compound. EXAMPLE 423D 2-(l//-benzimidazol-4-yloxy)-A^-[(5-chloro-6-{[(25)-4-(A',A'-dimethylglycyl)morpholin-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 423C for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500MHZ, pyridine-dj) 5 9.08 (d, IH), 8.60 (t, IH), 8.57 (s, IH), 8.01 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.25 (m, 2H), 7.15 (m, IH), 7.07 (d, 2H), 6.73-6.69 -547- (m, 2H), 4.86-4.36 (m, 4H), 4.05-3.90 (m, IH), 3.88 (d, IH), 3.62-3.18 (m, 4H), 3.04 (m, 4H), 2.87 (t, IH), 2.77 (s, 2H), 2.33 (m, 6H), 2.26 (m, 2H), 2.15 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H). EXAMPLE 424 2-(lH-benzimidazol-4-yloxy)-N-[(5-chloro-6-{[(2R)-4-(N,N-dimethylglycyl)moipholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl }piperazin-1 -yl)benzamide EXAMPLE 424A (/?)-te«-butyl2-((3-chloro-5-sulfamoylpyridin-2-yloxy)methyl)morpholine-4-carboxylate This EXAMPLE was prepared by substituting (/?)-tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate for 4-hydroxymethyl-tetrahydropyran in EXAMPLE 387B. EXAMPLE 424B (R)-5-chloro-6-(morpholin-2-ylmethoxy)pyridine-3-sulfonamide This EXAMPLE was prepared by substituting EXAMPLE 424A for EXAMPLE 415A in EXAMPLE 415B. EXAMPLE 424C (/?)-5-chloro-6-((4-(2-(dimethylamino)acetyl)morpholin-2-yl)methoxy)pyridine-3- sulfonamide This EXAMPLE was prepared by substituting EXAMPLE 424B for EXAMPLE 423B in EXAMPLE 423C. EXAMPLE 424D 2-( l«-benzimidazol-4-yloxy)-A?-[(5-chloro-6- {[(2/?)-4-(A',A/-dimethylglycyl)morpholin-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyI)-4,4-dimethylcyclohex-l-en-l- yljmethyl} piperazin-1 -yl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 424C for EXAMPLE 428D in EXAMPLE 428E. ^H NMR (500MHz, pyridine-ds) 8 9.08 (d, IH), 8.60 (t, IH), 8.57 (s, IH), 8.01 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.25 (m, 2H), 7.15 (m, IH), 7.07 (d, -548- 2H), 6.73-6.69 (m, 2H), 4.86-4.36 (m, 4H), 4.05-3.90 (m, IH), 3.88 (d, IH), 3.62-3.18 (m, 4H), 3.04 (m, 4H), 2.87 (t, IH), 2.77 (s, 2H), 2.33 (m, 6H), 2.26 (m, 2H), 2.15 (m, 4H), 1.97 (s, 2H), 1.39 (t, 2H), 0.94 (s, 6H). EXAMPLE 425 N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycyl)moipholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1- yl)-2-( 1 H-indazol-4-yloxy)benzamide This EXAMPLE was prepared by substituting EXAMPLE 400E for EXAMPLE IE and EXAMPLE 423C for EXAMPLE IF in EXAMPLE IG, and was purified by reverse-phase HPLC using a Waters Preparative LC4000 system with Phenomenex Luna C18 column and a water-acetonitrile mobile phase buffered with ammonium acetate. 'H NMR (500MHZ, pyridine-ds) 8 8.87 (dd, IH), 8.40 (t, 2H), 8.13 (dd, IH), 7.46 (d, 2H), 7.35 (d, IH), 7.15-7.10 (m, 3H), 6.87 (d, IH), 6.85 (s, IH), 6.50 (dd, IH), 4.84-4.46 (m, 4H), 4.02-3.90 (m, IH), 3.88 (m, IH), 3.60-3.33 (m, 2H), 3.25-3.15 (m, 6H), 2.89-2.84 (m, IH), 2.83 (s, 2H), 2.32-2.23 (m, 12H), 1.99 (s, 2H), 1.41 (t, 2H), 0.96 (s, 6H). 1250969 EXAMPLE 426 Gary Wang N-[(5-chloro-6-{[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 - yl)-2-( 1 H-indazol-4-yloxy)benzamide This EXAMPLE was prepared by substituting EXAMPLE 400E for EXAMPLE IE and EXAMPLE 424C for EXAMPLE IF in EXAMPLE IG, and was purified by reverse-phase HPLC using a Waters Preparative LC4000 system with Phenomenex Luna C18 column and a water-acetonitrile mobile phase buffered with ammonium acetate. 'H NMR (500MHz, pyridine-ds) 8 8.87 (dd, IH), 8.40 (t, 2H), 8.13 (dd, IH), 7.46 (d, 2H), 7.35 (d, IH), 7.15-7.10 (m, 3H), 6.87 (d, IH), 6.85 (s, IH), 6.50 (dd, IH), 4.84-4.46 (m, 4H), 4.02-3.90 (m, IH), 3.88 (m, IH), 3.60-3.33 (m, 2H), 3.25-3.15 (m, 6H), 2.89-2.84 (m, IH), 2.83 (s, 2H), 2.32-2.23 (m, 12H), 1.99 (s, 2H), 1.41 (t, 2H), 0.96 (s, 6H). -549- EXAMPLE 427 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[5- chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-indazol-4- yloxy)benzamide TTie title compound was prepared by substituting EXAMPLE 387B for EXAMPLE IF and EXAMPLE 400E for EXAMPLE 26C in EXAMPLE 177. 'H NMR (500MHz, dimethylsulfoxide-de) 8 13.09 (s, IH), 8.27 (d, IH), 7.85 (d, IH), 7.80 (s, IH), 7.59 (d, IH), 7.36 (d, 2H), 7.03-7.10 (m, 4H), 6.79 (dd, IH), 6.52 (d, IH), 6.13 (d, IH), 4.27 (d, 2H), 3.88 (dd, 2H), 3.19 (br s, 4H), 2.91 (br s, 2H), 2.36-2.40 (br, 3H), 2.18 (m, 2H), 2.05 (m, IH), 1.98 (s, 2H), 1.64-1.68 (m, 2H), 1.34-1.43 (m, 4H), 1.11-1.21 (m, 4H), 0.94 (s, 6H). EXAMPLE 428 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(3R)-l-(cyanomethyl)pyrrolidin-3-yl]amino}-3- nitrophenyl)sulfonyl]benzamide EXAMPLE 428A 8- {4- [2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-enylmethyl]piperazin-1 -yl} -6-oxa-2,11a- diazadibenzo[c,d,g]azulen-11 -one A solution of EXAMPLE 403G (4.5 g) in anhydrous dichloromethane (100 mL) was cooled in an ice bath and catalytic N,N-dimethylformamide was added. This was followed by the dropwise addition of a solution of oxalyl dichloride (1.231 mL) in anhydrous methylene chloride (5 mL). The ice bath was removed and the reaction stirred for 1 hour while warming to ambient temperature. The reaction was quenched by the addition of ice (150 mL) and saturated sodium bicarbonate solution (100 mL). The mixture was further diluted with saturated sodium bicarbonate solution (200 mL) and methylene chloride (200 mL). The organic layer was purified on silica gel, and was eluted with a 0,10, 25, and 100 % ethyl acetate in methylene chloride step gradient to provide the title compound. EXAMPLE 428B (R)-tert-h\xtyl 3 -(2-nitro-4-sulfamoylphenylamino)pynolidine-1 -carboxylate To a solution of (R)-tert-butyl 3-aminopyrrolidine-l-carboxylate (1.0 g), tetrahydrofuran (50 ml), N-ethyl-N-isopropylpropan-2-amine (5.61 mL) and N,N- -550- dimethylformamide (10 mL) was added 4-fluoro-3-nitrobenzenesulfonaniide (1.212 g) and the mixture was stirred for 18 hours. The crude product was isolated by concentration and was the material was purified on silica gel, and was elated with a 30, 50, and 75 % ethyl acetate in hexane step gradient to provide the title compound. EXAMPLE 428C (/?)-3-nitro-4-(pyrtolidin-3-ylamino)benzenesulfonamide A suspension of EXAMPLE 428B (2.018 g) in anhydrous dichloromethane (25 mL) was cooled in an ice bath and 2,2,2-trifluoroacetic acid (20 mL) was added. After stirring 15 minutes, the ice bath was removed and the reaction was allowed to come to ambient temperature over 2 hours. The reaction mixture was concentrated and the residue was dissolved in water and basified with aqueous sodium carbonate solution. The mixture was extracted repeatedly with 10 % methanol in methylene chloride and the organics were concentrated to provide the title compound. EXAMPLE 428D (/?)-4-(l-(cyanomethyl)pyrrohdin-3-ylamino)-3-nitrobenzenesulfonamide To a solution of EXAMPLE 428C (440 mg) in anhydrous N, N-dimethylformamide (10 mL) was added sodium carbonate (132 mg). To the resulting suspension was added 2-bromoacetonitrile (0.077 mL) and the mixture was heated at 60° C for 18 hours. The crude material was isolated by concentration and was purified on silica gel, and was eluted with a 0.5,2.5, and 5% methanol in methylene chloride step gradient to provide the title compound. EXAMPLE 428E 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chloiophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4-{[(3R)-l-(cyanomethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]benzamide To a solution of EXAMPLE 428D (82.6 mg) in tetrahydrofuran (7 mL) was added 2,3,4,6,7,8,9,10-octahydropyrimido[l,2-a]azepine (0.063 mL). This mixture was stirred at ambient temperature for 45 minutes and a solution of EXAMPLE 428A (117 mg) in tetrahydrofuran (3 mL) was added. After stirring 18 hours, the crude product was isolated by concentration and was purified by reverse phase chromatography with ammonium acetate buffer in acetonitrile to give the title compound. 'H NMR (400 MHz, pyridine-ds) 6 9.27 (d, -551- IH), 8.59 (s, IH), 8.55 (d, IH), 8.40 (dd, IH), 7.99 (d, IH), 7.54 (m, IH), 7.43 (d, 2H), 7.25 (m, IH), 7.16 (m, IH), 7.07 (d, 2H), 6.86 (d, IH), 6.69 (m, 2H), 5.73 (m, 2H), 4.15 (m, IH), 3.90 (s, 2H), 3.03 (m, 4H), 2.96 - 287. (m, 2H), 2.81 - 2.76 (m, 3H), 2.58 (m, IH), 2.32 - 2.23 (m, 3H), 2.14 (m, 4H), 1.97 (s, 2H), 1.73 (m, IH), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 429 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1- yl]methyl}piperazin-l-yl)-N-{[4-({(3R)-l-[2-(2-methoxyethoxy)ethyl]pyrrolidin-3- yl} amlno)-3-nitrophenyl]sulfonyl) benzamide EXAMPLE 429A (i?)-4-(l-(2-(2-methoxyethoxy)ethyl)pyrrolidin-3-ylamino)-3-nitiobenzenesulfonamide The title compound was prepared by substituting l-bromo-2-(2-methoxyethoxy)ethane for 2-bromoacetonitrile in EXAMPLE 428D. EXAMPLE 429B 2-( 1 H-benzimidazoI-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1-yl]methyl }piperazin-1 -yl)-N- {[4-( ((3R)-1 -[2-(2-methoxyethoxy)ethyl]pynolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}benzamide The title compound was prepared by substituting EXAMPLE 429A for EXAMPLE 428D in EXAMPLE 428E. ^H NMR (400 MHz, pyiidine-ds) 8 9.26 (d, IH), 8.58 (m, 2H), 8.38 (dd, IH), 8.01 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.25 (d, IH), 7.16 (d, IH), 7.07 (d, 2H), 6.85 (d, IH), 6.71 - 6.69 (m, 2H), 5.33 (m, 2H), 4.05 (m, IH), 3.63 (m, 4H), 3.54 (m, 2H), 3.29 (s, 3H), 3.03 (m, 4H), 2.86 (m, IH), 2.77 (m, 4H), 2.70 (t, 2H), 2.38 (m, IH), 2.27 -2.18 (m, 3H), 2.14 (m, 4H), 1.97 (s, 2H), 1.64 (m, IH), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 430 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N- [(4- {[(3R)-1 -(N,N-dimethylglycyl)pyrrolidin-3-yl]amino} -3- nitrophenyl)sulfonyl]benzamide EXAMPLE 430A ^)-4-(l-(2-(dimethylamino)acetyl)pyrrolidin-3-ylamino)-3-nitrobenzenesulfonamide -552- The title compound was prepared by substituting 2-(dimethylamino)acetyl chloride for 2-bromoacetonitrile in EXAMPLE 428D. EXAMPLE 430B 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl }piperazin-1 -yl)-N-[(4- {[(3R)-1 -(N,N-dimethylglycyl)pyrrolidin-3-yl]amino} -3- nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 430A for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (400 MHz, pyridine-dj) 5 9.25 (m, IH), 8.59 (d, IH), 8.47 - 8.35 (m, 2H), 8.01 (d, IH), 7.54 (d, IH), 7.44 (d, 2H), 7.25 - 7.20 (m, 2H), 7.16 - 6.92 (m, 4H), 6.71 (m, 2H), 5.55 (m, IH), 4.34 - 4.18 (m, IH), 4.03 (m, IH), 3.84 - 3.63 (m, 3H), 3.44 - 3.34 (m, 2H), 3.03 (m, 4H), 2.77 (s, 2H), 2.43 (m, 6H), 2.25 (m, 3H), 2.14 (m, 4H), 2.03 - 1.83 (m, 3H), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 431 2-( 1 H-benzimidazol-4-yloxy)-4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yI)-N- {[4-( {[4-(cyanomethyl)morpholin-2-yl]methyl} amino)-3- nitrophenyl]sulfonyl} benzamide EXAMPLE 431A 4-((4-(cyanomethyl)morpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide This EXAMPLE was prepared by substituting 2-bromo-acetonitrile for 2, 2-difluoroethyl iodide in EXAMPLE 415C at ambient temperature. EXAMPLE 43 IB 2-( 1 //-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl)piperazin-l-yl)-iV-{[4-({[4-(cyanomethyl)morpholin-2-yl]methyl}amino)-3- nitrophenyl]sulfonyl}benzamide This EXAMPLE was prepared by substitudng EXAMPLE 431A for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500MHz, pyridine-ds) 8 9.25 (d, IH). 8.87 (t, IH), 8.58 (s, IH), 8.38 (dd, IH), 8.00 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.25 (m, 2H), 7.16 (d, IH), 7.07 (d, 2H), 6.97 (d, IH), 6.73-6.68 (m, 2H), 3.96-3.85 (m, 2H), 3.78 (s, 2H), 3.66 (dt, -553- IH), 3.53-3.42 (m, 2H), 3.03 (m, 4H), 2.90 (d, IH), 2.76 (s, 2H), 2.61 (d, IH), 2.51 (dt, IH), 2.40 (t, IH), 2.25 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 432 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-N-[(4-{[(4-cyclopropylmorpholin-2-yl)methyl]amino)-3- nitrophenyl)sulfonyl]benzamide EXAMPLE 432A 4-((4-cyclopropylmorpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide A solution of EXAMPLE 415B (0.633 g) and (l-ethoxycyclopropoxy)triniethylsilane (1.601 ml) in anhydrous methanol (15 mL) and acetic acid (1.7 ml) was refluxed for 30 minutes and allowed to cool to room temperature. Sodium cyanoborohydride (0.377 g) was then added and the mixture was stirred at ambient temperature overnight. The reaction mixture was concentrated to dryness. The residue was mixed with 5% aqueous NaaCOs solution (25 mL) and extracted with ethyl acetate. The crude product was purified on a silica gel column eluting with 5% and 10% methanol in dichloromethane to provide the title compound. EXAMPLE 432B 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-7V-[(4-{[(4-cyclopropylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamide This EXAMPLE was prepared by substituting EXAMPLE 432A for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500MHZ, pyridine-ds) 8 9.25 (d, IH), 8.89 (t, IH), 8.57 (s, IH), 8.38 (dd, IH), 8.00 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.25 (m, 2H), 7.16 (d, IH), 7.07 (d, 2H), 6.98 (d, IH), 6.73-6.68 (m, 2H), 3.90-3.83 (m, 2H), 3.60 (dt, IH), 3.55- 3.41 (m, 2H), 3.03 (m, 4H), 2.96 (d, IH), 2.76 (s, 2H), 2.69 (d, IH), 2.35 (dt, IH), 2.26-2.20 (m, 3H), 2.14 (m, 4H), 1.97 (s, 2H), 1.59 (m, IH), 1.38 (t, 2H), 0.94 (s, 6H), 0.47-0.37 (m, 4H). -554- EXAMPLE 433 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(3-nitio-4-{[(4-oxetan-3-ylmoipholin-2- yl)methyl]amino} phenyl)sulfonyl]benzamide EXAMPLE 433A 3-nitro-4-((4-(oxetan-3-yl)morpholin-2-yl)methylamino)benzenesulfonamide This EXAMPLE was prepared by substituting oxetan-3-one for (1-ethoxycyclopiopoxy)-trimethylsilane in EXAMPLE 432A. EXAMPLE 433B 2-( l//-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-/V-[(3-nitro-4-{[(4-oxetan-3-ylmorpholin-2-yl)methyl]amino)phenyl)sulfonyl]benzamide This EXAMPLE was prepared by substituting EXAMPLE 433A for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500MHz, pyridine-ds) 8 9.25 (d, IH), 8.87 (t, IH), 8.57 (s, IH), 8.38 (dd, IH), 8.02 (d, IH), 7.53 (d, IH), 7.44 (d, 2H), 7.24 (m, 2H), 7.13 (d, IH), 7.07 (d, 2H), 6.98 (d, IH), 6.73-6.68 (m, 2H), 4.69-4.62 (m, 4H), 3.98-3.88 (m, 2H), 3.69 (dt, IH), 3.55-3.35 (m, 3H), 3.03 (m, 4H), 2.77 (s, 2H), 2.74 (d, IH), 2.44 (d, IH), 2.25 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.94 (m, IH), 1.87 (t, IH), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 434 N-{[5-chloro-6-({(3R)-l-[2-fluoro-l-(fluoromethyl)ethyl]pyrrolidin-3-yl}oxy)pyridin-3- yl] sulfonyl} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 - yl)-2-( 1 H-indazol-4-yloxy)benzamide EXAMPLE 434A (R)-5-chloro-6-(l-(l,3-difluoropropan-2-yl)pyrrolidin-3-yloxy)pyridine-3-sulfonamide EXAMPLE 422B (278 mg) and l,3-difluoropropan-2-one (94 mg) were suspended in dichloroethane (10 ml). N,N-dimethylformamide (1.5 mL) was added drop wise until a white milky suspension formed. The reaction mixture was stirred at room temperature for 15 minutes followed by the addition of sodium triacetoxyborohydride (424 mg). The reaction mixture was stirred at room temperature overnight. The solvent was removed under vacuum, -555- and the crude material was purified with 2.5-5% methanol/dichloromethane to afford the title compound. EXAMPLE 434B N-{[5-chloro-6-({(3R)-l-[2-fluoro-l-(fluoromethyl)ethyl]pyniolidin-3-yl}oxy)pyridin-3- yl]sulfonyl} -4-(4- {[2-(4-chIorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 - yl)-2-( 1 H-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE 26C and EXAMPLE 434A for EXAMPLE IF in EXAMPLE 177. 'H NMR (400MHZ, dimethylsulfoxide-d6) 8 12.96 (s, IH), 8.16 (d, IH), 7.79 (m, IH), 7.69 (m, 2H), 7.35 (d, 2H), 7.05 (m, 4H), 6.72 (m, IH), 6.39 (d, IH), 6.09 (dd, 3.05Hz, IH), 5.37 (m, IH), 4.66 (t, 2H), 4.54 (t, 2H), 2.91 (m, 12H), 2.23 (m, 7H), 1.97 (s, 2H), 1.82 (m, IH), 1.40 (t, 2H), 0.93 (s, 6H). EXAMPLE 435 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N- {[4- ({(3R)- l-[2-fluoro- l-(fluoromethyl)ethyl]pyrrc)lidin-3-yl) amino)-3-nitrophenyl]sulfonyl} -2- (lH-indazol-4-yloxy)benzamide EXAMPLE 435A (R)-1-(1,3-difluoropropan-2-yl)pyrrolidin-3-amine To a solution of (R)-tert-butyl pyrrolidin-3-ylcarbamate (0.500 g) and 1,3-difluoropropan-2-one (0.278 g) in dichloromethane (5 mL) was added sodium triacetoxyborohydride (0.853 g). After stirring for one hour, the reaction was quenched with saturated aqueous NaHCOj solution (5 mL). The mixture was extracted with dichloromethane (25 mL), and the organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated. The resulting residue was treated with HCl (4.0M in 1,4-dioxane, 4 mL) and methanol (1 mL) and stirred for one hour. The mixture was concentrated to give the title compound. EXAMPLE 435B (R)-4-( 1 -(1,3-difluoropropan-2-yl)pyrrolidin-3-ylamino)-3-nitrobenzenesulfonamide -556- To 4-fluoro-3-nitrobenzenesulfonamide (0.272 g) and EXAMPLE 435A (0.195 g) in tetrahydrofuran (3.0 mL) was added N-ethyl-N-isopropylpropan-2-aniine (0.512 mL) and the reaction stirred at room temperature. After stirring for six hours, the reaction was concentrated, loaded onto silica gel (Reveleris 40 g) and the product eluted using a gradient of 25-100% ethyl acetate/hexanes over 30 minutes to give the title compound. EXAMPLE 435C 4-{ 4-[2-(4-Chloro-phenyl)-4,4-dimethyl-cyclohex-1 -enylmethylj-piperazin-1 -yl} -2-[ 1 -(2-trimethylsilanyl-ethoxymethyl)-lH-indazol-4-yloxy]-benzoic acid methyl ester EXAMPLE 400D (1000 mg) was dissolved in N,N-dimethylformamide (12 mL) and sodium hydride (60% in mineral oil, 45 mg) was added. The solution was stirred at room temperature for 15 minutes, 2-(trimethylsilyl)ethoxymethyl chloride (299 mg) was added, and the solution was stirred at room temperature for 45 minutes. The solution was added to water and extracted with ethyl acetate. The extract was washed with brine, dried on anhydrous sodium sulfate, filtered, concentrated and purified by flash column chromatography on silica gel using 30-50% ethyl acetate in hexanes. EXAMPLE 435D 4- {4-I2-(4-Chloro-phenyl)-4,4-dimethyl-cyclohex-1 -enylmethyl]-piperazin-1 -yl} -2-[ 1 -(2-trimethylsilanyl-ethoxymethyl)-lH-indazol-4-yloxy]-benzoic acid The title compound was prepared by substituting EXAMPLE 435C for EXAMPLE ID in EXAMPLE IE. EXAMPLE 435E N- {4- {4- [2-(4-Chloro-phenyl)-4,4-dimethyl-cyclohex-1 -enylmethylj-piperazin-1 -yl} -2-[ 1 -(2- trimethylsilanyl-ethoxymethyl)-lH-indazol-4-yloxy]-benzoyl}-4-[(R)-l-(2-fluoro-l- fluoromethyl-ethyl)-pyrrolidin-3-ylamino]-3-nitro-benzenesulfonamide The title compound was prepared by substituting EXAMPLE 435D for EXAMPLE IE and EXAMPLE 435B for EXAMPLE IF in EXAMPLE IG. EXAMPLE 435F 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[4- ({(3R)-1 -[2-fluoro- l-(fluoromethyl)ethyl]pyrrolidin-3-yl) amino)-3-nitrophenyl]sulfonyl} -2- (lH-indazol-4-yloxy)benzamide -557- EXAMPLE 435E (103 mg) was dissolved in trifluoroacetic acid (1.8 mL) and water (0.2 mL) and stirred at room temperature for 90 minutes. The solvents were removed under vacuum, the residue dissolved in 1,4-dioxane (2 mL) and treated with IM sodium hydroxide (1 mL), and the solution stirred at room temperature for 30 minutes. The solution was added to a saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The extract was washed with brine, dried on anhydrous sodium sulfate, filtered, and the solvent removed under vacuum. 'H NMR (300MHZ, dimethylsulfoxide-de) 8 13.09 (bs, IH), 8.37 (m, 2H), 7.84 (d, IH), 7.58-7.45 (m, 2H), 7.36 (d, 2H), 7.17-7.03 (m, 4H), 6.95 (dd, IH), 6.84-6.76 (m, IH), 6.53 (dd, IH), 6.17 (t, IH), 4.72 (d, 2H), 4.56 (d, 2H), 4.23 (m, IH), 3.17 (m, 4H), 3.12-3.03 (m, 2H), 3.02-2.91 (m, 2H), 2.86-2.73 (m, 4H), 2.40-2.14 (m, 6H), 1.97 (bs, 2H), 1.70 (m, IH), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 436 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-N-( {4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nittophenyl}sulfonyl)-2-(lH-indazol-4- yloxy)benzamide EXAMPLE 436A 4-(l-cyclopropyl-piperidin-4-ylamino)-3-nitro-benzenesulfonamide The title compound was prepared by substituting l-cyclopropyl-piperidin-4-ylamine for l-(2-methoxy-ethyl)-piperidin-4-ylamine in EXAMPLE 189A. EXAMPLE 436B N-{4- {4-[2-(4-chlorophenyl)-4,4-dimethyl-cyclohex-1 -enylmethyl]-piperazin-1 -yl} -2-[ 1 -(2-trimethylsilanyl-ethoxymethyl)- lH-indazol-4-yloxy]-benzoyl} -4-(l -cyclopropyl-piperidin-4- ylamino)-3 -nitro-benzenesulfonamide The title compound was prepared by substituting EXAMPLE 435D for EXAMPLE IE and EXAMPLE 436A for EXAMPLE IF in EXAMPLE IG. EXAMPLE 436C 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitTC)phenyl}sulfonyl)-2-(lH-indazol-4- yloxy)benzamide -558- The title compound was prepared by substituting EXAMPLE 436B for EXAMPLE 435E in EXAMPLE 435F. 'H NMR (300MHZ, dimethylsulfoxide-dfi) 6 13.05 (bs, IH), 8.35 (d, IH), 8.17 (d, IH), 7.77 (bs, IH), 7.57 (td, 2H), 7.35 (d, 2H), 7.09-7.03 (m, 4H), 6.98 (d, IH), 6.77 (dd, IH), 6.48 (bs, IH), 6.17 (m, IH), 3.66 (m, IH), 3.12 (bs, 4H), 2.92 (m, 2H), 2.76 (bs, 2H), 2.21 (m, 8H), 1.97 (bs, 2H), 1.94 (m, 2H), 1.73 (m, IH), 1.55 (m, 2H), 1.40 (t, 2H), 0.93 (s, 6H), 0.46 (d, 2H), 0.35 (bs, 2H). EXAMPLE 437 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl) piperazin-1 -y])-N- {[4-( {[(2R)-4-(N,N-dimethylglycyl)morpholin-2- yl]methyl}amino)-3-nitrophenyl]sulfonyl}benzamide EXAMPLE 437A (/?)-/er/-butyl2-((2-nitro-4-sulfamoylphenylamino)methyl)morpholine-4-catboxylate The title compound was prepared by substituting {R)-tert-huty\ 2-(aminomethyl)moipholine-4-carboxylate for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 437B (■S)-4-(morpholin-2-ylmethylamino)-3-nitrobenzenesulfonamide The title compoimd was prepared by substituting EXAMPLE 437A for EXAMPLE 415A in EXAMPLE 415B. EXAMPLE 437C (/?)-4-((4-(2-(dimethylamino)acetyl)morpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 437B for EXAMPLE 423B in EXAMPLE 423C. EXAMPLE 437D 2-( lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- {[4-( {[(2R)-4-(N,N-dimethylglycyl)morpholin-2- yl]methyl} amino)-3-nitrophenyl]sulfonyl }benzamide -559- The title compound was prepared by substituting EXAMPLE 437C for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500MHZ, pyridine-ds) 8 9.25 (s, IH), 8.86 (t, IH), 8.57 (s, IH), 8.38 (t, IH), 8.02 (d, IH), 7.53 (d, IH), 7.44 (d, 2H), 7.24 (m, 2H), 7.13 (d, IH), 7.07 (d, 2H), 6.97 (dd, IH), 6.73-6.68 (m, 2H), 4.75,4.50 (dd, IH), 4.33,4.02 (dd, IH), 3.93 (m, IH), 3.85-3.70 (m, IH), 3.65-3.40 (m, 3H), 3.33 (dd, IH), 3.25-3.10 (m, 2H), 3.03 (m, 4H), 2.90 (m, IH), 2.77 (s, 2H), 2.27-2.25 (m, 8H), 2.14 (m, 4H), 1.97 (s, 2H), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 438 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-{[4-({[(2S)-4-(N,N-dimethylglycyl)niorpholin-2- yl]methyl} amino)-3-nitrophenyl]sulfonyl jbenzamide EXAMPLE 438A (S)-Iert-butyl2-((2-nitro-4-sulfamoylphenylamino)methyl)morpholine-4-carboxylate The title compound was prepared by substituting iS)-tert-buty\ 2-(aminomethyl)morpholine-4-carboxylate for (tetrahydiopyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 438B (7?)-4-(morpholin-2-ylmethylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 438A for EXAMPLE 415A in EXAMPLE 415B. EXAMPLE 438C (5)-4-((4-(2-(dimethylamino)acetyl)morpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 438B for EXAMPLE 423B in EXAMPLE 423C. -560- EXAMPLE 438D 2-( lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl }piperazin-1 -yl)-N- {[4-({ [(2S)-4-(N,N-dimethylglycyl)morpholin-2- yl]methyl)amino)-3-nitrophenyl]sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 438C for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500MHZ, pyridine-ds) 8 9.25 (s, IH), 8.86 (t, IH), 8.57 (s, IH), 8.38 (t, IH), 8.02 (d, IH), 7.53 (d, IH), 7.44 (d, 2H), 7.24 (m, 2H), 7.13 (d, IH), 7.07 (d, 2H), 6.97 (dd, IH), 6.73-6.68 (m, 2H), 4.75,4.50 (dd, IH), 4.33,4.02 (dd, IH), 3.93 (m. IH), 3.85-3.70 (m, IH), 3.65-3.40 (m, 3H), 3.33 (dd, IH), 3.25-3.10 (m, 2H), 3.03 (m, 4H), 2.90 (m, IH), 2.77 (s, 2H), 2.27-2.25 (m, 8H), 2.14 (m, 4H), 1.97 (s, 2H), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 439 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydrofuran-3- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 439A 3-nitro-4-((tetrahydrofuran-3-yl)methylamino)benzenesulfonamide The title compound was prepared by substituting (tetrahydrofiiran-3-yl)methylamine for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 439B 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl} piperazin-1 -yl)-N-( {3-nitro-4-[(tetrahydrofuran-3-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 439A for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500MHz, pyridine-ds) 6 9.26 (d, IH), 8.70 (t, IH), 8.57 (s, IH), 8.40 (dd, IH), 8.01 (d, IH), 7.51 (d, IH), 7.44 (d, 2H), 7.24 (m, 2H), 7.14 (d, IH), 7.07 (d, 2H), 6.89 (d, IH), 6.73-6.68 (m, 2H), 3.93-3.89 (m, IH), 3.83 (dd, IH), 3.83-3.68 (m, 2H), 3.33-3.23 (m, 2H), 3.03 (m, 4H), 2.77 (s, 2H), 2.55-2.50 (m, IH), 2.25 (m, 2H), 2.14 (m, 4H), 2.00-1.93 (m, 3H). 1.65-1.58 (m, IH), 1.38 (t, 2H), 0.94 (s, 6H). -561- EXAMPLE 440 Trans-2-( lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-cMorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-I(4- {[(4-methoxycyclohexyl)methyl]amino} -3 - nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 31 IB for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500 MHz, pyridine-ds) 5 9.29 (d, IH), 8.67 (t, IH), 8.59 (s, IH), 8.41 (dd, IH), 7.99 (d, IH), 7.52 (d, IH), 7.43 (d, 2H), 7.24 (m, IH), 7.17 (m, IH), 7.07 (d, 2H), 6.90 (d, IH), 6.72 - 6.68 (m, 2H), 5.97 (m, 2H), 3.29 (s, 3H), 3.14 (t, 2H), 3.02 (m, 5H), 2.76 (s, 2H), 2.25 (m, 2H), 2.13 (m, 4H), 2.07 (m, 2H), 1.97 (s, 2H), 1.82 (m, 2H), 1.57 (m, IH), 1.38 (t, 2H), 1.22 (m, 2H), 1.01 (m, 2H), 0.94(s, 6H). EXAMPLE 441 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl)piperazin-l-yl)-N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino]-3- mtrophenyl)sulfonyl]benzaniide The title compound was prepared by substituting EXAMPLE 409D for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500 MHz, pyridine-ds) 5 9.27 (d. IH), 8.84 (t, IH), 8.57 (s. IH), 8.41 (dd, IH), 7.99 (d, IH), 7.52 (d, IH), 7.43 (d, 2H), 7.23 (m, IH), 7.15 (m, IH), 7.14 - 7.02 (m, 3H), 6.70 (m, 2H), 6.49 (m, 2H), 3.86 (m, 2H), 3.76 - 3.69 (m, 3H), 3.65 (d, IH), 3.03 (m, 4H), 2.76 (s, 2H), 2.25 (m. 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.92 -1.76 (m, 4H), 1.38 (t,2H), 0.94 (s,6H). EXAMPLE 442 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1-yl]methyl}piperazin-l-yl)-N-({5-fIuoro-6-[(4-fluorotetrahydK)-2H-pyran-4-yl)methoxy]pyridin-3-yI} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 416D for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500 MHz, pyridine-ds) 5 9.02 (d, IH), 8.59 (s, IH), . 8.35 (m, IH), 8.01 (d, IH), 7.51 (d, IH), 7.44 (d, 2H), 7.22 (m, 2H), 7.12 (d, IH), 7.07 (d, 2H), 6.84 (m, IH), 6.73 (m, 2H), 4.59 (s, IH), 4.54 (s, IH), 3.89 - 3.74 (m, 4H), 3.05 (m, 4H), 2.78 (s, 2H), 2.26 (m, 2H),2.16 (m, 4H), 2.02 - 1.81 (m, 6H), 1.39 (t, 2H), 0.94 (s. 6H). -562- EXAMPLE 443 2-(lH-benzimidazol-4-yloxy)-N-({5-ch]oro-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl }piperazin-1 -yl)benzamide The title compound was prepared by substituting EXAMPLE 404A for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500 MHz, pyridine-ds) 5 9.12 (d, IH), 8.68 (d, IH), 8.59 (s, IH), 7.99 (d, IH), 7.52 (d, IH), 7.44 (d, 2H), 7.24 (d, IH), 7.15 (d, IH), 7.07 (d, 2H), 6.73 - 6.69 (m, 3H), 6.56 (m, IH), 4.56 (s, IH), 4.51 (s, IH), 3.91 - 3.76 (m, 4H), 3.04 (m, 4H), 2.77 (s, 2H), 2.26 (m, 2H), 2.15 (m, 4H), 1.99 - 1.85 (m, 6H), 1.39 (t, 2H), 0.94 (s, 6H). EXAMPLE 444 N-{[5-chloro-6-({(3R)-l-[2-fluoro-l-(fluoromethyl)ethyl]pyrTolidin-3-yl}methoxy)pyridin-3-yljsulfonyl} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1- yl)-2-( lH-indazol-4-yloxy)benzamide EXAMPLE 444A (R)-5-chloro-6-(( 1 -(1,3-difluoropropan-2-yl)pyrrolidin-3-yl)methoxy)pyridine-3-sulfonamide The tide compound was prepared by substituting EXAMPLE 445B for EXAMPLE 422B in EXAMPLE 434A. EXAMPLE 444B N- {[5-chloro-6-( {(3R)-1 - [2-fluoro-1 -(fluoromethyl)ethyl]pyrrolidin-3-yl} methoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l- yI)-2-(lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE 26C and EXAMPLE 444A for EXAMPLE IF in EXAMPLE 177. 'H NMR (400MHz, dimethylsulfoxide-dfi) S 12.98 (s, IH), 8.19 (d, IH), 7.81 (d, IH), 7.73 (s, IH), 7.66 (d, IH), 7.35 (d, 2H), 7.05 (m, 4H), 6.73 (dd, IH), 6.42 (d, IH), 6.10 (m, IH), 4.64 (s, 2H), 4.54 (d, 2H), 4.24 (m, 2H), 3.07 (s, 4H), 2.89 (s, 2H), 2.74 (m, 4H), 2.56 (m, 2H), 2.20 (m, 6H), 1.98 (m, 4H), 1.54 (m, IH). 1.40 (t, 2H), 0.91 (s, 6H). -563- EXAMPLE 445 N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]- 4.(4. {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide EXAMPLE 445A (R)-tert-butyl3-((3-chloio-5-sulfamoylpyridin-2-yloxy)methyl)pyrrolidine-l-carboxylate The title compound was prepared by substituting (R)-tert-butyl 3-(hydroxymethyl)pynolidine-l-carboxylate for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 387B. EXAMPLE 445B (R)-5-chloro-6-(pyrrolidin-3-ylmethoxy)pyridine-3-sulfonaniide The title compound was prepared by substituting EXAMPLE 445A for EXAMPLE 422A in EXAMPLE 422B. EXAMPLE 445C (R)-5-chloro-6-((l-(2,2-difluoroethyl)pynolidin-3-yl)melhoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 445B for EXAMPLE 422B in EXAMPLE 422C. EXAMPLE 445D N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidin-3-yl]methoxy)pyridin-3-yl)sulfonyl]- 4-(4-{[2-(4-chloiophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indazo]-4-yIoxy)benzamide The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE 26C and EXAMPLE 445C for EXAMPLE IF in EXAMPLE 177. 'H NMR (400MHz, dimethylsulfoxide-de) 8 12.98 (s, IH), 8.19 (d, IH), 7.81 (d, IH), 7.73 (s, IH), 7.66 (d, IH), 7.35 (d, 2H), 7.05 (m, 4H), 6.72 (dd, IH), 6.41 (d, IH), 6.10 (m, 2H), 4.23 (m, 2H), 3.07 (s, 4H), 2.82 (m, 5H), 2.62 (m, 3H), 2.24 (s, 4H), 2.17 (s, 2H), 1.94 (m, 3H), 1.53 (m, IH), 1.40 (t, 2H), 0.93 (s, 6H). -564- EXAMPLE 446 Trans-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2- (lH-indazol-4-yloxy)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino)-3- nitrophenyl)sulfonyl]benzamide EXAMPLE 446A 2-[l-(2-trimethylsilanyl-ethoxymethyl)-lH-indazol-4-yloxy]-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-N-(4-((trans-4- methoxycyclohexyl)methylamino)-3-nitrophenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 435D for EXAMPLE IE and EXAMPLE 31 IB for EXAMPLE IF in EXAMPLE 1G. EXAMPLE 446B Trans-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4-yloxy)-N-[(4- {[(4-methoxycyclohexyl)methyl]amino} -3-nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 446A for EXAMPLE 435E in EXAMPLE 435F. 'H NMR (300MHz, dimethylsulfoxide-de) 8 13.08 (bs, IH), 8.53 (t, IH), 8.37 (d, IH), 7.84 (d, IH), 7.53 (m, 2H), 7.35 (d, 2H), 7.09 (d, 2H), 7.05 (d, 2H), 6.94 (d, IH), 6.79 (m, IH), 6.51 (dd, IH), 6.18 (m, IH), 3.23 (s, 3H), 3.17-3.00 (m, 5H), 2.78 (bs, 2H), 2.30-2.13 (m, 8H), 2.02 (m, 2H), 1.97, (bs, 2H), 1.80 (m, 2H), 1.60 (m, IH), 1.40 (t, 2H), 1.07 (m, 4H), 0.93 (s, 6H). EXAMPLE 447 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl Ipiperazin- l-yl)-N-{ [4- (1,4-dioxan-2-ylmethoxy)-3 -nitrophenyljsulfonyl} -2-( 1 H-indazol-4-yloxy)benzamide EXAMPLE 447A N- {4- {4- [2-(4-Chloro-phenyl)-4,4-dimethyl-cyclohex- 1-enylmethyl] -piperazin-1 -yl} -2-[ 1 -(2-trimethylsilanyl-ethoxymethyl)-1 H-indazol-4-yloxy]-benzoyl} -4-([ 1,4]dioxan-2-ylmethoxy)- 3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 435D for EXAMPLE IE and EXAMPLE 297A for EXAMPLE IF in EXAMPLE IG. - 565 - EXAMPLE 447B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N- {[4-(l,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}-2-(lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 447A for EXAMPLE 435E in EXAMPLE 435F. 'H NMR (300MHZ, dimethylsulfoxide-de) 8 13.04 (bs, IH), 8.07 (bs, IH), 7.78 (t, 2H), 7.59 (d, IH), 7.36 (d, 2H), 7.25 (d, IH), 7.08 (d, 2H), 7.06 (d, 2H), 6.77 (d, IH), 6.48 (bs, IH), 6.15 (m, IH), 4.20 (t, 2H), 3.92-3.76 (m, 3H), 3.65 (m, 2H), 3.48 (td, 2H), 3.14 (bs, 4H), 2.80 (m, 2H), 2.38-2.13 (m, 6H), 1.97 (bs, 2H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 448 N-({5-chloro-6-[(l-cyclopropylpiperidin-4-yl)amino]pyridin-3-yl)sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide EXAMPLE 448A 5-chloro-6-(l-cyclopropyl-piperidin-4-ylamino)-pyridine-3-sulfonic acid amide The title compound was prepared by substituting l-cyclopiopyl-piperidin-4-ylamine for l-(2-methoxy-ethyl)-piperidin-4-ylamine and EXAMPLE 387A for 4-chloro-3- nitrobenzenesulfonamide in EXAMPLE 189A. EXAMPLE 448B 5-Chloro-6-( 1 -cyclopropyl-piperidin-4-ylamino)-pyridine-3-sulfonic acid 4- {4- [2-(4-chlorD- phenyl)-4,4-dimethyl-cyclohex-l-enyhnethyl]-piperazin-l-yl}-2-[l-(2-trimethylsilanyl- ethoxymethyl)-1 H-indazol-4-yloxy]-benzoylamide The title compound was prepared by substituting EXAMPLE 435D for EXAMPLE IE and EXAMPLE 448A for EXAMPLE IF in EXAMPLE IG. EXAMPLE 448C N-( {5-chloro-6-[( 1 -cyclopropylpiperidin-4-yl)amino]pyridin-3-yl} sulfonyl)-4-(4- {I2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide -566- The title compound was prepared by substituting EXAMPLE 448B for EXAMPLE 435E in EXAMPLE 435F. 'H NMR (300MHZ, dimethylsulfoxide-ds) 6 13.03 (bs, IH), 8.18 (d, IH), 7.79 (bs, IH), 7.65-7.58 (m, 2H), 7.36 (d, 2H), 7.33 (m, IH), 7.10 (d, 2H), 7.06 (d, 2H), 6.74 (dd, IH), 6.43 (bs, IH), 6.19 (m, IH), 3.95 (m, IH), 3.08 (m, 4H), 2.96 (m, 2H), 2.75 (bs, 2H), 2.37-2.10 (m, 9H), 1.97 (bs, 2H), 1.78 (m, 2H), 1.56 (m, 2H), 1.40 (t, 2H), 0.93 (s, 6H), 0.42 (d, 2H), 0.33 (bs, 2H). EXAMPLE 449 2-( 1 H-benzimidazol-4-yloxy)-N-( {5 -chloro-6- [(1 -cyclopropylpiperidin-4-yl)amino]pyridin-3-yl j sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy]cyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)benzanude EXAMPLE 449A 5-chIoro-6-(l-cyclopropylpiperidin-4-ylamino)pyridine-3-sulfonamide A mixture of EXAMPLE 387A (0.4 g), l-cyclopropylpiperidin-4-amine (0.3 g) and N,N-diisopr(^ylethylamine (0.37 mL) in dioxane (3 mL) was heated at 100° C for 18 hours. The crude product was isolated by concentration and was purified on silica gel, which was eluted with ethyl acetate to give the title compound. EXAMPLE 449B 2-( lH-benzimidazol-4-yloxy)-N-( {5 -chloro-6- [(1 -cyclopropylpiperidin-4-yl)amino]pyridin-3-yl) sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)benzamide The title compound was prepared by substituting EXAMPLE 449A for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500 MHz, pyridine-ds) 8 9.22 (m, IH), 8.55 (s, IH), 8.47 (s, IH), 8.00 (d, IH), 7.54 (d, IH), 7.44 (d, 2H), 7.25 (m, IH), 7.19 (m, IH), 7.07 (d, 2H), 7.01 (m, IH), 6.68 (m, 2H), 5.35 (m, 2H), 4.22 (m, IH), 3.04 - 2.95 (m, 6H), 2.77 (s, 2H), 2.29 - 2.24 (m, 4H), 2.14 (m, 4H), 2.03 (m, 2H), 1.97 (s, 2H), 1.70 (m, 2H), 1.52 (m, IH), 1.38 (t, 2H), 0.94 (s, 6H), 0.35 (m, 4H). -567- EXAMPLE 450 2-(l H-benzimidazol-4-yloxy)-4-(4- {l2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl Ipiperazin-1 -yl)-N-( {4-[( 1,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 336A for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500 MHz, pyridine-dsS) 8 9.24 (m, IH), 8.81 (m, IH), 8.56 (s, IH), 8.37 (dd, IH), 8.03 (d, IH), 7.52 (d, IH), 7.44 (d, 2H), 7.21 (m, IH), 7.11 (m, IH), 7.07 (d, 2H), 6.92 (d, IH), 6.71 (m, 2H), 5.33 (m, 2H), 3.94 (m, 2H), 3.78 (m, IH), 3.73 - 3.66 (m, 2H), 3.58 (m, IH), 3.51 - 3.36 (m, 3H), 3.03 (m, 4H), 2.77 (s, 2H), 2.26 (m, 2H), 2.15 (m, 4H), L97 (s, 2H), L39 (t, 2H), 0.94 (s, 6H). EXAMPLE 451 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcycIohex-l-en-l- yl]methyl}piperazin-l-yl)-N-({4-[(l-cyclopropylpiperidin-4-yl)amino]-3- nitropheny]} sulfony])benzamide EXAMPLE 451A 4-(l-cyclopropylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide To a solution of 4-fluoro-3-nitrobenzenesulfonamide (1.26 g) and 1-cyclopropylpiperidin-4-amine (0.802 g) in tetrahydrofuran (20 mL) was added N,N-diisopiopylethylamine (2.22 g) and 4-dimethylaminopyridine (35 mg). The mixture was heated at reflux for 18 hours and upon cooling was diluted with ethyl acetate (200 mL) and aqueous NaHCOs. The crude product was isolated by concentration of the organic layer and was purified on silica gel, which was eluted with 5% methanolic ammonia in methylene chloride to give the title compound. EXAMPLE 45 IB 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl)piperazin-l-yl)-N-({4-[(l-cyclopropylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 451 A for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500 MHz, pyridine-ds) 8 9.26 (m, IH), 8.59 (s, IH), -568- 8.46 (d, IH), 8.42 (dd, IH), 8.01 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.25 (d, IH), 7.17 (d, IH), 7.07 (d, 2H), 6.96 (d, IH), 6.72 - 6.67 (m, 2H), 5.48 (m, 2H), 3.54 (m, IH), 3.03 (m, 4H), 2.90 (m, 2H), 2.76 (s, 2H), 2.37 (m, 2H), 2.25 (m, 2H), 2.14 (m, 4H), 1.98 -1.91 (m, 4H), 1.56 (m, 3H), 1.38 (t, 2H), 0.94 (s, 6H), 0.42 (m, 4H). EXAMPLE 452 Trans-2-( lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1-yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholm-4-ylcyclohexyl)amino]-3-nitiophenyl) sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 204A for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500 MHz, pyridine-dj) 8 9.27 (m, 1 H), 8.59 (s, 1 H), 8.42 (dd, 1 H), 8.36 (d, 1 H), 8.01 (d, 1 H), 7.53 (d, 1 H), 7.43 (d, 2 H), 7.25 (m, 1 H), 7.17 (m, 1 H), 7.07 (d, 2 H), 6.95 (d, 1 H), 6.71 (d, 2 H), 6.33 (m, 2 H), 3.76 (m, 4 H), 3.40 (m, 1 H), 3.03 (m, 4 H), 2.76 (s, 2 H), 2.52 (m, 4 H), 2.25 (m, 3 H), 2.14 (m, 4 H), 2.07 (m, 2 H), 1.97 (m, 2 H), 1.89 (m, 2 H), 1.42 - 1.21 (m, 6 H), 0.94 (s, 6 H). EXAMPLE 453 2-(l H-benzimidazol-4-y]oxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 174A for EXAMPLE 428D in EXAMPLE 428E. ^H NMR (500 MHz, pyridine-ds) 8 9.25 (m, 2H), 8.59 (s, IH), 8.44 (m, IH), 8.00 (d, IH), 7.68 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.25 (m, IH), 7.17 (m, IH), 7.06 (d, 2H), 6.72 - 6.67 (m, 2H), 6.36 (m, IH), 2.02 (m, 4H), 2.93 (m, 4H), 2.76 (s, 2H), 2.74 - 2.61 (m, 2H), 2.35 - 2.22 (m, 5H), 2.19 (s, 3H), 2.16 - 2.10 (m, 4H), 1.97 (m, 2H), 1.38 (t,2H), 0.94 (s,6H). EXAMPLE 454 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl }piperazin-1 -yl)-N-[(4- {[(1 -methy]piperidin-4-y])methyl]amino} -3- nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 88A for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500 MHz, pyridine-ds) 8 9.28 (m, IH), 8.66 (m, IH), - 569 - 8.58 (s, IH), 8.40 (dd, IH), 8.02 (d, IH), 7.53 (d, IH), 7.44 (d. 2H), 7.24 (m, IH), 7.15 (m, IH), 7.07 (d, 2H), 6.89 (d, IH), 6.73 - 6.69 (m, 2H), 5.86 (m, 2H), 3.17 (t, 2H), 3.01 - 3.04 (m, 4H), 2.86 (m, 2H), 2.77 (s, 2H), 2.25 (m, 5H), 2.14 (m, 4H), 1.96 - 1.97 (s, 2H), 1.92 (m, 2H), 1.70 (m, 2H), 1.60 (m, IH), 1.48 - 1.37 (m, 4H), 0.94 (s, 6H). EXAMPLE 455 2-( lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl) piperarin- l-yl)-N-( {4- [({(2R)-4- [2-(2-methoxyethoxy)ethy l]morpholin-2- yl}methyl)amino]-3-nitrophenyl}sulfonyl)benzamide EXAMPLE 455A (/?)-4-((4-(2-(2-methoxyethoxy)ethyl)morpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 437B for EXAMPLE 415B and 2-(2-methoxyethoxy)ethyl bromide for 2,2-difluoroethyl iodide in EXAMPLE 415C. EXAMPLE 455B 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4-[(((2R)-4-[2-(2-methoxyethoxy)ethyl]morpholin-2-yl }methyl)amino]-3-nitrophenyI} sulfonyI)benzamide The title compound was prepared by substituting EXAMPLE 455A for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500MHZ, pyiidine-ds) 5 9.24 (d, IH), 8.85 (t, IH), 8.56 (s, IH), 8.36 (dd, IH), 8.03 (d, IH), 7.51 (d, IH), 7.44 (d, 2H), 7.24 (m, 2H), 7.12 (d, IH), 7.07 (d, 2H), 6.91 (d, IH), 6.73-6.68 (m, 2H), 3.93-3.86 (m, 2H), 3.72-3.61 (m, 5H), 3.53 (m, 2H), 3.48-3.40 (m, 2H), 3.28 (s, 3H), 3.03 (m, 4H), 2.95 (d, IH), 2.77 (s, 2H), 2.70 (d, IH), 2.69 (t, 2H), 2.27-2.10 (m, 8H), 1.97 (s, 2H), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 456 2-(lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l -en-1- yl]methyl )piperazin-l -yl)-N-[(4- {[(4,4-difluorocyclohexyl)methyl]amino} -3- nitrophenyl)sulfonyl]benzamide -570- The title compound was prepared by substituting EXAMPLE 412C for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500MHZ, pyridine-ds) 8 9.29 (d, IH), 8.73 (t, IH), 8.58 (s, IH), 8.42 (dd, IH), 7.99 (d, IH), 7.52 (d, IH), 7.43 (d, 2H), 7.24 (m, 2H), 7.17 (d, IH), 7.07 (d, 2H), 6.94 (d, IH), 6.72 (d, IH), 6.69 (dd, IH), 3.22 (t, 2H), 3.03 (m, 4H), 2.76 (s, 2H), 2.25 (m, 2H), 2.13 (m, 6H), 1.97 (s, 2H), 1.85-1.70 (m, 5H), 1.38 (t, 2H), 1.36-1.33 (m, 2H), 0.94 (s, 6H). EXAMPLE 457 N-[(4-{[(4-acetylmorpholin-2-yl)methyl]aniino}-3-nitrophenyl)sulfonyl]-2-(lH- benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl ] piperazin-1-yl)benzamide EXAMPLE 457A 4-((4-acetylmorpholin-2-yl)methylamino)-3-nitiobenzenesulfonamide A solution of EXAMPLE 415B (145 mg) and 7V-ethyl-^-isopropylpropan-2-amine (120 nl) in anhydrous dichloromethane (5 mL) and N.N-dimethylformamide (2 mL) was cooled with an ice bath and acetic anhydride (56 nl) was added dropwise. The mixture was stirred at room temperature for 3 hours and concentrated to dryness. The residue was triturated with water. The resulting solid was dried under vacuum to give the title compound. EXAMPLE 457B N-[(4-{[(4-acetylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-benzimida2ol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyc]ohex-1 -en-1 - yl]methyl} piperazin-1 -yl)benzamide The tiUe compound was prepared by substituting EXAMPLE 457A for EXAMPLE 428D in EXAMPLE 428E. *H NMR (500MHz, pyridine-ds) 8 9.24 (d, IH), 8.83 (t, IH), 8.56 (s, IH), 8.38 (dd, IH), 8.03 (d, IH), 7.51 (d, IH), 7.43 (d, 2H), 7.24 (m, 2H), 7.09 (d, IH), 7.07 (d, 2H), 6.91 (dd, IH), 6.72 (m, 2H), 3.89 (m, IH), 3.80-3.70 (m, IH), 3.60-3.40 (m, 4H), 3.06 (m, IH), 3.03 (m, 4H), 2.77 (s, 2H), 2.70 (m, IH), 2.26 (m, 2H), 2.18-2.13 (m, 5H), 2.09 (s, 3H), 1.97 (s, 2H), 1.38 (t, 2H), 0.94 (s, 6H). - 571 - EXAMPLE 458 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl Ipiperazin- l-yl)-N- {[4-( {[4-(methylsulfonyl)morpholin-2-yl]methyl} amino)-3- nitrophenyl]sulfonyl} benzamide EXAMPLE 458A 4-((4-(methylsulfonyl)morpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting methanesulfonyl chloride for acetic anhydride in EXAMPLE 457A. EXAMPLE 458B 2-(l H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- {[4-( {[4-(niethylsulfonyl)morpholin-2-yl]methyl} amino)-3- nitropheny 1] sulfony 1} benzamide The title compound was prepared by substituting EXAMPLE 458A for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500MHz, pyridine-ds) 5 9.23 (d, IH), 8.85 (t, IH), 8.57 (s, IH), 8.37 (dd, IH), 8.01 (d, IH), 7.52 (d, IH), 7.43 (d, 2H), 7.24 (m, 2H), 7.15 (d, IH), 7.07 (d, 2H), 6.97 (d, IH), 6.72 (m, 2H), 4.00-3.90 (m, 3H), 3.68-3.59 (m, 3H), 3.58-3.48 (m, IH), 3.06-3.02 (m, 7H), 2.98-2.89 (m, 2H), 2.77 (s, 2H), 2.25 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 459 4-(4- {(2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- {[6- ({4-fluoro-1 -[2-fluoro-1 -(fluoromethyl)ethyl]piperidin-4-yl} methoxy)-5- (trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(lH-indazol-4-yloxy)benzamide EXAMPLE 459A tert-butyl4-fluoro-4-((5-sulfamoyl-3-(trifluoromethyl)pyridin-2-yloxy)methyl)piperidine-l- carboxylate The title compound was prepared by substituting EXAMPLE 410E for EXAMPLE 329A and EXAMPLE 419A for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 329B. -572- EXAMPLE 459B 6-((4-fluoiopiperidin-4-yl)methoxy)-5-(trifluoromethyl)pyridine-3-sulfonauiide The title compound was prepared by substituting EXAMPLE 459A for EXAMPLE 422A in EXAMPLE 422B. EXAMPLE 459C 6-((l-(l,3-difluoropropan-2-yl)-4-fluoropiperidin-4-yl)methoxy)-5-(trifluoromethyl)pyridine- 3-sulfonamide The title compound was prepared by substituting EXAMPLE 459B for EXAMPLE 422B in EXAMPLE 434A. EXAMPLE 459D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N- {[6-({4-fluoro-1 -[2-fluoro-1 -(fluoromethyl)ethyl]piperidin-4-yl} methoxy)-5-(trifluon)methyl)pyridin-3-yl]sulfonyl}-2-(lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE 26C and EXAMPLE 459C for EXAMPLE IF in EXAMPLE 177. *H NMR (4(X)MHz, dimethylsulfoxide-dfi) 8 12.94 (d, IH), 8.40 (d, IH), 8.11 (d, IH), 7.68 (m, 2H), 7.35 (d, 2H), 7.06 (d, 2H), 6.99 (d, 2H), 6.71 (dd, IH), 6.39 (d, IH), 6.06 (t, IH), 4.67 (d, 2H), 4.55 (d, 2H), 4.47 (d, 2H), 3.07 (m, 5H), 2.74 (m, 6H), 2.19 (m, 6H), 1.90 (m, 6H), 1.40 (t, 2H), 0.93 (s, 6H). EXAMPLE 460 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-phenoxybenzamide The title compound was prepared as described in EXAMPLE 177 by replacing EXAMPLE 26C with EXAMPLE 18G. 'H NMR (400 MHz, dimethylsulfoxide-de) 6 12.87 (s, IH), 11.60 (s, IH), 8.58 (s, IH), 8.47 (d, IH), 8.11 (s, IH), 7.81 - 7.91 (m, IH), 7.76 (dd, IH), 7.59 - 7.66 (m, IH), 7.48 (d, IH), 7.34 (d, 2H), 7.00 - 7.11 (m, 5H), 6.73 (dd, IH), 6.67 (dd, IH), 6.08 (d, IH), 3.85 (dd, 2H), 3.20 - 3.30 (m, 4H), 3.04 (s, 4H), 2.77 (s, 2H), 2.17 (d, 6H), 1.96 (s, 2H), 1.81 - 1.92 (m, IH), 1.55 -1.66 (m, 2H), 1.39 (t, 2H), 1.17 - 1.32 (m, 2H), 0.93 (s, 6H). -573- EXAMPLE 461 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- {[5- chloro-6-(2-tetrahydrofuran-2-ylethoxy)pyridin-3-yl]sulfonyl}-2-(lH-indazol-4- yloxy)benzamide EXAMPLE 461A 5-chloro-6-(2-(tetrahydrofuran-2-yl)ethoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 387A for EXAMPLE 329A and 2-(tetrahydrofuran-2-yl)ethanol for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 329B. EXAMPLE 461B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N- {[5- chloro-6-(2-tetrahydiofuran-2-ylethoxy)pyridin-3-yl]sulfonyl}-2-(lH-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 461A for EXAMPLE IF and EXAMPLE 400E for EXAMPLE 26C in EXAMPLE 177C. 'H NMR (500MHz, dimethylsulfoxide-de) 8 13.08 (s, IH), 8.27 (d, J = 2.17 Hz, IH), 7.83 (d, J = 1.83 Hz, IH), 7.80 (s, IH), 7.58 (d, J = 8.85 Hz, IH), 7.36 (d, J = 8.54 Hz, 2H), 7.03-7.10 (m, 4H), 6.79 (dd, J = 9, 2.29 Hz, IH), 6.54 (d, J = 1.53 Hz, IH), 6.13 (d, J = 7.02 Hz, IH), 4.41-4.47 (m, 2H), 3.91-3.94 (m, IH), 3.71-3.80 (m, IH), 3.56-3.63 (m, 2H), 3.25 (br s, 2H), 2.33 (br s, 2H), 2.16-2.18 (m, 2H), 1.92-2.01 (m, 5H), 1.80-1.86 (m, 2H), 1.47-1.53 (m, IH), 1.42 (t, J = 6.26 Hz, 2H), 0.94 (s, 6H). EXAMPLE 462 Trans-2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl )piperazin-l -yl)-N-[(4- {[(4-cyanocyclohexyl)methyl]amino} -3- nitrophenyl)sulfonyl]benzamide EXAMPLE 462A 2-(trans-4-(aminomethyl)cyclohexyl)acetonitrile To a solution of tert-butyl (trans-4-(cyanomethyl)cyclohexyl)methylcarbamate (500 mg) in dichloromethane (5 mL) was slowly added trifluoroacetic acid (3 mL) at 0°C. The -574- mixture was warmed to room temperature, stirred for 1 hour. The title compound was obtained by concentration. EXAMPLE 462B 4-(( trans-4-cyanocyclohexyl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 462A for (tetrahydropyran-4-yl)methylamine in EXAMPLE IF. EXAMPLE 462C Trans-2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl Jpiperazin-1 -yl)-N-[(4- {[(4-cyanocyclohexyl)methyl]amino) -3-nitiophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 462B for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500 MHz, pyridine-ds) 8 9.29 (d, IH), 8.67 (t, IH), 8.59 (s, IH), 8.41 (dd, IH), 7.98 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.25 (m, IH), 7.19 (m, IH), 7.07 (d, 2H), 6.91 (d, IH), 6.73 - 6.68 (m, 2H), 5.24 (m, 2H), 3.13 (t, 2H), 3.03 (m, 4H), 2.76 (s, 2H), 2.43 (m, IH), 2.25 (m, 2H), 2.13 (m, 4H), 1.99 - 1.94 (m, 4H), 1.77 (m, H), 1.59 (m, IH), 1.46 (m, 2H), 1.38 (t, 2H), 0.99 - 0.90 (m, 8H). EXAMPLE 463 2-(lH-benziniidazol-4-yloxy)-N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl) sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 - yl)benzamide EXAMPLE 463A (4,4-difluorocyclohexyl)methanol To a slurry of lithium aluminum hydride (0.24 g) in diethyl ether (15 mL) was added dropwise ethyl 4,4-difluorocyclohexanecarboxylate (1.0 g) in diethyl ether (2 mL). The reaction heated at reflux under nitrogen for 4 hours. The reaction was cooled to 0° C, followed by the careful addition of water (0.24 mL), 4^ aqueous NaOH (0.24 mL), and water (0.72 mL). The reaction was diluted with diethyl ether (40 mL) and stirred with sodium sulfate for 30 minutes. The mixture was filtered though diatomaceous earth and the filtrate was concentrated to provide the tide compound. - 575 - EXAMPLE 463B 5-chloro-6-((4,4-difluorocyclohexyl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 463A for (tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 387A for EXAMPLE 329A in EXAMPLE 329B. EXAMPLE 463C 2-(lH-benzinnidazol-4-yloxy)-N-({5-chloro-6-[(4,4-difluorocyclohexyl)raethoxy]pyridin-3-yl) sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 - yl)benzamide The title compound was prepared by substituting EXAMPLE 463B for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500 MHz, pyridine-d?) 5 9.15 (d, IH), 8.69 (m, IH), 8.59 (s, IH), 7.99 (d, IH), 7.53 (d, IH), 7.44 (d, 2H), 7.24 (m, IH), 7.16 (m, IH), 7.07 (d, 2H), 6.70 (m, 2H), 5.45(m, 2H), 4.22 (d, 2H), 3.04 (m, 4H), 2.77 (s, 2H), 2.26 (m, 2H), 2.16 -2.08 (m, 6H), 1.97 (s, 2H), 1.86 -1.68 (m, 5H), 1.47 - L36 (m, 4H), 0.94 (m, 6H). EXAMPLE 464 N-( {3-chloro-4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy ]phenyl} sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide EXAMPLE 464A 3-chloro-4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide The title compound was prepared by substituting 3,4-dichlorobenzenesulfonamide for EXAMPLE 329A and EXAMPLE 306C for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 329B. EXAMPLE 464B N-(3-chloro-4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)phenylsulfonyl)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -((2- (trimethylsilyl)ethoxy)methyl)-lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 435D for EXAMPLE IE and EXAMPLE 464A for EXAMPLE IF in EXAMPLE IG. -576- EXAMPLE 464C N-( {3-chloro-4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy ]phenyl) sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin-l-yl)-2-( lH-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 464B for EXAMPLE 435E in EXAMPLE 435F. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 13.15 (s, IH), 11.74 - 11.31 (m, IH), 7.85 (s, IH), 7.67 (d, IH), 7.62 - 7.49 (m, 2H), 7.35 (d, 2H), 7.22 - 7.09 (m, 3H), 7.05 (d, 2H), 6.80 (d, IH), 6.53 (s, IH), 6.23 (d, IH), 4.26 (d, 2H), 3.79 (d, 2H), 3.62 (dd, 2H), 3.17 (s, 4H), 2.77 (d, 2H), 2.22 (d, 6H), 1.88 (dd, 6H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 465 N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2- (lH-indazol-4-yloxy)benzamide EXAMPLE 465A methyl 2-(lH-indazol-4-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 400C for tert-butyl piperazine-l-carboxylate and EXAMPLE 145E for EXAMPLE 27C in EXAMPLE lA. EXAMPLE 465B methyl 4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yl)-2-(l-((2-(trimethylsUyl)ethoxy)methyl)-lH-indazol-4- yloxy)benzoate The title compound was prepared by substituting EXAMPLE 465A for EXAMPLE 400D in EXAMPLE 435C. EXAMPLE 465C 4-(4-((4-(4-ch]orophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-1 -yl)-2-( 1 -((2-(trimethylsilyl)ethoxy)methyl)-1 H-indazol-4-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 465B for EXAMPLE 175D in EXAMPLE 175E. -577- EXAMPLE 465D N-(5-cWoro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridin-3-ylsulfonyl)-4-(4.((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yl)-2-(1 -((2-(trimethylsilyl)elhoxy)methyl)-1 H-indazol-4-yloxy)benzanude The title compound was prepared by substituting EXAMPLE 465C for EXAMPLE 27G and EXAMPLE 404A for EXAMPLE IF in EXAMPLE 27H. EXAMPLE 465E N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3 -yl]raethyl} piperazin-1 -yl)-2- (lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 465D for EXAMPLE 435E in EXAMPLE 435F, except here the final compound was purified by preparative HPLC using a C18 column, 250 x 50 mm, lO^i, and eluting with a gradient of 20-100% CH3CN vs. 0.1% trifluoroacetic aicd in water, followed by column chromatography eluting with 98/2 dichloromethane/methanol. 'H NMR (400 MHz, dimethylsulfoxide-de) 6 13.13 (s, IH), 8.28 (d, IH), 7.90 (d, IH), 7.83 (s, IH), 7.58 (d, IH), 7.39 (d, 2H), 7.17 (d, 2H), 7.08 (m, 2H), 6.82 (dd, IH), 6.57 (d, IH), 6.14 (d, IH), 4.52 (d, 2H), 4.15 (s, 2H), 3.80 (m, 2H), 3.60 (m, 2H), 3.20 (v br m, 4H), 2.98 (v br s, 2H), 2.35 (v br m, 4H), 2.18 (s, 2H), 1.87 (m, 4H), 1.20(s,6H). Example 466 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- {[5- cyano-6-(2-tetrahydro-2//-pyran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(l//-indazol-4- yloxy)benzamide EXAMPLE 466A 5-bromo-6-(2-(tetrahydro-2H-pyran-4-yl)ethoxy)pyridine-3-sulfonamide The title compound was prepared by substituting 2-(tetrahydro-2H-pyran-4-yl)ethanol for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 329B. EXAMPLE 466B 5-cyano-6-(2-(tetrahydro-2H-pyran-4-yl)ethoxy)pyridine-3-sulfonamide - 578 - The title compound was prepared by substituting EXAMPLE 466A for EXAMPLE 329A in EXAMPLE 333A. EXAMPLE 466C 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-A^- {[5 - cyano-6-(2-tetrahydro-27?-pyran-4-ylethoxy)pyridin-3-yl]sulfonyl)-2-(l//-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 466B for EXAMPLE IF and EXAMPLE 400E for EXAMPLE 26C in EXAMPLE 177C. 'H NMR (SOOMHz, dimethylsulfoxide-de) 8 13.04 (s, IH), 8.48 (d, IH), 8.13 (s, IH), 7.75 (s, IH), 7.62 (d, IH), 7.37 (d, 2H), 7.01-7.08 (m, 4H), 6.76 (dd, IH), 6.51 (d, IH), 6.08 (d, IH), 4.47 (t, 2H), 3.81-3.85 (m, 2H), 3.71-3.80 (m, IH), 2.18 (m, 2H), 1.99 (m, 2H), 1.62-1.72 (m, 5H), 1.42 (t, 2H), 1.23 (m, 2H), 0.94 (s, 6H). EXAMPLE 467 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(4-{[(lR,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino)-3- nitrophenyl)sulfonyl]benzamide EXAMPLE 467A 4-((lR,3R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-ylamino)-3-nitrobenzenesulfonamide This EXAMPLE was prepared by substituting (lR,3R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-amine for l-(2-methoxy-ethyl)-piperidin-4-ylamine in EXAMPLE 189A. EXAMPLE 467B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(4-{[(lR,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}-3- nitrophenyl)sulfonyl]benzamide This EXAMPLE was prepared by substituting EXAMPLE 26C for EXAMPLE IE and EXAMPLE 467A for EXAMPLE IF in EXAMPLE IG. 'H NMR (500MHz, dimethylsulfoxide -dg) 5 11.47 (br s, IH), 11.17 (s, IH), 9.43 (br s, IH), 8.69 (d, IH), 8.62 (d, IH), 7.90 (dd, IH), 7.52 (d, IH), 7.40 (m, 3H), 7|15 (d, IH), 7.06 (m, 3H), 6.85 (dd, IH), -579- 6.68 (m, IH), 6.39 (t, IH), 6.19 (br s, IH), 4.01 (m, IH), 3.91 (m, 2H), 3.58 (m, 3H), 3.01 (m, 3H), 2.73 (m, 5H), 2.32 (m, 6H), 2.16 (m, 6H), 2.0 (m, 2H), 1.45 (m, 2H), 0.94 (s, 6H). EXAMPLE 468 N-({3-nitro-4-[(tetrahydrD-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxy-4-(4- {(3-phenylpropanoyl)[(lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3- yl]amino)piperidin-l-yl)benzamide EXAMPLE 468A methyl 2-phenoxy-4-( 1,4-dioxa-8-azaspiro[4.5]decan-8-yl)benzoate l,4-dioxa-8-azaspiro[4.5]decane (1.18 g), methyl 4-fluoro-2-phenoxybenzoate (1.85 g), and K2CO3 (1.14 g) was stiired at 125°C in dimethylsulfoxide (25 mL) for 24 hours. The mixture was cooled, poured into 300 mL water, extracted three times with ether, and the ether extracts were combined, rinsed three times with water, and brine, and concentrated. The residue was chromatographed on silica gel using 10-30% ethyl acetate in hexanes as eluent to give the title compound. EXAMPLE 468B methyl 4-(4-oxopiperidin-1 -yl)-2-phenoxybenzoate EXAMPLE 468A (23.7 g) was heated to 80°C in a mixture of acetic acid (30 mL), tetrahydrofuran (40 mL) and water (30 mL) for 24 hours. The mixture was cooled and concentrated. The crude product was chromatographed on silica gel using 25% ethyl acetate in hexanes as the eluent to give the title compound. EXAMPLE 468C methyl 2-phenoxy-4-(4-((lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-ylamino)piperidin-1 -yl)benzoate EXAMPLE 468B (0.99 g) and (lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-amine (0.51 mL) wererefluxed in 200 mL methanol under a Dean-Stark trap for 24 hours. The solvent was boiled off to a volume of 75 mL, and the mixture was cooled to room temperature. NaBHj (0.115 g) was added and the mixture was stirred for 30 minutes. The reaction was quenched with 10 mL water, partially concentrated, and chromatographed on silica gel using 1% triethylamine in ethyl acetate as eluent to give the title compound. -580- EXAMPLE 468D methyl 2-phenoxy-4-(4-(3-phenyl-N-(( 1 S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1 ]heptan-3-yl)propanamido)piperidin-1 -yl)benzoate EXAMPLE 468C (320 mg), 3-phenylpropanoyl chloride (0.113 mL), and triethylamine (0.116 mL) were stirred ia dichloromethane (15 mL) for 24 hours. The reaction mixture was partially concentrated and the residue was chromatographed on silica gel using 20% ethyl acetate in hexanes as eluent to give the title compound. EXAMPLE 468E 2-phenoxy-4-(4-(3-phenyl-N-((lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl)propanamido)piperidin-1 -yl)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 468D for EXAMPLE ID in EXAMPLE IE. EXAMPLE 468F N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxy-4-(4-{(3-phenylpropanoyl)[(lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}piperidin-l-yl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 468E for EXAMPLE IE in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-de) 5 8.32 (m, 2H), 7.64 (m, 2H), 7.11-7.29 (m, 6H), 6.95 (dd, IH), 6.89 (dd, IH), 6.70 (m, 3H), 6.32 (m, IH), 3.85 (m, 3H), 3.70 (m, 3H), 2.91 (m, 6H), 2.65-2.80 (m, 6H), 1.91 (s, 6H), 1.61 (m, 4H), 1.16-1.36 (m, 4H). 1.11 (m, 6H), 0.95 (m, 4H), 0.87 (d, 2H). EXAMPLE 469 N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-phenoxy-4-(4-{(3- phenylpropanoyl)[(lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}piperidin-l- yl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 468E for EXAMPLE IE and EXAMPLE 7A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-dfi) 88.72 (m, IH), 8.44 (d, IH), 7.73 (dd, IH), 7.54 (m, IH), 7.12-7.28 (m, 6H), 7.05 (dd, IH), 6.95 (dd, IH), 6.82 (d, IH), 6.74 (m, 2H), 6.34 (m, IH), -581- 3.77 (m, 2H), 3.63 (m, 4H), 3.10 (m, 4H), 3.05 (m, 4H), 2.78 (m, 6H), 1.75-2.10 (m, 8H), 1.55 (m, 2H), 1.40 (m, 2H), 1.19 (m, 6H), I.Ol (m, 2H), 0.95 (m, 2H), 0.88 (d, 2H). EXAMPLE 470 N-( {3-mtro-4-[(tetrahydio-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-phenoxy-4-(4- {(3-phenylpropyl)[(lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino)piperidin-l- yl)benzamide EXAMPLE 470A methyl 2-phenoxy-4-(4-((3-phenylpropyl)((lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1 ]heptan-3-yl)amino)piperidin-1 -yl)benzoate EXAMPLE 468C (320 mg), 3-phenylpiopanal (111 mg), and NaBH(0Ac)3 (205 mg) were stirred in dichloromethane (15 mL) for 24 hours. The reaction mixture was chromatographed on silica gel using 20% ethyl acetate in hexanes as eluent to give the title compound. EXAMPLE 470B 2-phenoxy-4-(4-((3-phenylpropyl)((lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl)amino)piperidin-l-yl)benzoic acid This EXAMPLE was prepared by substituting EXAMPLE 470A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 470C N-( {3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-phenoxy-4-(4- {(3-phenylpropyl)[(lS,2S,3S,5R)-2,6,6-tiimethylbicyclo[3.Ll]hept-3-yl]amino)piperidin-l- yl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 470B for EXAMPLE IE in EXAMPLE IG. 'H NMR (300MHZ, dimethylsulfoxide-de) 8 8.57 (m, IH), 8.47 (d, IH), 7.50 (m, IH). 7.32 (m, IH), 7.12-7.31 (m, 7H), 6.99 (dd, IH). 6.81 (m, 3H). 6.37 (d. IH). 4.44 (t. IH), 3.84 (m. 4H). 3.37 (m, 2H), 3.25 (m. 2H). 3.06 (m. 2H), 2.70 (m, 4H), 2.57 (m, 4H), 1.82 (m, 2H), 1.77 (m. 4H). 1.52-1.71 (m. 8H), 1.25 (m, 3H), 1.15 (s, 3H), 0.95 (d, 2H), 0.93 (s. 3H), 0.74 (d, 2H). -582- EXAMPLE 471 N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-phenoxy-4-(4-{(3- phenylpropyl)[(lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}piperidin-l- yl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 470B for EXAMPLE IE and EXAMPLE 7A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300MHz, dimethylsulfoxide-de) 8 8.68 (m, IH), 8.40 (d, IH), 7.70 (dd, IH), 7.55 (d, IH), 7.11-7.29 (m, 7H), 7.01 (dd, IH), 6.95 (dd, IH), 6.76 (d, 2H), 6.34 (m, IH), 3.75 (m, 2H), 3.61 (m, 4H), 3.43 (m, 4H), 3.05 (m, 6H), 2.75 (m, 2H), 2.60 (m, 2H), 2.41 (m, 4H), 2.15 (m, IH), 1.82 (m, 4H), 1.69 (m, 2H), 1.51 (m, IH), 1.18 (m, 8H), 0.96 (m, IH), 0.94 (s, 3H). EXAMPLE 472 4-[4-(2- {[(lR,5S)-8-methyl-8-azabicyclo[3.2.1 ]oct-3-yl]amino }benzyl)piperazin-1 -yl]-N- ({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-phenoxybenzamide EXAMPLE 472A Ethyl 4-fluoro-2-phenoxybenzoate (6(X) mg) and piperazine (596 mg) were dissolved in anhydrous dimethyl sulfoxide and heated at 130°C overnight. The reaction mixture was cooled to nx)m temperature and diluted with ethyl acetate. The organic phase was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford the title compound. EXAMPLE 472B EXAMPLE 472A (400 mg), l-(bromomethyl)-2-nitrobenzene (277 mg) and sodium carbonate (408 mg) were suspended in anhydrous N,N-dimethylformamide (20 mL). The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was diluted with ethyl acetate. The organic phase was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Flash colunm purification with 10-40% ethyl acetate/hexane to afford the title compound. -583- EXAMPLE 472C A solution of EXAMPLE 472B (0.6 g) in methanol (20 ml) was added to Ra-Ni, solvent washed (0.480 g) in a 250 mL pressure bottle and stirred for 3 hours at 30 psi at room temperature. The mixture was filtered through a nylon membrane and concentrated to afford the product. EXAMPLE 472D This EXAMPLE was prepared by substituting (lR,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-one for 4'-chlorobiphenyl-2-caiboxaldehyde and EXAMPLE 472C for tert-butyl piperazine-1 -caiboxylate in EXAMPLE 1 A. EXAMPLE 472E This EXAMPLE was prepared by substituting EXAMPLE 472D for EXAMPLE 175D in EXAMPLE 175E. EXAMPLE 472F 4-[4-(2- {[(lR,5S)-8-methyl-8-azabicyclo[3.2.1 ]oct-3-yl]amino }benzyl)piperazin-1 -yl]-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-phenoxybenzamide This EXAMPLE was prepared by substituting EXAMPLE 472E for EXAMPLE 27G and EXAMPLE 7A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-d6) 8 11.66 (bs, IH), 9.90 (bs, IH), 9.56 (s, IH), 8.69 (t, IH), 8.50 (d, IH), 7.81 (dd, IH), 7.54 (d, IH), 7.22 (m, 5H), 7.01 (m, IH), 6.83 (m, 3H), 6.47 (s, IH), 3.84 (m, 4H), 3.65 (d, 6H), 3.54 (m, 4H), 3.43 (m, 2H), 3.19 (m, 8H), 2.68 (d, 3H), 2.34 (m, 2H), 2.25 (m,4H), 1.99(m,4H). EXAMPLE 473 4-[4-(2- {[(lR,5S)-8-methyl-8-azabicyclo[3.2.1 ]oct-3-yl]aniino }benzyl)piperazin-1 -yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-phenoxybenzamide This EXAMPLE was prepared by substituting EXAMPLE 472E for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-dg) 511.61 (bs, IH), 9.38 (bs, IH), 8.64 (s, IH), 8.47 (d, IH), 7.75 (dd, IH), 7.55 (d, IH), 7.23 (t, 3H), 7.15 (d, 2H), 6.98 (t, IH), 6.82 (d, 3H), 6.47 (s, 2H), 3.85 (m, 6H), 3.31 (m, 12H), 2.68 (d, 3H), 2.06 (m, 9H), 1.62 (m,2H), 1.29(m,2H). -584- EXAMPLE 474 4- {4- [2-(3-azabicyclo[3.2.2]non-3 -yl)benzyl]piperazin-1 -yl} -N-( {3 -nitro-4- [(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxybenzamide EXAMPLE 474A 2-Fluorobenzaldehyde (264 mg), (lS,5S)-3-azabicyclo[3.2.2]nonane (500 mg) and sodium carbonate (846 mg) were suspended in anhydrous dimethylsulfoxide (3mL). The reaction mixture was heated at 135°C overnight. The reaction mixture was cooled to room temperature and diluted with ethyl acetate. The organic phase was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. Flash column purification with 0-10% ethyl acetate/hexane provided the title compound. EXAMPLE 474B This EXAMPLE was prepared by substituting EXAMPLE 474A for 4'-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 113 A for tert-butyl piperazine-1-carboxylate in EXAMPLE lA. EXAMPLE 474C This EXAMPLE was prepared by substituting EXAMPLE 474B for EXAMPLE 175D in EXAMPLE 175E. EXAMPLE 474D 4-{4-[2-(3-azabicyclo[3.2.2]non-3-yl)benzyl]piperazin-l-yl}-N-({3-nitro-4-[(teO:ahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxybenzamide This EXAMPLE was prepared by substituting EXAMPLE 474C for EXAMPLE 27G in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-dg) 8 11.74 (bs, IH), 8.64 (t, IH), 8.47 (d, IH), 7.76 (dd, IH), 7.54 (m, 2H), 7.43 (d, 2H), 7.23 (m, 3H), 7.15 (d, IH), 6.98 (t, IH), 6.83 (m, 3H), 6.53 (d, IH), 4.45(bs, 2H), 3.87 (m, 4H), 3.30 (m, 6H), 3.06 (m, 8H), 1.89 (m, 7H), 1.64 (m, 6H), 1.29 (m, 2H). -585- EXAMPLE 475 4- {4-[2-(3-azabicyclo[3.2.2]non-3-yl)benzyl]piperaziii- 1-yl }-2-phenoxy-N-({ 4-[(tetrahydio-2H-pyran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonylJphenyI}sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 474C for EXAMPLE 27G and EXAMPLE 163A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-dfi) 8 1L78 (bs, IH), 8.11 (d, IH), 7.86 (dd, IH), 7.54 (d, 2H), 7.44 (d, 2H), 7.28 (m, 4H), 7.11 (d, IH), 7.04 (m, IH), 6.85 (m, 3H), 6.53 (d, IH), 4.46 (m, 2H), 3.86 (m, 4H), 3.28 (m, 6H), 3.10 (m, 4H), 2.98 (d, 4H), 1.97 (s, 2H), 1.84 (m, 5H), 1.64 (m, 6H), 1.26 (m,2H). EXAMPLE 476 4-{4-[2-(3-azabicyclo[3.2.2]non-3-yl)benzyl]piperazin-l-yl}-2-phenoxy-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 474C for EXAMPLE 27G and EXAMPLE 2A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-de) 811.19 (bs, IH), 9.83 (bs, IH), 7.52 (m, 6H), 7.33 (m, 3H), 7.12 (t, IH), 6.93 (d, 2H), 6.83 (m, IH), 6.56 (d, 2H), 6.47 (d, IH), 4.47 (s, 2H), 3.85 (m, 4H), 3.26 (m, 2H), 3.11 (m, 4H), 2.96 (m, 6H), 1.97 (s, 2H), 1.81 (m, 6H), 1.64 (m, 7H), 1.22 (m, 2H). EXAMPLE 477 4-{4-[2-(3-azabicyclo[3.2.2]non-3-yl)benzyl]piperazin-l-yl}-N-({4-[(3-niorpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-phenoxybenzamide This EXAMPLE was prepared by substituting EXAMPLE 474C for EXAMPLE 27G and EXAMPLE 7A for EXAMPLE IF in EXAMPLE 27H. 'H NMR (400MHz, dimethylsulfoxide-dfi) 8 11.77 (bs, IH), 10.04 (bs, IH), 8.69 (t, IH), 8.50 (d, IH), 7.81 (dd, IH), 7.55 (d, 2H), 7.43 (d, 2H), 7.24 (m, 3H), 7.15 (d, IH), 7.01 (t, IH), 6.84 (m, 3H), 6.52 (d, IH), 4.44 (s, 2H), 3.97 (s, 2H), 3.54 (m, 6H), 3.39 (m, 4H), 3.19 (m, 8H), 2.97 (d, 4H), 1.99 (m, 4H), 1.83 (m, 4H), 1.64 (m, 4H). EXAMPLE 478 4-(4-{2-[(4R,7S)-2,3,3a,4,7,7a-hexahydro-lH-4,7-methanoinden-5-yl]benzyl}piperazin-l- yl)-N-({ 3-nitro-4-[(tetrahydro-2H-pyran-4-yImethyl)ainino]phenyl} sulfonyl)-2- phenoxybenzamide -586- EXAMPLE 478A 4-(4-Methoxycarbonyl-3-phenoxy-phenyl)-piperazine-l-carboxylic acid tert-butyl ester This EXAMPLE was prepared by substituting piperazine-l-carboxylic acid tert-butyl ester for EXAMPLE IB in EXAMPLE ID. EXAMPLE 478B 4-(4-Carboxy-3-phenoxy-phenyI)-piperazine-l-carboxylic acid tert-butyl ester This EXAMPLE was prepared by substitudng EXAMPLE 478A for EXAMPLE ID m EXAMPLE IE. EXAMPLE 478C 4-(4-{3-Nitro-4-[(tetrahydro-pyran-4-ylmethyl)-amino]-benzenesulfonylaminocarbonyl}-3-phenoxy-phenyl)-piperazine-l-carboxylic acid tert-butyl ester This EXAMPLE was prepared by substituting EXAMPLE 478B for EXAMPLE IE in EXAMPLE IG. EXAMPLE 478D 3-Nitro-N-(2-phenoxy-4-piperazin-l-yl-benzoyl)-4-[(tetrahydro-pyran-4-ylmethyl)-amino]- benzenesulfonamide This EXAMPLE was prepared by substituting EXAMPLE 478C for EXAMPLE lA in EXAMPLE IB to isolate the title compound as the mono trifluoroacetic acid salt. EXAMPLE 478E Trifluoromethanesulfonicacid(4R,7S)-(2,3,3a,4,7,7a-hexahydro-lH-4,7-methano-inden-5- yl) ester (4R,7R)-octahydro-4,7-methano-inden-5-one (2.00 g) was dissolved in tetrahydrofuran (25 raL) and cooled to -78°C using an isopropyl alcohol / dry ice bath. Sodium bis(trimethylsilyl)-amide (IM in tetrahydrofuran, 14.65 mL) was added slowly. The solution was allowed to warm to room temperature, stirred for one hour, cooled to -78°C using an isopropyl alcohol / dry ice bath, and N-phenyltrifluoromethanesulfonimide (5.23 g) was added. The solution was allowed to warm to room temperature and stir for 16 hours. Hexane was added and the solution was stirred at room temperature for one hour, filtered, and the solvent removed imder vacuum. -587- EXAMPLE 478F (4R,7S)-2-(2,3,3a,4,7,7a-Hexahydro-lH-4,7-methano-inden-5-yl)-benzaldehycle EXAMPLE 478E (941 mg), 2-formylphenylboronic acid (600 mg), and potassium phosphate tribasic (1416 mg) were added to tetrahydrofuran (20 mL). The solution was degasses and flushed with nitrogen three times. Tetrakis(triphenylphospine)palladium(0) (244 mg) was added and the solution was heated at 60°C for 16 hours. The solution was cooled, added to water, and extracted with 50% ethyl acetate (hexanes). The extract was washed with brine, dried on anhydrous sodium sulfate, concentrated and purified by flash column chromatography on silica gel using 10% ethyl acetate (hexanes). EXAMPLE 478G 4-(4-{2-[(4R,7S)-2,3,3a,4,7,7a-hexahydro-lH-4,7-methanoinden-5-yl]benzyl}piperazin-l- yl)-N-({3-nitro-4-[(tetrahydio-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2- phenoxybenzamide EXAMPLE 478D (200 mg), EXAMPLE 478F (74 mg), and sodium cyanoborohydride resin (2.15 mmol/g, 144 mg) were added to tetrahydrofuran (3 mL) and acetic acid (0.7 mL) and stirred at room temperature for 16 hours. The solution was concentrated on vacuum and purified by flash column chromatography on sihca gel using 5% methanol (dichloromethane) to provide the title compound as the mono acetic acid salt. 'H NMR (300MHz, dimethylsulfoxide-d^) 6 11.94 (bs, IH), 8.64 (t, IH), 8.48 (d, IH), 7.76 (dd, IH), 7.51 (d, IH), 7.40 (m, IH), 7.27-7.18 (m, 5H), 7.16 (d, IH), 6.99 (tt, IH), 6.83 (dt, 2H), 6.78 (dd, IH), 6.41 (d, IH), 6.23 (d, IH), 3.87 (dd, 2H), 3.50 (m, 2H), 3.34 (t, 2H), 3.21 (bs, 4H), 2.73 (bs, IH), 2.63 (bs, IH), 2.46 (m, 4H), 2.11 (m, 2H), 1.95-1.75 (m, 4H), 1.91 (s, 3H), 1.66-1.52 (m, 6H), 1.28 (m, 2H), 1.02 (m, 2H), 0.85 (m, IH). EXAMPLE 479 4-[4-(2-{ 5-[( lR,5S)-8-azabicyclo[3.2.1 ]oct-8-ylmethyl]thien-2-yl }benzyl)piperazin-l-yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxybenzamide EXAMPLE 479A tert-buty 14-(4-(methoxy carbonyl)-3-phenoxyphenyl)piperazine-1 -caiboxylate -588- This EXAMPLE was prepared by substituting tert-butyl piperazine-l-carboxylate for EXAMPLE IB in EXAMPLE ID. EXAMPLE 479B 4-(4-(tert-butoxycarbonyl)piperazin- l-yl)-2-phenoxybenzoic acid This EXAMPLE was prepared by substituting EXAMPLE 479A for EXAMPLE ID in EXAMPLE IE. EXAMPLE 479C tert-butyl 4-(4-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonylcarbamoyl)-3-phenoxyphenyl)piperazine-l-carboxylate This EXAMPLE was prepared by substituting EXAMPLE 479B for EXAMPLE IE in EXAMPLE IG. EXAMPLE 479D N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)-2-phenoxy-4- (piperazin-1 -yl)benzamide This EXAMPLE was prepared by substituting EXAMPLE 479C for EXAMPLE lA in EXAMPLE IB. EXAMPLE 479E 2-((4-(4-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylaniino)phenylsulfonylcarbamoyl)-3-phenoxyphenyl)piperazin-1 -yl)methyl)phenylboronic acid EXAMPLE 479D (213 mg), 2-formylphenylboromc acid (54 mg), and sodium cyanoborohydride resin (2.38 mmol/g, 252 mg) were added to tetrahydrofuran (3.5 mL) and acetic acid (1.1 mL), and the solution was stirred at room temperature for 16 hours. The solution was purified by flash column chromatography on silica gel with 1% acetic acid and 10% methanol in dichloromethane. EXAMPLE 479F 8-((5-bromothiophen-2-yl)methyl)-8-azabicyclo[3.2.1 Joctane hydrochloride This EXAMPLE was prepared by substituting 5-bromothiophene-2-carbaldehyde for 4'-chlorobiphenyl-2-carboxaldehyde and 8-azabicyclo[3.2.1]octane hydrochloride for tert-butyl piperazine-l-carboxylate in EXAMPLE lA. -589- EXAMPLE 479G 4-(4-(2-(5-(8-azabicyclo[3.2.1]octan-8-ylmethyl)thiophen-2-yl)benzyl)piperazin-l-yl)-N-(3-nitro-4-((tetrahydio-2H-pyran-4-yl)methylamino)phenylsulfonyl)-2-phenoxybenzamide EXAMPLE 479E (80 mg), EXAMPLE 479F (42.5 mg), bis(triphenylphosphine)palladium(n) dichloride (7.7 mg), and lithium hydroxide (10.5 mg) were combined in a mixture of dimethoxyethane (1.6 mL), methanol (0.5 mL) and water (0.7 mL) in a microwave vial. The reaction mixture was heated in a CEM Discover microwave reactor at 150°C for 15 minutes. The crude material was purified by flash chromatography eluting with a gradient of 1% methanol/dichloromethane to 5% methanol/dichloromethane. 'H NMR (500MHz, dimethylsulfoxide-dfi) 8 8.33 (m, 2H), 7.64 (m, 2H), 7.44 (m, IH), 7.39 (m, IH), 7.32 (m, 2H), 7.12 (m, 3H), 6.90 (m, 2H), 6.85 (t, IH), 6.68 (m, 3H), 6.30 (d, IH), 3.83 (dd, 2H), 3.65 (s, 2H), 3.51 (s, 2H), 3.17 (m, 4H), 3.08 (m, 4H), 2.45 (m, 6H), 1.92 (m, 2H), 1.62 (m, 4H), 1.54 (m, 3H), 1.28 (m, 6H). EXAMPLE 480 4- [4-(2- {5- [(1 R,5S)-8-azabicyclo[3.2.1 ]oct-8-ylmethyl]thien-2-yl} benzylidene)piperidin-1 - yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2- phenoxybenzamide EXAMPLE 480A methyl 2-phenoxy-4-( 1,4-dioxa-8-azaspiro[4.5]decan-8-yl)benzoate Methyl 4-fluoro-2-phenoxybenzoate (2 g) and l,4-dioxa-8-azaspiro[4.5]decane (1.279 g) were combined in dimethylsulfoxideO (12 mL) in a 250 mL round-bottom flask. Sodium carbonate (1.291 g) was added. The reaction flask was sealed and heated to 130 °C ovemight. The reaction mixture was diluted with ethyl acetate, washed thoroughly with water and with brine, and dried over MgS04, filtered and concentrated to obtain the desired product. EXAMPLE 480B methyl 4-(4-oxopiperidin-1 -yl)-2-phenoxybenzoate EXAMPLE 480A was taken up in acetic acid (30%, 20 mL) and tetrahydrofiiran (10 mL). The reaction mixture was heated to 75°C ovemight. The volume was reduced under vacuum and the residue was neutralized with sodium hydroxide solution, and extracted with -590- ethyl acetate. The extracts were washed with water and with brine, dried over MgS04, filtered and concentrated under vacuum to obtain the desired product. EXAMPLE 480C methyl 4-(4-(2-bromobenzylidene)piperidin-1 -yl)-2-phenoxybenzoate Dimethylsulfoxide (22.88 mL) with sodium hydride (0.332 g) was heated to 70 °C for 1 hour, then cooled to room temperature and (2-bromobenzyl)triphenylphosphonium bromide (3.40 g) was added in several portions, and then stirred at room temperature for 1 hour. A solution of methyl 4-(4-oxopiperidin-l-yl)-2-phenoxybenzoate (1.8 g) in dimethylsulfoxide (5.20 mL) was then added and the reaction was heated to 70 °C over the weekend. The reaction was acidified with IM aqueous HCl solution and extracted with ether. The combined extracts were washed thoroughly with water and brine, dried over MgS04, filtered and concentrated under vacuum. The residue was purified by flash chromatography eluting with 0-20% ethyl acetate in hexanes. EXAMPLE 480D methyl 2-phenoxy-4-(4-(2-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzylidene)piperidin-1 -yl)benzoate EXAMPLE 480C (259 mg), bis(pinacolato)diboron (206 mg), [Ll'-bis(diphenylphosphino)ferrocene]dichloropalladium(n) dichloromethane (22 mg), and potassium acetate (159 mg) were combined in dimethyl sulfoxide (2.7 mL). The reaction was heated to 90°C for 36 hours. The reaction mixture was diluted with ethyl acetate, washed thoroughly with water and with brine, and dried over MgS04, filtered and concentrated under vacuum. The crude solid was washed with hexanes and with hexanes/ether (2:1) to obtain the desired product. EXAMPLE 480E 4-(4-(2-(5-(8-azabicyclo[3.2.1]octan-8-ylmethyl)thiophen-2-yl)benzylidene)piperidin-l-yl)- 2-phenoxybenzoic acid This EXAMPLE was prepared by substituting EXAMPLE 480D for EXAMPLE 479E in EXAMPLE 479G. -591- EXAMPLE 480F 4-(4-(2-(5-(8-azabicyclo[3.2.1]octan-8-ylmethyl)thiophen-2-yl)benzylidene)piperidin-l-yl)-N-(3-nitro-4-((tetrahydrD-2H-pyran-4-yl)methylamino)phenylsulfonyl)-2-phenoxybenzamide This EXAMPLE was prepared by substituting EXAMPLE 480E for EXAMPLE IE in EXAMPLE IG. 'H NMR (500MHz, dimethylsulfoxide -de) 8 n.54 (s, IH), 9.36 (br s, IH), 8.48 (d, IH), 7.76 (dd, IH), 7.53 (m, 2H), 7.34 (m, 3H), 7.25 (m, 4H), 7.16 (d, IH), 7.00 (t, IH), 6.84 (d, 2H), 6.81 (dd, IH), 6.44 (d, IH), 6.37 (br s, IH), 4.36 (d, 2H), 3.85 (m, 3H), 3.44 (m, 2H), 3.28 (m, 6H), 2.36 (m, 3H), 2.23 (m, 4H), 1.90 (m, 3H), 1.81 (m, 2H), 1.62 (m, 5H), 1.47 (m, IH), 1.29 (m, 2H). EXAMPLE 481 4-[4-(3-{5-[(lR,5S)-8-azabicyclo[3.2.1]oct-8-ylmethyl]thien-2-yl}benzyl)piperazin-l-yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxybenzamide EXAMPLE 481A 3-((4-(4-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyIcarbamoyl)-3-phenoxyphenyl)piperazin-1 -yl)methyl)phenylboronic acid This EXAMPLE was prepared by substituting 3-fonnylphenylboronic acid for 2-formylphenylboronic acid in EXAMPLE 479E. EXAMPLE 481B 4-(4-(3-(5-(8-azabicyclo[3.2.1]octan-8-ylmethyl)thiophen-2-yl)benzyl)piperazin-l-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)-2-phenoxybenzamide This EXAMPLE was prepared by substituting EXAMPLE 481A for EXAMPLE 479E in EXAMPLE 479G. 'H NMR (500MHz, dimethylsulfoxide -de) 6 11.76 (br s, IH), 9.55 (br s, IH), 8.55 (t, IH), 8.46 (d, IH), 7.75 (m, 2H), 7.54 (m, 2H), 7.40 (m, IH), 7.20 (m, 4H), 6.97 (m, IH), 6.86 (m, IH), 6.82 (m, 3H), 6.55 (m, IH), 4.41 (d, 2H), 3.88 (m, 6H), 3.43 (m, 3H), 3.30 (m, 6H), 3.06 (m, 6H), 1.90 (m, 4H), 1.65 (m, 5H), 1.30 (m, 3H). -592- EXAMPLE 482 N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-l-yl)-2-( 1 H-indazol-4- yloxy)benzamide EXAMPLE 482A (4,4-difluorocyclohexyl)methanol Lithium aluminum hydride (0.24 g) was slurried in diethyl ether (15 mL), ethyl 4,4-difluorocyclohexanecarboxylate (1.0 g) in diethyl ether (2 mL) was added drop wise, and the reaction was stirred under reflux under nitrogen for 4 hours. TTie reaction was cooled to 0° C, followed by the careful addition of water (0.24 mL), 4N aqueous NaOH (0.24 mL), and water (0.72 mL). Na2S04 and diethyl ether (40 mL) were added and the mixture was stirred at room temperature for 30 minutes. Filtration through diatomaceous earth and concentration of the fdtrate provided the title compound which was used without purification. EXAMPLE 482B 5-chloro-6-((4,4-difluorocyclohexyl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 482A for (tetrahydro-2H-pyran-4-yl)methanol and 5,6-dichloropyridine-3-sulfonamide for EXAMPLE 329A in EXAMPLE 329B. EXAMPLE 482C N-(5-chloro-6-((4,4-difluorocyclohexyl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(l-((2- (trimethylsilyl)ethoxy)methyl)-lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 482B for EXAMPLE IF and EXAMPLE 435D for EXAMPLE 27G in EXAMPLE 27H. EXAMPLE 482D N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl)sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide -593- The title compound was prepared by substituting EXAMPLE 482C for EXAMPLE 435E in EXAMPLE 435F. ^H NMR (500MHz, dimethylsulfoxide-de) 8 13.12 (br s, IH), 8.28 (d, IH), 7.87 (d, IH), 7.80 (s, IH), 7.59 (d, IH), 7.37 (d, 2H), 7.08 (m, 4H), 6.80 (dd, IH), 6.55 (d, IH), 6.14 (d, IH), 4.25 (d, 2H), 3.24 (br s, 4H), 3.00 (v br s, 2H), 2.45 (v br s, 4H), 2.20 (br m, 2H), 2.05 (m, 2H), 1.98 (s, 2H), L97 (m, IH), 1.90 (m, 4H), 1.42 (t, 2H), 1.38 (m, 2H), 0.94 (s, 6H). EXAMPLE 483 N-({6-[(trans-4-carbamoylcyclohexyl)methoxy]-5-chloropyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide EXAMPLE 483A Trans-N-(bis(4-methoxyphenyl)methyl)-4-(hydroxymethyl)cyclohexanecarboxamide To a solution of bis(4-methoxyphenyl)methanamine (846 mg), trans-4-(hydroxymethyl)cyclohexanecafboxylic acid (500 mg), and triethylamine (1.322 mL) in N,N-dimethylformamide (30 mL) was added benzotriazol-l- yloxytris(dimethylamino)phosphonium hexafluorophosphate reagent (1.677g). The resulting mixture was stirred for 3 hours, diluted with ethyl acetate, washed with water, aqueous NaOH and brine. The organic layer was dried over Na2S04, filtered, and concentrated. The residue was dissolved in dichloromethane and loaded into a silica cartridge, eluted with 0 -100% ethyl acetate in hexane to provide the title compound. EXAMPLE 483B (lr,4r)-N-(bis(4-methoxyphenyl)methyl)-4-((3-chloro-5-sulfamoylpyridin-2- yloxy)methyl)cyclohexanecarboxamide EXAMPLE 483A (L2 g) and EXAMPLE 387A (0.711 g) in tetrahydrofuran (30 mL) was treated with NaH (60%, 0.51 g) overnight. The reaction was quenched with aqueous NH4CI and the pH value of the mixture was adjusted to 4-5 with diluted aqueous HCl. The resulting mixture was extracted with dichloromethane. The dichloromethane layer was washed with brine and concentrated. The residue was purified by silica gel chromatography, and was eluted with 20% - 30% ethyl acetate in hexane to provide the title compound. -594- EXAMPLE 483C N-(6-((trans-4-(bis(4-methoxyphenyl)methylcarbamoyl)cyclohexyl)inethoxy)-5- chloiopyridin-3-ylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethy]cyclohex-l- enyl)methyl)piperazin-1 -yl)-2-( l-((2-(trimethylsilyl)ethoxy)methyl)- lH-indazol-4- yloxy)benzamide The title compound was prepared as described in EXAMPLE 177 by replacing EXAMPLE 26C and EXAMPLE IF with EXAMPLE 435D and EXAMPLE 483B, respectively. EXAMPLE 483D N-({6-[(trans-4-carbamoylcyclohexyl)methoxy]-5-chloropyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide EXAMPLE 483C (500 mg) in dichloromethane (10 mL) was treated with water (1 mL) and trifluoroacetic acid (5 mL) for 2 hours. The reaction mixture was concentrated and the residue was purified by reverse phase Gilson HPLC, eluted with 40% - 70% acetonitrile in 0.1% trifluoroacetic acid water over 40 minutes. The desired fractions were concentrated to remove the acetonitrile, neutralized with NaHCOs and extracted with dichloromethane. The dichloromethane layer was dried over Na2S04, filtered, and concentrated to provide the title compound. 'H NMR (500 MHz, dimethylsulfoxide-de) 5 13.11 (s, IH), 8.28 (d, IH), 7.86 (d, IH), 7.81 (s, IH), 7.59 (d, IH), 7.36 (d, 2H), 7.19 (s, IH), 7.03 - 7.12 (m, 4H), 6.80 (dd, IH), 6.66 (s, IH), 6.54 (d, IH), 6.14 (d, IH), 4.20 (d, 2H), 3.14 - 3.26 (m, 4H), 2.96 (s, 2H), 2.30 - 2.47 (m, 3H), 2.18 (s, 2H), 2.02 - 2.09 (m, IH), L98 (s, 2H), 1.71 -1.89 (m, 5H), 1.31 -1.46 (m, 4H), 1.03 - 1.16 (m, 2H), 0.94 (s, 6H). EXAMPLE 484 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-I-yl)-N-[(4- {[(trans-4-cyanocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indazol-4- yloxy)benzamide EXAMPLE 484A trans-4-(aminomethyl)cyclohexanecarbonitrile -595- To a solution of tert-butyl (trans-4-cyanocyclohexyl)methylcarbamate (500 mg) in dichloromethane (10 mL) was slowly added trifluoroacetic acid (2 mL) at 0"C. The reaction mixture was warmed to room temperature, stirred for 1 hour and concentrated to provide the title compound. EXAMPLE 484B 4-((trans-4-cyanocyclohexyl)methylamino)-3-nitrobenzenesulfonamide A mixture of 4-fluoro-3-nitrobenzenesulfonamide (347 mg) and EXAMPLE 484A (3(X) mg) in tetrahydrofuran (20 mL) was treated with triethylamine (1.4 mL) overnight and concentrated. The residue was triturated with ethyl acetate to provide the title compound. EXAMPLE 484C 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[(trans-4-cyanocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indazol-4- yloxy)benzamide A mixture of 4-dimethylaminopyridine (115.0 mg), l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (51.4 mg), EXAMPLE 435D (165 mg) and EXAMPLE 484B (96 mg) in dichloromethane (6 mL) was stirred overnight. To this mixture was added trifluoroacetic acid (5 mL) and the resulting mixture was stirred for 2 hours and concentrated. The residue was purified by reverse phase Gilson HPLC, eluted with 40% - 70% acetonitrile in 0.1% trifluoroacetic acid water over 40 minutes. The desired fractions were concentrated to remove acetonitrile, neutralized with NaHCOs and extracted with dichloromethane. The dichloromethane layer was dried over Na2S04, filtered, and concentrated to provide the title compound, 'H NMR (400 MHz, dimethylsulfoxide-dg) 8 13.10 (s, IH), 11.54 (s, IH), 8.56 (t, IH), 8.37 (d, IH), 7.81 (s, IH), 7.49 - 7.59 (m, 2H), 7.35 (d, 2H), 7.02 - 7.14 (m, 4H), 6.95 (d, IH), 6.80 (dd, IH), 6.52 (d, IH), 6.19 (d, IH), 3.25 (t, 2H), 3.16 (s, 4H), 2.80 (s, 2H), 2.60 - 2.70 (m, IH), 2.21 (d, 6H), 1.94 - 2.08 (m, 4H), 1.74 -1.84 (m, 2H), 1.58 -1.71 (m, IH), 1.36 -1.54 (m, 4H), 0.98 -1.12 (m, 2H), 0.93 (s, 6H). EXAMPLE 485 N-({5-chloro-6-[2-(lH-imidazol-l-yl)ethoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzamide -596- EXAMPLE 485A The title compound was prepared by substituting 2-(lH-imidazol-l-yl)ethanol for (tetrahydio-2H-pyran-4-yl)methanol and EXAMPLE 387A for EXAMPLE 329A in EXAMPLE 329B. EXAMPLE 485B N-(6-(2-(lH-imidazol-l-yl)ethoxy)-5-chloropyridin-3-ylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -eny l)methyl)piperazin-1 -yl)-2-( 1 -((2- (trimethylsilyl)ethoxy)methyl)-1 H-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 485A for EXAMPLE IF and EXAMPLE 435D for EXAMPLE IE in EXAMPLE IG. EXAMPLE 485C N-({5-chloro-6-[2-(lH-imidazol-l-yl)ethoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 485B for EXAMPLE 435E in EXAMPLE 435F. 'H NMR (500MHZ, dimethylsulfoxide-de) 5 13.03 (s, IH), 8.28 (m, 2H), 7.85 (d, IH), 7.77 (s, IH), 7.61 (d, IH), 7.44 (s, IH), 7.36 (d, 2H), 7.06 (d, 2H), 7.01-7.03 (m, 2H), 6.76 (dd, IH), 6.49 (d, IH), 6.10 (dd, IH), 4.65 (t, 2H), 4.50 (t, 2H), 3.11 (s, 4H), 2.88 (bs, 2H), 2.32-2.36 (m, 4H), 2.17-2.19 (m, 2H), 1.97-1.99 (m, 2H), 1.41 (t, 2H), 1.14-1.23 (m, 4H), 0.94 (s, 6H). EXAMPLE 486 N-({5-chloro-6-[(l-methyl-lH-imidazol-5-yl)medioxy]pyridin-3-y]}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide EXAMPLE 486A 5-chloro-6-(( 1 -methyl-1 H-imidazol-5-yl)methoxy)pyridine-3-sulfonamide -597- The title compound was prepared by substituting (1-methyl-lH-imidazol-5-yl)methanol for (tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 387A for EXAMPLE 329A in EXAMPLE 329B. EXAMPLE 486B N-(5-chloro-6-((l-methyl-lH-imidazol-5-yl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin- l-yl)-2-( 1 -((2- (trimethylsilyl)ethoxy)methyl)-lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 486A for EXAMPLE IF and EXAMPLE 435D for EXAMPLE IE in EXAMPLE IG. EXAMPLE486C N-({5-chloro-6-[(l-methyl-lH-imidazol-5-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 486B for EXAMPLE 435E in EXAMPLE 435F. 'H NMR (500MHZ, dimethylsulfoxide-de) 8 13.05 (s, IH), 8.29 (s, IH), 7.86 (d, IH), 7.78 (s, IH), 7.62 (d, IH), 7.36 (d, 2H), 7.04-7.07 (m, 4H), 6.77 (dd, IH), 6.49 (d, IH), 6.12 (dd, IH), 5.46 (s, 2H), 3.70 (s, 3H), 3.15 (s, 54H), 2.87 (bs, 2H), 2.32-2.36 (m, 4H), 2.17-2.19 (m, 2H), 1.98 (s, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 487 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl )piperazin-1 -yl)-N- {[5- fluoro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sidfonyl}-2-(lH-indazol-4- yloxy)benzamide EXAMPLE 487A 5-bromo-3-fluoro-2-((tetrahydro-2H-pyran-4-yl)raethoxy)pyridine The title compound was prepared by substituting 5-bromo-2,3-difluoropyridine for 4-fluoro-3-nitn)benzenesiilfonanude in EXAMPLE 279A. EXAMPLE 487B tert-butyl5-fluoro-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyridin-3-ylcarbamate -598- The title compound was prepared by substituting EXAMPLE 487A for EXAMPLE 416A in EXAMPLE 416B. EXAMPLE 487C 5-fluoro-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonyl chloride The title compound was prepared by substituting EXAMPLE 487B for EXAMPLE 416B in EXAMPLE 416C. EXAMPLE 487D 5-fluoro-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 487C for EXAMPLE 416C in EXAMPLE 416D. EXAMPLE 487E 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-N-(5-fluoro-6-((tetrahydro-2H-pyran-4-yl)methoxy)pyridin-3-ylsulfonyl)-2-( 1 -((2-(trimethylsilyl)ethoxy)methyl)-lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 435D for EXAMPLE IE and EXAMPLE 487D for EXAMPLE IF in EXAMPLE IG. EXAMPLE 487F EXAMPLE 487E (0.195 g) was treated with trifluoroacetic acid (2.311 mL) and stirred at ambient temperature for 3 hours. The reaction mixture was concentrated, dissolved in dioxane (3.0 mL), treated with IN NaOH (2.0 mL), and stirred for 3 days. 4N NaOH (1.0 mL) was added and stirring was continued for 4 hours. Saturated NaHCOj solution was added and the mixture was extracted with CH2CI2. The oiganic layers were combined, washed with saturated NH4CI solution, dried (MgS04), filtered, concentrated and chromatographed on silica gel with 0 to 4% methanol in CH2CI2 as the eluent. The product was dissolved in CH3CN, concentrated and dried in a vacuum oven at 80 °C. 'H NMR (400 MHz, pyridine-ds) 8 14.70 (s, IH), 8.86 (d, IH), 8.39 (d, IH), 8.06 (d, IH), 8.00 (dd, IH), 7.47 (m, 2H), 7.35 (d, IH), 7.12 (m, 3H), 6.88 (m, 2H), 6.48 (d, IH), 4.21 (d, 2H), 3.96 (dd, 2H), 3.30 (m, 2H), 3.18 (m, 4H), 2.83 (s, 2H), 2.31 (t, 2H), 2.24 (m, 4H), 1.95 (m, 3H), 1.57 (dd, 2H), 1.38 (m, 4H), 0.96 (s, 6H). -599- EXAMPLE 488 N- {[5-ch]oro-6-(l ,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -y l)-2-( 1 H-indazol-4-yloxy)benzamide EXAMPLE 488A 6-((L4-dioxan-2-yl)methoxy)-5-chloropyridine-3-sulfonamide The title compound was prepared by substituting (l,4-dioxan-2-yl)methanol for (tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 387A for EXAMPLE 329A in EXAMPLE 329B. EXAMPLE 488B N-(6-((l,4-dioxan-2-yl)methoxy)-5-chloropyridin-3-ylsulfonyl)-4-(4-((2-(4-chlorophenyl)- 4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(l-((2-(trimethylsilyl)ethoxy)methyl)- lH-indazol-4-yloxy)benzainide The title compound was prepared by substituting EXAMPLE 488A for EXAMPLE IF and EXAMPLE 435D for EXAMPLE IE in EXAMPLE IG. EXAMPLE488C N- {[5-chloro-6-( 1,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indazol-4-y loxy)benzaniide The title compound was prepared by substituting EXAMPLE 488B for EXAMPLE 435E in EXAMPLE 435F. 'H NMR (500MHZ, dimethylsulfoxide-dg) 8 13.06 (s, IH), 8.23 (s, IH), 7.85 (d, IH), 7.79 (s, IH), 7.60 (d, IH), 7.36 (d, 2H), 7.02-7.09 (m, 4H), 6.76-6.79 (m, IH), 6.51 (s, IH), 6.11 (d, IH), 4.35-4.37 (m, 2H), 3.75-3.92 (m, 4H), 3.59-3.68 (m, 2H), 3.41-3.54 (m, 4H), 3.17 (s, 54H), 2.89 (s, 2H), 2.34 (bs, 4H), 2.17-2.19 (m, 2H), 1.98 (s, 2H), 1.41 (t,2H), 0.94 (s,6H). EXAMPLE 490 N-({5-chloro-6-[(4,4-difluoro-l-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide -600- EXAMPLE 490A 1, l-difluoro4-methylenecyclohexane Butyllithium (12.32 mL, 2.5 M solution in hexanes) was added to a solution of methyltriphenylphosphonium chloride (9.63 g) in tetrahydrofuran (50 mL) at 0°C, and the reaction was stirred for 5 minutes. 4,4-Difluorocycleohexanone (3.76 g) in dioxane (150 mL)was then added, and the reaction was stirred for 30 minutes. Water (3 mL) was added, and then hexane (150 mL) was slowly added, the reaction was filtered, and the solution carried on in the next step. EXAMPLE 490B 4,4-difluoro-1 -(hydroxymethyl)cyclohexanol To the solution from EXAMPLE 490A was added water (75 mL), then N-metthylmorpholine-N-oxide (6.4 mL, 50% solution in water) and OSO4 (14.2 g, 2.5 wt % solution in tert-butanol) were added, and the reaction was stirred for 96 hours at 50''C. The solution was cooled to room temperature, treated with saturated aqueous Na2S203 solution (100 mL) for 30 minutes, and then acidified with concentrated aqueous HCl. The solution was then extracted three times with ethyl acetate, and the organic layers were combined, washed with IM aqueous HCl, and brine, and concentrated. The crude mixture was chromatographed on silica gel using 10-100% ethyl acetate in hexanes, and then 5% methanol in ethyl acetate to give the product. EXAMPLE 490C 5-chloro-6-((4,4-difluoro-l-hydroxycyc]ohexyl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 490B for tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 387A for EXAMPLE 329A in EXAMPLE 329B. EXAMPLE 490D N-( {5-chloro-6- [(4,4-difluoro-1 -hydroxycyclohexyl)methoxy ]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol- 4-yloxy)benzamide A mixture of 4-dimethylaminopyridine (28 mg), l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (62 mg), EXAMPLE 435D (108 mg) and EXAMPLE 490C (55 mg) in dichloromethane (4 mL) was stirred overnight. The mixture was chromatographed on silica gel using 50-100% ethyl acetate in hexanes, and then -601- 5% methanol in ethyl acetate as eluent to give the protected product. This material was taken up in IM tetrabutyl ammonium fluoride (8 mL) and the resulting mixture was stirred for 4 days at 50°C and concentrated. The residue was neutralized with NaHCOs and extracted with dichloromethane. The dichloromethane layer was concentrated and chromatographed on silica gel using 50-100% ethyl acetate in hexanes, and then 5% methanol in ethyl acetate as eluent to give the product. ^H NMR (300MHz, dimethylsulfoxide-de) 5 13.05 (br s, IH), 8.24 (s, IH), 7.83 (d, IH), 7.60 (m, 3H), 7.35 (d, 2H), 7.06 (d, 2H), 7.05 (d, IH), 6.75 (d, IH), 6.47 (s, IH), 6.12 (dd, IH), 4.87 (s, IH), 4.23 (s, 2H), 3.13 (m, 2H), 3.02 (m, 2H), 2.77 (m, IH), 2.27 (m, 2H), 2.17 (m, 4H), 1.97 (s, 2H), 1.91 (m, 2H), 1.74 (m, 4H), 1.60 (m, 2H), 1.40 (m, 2H), 1.31 (m, IH), 0.94 (s, 3H), 0.91 (m, 2H). EXAMPLE 491 N-({5-chloro-6-[(2,2-difluorocyclopropyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( 1 H-indazol-4- yloxy)benzamide EXAMPLE 491A 5-chloro-6-((2,2-difluorocyclopropyl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting (2,2-difluorocyclopropyl)methanol for (tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 387A for EXAMPLE 329A in EXAMPLE 329B. EXAMPLE 49 IB N-(5-chloro-6-((2,2-difluorocyclopropyl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -((2- (trimethylsilyl)ethoxy )methyl)-1 H-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 435D for EXAMPLE IE and EXAMPLE 491A for EXAMPLE IF in EXAMPLE IG. EXAMPLE 491C N-({5-chloro-6-[(2,2-difluorocyclopropyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yI]methyl}piperazin-I-yl)-2-(lH-indazol-4- yloxy)benzamide -602- EXAMPLE 491B (0.196 g) was treated with tetrabutyl ammonium fluoride (IM in tetrahydrofuran) (2.000 mL), heated at 50 °C overnight, cooled to room temperature and then treated with IN aqueous NaOH solution (2.0 mL). The mixture was stirred for 5 hours at ambient temperature and then extracted with CH2CI2. The extracts were combined, washed with brine, dried (MgS04), filtered and concentrated. The residue was purified by reverse phase HPLC on a C18 column using a gradient of 20-80% acetonitrile/0.1% trifluoroacetic acid in water to give the title compound as the trifluoroacetate salt. The trifluoroacetic acid salt was dissolved in dichloromethane, washed with saturated aqueous NaHCOs solution and brine, dried (Na2S04), filtered, concentrated, slurried in CH3CN, concentrated again and dried overnight in a vacuum oven at 80 °C to give the title compound. 'H NMR (400 MHz, pyridine-ds) 8 14.62 (s, IH), 8.88 (d, IH), 8.37 (m, 2H), 8.06 (d, IH), 7.46 (d, 2H), 7.34 (d, IH), 7.11 (m, 3H), 6.87 (m, 2H), 6.48 (d, IH), 4.53 (m, IH), 4.43 (m, IH), 3.17 (m, 4H), 2.82 (s, 2H), 2.27 (m, 7H), 1.99 (s, 2H), 1.56 (m, IH), 1.38 (m, 3H), 0.96 (s, 6H). EXAMPLE 492 N-((5-chloro-6-[(trans-4-cyanocyclohexyl)methoxy]pyridin-3-yl)su]fonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide A solution of EXAMPLE 483D (50 mg) in dioxane (12 mL) and pyridine (1.2 mL) was cooled in an ice-water bath. The mixture was slightly warmed by removing the ice bath and then trifluoroacetic acid (0.3 mL) was added. The reaction was stirred for 1 hour and quenched with methanol and aqueous NaOH. The resulting mixture was stirred for 1 hour and concentrated. The residue was purified by reverse phase HPLC, and eluted with 40% -70% acetonitrile in 0.1% trifluoroacetic acid water over 40 minutes. The desired fractions were concentrated to remove acetonitrile, neutralized with NaHCOs and extracted with dichloromethane. The dichloromethane layer was dried over Na2S04, filtered, concentrated and dried to provide the title compound. 'H NMR (400 MHz, dimethylsulfoxide-de) S 13.10 (s, IH), 8.27 (d, IH), 7.85 (d, IH), 7.80 (s, IH), 7.58 (d. IH), 7.37 (d, 2H), 7.02 - 7.11 (m, 4H), 6.80 (dd, IH), 6.54 (d, IH), 6.14 (d, IH), 4.19 (d, 2H), 3.22 (s, 4H), 2.97 (s, 2H), 2.59 -2.71 (m, IH), 2.41 (s, 2H), 2.18 (s, 2H), 2.05 (dd, 2H), 1.98 (s, 2H), 1.79 - 1.90 (m, 3H), 1.47 - 1.62 (m, 2H), 1.42 (t, 2H), 1.04-1.19 (m, 2H), 0.94 (s, 6H). -603- EXAMPLE 493 N-({5-chloro-6-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl }piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide EXAMPLE 493A 4-(hydroxymethyl)-1 -methylcyclohexanol 4-(Hydroxymethyl)cyclohexanone (800 mg) in tetrahydrofuran (15 mL) was treated with 3 M methylmagnesium chloride in tetrahydrofuran (6.24 mL) at 0°C. The reaction was warmed to room temperature over 2 hours and quenched with methanol and water. The resulting mixture was concentrated and the residue was suspended in ethyl acetate. The precipitates were filtered off and the filtrate was concentrated. The residue was purified by chromatography, eluting with 0-100% ethyl acetate in hexane to provide the title compound. EXAMPLE 493B 5-chloro-6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3-sulfonamide EXAMPLE 493A (970 mg) and EXAMPLE 387A (1.6 g) in N,N-dimethylfonnamide (8 mL) were treated with sodium hydride (1.8 g, 60%) at room temperature for 2 days. The reaction was quenched with water. The resulting mixture was neutralized with diluted aqueous HCl, and extracted with ethyl acetate. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by a reverse phase chromatography, and was eluting with 30-45% acetonitrile in 0.1% trifluoroacetic acid water to provide the title compound. EXAMPLE 493C 5-chloro-6-((cis-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3-sulfonamide EXAMPLE 493A (970 mg) and EXAMPLE 387A (1.6 g) in N,N-dimethylformamide (8 mL) were treated with sodium hydride (1.8 g, 60%) at room temperature for 2 days. The reaction was quenched with water. The resulting mixture was neutralized with diluted aqueous HCl, and extracted with ethyl acetate. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by a reverse phase chromatography, and was eluting with 30-45% acetonitrile in 0.1% trifluoroacetic acid water to provide the title compound. -604- EXAMPLE 493D N-({5-chloro-6-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-cMorophenyl)-4,4-dimethylcyclohex-l -en-1 -yljmethyl }piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide A mixture of 4-dimethylaminopyridine (175.0 mg), l-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydnx;hloride (82 mg), EXAMPLE 435D (251 mg) and EXAMPLE 493C (120 mg) in dichloromethane (6 mL) was stirred overnight and concentrated. The residue was dissolved in a 1 M tetrabutyl ammonium fluoride monohydrate tetrahydrofuran solution (11 mL) and the resulting solution was refluxed for 9 hours and concentrated. The residue was purified by reverse phase HPLC, eluted with 40% - 70% acetonitrile in 0.1% trifluoroacetic acid water over 40 minutes. The desired fractions were concentrated to remove acetonitrile, neutralized with NaHCOs and extracted with dichloromethane. The dichloromethane layer was dried over Na2S04, filtered, concentrated and dried to provide the title compound. 'H NMR (400 MHz, dimethylsulfoxide-d^) 8 13.11 (s, IH), 8.27 (d, IH), 7.85 (d, IH), 7.81 (s, IH), 7.59 (d, IH), 7.36 (d, 2H), 7.03 - 7.11 (m, 4H), 6.80 (dd, IH), 6.54 (d, IH), 6.14 (d, IH), 4.20 (d, 2H), 3.96 (s, IH), 3.21 (s, 4H), 2.86 -3.05 (m, IH), 2.40 (s, 2H), 2.18 (s, 2H), 1.98 (s, 2H), 1.63 -1.78 (m, IH), 1.50 -1.62 (m, 4H), 1.36 - 1.49 (m, 4H), 1.20 - 1.34 (m, 2H), 1.10 (s, 3H), 0.94 (s, 6H). EXAMPLE 494 N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide EXAMPLE 494A 4-Hydroxy-indazole-l-carboxylic acid tert-butyl ester and 4-hydroxy-indazole-2-carboxylic acid tert-butyl ester 4-Hydroxyindazole (3.94 g) was added to tetrahydrofuran (250 mL) and cooled to 0°C using an ice bath. Sodium hydride (60% dispersion in mineral oil, 1.23 g) was added, and the mixture was stirred at 0°C for five minutes. The mixture was allowed to warm to room temperature and stirred for an additional 20 minutes. The mixture was again cooled to 0°C using an ice bath, and tert-butyldimethylchlorosilane (4.65 g) was added. The mixture was allowed to warm to room temperature and stirred for 16 hours. The solvent volume was -605- reduced under vacuum, the residue vacuum filtered over a pad of silica gel and washed with ethyl acetate, and the solvent was removed under vacuum. To the residue was added acetonitrile (200 mL), di-tert-butyl dicarbonate (7.06 g), and 4-(dimethylamino)pyridine (0.359 g). The mixture was stirred at room temperature for three hours, and the solvent was removed under vacuum. To the residue was added tetrahydrofuran (200 mL) and tetrabutylammonium fluoride (IM in tetrahyrdofiiran, 82 mL). The mixture was stirred at room temperature for four days, the solvent removed under vacuum, and the residue taken up in ethyl acetate. The mixture was extracted with saturated aqueous ammonium chloride, extracted with brine, and dried on anhydrous sodium sulfate. The mixture was vacuum filtered over silica gel, and the solvent removed under vacuum to give a mixture of the two products, which was used in the next step without further purification. EXAMPLE 494B 4-Fluoro-2-(lH-indazol-4-yloxy)-benzoic acid methyl ester EXAMPLE 494A (5.56 g) was added to diglyme (200 mL), and potassium tert-butoxide (IM in tetrahydrofuran, 30.8 mL) was added. The mixture was stirred at room temperature for 15 minutes, methyl 2,4-difluorobenzoate was added, and the mixture was heated at 115°C for 16 hours. The mixture was cooled, the solvent was removed under vacuum, the residue was taken up in dichloromethane (1(X) mL), and trifluoroacetic acid (22.6 mL) was added. The mixture was stirred at room temperature for 16 hours, the solvent was removed under vacuum, the residue was taken up in ethyl acetate and washed with a saturated aqueous sodium bicarbonate mixture, and the organic layer was dried with anhydrous sodium sulfate. The material was purified by flash column chromatography on silica gel using 30% ethyl acetate (in hexanes) increasing to 40% ethyl acetate (in hexanes). EXAMPLE 494C 2-(lH-Indazol-4-yloxy)-4-piperazin-l-yl-benzoic acid methyl ester EXAMPLE 494B (2.00 g) and piperazine (2.71 g) were added to dimethylsulfoxide (60 mL) and heated to 100°C for one hour. The mixture was cooled, added to dichloromethane, washed with water twice, washed with a saturated aqueous sodium bicarbonate mixture, and dried on anhydrous sodium sulfate. After filtration, the solvent was removed under vacuum. -606- EXAMPLE 494D methyl 4,4-dimethyl-2-(trifluoromethylsulfonyloxy)cyclohex- l-enecarboxylatB To a suspension of hexane washed NaH (17 g) in dichloromethane (700 mL), 5,5-dimethyl-2-methoxycaibonylcyclohexanone (38.5 g) was added dropwise at 0°C. After stirring for 30 minutes, the mixture was cooled to -78°C and trifluoromethanesulfonic anhydride (40 mL) was added. The reaction mixture was warmed to room temperature and stirred for 24 hours. The organic layer was washed with brine, dried (Na2S04), filtered, and concentrated to give the product. EXAMPLE 494E methyl 2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enecarboxylate EXAMPLE 494D (62.15g), 4-chlorophenylboronic acid (32.24 g), CsF (64 g) and tetrakis(triphenylphosphine)palladium(0) (2g) in 2:1 1,2-dimethoxyethane/methanol (6(X) mL) were heated to 70''C for 24 hours. The mixture was concentrated. Ether (4x 200 mL) was added and the mixture was filtered. The combined ether solution was concentrated to give the product. EXAMPLE 494F (2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methanol To a mixture of LiBH4 (13g), EXAMPLE 494E (53.8 g) and ether (400 mL), methanol (25 mL) was added slowly by syringe. The mixture was stirred at room temperature for 24 hours. The reaction was quenched with IN aqueous HCl with ice-cooling. The mixture was diluted with water and extracted with ether (3x lOOmL). The extracts were dried (Na2S04), and concentrated. The crude product was chromatographed on silica gel with 0-30% ethyl acetate/hexanes. EXAMPLE 494G 2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enecarbaldehyde To a solution of EXAMPLE 494F in dichloromethane (120 mL) at 0°C was added Dess-Martin periodinane (17.7 g) and the reaction was allowed to warm to room temperature. The reaction was diluted with dichloromethane (2(X) mL), washed twice with saturated aqueous NaHC03 solution and brine, dried over Na2S04, filtered, and concentrated. The crude product was filtered through a silica gel plug to give the title compound. -607- EXAMPLE 494H 4- {4-[2-(4-Chloio-phenyl)-4,4-dimethyl-cyclohex-1 -enylmethyl]-piperazin-1 -yl} -2-( 1H-indazol-4-yloxy)-benzoic acid methyl ester To dichloromethane (60 mL) was added EXAMPLE 494C (2.500 g) and EXAMPLE 494G (2.029 g). The solution was stirred at room temperature for 30 minutes, sodium triacetoxyborohydride (1.804 g) was added, and the solution stirred at room temperature for 16 hours. The solution was diluted with ethyl acetate, washed with a saturated aqueous solution of sodium bicarbonate, washed with brine, and the organic layer dried on anhydrous sodium sulfate. After filtration, the solution was concentrated and purified by flash column chromatography on silica gel using 20-50% ethyl acetate in hexanes. EXAMPLE 4941 methyl 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-enyl)methyl)piperazin-1-yl)-2-(l-trityl-lH-indazol-4-yloxy)benzoate EXAMPLE 494H (3(X) mg) was dissolved in dichloromethane (1.5 mL), cooled to 0 °C, then triethylamine (0.22 mL) and trityl chloride (145 mg) were added. The reaction was allowed to warm to room temperature overnight. The reaction mixture was directly put on a silica gel column and eluted with 10-30% ethyl acetate in hexanes to give the title compound. EXAMPLE 494J 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -trityl- lH-indazol-4-yloxy)benzoic acid EXAMPLE 4941 (0.591 g) was dissolved in tetrahydrofuran (6 mL) and methanol (2 mL) and to the resulting solution was added IM aqueous LiOH solution (2.14 mL) and the reaction was heated to 60°C for 5 hours. The reaction was cooled and diluted with dichloromethane (100 mL) and water (10 mL), and then quenched with IN aqueous HCl (2 mL). The organic layer was separated, washed with brine (25 mL) and concentrated. Silica gel chromatography (Reveleris 40 g) eluting with a gradient of 1% to 4% methanol/dichloromethane over 30 minutes gave the title compound. EXAMPLE 494K 4-(hydroxymethyl)-1 -methylcyclohexanol 4-(Hydroxymethyl)cyclohexanone (800 mg) in tetrahydrofuran (15 mL) was treated with 3 M methylmagnesium chloride in tetrahydrofuran (6.24 mL) at 0°C. The reaction was -608- warmed to room temperature over 2 hours and was quenched with methanol and water. The resulting mixture was concentrated and the residue was suspended in ethyl acetate. The precipitates were filtered off and the filtrate was concentrated. The residue was purified by chromatography, eluting with 0-100% ethyl acetate in hexane to provide the title compound. EXAMPLE 494L 5,6-dichloropyridine-3 -sulfonamide To a solution of 5,6-dichloropyridine-3-sulfonyl chloride (32.16 g) in isopropyl alcohol (300 noL) at 0 °C was added a 30% aqueous solution of NH4OH (50.8 mL). After stirring overnight, the solvent was reduced to 1/3 of the original volume. It was then partitioned between water and ethyl acetate. The aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was chromatographed on silica gel. The material was then slurried in 1:9 ethyl acetate/hexanes, filtered and dried under vacuum to give the title compound. EXAMPLE 494M 5-chloro-6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3-sulfonamide EXAMPLE 494K (970 mg) and EXAMPLE 494L (1.6 g) in N.N-dimethylformamide (8 mL) were treated with sodium hydride (1.8 g, 60%) at room temperature for 2 days. The reaction was quenched with water. The resulting mixture was neutralized with diluted aqueous HCl, and extracted with ethyl acetate. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by a reverse phase chromatography, and was eluting with 30-45% acetonitrile in 0.1% trifluoroacetic acid/water to provide the title compound. EXAMPLE 494N N-({5-chIoro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -y IJmethyl }piperazin-1 -yl)-2-( 1 H-indazol- 4-yloxy)benzamide A mixture of EXAMPLE 494J (3.4 g), EXAMPLE 494M (L539 g),.N, N-dimethylpyridin-4-amine (2.043 g) and N'-((ethylimino)methylene)-N^,N^-dimethylpropane-1,3-diamine hydrochloride (1.042 g) in dichloromethane (65 mL) was stirred overnight. -609- Water (5 mL) was added. The resulting mixture was cooled in an ice bath and then trifluoroacetic acid (5 mL) was slowly added. The mixture was stirred while warmed from 0°C to room temperature and then stirred at room temperature for 2 hours. The reaction mixture was concentrated without heating and the residue was suspended in a mixture of dimethylsulfoxide and methanol (1:1,40 mL). The precipitates were filtered off. The filtrate was loaded onto a C18 column, eluted with 40%-70% acetonitrile in 0.1% trifluoroacetic acid water. The desired fractions were concentrated to remove acetonitrile, neutralized with NaHCOa and extracted with dichloromethane. The organic layer was dried over Na2S04, filtered, concentrated and dried to provide the tide compound. 'H NMR (500 MHz, dimethylsulfoxide-de) 6 13.11 (s, IH), 8.28 (d, IH), 7.85 (d, IH), 7.81 (s, IH), 7.59 (d, IH), 7.37 (d, 2H), 7.03 - 7.12 (m, 4H), 6.80 (dd, IH), 6.54 (d, IH), 6.14 (d, IH), 4.18 - 4.31 (m, 3H), 3.15 - 3.26 (m, 4H), 2.96 (s, 2H), 2.28 - 2.48 (m, 3H), 2.18 (s, 2H), 1.98 (s, 2H), 1.69 -1.82 (m, 3H), 1.56 (d, 2H), 1.34 - 1.45 (m, 4H), 1.16 - 1.27 (m, 2H), 1.11 (s, 3H), 0.94 (s, 6H). EXAMPLE 496 N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yI)methoxy]phenyl}sulfonyl)-4-(4-{[4-(4- chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2-(lH- indazol-4-yloxy)benzamide EXAMPLE 496A 3-chloro-4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 306C for (tetrahydro- 2H-pyran-4-yl)methanol and 3-chloro-4-fluorobenzenesiilfonamide for EXAMPLE 329A in EXAMPLE 329B. EXAMPLE 496B N-(3-chloro-4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)phenylsulfonyl)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -((2- (trimethylsilyl)ethoxy )methyl)-1 H-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 496A for EXAMPLE IF and EXAMPLE 435D for EXAMPLE 27G in EXAMPLE 27H. -610- EXAMPLE 496C N-( {3-chloro-4- [(4-fluorotetrahydro-2H-pyran-4-y l)methoxy]phenyl} sulfonyl)-4-(4- {[4-(4- chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 496B for EXAMPLE 435E in EXAMPLE 435F. ^H NMR (400MHz, dimethylsulfoxide-de) 5 13.16 (s, IH), 11.62 (v br s, IH), 7.86 (s, IH), 7.67 (d, IH), 7.59 (dd, IH), 7.55 (d, IH), 7.39 (d, 2H), 7.15 (m, 5H), 6.80 (dd, IH), 6.52 (d, IH), 6.22 (d, IH), 4.25 (d, 2H), 4.14 (s, 2H), 3.80 (m, 2H), 3.60 (m, 2H), 3.17 (br m, 4H), 2.88 (s, 2H), 2.25 (br m, 4H), 2.16 (s, 2H), 1.90 (m, 4H), 1.20 (s, 6H). EXAMPLE 497 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-(trifluoromethyl)phenyl) sulfonyl)-2-( 1H- indazol-4-yIoxy)benzamide EXAMPLE 497A 4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)-3-(trifluoromethyl)benzenesulfonamide The tide compound was prepared by substituting EXAMPLE 306C for (tetrahydro-2H-pyran-4-yl)methanol and 4-fluoro-3-(trifluoromethyl)benzenesulfonamide for EXAMPLE 329A in EXAMPLE 329B. EXAMPLE 497B 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-N-(4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)-3-(trifluoromethyl)phenylsulfonyl)-2-(l-trityl- lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 498C for EXAMPLE IE and EXAMPLE 497A for EXAMPLE IF in EXAMPLE IG. EXAMPLE 497C 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-N-( {4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(lH- indazol-4-yloxy)benzamide -611- EXAMPLE 497B (0.1557 g) in dichloromethane (1.5 mL) at 0 °C was treated dropwise with trifluoroacetic acid (1.041 mL), stirred for 1 hour, diluted with CH2CI2 and basified with saturated NaHCOs solution. The layers were separated and the organic layer was washed with water and brine, dried (Na2S04), filtered and concentrated. The concentrate was chromatographed on silica gel with 0 to 4% methanol in CH2CI2 as the eluent. 'H NMR (500 MHz, pyridine -ds) 6 14.59 (s, IH), 8.58 (d, IH), 8.39 (dd, IH), 8.36 (s, IH), 8.07 (d, IH), 7.46 (m, 2H), 7.37 (d, IH), 7.17 (t, IH), 7.09 (m, 3H), 6.85 (dd, IH), 6.82 (d, IH), 6.55 (d, IH), 4.21 (d, 2H), 3.86 (m, 2H), 3.78 (td, 2H), 3.15 (m, 4H), 2.81 (s, 2H), 2.29 (t, 2H), 2.21 (m, 4H), 1.95 (m, 6H), 1.41 (t, 2H), 0.95 (s, 6H). EXAMPLE 498 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N- {[3- chloro-4-(tetrahydro-2H'Pyran-4-ylmethoxy)phenyl]sulfonyl)-2-(lH-indazol-4- yloxy)benzamide EXAMPLE 498A 3-chloro-4-((tetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide The title compound was prepared by substituting 3-chloro-4-fluorobenzenesulfonamide for EXAMPLE 329A in EXAMPLE 329B. EXAMPLE 498B methyl 4-(4-((2-(4-chlC)rophenyl)-4,4-dimethylcyclohex- l-enyl)methyl)piperazin-1-yl)-2-(l-trityl-lH-indazol-4-yloxy)benzoate EXAMPLE 400D (300 mg) was dissolved in dichloromethane (1.5 mL), cooled to 0° C, then triethylamine (0.22 mL) and trityl chloride (145 mg) were added. The reaction was allowed to come to room temperature overnight. The reaction mixture was directly put on a silica gel column and eluted with 10-30% ethyl acetate in hexanes to give the title compound. EXAMPLE 498C 4-(4-((2-(4-chlorophenyl)-4,4'dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -trityl- lH-indazol-4-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 498B for EXAMPLE 175D in EXAMPLE 175E. -612- EXAMPLE 498D N-(3-chloro-4-((tetrahydro-2H-pyran-4-yl)methoxy)phenylsulfonyl)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -trityl-1 H-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 498C for EXAMPLE IE and EXAMPLE 498A for EXAMPLE IF in EXAMPLE IG. EXAMPLE 498E 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[3- chIoro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl) -2-( 1 H-indazol-4- yloxy)benzamide EXAMPLE 498D (150 mg) was dissolved in dichloromethane (3.5 mL) and trifluoroacetic acid (3.5 mL). After stirring at room temperature for 30 minutes, the reaction was poured into saturated aqueous NaHCOa and extracted with dichloromethane. The organic layer was washed with brine and dried over Na2S04. After filtration and concentration the residue was purified by reverse phase HPLC on a C18 column using a gradient of 40-60% acetonitrile/0.1% trifluoroacetic acid in water to give the title coriipound as the trifluoroacetate salt. The trifluoroacetic acid salt was dissolved in dichloromethane (6 mL) and washed with 50% aqueous NaHCOs. The organic layer was dried over anhydrous Na2S04, filtered, and concentrated to give the title compound. H NMR (400MHz, dimethylsulfoxide-de) 5 13.16 (s, IH), 7.85 (s, IH), 7.64 (d, IH), 7.57 (dd, IH), 7.55 (d, IH), 7.35 (d, 2H), 7.35 (m, 3H), 7.04 (d, 2H), 6.80 (dd, IH), 6.53 (d, IH), 6.22 (d, IH), 3.97 (d, 2H), 3.88 (m, 2H), 3.35 (m, 2H), 3.18 (br m, 4H), 2.80 (s, 2H), 2.27 (br m, 4H), 2.18 (br m, 2H), 2.04 (m, IH), 1.97 (s, 2H), 1.69 (m, 2H), 1.40 (m, 4H) 0.93 (s, 6H). EXAMPLE 499 2-(lH-benzimidazol-4-yloxy)-N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)benzamide The title compound was prepared by substituting EXAMPLE 496A for EXAMPLE 428D in EXAMPLE 428E. ^H NMR (500MHz, pyridine-ds) 6 8.58 (s, IH), 8.53 (d, IH), 8.33 (dd, IH), 7.96 (d, IH), 7.54 (d, IH), 7.43 (d, 2H), 7.26 (t, IH), 7.20 (m, 2H), 7.07 (d, -613- 2H), 7.04 (d, IH), 6.72-6.68 (m, 2H), 4.17 (d, 2H), 3.89 (m, 2H), 3.83 (m, 2H), 3.03 (m, 4H), 2.76 (s, 2H), 2.26 (m, 2H), 2.14 (m, 4H), 2.03-1.95 (m, 6H), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 500 2-( 1 H-benzimidazol-4-yloxy )-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl)piperazin-l-yl)-N-{[5-chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyTidin-3- yl]sulfonyl}benzamide The title compound was prepared by substituting EXAMPLE 387B for EXAMPLE 428D in EXAMPLE 428E. ^H NMR (500MHz, pyridine-ds) 5 9.16 (d, IH), 8.72 (d, IH), 8.59 (s, IH), 7.97 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.25 (t, IH), 7.20 (m, 2H), 7.07 (d, 2H), 6.73-6.68 (m, 2H), 4.21 (d, 2H), 3.99 (dd, 2H), 3.33 (dt, 2H), 3.03 (m, 4H), 2.77 (s, 2H), 2.25 (m, 2H), 2.14 (m, 4H), 1.98 (m, IH), 1.97 (s, 2H), 1.60 (d, 2H), 1.43 (m, 2H), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 501 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N-( {3-cyano-4-[(4-fluorotetrahydio-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-indazol-4- yloxy)benzamide EXAMPLE 501A 3-cyano-4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)benzenesulfonamide The title compound was prepared by substituting (4-fluorotetrahydro-2H-pyran-4-yl)methanol for (tetrahydio-2H-pyran-4-yl)methanol and 3-cyano-4-fluorobenzenesulfonamide for EXAMPLE 329A in EXAMPLE 329B. EXAMPLE 501B 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-N-(3-cyano- 4-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)phenylsulfonyl)-2-(l-((2- (trimethylsilyl)ethoxy)methyl)-lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 501A for EXAMPLE IF and EXAMPLE 435D for EXAMPLE IE in EXAMPLE IG. -614- EXAMPLE 50IC 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}pipeiazin-l-yl)-N-({3-cyano-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 50IB for EXAMPLE 435E in EXAMPLE 435F. 'H NMR (300 MHz, dimethylsulfoxide-d^) 8 13.09 (s, IH), 7.85 (m, 2H), 7.79 (s, IH), 7.57 (d, IH), 7.35 (d, 2H), 7.22 (m, IH), 7.13 (m, 2H), 7.05 (d, 2H), 6.78 (dd, IH), 6.50 (d, IH), 6.17 (dd, IH), 4.34 (d, 2H), 3.79 (m, 2H), 3.63 (m, 2H), 3.16 (m, 4H), 2.82 (m, 2H), 2.27 (m, 4H), 2.17 (m, 3H), 1.97 (m, 2H), 1.91 (m, 2H), 1.85 (m, 2H), 1.40 (t,2H), 0.94 (s,6H). EXAMPLE 502 N- {[3-chloK)-4-( 1,4-dioxan-2-ylmethoxy)phenyl]sulfonyl} -4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex- l-en-l-yl]methyl Ipiperazin- l-yl)-2-(lH-indazol-4-yloxy)benzamide EXAMPLE 502A 4-((l,4-dioxan-2-yl)methoxy)-3-chlorobenzenesulfonamide The title compound was prepared by substituting (l,4-dioxan-2-yl)methanol for (tetrahydro-2H-pyran-4-yl)methanol and 3-chloro-4-fluorobenzenesulfonamide for EXAMPLE 329A in EXAMPLE 329B. EXAMPLE 502B N-(4-((l,4-dioxan-2-yl)methoxy)-3-chlorophenylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -((2-(trimethylsilyl)ethoxy)methyl)-1H- indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 502A for EXAMPLE IF and EXAMPLE 435D for EXAMPLE IE in EXAMPLE IG. EXAMPLE 502C N- {[3-chloro-4-( 1,4-dioxan-2-ylmethoxy)phenyl]sulfonyl} -4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-inda2ol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 502B for EXAMPLE 435E in EXAMPLE 435F. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 13.02 (s, IH), 7.78 -615- (m, IH), 7.63 (m, IH), 7.58 (m, IH), 7.42 (m, IH), 7.35 (d, 2H), 7.11 (d, 2H), 7.06 (d, 2H), 6.99 (m, IH), 6.74 (m, IH), 6.42 (m, IH), 6.15 (m, IH), 4.06 (m, 2H), 3.83 (m, 2H), 3.65 (m, 2H), 3.47 (m, 2H), 3.07 (m, 4H), 2.75 (m, 2H), 2.21 (m, 6H), 1.97 (m, 2H), 1.40 (t, 2H), 1.23 (m, IH), 0.93 (s, 6H). EXAMPLE 503 2-(lH-benzimidazol-4-yloxy)-N-[(5-chloro-6-{[(2S)-4-cyclopropylmorpholin-2- yl]methoxy)pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)benzamide EXAMPLE 503A (S)-5-chloro-6-((4-cyclopropylmorpholin-2-yl)methoxy)pyridine-3-sulfonaminde The title compound was prepared by substituting EXAMPLE 423B for EXAMPLE 415B in EXAMPLE 432A. EXAMPLE 503B 2-(lH-benziniidazol-4-yloxy)-N-[(5-chloro-6-{[(2S)-4-cyclopropylmorpholin-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)benzamide The title compound was prepared by substituting EXAMPLE 503A for EXAMPLE 428D in EXAMPLE 428E. ^H NMR (400 MHz, pyridine-ds) 6 9.08 (d, IH), 8.64 (m, IH), 8.56 (s, IH), 7.99 (d, IH), 7.51 (d, IH), 7.43 (d, 2H), 7.23 (d, IH), 7.13 (m, IH), 7.07 (d, 2H), 6.71 (m, 2H), 6.51 (m, IH), 5.86 (m, IH), 4.62 - 4.57 (m, IH), 4.52 - 4.48 (m, IH), 3.99 (m, 1 H), 3.84 (m, IH), 3.57 (m, IH), 3.04 (m, 5H), 2.77 (s, 2H), 2.69 (m, IH), 2.40 - 2.32 (m, 2H), 2.29 - 2.23 (m, 2H), 2.15 (m, 4H), 1.97 (s, 2H), 1.59 (m, IH), 1.39 (t, 2H), 0.94 (s, 6H), 0.48 - 0.36 (m, 4H). EXAMPLE 504 N-[(5-chloro-6-{[(2S)-4-cyclopropylmorpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H -indazol- 4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 503A for EXAMPLE IF and EXAMPLE 400E for EXAMPLE 26C in EXAMPLE 177. 'H NMR (400 MHz, -616- pyridine-ds) 8 8.86 (d, IH), 8.38 (d, 2H), 8.14 (d, IH), 7.47 (d, 2H), 7.34 (d, IH), 7.13 - 7.10 (m, 3H), 6.88 - 6.85 (m, 2H), 6.49 (d, IH), 5.41 (m, 2H), 4.62 - 4.57 (m, IH), 4.51 - 4.47 (m, IH), 3.98 (m, IH), 3.84 (m, IH), 3.57 (m, IH), 3.16 (m, 4H), 3.02 (m, IH), 2.83 (s, 2H), 2.69 (m, IH), 2.38 - 2.27 (m, 4H), 2.24 (m, 4H), 1.99 (s, 2H), 1.58 (m, IH), 1.41 (t, 2H), 0.96 (m, 6H), 0.48 - 0.36 (m, 4H). EXAMPLE 505 methyl 2- {[(4- {[4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-2-(lH-indazol-4-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)amino]methyl} morpholine-4-carboxylate EXAMPLE 505A methyl 2-((2-nitro-4-sulfamoylphenylamino)methyl)morpholine-4-carboxylate The title compound was prepared by substituting methyl chloroformate for acetyl chloride in EXAMPLE 457A. . EXAMPLE 505B methyl 2- {[(4- {[4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indazol-4-yloxy)benzoyl]suIfamoyl} -2-nitrophenyl)amino]methyl} moiphorme-4-carboxylate The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE 26C and EXAMPLE 505A for EXAMPLE IF in EXAMPLE 177. ^H NMR (500MHz, pyridine-dj) 6 14.58 (bs, IH), 9.05 (d, IH), 8.82 (t, IH), 8.36 (s, IH), 8.18 (d, IH), 8.12 (d, IH), 7.45 (d, 2H), 7.34 (d, IH), 7.15 (t, IH), 7.10 (d, 2H), 6.87-6.82 (m, 3H), 6.53 (d, IH), 4.29,4.03 (bd, IH), 3.86 (m, IH), 3.73 (m, 2H), 3.71 (s, 3H), 3.54-3.40 (m, 3H), 3.14 (m, 4H), 2.96 (dt, IH), 2.85 (m, IH), 2.82 (s, 2H), 2.30 (m, 2H), 2.22 (m, 4H), 1.99 (s, 2H), 1.41 (t, 2H), 0.96 (s, 6H). EXAMPLE 506 2- {[(4- {[4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)- 2-( 1 H-indazol-4-yloxy)benzoyl]sulfamoyl} -2-nitrophenyl)amino]methyl} -N-ethyl-N- methylmorpholine-4-carboxamide -617- EXAMPLE 506A N-ethyl-N-methyl-2-((2-nitro-4-sulfamoylphenylamino)methyl)morpholine-4-carboxamide The title compound was prepared by substituting ^-ethyl-A^-methyl-carbamoyl chloride for acetyl chloride in EXAMPLE 457A. EXAMPLE 506B 2- {[(4- {[4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-(lH-mdazol-4-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}-N-ethyl-N-methylmorpholine-4-carboxamide The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE 26C and EXAMPLE 506A for EXAMPLE IF in EXAMPLE 177. ^H NMR (SOOMHz, pyridine-ds) 8 14.58 (bs, IH), 9.07 (d, IH), 8.82 (t, IH), 8.37 (s, IH), 8.13 (m, 2H), 7.45 (d, 2H), 7.34 (d, IH), 7.15 (t, IH), 7.11 (d, 2H), 6.87 (d, IH), 6.83-6.79 (m, 2H), 6.54 (d, IH), 3.92-3.85 (m, 2H), 3.75 (m, IH), 3.62 (dt, IH), 3.50 (m, IH), 3.40 (m, 2H), 3.21 (q, 2H), 3.14 (m, 4H), 3.00 (dt, IH), 2.82 (s, 2H), 2.76 (s, 3H), 2.30 (m, 2H), 2.23 (m, 4H), 1.99 (s, 2H), 1.41 (t, 2H), 1.06 (t, 3H), 0.96 (s, 6H). EXAMPLE 507 2-{ [(4- {[2-(lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1- en-1 -yl]methyl )piperazin-1 -yl)benzoyl]sulfamoyl) -2-nitrophenyl)amino]methyl} -N-ethyl-N- methylmorpholine-4-carboxamide The title compound was prepared by substituting EXAMPLE 506A for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500MHz, pyridine-dj) 8 9.25 (d, IH), 8.86 (t, IH), 8.56 (s, IH), 8.35 (dd, IH), 8.01 (d, IH), 7.52 (d, IH), 7.43 (d, 2H). 7.25 (m, IH), 7.13 (d, IH), 7.07 (d, 2H), 6.94 (d, IH), 6.73-6.68 (m, 2H), 3.96-3.85 (m, 2H), 3.87 (m, IH), 3.64 (dt, IH), 3.53 (m, IH), 3.48-3.41 (m, 2H), 3.21 (q, 2H), 3.03 (m, 5H), 2.92 (dd, IH), 2.90 (d, IH), 2.76 (s, 5H), 2.25 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.38 (t, 2H), 1.06 (t, 3H), 0.94 (s, 6H). EXAMPLE 508 N-({5-chloro-6-[(trans-4-ethyl-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide -618- EXAMPLE 508A l-ethyl-4-(hydroxymethyl)cyclohexanol 4-(Hydioxymethyl)cyclohexanone (1.22 g) in tetrahydrofuran (20 mL) was treated with IM ethylmagnesium bromide in tetrahydrofuran (28.6 mL) at 0°C. The reaction was warmed to room temperature over 4 hours and quenched with methanol (2 mL) and water (2 mL). The resulting mixture was concentrated and the residue was suspended in ethyl acetate. The precipitates were filtered off and the filtrate was concentrated and purified by flash chromatography, eluted with 0-100% ethyl acetate in hexane to provide the title compound. EXAMPLE 508B 5-chloro-6-((trans-4-ethyl-4-hydroxycyclohexyl)methoxy)pyridine-3-sulfonamide The title compound was prepared as described in EXAMPLE 493B by replacing EXAMPLE 493A with EXAMPLE 508A. EXAMPLE 508C 5-chloro-6-((cis-4-ethyl-4-hydroxycyclohexyl)methoxy)pyiidine-3-sulfonamide The title compound was prepared as described in EXAMPLE 493B by replacing EXAMPLE 493A with EXAMPLE 508A. EXAMPLE 508D N-({5-chloro-6-[(trans-4-ethyl-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide The title compound was prepared as described in EXAMPLE 177 by replacing EXAMPLE 26C and EXAMPLE IF with EXAMPLE 400E and EXAMPLE 508B, respectively, 'H NMR (400 MHz, dimethylsulfoxide-de) 5 13.20 (s, IH), 8.37 (d, IH), 7.95 (d, IH), 7.91 (s, IH), 7.70 (d, IH), 7.47 (d, 2H), 7.14 - 7.21 (m, 4H), 6.89 (dd, IH), 6.63 (d, IH), 6.25 (dd, IH), 4.34 (d, 2H), 4.11 (s, IH), 3.24 - 3.33 (m, 4H), 3.02 (d, 2H), 2.46 (s, 4H), 2.28 (s, 2H), 2.09 (s, 2H), 1.77 -1.96 (m, 3H), 1.61 - 1.76 (m, 3H), 1.48 - 1.60 (m, 4H), 1.21 - 1.47 (m, 5H), 1.04 (s, 6H), 0.91 (t, 3H). -619- EXAMPLE 509 N-( {5-chlorD-6-[(cis-4-ethyl-4-hydroxycyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2- (4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide The title compound was prepared as described in EXAMPLE 177 by replacing EXAMPLE 26C and EXAMPLE IF with EXAMPLE 400E and EXAMPLE 508C, respectively. 'H NMR (400 MHz, dimethylsulfoxide-de) 8 13.10 (s, IH), 8.26 (d, IH), 7.84 (d, IH), 7.80 (s, IH), 7.59 (d, IH), 7.36 (d, 2H), 7.03 - 7.11 (m, 4H), 6.79 (dd, IH), 6.53 (s, IH), 6.12 - 6.15 (m, IH), 4.20 (d, 2H), 3.77 (s, IH), 3.11 - 3.24 (m, 4H), 2.88 (s, 2H), 2.24 -2.41 (m, 3H), 2.18 (s, 2H), 1.98 (s, 2H), 1.71 (s, IH), 1.55 (d, 5H), 1.18 - 1.49 (m, 9H), 0.94 (s, 6H), 0.83 (t, 3H). EXAMPLE 510 5-chloro-N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l -en- l-yl]methyl }piperazin-1 - yl)-2-( 1 H-indazol-4-yloxy)benzaniide EXAMPLE 510A methyl 2-(lH-indazol-4-yloxy)-5-chloio-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l- enyl)methyl)piperazin-1 -yl)benzoate A mixture of EXAMPLE 400D (0.5 g) and l-chloropyrrolidine-2,5-dione (0.126 g) in acetonitrile (10 mL) was stirred at room temperature for 4 hours. The solvent was removed, and the residue was purified by flash column chromatography on silica gel to give the title compound. EXAMPLE 5lOB 2-( 1 H-indazol-4-yloxy)-5 -chloro-4-(4-((2-(4-chIorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)benzoic acid The title compound was prepared by substituting EXAMPLE 435C for EXAMPLE ID in EXAMPLE IE. -620- EXAMPLE 5IOC 5-chloro-N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcycIohex-1 -en- l-yl]methyl }piperazin-1- yl)-2-(lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 404A for EXAMPLE IF and EXAMPLE 510B for EXAMPLE 26C in EXAMPLE 177. ^H NMR (500MHz, dimethylsulfoxide-de) 8 13.22 (s, IH), 8.38 (d, IH), 8.03 (d, IH), 7.54 (d, 2H), 7.19-7.26 (m, 4H), 6.83 (s, IH), 6.34 (d, IH), 4.60 (d, 2H), 3.88-3.93 (m, 2H), 3.70-3.73 (m, 2H), 3.15 (br s, 4H), 2.86 (br s, 2H), 2.30 (bs, 2H), 2.13 (s, 2H), 1.94-2.05 (m, 4H), 1.55 (t, 2H), 1.06 (s, 6H). EXAMPLE 511 5-chloro-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)- N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 409D for EXAMPLE IF and EXAMPLE 510B for EXAMPLE 26C in EXAMPLE 177. 'H NMR (500MHz, dimethylsulfoxide-da) 5 13.07 (s, IH), 8.46 (s, IH), 8.33 (s, IH), 8.03 (d, IH), 7.75 (s, IH), 7.68 (s, IH), 7.60-7.62 (m, IH), 7.38 (d, 2H), 7.06-7.11 (m, 5H), 6.69 (d, IH), 6.20 (d, IH), 3.67-3.77 (m, 4H), 3.50-3.55 (m, 2H), 2.89 (br s, 6H), 2.14 (bs, 2H), 1.97 (s, 2H), 1.76-1.82 (m, 4H), 1.39 (t, 2H), 0.92 (s, 6H). EXAMPLE 512 N-({5-chloro-6-[(cis-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 - yl)-2-( 1 H-indazol-4-yloxy)benzamide EXAMPLE 512A A dimethylsulfoxide (40 mL) solution of l,4-dioxaspiro[4.5]decan-8-one (6.25 g) was added dropwise to a solution of trimethylsulfoxonium iodide (8.8 g) and potassium t-butoxide (4.5 g) in dimethylsulfoxide (50 mL). The mixture was stirred at room temperature overnight. The mixture was then poured over ice-water and extracted with ethyl ether (3x 200 mL). The -621- combined organic extracts were washed with water and brine, dried over Na2S04. Filtration and evaporation of solvent gave the crude product EXAMPLE 512B (8-fluoro-1,4-dioxaspiro [4.5 ]decan-8-yl)methanol A solution of pyridine hydrofluoride (4 g) in dichloromethane (10 mL) was added dropwise to a solution of EXAMPLE 512A (1.7 g) in dichloromethane (20 mL) in a polyethylene bottle at 0°C. The mixture was stirred at room temperature overnight. TLC showed the reaction was complete. The mixture was carefully poured over a mixture of ice-water and NazCOa and extracted with ethyl acetate (2x 300mL). After washing with water and brine, the organic layer was dried over Na2S04. Filtration and evaporation of the solvent gave the crude product. EXAMPLE 512C 5-chloro-6-((8-fluoro-l,4-dioxaspiro[4.5]decan-8-yl)methoxy)pyridine-3-sulfonamide To a solution of EXAMPLE 512B (500 mg) in N,N-dimethylformamide (5 mL) was added NaH (65% in mineral oil, 252 mg) at room temperature. The mixture was stirred for 30 minutes, and then 5,6-dichloropyridine-3-sulfonamide (0.6 g) was added. The mixture was stirred at room temperature overnight. The mixture was poured over aqueous NH4CI and extracted with ethyl acetate (3x 100 mL). The combined organic layers were washed with water, brine and dried over Na2S04. After filtration and evaporation of the solvent, the residue was loaded on a silica gel cartridge and eluted with 30% ethyl acetate in hexane to give the pure product. EXAMPLE 512D 5-chloro-6-((l-fluoro-4-oxocyclohexyl)methoxy)pyridine-3-sulfonamide To a solution of EXAMPLE 512C (1.6 g) and pyridinium p-toluenesulfonate (1.2 g) in acetone (10 mL) was added water (2 mL) and the mixture was stirred in a CEM Discover microwave reactor at lOO^C for 10 minutes. The mixture was diluted with dichloromethane (300 mL) and washed with aqueous NaHCOj, water, brine and dried over Na2S04. Filtration and evaporation of the solvent gave the crude product. -622- EXAMPLE 512E 5-chloro-6-((cis-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3-sulfonainide To a solution of EXAMPLE 512D (L2 g) in tetrahydrofuran (30 mL) was added dropwise a solution of methylmagnesium bromide (5 mL, 3.0M in ether) at 0°C. Upon the addition, the reaction mixture solidified. More tetrahydrofuran (10 mL) was added to the mixture and stirring was continued for 1 hour. The mixture was poured over aqueous NH4CI and extracted with ethyl acetate (3x 300mL). The combined organic layers were washed with water, brine and dried over Na2S04. The mixture was filtered and the solvent was evaporated, and the crude residue was dissolved in dimehtylsulfoxide/methanol (20 mL, 1:1) and loaded on HPLC (GUson, C18 (lOOA) 250 x 121.2 mm (10 micron), conditions: 20% acetonitrile to 45% acetonitrile in 40 minutes) to separate the two isomers, of which EXAMPLE 512E is the cis isomer. EXAMPLE 512F N-({5-chloro-6-[(cis-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 - yl)-2-( lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 512E for EXAMPLE 493C in EXAMPLE 493D. 'H NMR (300 MHz, dimethylsulfoxide-dg) 6 13.04 (s, IH), 8.26 (d, IH), 7.87 (d, IH), 7.78 (s, IH), 7.61 (d, IH), 7.36 (d, 2H), 7.06 (m, 5H), 6.77 (dd, IH), 6.49 (s, IH), 4.49 (d, 2H), 4.35 (s, IH), 3.16 (m, 5H), 2.88 (m, 2H), 2.26 (m, 4H), 1.95 (m, 4H), 1.68 (m, 4H), 1.43 (m, 4H), 1.12 (s, 3H), 0.94 (s, 6H). EXAMPLE 513 N-({5-chloro-6-[(trans-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimelhylcyclohex-1 -en-1 -yljmethyl jpiperazin-1 - yl)-2-(lH-indazol-4-yloxy)benzamide EXAMPLE 513 A 5-chloro-6-((trans-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3-sulfonamide This compound was also isolated as a product of EXAMPLE 512E. -623- EXAMPLE 513B N-({5-chloro-6-[(trans-l-fluoto-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 - yl)-2-( 1 H-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE IE and EXAMPLE 513A for EXAMPLE IF in EXAMPLE IG. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 13.06 (s, IH), 8.24 (d, IH), 7.87 (d, IH), 7.79 (s, IH), 7.60 (d, IH), 7.36 (d, 2H), 7.06 (m, 5H), 6.78 (dd, IH), 6.51 (d, IH), 6.13 (dd, IH), 4.45 (d, 2H), 4.15 (s, IH), 3.18 (m, 4H), 2.86 (m, 2H), 2.27 (m, 4H), 1.85 (m, 6H), 1.48 (m, 7H), 1.15 (s, 3H), 0.94 (s, 6H). EXAMPLE 514 2-( lH-benzotriazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide EXAMPLE 514A 4-(teit-butyldimethylsilyloxy)- lH-benzo[d] [ 1,2,3]triazole lH-benzo[d][l,2,3]triazol-4-ol (2.0 g) in tetrahydrofuran (30 mL) was treated with 60% sodium hydride (0.622 g). After 10 minutes, tert-butylchlorodimethylsilane (2.454 g) was added. The solution was stirred for 16 hours. The solvent was removed, and the residue was purified by flash colunm chromatography on silica gel using 10-50% ethyl acetate in hexanes as eluent to give the title compound. EXAMPLE 514B 4-(tert-butyldimethylsilyloxy)-l-((2-(trimethylsilyl)ethoxy)methyl)-lH-benzo[d] [ 1,2,3]triazole EXAMPLE 514A (1.5 g) in tetrahydrofuran (30 mL) was treated with 60% sodium hydride (0.253 g). After 10 minutes, (2-(chloromethoxy)ethyl)trimethylsilane (1.1 g) was added. The solution was stirred for 2 hours. The reaction mixture was partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried -624- over MgS04, filtered, and concentrated. The residue was purified by flash chromatography on silica gel using 5% ethyl acetate in hexanes as eluent to give the desired product. EXAMPLE 514C 1 -((2-(trimethylsilyl)ethoxy)methyl)-1 H-benzo[d] [ 1,2,3 ] triazol-4-ol A mixture of EXAMPLE 514B (1.32 g) and 1.0 N tetrabutyl ammonium fluoride (10.4 mL) in tetrahydrofuran (15 mL) was stirred for 2 hours. The solvent was removed, and the residue was partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography on silica gel using 10% ethyl acetate in hexanes as eluent to give the title compound. EXAMPLE 514D methyl 4-fluoro-2-( l-((2-(trimethylsilyl)ethoxy)methyl)- lH-benzo[d][ 1,2,3]triazol-4- yloxy)benzoate The title compound was prepared by substituting EXAMPLE 5140 for lH-indazol-5-ol and methyl 2,4-difluorobenzoate for ethyl 2,4-difluorobenzoate in EXAMPLE 20A. EXAMPLE 514E methyl 4-(4-((2-(4-ch]orophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(l-((2-(trimethylsilyl)ethoxy)methyl)-lH-benzo[d][l,2,3]triazol-4-yloxy)benzoate The title compound was prepared by substituting EXAMPLE 514D for EXAMPLE 20A in EXAMPLE 20D. EXAMPLE 514F 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -((2-(trimethylsilyl)ethoxy)methyl)-1 H-benzo[d] [ 1,2,3]triazol-4-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 514E for EXAMPLE ID in EXAMPLE IE. -625- EXAMPLE 514G 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-N-(4-((4- fluorotetrahydro-2H-pyran-4-yl)methylamino)-3-nitrophenylsulfonyl)-2-(l-((2- (trimethylsilyl)ethoxy)methyl)-lH-benzo[d][l,2,3]triazol-4-yloxy)benzamide The tiUe compound was prepared by substituting EXAMPLE 514F for EXAMPLE IE and EXAMPLE 409D for EXAMPLE IF in EXAMPLE IG. EXAMPLE 514H 2-(lH-benzotriazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-N-[(4-{[(4-fluorotetrahydro-2H-pyTan-4-yl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 514G for EXAMPLE 498D in EXAMPLE 498E. 'H NMR (SOOMHZ, dimethylsulfoxide-de) 8 8.58 (s, IH), 8.33 (d, IH), 7.62 (d, IH), 7.56 (d, IH), 7.34-7.38 (m, 3H), 7.04-7.10 (m, 4H), 6.80 (dd, IH), 6.53 (s, IH), 6.41 (d, IH), 3.70-3.80 (m, 3H), 3.52-3.58 (m, 2H), 3.17 (br s, 4H), 2.81 (br s, 6H), 2.17-2.32 (m, 6H), 1.97 (s, 2H), 1.78-1.87 (m, 4H), 1.40 (t, 2H), 0.94 (s, 6H). EXAMPLE 515 2-(IH-benzotriazol-4-yloxy)-N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl }sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1- yl]methyl} piperazin-1 -yl)benzamide EXAMPLE 515A N-(5-chloro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2- (4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin- l-yl)-2-( 1 -((2- (trimethylsilyl)ethoxy)methyl)-lH-benzo[d][l,2,3]triazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 514F for EXAMPLE IE and EXAMPLE 404A for EXAMPLE IF in EXAMPLE IG. EXAMPLE 515B 2-( 1 H-benzotriazol-4-yloxy)-N-( {5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl }piperazin-1 -yl)benzamide -626- The title compound was prepared by substituting EXAMPLE 515 A for EXAMPLE 498D in EXAMPLB 498E. 'H NMR (500MHZ, dimethylsulfoxide-de) 5 8.21 (s, IH), 7.86 (d, IH), 7.65 (d, IH), 7.36-7.38 (m, 3H), 7.06-7.10 (m, 3H), 6.79 (dd, IH), 6.56 (s, IH), 6.30 (s, IH), 4.48 (d, 2H), 3.77-3.81 (m, 3H), 3.59-3.64 (m, 3H), 3.23 (br s, 4H), 2.19 (s, 2H), 1.87-1.99 (m, 6H), 1.42 (t, 2H), 0.94 (s, 6H). EXAMPLE 516 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl) piperazin-1 -yl)-N- {[3-chloro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 498A for EXAMPLE 428D and in EXAMPLE 428E. *H NMR (500 MHz, pyridine-ds) 5 9.27 (d, IH), 8.59 (s, IH), 8.55 (d, IH), 8.40 (dd, IH), 7.99 (d, IH), 7.54 (m, IH), 7.43 (d, 2H), 7.25 (m, IH), 7.16 (m, IH), 7.07 (d, 2H), 6.86 (d, IH), 6.69 (m, 2H), 5.73 (m, 2H), 4.15 (m, IH), 3.90 (s, 2H), 3.03 (m, 4H), 2.96 - 287. (m, 2H), 2.81 - 2.76 (m, 3H), 2.58 (m, IH), 2.32 - 2.23 (m, 3H), 2.14 (m, 4H), 1.97 (s, 2H), 1.73 (m, IH), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 517 N-[(3-chloro-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide EXAMPLE 517 A ethyl 4-fluoro- l-(oxetan-3-yl)piperidine-4-carboxylate To 1-fert-butyl 4-ethyl 4-fluoropiperidine-l,4-dicarboxylate (1.0 g) was added HCl (4.0M in dioxane, 4.5 mL). After 1 hour the reaction was concentrated and dried under high vacuum. The resulting solid was dissolved in dichloromethane (5 mL) and treated with sodium triacetoxyborohydride (1.2 g) and oxetan-3-one (0.26 g) and stirred ovemight. The reaction was quenched with saturated aqueous NaHCOs solution (20 mL) and extracted into dichloromethane (2 x 25 mL). The organic layer was dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 80 g) eluting with a gradient of 0.5% to 3.75% methanol/dichloromethane over 40 minutes (flow = 30 mL/minutes) gave the title compound. -627- EXAMPLE 517B (4-fluorO'l-(oxetan-3-yl)piperidin-4-yl)methanol To a solution of EXAMPLE 517A (0.59 g) in tetrahydrofuran (5 mL) was added lithium aluminum hydride (L8 oiL) at 0°C. The reaction was removed from the ice bath and allowed to warm to room temperature. The reaction was quenched by the dropwise addition of 0.6 noL of water followed by 0.2 ml of 2N aqueous NaOH. The reaction was filtered through diatomaceous earth, rinsed with ethyl acetate (50 mL) and concentrated. Silica gel chromatography over silica gel (Reveleris 40 g) eluting with a gradient of 0.75% to 7.5% methanol/dichloromethane over 30 minutes (flow = 40 ml/minutes) gave the title compound. EXAMPLE 517C 3-chloro-N,N-bis(2,4-dimethoxybenzyl)-4-fIuorobenzenesulfonamide To a solution of bis(2,4-dimethoxybenzyl)amine (12 g) and 3-chloro-4-fluorobenzene-1-sulfonyl chloride (8.66 g) in dichloromethane (120 mL) was added N,N-diisopropylethylamine (13.5 mL) and catalytic amount of 4-dimethylaminopyridine. The mixture was stirred at room temperature overnight. The mixture was diluted with ethyl acetate (600 mL) and washed with 5% aqueous HCl, water and brine. After drying over Na2S04, the mixture was filtered and the filtrate was concentrated under vacuum to give crude product which was loaded on a 400 g silica gel column and eluted with 30% ethyl acetate in hexane to give the title compound. EXAMPLE 517D 3-chloro-N,N-bis(2,4-dimethoxybenzyl)-4-((4-fluoro-l-(oxetan-3-yl)piperidin-4- yl)methoxy)benzenesulfonamide To a solution of EXAMPLE 517B (0.100 g) in tetrahydrofuran (3 mL) was added sodium hydride (0.042 g). After stirring for 15 minutes, EXAMPLE 517C (0.270 g) was added in one portion and the reaction stirred at room temperature for 16 hours then heated to 50''C for 2 hours. The reaction was cooled and quenched with water (20 mL) and extracted into dichloromethane (2 x 30 mL). The organics were combined, washed with brine (25 mL), dried over magnesium sulfate, filtered and concentrated. The resulting oil was loaded onto silica gel (Reveleris 40 g) and eluted using a gradient of 0.5% to 5% methanol/dichloromethane over 30 minutes (flow = 40 ml/minute) to give the title compound. -628- EXAMPLE 517E 3-chloro-4-((4-fluoro-l-(oxetan-3-yl)piperidin-4-yl)methoxy)benzenesulfonamide To a solution of EXAMPLE 517D (0.258 g) in dichloromethane (3 mL) was added trifluoioacetic acid (2 mL) dropwise. The reaction was stirred for 1 hour then quenched by the addition of saturated NaHCOs solution (20 mL). The reaction was extracted with dichloromethane (2 x 50 mL), the dichloromethane layer was concentrated, ethyl acetate (20 mL) was added and the resulting solid was filtered. The organic layer was diluted to 50 ml, washed with brine (25 mL), dried over magnesium sulfate, fdtered and concentrated. The resulting oil was treated with dichloromethane and concentrated,and the solid was triturated with ethyl acetate and filtered to give the title compound. EXAMPLE 517F The title compound was prepared by substituting EXAMPLE 498C for EXAMPLE IE and EXAMPLE 517E for EXAMPLE IF in EXAMPLE IG. EXAMPLE 517G N- [(3-chloro-4- {[4-fluoro-1 -(oxetan-3-yl)piperidin-4-yl]methoxy} phenyl)sulfonyl]-4-(4- {[2- (4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 517F for EXAMPLE 497B in EXAMPLE 497C. 'H NMR (300 MHz, dimethylsulfoxide-dg) 8 13.14 (d, IH), 11.61 - 11.29 (m, IH), 7.84 (d, IH), 7.67 (d, IH), 7.61 - 7.56 (m, IH), 7.54 (d, IH), 7.38 - 7.31 (m, 2H), 7.21 - 7.09 (m, 3H), 7.08 - 7.01 (m, 2H), 6.87 - 6.72 (m, IH), 6.52 (d, IH), 6.23 (dd, IH), 4.55 (t, 2H), 4.45 (t, 2H), 4.24 (d, 2H), 3.55 - 3.41 (m, IH), 3.16 (s, 4H), 2.80 (s, 2H), 2.69 - 2.54 (m, 2H), 2.38 - 1.67 (m, 14H), 1.40 (s, 2H), 0.93 (s, 6H). EXAMPLE 518 N-({ 5-chloro-6- [(cis- l-fluoro-4-hydroxycyclohexyl)methoxy ]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol- 4-yloxy)benzamide EXAMPLE 518 A 5-chloro-6-((cis-l-fluoro-4-hydroxycyclohexyl)methoxy)pyridine-3-sulfonamide -629- To a solution of EXAMPLE 512D (336 mg) in tetrahydrofuran (10 mL) was added NaBHt (75 mg). The mixture was stirred at room temperature for 45 minutes. The mixture was diluted with ethyl acetate (3(X) mL) and washed with 2N aqueous NaOH, water, and brine. After drying over Na2S04, the mixture was filtered, and the solvent was evaporated to give the crude product. EXAMPLE 518B N-({5-chloro-6-[(cis-l-fluoro-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol- 4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 518A for EXAMPLE 493C in EXAMPLE 493D. 'H NMR (3(K) MHZ, dimethylsulfoxide-de) 6 12.94 (s, IH), 8.17 (d, IH), 7.82 (d, IH), 7.71 (s, IH), 7.66 (d, IH), 7.35 (d, 2H), 7.04 (m, 5H), 6.71 (dd, IH), 6.40 (d, IH), 6.09 (m, IH), 4.61 (d, IH), 4.38 (d, 2H). 3.47 (m, IH), 3.17 (d, IH), 3.06 (m, 4H), 2.74 (m, 2H), 2.24 (m, 5H), 1.99 (m, 5H), L56 (m, 7H), 0.92 (m, 6H) EXAMPLE 519 2-( lH-benzotriazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N-( {4-[(4-fluorotetrahydro-2H-pyTan-4-yl)methoxy ] -3 - nitrophenyl} sulfonyl)benzamide EXAMPLE 519A 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-N-(4-((4- fluorotetrahydro-2H-pyran-4-yl)methoxy)-3-nitrophenylsulfonyl)-2-( 1 -((2- (trimethylsilyl)ethoxy)methyl)-lH-benzo[d][l,2,3]tiiazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 514F for EXAMPLE IE and EXAMPLE 306D for EXAMPLE IF in EXAMPLE IG. EXAMPLE519B 2-( 1 H-benzotriazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl) sulfonyl)benzamide -630- The title compound was prepared by substituting EXAMPLE 519A for EXAMPLE 498D in EXAMPLE 498E. 'H NMR (500MHZ, dimethylsulfoxide-de) 5 8.04 (d, IH), 7.73 (d, IH), 7.65 (d, IH), 7.35-7.38 (m, 3H), 7.18-7.19 (m, IH), 7.05-7.09 (m, 3H), 6.78 (dd, IH), 6.52 (s, IH), 6.32 (s, IH), 4.34 (d, 2H), 3.78-3.82 (m, 2H), 3.59-3.64 (m, 2H), 3.23 (br s, 4H), 2.83 (br s, 2H), 2.18-2.30 (m, 6H), 1.82-1.98 (m, 6H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 520 N-[(5-chloro-6-{[(lR,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2- yl]methoxy)pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-indazol-4-yloxy)benzaniide EXAMPLE 520A < lR,4S)-methyl spiro[bicyclo[2.2.1 ]heptane-2,2'-[ 1,3]dioxolane]-5-carboxylate A mixture of l,4-dioxaspiro[4.4]non-6-ene (5 g), methyl acrylate (10.24 g), and hydroquinone (0.13 g) was heated in an autoclave at 100° C in acetonitrile (12 mL) for three days. After cooling, the solvent was removed, and residue was purified by flash chromatography on silica gel eluting with 4:1 hexane/ethyl acetate to give the title compound as a mixture of two 5-isomers. EXAMPLE 520B (lR,4S)-spiro[bicyclo[2.2.1]heptane-2,2'-[l,3]dioxolane]-5-yImethanol EXAMPLE 520A (1.0 g) in tetrahydrofuran was cooled to 0 °C. To this solution was added 1.0 N lithium aluminum hydride (2.8 mL) dropwise. The reaction mixture was stirred for 2 hours. Water (0.4 mL) was added followed by 2 N aqueous NaOH (0.2 mL). The solid was filtered off, and the filtrate was concentrated. Toluene was added, and it was then distilled off to move trace amounts of water. The title compound was used for the next reaction without further purification. EXAMPLE 520C 5-chloro-6-(((lS,2R,4R)-5-oxobicyclo[2.2.1]heptan-2-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 520B for (tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 387A for EXAMPLE 329A in EXAMPLE 329B. -631- The two isomers were isolated by reverse phase Prep HPLC. The desired fractions were collected, and the solvents were removed under reduced vacuum at 60°C. During this process, a lot of solid formed. It was then partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered and concentrated to give the desired ketone. EXAMPLE 520D 5-chloro-6-(((lS,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]heptan-2-yl)methoxy)pyridine-3-sulfonamide EXAMPLE 520C (0.44 g) in tetrahydrofioran (15 mL) was treated with 3.0 M methylmagnesium bromide (5.3 mL) at 0 °C. The mixture was stirred for 16 hours. The reaction mixture was then partitioned between ethyl acetate and 0.05 N aqueous HCl (20 mL). The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate three times. Tlie combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash column chromatography on siUca gel using 10-50% ethyl acetate in hexanes as eluent to give the title compound. EXAMPLE 520E N-[(5-chlorx)-6- {[(lR,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1 ]hept-2-yl]methoxy)pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl} piperazin-1 -yl)-2-( 1 H-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE IE and EXAMPLE 520D for EXAMPLE IF in EXAMPLE IG. ^H NMR (500MHz, dimethylsulfoxide-d6) 5 13.10 (s, IH), 8.28 (d, IH), 7.84 (d, IH), 7.82 (s, IH), 7.59 (d, IH), 7.36 (d, 2H), 7.04-7.11 (m, 4H), 6.80 (dd, IH), 6.54 (d, IH), 6.14 (d, IH), 4.41-4.46 (m, 2H), 4.35 (s, IH), 3.20 (br s, 4H), 2.93 (br s, 2H), 2.31-2.37 (m, 4H), 2.17-2.02 (m, 4H), 1.98-L99 (m, 2H), 1.89 (d, IH), 1.68-1.71 (m, IH), L56 (d, IH), 1.31-L48 (m, 7H), 1.20 (s,6H), 0.94 (s,6H). -632- EXAMPLE 521 N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-5,5-difluorocyclohex- 1-en-l -yljmethyl )piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide EXAMPLE 521A ethyl 5,5-difluoro-2-oxocyclohexanecaiboxylate To a solution of diethyl 4,4-difluoroheptanedioate (4.3 g) in toluene (50 mL) was added potassium 2-methylpropan-2-olate (2.87 g) and the reaction stirred overnight at room temperature. The reaction was quenched with IN aqueous HCl (1(X) mL) and extracted with diethyl ether (150 mL). The ether layer was washed with brine (50 mL), dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 40 g) eluting with a gradient of 1% to 5% ethyl acetate/hexanes gave the title compound. EXAMPLE 521B ethyl 5,5-difluoro-2-(trifluoromethylsulfonyloxy)cyclohex-l-enecarboxylate To a solution of EXAMPLE 521A (2.37 g) in dichloromethane (40 mL) at 0°C was added N,N-diisopropylethylamine (5.02 mL) followed by trifluoromethanesulfonic anhydride (2.33 mL) and the reaction was allowed to slowly warm to room temperature. After stirring overnight the reaction was quenched with 10 ml of water then IN aqueous HCl (100 mL). TTie reaction was extracted with dichloromethane (3 x 75 mL), the combined organics were washed with brine (50 mL) and concentrated. Silica gel chromatography (Reveleris 40 g) eluting with a gradient of 1% to 25% ethyl acetate/hexanes gave the title compound. EXAMPLE 521C ethyl 2-(4-chlorophenyl)-5,5-difluorocyclohex- l-enecarboxylate A solution of EXAMPLE 521B (3.47 g), 4-chlorophenylboronic acid (1.925 g) and cesium fluoride (3.43 g) in 30 ml of dimethoxyethane and 15 ml of ethanol was degassed with nitrogen for 5 minutes. Tetrakis(triphenylphosphine)palladium(0) (0.237 g) was added and the reaction was heated to 70°C. The reaction was diluted with ether (200 mL) and washed with IN aqueous HCl (100 mL), brine (100 mL), dried over magnesium sulfate, filtered and concentrated. Silica gel chromatography (Reveleris 40 g) eluting with a gradient of 1% to 8% ethyl acetate/hexanes over 40 minutes gave the title compound. -633- EXAMPLE 52ID (2-(4-chlorophenyl)-5,5-difluorocyclohex-l-enyl)methanol To a solution of EXAMPLE 521C (L84 g) in diethyl ether (25 mL) at 0°C was added lithium aluminum hydride (l.OM, 4.28 mL). The reaction was quenched with the dropwise addition of water, then IN aqueous HCl (50 mL) was added and the reaction was diluted with diethyl ether (100 mL). The organic layer was separated, washed with brine (50 mL) dried over magnesium sulfate, filtered, and concentrated to give the title compound. EXAMPLE 521E 2-(4-chlorophenyl)-5,5-difluorocyclohex-l-enecarbaldehyde To a solution of EXAMPLE 52ID (1.38 g) in dichloromethane (25 mL) was added Dess-Martin periodinane (2.489 g) and the reaction stirred for 1 hour at room temperature. The reaction was quenched with IN aqueous NaOH solution (75 mL) and the product extracted into dichloromethane (2 x 100 mL). The combined organics were washed with brine (75 mL), dried over magnesium sulfate, filtered and concentrated. Silica gel chromatography (Reveris 80 g) eluting with a gradient of 1% to 10% ethyl acetate/hexanes over 40 minutes gave the title compound. EXAMPLE 521F methyl 2-(lH-indazol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-5,5-difluorocyclohex-l-enyl)methyl)piperazin-1 -yl)benzoate To a solution of EXAMPLE 52 IE (1.05 g) in dichloromethane (10 mL) was added EXAMPLE 400C (1.31 g) followed by sodium triacetoxyhydroborate (1.18 g) and the reaction was stirred overnight at room temperature. The reaction was quenched with saturated NaHCOs (50 noL) and extracted with dichloromethane (2 x 100 mL). The combined organic layers were dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 80 g) eluting with a gradient of 0.5% to 5% methanol/dichloromethane over 40 minutes gave the title compound. EXAMPLE 52IG methyl 4-(4-((2-(4-chlorophenyl)-5,5-difluorocyclohex-l-enyl)methyl)piperazin-l-yl)-2-(l- trityl-lH-indazol-4-yloxy)benzoate To a solution of EXAMPLE 521F (1.81 g) and triethylamine (0.85 mL) in dichloromethane (10 mL) was added trityl-chloride (1.06 g) and the reaction stirred at room -634- temperature. After stirring for 16 hours the reaction was loaded onto silica gel (Reveleris 80 g) and eluted using a gradient of 0.1% to 1.5% methanol/dichloromethane over 40 minutes (flow = 40 ml/min) to give the title compound. EXAMPLE 52IH 4-(4-((2-(4-chlorophenyl)-5,5-difluorocyclohex-1 -enyl)methyl)piperazin-1 -y l)-2-( 1 -trityl-1H- indazol-4-yloxy)benzoic acid To a solution of EXAMPLE 52IG (2.51 g) in tetrahydrofuran (30 mL) and methanol (10 mL) was added lithium hydroxide (l.OM, 10 mL) and the solution heated to 60°C. After 4 hours the reaction was cooled, diluted with dichloromethane (150 mL) and quenched with IN aqueous HCl (10 mL) and water (30 mL). The organic layer was washed with brine (50 mL), dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 120 g) eluting with a gradient of 0.25% to 2.5% methanol/dichloromethane over 40 minutes gave the title compound. EXAMPLE 5211 N-(5-chloro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2- (4-chlorophenyl)-5,5-difluorocyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -trityl-1 H-indazol- 4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 521H for EXAMPLE IE and EXAMPLE 404A for EXAMPLE IF in EXAMPLE IG. EXAMPLE 521J 2-(lH-indazol-4-yloxy)-N-(5-chloro-6-((4-fluorotetrahydro-2H-pyran-4-yl)methoxy)pyridin- 3-ylsulfonyl)-4-(4-((2-(4-chlorophenyl)-5,5-difluorocyclohex-1 -enyl)methyl)piperazin-1 - yl)benzamide To a solution of EXAMPLE 5211 (0.24 g) dichloromethane (1 mL) was added trifluoroacetic acid (0.5 mL). After stirring for 1 hour, the reaction was concentrated, dissolved in dichloromethane (5 mL) and quenched with saturated NaHCOs (5 mL). The reaction was diluted with water (10 mL) and saturated NaHCOs (15 mL) and the product extracted into dichloromethane (2 x 25 mL). The combined organics were washed with brine (25 mL), dried over magnesium sulfate, filtered, and concentrated. The residue was loaded onto silica gel (Reveleris 40 g) and eluted using a gradient of 0.5% to 3% methanol/dichloromethane over 30 minutes (flow = 40 ml/minutes). The product was -635- collected, concentrated, dissolved in acetonitrile and concentrated, and dried in vacuum oven at 75 °C overnight to give the title compound. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 13.12 (s, IH), 12.24 -11.44 (m, IH), 8.31 (d, IH), 7.91 (d, IH), 7.83 (s, IH), 7.57 (d, IH), 7.40 (d, 2H), 7.13 (d, 4H), 6.81 (dd, IH), 6.56 (d, IH), 6.16 (dd, IH), 4.52 (d, 2H), 3.79 (dt, 2H), 3.70 - 3.51 (m, 2H), 3.20 (s, 4H), 2.76 (dd, 4H), 2.49 (m, 8H), 2.02 - 1.71 (m, 4H). EXAMPLE 522 N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- {[2-(4-chlorophenyl)-5,5-difluorocyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide EXAMPLE 522A 5-chloro-6-((4-fluoro-l-(oxetan-3-yl)piperidin-4-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 387A for EXAMPLE 329A and EXAMPLE 517B for (tetrahydro-2H-pyran-4-yI)methanol in EXAMPLE 329B. EXAMPLE 522B N-(5-chloro-6-((4-fluorD-l-(oxetan-3-yl)piperidin-4-yl)methoxy)pyridin-3-ylsulfonyl)-4-(4- ((2-(4-chloiophenyl)-5,5-difluorocyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -trityl-1H- indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 521H for EXAMPLE IE and EXAMPLE 522A for EXAMPLE IF in EXAMPLE IG. EXAMPLE 522C 2-(lH-indazol-4-yloxy)-N-(5-chloro-6-((4-fluoro-l-(oxetan-3-yl)piperidin-4-yl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2-(4-chlorophenyl)-5,5-difluorocyclohex-l-enyl)methyl)piperazin- l-yl)benzamide The title compound was prepared by substituting EXAMPLE 522B for EXAMPLE 5211 in EXAMPLE 521J. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 13.10 (s, IH), 11.54 (s, IH), 8.29 (d, IH), 7.90 (d, IH), 7.81 (s, IH), 7.58 (d, IH), 7.40 (d, 2H), 7.13 (d, 4H), 6.80 (dd, IH), 6.53 (d, IH), 6.15 (dd, IH), 4.53 (d, 6H), 3.60 (s, IH), 3.18 (s, 4H), 2.74 (dd, 8H), 2.41 -1.70 (m,12H). -636- EXAMPLE 523 2-( lH-benzotriazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-l -yl)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 523A 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-N-(3-nitro-4- ((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)-2-( 1 -((2- (trimethylsilyl)ethoxy)methyl)-lH-benzo[d][l,2,3]triazol-4-yloxy)benzaniide The title compound was prepared by substituting EXAMPLE 514F for EXAMPLE IE in EXAMPLE IG. EXAMPLE 523B 2-( 1 H-benzotriazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {3 -nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 523A for EXAMPLE 498D in EXAMPLE 498E. ^H NMR (500MHz, dimethylsulfoxide-de) 5 8.51 (s, IH), 8.30 (d, IH), 7.57-7.59 (m, 2H), 7.33-7.38 (m, 3H), 7.04-7.10 (m, 3H), 6.90 (d, IH), 6.79 (dd, IH), 6.52 (d, IH), 6.39 (d, IH), 3.87 (dd, 2H), 3.143 (br s, 4H), 2.78 (br s, 2H), 2.17-2.23 (m, 6H), 1.88-1.97 (m, 3H), 1.63-1.66 (m, 2H), 1.40 (t, 2H), 1.23-1.32 (m, 2H), 0.93 (s, 6H). EXAMPLE 524 4-(4- {[2-(4-chlorophenyl)-5,5-difluorocyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( IH- indazol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide EXAMPLE 524A 4-(4-((2-(4-chlorophenyl)-5,5-difluorocyclohex-l-enyl)methyl)piperazin-l-yl)-N-(3-nitro-4- ((tetrahydro-2H-pyran-4-yl)methy1amino)phenylsu]fonyl)-2-(l-trityl-lH-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 521H for EXAMPLE IE in EXAMPLE IG. -637- EXAMPLE 524B 2-(lH-indazol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-5,5-difluorocyclohex-l-enyl)methyl)piperazin-1 -yl)-N-(3 -nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 524A for EXAMPLE 5211 in EXAMPLE 521J. 'H NMR (300 MHz, dimethylsulfoxide-de) 5 13.10 (d, IH), 11.63 (s, IH), 8.57 (t, IH), 8.38 (d, IH), 7.81 (d, IH), 7.52 (d, 2H), 7.39 (d, 2H), 7.11 (dd, 4H), 7.00 (d, IH), 6.80 (dd, IH), 6.52 (d, IH), 6.20 (dd, IH), 3.86 (dd, 2H), 3.29 (d, 4H), 3.16 (s, 4H), 2.83 - 2.60 (m, 4H), 2.49 (s, 2H), 2.34 - 2.01 (m, 6H), 1.89 (dd, IH), 1.63 (d, 2H), 1.27 (qd, 2H). EXAMPLE 525 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- indazol-4-yloxy)benzamide EXAMPLE 525A tert-buty](4-hydn>xy-4-methylcyclohexyl)methylcarbamate To a vigorous stirring solution of tert-butyl (4-oxocyclohexyl)methylcarbamate (1.7 g) in tetrahydrofuran (40 mL) at -78°C was dropwise added 1.6 M methyllithium (14.02 mL) in ether. After completion of the addition, the mixture was stirred at -78°C for 1.2 hours and poured into a cold aqueous NHjCl solution. The resulting mixture was extracted with dichloromethane (3x 100 mL) and the organic layer was dried over Na2S04, filtered, and concentrated. The residue was dissolved in dichloromethane and loaded onto an Analogix purification system, and was eluted with 0 - 50% ethyl acetate in dichloromethane to provide die title compound. EXAMPLE 525B 4-(aminomethyl)-1 -methylcyclohexanol EXAMPLE 525A (1.3 g) in dichloromethane (5 mL) at 0°C was treated with trifluoroacetic acid (2.1 mL) and a few drops of water for 1 hours. The reaction mixture was concentrated and the residue was directly used for next step. -638- EXAMPLE 525C 4-((trans-4-hydroxy-4-methylcyclohexyl)methylamino)-3-nitrobenzenesulfonamide EXAMPLE 525B (732 mg) and 4-fluoro-3-nitrobenzenesulfonamide (LI g) in tetrahydrofuran (15 mL) were treated with triethylamine overnight. The reaction mixture was concentrated and the residue was purified by a reverse phase chromatography, elating with 30% - 50% acetonitrile in 0.1% trifluoroacetic acid water solution to provide the title compound. EXAMPLE 525D 4-((cis-4-hydroxy-4-methylcyclohexyl)methylamino)-3-nitrobenzenesulfonamide EXAMPLE 525B (732 mg) and 4-f]uoro-3-nitrobenzenesulfonamide (1.1 g) in tetrahydrofuran (15 mL) were treated with triethylamine overnight. The reaction mixture was concentrated and the residue was purified by a reverse phase chromatography, eluting with 30% - 50% acetonitrile in 0.1% trifluoroacetic acid water solution to provide the title compound, EXAMPLE 525E 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N- [(4- {[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino} -3-nitrophenyl)sulfonyl] -2-( 1H- indazol-4-yloxy)benzamide The title compound was prepared as described in EXAMPLE 177 by replacing EXAMPLE 26C and EXAMPLE IF with EXAMPLE 400E and EXAMPLE 525C, respectively. 'H NMR (400 MHz, dimethylsulfoxide-d6) 8 13.10 (s, IH), 11.54 (s, IH), 8.53 (t, IH), 8.37 (d, IH), 7.82 (s, IH), 7.48 - 7.58 (m, 2H), 7.32 - 7.39 (m, 2H), 7.02 - 7.11 (m, 4H), 6.95 (d, IH), 6.80 (dd, IH), 6.52 (d, IH), 6.17 (dd, IH). 4.25 (s, IH), 3.26 - 3.31 (m, 2H). 3.17 (s, 4H), 2.80 (s, 2H), 2.21 (d, 6H), 1.97 (s, 2H), 1.60 - 1.75 (m, 3H), 1.56 (d, 2H), 1.30 -1.43 (m, 4H), 1.08 -1.19 (ra, 5H), 0.93 (s, 6H). EXAMPLE 526 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N-[(4- {[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitiophenyl)sulfonyl]-2-(lH-indazol- 4-yloxy)benzamide -639- The title compound was prepared as described in EXAMPLE 177 by replacing EXAMPLE 26C and EXAMPLE IF with EXAMPLE 400E and EXAMPLE 525D, respectively. 'H NMR (400 MHz, dimethylsulfoxide-de) 8 13.11 (d, IH), 11.55 (s, IH), 8.56 (t, IH), 8.37 (d, IH), 7.81 (s, IH), 7.50 - 7.55 (m, 2H), 7.33 - 7.38 (m, 2H), 7.04 - 7.13 (m, 4H), 6.95 (d, IH), 6.80 (dd, IH), 6.52 (d, IH), 6.17 (d, IH), 3.97 (s, IH), 3.26 (t, 2H), 3.16 (s, 4H), 2.79 (s, 2H), 2.20 (d, 6H), 1.97 (s, 2H), 1.46 - 1.61 (m, 5H), 1.35 - 1.45 (m, 4H), 1.19 -1.30 (m, 2H), 1.09 (s, 3H), 0.93 (s, 6H). EXAMPLE 527 2-( 1 H-benzotriazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl Ipiperazin- l-yl)-N- {[4-( {[(2S)-4-cyclopropylmorpholin-2-yl]methyl} amino)-3- nitrophenyljsulfonyl} benzamide EXAMPLE 527A (S)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-N-(4-((4- cyclopropylmorpholin-2-yl)methy]amino)-3-nitrophenylsulfonyl)-2-(l-((2- (trimethylsilyl)ethoxy)methyl)-IH-benzo[d][l,2,3]triazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 514F for EXAMPLE IE and EXAMPLE 529A for EXAMPLE IF in EXAMPLE IG. EXAMPLE 527B 2-(l H-benzotriazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimeihylcyclohex-1 -en-1 - yl]methyl Ipiperazin- l-yl)-N- {[4-( {[(2S)-4-cyclopropylmorpholin-2-yl]melhyl} amino)-3- nitrophenyl]sulfonyl} benzamide The title compound was prepared by substituting EXAMPLE 527A for EXAMPLE 498D in EXAMPLE 498E. 'H NMR (500MHz, dimethylsulfoxide-dg) 8 8.56 (s, IH), 8.31 (s, IH), 7.55-7.60 (m, 2H), 7.34-7.38 (m, 3H), 7.04-7.10 (m, 3H), 6.92 (d, IH), 6.80 (dd, IH), 6.53 (d, IH), 6.38 (d, IH), 3.84 (d, IH), 3.55 (m, IH), 3.41-3.54 (m, 6H), 3.17 (m, 4H), 2.74-2.94 (m, 6H), 2.15-2.36 (m, lOH), 1.97 (s, 2H), 1.69 (t, 2H), 1.40 (t, 2H), 0.94 (s, 6H), 0.35-0.44 (m, 4H). -640- EXAMPLE 528 N-[(5-chloro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide EXAMPLE 528A N-(5-chloro-6-((4-fluoio-l-(oxetan-3-yl)piperidin-4-yl)methoxy)pyridin-3-ylsulfonyl)-4-(4- ((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(l-trityl-lH- indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 522A for EXAMPLE IF and EXAMPLE 498C for EXAMPLE IE in EXAMPLE IG. EXAMPLE 528B N-[(5-ch]oro-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 528A for EXAMPLE 542E in EXAMPLE 542F. 'H NMR (400 MHz, dimethylsulfoxide-de) 8 13.08 (s, IH), 8.26 (d, IH), 7.88 (d, IH), 7.79 (m, IH), 7.60 (d, IH), 7.37 (d, 2H), 7.07 (m, 4H), 6.79 (dd, IH), 6.53 (d, IH), 6.13 (d, IH), 4.57 (t, 2H), 4.52 (s, IH), 4.47 (m, 3H), 3.55 (m, 2H), 3.18 (m, 4H), 2.94 (m, 2H), 2.67 (m, 2H), 2.38 (m, 3H), 2.18 (m, 4H), 1.97 (m, 5H), 1.80 (m, IH), 1.41 (t,2H), 0.94 (s,6H). EXAMPLE 529 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[4- ({[(2S)-4-cyclopropy]morpholin-2-yl]methyl )amino)-3-nitrophenyl]sulfonyl) -2-( 1 H-indazol- 4-yloxy)benzamide EXAMPLE 529A (S)-4-((4-cyclopropylmorpholin-2-yl)methylamino)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 438B for EXAMPLE 415B in EXAMPLE 432A. -641- EXAMPLE 529B 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-N- {[4- ({[(2S)-4-cyclopropylmorpholin-2-yl]methyl} amino)-3 -nitrophenyljsulfonyl} -2-( 1 H-indazol- 4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE 26C and EXAMPLE 529A for EXAMPLE IF in EXAMPLE 177. 'H NMR (500MHz, pyridine-ds) 5 14.58 (bs, IH), 9.05 (d, IH), 8.87 (t, IH), 8.37 (s, IH), 8.16 (dd, IH), 8.08 (d, IH), 7.45 (d, 2H), 7.34 (d, IH), 7.15 (t, IH), 7.10 (d, 2H), 6.90-6.80 (m, 3H), 6.52 (d, IH), 3.90-3.81 (m, 2H), 3.57 (dt, IH), 3.50-3.42 (m, 2H), 3.15 (m, 4H), 2.93 (m, IH), 2.82 (s, 2H), 2.71 (m, IH), 2.31 (dt, IH), 2.30 (m, 2H), 2.22 (m, 4H), 2.21 (m, IH), 1.99 (s, 2H), 1.58 (m, IH), 1.41 (t, 2H), 0.96 (s, 6H), 0.40 (m, 4H). EXAMPLE 530 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-I-en-l- yl]methyl }piperazin- l-yl)-N- {[4-( {[(2S)-4-cyclopropylmorpholin-2-yl]methyl} amino)-3- nitrophenyl]sulfonyl }benzamide The title compound was prepared by substituting EXAMPLE 529A for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500MHz, pyridine-dj) 5 9.25 (d, IH), 8.90 (t, IH), 8.57 (s, IH), 8.37 (dd, IH), 7.99 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.24 (d, IH), 7.17 (d, IH), 7.07 (d, 2H), 6.97 (d, IH), 6.73-6.68 (m, 2H), 3.92-3.85 (m, 2H), 3.59 (dt, IH), 3.50-3.40 (m, 2H), 3.02 (m, 4H), 2.95 (d, IH), 2.76 (s, 2H), 2.69 (d, IH), 2.36 (dt, IH), 2.20-2.20 (m, 3H), 2.14 (m, 4H), 1.97 (s, 2H), 1.59 (m, IH), 1.38 (t, 2H), 0.93 (s, 6H), 0.41 (m, 4H). EXAMPLE 531 N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-5,5-difluorocyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol- 4-yloxy)benzamide EXAMPLE 531A ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate To a solution of ethyl 4-oxocyclohexanecarboxylate (31.8 g) in toluene (100 mL) was added ethylene glycol (36.5 mL) and p-toluenesulfonic acid monohydrate (0.426 g). The two phase mixture was stirred rapidly at ambient temperature for 72 hours. The reaction was -642- diluted with water (900 mL) and extracted with ether (900 mL). The organic layer was washed with saturated sodium bicarbonate solution and brine, and then dried over anhydrous sodium sulfate. After filtration, the title compound was obtained by concentration of the filtrate under high vacuum. EXAMPLE 53 IB l,4-dioxaspiro[4.5]decan-8-ylmethanol To a suspension of lithium aluminum hydride (8.19 g) in tetrahydrofiiran (4(X) mL) was added slowly dropwise a solution of EXAMPLE 531A (37.8 g) in tetrahydrofuran (75 mL). The mixmre was then heated at reflux for 2 hours. The reaction mixture was cooled in an ice bath and quenched very slowly with water (8 mL). Then added sequentially were 4N aqueous sodium hydroxide (8 mL), ether (200 mL), water (24 mL), ether (500 mL) and anhydrous sodium sulfate (250 g). The resulting mixture was stirred rapidly for 2 hours and then filtered. The title compound was isolated by concentration of the filtrate. EXAMPLE 53IC 8-(benzyloxymethyl)-1,4-dioxaspiro[4.5]decane To a suspension of sodium hydride (60% oil dispersion) (8.86 g) in tetrahydrofuran (170 mL) was added a solution of EXAMPLE 53 IB (30.52 g) in tetrahydrofuran (100 mL). This mixture was stirred for 30 minutes and benzyl bromide (24 mL) was added. After stirring for 72 hours, the reaction was quenched with saturated aqueous ammonium chloride solution (400 mL) and diluted with ether (500 mL). The layers were separated and the aqueous layer was extracted with ether (2 X 150 mL). The combined organics were dried over sodium sulfate, filtered and concentrated. The crude product was purified on silica gel eluting with a 0, 10, 15, 75 % ethyl acetate in hexanes step gradient to give the title compound. EXAMPLE 53 ID 4-(benzyloxymethyl)cyclohexanone To a solution of EXAMPLE 53IC (43.02 g) in dioxane (500 mL) was added water (125 mL) and 2M hydrochloric acid (90 mL). The mixture was heated at 85 °C for 18 hours. Upon cooling, the reaction mixture was diluted with brine (1500 mL), saturated sodium bicarbonate solution (300 mL) and ether (1000 mL). The organic layer was dried over sodium sulfate, filtered and concentrated. The crude product was purified on silica gel -643- eluting with a 5,15, 25,50% ethyl acetate in hexanes step gradient to give the title compound. EXAMPLE 531E trans-4-(benzyloxymethyl)-l-methylcyclohexanol To 2,6-di-t-butyl-4-methylphenol (83.4 g) in toluene (1100 mL) was added 2.0M (in hexanes) (CH3)3A1 (95 mL) somewhat carefully to control methane evolution and a small exothemi. Tlie reaction mixture was stirred at ambient temperature under N2 for 75 minutes and was then cooled to -77° C. A solution of EXAMPLE 531D (14 g) in toluene (15 mL) was added dropwise, keeping the temperature below -74 °C. Methyllithium (1.6M in diethyl ether) (120 mL) was then added dropwise, keeping the temperature below -65 °C. The resulting mixture was stirred at -77 °C under N2 for 2 hours. The reaction mixture was then poured into IN aqueous HCl (16(X) mL), rinsing the flask with toluene. The organic layer was washed with brine and the combined aqueous layers were extracted with diethyl ether. The combined organic layers were dried (Na2S04), filtered and concentrated. The concentrate was chromatographed on 650 g of spherical silica gel using 2.5 L of 80/20 hexanes/ethyl acetate, then 3.0 L of 75/25 hexanes/ethyl acetate, and finally 4.0 L of 70/30 hexanes/ethyl acetate as the eluents to give the title compound. EXAMPLE 53 IF trans-4-(hydroxymethyl)-1 -methylcyclohexanol EXAMPLE 531E (12.6 g) and ethanol (120 mL) were added to wet 20% Pd(0H)2/C (1.26 g) in a 500 mL SS pressure bottle. The reaction mixture was stirred at ambient temperature under 30 psi hydrogen gas. Hydrogen uptake ceased at 5 minutes. The mixture was filtered through a nylon membrane rinsing with ethanol. The filtrate was concentrated and then azeotroped with toluene (100 mL) to remove any remaining ethanol. The concentrate was dried under high vacuum for 40 minutes to give the title compound. EXAMPLE 53IG 5-chloro-6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 387A for 4-fluoro-3-nitrobenzenesulfonamide and EXAMPLE 53IF for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 279A. -644- EXAMPLE 53IH N-(5-chloro-6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridin-3-ylsulfonyl)-4-(4- ((2-(4-chlorophenyl)-5,5-difluorocyclohex-l-enyl)methyl)piperazin-l-yl)-2-(l-trityl-lH- mdazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 52IH for EXAMPLE IE and EXAMPLE 531G for EXAMPLE IF in EXAMPLE IG. EXAMPLE 5311 2-(lH-indazol-4-yloxy)-N-(5-chloro-6-((trans-4-hydroxy-4- methylcyclohexyl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2-(4-chlorophenyl)-5,5- difluorocyclohex-1 -enyl)methyl)piperazin- l-yl)benzamide The title compound was prepared by substituting EXAMPLE 53IH for EXAMPLE 5211 in EXAMPLE 521J. 'H NMR (300 MHz, dimethylsulfoxide-d^) 5 13.13 (s, IH), 12.05 -11.55 (m, IH), 8.29 (d, IH), 7.92 - 7.78 (m, 2H), 7.56 (d, IH), 7.47 - 7.33 (m, 2H), 7.19 -6.98 (m, 4H), 6.82 (dd, IH), 6.56 (d, IH), 6.16 (dd, IH), 4.25 (d, 3H), 3.20 (s, 4H), 2.72 (s, 4H), 2.48 - 2.40 (m, 2H), 2.41 - 2.03 (m, 6H), 1.76 (s, 3H), 1.54 (s, 2H), 1.38 (m, 2H), 1.21 (m,2H), l.ll(s,3H). EXAMPLE 532 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-N-( {4-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl)sulfonyl)-2-(lH-indazol-4- yloxy)benzamide EXAMPLE 532A 4-((cis-4-hydroxy-4-methylcyclohexyl)methoxy)-3-nitrobenzenesulfonamide EXAMPLE 493A (732 mg) and 4-fluoro-3-nitrobenzenesulfonamide (1.2 g) in tetrahydrofiiran (40 mL) were treated with 60% sodium hydride (1.6 g) for 3 days. The reaction was quenched with water. The resulting mixture was neutralized with diluted aqueous HCl, and extracted with ethyl acetate. The organic layer was dried over Na2S04, filtered and concentrated. The residue was purified by a reverse phase chromatography, eluting with 30-50% acetonitrile in 0.1% trifluoroacetic acid water to provide the title compound. -645- EXAMPLE 532B 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-N-(4-((cis-4- hydroxy-4-methylcyclohexyl)methoxy)-3-nitrophenylsulfonyl)-2-(l-trityl-lH-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 532A for EXAMPLE IF and EXAMPLE 498C for EXAMPLE IE in EXAMPLE IG. EXAMPLE 532C 4-(4- {[2-(4-cWorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-N-( {4-[(cis-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 532B for EXAMPLE 542E in EXAMPLE 542F. 'H NMR (400 MHz, dimethylsulfoxide-de) 8 13.09 (s, IH), 8.10 (m, IH), 7.81 (s, IH), 7.78 (dd, IH), 7.56 (d, IH), 7.36 (d, 2H), 7.28 (d, IH), 7.11 (m, 2H), 7.06 (d, 2H), 6.80 (dd, IH), 6.52 (d, IH), 6.17 (dd, IH), 4.02 (d, 2H), 3.96 (s, IH), 3.18 (m, 4H), 2.86 (m, 2H), 2.17 (m, 2H), 1.98 (m, 3H), 1.69 (m, 2H), 1.55 (m, 4H), 1.41 (m, 5H), 1.29 (m, 3H), 1.11 (s, 3H), 0.94 (m, 6H). EXAMPLE 533 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin-1 -yl)-N-( {4-[(trans-4-hydtoxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-indazol-4- yloxy)benzamide EXAMPLE 533A 4-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)-3-nitrobenzenesulfonamide The title compound was prepared by substituting EXAMPLE 53IF for (tetrahydro- 2H-pyran-4-yl)methanol and 4-fluoro-3-nitrobenzenesulfonamide for EXAMPLE 329A in EXAMPLE 329B. EXAMPLE 533B 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-N-(4-((trans- 4-hydroxy-4-methylcyclohexyl)methoxy)-3-nitrophenylsulfonyl)-2-( 1 -trityl-1 H-indazol-4- yloxy)benzamide -646- The title compound was prepared by substituting EXAMPLE 533A for EXAMPLE IF and EXAMPLE 498C for EXAMPLE IE in EXAMPLE IG. EXAMPLE 533C 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyc]ohex- 1-en- l-yl]methyl}piperazin- l-yl)-N-({4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 533B for EXAMPLE 542E in EXAMPLE 542F. 'H NMR (400 MHz, dimethylsulfoxide-de) 8 13.11 (s, IH), 8.11 (m, IH), 7.81 (m, 2H), 7.57 (dd, IH), 7.36 (d, 2H), 7.28 (m, IH), 7.11 (m, 2H), 7.06 (d, 2H), 6.80 (dd, IH), 6.52 (d, IH), 6.18 (d, IH), 4.27 (s, IH), 4.06 (d, 2H), 3.16 (m, 4H), 2.81 (m, 2H), 2.20 (m, 4H), 1.98 (m, 2H), 1.74 (m, 3H), 1.57 (m, 2H), 1.40 (m, 4H), 1.24 (m, 3H), 1.11 (s,3H), 0.94 (s,6H). EXAMPLE 534 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(3- cyano-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-2-(lH-indazol- 4-yloxy)benzamide EXAMPLE 534A 3-cyano-4-((4-fluoro-l-(oxetan-3-yl)piperidin-4-yl)methoxy)benzenesulfonamide To a solution of EXAMPLE 517B (0.185 g) in tetrahydrofiiran (5 mL) was added sodium hydride (0.090 g). After 30 minutes, 3-cyano-4-fluorobenzenesulfonamide (0.178 g) was added in one portion. The reaction was stirred at room temperature for 2 hours. The reaction was quenched with IN aqueous HCl (4 mL), diluted with dichloromethane (30 mL) and saturated aqueous NaHCOs (25 mL). The organic layer was dried over magnesium sulfate, filtered and concentrated. The resulting solid material was triturated with dichloromethane and filtered to give the tide compound. EXAMPLE 534B 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-N-(3-cyano- 4-((4-fluoro-l-(oxetan-3-yl)piperidin-4-yl)methoxy)phenylsulfonyl)-2-(l-trityl-lH-indazol-4- yloxy)benzamide -647- The title compound was prepared by substituting EXAMPLE 521H for EXAMPLE IE and EXAMPLE 534A for EXAMPLE IF in EXAMPLE IG. EXAMPLE 534C 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N- [(3 - cyano-4- {[4-fluoro-1 -(oxetan-3-yl)piperidin-4-yl]methoxy }phenyl)sulfonyl]-2-( IH-indazol- 4-yloxy)benzaniide The title compound was prepared by substituting EXAMPLE 534B for EXAMPLE 5211 in EXAMPLE 521J. 'H NMR (300 MHz, dimethylsulfoxide-de) 813.11 (s, IH), 11.64 -11.28 (m, IH), 7.95 - 7.75 (m, 3H), 7.56 (d, IH), 7.44 - 7.26 (m, 2H), 7.22 (d, IH), 7.09 (ddd, 4H), 6.81 (s, IH), 6.52 (d, IH), 6.18 (dd, IH), 4.51 (dt, 4H), 4.33 (d, 2H), 3.50 (s, IH), 3.18 (s, 8H), 2.49 - 1.68 (m, 14H), 1.42 (d, 2H), 0.94 (s, 6H). EXAMPLE 535 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7- ylmethoxy)phenyl]sulfonyl} benzamide EXAMPLE 535A diethyl 1,4-dioxaspiro[4.5]decane-8,8-dicarboxylate A 500 mL round-bottomed flask was charged with diisopropylamine (16 mL) and tetrahydrofiiran (311 mL). The solution was cooled to -78''C under N2 and n-BuLi (2.5 M in hexanes, 44.8 mL) was added. The reaction was stirred for 30 minutes at -78 °C and ethyl l,4-dioxaspiro[4.5]decane-8-carboxylate (20 g) was added as a tetrahydrofiiran solution (ca. 10 mL). The solution was stirred at -78 °C for 1 hour and ethyl chloroformate (9 mL) was added neat After stirring at -78 °C for 10 minutes, the reaction was warmed to room temperature over 2 hours. The reaction was quenched with saturated aqueous NH4CI and diluted with diethyl ether. The layers were separated, the aqueous layer was extracted with diethyl ether and the combined organics were dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix, 0-65% hexanes / ethyl acetate). EXAMPLE 535B l,4-dioxaspiro[4.5]decane-8,8-diyldimethanol -648- To a 1 L round-bottomed flask was added EXAMPLE 535A (26.6 g) and tetrahydrofuran (310 mL). The solution was cooled to 0°C and lithium aluminum hydride (2M in tetrahydrofuran, 62 mL) was added via syringe. The reaction was allowed to warm to room temperature and stirred overnight. The mixture was cooled back down to 0°C, quenched slowly with 4.7 mL water, 4.7 ml 10% aqueous NaOH and 14 mL water, and allowed to stir until salts were formed and then the mixture was filtered through a Supelco 90 mm silica gel Buchner funnel. The filtrate was concentrated by rotary evaporation and the residue was purified by regular phase flash column chromatography (Analogix, 0-80% hexanes / elhyl acetate). EXAMPLE 535C 2,8,ll-trioxadispiro[3.2.4.2]tridecane To a 1 L round-bottomed flask was added EXAMPLE 535B (13 g) in tetrahydrofuran (321 mL). The solution was cooled to -78°C under N2 and n-butyllithium (25.7 mL) was added dropwise via syringe. After the addition was complete, the reaction was stirred for 30 minutes and a tetrahydrofuran solution of toluene-2-sulfonyl chloride (12.25 g) was added via addition funnel. The reaction was allowed to stir overnight, gradually warming to room temperature. The reaction was recooled to -78 "C and n-butyllithium (25.7mL) was added. The reaction was allowed to warm to room temperature and stirred for 3 hours. The reaction was quenched with saturated aqueous NH4CI and diluted with diethyl ether. The layers were separated, the aqueous layer was extracted with diethyl ether and the combined organics were dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix, 0-20% acetone / hexanes). EXAMPLE 535D 2-oxasptro[3.5]nonan-7-one To a 500 mL round-bottomed flask was added EXAMPLE 535C (11 g) in 80 % acetic acid (200 mL). The reaction was heated to 65°C and stirred for about 4 hours. Most of the acetic acid and water were removed by rotary evaporation and the residue was purified by regular phase flash column chromatography (Analogix, 0-65% hexanes/ethyl acetate). EXAMPLE 535E 7-methylene-2-oxaspiro[3.5]nonane -649- To a 250 mL round-bottomed flask was added methyltriphenylphosphonium iodide (4.33 g) in tetrahydrofuran (35.7 mL). The suspension was cooled to -15°C. n-Butyllithium (2.5 M in hexanes, 4.28 mL) was added dropwise. The mixture was stirred at -15°C for 40 minutes and EXAMPLE 535D (1 g) was added as a tetrahydrofuran (ca. 5 mL) solution. The mixture was stirred at -15°C for about 15 minutes and warmed to room temperature. After L5 hours the reaction was complete and was quenched with saturated aqueous NH4CI and diluted with diethyl ether. The layers were separated and the aqueous layer was extracted (2x) with diethyl ether. The combined organics were washed with brine, dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase chromatography (Analogix, 0-50% hexanes/ethyl acetate). EXAMPLE 535F 2-oxaspiro[3.5]nonan-7-ylmethanol To a 25 mL round-bottomed flask was added EXAMPLE 535E (568 mg) and tetrahydrofuran (4.11 mL). 9-BorabicycIo[3.3. l]nonane (0.5 M in tetrahydrofuran, 24.7 mL) was added and the reaction was allowed to stir for 2 hours at room temperature. Ethanol (11 mL) was added followed by aqueous NaOH (5M, 4.11 mL) and then 30% hydrogen peroxide (2.1 mL) was added. The reaction was heated at 50°C for 2 hours. Most of the ethanol and tetrahydrofuran was removed by rotary evaporation and the residue was diluted with water and ethyl acetate. The aqueous layer was extracted with ethyl acetate (3x) and the combined organics were dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix, 0-70 % hexanes / ethyl acetate). EXAMPLE 535G 4-(2-oxaspiro[3.5]nonan-7-ylmethoxy)-3-nitrobenzenesulfonamide EXAMPLE 535G was prepared by substituting EXAMPLE 535F for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 279A. EXAMPLE 535H 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7- ylmethoxy)phenyl]sulfonyl} benzamide -650- In a 4 mL vial was added EXAMPLE 498C (171 mg) and EXAMPLE 535G (75 mg) in dichloromethane (1052 pi) to give a colorless solution. l-Ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride (64.5 mg) and 4-dimethylaminopyridine (77 mg) were added and the solution was stirred overnight at room temperature. The reaction was loaded directly onto silica gel and chroraatographed by regular phase flash column chromatography (Analogix, 0-100% hexanes / ethyl acetate). The fractions were combined, concentrated, treated with 50% trifluoroacetic acid in dichloromethane (2 mL) and stirred for 2 hours. The volatiles were removed by a stream of nitrogen, the residue was taken up in dichloromethane, loaded directly onto silica gel and purified by flash colunon column chromatography (Analogix, 0.4 - 4% dichloromethane / methanol), 'H NMR (300 MHz, dimethylsulfoxide-dfi) 5 13.10 (s, IH) 8.11 (d, IH) 7.76 - 7.84 (m, 2H) 7.55 (d, IH) 7.36 (d, 2H) 7.27 (d, IH) 7.02 - 7.15 (m, 4H) 6.79 (dd, IH) 6.52 (d, IH) 6.18 (dd, IH) 4.30 (s, 2H) 4.21 (s, 2H) 4.00 (d , 2H) 3.11 - 3.26 (m, 4H) 2.85 (s, 3H) 2.70 - 2.75 (m, IH) 2.22 - 2.46 (m, 3H) 2.13 - 2.22 (m, 3H) 2.07 (d, 2H) 1.98 (s, 2H) 1.66 - 1.77 (m, 3H) 1.36 - 1.50 (m, 4H) 0.98 -1.16 (m, 2H) 0.94 (s, 6H). EXAMPLE 536 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[5-chloro-6-(5,6,7,8-tetrahydroimidazo[ 1,2-a]pyridin-6-ylmethoxy)pyridin-3-yl]sulfonyl} -2- (1 H-indazol-4-yloxy)benzamide EXAMPLE 536A methyl 5,6,7,8-tetrahydroimidazo[ 1,2-a]pyridine-6-carboxylate To a 50 ml pressure bottle were placed methyl imidazo[l,2-a]pyridine-6-carboxylate (0.26 g ), acetic acid (10 mL), and wet 5% palladium on carbon (0.052 g). The reaction mixture was stirred for 16 hours at 30 psi and 50 °C. The solid was filtered off, and the filtrate was concentrated. The residue was dissolved in ethyl acetate. It was then washed with saturated sodium bicarbonate, brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel to give the title compound. EXAMPLE 536B (5,6,7,8-tetrahydroimidazo[l,2-a]pyridin-6-yl)methanol -651- The title compound was prepared by substituting EXAMPLE 5 36A for EXAMPLE 339A in EXAMPLE 339B. EXAMPLE 536C 5-chloro-6-((5,6,7,8-tetrahydroinudazo[l,2-a]pyridin-6-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 536B for (tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 387A for EXAMPLE 329A in EXAMPLE 329B. EXAMPLE 536D N-(5-chloro-6-((5,6,7,8-tetrahydroimidazo[l,2-a]pyridin-6-yl)methoxy)pyridin-3-ylsulfonyl)- 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -((2- (trimethylsilyl)ethoxy)methyl)-lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 435D for EXAMPLE IE and EXAMPLE 536C for EXAMPLE IF in EXAMPLE IG. EXAMPLE 536E 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[5-chloro-6-(5,6,7,8-tetrahydroimidazo[l,2-a]pyridin-6-ylmethoxy)pyridin-3-yl]sulfonyl}-2- (lH-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 536D for EXAMPLE 435E in EXAMPLE 435F. ^H NMR (500MHz, dimethylsulfoxide-de) 8 12.97 (s, IH), 8.20 (d, IH), 7.84 (d, IH), 7.72 (s, IH), 7.66 (d, IH), 7.35 (d, 2H), 7.29 (s, IH), 7.15 (s, IH), 7.03-7.07 (m, 4H), 6.72 (dd, IH), 6.40 (d, IH), 6.09 (dd, IH), 4.35-4.48 (m, 2H), 4.24-4.28 (m, IH), 3.84-3.90 (m, IH), 3.06 (br s, 4H), 2.83-2.92 (m, 2H), 2.76 (s, 2H), 2.09-2.23 (m, 8H), 1.97 (s, 2H), 1.76 (m, IH), 1.40 (t, 2H), 0.93 (s, 6H). EXAMPLE 537 2-(lH-benzimidazol-4-yloxy)-N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)benzamide The title compound was prepared by substituting EXAMPLE 493B for EXAMPLE 428D and in EXAMPLE 428E. 'H NMR (500 MHz, pyridine-ds) 8 9.17 (d, IH), 8.70 (d, IH), 8.57 - 8.58 (s, IH), 7.98 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.24 (t, IH), 7.16 (d, IH), -652- 7.07 (d, 2H), 6.70 (m, 2H), 5.94 (m, 3H), 4.30 (d, 2H), 3.03 (m, 4H), 2.77 (s, 2H), 2.25 (m, 2H), 2.13 (m, 4H), 1.97 (s, 2H), 1.94 - 1.87 (m, 5H), 1.76 (m, 2H), 1.43 - 1.28 (m, 7H), 0.94 (m, 6H). EXAMPLE 538 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin- l-yl)-N-[(5-cyano-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy)pyridin-3-yl)su]fonyl]-2-(lH- mdazol-4-yloxy)benzamide EXAMPLE 538A 5-bromo-6-((4-fluoro-l-(oxetan-3-yl)piperidin-4-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 517B for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 329B. EXAMPLE 538B 5-cyano-6-((4-fluoro-l-(oxetan-3-yl)piperidin-4-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 538A for EXAMPLE 329B in EXAMPLE 333A. EXAMPLE 538C 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-N-(5-cyano- 6-((4-fluoro-l-(oxetan-3-yl)piperidin-4-yl)methoxy)pyridin-3-ylsulfonyl)-2-(l-trityl-lH- indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 498C for EXAMPLE IE and EXAMPLE 538B for EXAMPLE IF in EXAMPLE IG. EXAMPLE 538D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N- [(5 -cyano-6-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(lH- indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 538C for EXAMPLE 5211 in EXAMPLE 521J. 'H NMR (300 MHz, dimethylsulfoxide-da) 8 13.03 (s, IH), 8.49 (d, IH), 8.19 (s, IH), 7.74 (s, IH), 7.62 (d, IH), 7.37 (d, 2H), 7.14 - 6.94 (m, 3H), 6.77 (dd, IH), -653- 6.51 (s, IH), 6.09 (dd, IH), 4.53 (dt, 6H), 3.60 (s, 3H), 2.84 (dd, 8H), 2.46 - 1.71 (m, 12H), 1.44 (d,2H), 0.94 (s,6H). EXAMPLE 539 N-( {5-chloro-6- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy ]pyiidin-3 -yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-l-en-l-yl]methyl)piperazin-l- yl)-2-( 1 H-indazol-4-yloxy)benzamide EXAMPLE 539A ethyl 8-methyl-1,4-dioxaspiK)[4.5]decane-8-carboxylate To a 500 mL round-bottomed flask was added diisopropylamine (7.98 mL) in tetrahydrofuran (233 mL). The mixture was cooled to -78°C under N2 and n-butyllithium (2.5 M in hexanes, 22.40 mL) was added. The reaction was stirred for 30 minutes and ethyl l,4-dioxaspiro[4.5]decane-8-carboxylate (10 g) was added. The reaction was allowed to stir for 1.5 hours upon which time CH3I (4.38 mL) was added. The reaction was allowed to warm to room temperature overnight with stirring. Water was added and the aqueous layer was extracted with ethyl acetate. The combined organics were dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by normal phase flash column chromatography (Analogix, 0-50% hexanes / ethyl acetate). EXAMPLE 539B (8-methyl-1,4-dioxaspiro[4.5 ]decan-8-yl)methanol To a 500 mL round-bottomed flask was added lithium aluminum hydride (1,772 g) in tetrahydrofuran (234 mL). The mixture was cooled to 0°C and EXAMPLE 539A (10.66 g) was added via addition iunnel. The reaction was stirred overnight at room temperature and then cooled back down to 0°C. The excess lithium aluminum hydride was slowly quenched with 1.8 mL water, 1.8 mL aqueous NaOH (5N) and 5.6 mL water. The suspension was stirred until the salts turned white and then filtered through a plug of silica gel. The filtrate was concentrated by rotary evaporation and the residue was purified by regular phase flash column chromatography (Analogix, 0-75% hexanes / ethyl acetate). EXAMPLE 539C 8-(methoxymethyl)-8-methyl-1,4-dioxaspiro[4.5]decane -654- To a 250 mL round-bottomed flask was added NaH (0.902 g) and tetrahydrofiiran (37.6 mL). EXAMPLE 539B (3.8 g) was added as a letrahydrofuran solution at room temperature. The suspension was stirred for 30 minutes and then CH3I (0.611 mL) was added. The reaction was stirred under N2 overnight, carefully quenched with brine and diluted with water and ether. The aqueous layer was extracted with ether (2x) and the combined organics were dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by flash column chromatography (Analogix, 0-60% hexanes / ethyl acetate). EXAMPLE 539D 4-(methoxymethyl)-4-methylcyclohexanone The title compound was prepared by substituting EXAMPLE 539C for EXAMPLE 535C in EXAMPLE 535D. EXAMPLE 539E 2-chloro-5-(methoxymethyl)-5-methylcyclohex-l-enecaibaldehyde To a 25 mL round-bottomed flask was added N,N-dimethylformamide (0.70 mL) and dichlotomethane (3.31 mL). The solution was cooled to OT and POCI3 (0.772 mL) was added dropwise under nitrogen. After the addition was complete, the solution was warmed to room temperature and stirred for 35 minutes. EXAMPLE 539D (1.035 g) was then added as a dichloromethane solution and the mixture was allowed to stir overnight at room temperature. The reaction was poured into ice and NaHCOj, warmed to room temperature, and extracted with dichloromethane (2x). The combined aqueous was extracted with diethyl ether and then the combined organics were dried (Na2S04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix, 0-45% hexanes / ethyl acetate). EXAMPLE 539F 2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-l-enecaibaldehyde To a 20 mL vial was added EXAMPLE 539E (700 mg) and 4-chlorophenylboronic acid (648 mg) in water (3.8 mL). Tetrabutylammonium bromide (1.1 g) and potassium carbonate (1.2 g) were added followed by palladium (II) acetate (23.3mg). The mixture was degassed with nitrogen for 2 minutes, the vial was capped and the reaction was heated at 45°C overnight. The reaction mixture was diluted with ethyl acetate and water and the - 655 - aqueous layer was extracted with ethyl acetate (3x). The combined organics were dried (NaS04), filtered and concentrated by rotary evaporation. The residue was purified by regular phase flash column chromatography (Analogix, 0-60% hexanes / ethyl acetate). EXAMPLE 539G methyl 2-(lH-indazol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-5-(methoxymethyl)-5- methylcyclohex-l-enyl)methyl)piperazin-l-yl)benzoate To a 20 mL vial was added EXAMPLE 400C (531 mg) and EXAMPLE 539F (420 mg) in dichloromethane (8 mL). Sodium triacetoxyborohydride (415 mg) was added. The reaction was stirred for 2 days at room temperature and then quenched with saturated aqueous NaHCOs. The aqueous layer was extracted with dichloromethane (3x), dried (MgS04), filtered and concentrated by rotary evaporation. The residue was pimfied by regular phase flash column chromatography (Analogix, 0.4% - 4% dichloromethane/methanol). EXAMPLE 539H methyl 4-(4-((2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -trityl-1 H-indazol-4-yloxy )benzoate To a 25 mL round-bottomed flask was added EXAMPLE 539G (704 mg) in dichloromethane (5 mL). Triethylamine (319 |il) was added followed by trityl-chloride (399 mg). The reaction was stirred overnight and diluted with water and dichloromethane. The aqueous layer was extracted with dichloromethane (2x) and the combined organics were dried (MgS04), filtered and concentrated by rotary evaporation. The residue was taken up in dichloromethane and passed over a pre-packed Supelco silica gel buchner fimnel and the non-polar impurities were rinsed off with dichloromethane. The product was eluted with 5% methanol in dichloromethane. The residue was concentrated by rotary evaporation and the residue was used in the next step without further purification. EXAMPLE 5391 4-(4-((2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(l-trityl- lH-indazol-4-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 539H for EXAMPLE 175D in EXAMPLE 175E. -656- EXAMPLE 539J N-(5-chloro-6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridin-3-ylsulfonyl)-4-(4- ((2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-l-enyl)methyl)piperazin-l-yl)-2- (1 -trityl-1 H-indazol-4-yloxy)benzamide The title compound was prepared substituting EXAMPLE 5391 for EXAMPLE IE and EXAMPLE 493B for EXAMPLE IF in EXAMPLE IG. EXAMPLE 539K N-({5-chlorD-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-l-en-l-yl]methyl}piperazin-l- yl)-2-( 1 H-indazol-4-yloxy)benzamide The title compound was prepared substituting EXAMPLE 5 39J for EXAMPLE 542E in EXAMPLE 542F. IH NMR (300 MHz, dimethylsulfoxide-de) 8 13.10 (s, IH) 8.28 (d, IH) 7.77 - 7.91 (m, 2H) 7.58 (d, IH) 7.37 (d, 2H) 6.99 - 7.19 (m, 4H) 6.80 (dd, IH) 6.54 (s, IH) 6.15 (dd, IH) 4.10 - 4.34 (m, 3H) 3.26 (s, 3H) 3.05 - 3.21 (m, 6H) 2.12 - 2.29 (m, 4H) 2.09 (s, IH) 1.85 - 1.98 (m, IH) 1.68 - 1.81 (m, 4H) 1.50 - 1.63 (m, 4H) 1.31 - 1.45 (m, 3H) 1.13 -1.30 (m, 2H) 1.11 (s, 3H) 0.94 (s, 3H). EXAMPLE 540 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)-N- {[3-nitro-4-( {[(2S)-4-(oxetan-3-yl)morpholin-2- yl]methyl} amino)pheny IJsulfonyl} benzamide EXAMPLE 540A (S)-3-nitro-4-((4-(oxetan-3-yl)morpholin-2-yl)methylamino)benzenesulfonamide A round-bottom flask was charged with EXAMPLE 438B (1.012 g), anhydrous methanol (15 mL) and acetic acid (2.75 mL). Oxetan-3-one (0.461 g) was added and the mixture was stirred at room temperature for 30 minutes. Sodium cyanoborohydride (0.603 g) was then added and the mixture was stirred at room temperature overnight. The mixture was concentrated and the residue taken up in 5% aqueous Na2C03 solution (15 mL). The mixture was extracted with ethyl acetate, and the combined organic layers were concentrated. The crude product was purified on a silica gel column eluting with 5% and 10% methanol in CH2CI2 giving the title compound. -657- EXAMPLE 540B 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4-yloxy)-N-{ [3-nitro-4-({ [(2S)-4-(oxetan-3-yl)moipholin-2-yl]methyl} amino)phenyl]sulfonyl} benzamide The title compound was prepared by substituting EXAMPLE 4(X)E for EXAMPLE 26C and EXAMPLE 540A for EXAMPLE IF in EXAMPLE 177. ^H NMR (500MHz, pyridine-ds) 6 14.58 (bs, IH), 9.05 (d, IH), 8.85 (t, IH), 8.37 (s, IH), 8.17 (dd, IH), 8.02 (d, IH), 7.45 (d, 2H), 7.34 (d, IH), 7.15 (t, IH), 7.10 (d, 2H), 6.90-6.80 (m, 3H), 6.53 (d, IH), 4.67-4.61 (m, 4H), 3.94-3.90 (m, 2H), 3.68 (dt, IH), 3.47 (m, IH), 3.44-3.34 (m, 2H), 3.14 (m, 4H), 2.82 (s, 2H), 2.71 (d, IH), 2.44 (d, IH), 2.30 (m, 2H), 2.22 (m, 4H), 1.99 (s, 2H), 1.95 (dt, IH), 1.84 (t, IH), 1.41 (t, 2H), 0.96 (s, 6H). EXAMPLE 541 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- {[3-nitro-4-( {[(2S)-4-(oxetan-3-yl)morpholin-2- yl]methyl} amino)phenyl]sulfonyl} benzamide The title compound was prepared by substituting EXAMPLE 540A for EXAMPLE 428D in EXAMPLE 428E. ^H NMR (500MHz, pyridine-dj) 8 9.25 (d, IH), 8.87 (t, IH), 8.57 (s, IH), 8.38 (dd, IH), 8.01 (d, IH), 7.52 (d, IH), 7.43 (d, 2H), 7.24 (d, IH), 7.14 (d, IH), 7.07 (d, 2H), 6.97 (d, IH), 6.73-6.68 (m, 2H), 4.69-4.62 (m, 4H), 3.97-3.89 (m, 2H), 3.69 (dt, IH), 3.51 (m, IH), 3.47-3.35 (m, 2H), 3.03 (m, 4H), 2.77 (s, 2H), 2.74 (d, IH), 2.43 (d, IH), 2.25 (m, 2H), 2.14 (m, 4H), 1.97 (s, 2H), 1.95 (m, IH), 1.86 (t, IH), 1.38 (t, 2H), 0.94 (s, 6H). EXAMPLE 542 N- [(5-chloro-6- {[trans-4-(2-hydroxypropan-2-yl)cyclohexyl]methoxy} pyridin-3 -yl)sulfonyl]- 4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide EXAMPLE 542A trans-methyl 4-((tert-butyldimethylsilyloxy)methyl)cyclohexanecarboxylate -658- Trans-methyl 4-(hydroxymethyl)cyclohexanecarboxylate was dissolved in dichloromethane (30 niL), then imidazole (1.0 g) and tert-butylchlorodimethylsilane (1.6 g) were added. The reaction was stirred at room temperature overnight. The reaction mixture was then concentrated, dissolved in ethyl acetate and washed with l^V aqueous HCl, water, and brine. The organic layer was dried over Na2S04. The title compound was obtained after filtration and concentration. EXAMPLE 542B 2-(trans-4-((tert-butyldimethylsilyloxy)methyl)cyclohexyl)propan-2-ol EXAMPLE 542A (1.4 g) was dissolved in tetrahydrofuran (15 mL), then a solution of 3.0M methylmagnesium chloride in tetrahydrofuran (3.4 mL) was carefiilly added and the reaction allowed to stir at room temperature under nitrogen overnight. The reaction was then poured into saturated aqueous NH4CI and extracted with ethyl acetate. The organic layer was washed with brine and dried over Na2S04. After filtration and concentration the product was purified by column chromatography on silica gel using 9/1 hexanes/ethyl acetate. EXAMPLE 542C 2-(trans-4-(hydroxymethyl)cyclohexyl)propan-2-ol EXAMPLE 542B was dissolved in tetrahydrofuran (10 mL), then a solution of l.OM tetrabutylammonium fluoride in tetrahydrofuran (17.5 mL) was added and the reaction was stirred at room temperature overnight. The reaction was concentrated and the residue was purified by column chromatography on silica gel using 50-70% ethyl acetate in hexanes. EXAMPLE 542D 5-chloro-6-((trans-4-(2-hydroxypropan-2-yl)cyclohexyl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 542C for (tetrahydro-2H-pyran-4-yl)methanol and 5,6-dichloropyridine-3-sulfonamide for EXAMPLE 329A in EXAMPLE 329B, except here dimethylformamide was used in place of tetrahydrofuran. EXAMPLE 542E N-(5-chloro-6-((trans-4-(2-hydroxypropan-2-yl)cyclohexyl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-(2-trityl-2H- indazol-4-yloxy)benzamide -659- The title compound was prepared by substituting EXAMPLE 498C for EXAMPLE IE and EXAMPLE 542D for EXAMPLE IF in EXAMPLE IG. EXAMPLE 542F N-[(5-chloro-6-{[trans-4-(2-hydroxypropan-2-yl)cyclohexyl]methoxy}pyridin-3-yl)sulfonyl]- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide EXAMPLE 542E (310 mg) was dissolved in dichloromethane (2.5 mL), and p-toluenesulfonic acid monohydrate (27 mg) was added. After stirring at room temperature for 30 minutes, the reaction was poured into saturated aqueous NaHCOs and extracted with dichloromethane. The organic layer was washed with brine and dried over Na2S04. After filtration and concentration the residue was purified by column chromatography on silica gel using 2-10% methanol in dichloromethane. H NMR (500MHz, dimethylsulfoxide-de) 8 13.10 (s, IH), 8.27 (d, IH), 7.85 (d, IH), 7.81 (s, IH), 7.58 (d, IH), 7.37 (d, 2H), 7.06 (m, 4H), 6.80 (dd, IH), 6.54 (d, IH), 6.13 (d, IH), 4.19 (d, 2H), 4.00 (s, IH), 3.21 (br s, 4H), 2.96 (v br s, 2H), 2.40 (br s, 4H), 2.19 (br m, 2H), 1.98 (s, 2H), 1.83 (br m, 4H), 1.70 (br m, IH), 1.42 (t, 2H), 1.18 (brm, IH), 1.02 (br m, 4H), 1.02 (s, 6H), 0.93 (s, 6H). EXAMPLE 543 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-en-l-yl]methyl }piperazin- l-yl)-N-( {3- cyano-4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-2-(lH-indazol-4- yloxy)benzamide EXAMPLE 543A 3-cyano-4-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)benzenesulfonamide The title compound was prepared by substituting EXAMPLE 53IF for EXAMPLE 517B in EXAMPLE 534A. EXAMPLE 543B 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-N-(3-cyano-4-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)phenylsulfonyl)-2-(l-trityl-lH-indazol-4- yloxy)benzamide -660- This EXAMPLE was prepared by substituting EXAMPLE 498C for EXAMPLE IE and EXAMPLE 543A for EXAMPLE IF in EXAMPLE IG. EXAMPLE 543C 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({3- cyano-4-[(trans-4-hydroxy-4-methylcyclohexyl)inethoxy]phenyl}sulfonyl)-2-(lH-indazo]-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 543B for EXAMPLE 5211 in EXAMPLE 521J. 'H NMR (300 MHz, dimethylsulfoxide-dfi) 5 13.12 (s, IH), 11.70 -11.35 (m, IH), 7.87 (d, IH), 7.81 (t, 2H), 7.55 (d, IH), 7.39 - 7.33 (m, 2H), 7.20 - 7.10 (m, 3H), 7.09 - 7.03 (m, 2H), 6.80 (dd, IH), 6.53 (d, 7 = 2.1 Hz, IH), 6.18 (dd, IH), 4.26 (s, IH), 4.05 (d, 2H), 3.19 (s, 4H), 2.86 (s, 2H), 2.17 (m, 6H), 1.98 (s, 2H), 1.77 (m, 3H), 1.56 (m, 2H), 1.42 (m, 6H), 1.12 (s, 3H), 0.94 (s, 6H). EXAMPLE 544 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N-( {5- cyano-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- indazol-4-yloxy)benzamide EXAMPLE 544A 5-bromo-6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 53IF for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 329B. EXAMPLE 544B 5-cyano-6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 544A for EXAMPLE 329B in EXAMPLE 333A. EXAMPLE 544C 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-N-(5-cyano- 6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridin-3-ylsulfonyl)-2-(l-trityl-lH- indazol-4-yloxy)benzamide -661- The title compound was prepared by substituting EXAMPLE 498C for EXAMPLE IE and EXAMPLE 544B for EXAMPLE IF in EXAMPLE IG. EXAMPLE 544D 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N-( {5- cyano-6-[(trans-4-hydroxy-4-niethylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH- indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 544C for EXAMPLE 5211 in EXAMPLE 521J. 'H NMR (300 MHz, dimethylsulfoxide-d^) 8 13.07 (s, IH), 8.50 (d. IH), 8.23 - 8.12 (m, IH), 7.76 (s, IH), 7.60 (d, IH), 7.37 (d, 2H), 7.07 (dd, 4H), 6.87 -6.72 (m, IH), 6.54 (d, IH), 6.17 - 6.03 (m, IH), 4.29 (d, 3H), 3.25 - 3.11 (m, 4H), 2.19 (s, 4H), 2.00 (s, 2H), 1.76 (s, 4H), 1.55 (s, 3H), 1.48 - 1.31 (m, 4H), 1.31 - 1.14 (m, 4H), 1.12 (s, 3H), 0.94 (s, 6H). EXAMPLE 545 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)-N-({5-nitro-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3- yl} sulfonyl)benzamide EXAMPLE 545A 6-amino-5-nitropyridine-3-sulfonic acid 6-Aminopyridine-3-sulfonic acid (20 g) in concentrated H2SO4 (80 mL) was heated at 50 °C until it was completely dissolved. To this solution was added fuming HNO3 dropwise over 20 minutes. The rate of addition was kept slow so that the internal temperature did not exceeded 55 °C. After the addition was complete, the reaction mixture was heated at 50 °C for 1 hour. After the mixture cooled to room temperature, it was poured into 150 g of ice. The mixture was stirred for another 1 hour. The whole flask was cooled to 0 °C, and was kept at 0 °C for another 2 hoiirs. The solid was collected by filtration, and was washed with cold 1:1 water/ethanol (20 mL), followed by diethyl ether (10 mL). The solid was dried in a vacuum oven overnight to give the title compound. EXAMPLE 545B 6-hydroxy-5 -nitropyridine-3-sulfonic acid -662- EXAMPLE 545A (4.0 g) in HCl (37%, 12 mL) and water (50 mL) was treated with sodium nitrite (1.19 g) in water (8 mL) dropwise at 0 °C. After the addition was complete, the reaction mixture was stirred at 0 °C for 1 hour. The mixture was then heated under reflux for 2 hours. Water was distilled off to give a near dry residue. After it cooled to room temperature, a solution of 1:1 ethanol/water (20 mL) was added. The resulting suspension was cooled to 0 °C, and kept at 0 °C for 1 hour. The solid was collected by filtration to give the title compound. EXAMPLE 545C 6-chloK)-5-nitropyridine-3-sulfonyl chloride A mixture of EXAMPLE 545B (2.6 g), PCI5 (5.91 g), and POCI3 (10 mL) was heated at 120 °C for 4 hours. The initial suspension became a clear solution. The excess of POCI3 was distiUed off. After it was cooled to room temperature, the residue was poured into 50 g of crushed ice. The solid was extracted into ethyl acetate. The aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated to give the crude product that was used for the next reaction without further purification. EXAMPLE 545D 6-chloro-5-nitropyridine-3-sulfonamide EXAMPLE 545C in tetrahydrofuran (10 mL) was cooled to -10 °C. To this solution was added concentrated ammonium hydroxide (0.82 mL) dropwise. The solution was stirred at -10 °C for 10 minutes. The solvent was removed under pressure at room temperature. The residue was partitioned between water and ethyl acetate. The aqueous layer was extracted with additional ethyl acetate. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash column chromatography on silica gel to give the title compound. EXAMPLE 545E 5-nitro-6-((tetrahydro-2H-pyran-4-yl)methylamino)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 545D for 4-fluoro-3-nitrobenzenesulfonamide in EXAMPLE IF. -663- EXAMPLE 545F 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-N-(5-nitro-6- ((tetrahyclro-2H-pyran-4-yl)methylamino)pyridin-3-ylsulfonyl)-2-(l-trityl-lH-indazol-4- yloxy)benzaniide The title compound was prepared by substituting EXAMPLE 498C for EXAMPLE IE and EXAMPLE 545E for EXAMPLE IF in EXAMPLE IG. EXAMPLE 545G 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)-N-({5-nitro-6-[(tetraliydro-2H-pyran-4-ylmethyl)amino]pyridin-3- yl} sulfonyl)benzamide The title compound was prepared by substituting EXAMPLE 545F for EXAMPLE 542E EXAMPLE 542F. 'H NMR (500MHZ, dimethylsulfoxide-de) 8 13.03 (s, IH), 8.66 (br s, IH), 8.49 (d, IH), 8.45 (d, IH), 7.78 (s, IH), 7.57 (d, IH), 7.36 (d, 2H), 7.01-7.07 (m, 4H), 6.79 (dd, IH), 6.52 (s, IH), 6.11 (dd, IH), 3.84 (dd, 2H), 3.51 (t, IH), 3.23-3.29 (m, 2H), 3.17 (br s, 4H), 2.84 (br s, 2H), 2.16-2.34 (m, 6H), 1.98 (s, 2H), 1.58-1.61 (m, 2H), 1.41 (t, 2H), 0.94 (s, 6H). EXAMPLE 546 2-(lH-benzotriazol-4-yloxy)-N-({5-chloro-6-[(trans-4-hydroxy-4- methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chIorophenyl)-4,4- dimethy Icyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)benzamide EXAMPLE 546A N-(5-chloro-6-(((lr,4r)-4-hydroxy-4-methylcyclohexyl)methoxy)pyridin-3-ylsulfonyl)-4-(4- ((2-(4-chlorophenyl)-4,4-dimethylcyclohex- l-enyl)methyl)piperazin-1 -yl)-2-( 1 -((2- (trimethylsilyl)ethoxy)methyl)- lH-benzo[d] [ l,2,3]triazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 514F for EXAMPLE IE and EXAMPLE 493B for EXAMPLE IF in EXAMPLE 10. -664- EXAMPLE 546B 2-(l H-benzotriazol-4-yloxy)-N-( {5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridm-3-yl}sulfonyl)-4-(4-{I2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)benzamide EXAMPLE 546A (0.22 g) in tetrahydrofiaran (10 mL) was treated with LO N tetrabutyl ammonium fluoride (4.3 M). The reaction mixture was heated at 50 °C for 3 hours. The solvent was removed, and the residue was partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed with brine, dried over MgS04, filtered, and concentrated. The residue was purified by reverse phase Gilson Prep HPLC system with a Phenomenex prep column (Luna, 5 |i, C18(2), 250X21.20 mm, 5 A) eluting with 20-80% acetonitrile in water with 0.1% trifluoroacetic acid to give the title compound. ^H NMR (500MHz, dimethylsulfoxide-de) 8 8.24 (s, IH), 7.86 (d, IH), 7.63 (d, IH), 7.36-7.38 (m, 3H), 7.06-7.09 (m, 3H), 6.81 (dd, IH), 6.57 (d, IH), 6.33 (d, IH), 4.32 (s, IH), 4.22 (d, 2H), 3.00 (br s, 4H), 2.41 (br s, 2H), 2.19 (s, 2H), 1.99 (s, 2H), 1.73-1.77 (m, 2H), 1.56-1.59 (m. 2H), 1.36-1.43 (m, 4H), 1.12-1.27 (m, 6H), 0.94 (s, 6H). EXAMPLE 547 N-( {3-chloro-4- [(cis-4-cyano-1 -fluorocyclohexyl)methoxy]phenyl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzamide EXAMPLE 547A l-oxaspiro[2.5]octane-6-carbonitrile A solution of 4-oxocyclohexanecaibonitrile (1.90 g) in dimethylsulfoxide (8 mL) was added dropwise to a solution of potassium t-butoxide (2.60 g) and trimethylsulfoxonium iodide (5.09 g) in dimethylsulfoxide (30 mL) at room temperature. The mixture was stirred overnight, diluted with 20% brine, and extracted with 3x ethyl acetate. The combined organic layers were washed with 20% brine, dried over Na2S04, and concentrated. The crude was purified on a 40 g column using an ISCO Companion flash system eluting with hexane/ethyl acetate (6:4 to 5:5) to give the desired product. -665- EXAMPLE 547B cis-4-fluoro-4-(hydK)xymethyl)cyclohexanecarbomtrile A solution of pyridine hydrofluoride (2.25 g) in dichloromethane (8 mL) was added dropwise to a solution of EXAMPLE 547A (0.780 g) in dichloromethane (8 mL) in a polyethlene bottle at 0°C. The reaction was slowly warmed to room temperature and stirred for 43 hours. The reaction mixture was slowly added to ice-cold saturated aqueous NaaCOs until pH=8-9 and extracted twice with ethyl acetate. The combined organic layers were dried over Na2S04, concentrated, and purified on an 80g silica column using an ISCO Companion flash system eluting with hexane/ethyl acetate (65:35 to 55:45) to give the desired product. EXAMPLE 548A was also isolated ftom this reaction. EXAMPLE 547C 3-chloro-4-((cis-4-cyano-1 -fluorocyclohexyl)methoxy )-N,N-bis(2,4-dimethoxybenzyl)benzenesulfonamide The title compound was prepared as described in EXAMPLE 329B by replacing EXAMPLE 329A with EXAMPLE 517C and (tetrahydro-2H-pyran-4-yl)methanol with EXAMPLE 547B. EXAMPLE 547D 3-chloro-4-((cis-4-cyano-l-fluorocyclohexyl)methoxy)benzenesulfonamide The title compound was prepared as described in EXAMPLE 517E by replacing EXAMPLE 517D with EXAMPLE 547C. EXAMPLE 547E N-(3-chloro-4-((cis-4-cyano-l-fluorocyclohexyl)methoxy)phenylsulfonyl)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -trityl-1 H-indazol-4- yloxy)benzamide. The title compound was prepared as described in EXAMPLE IG by replacing EXAMPLE IE with EXAMPLE 498C and EXAMPLE IF with EXAMPLE 547D. EXAMPLE 547F 2-(lH-indazol-4-yloxy)-N-(3-chloro-4-((cis-4-cyano-l- fluorocyclohexyl)methoxy)phenylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1 -enyl)methyl)piperazin-1 -yl)benzamide. -666- The title compound was prepared as described in EXAMPLE 497C by replacing EXAMPLE 497B with EXAMPLE 547E. 'H NMR (300 MHz, dimelhylsulfoxide-dg) 8 13.14 (s, IH), 11.18-12.10 (bs, IH), 7.84 (s, IH), 7.66 (d, IH), 7.48-7.63 (m, 2H), 7.28-7.42 (m, 2H), 7.09-7.24 (m, 3H), 7.05 (m, 2H), 6.80 (dd, IH), 6.52 (d, IH), 6.14-6.31 (m, IH), 4.20 (d, 2H), 3.05-3.26 (m, 4H), 2.69-2.93 (m, 3H), 2.10-2.37 (m, 6H), 1.89-2.11 (m, 7H), 1.50-1.85 (m, 4H), 1.40 (t, IH), 0.94 (s, 6H). EXAMPLE 548 N-({3-chloro-4-[(trans-4-cyano-l-fluorocyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzaniide EXAMPLE 548A trans-4-fluoro-4-(hydroxymethyl)cyclohexanecaibonitrile The title compound was prepared and isolated as described in EXAMPLE 547B. EXAMPLE 548B 3-chloro-4-((trans-4-cyano-1 -fluorocyclohexyl)methoxy)-N,N-bis(2,4-dimethoxybenzyI)benzenesulfonamide The title compound was prepared as described in EXAMPLE 329B by replacing EXAMPLE 329A with EXAMPLE 517C and (tetrahydro-2H-pyran-4-yl) methanol with EXAMPLE 548A. EXAMPLE 548C 3-chloro-4-((trans-4-cyano-l-fluorocyclohexyl)methoxy)benzenesulfonamide The title compound was prepared as described in EXAMPLE 517E by replacing EXAMPLE 517D with EXAMPLE 548B. EXAMPLE 548D N-(3-chloro-4-((trans-4-cyano-l-fluorocyclohexyl)methoxy)phenylsulfonyl)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -trityl-1 H-indazol-4- yloxy)benzamide -667- The title compound was prepared as described in EXAMPLE IG by replacing EXAMPLE IE with EXAMPLE 498C and EXAMPLE IF with EXAMPLE 548C. EXAMPLE 548E N-(3-chloro-4-((trans-4-cyano-l-fluorocyclohexyl)methoxy)phenylsulfonyl)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -trityl-1 H-indazol-4- yloxy)benzamide The title compound was prepared as described in EXAMPLE 497C by replacing EXAMPLE 497B with EXAMPLE 548D. 'H NMR (300 MHz, dimethylsulfoxide-de) 8 13.15 (s, IH), 11.50 (s, IH), 7.85 (s, IH), 7.67 (d, IH), 7.46-7.64 (m, 2H), 7.35 (d, 2H), 7.11-7.23 (m, 3H), 7.05 (d, 2H), 6.80 (dd, IH), 6.52 (d, IH), 6.23 (d, IH), 4.30 (d, 2H), 3.10-3.25 (m, 5H), 2.81 (s, 2H), 2.09-2.35 (m, 6H), 1.70-2.07 (m, lOH), 1.40 (t, 2H), 0.83-1.02 (m, 6H). EXAMPLE 549 N-( {5-chloro-6-[(cis-4-cyano- l-fluorocyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chloTophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide EXAMPLE 549A 5-chloro-6-((cis-4-cyano-l-fluorocyclohexyl)methoxy)pyridine-3-sulfonamide The title compound was prepared as described in EXAMPLE 329B by replacing EXAMPLE 329A with EXAMPLE 387A and (tetrahydro-2H-pyran-4-yl)methanol with EXAMPLE 547B. EXAMPLE 549B N-(5-chloro-6-((cis-4-cyano-l-fluorocyclohexyl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -trityl-1 H-indazol-4- yloxy)benzamide The title compound was prepared as described in EXAMPLE IG by replacing EXAMPLE IE with EXAMPLE 498C and EXAMPLE IF with EXAMPLE 549A. EXAMPLE 549C -668- 2-( 1 H-indazol-4-yloxy)-N-(5-chloro-6-((cis-4-cyano-1 -fluorocyclohexyl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l- yl)benzamide The title compound was prepared as described in EXAMPLE 497C by replacing EXAMPLE 497B with EXAMPLE 549B. 'H NMR (400 MHz, pyridine-ds) 5 8.92 (d, IH), 8.39 (bs, 2H), 8.07 (d, IH), 7.46 (d, 2H), 7.36 (d, IH), 7.13 (m, 2H), 6.86 (m, 3H), 6.50 (d, IH), 4.50 (m, 2H), 3.17 (m, 3H), 3.01 (m, IH), 2.82 (s, 2H), 2.30 (m, 2H), 2.24 (m, 3H), 2.23 (m, 4H), 1.97-2.04 (m, 4H), 1.83-1.90 (m, 2H), 1.77 (m, 2H), 1.41 (t, 2H), 0.96 (s, 6H). EXAMPLE 550 N-({5-chloro-6-[(trans-4-cyano-l-fluorocyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol- 4-yloxy)benzamide EXAMPLE 550A 5-chloro-6-((trans-4-cyano-l-fluoiocyclohexyl)methoxy)pyridine-3-sulfonainide The title compound was prepared as described in EXAMPLE 329B by replacing EXAMPLE 329A with EXAMPLE 387A and (tetrahydro-2H-pyran-4-yl)methanol with EXAMPLE 548A. EXAMPLE 550B N-(5-chloro-6-((trans-4-cyano-l-fluorocyclohexyl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2- (4-chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 - trityl-1H- indazol-4-yloxy)benzamide The title compound was prepared as described in EXAMPLE IG by replacing EXAMPLE IE with EXAMPLE 498C and EXAMPLE IF with EXAMPLE 550A. EXAMPLE 550C 2-(lH-indazol-4-yloxy)-N-(5-chloro-6-((trans-4-cyano-l-fluorocyclohexyl)methoxy)pyridin- 3-ylsulfonyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l- yl)benzamide The title compound was prepared as described in EXAMPLE 497C by replacing EXAMPLE 497B with EXAMPLE 550B. 'H NMR (400 MHz, pyridine-ds) 8 8.92 (d, IH), -669- 8.39 (bs, 2H), 8.07 (d, IH), 7.46 (d, 2H), 7.36 (d, IH), 7.13 (m, 2H), 6.86 (m, 3H), 6.50 (d, IH), 4.50 (m, 2H), 3.17 (m, 3H), 3.01 (m, IH), 2.82 (s, 2H), 2.30 (m, 2H), 2.24 (m, 3H), 2.23 (m, 4H), 1.97-2.04 (m, 4H), 1.83-1.90 (m, 2H), 1.77 (m, 2H), 1.41 (t, 2H), 0.96 (s, 6H). EXAMPLE 551 N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2- (lH-indazol-4-yloxy)benzamide EXAMPLE 551A methyl 4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-1 -yl)-2-( 1 -trityl-1 H-indazol-4-yloxy)benzoate The title compound was prepared by substituting EXAMPLE 465A for EXAMPLE 400D in EXAMPLE 498B. EXAMPLE 55 IB 4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-1 -yl)-2-(1 -trityl-1 H-indazol-4-yloxy)benzoic acid The title compound was prepared by substituting EXAMPLE 551A for EXAMPLE 175D in EXAMPLE 175E. EXAMPLE 55IC N-(5-chloro-6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridin-3-ylsulfonyI)-4-(4-((4-(4-chlorophenyI)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yl)-2-(l- trityl-1 H-indazol-4-yloxy )benzamide The title compound was prepared by substituting EXAMPLE 55IB for EXAMPLE IE and EXAMPLE 493B for EXAMPLE IF in EXAMPLE IG. EXAMPLE 55 ID N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2- (lH-indazol-4-yloxy)benzamide -670- The title compound was prepared by substituting EXAMPLE 55IC for EXAMPLE 542E in EXAMPLE 542F. 'H NMR (400MHZ, dimethylsulfoxide-de) 6 13.13 (s, IH), 8.27 (d, IH), 7.85 (d, IH), 7.81 (s, IH), 7.57 (d, IH), 7.38 (d, 2H), 7.15 (d, 2H), 7.08 (m, 2H), 6.80 (dd, IH), 6.56 (d, IH), 6.14 (d, IH), 4.26 (s, IH), 4.25 (d, 2H), 4.15 (s, 2H), 3.20 (br s, 4H), 2.95 (v br s, 2H), 2.31 (br s, 4H), 1.98 (s, 2H), 1.77 (na, 3H), 1.58 (m, 2H), 1.39 (m, 2H), 1.22 (m, 2H), 1.20 (s, 6H), 1.10 (s, 3H). EXAMPLE 552 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(trans-4-hydioxy-4-methylcyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 525C for EXAMPLE 428D and in EXAMPLE 428E. ^H NMR (500 MHz, pyridine-ds) 6 9.30 (m, IH), 8.69 (t, IH), 8.59 (s, IH), 8.41 (dd, IH), 7.99 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.25 (t, IH), 7.18 (d, IH), 7.07 (d, 2H), 6.94 (d, IH), 6.72 - 6.68 (m, 2H), 5.85 (m, 3H), 3.22 (t, 2H), 3.02 (m, 4H), 2.76 (s, 2H), 2.25 (m, 2H), 2.13 (m, 4H), 1.97 (s, 2H), 1.92 - 1.85 (m, 4H), 1.78 - 1.71 (m, 3H), 1.43 - 1.36 (m, 5H), 1.33 - I.2I (m, 2H), 0.94 (s, 6H). EXAMPLE 553 N-({5-chIoro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1 -en-1 -yljmethyl }piperazin- I-yl)-2-( IH- indazol-4-yloxy)benzamide EXAMPLE 553A 2-chloro-5-methoxy-5-methylcyclohex-I-enecarbaldehyde N,N-dimethylformamide (1.298 mL) in dichloromethane (2.0 mL) at -10 °C was treated dropwise with POCI3 (1.426 mL). The mixture was stirred for 5 minutes and then warmed to room temperature and stirred 30 minutes. The solution was cooled to -10 °C, treated dropwise with a solution of 4-methoxy-4-methylcyclohexanone (1.74 g) in dichloromethane (2.5 mL) and stirred for 4 hours at ambient temperature. The reaction mixture was poured over a mixture of ice and 25% sodium acetate solution. When the ice had melted, the reaction mixture was poured into a s^aratory funnel and extracted with diethyl ether (4 x 125 mL). The diethyl ether extracts were washed with aqueous NaHCOs -671- solution and brine, dried (MgS04), filtered and concentrated. The concentrate was chromatographed on silica gel with 0 to 5% ethyl acetate in hexanes as the eluent. EXAMPLE 553B 2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1 -enecarbaldehyde EXAMPLE 553A (L55 g), 4-chlorophenylboionic acid (1.542 g), palladium(n) acetate (0.055 g), K2CO3 (2.84 g) and tetrabuylammonium bromide (2.65 g) were combined in a 50-mL round-bottomed flask equipped with a magnetic stir bar. Water (9.13 mL) was added. The vial was flushed with nitrogen, capped and stirred at 45 °C for 14 hours. The reaction mixture was cooled to room temperature and partitioned between brine and diethyl ether. The organic layer was washed with brine, dried (MgS04), filtered flirough a plug of diatomaceous earth, concentrated and chromatographed on silica gel with 5 to 20% ethyl acetate in hexanes as the eluent. EXAMPLE 553C methyl 2-(lH-indazol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-l- enyl)methyl)piperazin-1 -yl)benzoate The title compound was prepared by substituting EXAMPLE 553B for 4-chlorobiphenyl-2-carboxaldehyde and EXAMPLE 40(X;; for tert-butyl piperazine-1-carboxylate in EXAMPLE lA except that a small amount of dimethylsulfoxide was added to the reaction mixture to dissolve the reactants. EXAMPLE 553D methyl 4-(4-((2-(4-chloTophenyl)-5-methoxy-5-methylcyclohex-l-enyl)methyl)piperazin-l-yl)-2-(l-trityl-lH-indazol-4-yloxy)benzoate EXAMPLE 553C (L46 g) in dichloromethane (11.84 mL) was treated sequentially with trityl chloride (0.667 g) and triethylamine (0.990 mL) and stirred for 7 days at room temperature. The reaction mixture was concentrated and chromatographed on silica gel with 0 to 4% methanol in CH2CI2 as the eluent. EXAMPLE 553E 4-(4-((2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 - trityl-lH-indazol-4-yloxy)benzoic acid -672- The title compound was prepared by substituting EXAMPLE 553D for EXAMPLE 175D in EXAMPLE 175E. EXAMPLE 553F N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy)pyridin-3-yl}sulfonyl)-4-(4-((2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1 -enyl)methyl)piperazin-1 -y l)-2-( 1 -trityl- 1 H-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 553E for EXAMPLE IE and EXAMPLE 53IG for EXAMPLE IF in EXAMPLE IG. EXAMPLE 553G N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyTidin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-5-methoxy-5 -methylcyclohex-1 -en-1 -yljmethy 1 }piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 553F for EXAMPLE 542E in EXAMPLE 542F. 'H NMR (500 MHz, pyridine -dj) 5 14.62 (s, IH), 8.95 (d, IH), 8.39 (d, IH), 8.38 (d, IH), 8.06 (d, IH), 7.44 (m, 2H), 7.37 (d, IH), 7.14 (m, 3H), 6.86 (m, 2H), 6.50 (d, IH), 4.29 (d, 2H), 3.24 (s, 3H), 3.17 (t, 4H), 2.82 (m, 2H), 2.62 (d, IH), 2.52 (m, IH), 2.25 (m, 6H), 1.88 (m, 6H), 1.75 (m, 2H), 1.64 (m, IH), 1.41 (s, 3H), 1.32 (m, 2H), 1.24 (s,3H). EXAMPLE 554 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(5- chloro-6-{[l-(l,3-thiazol-2-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(lH-indazol- 4-yloxy)benzamide EXAMPLE 554A methyl 1 -(thiazol-2-yl)piperidine-4-carboxylate A mixture of methyl piperidine-4-carboxylate (2.045 g), 2-bromothiazoIe (1.64 g), and CS2CO3 (5.86 g) in N,N-dimethylformamide (15 mL) was heated at 100 °C overnight. After the mixture was cooled to room temperature, the reaction mixture was partitioned between water and ethyl acetate. The organic layer was separated, and the aqueous layer was extracted with additional ethyl acetate three times. The combined organic layers were washed -673- with brine, dried over MgS04, filtered, and concentrated. The residue was purified by flash chromatography on silica gel to give the title compound. EXAMPLE 554B (1 -(thiazol-2-yl)piperidin-4-yl)methanol The title compound was prepared by substituting EXAMPLE 554A for EXAMPLE 520A in EXAMPLE 520B. EXAMPLE 554C 5-chloro-6-((l-(thiazol-2-yl)piperidin-4-yl)methoxy)pyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 554B for (tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 387A for EXAMPLE 329A in EXAMPLE 329B. EXAMPLE 554D N-(5-chloio-6-((l-(thiazol-2-yl)piperidin-4-yl)methoxy)pyridin-3-ylsulfonyl)-4-(4-((2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -enyl)methyl)piperazin-1 -yl)-2-( 1 -trityl-1 H-indazol-4- yloxy)benzamide The title compound was prepared by substituting EXAMPLE 498C for EXAMPLE IE and EXAMPLE 554C for EXAMPLE IF in EXAMPLE IG. EXAMPLE 554E 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-N- [(5 - chloro-6-{[l-(l,3-thiazol-2-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(lH-indazol- 4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 554D for EXAMPLE 542E in EXAMPLE 545F. 'H NMR (500MHZ, dimethylsulfoxide-de) 8 13.17 (s, IH), 9.50 (s, IH), 8.32 (d, IH), 7.88 (d, IH), 7.83 (s, IH), 7.59 (d, IH), 7.40 (d, 2H), 7.18 (d, IH), 7.04-7.13 (m, 4H), 6.87 (d, IH), 6.84 (d, IH), 6.66 (d, IH), 6.14 (d, IH), 4.30 (d, 2H), 3.94-3.99 (m, 2H), 3.80-3.82 (m, 2H), 3.05-3.12 (m, 6H), 2.78 (br s, 2H), 2.25 (s, 2H), 2.04-2.12 (m 4H), 1.86-1.89 (m, 2H), 1.41-1.49 (m, 5H), 0.96 (s, 6H). -674- EXAMPLE 555 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- [(6-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino)-5-nitropyridin-3-yl)suIfonyl]-2-(lH- indazol-4-yloxy)benzamide EXAMPLE 555A tert-butyl(4-hydroxy-4-raethylcyclohexyl)methylcarbamate A solution of tert-butyl (4-oxocyclohexyl)methylcarbamate (LOO g) was dissolved in tetrahydrofuran (20 mL) and cooled to -78°C. Methylmagnesium bromide (4.40 mL) was added dropwise. The reaction was stirred for 2 hours at -78°C then allowed to warm to 0°C and stirred for 30 minutes. The resulting suspension was quenched with water (10 mL), diluted with ether (50 mL) and washed with ammonium chloride (25 mL) and brine (25 mL), dried over magnesium sulfate, filtered, and concentrated. Silica gel chromatography (Reveleris 80 g) eluting using a gradient of 5% to 50% ethyl acetate/dichloromethane over 30 minutes (flow = 60 ml/min) gave the title compound as a -2:1 mixture of cis and trans isomers. EXAMPLE 555B 4-(aminomethyl)-l-methylcyclohexanol trifluoroacetic acid salt To a solution of EXAMPLE 555A (0.75 g) in dichloromethane (3 mL) was added a few drops of water followed by trifluoroacetic acid (1.19 mL) and the reaction stirred at room temperature. After stirring for 2 hours, additional trifluoroacetic acid (0.5 mL) was added. After an additional 4 hours, the reaction mixture was concentrated and dried under high vacuum. The resulting oily solid was triturated with diethyl ether with sonication. Filtration and washing with diethyl ether gave the title compound as a mixture of cis and trans isomers.. EXAMPLE 555C 6-((cis-4-hydroxy-4-methylcyclohexyl)methylamino)-5-nitropyridine-3-sulfonamide The title compound was prepared by substituting EXAMPLE 545D for EXAMPLE 387A and EXAMPLE 555B for (4-fluorotetrahydro-2H-pyran-4-yl)methanamine in EXAMPLE 413A. Two isomers were isolated by reverse phase Gilson Prep HPLC system with a Phenomenex prep colunrn (Luna, 5 n, CI8(2), 250X21.20 mm, 5 A) eluting with 20-80% acetonitrile in water with 0.1% trifluoroacetic acid. -675- EXAMPLE 555D 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-l-yl)-N-(6- (((1 s,4s)-4-hydroxy-4-methylcyclohexyl)methylamino)-5-nitropyridin-3-ylsulfony l)-2-( 1- trityl- lH-indazol-4-yloxy )benzamide The title compound was prepared by substituting EXAMPLE 498C for EXAMPLE IE and EXAMPLE 555C for EXAMPLE IF in EXAMPLE IG. EXAMPLE 555E 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- [(6-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridin-3-yl)sulfonyl]-2-(lH- inda2oI-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 555D for EXAMPLE 542E in EXAMPLE 542F. 'H NMR (500MHZ, dimethylsulfoxide-d^) 8 13.04 (s, IH), 8.85 (s, IH), 8.48 (d, IH), 8.44 (d, IH), 7.79 (s, IH), 7.57 (d, IH), 7.36 (d, 2H), 6.96-7.07 (m, 4H), 6.80 (dd, IH), 6.54 (d, IH), 6.11 (dd, IH), 3.95 (s, IH), 3.48 (t, 2H), 3.19 (s, 4H), 2.87 (br s, 2H), 2.30-2.34 (m, 4H), 2.18 (m 2H), 1.97-1.99 (m, 2H), 1.35-1.55 (m, lOH), 1.20-1.26 (m, 4H), 1.08 (s, 3H), 0.94 (s, 6H). EXAMPLE 556 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N-( {6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl)sulfonyI)- 2-( 1 H-indazol-4-yloxy)benzamide EXAMPLE 556A 6-((trans-4-hydroxy-4-methylcyclohexyl)methoxy)-5-(trifluoromethyl)pyridine-3- sulfonamide This EXAMPLE was prepared by substituting EXAMPLE 493A for (tetrahydro-2H-pyran-4-yl)methanol and EXAMPLE 410E for EXAMPLE 329A in EXAMPLE 329B. The crude reaction products were purified by reverse phase Gilson Prep HPLC system with a Phenomenex prep column (Luna, 5 \i, CI8(2), 250X21.20 mm, 5 A) eluting with 20-80% acetonitrle in water with 0.1% trifluoroacetic acid to give the title compound. -676- EXAMPLE 556B The title compound was prepared by substituting EXAMPLE 498C for EXAMPLE IE and EXAMPLE 556A for EXAMPLE IF in EXAMPLE IG. EXAMPLE 556C 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-N-( {6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)- 2-( 1 H-indazol-4-yloxy)benzamide The title compound was prepared by substituting EXAMPLE 556B for EXAMPLE 542E in EXAMPLE 542F. ^H NMR (500MHz, dimethylsulfoxide-dg) 8 13.06 (s, IH), 8.49 (s, IH), 8.13 (d, IH), 7.77 (s, IH), 7.61 (d, IH), 7.37 (d, 2H), 7.01-7.08 (m, 4H), 6.78 (dd, IH), 6.51 (s, IH), 6.12 (dd, IH), 4.26-4.30 (m, 3H), 3.18 (s, 4H), 2.91 (br s, 2H), 2.31-2.35 (m, 2H), 2.16-2.18 (m 2H), 1.97-1.99 (m, 2H), 1.68-1.75 (m, 4H), 1.55-1.58 (m, 2H), 1.26 (m, 2H), 1.10 (s, 3H), 0.94 (s, 6H). EXAMPLE 557 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-N-[(4-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide The title compound was prepared by substituting EXAMPLE 525D for EXAMPLE 428D in EXAMPLE 428E. 'H NMR (500MHz, pyridine-ds) 6 9.29 (d, IH), 8.58 (s, IH), 8.40 (dd, IH), 8.00 (d, IH), 7.53 (d, IH), 7.43 (d, 2H), 7.25 (m, 2H), 7.18 (d, IH), 7.07 (d, 2H), 6.91 (d, IH), 6.73-6.68 (m, 2H), 3.21 (t, 2H), 3.02 (m, 4H), 2.76 (s, 2H), 2.25 (m, 2H), 2.13 (m, 4H), 1.97 (s, 2H), 1.90-1.79 (m, 4H), 1.70-1.60 (m, 3H), 1.45-1.30 (m, 8H), 0.94 (s, 6H). EXAMPLE 558 N-(4-{ [4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin-1 -yl)-2- (1 H-indazol-4-yloxy)benzoy] Jsulfamoyl} -2-nitrophenyl)-4-cyanopiperidine-1 -carboxamide EXAMPLE 558A 4-cyanopiperidine-1-carboxamide A round-bottom flask containing phosgene (20%wt in toluene, 3.16 mL) and dichloromethane (10 mL) was cooled with an ice bath. A solution of N-ethyl-N- -677- isopropylpropan-2-amine (1.393 mL) and piperidine-4-carbonitrile (0.441 g) in dichloromethane (5 mL) was added via a syringe dropwise. The mixture was stirred at room temperature overnight and then concentrated to dryness. The residue was dissolved in methanol (10 mL) and 2 mL of 7 N NH3 in methanol. The mixture was stirred at 50 °C overnight. The mixture was concentrated and the residual solid was mixed with brine (5 mL) and extracted with ethyl acetate (8x 25 mL). The organic solution was dried (MgS04), filtered and concentrated. The crude material was purified on a silica gel column eluting with 5-10% methanol in CH2CI2. EXAMPLE 558B 4-cyano-N-(2-nitro-4-sulfamoylphenyl)piperidine-1 -carboxamide The title compound was prepared by substituting EXAMPLE 558A for (tetrahydro-2H-pyran-4-yl)methanol in EXAMPLE 279A. EXAMPLE 558C N-(4-(N-(2-(lH-indazol-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-enyl)methyl)piperazin-1 -yl)benzoyl)sulfamoyl)-2-nitrDphenyl)-4-cyanopiperidine-1 - carboxamide The title compound was prepared by substituting EXAMPLE 400E for EXAMPLE 26C and EXAMPLE 558B for EXAMPLE IF in EXAMPLE 177. 'H NMR (500MHZ, pyridine-ds) 6 14.58 (bs, IH), 10.43 (s, IH), 9.05 (d, IH), 8.56 (d, IH), 8.36 (s, IH), 8.16 (d, IH), 8.10 (d, IH), 7.45 (d, 2H), 7.35 (d, IH), 7.14 (d, IH), 7.11 (d, 2H), 6.85 (m, 2H), 6.49 (d, IH), 3.79 (m, 2H), 3.46 (m, 2H), 3.16 (m, 4H), 2.98 (m, IH), 2.82 (s, 2H), 2.30 (t, 2H), 2.24 (m, 4H), 1.99 (s, 2H), 1.85 (m, 2H), 1.79 (m, 2H), 1.41 (t, 2H), 0.96 (s, 6H). -678- WHAT IS CLAIMED IS: 1. A compound having formula I O Q O E^ (I), or a therapeutically acceptable salt, prodrug or salt of prodrug thereof, A' is N or C(A^); one or two or three or each of A^, B*, D' and E* are independently selected R', OR', SR\ S(0)R\ SOIR', C(0)R', C(0)0R\ 0C(0)R', NHR', N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R', NHC(0)0R\ NR'C(0)NHR', NR'C(0)N(R')2, SO2NHR', S02N(R')2, NHSO2R', NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independently selected H, F, CI, Br, I, CN, CF3, C(0)OH, C(0)NH2 or CCOOR'"^; and Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R", OR'^ C(0)R", C(0)0R", SR", NH2, NHR", N(R")2, NHC(0)R", C(0)NH2, C(0)NHR", C(0)N(R")2, NHS(0)R" or NHSO2R''; or B' and Y\ together with the atoms to which they are attached, are imidazole or triazole; and one or two or each of A^ D' and E' are independently selected R\ OR', SR', S(0)R\ S02R\ C(0)R', C(0)0R\ 0C(0)R', NHR\ N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R', NHC(0)0R\ NHC(0)NHR', N(CH3)C(0)N(CH3)R', SO2NHR', S02N(R')2, NHS02R\ NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independenUy selected H, F, CI, Br, I, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; R'isR^R^R''o^R^ R''^ is Ci-Ce-alkyl, C3-C6-alkenyl or Cs-Ce-alkynyl; R^ is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^^ is cycloalkane or heterocycloalkane; R^ is heteroaryl which is unfused or fused with benzene, heteroarene or R^^; R^'^ is cycloalkane or heterocycloalkane; -679- R'' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heteixKycloalkenyl, each of which is unfused or fused with arene, heteroarene or R'*^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^ NC(R*^)(R^^), R\ OR^ SR\ S(0)R^ SOaR^ NHR^ N(R^)2, C(0)R^ C(0)NH2, C(0)NHR^ NHC(0)R^ NHSOzR^ NHC(0)0R\ SO2NH2, S02NHR^ S02N(R^)2, NHC(0)NH2, NHC(0)NHR^ NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR' , OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R* is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R^ and R^^ are independendy selected alkyl or, together with the N to which diey are attached, R^; R*^ is aziridin-1-yl, azetidin-1-yl, pyrrolidin-l-yl or piperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R^isR*,R',R"'orR"; R* is phenyl which is unfused or fused with arene, heteroarene or R*^; R*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl which is unfused or fused with arene, heteroarene or R'^; R'"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is C3-C]o-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R*""^; R'""^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R'^ OR'^, NHR'\ N(R'^)2, C(0)NH2, C(0)NHR'^ C(0)N(R'^)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R'^isR",R".R"orR"'; R" is phenyl which is unfused or fused with arene, heteroarene or R""^; R"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is heteroaryl, each of which is unfused or fused with arene, heteroarene or R''*'^; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -680- R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with arene, heteroarene or R''"^; R'^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'* is alkyl, alkenyl or alkynyl; R'^isR^R",R^orR^'; R'* is phenyl which is unfused or fused with arene, heteroarene or R'*^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is heteroaiyl which is unfused or fused with arene, heteroarene or R''^; R"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^" is Cs-Cio-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is 00 A 01^ A unfused or fused with arene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^\ 0R^\ NHR^^ N(R^\, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^^isR^,R^orR"; R^^ is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'* is heteroarene which is unfused or fused with arene, heteroarene or R^'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is Cs-Ce-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected 0, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^^*^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; Z' is R^* or R", each of which is substituted with R^, R^' or R^°, each of which is substituted with F, CI, Br, I, CH2R^^ CH(R^')(R"), C(R^')(R^'^)(R"), C(0)R", OR", SR", S(0)R", SO2R", NHR" or N(R")R"; R^* is phenyl which is unfused or fused with arene or heteroarene; R is heteroarene which is unfused or fused with arene or heteroarene; R^ is phenyl which is unfused or fiised with arene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -681- R^^ is heteroaryl or R^''"'; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^" is cycloalkyl or cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroaiene or R^"^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' and R^"^ are independently F, CI, Br or aDcyl or are taken together and are Ci-Cs-spiroalkyl; R^^ is R^^ C(0)R^^ or C(0)0R"; R^^isR^orR^^ R^"* is phenyl which is unfused or fused with aryl, heteroaryl or R^"*"^; R^'^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl which is unsubstituted or substituted with R^^; R^* is phenyl which is unfused or fused with arene, heteroarene or R^^^; R^*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is R^\ R^' or R'", each of which is substituted with F, CI, Br, I, R"", OR"', NHR"', N(R'*')2, NHC(0)OR'", SR*\ S(0)R'" or SOZR"'; R^* is phenyl which is unfused or fused with arene, heteroarene or R^^; R^*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl which is unfused or fused with arene, heteroarene or R^'^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'"' is Cs-Cg-cycloalkyl or C4-Cg-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R""'^; R'*"'^ cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"^sR"^R"^R^orR*^ R"^ is phenyl which is unfused or fused with arene, heteroarene or R''^^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"^ is heteroaryl which is unfijsed or fused with arene, heteroarene or R''^^; R"*^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R is Ca-Cg-cycloalkyl or C4-C7-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced witii independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 -682- or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'"'^; R"^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two independently selected R^^, OR^, NHR''^ N(R^)2, C(0)NH2, CCONHR^^, C(0)N(R'^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^isR^R^orR^'; R"*^ is phenyl which is unfused or fused with arene, heteroarene or R"^'^; R''^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"* is heteroaryl or R''*^; R''*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"' is Ca-Ce-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independenUy selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'"'^; R'*''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein the moieties represented by R^ and R^' are further substituted by one or two or three of independently selected R^^, OR^""^, SR*^, S(0)R^°'^, SOzR^"'^ or NHR^"^; R^°^isR^'^R''^R^2^orR^'*^ R*'"^ is phenyl which is unfused or fused with benzene, heteroarene or R^''^, wherein R^'*^^ is cycloalkane, cycloalkene or heterocycloalkane heterocycloalkene, R^^ is heteroaryl; R^^'^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl; each having one or two CH2 moieties unreplaced or replaced with independently selected 0, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^^'^; wherein R^^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^*'^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R^^^, OR"'^, SR^^'^, S(0)R^^^, S02R"'^, NHR^'^, N(R"'^)2, C(0)R^^^, C(0)NH2, C(0)NHR^'^, NHC(0)R^^'^, NHS02R^^'^, NHC(0)OR^^'^, SO2NH2, SOZNHR^^^, S02N(R"^)2, NHC(0)NH2, NHC(0)NHR"'^, OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R*''^ is alkyl, alkenyl, alkynyl, phenyl or heteroaryl, or R^*'^; -683- R^^'^ is Cs-Ce-cycloalkyl or C4-C6-cycloalkyl, each having one or two CH2 moieties unreplaced or replaced with independenUy selected O, C(0), CMOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N; wherein moieties represented byRRR,R,R ,R,R R,R ,R ,R ,R , pl8 pl9 p20 p23 p24 p25 p26 p27 p28 p29 p30 „34 „36 „38 „39 ^40 42 „43 K ,K ,K ,K ,K , K. ,K , IS. ,K. ,r\. ,I\. ,R , K. ,K. ,K ,I\. ,1s. , K. , R^.R^^R^. andR^^ are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five independently selected R^°^^, R^", 0R^°, SR^°, S(0)R^°, SO2R''', C(0)R^^ CO(0)R^°, 0C(0)R^'', 0C(0)0R'°, NH2, NHR^^ N(R'°)2, C(0)NH2, C(0)NHR^°, C(0)N(R^)2, C(0)NH0H, C(0)NH0R^'', C(0)NHS02R^°, CCONR^^SOzR^", SO2NH2, S02NHR'°, S02N(R^'')2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^°, C(N)N(R^°)2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R^"'^ is spirocyclyl; R^%sR'\R",R^^orR'''; R'' is phenyl which is unfused or fused with arene, heteroarene or R^'^; R"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R*^ is heteroaryl; R^^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R ; wherein R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^* is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R'^ OR^', SR^^ S(0)R", S02R^^ NHR^^ N(R^\, C(0)R", C(0)NH2, C(0)NHR^', NHC(0)R^^ NHSO2R", NHC(0)0R", SO2NH2, S02NHR^^ S02N(R^^)2, NHC(0)NH2, NHC(0)NHR", OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl or R*^; wherein the alkyl, alkenyl, alkynyl are unsubstitated or substituted with OCH3; and R^^ is Cs-Cg-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N. -684- 2. A compound having formula 11 v (R'°°)n 1^ _ r R" (n), or a therapeutically acceptable salt, prodrug or salt of prodrug thereof, wherein R'**" is as described for substituents on R^^; n is 0,1,2, or 3; A' is N or C(A^); one or two or three or each of A^, B\ D' and E' are independently selected R', 0R\ SR\ S(0)R', SOZR', C(0)R\ C(0)0R', 0C(0)R\ NHR', N(R')2. C(0)NHR', C(0)N(R')2, NHC(0)R', NHC(0)0R\ NR'C(0)NHR\ NR^C(0)N(R^)2, SO2NHR', S02N(R')2, NHSO2R', NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independenUy selected H, F, CI, Br, I, CN, CF3, C(0)OH, C(0)NH2 or CCOOR'"^; and Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R", OR", C(0)R'^ C(0)0R", SR", NH2, NHR", N(R")2, NHC(0)R", C(0)NH2, C(0)NHR'\ C(0)N(R''')2, NHS(0)R" or NHSO2R"; or B' and Y\ together with the atoms to which they are attached, are imidazole or triazole; and one or two or each of A^, D' and E' are independently selected R\ 0R\ SR\ S(0)R\ SO2R', C(0)R\ C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R\ NHC(0)0R\ NHC(0)NHR\ N(CH3)C(0)N(CH3)R\ SOZNHR', S02N(R')2, NHS02R\ NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independently selected H, F, CI, Br, I, CF3, C(0)OH, C(0)NH2 or C(0)0R'^; -685- R'isR^R^R''orR^; R''^ is Ci-Ce-alkyl, Cs-Ce-alkenyl or Cs-Ce-alkynyl; R^ is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^'^ is cycloalkane or heterocycloalkane; R^ is heteroaryl which is unfused or fused with benzene, heteroarene or R^'^; R^'^ is cycloalkane or heterocycloalkane; R"* is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with arene, heteroarene or R"*^; R''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^ NC(R^)(R^^), R^ OR^ SR\ S(0)R', SOJR^ NHR^ N(R^)2, C(0)R^ C(0)NH2, C(0)NHR^ NHC(0)R^ NHSOiR^ NHC(0)0R\ SO2NH2, S02NHR^ S02N(R^)2, NHC(0)NH2, NHC(0)NHR^ NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR\ OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^ is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R^^ and R^^ are independently selected alkyl or, together with the N to which they are attached, R*^; R^ is aziridin-l-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidin-l-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R^isR*,R',R'%rR"; R* is phenyl which is unfused or fused with arene, heteroarene or R*'^; R*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl which is unfused or fused with arene, heteroarene or R'^; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is C3-Cio-cycloalkyl or C4-C]o-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'"^; R'"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R'^ 0R'^ NHR'^ N(R'^)2, C(0)NH2, C(0)NHR'^ C(0)N(R'^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; -686- R'^isR",R'^R''orR'^ R" is phenyl which is unfused or fused with aiene, heteroarene or R"'^; R""^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'* is heteroaryl, each of which is unfused or fused with arene, heteroarene or R''*^; R'"*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with arene, heteroarene or R'^'^; R'^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is alkyl, alkenyl or alkynyl; R'^isR'«,R'',R^orR^'; R'* is phenyl which is unfused or fiised with arene, heteroarene or R'*'^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'' is heteroaryl which is unfused or fiosed with arene, heteroarene or R"^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^" is C3-C]o-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^"'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^^ 0R^^ NHR^^ N(R")2, C(0)NH2, C(0)NHR", C(0)N(R^^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^^isR^,R^%rR^^ R^^ is phenyl which is unfused or fused with arene, heteroarene or R^"^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroarene which is unfused or fused with arene, heteroarene or R^*"^; R^*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^^"^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^" is cycloalkyl or cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and -687- one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^"^; R^*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is substituted with F, CI, Br, I, CH2R", CH(R^')(R^^), C(R^')(R^"^)(R^^), C(0)R^^ OR", SR", S(0)R", SOZR", NHR" or N(R^^)R"; R^' and R^'^ are independently F, CI, Br or alkyl or are taken together and are Ci-Cs-spiroalkyl; R^^ is R^\ C(0)R^^ or C(0)OR^^ R^isR^orR"; R^'' is phenyl which is unfused or fused with aryl, heteroaryl or R^'*'^; R^"*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl which is unsubstituted or substituted with R^; R^^ is phenyl which is unfused or fused with arene, heteroarene or R^^'^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is R^, R^' or R"^, each of which is substituted with F, CI, Br, I, R''\ 0R'*\ NHR"", NCR''*)!, NHC(0)OR''', SR"*', S(0)R^* or SO2R'''; R^* is phenyl which is unfused or fused with arene, heteroarene or R^*"^; R^*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl which is unfused or fused with arene, heteroarene or R^'^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'"' is Cs-Cg-cycloalkyl or C4-C8-cycloaIkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'*"'^; R**^ cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^•isR^^R^^R^orR^^; R''^ is phenyl which is unfused or fused with arene, heteroarene or R''^'^; R''^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"^ is heteroaryl which is unfused or fused with arene, heteroarene or R'*^'^; R''^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"^ is Ca-Cg-cycloalkyl or C4-C7-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected 0, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'*^'^; R**"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -688- • R''^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two independently selected R"*, OR^, NHR^^ N(R%, C(0)NH2, CCONHR'^, C(0)N(R'*)2, OH, (O), C(0)0H, N3, CN, NH2, CF3. CF2CF3, F, CI, Br or I substituents; R^isR^\R^orR^'; R*^ is phenyl which is unfused or fused with arene, heteroarene or R"^"^; R"*^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'** is heteroaryl or R'**^; R"*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*' is C3-C6-cycloaIkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'"'^; R''^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein moieties represented byRRR,R,R ,R,R R,R ,R ,R ,R , „18 „19 „20 „23 „24 „25 „26 p27 „28 „29 p30 „34 p36 p38 „39 „40 „42 „43 44 47 4S 49 R , R , R , and R are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five independently selected R^°'^, R^, Qj^so 51^50 S(0)R'°, S02R^°, C(0)R'°, C0(0)R^°, 0C(0)R^^ 0C(0)0R^, NH2, NHR^", N(R^'')2, C(0)NH2, C(0)NHR^°, C(0)N(R^)2, C(0)NHOH, C(0)NHOR^°, C(0)NHS02R^'', C(0)NR^°S02R^", SO2NH2, S02NHR^'', S02N(R"')2, CF3, CF2CF3, C(0)H, C{0)OH, C(N)NH2, C(N)NHR*'', C(N)N(R^'')2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R^°^ is spirocyclyl; R*''isR5>,R",R^'orR5^ R^' is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroaryl; R^' is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected 0, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfiised or fused with arene, heteroarene or R*^"; wherein R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -689- R^'* is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R*^ OR", SR", S(0)R^^ S02R'^ NHR", N(R^^)2, C(0)R^^ C(0)NH2, C(0)NHR^^ NHC(0)R^^ NHSO2R", NHC(0)0R^^ SO2NH2, S02NHR*^ S02N(R*^)2, NHC(0)NH2, NHC(0)NHR^^ OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl or R^*; wherein the alkyl, alkenyl, alkynyl are unsubstituted or substituted with OCHs; and R^* is C3-C8-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independenUy selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N. 3. A compound having formula III Y' (ni), or a therapeutically acceptable salt, prodrug or salt of prodrug thereof, wherein R'"" is as described for substituents on R^^; nisO, 1,2, or 3; A' is N or C(A^); one or two or three or each of A^, B', D' and E^ are independently selected R', OR', SR\ S(0)R\ S02R\ C(0)R\ C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR\ C(0)N(R^)2, NHC(0)R\ NHC(0)0R\ NR'C(0)NHR', NR'C(0)N(R')2, SO2NHR', S02N(R')2, -690- NHSOZR', NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independently selected H, F, CI, Br, I, CN, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; and Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R'\ 0R'\ C(0)R", C(0)0R'^ SR*^ NH2, NHR^^ N(R")2, NHC(0)R", C(0)NH2, C(0)NHR", C(0)N(R'')2, NHS(0)R" or NHS02R'^ or B' and Y', together with the atoms to which they are attached, are imidazole or triazole; and one or two or each of A^, D' and E' are independently selected R\ OR', SR', S(0)R\ SO2R', C(0)R', C(0)0R\ 0C(0)R\ NHR', N(R')2, C(0)NHR\ C(0)N(R^)2, NHC(0)R\ NHC(0)0R\ NHC(0)NHR\ N(CH3)C(0)N(CH3)R\ S02NHR\ S02N(R')2, NHS02R\ NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independently selected H, F, Cl, Br, I, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; R'isR^R^R''orR^; R''^ is Ci-Ce-alkyl, Cs-Ce-alkenyl or Cs-Ce-alkynyl; R^ is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^'^ is cycloalkane or heterocycloalkane; R^ is heteroaryl which is unfused or fused with benzene, heteroarene or R^'^; R^'^ is cycloalkane or heterocycloalkane; R* is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with arene, heteroarene or R'*'^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R*, NC(R^)(R*^), R^ 0R\ SR^ S(0)R\ S02R\ NHR^ N(R^)2, C(0)R\ C(0)NH2, C(0)NHR^ NHC(0)R^ NHS02R^ NHC(0)0R\ SO2NH2, S02NHR^ S02N(R')2, NHC(0)NH2, NHC(0)NHR^ NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR\ OH, (0), C(0)OH, (O), N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I substituents; R^ is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, Cl, Br, I, NH2, NH(CH3) or N(CH3)2; R*'^ and R^^ are independently selected alkyl or, together with the N to which they are attached, R^; R*^ is aziridin-1-yl, azetidin-l-yl, pyrrolidin-l-yl or piperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; -691- R^sR^R^R'%rR"; R* is phenyl which is unfiised or fused with arene, heteroarene or R*'^; R*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl which is unfused or fused with arene, heteroarene or R''^; R''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'** is Cs-Cio-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties umeplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties umeplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'"'^; R'""^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R'^ 0R'^ NHR'^ N(R'^)2, C(0)NH2, C(0)lSfHR'^ C(0)N(R'^)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R•^isR",R'^R'^orR'^ R" is phenyl which is unfused or fused with arene, heteroarene or R"'^; R"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''' is heteroaryl, each of which is unfused or fused with arene, heteroarene or R''*'^; R'"*"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'* is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with arene, heteroarene or R^^"^; R*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'* is alkyl, alkenyl or alkynyl; R'^sR^R^R^orR^'; R'* is phenyl which is unfused or fused with arene, heteroarene or R'*'^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is heteroaryl which is unfused or fiised with arene, heteroarene or R"'*; R"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^" is Cs-Cio-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties umeplaced or replaced with N, and each of which is unfused or fiised with arene, heteroarene or R^"^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -692- R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^^ 0R^^ NHR^^ N(R^^)2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^^isR^,R^%rR"; R^^ is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^" is heteroarene which is unfused or fused with arene, heteroarene or R^'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^" is cycloalkyl or cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independendy selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^"^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is substituted with F, CI, Br, I, CH2R^', CH(R^')(R"), C(R^')(R^'^)(R^'), C(0)R^^ OR", SR", S(0)R", SO2R", NHR" or N(R^^)R"; R^' and R^'^ are independently F, CI, Br or alkyl or are taken together and are C2-C5-spiroalkyl; R^^ is R^^ C(0)R^^ or C(0)0R"; R"isR**orR^^ R^"* is phenyl which is unfused or fused with aryl, heteroaryl or R^^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl which is unsubstituted or substituted with R^; R^* is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is R^, R^' or R"", each of which is substituted with F, CI, Br, I, R'", OR'*', NHR"', N(R'*')2, NHC(0)0R'", SR"', S(0)R'" or SO2R'*'; R^* is phenyl which is unfused or fused with arene, heteroarene or R^*'^; R^*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl which is unfused or fused with arene, heteroarene or R^'^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -693- R^ is Ca-Cg-cycloalkyl or C4-C8-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'"'^; R'*"'^ cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R*^sR^^R^^R^orR^^ R''^ is phenyl which is unfused or fused with arene, heteroarene or R'*^'^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*^ is heteroaryl which is unfused or fused with arene, heteroarene or R'*^^; R'*^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"^ is Cs-Cg-cycloalkyl or C4-C7-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R"*^^; R'**^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two independenUy selected R'*^, OR"^, NHR'*^ N(R'^)2, C(0)NH2, C(0)NHR'^, C(0)N(R'^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^isR^^R^orR^'; R"*^ is phenyl which is unfused or fused with arene, heteroarene or R'*^'^; R''^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"** is heteroaryl or R"*"^; R''*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'*' is Cs-Ce-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independenUy selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R*'^; R"""^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein moieties represented by R^ R^ R^*, R^, R^, R^ R^^ R^, R'°, R'^ R^"*, R'^ „18 „19 „20 „23 „24 „25 p26 „27 „28 „29 „30 p34 „36 „38 „39 p40 n42 „43 1\ , t\. ,R ,K ,R , K. ,K ,K ,K ,K ,K ,K ,K ,K ,K ,K ,K ,K , 44 47 48 49 R , R , R , and R are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or diree or four or five independenfly selected R^""^, R^", 0R^°, SR^°, S(0)R^°, SOzR^", C(0)R^°, C0(0)R^'', 0C(0)R'°, 0C(0)0R^'', NH2, NHR^", -694- NCR^")!, G(0)NH2, C(0)NHR^'', C(0)N(R^)2, C(0)NHOH, CCONHOR^", C(0)NHS02R^'', C(0)NR^°S02R^°, SO2NH2, SO2NHR''", S02N(R^'')2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^°, C(N)N(R'*')2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R^°'^ is spiiocyclyl; R^°isR^',R",R^^orR^^ R^' is phenyl which is unfused or ftised with arene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroaiyl; R^^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^^^; wherein R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'* is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R'^ 0R'^ SR^^ S(0)R", S02R^^ NHR'^ N(R^^)2, C(0)R^', C(0)NH2, C(0)NHR^^ NHC(0)R^^ NHS02R^^ NHC(0)0R'^ SO2NH2, S02NHR^^ S02N(R^^)2, NHC(0)NH2, NHC(0)NHR^^ OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl or R*^; wherein the alkyl, alkenyl, alkynyl are unsubstituted or substituted with OCH3; and R^* is Cs-Cg-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected 0, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N. -695- 4. . A compound having formula IV Y' r (IV), or a therapeutically acceptable salt, prodrug or salt of prodrug thereof, wherein R'*'*' is as described for substituents on R^^; nisO, 1, 2, or 3; A' is N or C(A^); one or two or three or each of A^, B', D' and E' are independently selected R', 0R\ SR\ S(0)R\ S02R\ C(0)R\ C(0)0R', 0C(0)R', NHR', N(R')2, C(0)NHR', C(0)N(R')2, NHC(0)R\ NHC(0)0R\ NR'C(0)NHR', NR^C(0)N(R')2, SO2NHR', S02N(R>)2, NHS02R*, NHSO2NHR' or N(CH3)S02N(CH3)R\ and the remainder are independently selected H, F, CI, Br, I, CN, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; and Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R", OR", C(0)R", C(0)0R'^ SR", NH2, NHR'^ N(R")2, NHC(0)R", C(0)NH2, C(0)NHR", C(0)N(R'^)2, NHS(0)R" or NHSO2R"; or B' and Y\ together with the atoms to which they are attached, are imidazole or triazole; and one or two or each of A^, D' and E' are independently selected R\ OR', SR', S(0)R\ SO2R', C(0)R', C(0)0R\ 0C(0)R\ NHR', N(R')2, C(0)NHR\ C(0)N(R')2, NHC(0)R', NHC(0)0R\ NHC(0)NHR\ N(CH3)C(0)N(CH3)R\ S02NHR\ S02N(R')2, NHSO2R', NHSO2NHR' or N(CH3)S02N(CH3)R\ and the remainder are independenUy selected H, F, CI, Br, I, CF3, C(0)OH, C(0)NH2 or C(0)0R'^; -696- R'is R^ R\ R" or R^ R''^ is Ci-C6-alkyl, Cs-Ce-alkenyl or Cs-Ce-alkynyl; R^ is phenyl which is unftised or fused with arene, heteroarene or R^'^; R^^ is cycloalkane or heterocycloalkane; R^ is heteroaryl which is unfused or fused with benzene, heteroarene or R^*^; R^'^ is cycloalkane or heterocycloalkane; R'' is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with arene, heteroarene or R"*^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^ NC(R^)(R^^), R\ OR^ SR\ S(0)R^ S02R\ NHR^ N(R')2, C(0)R^ C(0)NH2, C(0)NHR^ NHC(0)R\ NHSOaR^ NHC(0)0R^ SO2NH2, S02NHR^ S02N(R')2, NHC(0)NH2, NHC(0)NHR^ NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR\ OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R* is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R** and R*^ are independently selected alkyl or, together with the N to which they are attached, R*^; R**^ is aziridin-l-yl, azetidin-1-yl, pynolidin-1-yl orpiperidin-l-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; R^isR*,R',R'''orR"; R* is phenyl which is unfused or fused with arene, heteroarene or R*^; R*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl which is unfused or fused with arene, heteroarene or R'^; R''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is C3-C]o-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'""^; R'°^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R'^ 0R'^ NHR'^ N(R'^)2, C(0)NH2, C(0)NHR'\ C(0)N(R'^)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; -697- R'^isR",R'^R"orR'^ R" is phenyl which is unfused or fused with arene, heteroarene or R"'^; R"* is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''* is heteroaiyl, each of which is unfused or fused with arene, heteroarene or R*""^; R^''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with arene, heteroarene or R'^^; R'^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'* is alkyl, alkenyl or alkynyl; R"isR'«,R",R^%rR^'; R'* is phenyl which is unfused or fused with arene, heteroarene or R'*"^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'' is heteroaryl which is unfused or fused with arene, heteroarene or R''^; R'''^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^" is Cs-Cio-cycloalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independendy selected R^^ 0R^^ NHR^^ N(R")2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^^isR^,R^orR^^ R^^ is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroarene which is unfused or fused with arene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^^^; R^"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R is cycloalkyl or cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and -698- one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^"^; R'°^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is substituted with F, CI, Br, I, CH2R", CH(R^')(R"), C(R^')(R^''^)(R"), C(0)R^\ OR", SR", S(0)R", SO2R", NHR" or N(R")R"; R^' and R^''^ are independently F, CI, Br or alkyl or are taken together and are Cz-Cs-spiroalkyl; R^^ is R^^ C(0)R^^ or C(0)OR^^; R^isR'^orR^^ R^'' is phenyl which is unfused or fused with aryl, heteroaryl or R^"'^; R^'*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is alkyl which is unsubstituted or substituted with R^; R^^ is phenyl which is unfused or fused with arene, heteroarene or R^^"^; R^^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is R^, R^' or R'^, each of which is substituted with F, CI, Br, I, R'", OR"", NHR"*', N(R^')2, NHC(0)OR'", SR'*', S(0)R'" or SO2R'"; R^* is phenyl which is unfused or fiised with arene, heteroarene or R^"^; R^*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl which is unfused or ftised with arene, heteroarene or R^''^; R^'"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R""* is Cj-Cg-cycloalkyl or C4-C8-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'*"'^; R**^ cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'isR^^R^^R^orR^^ R''^ is phenyl which is unfused or fused with arene, heteroarene or R'*^'^; R"^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"*^ is heteroaryl which is unfused or fused with arene, heteroarene or R"*^^; R'*^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"*^ is Cs-Cg-cycloalkyl or C4-C7-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R''^'^; R**'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -699- R'*^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two independently selected R^^, OR"^, NHR''^ N(R^)2, C(0)NH2, C(0)NHR'^, C(0)N(R'^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^isR^U'^orR^'; R'*^ is phenyl which is unfused or fused with arene, heteroarene or R'*''^; R''^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'** is heteroaryl or R'**'^; R'**'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected 0, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'*''^; R''^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein moieties represented byRRR,R,R ,R,R R,R ,R ,R ,R , „18 „19 p20 „23 „24 „25 p26 „27 „28 „29 „30 „34 „36 „38 ^39 „40 42 „43 K. ,1s. ,K ,xs ,ts ,1V ,lv ,ix ,lv ,l\ ,l\ ,lx ,Jx ,lx ,l\. ,1\. ,lv ,1\. , 44 47 48 49 R , R , R , and R are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five independently selected R^"'^, R^", OR^", SR^", S(0)R^'', SOzR^", C(0)R^°, CO(0)R^°, OC(0)R^", 0C(0)0R^, NHj, NHR^°, N(R'°)2, C(0)NH2, C(0)NHR^°, C(0)N(R^)2, C(0)NH0H, C(0)NH0R^°, C(0)NHS02R^'', C(0)NR^°S02R^'', SO2NH2, S02NHR^'', S02N(R^°)2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^°, C(N)N(R^'')2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R^"'^ is spirocyclyl; R^^sR^^R5^R^^orR^^ R^' is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is heteroaryl; R^^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'^^; wherein R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -700- R^* is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R'^ 0R^^ SR^^ S(0)R^^ S02R'^ NHR^', N(R^^)2, C(0)R", C(0)NH2, C(0)NHR^^ NHC(0)R^^ NHS02R^^ NHC(0)0R^^ SO2NH2, S02NHR^^ S02N(R^^)2, NHC(0)NH2, NHC(0)NHR*^ OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI, Br or I substituents; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl or R^^; wherein the alkyl, alkenyl, alkynyl are unsubstituted or substituted with OCH3; and R^* is Cs-Cg-cycloaUcyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N. 5. A compound having formula V (R'~)n. JL O / r (V), or a therapeutically acceptable salt, prodrug or salt of prodrug thereof, wherein R'"" is as described for substituents on R^*; n is 0, 1, 2, or 3; A' is N or C(A^); one or two or three or each of A^, B\ D' and E' are independently selected R', 0R\ SR\ S(0)R', SO2R', C(0)R\ C(0)0R', 0C(0)R', NHR\ N(R')2, C(0)NHR', C(0)N(R>)2, NHC(0)R', NHC(0)0R', NR'C(0)NHR', NR'C(0)N(R')2, S02NHR\ S02N(R')2, -701- NHS02R\ NHSO2NHR' or N(CH3)S02N(CH3)R\ and the remainder are independently selected H, F, CI, Br, I, CN, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; and Y' is H, CN, NO2, C(0)OH, F, CI, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R'^ 0R'\ C(0)R", C(0)0R'\ SR'^ NH2, NHR", N(R'^)2, NHC(0)R", C(0)NH2, C(0)NHR", C(0)N(R")2, NHS(0)R" or NHSO2R"; or B' and Y', together with the atoms to which they are attached, are imidazole or triazole; and one or two or each of A^ D' and E' are independently selected R\ 0R\ SR', S(0)R\ SO2R', C(0)R', C(0)0R\ 0C(0)R\ NHR\ N(R')2, C(0)NHR\ C(0)N(R^)2, NHC(0)R\ NHC(0)0R', NHC(0)NHR\ N(CH3)C(0)N(CH3)R\ SO2NHR', S02N(R')2, NHSO2R', NHSO2NHR' or N(CH3)S02N(CH3)R', and the remainder are independently selected H, F, CI, Br, I, CF3, C(0)OH, C(0)NH2 or C(0)0R''^; R' is R^ R^ R" or R^ R'^ is Ci-C6-alkyl, C3-C6-alkenyl or C3-C6-alkynyl; R^ is phenyl which is unfused or fused with arene, heteroarene or R^; R^'^ is cycloalkane or heterocycloalkane; R^ is heteroaryl which is unfused or fused with benzene, heteroarene or R^^; R^^ is cycloalkane or heterocycloalkane; R* is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with arene, heteroarene or R'*'^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R^ NC(R^)(R*^), R\ OR^ SR^ S(0)R^ S02R^ NHR^ N(R^)2, C(0)R\ C(0)NH2, C(0)NHR^ NHC(0)R^ NHSOaR^ lSfHC(0)0R\ SO2NH2, SOzNHR^ S02N(R^)2, NHC(0)NH2, NHC(0)NHR^ NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR\ OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^ is C2-C5-spiroalkyl, each of which is unsubstituted or substituted with OH, (O), N3, CN, CF3, CF2CF3, F, CI, Br, I, NH2, NH(CH3) or N(CH3)2; R*"^ and R^^ are independently selected alkyl or, together with the N to which they are attached, R^; R^ is aziridin-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidin-1-yl, each having one CH2 moiety unreplaced or replaced with O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH; -702- R^sR«,R',R'%rR"; R* is phenyl which is unfiised or fused with arene, heteioaiene or R*'^; R*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R' is heteroaryl which is unfused or fused with arene, heteroarene or R'^; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is C3-Cio-cyclaalkyl or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'"'^; R'"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is alkyl, alkenyl or aDcynyl, each of which is unsubstituted or substituted with one or two or three independently selected R'^ 0R'^ NHR", N(R'^)2, C(0)NH2, C(0)^fHR'^ C(0)N(R'^)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R'MsR",R'^R>^orR'^ R'^ is phenyl which is unfused or fused with arene, heteroarene or R"^; R"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'* is heteroaryl, each of which is unfused or fused with arene, heteroarene or R'"*^; R"'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene, each of which is unfused or fused with arene, heteroarene or R"^; R'^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'^ is alkyl, alkenyl or alkynyl; R'^isR'«,R",R^%rR^'; R'* is phenyl which is unfused or fiised with arene, heteroarene or R'*'^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is heteroaryl which is unfused or fused with arene, heteroarene or R^''^; R''"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^** is C3-Cio-cycloalkyI or C4-Cio-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R ; R is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; - 703 - R^' is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independendy selected R^^ OR^^ NHR^^ N(R")2, C(0)NH2, C(0)NHR^^ C(0)N(R^^)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^^isR^,R^%rR^^ R^^ is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^^'^ is cycloaDcane, cycloalkene, heterocycloalkane or heterocycloalkene; R^ is heteroarene which is unfused or fused with arene, heteroarene or R^^; R^'^ is cycloalkane, cycloalkene, heterocycloalkiane or heterocycloalkene; R" is Cs-Ce-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^^'^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^" is cycloalkyl or cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R^°^; R^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; each of which is substituted with F, CI, Br, I, CH2R^\ CH(R^')(R^''), C(R^')(R^''^)(R^^), C(0)R^^ OR^^ SR", S(0)R", S02R^^ NHR^^ or N(R^^)R^^; R^'andR^*'^ are independently F, CI, Br or alkyl or are taken together and are C2-C5-spiroalkyl; R^^ is R^^ C(0)R^^ or C(0)0R"; R^^isR^orR^^ R^'* is phenyl which is unfused or fused with aryl, heteroaryl or R^"'^; R^'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is alkyl which is unsubstituted or substituted with R^; R^* is phenyl which is unfused or fused with arene, heteroarene or R^^'^; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R" is R^*, R^' or R**, each of which is substituted with F, Cl, Br, I, R"", OR"', NHR"", N(R''')2, NHC(0)OR'", SR"\ S(0)R'" or SO2R'"; R^* is phenyl which is unfused or fused with arene, heteroarene or R^'^; R^*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^' is heteroaryl which is unfused or fused with arene, heteroarene or R^''^; R^'"^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; -704- R'*" is Cs-Cg-cycloalkyl or C4-Cg-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R''"'^; R'*"'^ cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'isR^^R^^R^orR^^ R'*^ is phenyl which is unfused or fused with arene, heteroarene or R"*^^; R''^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"*^ is heteroaryl which is unfused or fused with arene, heteroarene or R'*^^; R''^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is Cs-Cg-cycloalkyl or C4-C7-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'"'^; R''^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R''^ is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two independenUy selected R^^, OR^^, NHR^^, N(R^)2, C(0)NH2, CCONHR**, C(0)N(R'**)2, OH, (O), C(0)OH, N3, CN, NH2, CF3, CF2CF3, F, CI, Br or I substituents; R^isR^R^orR^'; R''^ is phenyl which is unfused or fused with arene, heteroarene or R"*^^; R''^'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R"^ is heteroaryl or R"**^; R"*^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R'" is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is unfused or fused with arene, heteroarene or R'"^; R'*'^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; wherein moieties represented by R^ R^ R^, R^ R^, R^ R^"^ R^ R^°, R'^ R^"*, R^pl8 pl9 „20 p23 p24 p25 p26 p27 p28 p29 p30 p34 p36 p38 p39 p40 p42 p43 K ,lx ,lv ,lv ,1\ ,K ,1^ ,1V , t\. ,lv ,K ,K ,K ,K ,K ,lv ,K ,K , 44 47 48 49 R , R , R , and R are independently unsubstituted, further unsubstituted, substituted or further substituted with one or two or three or four or five independently selected R^°'^, R^, 0R^°, SR^°, S(0)R^°, SOzR^", C(0)R^'', CO(0)R^'', 0C(0)R^'', OC(0)OR^", NH2, NHR^", -705- N(R^'')2, C(0)NH2, C(0)NHR^'*, C(0)N(R^)2, C(0)NHOH, C(0)NHOR^'', C(0)NHS02R^'', C(0)NR^''S02R^°, SO2NH2, S02NHR^'', S02N(R^°)2, CF3, CF2CF3, C(0)H, C(0)OH, C(N)NH2, C(N)NHR^°, C(N)N(R^'')2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, CI, Br or I substituents; R^^isR^'.R^^R^^orR^'; R^' is phenyl which is unfused or fused with arene, heteroarene or R^'°; R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^^ is heteroaiyl; R^^ is C3-C6-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N, and each of which is 53B unfused or fused with arene, heteroarene or R ; wherein R^^^ is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene; R^'* is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three independently selected R", 0R^^ SR", S(0)R^^ S02R^^ NHR^^ N(R")2, C(0)R'^ C(0)NH2, C(0)NHR", NHC(0)R'^ NHS02R^^ NHC(0)0R", SO2NH2, S02NHR^^ S02N(R^^)2, NHC(0)NH2, NHC(0)NHR^^ OH, (O), C(0)OH, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, CI. Br or I substituents; R^^ is alkyl, alkenyl, alkynyl, phenyl, heteroaryl or R^^; wherein the alkyl, alkenyl, alkynyl are unsubstituted or substituted with OCH3; and R^* is C3-C8-cycloalkyl or C4-C6-cycloalkenyl, each having one or two CH2 moieties unreplaced or replaced with independently selected O, C(0), CNOH, CNOCH3, S, S(0), SO2 or NH and one or two CH moieties unreplaced or replaced with N. 6. The compound of claim 1, claim 2, claim 3, claim 4, or claim 5, wherein A' is C(A^); and A^ is H. 7. The compound of claim 1, claim 2, claim 3, claim 4, or claim 5, wherein A'isC(A^)orN; A^ is H; and B^ is NHR'. -706- 8. The compound of claim 1, claim 2, claim 3, claim 4, or claim 5, wherein A'isC(A~)orN; A^ is H; B' is NHR'; and D' is H. 9. The compound of claim 1, claim 2, claim 3, claim 4, or claim 5, wherein A'isC(A^)orN; A^ is H; B' is NHR"; D' is H; and E' is H. 10. The compound of claim 1, claim 2, claim 3, claim 4, or claim 5, wherein A'isC(A^)orN; A^ is H; B^isNHR'; D' is H; E' is H; and Y' is NO2. 11. A compound of claim 1, wherein the compound is chosen from: 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-phenoxy-N-((4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-(benzyloxy)-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(2-phenylethoxy)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(phenylthio)benzamide; -707- 4-(4-((4'-chloro-1, l!-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(phenylthio)-N-((4-((tetrahydro- 2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-morpholin-4- ylpropyl)ainino)-3-nitrophenyl)sulfonyl)-2-(phenylthio)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(phenylsulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(phenylsulfinyl)benzamide; 2-benzyl-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-benzyl-4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-benzyl-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-cWoro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(2-phenylethyl)benzamide; 2-(benzylamino)-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-anilino-4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 2-anilino-4-(4-((4'-chlon)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-methoxy-N-((3-nitro-4- ((tetTahydro-2H-pyran-4-ylmethyl)amino)phenyI)sulfonyl)benzamide; 4-(4-((2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- morpholin-4-ylprDpyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indazol-5-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indazol-5-yloxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; -708- 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(l,2,3,4-tetrahydroquinolin-6- yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yI)methyl)piperazin-l-yl)-N-((4-((l- methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)-2-(l,2,3,4-tetrahydroquinolin-6- yloxy)benzamide; 4-(4-((4'-chloro-4-(pyrrolidin-1 -ylmethyl)-1,1 '-biphenyl-2-yl)methyl)piperaziii-1 -yl)-2-( IH- indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)aniino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-pyrrolidin-1 -ylethyl)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(( 1 - cyclopentylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzanude 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)-3-isobutylpiperazin-l-yl)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-(2,4-dioxo-3- azabicyclo(3.2.0)hept-3-yl)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -y l)-N-((4-(4-methyl-6-oxo-1,4,5,6- tetrahydropyridazin-3-yl)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4.((4'-chloio-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-(3,3-dimethyl-2- oxoazetidin-l-yl)phenyl)sulfonyl)-2-phenoxybenzamide; 4.(4.((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-(4-nitro-2H-l,2,3-triazol-2- yl)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-phenoxy-N-((2-(2-piperidin-1 - ylethoxy)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((3-(((( 1-ethylpyniolidin-2- yl)methyl)amino)carbonyl)-4-methoxyphenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-( 1 -naphthyloxy)-N-((3-nitTO-4- ((tetrahydro-2H-pyran-4-ylmethyl)an[iino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-naphthyloxy)-N-((3-nitro-4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-niorpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(2-naphthyloxy)benzamide; -709- 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(2-naphthyloxy)-N-((4- ((tetTahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(quinolin-7-yloxy)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-l -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(quinolin-6-yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yI)methyl)piperazin-l-yl)-2-(lH-indol-5-yloxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(isoquinolin-5-yloxy)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(isoquinolin-5-yloxy)benzamide; 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (diraethylaniino)propyl)ammo)-3-nitrophenyl)sulfonyl)-2-(quinolin-6-yloxy)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)beiizamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)-N-((3-nitro- 4-((tetrahydro-2H-pyran-4-ylmethyl)ainino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(lH-indol-4-yloxy)benzamide; 4.(4-((4'-ch]oro-1, l'-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((4-((3- (dimethylamino)propyl)ammo)-3-nitrophenyl)sulfonyl)-2-(lH-mdol-6-yloxy)benzamide; 4-(4-((4'-ch]oro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2-(isoquinolin-7-yloxy)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-N-((4-((3- (dimethylamino)propyl)ammo)-3-nitiophenyl)sulfonyl)-2-(isoquinolin-7-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- mdol-5-yloxy)-N-((4-((3-moipholin-4-ylpropyl)amino)-3-iiitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitTophenyl)sulfonyl)benzan[iide; -710- 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)niethyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitTOphenyl)suIfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzaniide; 4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-mtrophenyl)sulfonyl)-2-(lH-indol-4-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)ammo)-3-nitrophenyl)sulfonyl)-2-(lH-indol-4-yloxy)benzamide; 4-(4-((4'-chIoro-1,1 '-biphenyl-2-yl)niethyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(lH-indol-5-yloxy)-N-((4-((3- moipholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-methoxyphenyl)sulfonyl)-2- phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-methylphenyl)sulfonyl)-2- phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-5-yloxy)-N-((4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)-N-((4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylammo)propyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-((4-((3- morpholin-4-ylpropyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; N-((3-((chloro(difluoro)methyl)sulfonyl)-4-((3- (dimethylamino)propyl)amino)phenyl)sulfonyl)-4-(4-((2-(4-chlorophenyI)-4,4- dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH-indol-5-yloxy)benzamide; -711- 2-( 1 H-indol-4-yloxy)-4-(4-((2-(4-niethoxyphenyl)-4,4-dimethylcyclohex-1 -en-1 - yl)methyl)piperazin-1 -yl)-N-((3 -nitTO-4-((3-pyrrDlidin-1 - ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4,4-dimethyl-2-(4-(trifluoromethyl)phenyl)cyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)- 2-( 1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 - ylpropyl)aniino)phenyl)sulfonyl)benzamide; 4-(4-((4,4-dimethyl-2-(4-(trifluoiomethoxy)phenyl)cyclohex-1 -en-1 -yl)methyl)piperazin-1 - yl)-2-(lH-indol-4-yloxy)-N-((3-nitro-4-((3-pynolidin-l- ylpropyl)aniino)phenyl)sulfonyl)benzamide; 4-(4-((4,4-dimethyl-2-(3 -(trifluoromethyl)phenyl)cyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)- 2-(lH-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 - ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(3-fluorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-l-ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-fluorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-l-ylpropyl)amino)phenyl)sulfonyl)benzamide; N-((3-((chloro(difluoro)methyl)sulfonyl)-4-((l-methylpiperidin-4-yl)amino)phenyl)sulfonyl)- 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)cyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH-indol-5-yloxy)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(phenoxymethyl)benzamide; 4-(4-((4'-chloro-1,1'-bipheny 1-2-y l)methyl)piperazin-1-yl)-N-((4-((3-morpholin-4- ylpropyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-bipheny l-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(pyridin-3-yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-(pyridin-3-yloxy)-N-((4- ((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzanude; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-(((lR)-3-(dimethylamino)- l-((phenylthio)methyl)propyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; -712- 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3 -nitro-4-((tetrahydro-2H- pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(pyridin-4-yloxy)benzamide; 4-(4-((4'-chloro-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-((3-morpholin-4- ylpiopyl)amino)-3-nitrophenyl)sulfonyl)-2-(pyridin-3-yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-(pyridin-4-yloxy)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((2-(4-methylpiperazin-1 - yl)ethyl)ammo)-3-nitiophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-(4-methylpiperazin-1 - yl)propyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-ch]oro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)(methyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-(((l -methylpiperidin-4- yl)methyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1'-bipheny l-2-yl)methyl)piperazin-1-yl)-N-((4-(( 1-methy lpiperidin-4- yl)aimno)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-cyano-4-((3- (dimethylamino)propyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1'-bipheny l-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((3 -pyrrolidin-1 - ylpropyl)amino)phenyl)sulfonyl)-2-phenoxybenzaniide; 4-(4-((4'-chloio-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)ammo)-3-(trifluoromethyl)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (isopropyI(methyl)amino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-(3- (dimethylamino)propoxy)-3-nitrophenyl)sulfonyI)-2-phenoxybenzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((4-((2-(4-methylpiperazin-l-yl)ethyl)ammo)-3- nitrophenyl)sulfonyl)benzaimde; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl)methyl)piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-((4-((3-(4-methylpiperazin-l-yl)propyl)amino)-3- nitiDphenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((3-nitro-4-((3-pyrrolidin-l-ylpropyl)amino)phenyl)sulfonyl)benzamide -713- 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yIoxy)-N-((4-((l-melhylpiperidin-4-yl)ammo)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((4-((3-(4-methylpiperazin-l-yl)propyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(3- (dimethylamino)propoxy)-3-nitrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((4-((2-(4-methylpiperazin-l-yl)ethyl)ammo)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-l-ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((4-((l-methylpiperidin-4-yl)animo)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((4-(((l-methylpiperidin-4-yl)methyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((4-((( 1 -methylpiperidin-4-y l)methyl)amino)-3- nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-N-((4-(3- (dimethylamino)propoxy)-3-nitrophenyl)sulfonyl)-2-(lH-indol-4-yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-((4-(4-methylpiperazin-l-yl)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((3-nitro-4-(( 1 -(2,2,2-trifluoroethyl)piperidin-4- yl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(((4-(dimethylamino)-l-methylpiperidin-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)mediyl)piperazin-l-yl)-2-(2,3-dihydro-l,4-benzodioxin-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmelhyl)amino)phenyl)sulfonyl)benzamide; 5-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-1,1 '-biphenyl-2-carboxamide; -714- 5-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitiophenyl)sulfony])-1, r-biphenyl-2-carboxamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyI)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-4-(3-piperidin-l-ylpropoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-ch]oro-4-(2-morpholin-4-ylethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-4-(3-(dimethylamino)propoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2- phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(3-piperidin- l-ylpropoxy)-l, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2- phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(3-(dimethylanaino)prDpoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2- phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyI)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)su]fonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-1,1 '-biphenyl-2-yl)methy l)piperazin-1 -yl)-N- ((3-nitro-4-((3-pyrrolidin-l-ylpropyl)aniino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-3-(2-(dimethylanuno)ethoxy)-1, r-biphenyl-2-yl)melhyl)piperazin- l-yl)-N- ((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N- ((3-nitro-4-((3 -pyrrolidin-1 -ylpiopyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- phenoxy-N-((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylanuno)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (1 H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; -715- 4-(4-((4'-chloro-4-(2-(diniethylamino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-morpholin-4-y lethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)-1, r-biphenyl-2-yl)methyl)piperazin- l-yl)-2- (lH-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-3-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-morpholin-4-ylethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (lH-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-ch]oro-3-(2-inorpholin-4-ylethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (lH-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)atnino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-3-(2-inorpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylainino)ethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N- ((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-3-(2-(dimethylaiiuno)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-. (lH-indol-5-yloxy)-N-((3-nitro-4-((3-pyiToIidin-l- ylpropyl)ainino)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((3-pyiTolidin-l- ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((4'-cMoro-4-(2-morpholin-4-ylethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2- (lH-indol-5-yloxy)-N-((3-nitro-4-((3-pyrTolidin-l- ylpropyl)amino)phenyl)sulfonyl)beiizamide; -716- 4-(4-((4'-chloro-4-(2-(dimethylamino)ethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N- ((3-nitio-4-((l-(2,2,2-trifluoroethyl)piperidin-4-yl)amino)phenyl)sulfonyl)-2- phenoxybenzamide; 4-(4-((4'-chloro-4-(2-pyrrolidin-1 -ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3- nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-4-(2-(diisopropylamino)ethoxy)-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)- N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2- phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyI)piperazin-1 -yl)-2-(2,3 -dihydro-1 H-indol-5-yloxy)- N-((3-nitTO-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclohept-1 -en- l-yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)- N-((3-nitro-4-((3-pyrrolidin-l-ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclooct-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH-indol-4-yloxy)-N- ((3-nitro-4-((3-pyrrolidin-l-ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclopent-1 -en-1 -y l)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)- N-((3-nitro-4-((3-pyrrolidin-l-ylpropyl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclopent-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-((4-((l-methylpiperidin-4-yl)amino)-3-mtrophenyl)sulfonyl)benzamide; 4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yl)-2- (1 H-indol-4-yloxy)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzaniide; 4-(4-((2-(4-chlorophenyl)cyclooct-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH-indol-4-yloxy)-N- ((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclohept-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy )- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclopent-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-4-yloxy)- N-((4-((l-methylpiperidin-4-yl)amino)-3-mtrophenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)cyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(lH-indol-4-yloxy)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-l-yl)-2- (1 H-indol-5-yloxy)-N-((4-(( 1 -methylpiperidin-4-yl)amino)-3- nitrophenyl)sulfonyl)benzaniide; 4-(4-((2-(4-chlorophenyl)cyclohept-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( 1 H-indol-5 -yloxy)- N-((4-((l-methylpiperidin-4-yl)amino)-3-nitiophenyl)sulfonyl)benzamide; -717- 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin- l^yl)-N-((4-(( 1 - methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1, l'-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((2- (dimethylamino)ethyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzaniide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((4-((3-morpholin-4- ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((4- (dimethylamino)butyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1, r-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-(( 1 - (phenylsulfonyl)piperidin-4-yl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((l-(quinolin-8- ylsulfonyl)piperidm-4-yl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-2-phenoxy-N-((4-((l- (phenylsulfonyl)piperidin-4-yl)amino)-3- ((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-phenoxy-N-((4-(( 1 -(quinolin-8- ylsulfonyl)piperidin-4-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)suIfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-(((lS)-3-(dimethylamino)-l- thien-2-ylpropyl)amino)-3-nitrophenyl)sulfonyl)-2-phenoxybeiizamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((thien-2- ylmethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-phenoxy-N-((4-((tBtrahydro-2H- pyran-4-ylmethyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide; 4-(4-((4'-chloro-l,l'-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((2-(lH-l,2,3- triazol-l-yl)ethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4.(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((2-(2H-l,2,3- triazol-2-yl)ethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((4-((3- (dimethylamino)propyl)ainino)-3-nitrophenyl)sulfonyl)-2-(2-naphthyloxy)benzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((2-(2-oxopyridin- l(2H)-yl)ethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; -718- 4-(4-((4'-chloro-l,r-biphenyl-2-yl)methyl)piperazin-l-yl)-N-((3-nitro-4-((2-(pyridin-2- yloxy)ethyI)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((4'-chloro-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-N-((3 -nitro-4-((2-pyridin-4- ylethyl)amino)phenyl)sulfonyl)-2-phenoxybenzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)su]fonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3- (dimethylamino)propyl)amino)-3-(trifluoromethyl)phenyl)sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((3- cyano-4-((3-(dimethylamino)propyl)amino)phenyl)sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl)methyl)piperazin-1 -yl)-2-(l//- indol-5-yloxy)-A^-((3-nitro-4-(( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino)phenyl)sulfonyl)benzamide; 4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-( IH- indol-5-yloxy)-^-((4-((4-methylpiperazin-l-yl)amino)-3-nitrophenyl)sulfonyl)benzamide; 4.(4-(l.(4'.chloro-l,l'-biphenyl-2-yl)ethyl)piperazin-l-yl)-2-(l//-indol-4-yloxy)-A^-((3-nitK)- 4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamide; ^-((4-(((4-aminotetrahydro-2H-pyran-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-4-(4-((2- (4-ch]orophenyl)-4,4-dimethylcyclohex-l-en-l-yl)methyl)piperazin-l-yl)-2-(l//-indol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl }piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)ainino]phenyl}sulfonyl)benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- (1 H-indol-5-yloxy)-N-( {4- [(4-morpholin-4-ylcyclohexyl)anuno]-3 - nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-diraethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(3-mtro-4- {[(3S)-tetrahydro-2H-pyran-3- ylmethyI]aniino}phenyl)sulfonyl]benzamide; -719- 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- I-yl]methyl)piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(3-nitro-4- {[(3R)-tetrahydro-2H-pyran-3- ylmethyl]aniino}phenyl)sulfonyl]benzamide; 4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl} piperazin-1 -yl)- 2-(lH-indol-5-yloxy)-N-({3-nitTO-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1) sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-diraethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N- [(4- {[(4-hydroxy-1 -niethylpiperidin-4-yl)methyl]amino) -3 -nitrophenyl)sulfonyl]-2-( 1 H-indol-5 - yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-3-fluoro- 2-( 1 H-indol-5-yloxy)-N-( {4- [(1 -methylpiperidin-4-yl)amino] -3- nitiophenyl}sulfonyl)benzainide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-3-fluoro- 2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)aniino]phenyl) sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[(4-hydroxy-l-methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide; N-[(4- {[(3S,4R)-1 -benzyl-3-hydroxypiperidin-4-yl]amino )-3-nitrophenyl)sulfonyl]-4-(4- {[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl )piperazin-1 -yl)-2-( lH-indol-5- yloxy)benzamide; N-[(4-{[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino)-3-nitrophenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(4- {[ l-(2-methoxyethyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzannide; 4-(4- {[2-(4-chlorophenyI)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( IH- indol-4-yloxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-N- [(4- {[l-(2-hydroxyethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide; -720- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( IH- indol-4-yloxy)-N-[(4-{[l-(2-methoxyethyl)piperidin-4-yl]amino}-3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl Jmethyl} piperazin-1 -y])-N- [(4- {[l-(3-hydioxypropyl)piperidin-4-yl]amino}-3-nitiophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide; 4- [4-( {4'-chloro-3- [3-(dimethylamino)propyl] -1,1 '-biphenyl-2-yl} methyl)piperazin-1 -yl]-2- (1 H-indol-4-yloxy)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)aniino]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- [(4- {[l-(3-hydroxypropyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4- {4-[(4'-chloro-4-morpholin-4-yl-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-( 1 H-indol-4- yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide; 4- [4-( {4'-chloro-3- [2-(dimethylamino)ethoxy ]-1,1 '-biphenyl-2-yl} methyl)piperazin-1 -yl]-2- (1 H-indol-4-yloxy)-N-( {3-nitio-4- [(1 -tetrahydio-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[4-(diethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chloropheny])-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N- [(4- {[4-(dimethylamino)cyclohexyl]aniino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[4-(diethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-4- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-({4-[(4-morphoIin-4-ylcyclohexyl)amino]-3- nitrophenyl}sulfonyl)benzamide; 4- [4-( {4'-chloro-3- [2-(dimethylamino)ethoxy ]-1,1 '-biphenyl-2-yl} methyl)piperazin-1 -yl] -2- (1 H-indol-4-yloxy )-N-( {4- [(1 -methylpiperidin-4-y l)amino]-3- nitropheny 1} sulfony l)benzainide; 4- {4-[ l-(4'-chloro-1,1 '-biphenyl-2-yl)ethyl]piperazin- 1-yl} -2-(lH-indol-4-yloxy)-N-({4-[( 1- methylpiperidin-4-yl)amino]-3-nitiophenyl}sulfonyl)benzamide; -721- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N- {[4-({[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl}amino)-3-nitTOphenyl]sulfonyl}-2-(lH-indol-5-yloxy)benzamide; N-( {4-[(2-aminocyclohexyl)amino]-3-nitrophenyl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -y l)-2-( 1 H-indol-5-yloxy)benzamide; 4-[4-({4'-chloro-4-[3-(dimethylamino)prop-l-ynyl]-l,r-biphenyl-2-yl}methyl)piperazin-l-yl]-2-(lH-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydio-2H-pyran-4-ylraethyl)amino]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-[(3-nitro-4- {[ l-(4,4,4-t^ii^uorobutyl)piperidin-4-yl]amino}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-[(4-{[2-(4-hydroxy-l-methylpiperidm-4-yl)ethyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5-yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-2-(lH-indol-5-yloxy)-N-[(3-nitro-4-{[l-(l,3-thiazol-2-yl)piperidin-4-yl]amino}phenyl)sulfonyI]benzamide; 4-(4- {[4'-chloro-4-(2-hydroxyethoxy)-1,1 '-biphenyl-2-yl]methyl) piperazin- l-yl)-2-( 1H-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-[(4-{[l-(cyclopropylmethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( IH-indol-5-yloxy)-N-[(3-nitro-4-{[l-(4,4,4-trifluorobutyl)piperidin-4-yl]araino}phenyl)sulfonyl]benzamide; 4-{4-[l-(4'-chloro-l,l'-biphenyl-2-yl)ethyl]piperazin-l-yl}-2-(lH-indol-4-yloxy)-N-({4-[(4-methylpiperazin- l-yl)amino]-3-nitrophenyl }sulfonyl)benzamide; 4-[4-{[2-(4-chlorophenyl)-4,4-dimethyIcyclohex-l-en-l-yl]methyl}-3-(hydroxyniethyl)piperazin-1 -yl]-2-( 1 H-indol-5-yloxy)-N-( {4- [(1 -raethylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)benzamide; -722- 4-[4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)-3- (hydroxymethyl)piperazin-l-yl)-2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H- pyran-4-ylpiperidin-4-yl)amino]phenyl }sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl ]methyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl}suIfonyl)benzamide; 4-(4-{[4'-chloro-4-(2-hydroxyethoxy)-l,r-biphenyl-2-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -y])-2-( IH- indol-5-yloxy)-N-[(3-nitro-4-{[3-(3-oxopiperazin-l- yl)propyl]amino}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-y])-2-(lH- indol-4-yloxy)-N-[(3-nitro-4- {[3-(3-oxopiperazin-1 - yl)propyl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indol- 5-yIoxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3-nitiDphenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-( {3-nitro-4-[( 1 -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)anuno]phenyl} sulfonyl)benzaniide; 4-(4- {[2-(4-chlorophenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl Jpiperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-({4-[(4-methylpiperazin-1 -yl)amino]-3-nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl}piperazin- l-yl)-N-[(4- {[l-(2,3-dihydro-lH-inden-2-yl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol- 4-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[l-(2,3-dihydro-lH-inden-2-yl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol- 5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-[(4-{[(l-morpholin-4-ylcyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl Jpiperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(3-nitro-4-{[l-(l,3-thiazol-2-ylmethyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamide; -723- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(3-nitro-4-{[l-(l,3-thiazol-4-ylmethyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N- {[4- ({[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]methyl}anuno)-3-nitrophenyl]sulfonyl}-2- (1 H-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N- [(4- {[4-(2-hydroxyethyl)piperazin-l-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(4- {[(3S)-1 -methylpyrrolidin-3-yl]amino} -3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin-1 -yl)-N- [(4- {[ 1 -(3-fluoropropyl)piperidin-4-yl]amino }-3-nitrophenyl)sulfonyl]-2-( 1 H-indol-5- yloxy)benzamide; 4- [4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 -yl]niethyl} -3- (hydroxymethyl)piperazin-l-yl]-2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(tettahydro-2H-pyran- 4-ylmethyl)amino]phenyl} siilfonyl)benzamide; N-[(4- {[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino} -3-nitrophenyl)sulfonyl]-4-[4- {[2- (4-chloix)phenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }-3-(hydroxymethyl)piperazin-1- yl] -2-( 1 H-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -yl)-N- [(4- {[(l-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl Jpiperazin- l-yl)-2-( IH- indol-4-yloxy)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]niethyl} piperazin- l-yl)-N- [(4- {[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol- 5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N- [(4- {[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]amino} -3-nitrophenyl)sulfonyl]-2-( IH-indol- 4-yloxy)benzamide; -724- 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl)piperazin- l-yl)-N-({4- [(2-hydToxy-l-tetrahydro-2H-pyran-4-ylethyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl Jmethyl) piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-{[3-nitro-4-({l-[2-(lH-pyrazol-l-yl)ethyl]piperidin-4- yl) amino)phenyl]sulfonyl }benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-{[4-(methylamino)-3-nitrophenyl]sulfonyl}benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljniethyl) piperazin-1 -yl)-2-( IH- indol-4-yloxy)-N-{[4-(methylamino)-3-nitrophenyl]sulfonyl}benzamide; 4.{4.[l.(4'.chloro-l,l'-biphenyl-2-yl)ethyl]piperazin-l-yl}-2-(lH-indol-4-yloxy)-N-({4-[(3- morpholin-4-ylpropyl)aniino]-3-nitrophenyl)sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-5-morpholin-4-ylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2- (lH-indol-5-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; N-[(4-{[(l-aminocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(3-nitro-4-{[2-(2-oxopyiTolidin-l- yl)ethyl]amino}phenyl)sulfonyl]benzamide; 4-{4-[l-(4'-chloro-l,l'-biphenyl-2-yl)ethyl]piperazin-l-yl}-2-(lH-indol-5-yloxy)-N-({3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4- {1 -[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl )piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzaniide; 4-(4- {1 -[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl )piperazin-1 -yl)-2-(l H- indol-5-yloxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3-mtrophenyl}sulfonyl)benzamide; -725- 4- {4-[( IR)-1 -(4'-chloro-1,1 '-biphenyl-2-yl)ethyl]piperazin-1 -yl) -2-( 1 H-indol-4-yloxy)-N- ({3-nitio-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)benzamide; 4- {4-[( 1S)-1 -(4'-chloro-1,1 '-biphenyl-2-yI)ethyI]piperazin- 1-yl} -2-( 1 H-indol-4-yloxy )-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4- {1 -[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl Jpiperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(3-moipholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4-{l-[2-(4-chlorophenyI)-4,4-dimethyIcyclohex-l-en-l-yl]ethyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-( {3-nitio-4-[(l -tetrahydro-2H-pyran-4-ylpiperidin-4- yl)anuno]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N-( {4- [(cyclohexyImethyl)amino]-3-nitrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-{[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl)benzanude; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-3- ylmethyl)amino]phenyl} suIfonyl)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methy] }piperazin-1 -y])-2-( 1H- indol-4-yloxy)-N-{[4-(morpholin-4-ylamino)-3-nitiophenyl]sulfonyl}benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-{[3-nitro-4-(tetrahydro-2H-pyran-4-ylamino)phenyl]sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethyIcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(4-{[(3-methyloxetan-3-yl)methyl]aniino)-3- nitrophenyl)sulfonyl]benzainide; 4-(4-{[2-(4-cMorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({4-[(4-methoxycyclohexyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethy] jpiperazin-1 -yl)-N- [(4- {[3-(l,l-dioxidothiomorpholin-4-yl)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chIorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-[(3-nitro-4- {[2-(2-oxopiperidin-1 - yl)ethyl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl jpiperazin- l-yl)-2-( IH- indoI-5-yloxy)-N-[(3-nitro-4- {[2-(2-oxoimidazolidin-1 - yl)ethyl]amino}phenyl)sulfonyl]benzamide; -726- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({3-nitro-4-[(2-pyridin-4-ylethyl)amino]phenyl)sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmetiiyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(4-moipholin-4-yl-3-nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-{[4-(4-methoxypiperidin-l-yl)-3-nitrophenyl]sulfonyl}benzamide; 4-(4- {[2-(4-chlorophenyl)-5-pyrrolidin-1 -ylcyclohex- 1-en-l -yl]naethyl}piperazin-1 -yl)-2- (lH-indol-5-yloxy )-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4- ylmethyl)aniino]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(3-nitro-4- {[2-(3-oxopiperazin-1 - yl)ethyl]amino}phenyl)sulfonyl]benzamide; 4-[4-( {4'-chloro-4- [2-(dimethylamino)ethoxy] -1,1 '-biphenyl-2-yl }methyl)piperazin-1 -yl]-2- (lH-indol-4-yloxy)-N-({4-[(4-methylpiperazin-l-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-l -yl]methyl }piperazin-1 -yl)-N- [(4- {[(l,l-dioxidotetrahydrothien-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl) piperazin-1 -yl)-N-( {4- [(l,l-dioxidotetrahydrothien-3-yl)amino]-3-nitxophenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzaniide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl)piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-{[4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3- (trifluoromethyl)phenyl]sulfonyl} benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-N-( {4- [2- (l,3-dioxolan-2-yl)ethyl]-3-nitiophenyl }sulfonyl)-2-( 1 H-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl}piperazin-l-yl)-2-( IH- indol-5-yloxy)-N-{[3-nitro-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl}benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl) piperazin- l-yl)-2-( IH- indol-4-yloxy)-N-[(3-nitro-4- {[2-(3-oxopiperazin-1 - yl)ethyl]amino}phenyl)sulfonyl]benzamide; -727- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(l-methyl-5-oxopyrroUdin-3-yl)amino]-3- nitrophenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-( {4-[( l-methyl-6-oxopiperidin-3-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( IH- indol-4-yloxy)-N- {[3-nitio-4-(piperidin-1 -ylamino)phenyl]sulfonyl} benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-{[3-mtro-4-(piperidin-l-ylamino)phenyl]sulfonyl}benzamide; 4-(4- {[4-(4-chlorophenyl)- 1-methyl- lH-pyrazol-5-yl]methyl )piperazin-1 -yl)-2-( lH-indol-5- yloxy)-N-( {3-nitro-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]mediyl} piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-({4-[(3-methyloxetan-3-yl)methoxy]-3-nitrophenyl)sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5 -yloxy)-N-[(3-nitro-4- {[(1 -oxidotetrahydio-2H-thiopyran-4- yl)methyl]amino}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({3-nitro-4-[(l,3-thiazol-5-ylmethyl)aniino]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-{[3-nitto-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl)benzanude; 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]pheny 1} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({3-nitio-4-[(2-tetrahydio-2H-pyran-4- ylethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethyIcyclohex- 1-en- l-yl]methyl) piperazin- l-yl)-2-( IH- indol-4-yloxy)-N-[(3-nitro-4- {[2-(trifluoromethoxy)ethyI]anuno }phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -y l]methyl) piperazin- l-yl)-2-( 1H- indol-4-yloxy)-N-[(4- {[2-(2-methoxyethoxy)ethyl]amino} -3- nitrophenyl)sulfonyl]benzamide; -728- 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-[(4-{[3-(methylsuIfonyl)propyl]amino}-3-nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[3-( 1,1 -dioxidothiomoipholin-4-yl)propyl lamino} -3-nitrophenyl)sulfonyl]-2-( 1 H-indol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl ]methyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N- {[3-nitro-4-(2-tetrahydro-2H-pyran-4-yIethyl)phenyl]sulfonyl }benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl )piperazin-1 -y] )-N- {[4- (l,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}-2-(lH-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-[(4- {[2-(2-methoxyethoxy)ethyl]amino} -3- nitrophenyl)sxilfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcycIohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({4- [(1,1 -dioxidotetrahydrothien-3 -yl)amino]-3-nitrophenyl} sulfonyl)-2-( 1 H-indol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(3-nitro-4- {[2-(trifluoromethoxy)ethyl]amino )phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin- l-yl)-N- [(4- {[(1,1 -dioxidotetrahydro-2H-thiopyran-4-yl)methyl]amino} -3-nitrophenyl)sulfonyl]-2-( 1H- indol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [(2,2-difluoroethyl)amino]-3-nitrophenyl) sulfonyl)-2-( lH-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin- l-yl)-2-( IH- indol-4-yloxy)-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzainide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl )piperazin-1 -y])-2-( 1H- indol-5-yloxy)-N-({4-[(tetrahydro-2H-pyran-4-ylmethyI)aminoJ-3- [(trifluoromethyl)sulfonylJphenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- 1-ylJmethyl Jpiperazin- l-yl)-N-( {4- [(4,4-difluorocyclohexyl)aminoJ-3-nitrophenyl)sulfony])-2-(lH-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- 1-ylJmethyl Jpiperazin- l-yl)-N-({ 4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxyJ-3-nitrophenyl}sulfonyl)-2-(lH-indol-4- yloxy)benzamide; -729- 4-(4- {[4-(4-chlorophenyl)-1 -isopropyl-6-oxo-1,6-dihydropyridin-3-yl]methyl} piperazin-1 - yl)-2-(lH-indol-5-yloxy)-N-({3-nitro-4-[(tetiahydro-2H-pyran-4- ylmethyl)anuno]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-[(4- {[(tetrahydro-2H-pyran-4- ylmethyl)amino]caibonyl}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( 1H- indol-4-yloxy)-N-({4-[(2-methoxyethyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N- [(4- {[(4-hydroxycyclohexyl)mediyl]amino}-3-nitropheny])sulfonyl]-2-(lH-indol-5- yloxy)benzaniide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(4- {[(4-methoxycyclohexyl)methyl]amino} -3- nitiophenyl)sulfonyl]benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N- [(4- {[(4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)ben2amide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-[(4- {[(4-methoxycyclohexyl)methyl]amino} -3- nitrophenyl)sulfonyl]benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( IH- indol-4-yloxy)-N- {[3-nitrD-4-(2-tetrahydro-2H-pyran-4- ylethoxy)phenyl]sulfonyl}benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl )piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-({4-[(2-methoxyethyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( IH- indol-4-yloxy)-N-({4-[3-(methylsulfonyl)propoxy]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl) piperazin- l-yl)-2-( IH- indol-5-yloxy)-N-({4-[(3-methoxypropyl)amino]-3-nitrophenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]niethyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-( {4- [(3 -methoxypropyl)amino] -3-nitrophenyl} sulfonyl)benzamide; -730- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-N-( {4- [(2-cyanoethyl)aniino]-3-mtrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({4- [(2-cyanoethyl)amino]-3-nitrophenyl)sulfonyl)-2-(lH-indol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- {[4- ({[(3R)-4-hydroxy-1 -adamantyl]methyl} amino)-3-nitrophenyl]sulfonyl} -2-(l H-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[4- ({[Cis-4-hydioxy-l-adamantyl]methyl}amino)-3-nitrophenyl]sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyI)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-({3-nitro-4-[(3,3.3-trifluoiopropyl)amino]phenyl)sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-( {3 -nitro-4-[(3,3,3-trifluoropropyl)amino]phenyl} sulfonyl)benzamide; N-({5-bromo-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl)sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]niethyl)piperazin-l-yl)-2-(lH-indol-4- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-[(4- {[(1,1 -dioxidotettahydrothien-3-yl)methyl]amino} -3 -nitrophenyl)sulfonyl]-2-( 1 H-indol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin- l-yl)-N-( {4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzaniide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({4-(methylamino)-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; N-{[5-bromo-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5-' yloxy)benzamide; 4-(4-{[4-(4-chlorophenyl)-6-isopropoxypyridin-3-yl]methyl)piperazin-l-yl)-2-(lH-indol-5- yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-{[6-(tetrahydro-2H-pyran-4-ylmethoxy)-5-(l,3-thiazol-2-yl)pyridin-3- yl]sulfonyl}benzamide; -731- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(4-{[(2-methoxyethyl)amino]caibonyl)phenyl)sulfonyl]benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N- {[5- cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-indol-5- yloxy)benzamide; N-({4-[( 1 -acetylpiperidin-4-yl)amino]-3-nitrophenyl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)- 4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(4- {[ l-(methylsulfonyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(1,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl} sulfonyl)-2-(l H-indol-5-yloxy)benzamide; N-({4-[(l-acetylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)- 4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-4-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-[(4- {[ l-(methylsulfonyl)piperidin-4-yl]amino} -3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[4'-chloro-5-(trifluoromethyl)-1,1 '-biphenyI-2-yl]methyl} piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[4'-chloro-5-(trifluoromethyI)-1,1 '-biphenyl-2-yl]methyl} piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-{[3-nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}benzamide; 4- {4-[(5 -tert-butyl-4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-( 1 H-indol-5-yloxy)- N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide; 4- {4- [(5-tert-butyl-4'-chloro-1, r-biphenyl-2-yl)methyl]piperazin-1 -yl} -2-( 1 H-indol-5-yloxy)- N- {[3-nitio-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl }benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin- l-yl)-2-( 1H- indol-4-yloxy)-N-({3-mtro-4-[(2,2,2-trifluoroethyl)amino]phenyl}sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}pipeiazin-l-yl)-2-(lH- indol-5-yloxy)-N-( {3-nitio-4-[(2,2,2-trifluoroethyl)amino]phenyl) sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(3-{[(tetrahydro-2H-pyran-4- ylmethyl)aniino]carbonyl}phenyl)sulfonyl]benzamide; -732- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin- l-yl)-N-( {4- [(2R)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4- [(2S)-l,4-dioxan-2-ylmethoxy]-3-nitrophenyl)sulfonyl)-2-(lH-indol-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-4-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; N-({5-bromo-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl)sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indol-5- y]oxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-2-( 1H- indol-5-yloxy)-N-({4-[(2-morpholin-4-ylethyl)amino]-3- [(trifluoromethyl)sulfonyl]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({5- cyano-6-[(tetrahydio-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyI)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(l-methylpiperidin-4-yl)oxy]-3-nitrophenyl}sulfonyl)benzainide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en- l-yl]methyl} piperazin- l-yl)-2-( IH- indol-5 -yloxy)-N-( {4- [(1 -methylpiperidin-4-y l)methoxy]-3-nitrophenyl }sulfonyl)benzamide; 4-(4-{[4-(4-chlorophenyl)-l-(3-hydroxypropyl)-l,2,5,6-tetrahydropyridin-3- yl]methyl}piperazin-l-yl)-2-(lH-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; benzyl 4-({ [4-( {[4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-2-( 1 H-indol-5-yloxy)benzoyl]amino} sulfonyl)-2- nitrophenyl]amino} methyl)piperidine-1 -carboxylate; N- {[3-(aminocaibonyl)-4-(tetrahydro-2H-pyran-4-ylmethoxy)plienyl]sulfonyl} -4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-I-yl)-2-(lH-indol-5- yloxy)benzamide; -733- 4-(4- {[4'-chloro-5-(trifluoromethyl)-1,1 '-biphenyl-2-yl]methyl }piperazin-1 -yl)-2-( 1 H-indol- 5-yloxy)-N-({3-nitro-4-[(l-tetrahydrD-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 4- {4-[(5-tert-butyl-4'-chloro-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl) -2-( 1 H-indol-5-yloxy)- N-( {3-nitro-4-[( l-tetrahydro-2H-pyran-4-ylpiperidm-4-yl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(4- {[(1-methyl-1 H-imidazol-5-yl)methyl]amino} -3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N- {[4-(morpholin-4-ylsulfonyl)phenyl]sulfonyl }benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N-( {4- [(l,l-dioxidothiomorpholin-4-yl)anuno]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-({4-[(4-moipholin-4-ylcyclohexyl)amino]-3- nitiophenyl)sulfonyl)benzaiiiide; N-{[5-bromo-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-4- yloxy)benzaniide; 4-(4- {[2-(4-clilorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( 1H- indol-4-yloxy)-N-{[6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-5-(l,3-thiazol-2-yl)pyridin- 3-yl]sulfonyl }benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin- l-yl)-N-( {3- cyano-4- [(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-( 1 H-indol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin- l-yl)-N-( {3- cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N-( {4- [(3,3-dimethylbutyl)amino]-3-nitrophenyl} sulfonyl)-2-( 1 H-indol-5 -yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N- [(4- {[(lS)-l-(hydroxymethyl)-3-methylbutyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; -734- 4-(4-{[2-(4-chlorophenyI)-4,4-dimethylcyclohex-1 -en-1 -yl]niethyl)piperazin- l-yl)-2-(IH- • indol-5-yloxy)-N-[(3-nitro-4- {[(2R)-tetrahydrofuran-2- ylmethyl]amino}phenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]niethyl) piperazin-1 -yl)-N- [(4- {[(1R)-1 -(hydroxymethy l)-2-methylpropyl]amino} -3-nitrophenyl)sulfony 1] -2-( 1 H-indol-5 - yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en- l-yl]methyl Ipiperazin- l-yl)-2-( IH- indol-5-yloxy)-N-({4-[(4-methoxyphenyl)amino]-3-nitrophenyl}sulfonyl)benzamide; N-[(4-{[2-(l,3-benzodioxol-5-yl)ethyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4- ch]orophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl )piperazin-1 -yl)-2-(l H-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indol-5-yloxy)-N-[(3-iutro-4- {[3-(2-oxopyirolidin-1 - yl)propyl]amino}phenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({4- [(4-hydroxyphenyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5-yloxy)benzamide; N- {[4-({ 2-[4-(aminosulfonyl)phenyl]ethyl} amino)-3-nitrophenyl]sulfonyl} -4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcycIohex-1 -en-1 -yljmethyl Jpiperazin-1 -yl)-2-( 1 H-indol-5- yloxy)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- [(4- {[3-(lH-imidazoI-l-yl)propyl]amino}-3-nitrophenyI)sulfonyl]-2-(lH-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimediylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-[(3-nitro-4-{[(lS)-l-phenylethyl]amino}phenyl)sulfonyl]benzamide; N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indol-5- yloxy)ben2amide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-[(4-{[2-(2-methoxyethoxy)ethyl]thio)-3-nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N-[(4- {[2-(2-methoxyethoxy)ethyl]thio} -3-nitrophenyl)sulfonyl]benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-{[4-(methylsulfonyl)phenyl]sulfonyl}benzamide; -735- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indol-4-yloxy)-N- {[4-(methylsulfonyl)phenyl]sulfonyl }benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [(2,2-dimethyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitiiophenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({5- cyano-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-indol-5- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- {[5 - cyano-6-(tetrahydro-2H-pyran-4-ylinethoxy)pyridin-3-yl]sulfonyl}-2-(lH-indol-4- yIoxy)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl jpiperazin- l-yl)-N- {[5- chloro-6-(tetrahydiD-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl)-2-(lH-indol-4- yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-{[5- cyano-6-(2-morpholin-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(lH-indol-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indol-5-yloxy)-N-({3-nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)oxy]phenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl jpiperazin- l-yl)-2-( IH- indol-5-yloxy)-N-({4-[(4-morpholin-4-ylbut-2-ynyl)oxy]-3-nitrophenyl}sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl)piperazin- l-yl)-N- {[5- ethynyl-6-(tetrahydro-2H-pyran-4-ylmetiioxy)pyridin-3-yl]sulfonyl}-2-(lH-indol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 -yl)-N- {[5 - cyano-6-(2-moipholin-4-ylethoxy)pyridin-3-yl]sulfonyl j -2-( lH-indol-4-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyljpiperazin-l-yl)-N-({5- cyano-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(lH-indol-4- yloxy)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethyIcyclohex-1 -en-1 -yljmettiyl j piperazin- l-yl)-N-( {4- [(3-hydroxy-4-methoxyphenyl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indol-5- yloxy)benzaniide; -736- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl) piperazin-1 -yl)-2-(2,3- dihydro-lH-indol-4-yloxy)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {4- [(l-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(pyridin-3-ylamino)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-({3- nitro-4-[(l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)-2-(pyridin-3- ylamino)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({3- mtro-4-[( l-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl} sulfonyl)-2-(pyridin-3- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl )piperazin-1 -yl)-N-( {3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(l,2,3,4- tetrahydroisoquinolin-5-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-2-( IH- indazol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimediylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indazol-4-yloxy)-N-({3-nitro-4-[(l-tetrahydio-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl) sulfonyl)benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2- (lH-indazol-4-yloxy)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl} sulfonyl)benzamide; 2-( lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)aniino]phenyl} sulfonyl)benzamide; N-({5-chloro-6-[(4-fluorotelxahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimediylcyclohex-1 -en-1 -yl ]methyl} piperazin-1 -yl)-2-( 1 H-indazol- 4-yloxy)benzamide; N-( {5-chloix)-6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy ]pyridin-3-yl) siilfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin- l-yl)-2-( lH-indol-4- yloxy)benzamide; -737- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-N-( {5- cyano-6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-y 1} sulfonyl)-2-( 1 H-indazol- 4-yloxy)benzaniide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-N-[(4-{[(3R)-l-(2,2-difluoroethyl)pyiTolidin-3-yl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl} sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-[(4- {[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino) -3-nitrophenyl)sulfonyl]-2-( 1 H-indazol- 4-yloxy)benzamide; 4-(4-{[2-(4-chloropheny])-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[6- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2- (lH-indazol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-N- [(4- {[(4-cyclopropylmorpholin-2-yl)metliyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indazol-4- yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en- l-yl]methyl} piperazin- l-yl)-N-[(4- {[(4,4-difluorocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indazol-4- yloxy)benzamide; N-[(5-chloio-6-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]aniino)pyridin-3-yl)sulfonyl]-4- (4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide; Trans-N-( {5-chloro-6-[(4-methoxycyclohexyl)methoxy ]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide; 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chloiophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-{[4-({[4-(2,2-difluoroethyl)morpholin-2-yl]methyl}amino)-3- nitrophenyljsulfonyl }benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin- l-yl)-N-( {5- fluoro-6- [(4-fluorotetrahydro-2H-pyran-4-y l)methoxy ]pyridin-3 -yl} sulfonyl)-2-( 1 H-indazol- 4-yloxy)benzamide; -738- 2-(l H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl} piperazin-1 -yl)-N-( {3-nitro-4- [(1 -tetrahydio-2H-pyran-4-y]piperidin-4- yl)amino]phenyl} sulfonyl)benzamide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-N-({4-[(l-methylpiperidin-4-yl)amino]-3- nitrophenyl} sulfonyl)benzamide; N-[(5-chloro-6-{[l-(cyanomethyl)-4-fluoropiperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[5- chloro-6-(tetrahydrofuran-3-ylmethoxy)pyridin-3-yl]sulfonyl)-2-(lH-indazol-4- yloxy)benzamide; Trans-N-({5-chloro-6-[(4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcycIohex- 1-en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide; N-[(5-chloro-6-{[(3R)-l-(2,2-difluoioethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide; 2-( lH-benzimidazol-4-yloxy)-N-[(5-chloro-6- {[(2S)-4-(N,N-dimethylglycyl)moipholin-2- yl]methoxy}pyridin-3-yl)siilfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dmiethylcyclohex-l-en-l- yljmethyl} piperazin-1 -yl)benzamide; 2-(lH-benzimidazol-4-yloxy)-N-[(5-chloro-6-{[(2R)-4-(N,N-dimethylglycyI)morpholin-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl)piperazin-l-yl)benzamide; N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin-1 - yl)-2-(lH-indazol-4-yloxy)benzamide; N-[(5-chloro-6-{[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3- yl)sulfonyl]-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl }piperazin-1 - yl)-2-(lH-indazol-4-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[5- chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(lH-indazol-4- yloxy)benzamide; -739- 2-( 1 H-benziniidazol-4-yloxy)-4-(4- {[2-(4-chIorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(3R)-l-(cyanomethyl)pyrrolidin-3-yl]amino}-3- nitiophenyl)sulfonyl]benzamide; 2-( 1 H-benziinidazol-4-yloxy)-4-(4- {[2-(4-chloiopheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-{[4-({(3R)-l-[2-(2-methoxyethoxy)ethyl]pyrrolidin-3- yl)amino)-3-nitrophenyl]sulfonyl}benzamide; 2-(lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-l- yl]methyl}piperazin-l-yl)-N-[(4-{[(3R)-l-(N,N-dimethylglycyl)pyrTolidin-3-yl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl) piperazin-1 -yl)-N- {[4-( {[4-(cyanomethyl)moipholin-2-yl]methyl} amino)-3 - nitiophenyl]sulfonyl}benzamide; 2-(l H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(4-cyclopropylmorpholin-2-yl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - y]]methyl}piperazin-l-yl)-N-[(3-nitro-4-{[(4-oxetan-3-ylmorpholin-2- yl)methyl]aniino}phenyl)sulfonyl]benzamide; N-{[5-chloro-6-({(3R)-l-[2-fluoro-l-(fluoromethyl)ethyl]pyrrolidm-3-yl}oxy)pyridin-3- yljsulfonyl} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 - yl)-2-( 1 H-indazol-4-yloxy)benzanude; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-{[4- ({(3R)-l-I2-fluoro-l-(fluoromethyl)ethyl]pyrrolidin-3-yl}anuno)-3-nitrophenyl]sulfonyl}-2- (1 H-indazol-4-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4- [(l-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(lH-indazol-4- yloxy)benzaniide; 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chloK>phenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl} piperazin-1 -yl)-N- {[4-( {[(2R)-4-(N,N-dimethylglycyl)morpholin-2- yl]methyl} amino)-3-nitrophenyl]sulfonyl }benzamide; 2-( lH-benzimidazol-4-yIoxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcycloliex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- {[4-( {[(2S)-4-(N,N-dimethylglycyl)morpholin-2- yl]methyl} amino)-3-nitrophenyl]sulfonyl} benzamide; -740- 2-(lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethyIcyclohex- 1-en-1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydrofuran-3- ylmethyl)amino]phenyl}sulfonyl)ben2araide; Trans-2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl Ipiperazin- l-yl)-N-[(4-{ [(4-fluorotetrahydro-2H-pyran-4-yl)methyI]amino }-3- nitrophenyl)sulfonyl]benzaniide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 - yI]methyl)piperazin-l-yl)-N-({5-fluoro-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl} sulfonyl)benzamide; 2-(lH-benzimidazol-4-yloxy)-N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)benzamide; N- {[5-chloro-6-( {(3R)-1 - [2-fluoro-1 -(fluoromethyl)ethyl]pyrrolidin-3-yl} methoxy )pyridin-3- yl]sulfonyl} -4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 - yl)-2-(lH-indazol-4-yloxy)benzanude; N-[(5-chloro-6-{[(3R)-l-(2,2-difluoroethyl)pyrrolidm-3-yl]methoxy}pyridin-3-yl)sulfonyl]- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl jpiperazin- l-yl)-2-( IH- indazol-4-yloxy)benzamide; Trans-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -yl)-2- (lH-indazoI-4-yloxy)-N-[(4-{[(4-methoxycyclohexyl)methyl]anuno)-3- nitrophenyl)sulfonyl]benzamide; 4-(4- {[2-(4-chIorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N- {[4- (1,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl} -2-( 1 H-indazol-4-yloxy)benzamide; N-({5-chloro-6-[(l-cyclopropylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- ch]orophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzamide; 2-(lH-benziinidazol-4-yloxy)-N-({5-chloro-6-[(l-cyclopropylpiperidin-4-yI)amino]pyridin- 3-yl}sulfonyl)-4-(4-{[2-(4-chloiophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin- l-yl)benzamide; -741- 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin- l-yl)-N-({ 4-[( 1,4-dioxan-2-ylmethyl)aiiuno]-3- nitrophenyl} sulfonyl)benzanude; 2-( 1 H-benzimidazol-4-y loxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-( {4-[( 1 -cyclopropylpiperidin-4-y l)amino]-3 - nitrophenyl} sulfonyl)benzamide; Trans-2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-morpholin-4-y]cyclohexyl)amino]-3- nitrophenyl}sulfonyl)benzamide; 2-(l H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-methylpiperazin-l-yl)aniino]-3- nitrophenyl)sulfonyl)benzamide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N-[(4- {[(1 -methylpiperidin-4-yl)methyl]amino} -3- nitrophenyl)sulfonyl]benzainide; 2-(l H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcycloliex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[({(2R)-4-[2-(2-methoxyethoxy)ethyl]morpholin-2- yl)methyl)amino]-3-nitK)phenyl}sulfonyl)benzamide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(4,4-difluorocyclohexyl)methyl]amino}-3- nitK)phenyl)sulfonyl]benzamide; N-[(4-{[(4-acetylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)benzamide; 2-(lH-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-N-{[4-({[4-(methylsulfonyl)niorpholin-2-yl]methyl}amino)-3- nitrophenyljsulfonyl )benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- I-en-1 -yljmethyl }piperazin- l-yl)-N- {[6- ({4-fluoro-1 - [2-fluoro- l-(fluoromethyl)ethyl]piperidin-4-yl} methoxy)-5- (trifluoromethyl)pyridin-3-yl]sulfonyl) -2-( 1 H-indazol-4-yloxy)benzanude; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- I-en- l-yl]methyl }piperazin- I-yl)-N-({ 3- nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-phenoxybenzamide; -742- 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 -y])-N- {[5- chloro-6-(2-tetrahydrofuran-2-ylethoxy)pyridin-3-yl]sulfonyl}-2-(lH-indazol-4- yloxy)ben2amide; Trans-2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethy Icyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(4-cyanocyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; 2-(lH-benzimidazol-4-yloxy)-N-({5-chloro-6-[(4,4-difluorocyclohexyl)medioxy]pyridin-3- yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 - yl)benzamide; N-({3-chloio-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- ch]orophenyl)-4,4-diniethylcyclohex- 1-en- l-yl]methyl }piperazin-1 -yl)-2-( lH-indazol-4- yloxy)benzamide; N-({5-chloio-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2- (1 H-indazol-4-yloxy)benzainide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1-yljmethyl} piperazin- l-yl)-N-{ [5- cyano-6-(2-tetrahydro-2//-pyran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(lH-indazol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-2-( IH- indol-5-yloxy)-N-[(4-{[(lR,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]amino}-3- nitrophenyl)sulfonyl]benzamide; N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-2-phenoxy-4-(4- {(3-phenylpropanoyl)[(lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3- yljamino} piperidin-1 -yl)benzamide; N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl)sulfonyl)-2-phenoxy-4-(4-{(3- phenylpropanoyl)[(lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}piperidin-l- yl)benzamide; N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-2-phenoxy-4-(4- {(3-phenylpiopyl)[( lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1 ]hept-3-yl]amino }piperidin-1 - yl)benzamide; N-({ 4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl} sulfonyl)-2-phenoxy-4-(4- {(3- phenylpropyl)[(lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}piperidin-l- yl)benzamide; -743- 4-[4-(2- {[(1 R,5S)-8-me%l-8-azabicyclo[3.2.1 ]oct-3-yl]amino) benzyl)piperazin-1 -yl]-N- ({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-phenoxybenzamide; 4-[4-(2-{[(lR,5S)-8-methyl-8-azabicyclo[3.2.1 ]oct-3-yl]amino} benzyl)piperazin-1-yl]-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-2-phenoxybenzamide; 4- {4-[2-(3-azabicyclo[3.2.2]non-3-yl)benzyl]piperazin-l-yl} -N-({ 3-nitro-4-[(tetrahydro-2H- pyran-4-ylmethyl)amino]phenyl} sulfonyl)-2-phenoxybenzamide; 4-(4-[2-(3-azabicyclo[3.2.2]non-3-yl)benzyl]piperazin-l-yl}-2-phenoxy-N-({4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]-3-[(trifluoromethyI)sulfonyl]phenyl}sulfonyl)benzamide; 4-{4-[2-(3-azabicyclo[3.2.2]non-3-yl)benzyl]piperazin-l-yl}-2-phenoxy-N-({4-[(tetrahydro- 2H-pyran-4-ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-{4-[2-(3-azabicyclo[3.2.2]non-3-yl)benzyl]piperazin-l-yl}-N-({4-[(3-morpholin-4- ylpropyl)amino]-3-nitrophenyl) sulfonyl)-2-phenoxybenzamide; 4-(4-{2-[(4R,7S)-2,3,3a,4,7,7a-hexahydro-lH-4,7-methanoinden-5-yl]benzyl}piperazin-l- yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-2- phenoxybenzamide; 4-[4-(2-{5-[(lR,5S)-8-azabicyclo[3.2.1]oct-8-ylmethyl]thien-2-yl}benzyl)piperazin-l-yl]-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}suIfonyl)-2-phenoxybenzamide; 4-[4-(2-{5-[(lR,5S)-8-azabicyclo[3.2.1]oct-8-ylmethyl]thien-2-yl}benzylidene)piperidin-l- yl]-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-2- phenoxybenzamide; 4.[4.(3.{5.[(lR,5S)-8-azabicyclo[3.2.1]oct-8-ylmethyl]thien-2-yl}benzyl)piperazin-l-yl]-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl)sulfonyl)-2-phenoxybenzamide; N-({5-chloro-6-[(4,4-difluorocyclohexyl)methoxy]pyridin-3-yl }sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethyIcyclohex-1 -en-1 -yljmethyl jpiperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide; N-({6-[(trans-4-caibamoylcyclohexyl)methoxy]-5-chloropyridin-3-yl)sulfonyl)-4-(4-{[2-(4- ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]metiiyl jpiperazin-1 -yl)-N- [(4- {[(trans-4-cyanocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH-indazol-4- yloxy)benzaraide; N-( {5-chloio-6-[2-(l H-imidazol-1 -yl)ethoxy]pyridin-3-yl) sulfonyl)-4-(4- {[2-(4- ch]orophenyl)-4,4-dimethylcyclohex- 1-en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzainide; -744- N-({5-chloro-6-[(l-methyl-lH-imidazol-5-yl)methoxy]pyridin-3-yl)sulfonyl)-4-(4-{[2-(4-ch]orophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( 1 H-mdazol-4-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl)piperazin-l-yl)-N-{[5- fluoro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl} -2-( lH-indazol-4- yloxy)benzamide; N- {[5-chloro-6-(l ,4-dioxan-2-ylmethoxy)pyridin-3-yl]sulfonyl) -4-(4- {[2-(4-chlorophenyl)- 4,4-dimethyIcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4-yloxy)benzamide; N-({5-cWoro-6-[(4,4-difluoro-l-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcycIohex-1 -en-1 -yljmethyl }piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzaniide; N-( {5-chloro-6- [(2,2-difluorocyclopropyl)methoxy ]pyridin-3 -yl} sulfonyl)-4-(4- {[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide; N-({5-chloro-6-[(txans-4-cyanocyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzanude; N-( {5-chloro-6- [(cis-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide; N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dinaethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( 1 H-indazol- 4-yloxy)benzamide; N-({3-chloio-4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[4-(4- chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2-(lH- indazol-4-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({4- [(4-fluorotetrahydro-2H-pyran-4-yl)methoxy ] -3-(trifluoromethyl)phenyl} sulfonyl)-2-( 1H- indazol-4-yloxy)benzamide; 4-(4- {[2-(4-ch]orophenyl)-4,4-dimethylcyclohex- 1-en-1 -yljmethyl} piperazin- l-yl)-N- {[3- chloro-4-(tetrahydio-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-2-(lH-indazol-4- yloxy)benzamide; -745- 2-(lH-benzimidazol-4-yloxy)-N-({3-chloro-4-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]phenyl) sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyc]ohex-1 -en-1 - yl]methyl}piperazin-l-yl)benzamide; 2-( 1 H-benziinidazol-4-yloxy)-4-(4- {[2-(4-chloropheny l)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-{[5-chloro-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridm-3- yl]sulfonyl }benzamide; 4-(4-{ [2-(4-ch]orophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl }piperazin- l-yl)-N-({ 3- cyano-4-[(4-fluoiotetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-2-(lH-indazol-4- yloxy)benzamide; N- {[3-chloro-4-( 1,4-dioxan-2-ylmethoxy)phenyl]sulfonyl} -4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en- l-yljmethyl }piperazin-1 -yl)-2-( 1 H-indazol-4-yloxy)benzamide; 2-(lH-benzimidazol-4-yloxy)-N-[(5-ch]oro-6-{[(2S)-4-cyclopropylmorpholin-2- yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethyIcyclohex-l-en-l- yljmethyl} piperazin-1 -yl)benzamide; N-[(5-chloro-6- {[(2S)-4-cyclopropylmoipholin-2-yl]methoxy }pyridin-3-yl)sulfonyl]-4-(4- {[2-(4-chloiophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl }piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide; methyl 2- {[(4- {[4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-2-(lH-indazol-4-yloxy)benzoyl]sulfamoyl}-2- nitrophenyl)anuno]methyl)morpholine-4-caiboxylate; 2- {[(4- {[4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)- 2-(lH-indazol-4-yloxy)benzoyl]sulfamoyI)-2-nitrophenyl)amino]methyl}-N-ethyl-N- methylmorpholine-4-cait»oxamide; 2- {[(4- {[2-( 1 H-benziniidazol-4-yloxy)-4-(4- {[2-(4-chlorDphenyl)-4,4-dimethylcyclohex-1 - en-1 -yljmethyl Jpiperazin- l-yl)benzoyl]sulfamoyl} -2-nitrophenyl)amino]methyl) -N-ethyl-N- methylmorpholine-4-carboxam ide; N-({5-chloro-6-[(trans-4-ethyl-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( 1 H-indazol- 4-yloxy)benzamide; N-({5-chloro-6-[(cis-4-ethyl-4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzamide; -746- 5-chloro-N-({5-chloro-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3- yl) sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin-1 - yl)-2-( 1 H-indazol-4-yloxy)benzamid e; 5-chloro-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -y l]methyl) piperazin-1 -yl)- N-[(4-{[(4-fluorotetrahydro-2H-pyran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(lH- indazol-4-yloxy)benzamide; N-({5-chloio-6-[(cis-l-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3- yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 - yl)-2-( 1 H-indazol-4-yloxy)benzamid e; N-( {5-chloro-6- [(trans-1 -fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3 - yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 -yl]methyl jpiperazin-1 - yl)-2-(lH-indazol-4-yloxy)benzam ide; 2-( 1 H-benzotriazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl} piperazin-1 -yl)-N- [(4- {[(4-fluorotetrahydro-2H-pyran-4-yl)methyl] amino} -3- nitrophenyl)sulfonyl]benzamide; 2-(lH-benzotriazol-4-yloxy)-N-({5-chlon)-6-[(4-fluorotetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl }piperazin- l-yl)benzamide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]metliyl}piperazin-l-yl)-N-{[3-chloro-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl}benzamide; N-[(3-chloro-4-{[4-fluoro-l-(oxetan-3-yl)piperidin-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl Jpiperazin-1 -yl)-2-( lH-indazol-4- yloxy)benzamide; N-( {5-chloro-6- [(cis-1 -fluoro-4-hydroxycyclohexyl)methoxy ]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl }piperazin-1 -yl)-2-( IH-indazol- 4-yloxy)benzamide; 2-( 1 H-benzotriazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({4-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]-3- nitrophenyl} sulfonyl)benzamide; -747- N-[(5-chloro-6- {[(lR,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2. l]hept-2- yI]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl}piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzamide; N-({5-chloK)-6-[(4-fluorotetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl)sulfonyl)-4-(4- {[2-(4-chlorophenyl)-5,5-difluorocyclohex-l -en- l-yl]methyl}piperazin-1 -yl)-2-(l H-indazol- 4-yloxy)benzamide; N-[(5-chloro-6- {[4-fluoro- l-(oxetan-3-yl)piperidin-4-yl]methoxy }pyridin-3-yl)sulfonyl]-4- (4-{[2-(4-ch]orophenyl)-5,5-difluorocyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH- indazol-4-yloxy)benzamide; 2-( 1 H-benzotriazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl)sulfonyl)benzamide; 4-(4-{[2-(4-chlorophenyl)-5,5-difluorocyclohex-l-en-l-yl]methyl)piperazin-l-yl)-2-(lH- indazol-4-yloxy)-N-( {3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl} sulfonyl)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl jpiperazin- l-yl)-N-[(4- {[(trans-4-hydroxy-4-methylcydohexyl)methyl]amino}-3-nitrophenyl)su]fonyl]-2-(lH- indazol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin- l-yl)-N- [(4- {[(cis-4-hydroxy-4-methylcyclohexyl)methyl]ainino} -3-nitrophenyl)sulfonyl]-2-(lH-indazol- 4-yloxy)benzamide; 2-( lH-benzotriazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yljmethyl Ipiperazin- l-yl)-N- {[4-( {[(2S)-4-cyclopropylmorpholin-2-yl]methyl) amino)-3- nitrophenyl]sulfonyl }benzamide; N-[(5-chloro-6- {[4-fluoro- l-(oxetan-3-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4- (4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en- l-yl]methyl} piperazin-1 -yl)-N- {[4- ({[(2S)-4-cyclopropylmorpholin-2-yl]methyI) anuno)-3-nitrophenyl]sulfonyl} -2-(lH-indazol- 4-yloxy)benzamide; 2-( lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl Ipiperazin-1 -yl)-N- {[4-( {[(2S)-4-cycIopropylmorpholin-2-yl]methyl) amino)-3- nitrophenyl]sulfonyl jbenzamide; -748- N-( {5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)niethoxy]pyridin-3-yl} suIfonyl)-4-(4- {[2-(4-chloiophenyl)-5,5-difluorocyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol- 4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl ]methyl) piperazin- l-yl)-N-( {4- [(cis-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}suIfonyl)-2-(lH-indazol-4- yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N-( {4- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl)sulfonyl)-2-(lH-indazol-4- yloxy)benzainide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N- [(3 - cyano-4- {[4-fluoro-1 -(oxetan-3-yl)piperidin-4-yl]methoxy )plienyl)sulfonyl]-2-( 1 H-indazol- 4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( IH- indazol-4-yloxy)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7- ylmethoxy)phenyl]sulfonyl}benzaniide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N- {[5- chloro-6-(5,6,7,8-tetrahydroimidazo[ 1,2-aJpyridin-6-ylmethoxy)pyridin-3-ylJsulfonyl J -2- (lH-indazol-4-yloxy)benzami de; 2-(lH-benzimidazol-4-yloxy)-N-({5-chloro-6-[(trans-4-hydiDxy-4- methylcyclohexyl)methoxyJpyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -y l)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl) piperazin- l-yl)-N- [(5- cyano-6- {[4-fluoro-1 -(oxetan-3-yl)piperidin-4-ylJmethoxy )pyridin-3-yl)sulfonylJ-2-( IH- indazol-4-yloxy)benzamide; N-( {5-chloiD-6- [(trans-4-hydroxy-4-methylcyclohexyl)methoxyJpyridin-3 -yl} sulfonyl)-4-(4- {[2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-1 -en-1 -yljmethyl} piperazin-1 - yl)-2-( 1 H-indazol-4-yloxy)b enzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yljmethyl J piperazin- l-yl)-2-( IH- indazol-4-yloxy)-N-{ [3-nitro-4-({ [(2S)-4-(oxetan-3-yI)morpholin-2- yl Jmethyl} amino)phenylJsulfonyl Jbenzamide; -749- 2-(lH-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en-1 - yl]methyl}piperazin- l-yl)-N- {[3-nitro-4-({ [(2S)-4-(oxetan-3-yl)morpholin-2- yljmethyl) amino)phenyl]sulfonyl }benzamide; N-[(5-chloro-6-{[trans-4-(2-hydroxypropan-2-yl)cyclohexyl]methoxy}pyridin-3-yl)sulfonyl]- 4-(4- {t2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl) piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyl)-4,4-dimethylcyclohex- 1-en- l-yl]methyl jpiperazin- l-yl)-N-({ 3- cyano-4-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl} sulfonyl)-2-( 1 H-indazol-4- y]oxy)benzaniide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-N-({5- cyano-6- [(trans-4-hydroxy-4-methylcyclohexyl)niethoxy]pyridin-3 -yl) sulfonyl)-2-( 1H- indazol-4-yloxy)benzamide; 4-(4-{ [2-(4-chlorophenyI)-4,4-diniethylcyclohex- 1-en- l-yl]methyl)piperazin- l-yl)-2-( IH- indazol-4-yloxy)-N-({5-nitro-6-[(tetTahydro-2H-pyran-4-ylmethyl)amino]pyridin-3- yl} sulfonyl)benzamide; 2-( lH-benzotriazol-4-yloxy)-N-( {5 -chloro-6-[(trans-4-hydroxy-4- methylcyclohexyl)methoxy]pyridin-3-yl} sulfonyl)-4-(4- {[2-(4-chIorophenyl)-4,4- dimethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -y l)benzamide; N-({3-cliloro-4-[(cis-4-cyano-l-fluorocyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl Jpiperazin-1 -yl)-2-( 1 H-indazol-4- yloxy)benzamide; N-({3-chloro-4-[(trans-4-cyano-l-fluorocyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4- chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzamide; N-({5-chloro-6-[(cis-4-cyano-l-fluorocyclohexyl)methoxy]pyTidin-3-yl}sulfonyl)-4-(4-{[2- (4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl}piperazin-l-yl)-2-(lH-indazol-4- yloxy)benzaniide; N-({5-chIoro-6-[(trans-4-cyano-l-fluorocyclohexyI)methoxy]pyridin-3-yI}sulfonyl)-4-(4- {I2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2-( 1 H-indazol- 4-yloxy)benzamide; N-({5-chloro-6-[(trans-4-liydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-l-yl)-2- (lH-indazol-4-yloxy)benzami de; - 750 - 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl)piperazin-l-yl)-N-[(4-{[(trans-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; N-({5-chloro-6-[(trans-4-hydroxy-4-methylcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4- {[2-(4-chloK)phenyl)-5-methoxy-5-methylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-2-( 1H- indazol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-diniethylcyclohex-1 -en-1 -yljmethyl} piperazin-1 -yl)-N- [(5- chloro-6-{[l-(l,3-thiazol-2-yl)piperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(lH-indazol- 4-yloxy)benzamide; 4-(4- {[2-(4-clilorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N- [(6- {[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino} -5-nitropyridin-3-yl)sulfonyl]-2-( 1H- indazol-4-yloxy)benzamide; 4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-N-( {6- [(trans-4-hydroxy-4-methylcyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)- 2-( lH-indazol-4-yloxy)benz amide; 2-( 1 H-benzimidazol-4-yloxy)-4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 - yl]methyl}piperazin-l-yl)-N-[(4-{[(cis-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamide; N-(4- {[4-(4- {[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl} piperazin-1 -yl)-2- (lH-indazol-4-yloxy)benzoyl]sulfamoyl}-2-nitTophenyl)-4-cyanopiperidine-l-carboxamide; and therapeutically acceptable salts, prodrugs, salts of prodrugs and metabolites thereof. 12. A composition for treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer, said composition comprising an excipient and a therapeutically effective amount of the compound of claim 1. 13. A method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies -751- of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient a therapeutically effective amount of a compoimd of claim 1. 14. A method of treating bladder cancer, brain cancer, breast cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small cell lung cancer or spleen cancer in a patient, said method comprising administering to the patient therapeutically effective amount of the compound of claim 1 and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent. Dated thisa^**" day of April 2012 Of Anand and Anand Advocates Agents for the Applicant - 752 -